<SEC-DOCUMENT>0000721371-21-000011.txt : 20210205
<SEC-HEADER>0000721371-21-000011.hdr.sgml : 20210205
<ACCEPTANCE-DATETIME>20210205163820
ACCESSION NUMBER:		0000721371-21-000011
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210205
DATE AS OF CHANGE:		20210205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CARDINAL HEALTH INC
		CENTRAL INDEX KEY:			0000721371
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				310958666
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11373
		FILM NUMBER:		21596435

	BUSINESS ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017
		BUSINESS PHONE:		6147573033

	MAIL ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CARDINAL DISTRIBUTION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cah-20201231.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:9f2b874d-aa0f-4f0c-98af-f0bcbd3c3f24,g:771f989f-b1cf-4cd9-b16a-9064b3a47170,d:ac867f2b870144f0baf920261d30f765--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:cah="http://www.cardinal.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cah-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV80L2ZyYWc6NjczYmU1NTkxNjdlNDU5ZDkxZDA3MzQ4NmJiOTFjNWYvdGFibGU6ZDYyNzk1OTFjNDYxNGQ1M2FjMjczODdkYmM5ZDNiZGYvdGFibGVyYW5nZTpkNjI3OTU5MWM0NjE0ZDUzYWMyNzM4N2RiYzlkM2JkZl8yLTEtMS0xLTA_ab4c95de-2326-404a-869e-cbea67a09933">0000721371</ix:nonNumeric><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV80L2ZyYWc6NjczYmU1NTkxNjdlNDU5ZDkxZDA3MzQ4NmJiOTFjNWYvdGFibGU6ZDYyNzk1OTFjNDYxNGQ1M2FjMjczODdkYmM5ZDNiZGYvdGFibGVyYW5nZTpkNjI3OTU5MWM0NjE0ZDUzYWMyNzM4N2RiYzlkM2JkZl8zLTEtMS0xLTA_4aeb9e7f-9494-4725-b77a-3329abdeb9d7">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV80L2ZyYWc6NjczYmU1NTkxNjdlNDU5ZDkxZDA3MzQ4NmJiOTFjNWYvdGFibGU6ZDYyNzk1OTFjNDYxNGQ1M2FjMjczODdkYmM5ZDNiZGYvdGFibGVyYW5nZTpkNjI3OTU5MWM0NjE0ZDUzYWMyNzM4N2RiYzlkM2JkZl80LTEtMS0xLTA_0cef7fb8-7432-4645-b2f6-123c57f90c1d">2021</ix:nonNumeric><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV80L2ZyYWc6NjczYmU1NTkxNjdlNDU5ZDkxZDA3MzQ4NmJiOTFjNWYvdGFibGU6ZDYyNzk1OTFjNDYxNGQ1M2FjMjczODdkYmM5ZDNiZGYvdGFibGVyYW5nZTpkNjI3OTU5MWM0NjE0ZDUzYWMyNzM4N2RiYzlkM2JkZl81LTEtMS0xLTA_6fc461cc-3ca3-4cbb-9e02-c37700152307">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV80L2ZyYWc6NjczYmU1NTkxNjdlNDU5ZDkxZDA3MzQ4NmJiOTFjNWYvdGFibGU6ZDYyNzk1OTFjNDYxNGQ1M2FjMjczODdkYmM5ZDNiZGYvdGFibGVyYW5nZTpkNjI3OTU5MWM0NjE0ZDUzYWMyNzM4N2RiYzlkM2JkZl82LTEtMS0xLTA_5207f150-7049-4790-8e1a-c8dc71e46770">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cah-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i77ba0c60824e4b95b074e0fa4e5f5b85_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6d8949488e504051b168d44d36fc8172_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf177919053f4d84b5deede4be106b52_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d920529cbde451191352192e3af656c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ea5286e8327464ba54819290fd52747_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae2531be3ff4d52a622e624ada4da07_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf5ab90557c4000a09c6f27f8f43161_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i330e68ab5e5340ebadc011e5a0a59586_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i866db22bd82141a4a400612301c75ffb_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0f0b3868edd4abb9835771227d980e0_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02b85a2b00dd4f0491c62b22e62fdd52_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief43f820ca8b46dbb807687b9aba78b0_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i333fddf2954c4f8f84d124aceab9eb34_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if43031c026d442a18ff9382d1b9cffc6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c921ca8f3fd4b668c26209f32686128_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic337060106e84e76a53c24d5a516bded_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i531c55176bb64260a4950658a062d0e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cd1437e597b4e2682afe89f0b8f38a1_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe8fb0429c640549ebd225f00c39fdd_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90bccc700f344156818dd2a91922ae30_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08f87960dc81422e8cc8681a4821d475_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3530dfeec0384b169ee4ba603c672780_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c429f356e364a318686f6a96b4c0d70_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f0d9a0a1c01475c97b8ad225ba6ed8a_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i087a2162c6ab4ee08231b8375275a66f_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic709b0f6e31348dc92cb361418750b1a_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i356ad0db94fd4af2945d43260c52b004_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a37151dd9974055b9fd8a3b9f329fda_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ffbcc7b8b47419fafc54db6c65fa67c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i961814e0fb934b26a59874c0a47b5c36_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34bce33b39294b5990a6d2671d45efc1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a67a68103174862933d81e69761227a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae7680d35a94fe791314d93518ad333_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15dfaa9ce43d4c8dbe8e43f793325ab5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc62359854904e73a95bee6e706c2f64_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02eca4589f2a4542b34a4ac4b0e54bbc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i327c9e14b86548eeaa15e0b1195a1713_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d7546c5d1f84a4a8f9ddb1310f520fc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83d7259b2a09452ea238e9d70eb94fcb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b3c71ac478a4d02806d3987db7fca7c_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342dbbcc001646b78a3682ec6c4a043a_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ac4657e05a9499ab00fb27b5751039b_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69b8b80a81a246308be8e9d7ae9fb68e_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c695c989c1c488a9a822944847a51bb_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7239edd43644a128d30e8bbd0ab2a9e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i964a6019a431419c8e09883bc4b9d02c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41b5d7dfd6a54361850263e4fd529847_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ae7a3375f4c4b319354a025e78a9375_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7285527fa33149449338e908558152ee_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9263daec240f40e18bbc79b563561d69_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea6044c7ef014ad7b58ff6abb8cf7620_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdfa6e7ff1fd4ff4894046a2aef75fa0_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i316bc31c1a6f4eb1a59f8bfb2c2df15c_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4523a176fdd843a1871b85358e66f672_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f12e42d72c7409cbec2d494d04aea14_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i715f3cb5de28419892c4abe4c201b08b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29dfcbbc4b87452b99f5496e7a8ee237_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cb6bb1cf27c4f7a8d9e429c5c296315_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaca494a8cb54963b9c8eabe88a49bf4_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id23cc7d0aa564d63919be6c6c1cfef81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79f208ee71c540dc96e55d1ea0309d92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98dea8eab827433d8bb7d45c1cfb404b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14b14c71bbc54f248f49427b82d4c76a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib84ce22fc5e7432ea0e7678515ad59b0_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9662598991e54a289ce467d4c55860b1_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63febb3b06bd4185a6a3f45a6da44204_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb5434fa06a945a9812fd66b941db4b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0576298a2e542fd95ac14b7815c72ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec244ced74e54c48890cb31ded0bdebf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a7db73217be4f9980a875418215b27c_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3386edf96d3941c387073f4c10dfd3a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20ba7d43ca1e4e5bad3683d334fed42a_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94ec4ab4e33146c497406aa05665b794_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3be0113a67424f1d89bc62eba84876b6_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56f4dc613d0944dfb65ad3407fdd7d98_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i036a1401ef2c457fb47d9dd79ed6fc99_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e4b7722d85145d78ebc17885b5a4d24_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a47a213956c4b9eb61252e2288e47f9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i474cf5f364454a11b22f24b06699e4df_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:FloatingRateNotesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2a9682f8564e3fb789bdc866101ff9_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c200f19e4364602a4c4db803bbe7e50_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.4Notesdue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01211baf31064f409c8fa4c5b5b54b09_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i770887e4d98143a78ad85ee309204ca5_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A3.2Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaae728c0a7a4428ab31591199c01df2c_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:FloatingRateNotesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bea82ad95804e6abff0fd8562560862_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A3.41Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2763cf8f732c46ac822b3a4e9cc9afce_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A4.6Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i907c1e70968546c7bd30ff773af28457_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A4.9Notesdue2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9f2efa674d6441590242649316ec9a6_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A4.368Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92aefd5c72f64cb89f421ad0100e879f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia70ce6414d4f4266bf2f26ca4eafbb15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91ee5d4795d74c0d97f3782625ff9fd1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie044a19677f140da979d3894dde5c9de_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0763235728b4e798df4a93f91297014_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24af2662052e41a9916032cdb61e8d12_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i90dc05ceb60c40f0ac677345f92bae29_I20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38d2978456e542b7b3180f73a3e78c5f_I20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="stateag"><xbrli:measure>cah:StateAG</xbrli:measure></xbrli:unit><xbrli:context id="i56512e9ae3444aa3993b873d559a9163_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id328a673f19941118ace9480b141deae_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia24262f3a922415db5013e0f3ae80122_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>cah:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i2a4ad47536df474f94e261a74c430702_I20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b7d20f207654f5896c816a15da9291c_I20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b50640db30b49a9aeed0c6c228e045d_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>cah:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i8a7e2cc7591649299a8be4db64de4bf6_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf2d67987fbf44f9b89a411201940603_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a938e1fa9214d8cb46bb9c82947ad31_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0b1626635494e759538b3e69c1d8c44_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06d03eb8370c4ad5b575e1b109ddc573_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i028cb05d5d774ece897a4eae7abde3c9_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:DOJInvestigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87230ed321a245fc91bc68615d9f61a5_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4465d750964497c99036784264b593a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic03700ae57af494fb31290e42a1720fd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f1203c9a1ad44c4874a799063ecc408_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7325d606c00e4365b83eaf72e2f134be_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08769690807c428b9015f5d581f80d13_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbe4dd4c7b6c4b83bbef659b5664d7ff_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2334754903a5458bb5821f0515733377_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f1f3a98a99a4d27b6451bfb560ba396_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6112186cca62432382db406081a60a17_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i888db2833efb4657a6fefd55514539c8_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab7bd98acbea40449f8bd35c7616c720_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f7180f4c5144dceb597f6050eb94368_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26e6e263c6fd4a699bb0c1af198967e1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93d039e782a9419a9742c71dc850ce33_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65806b475fdc4876a59494d73901adb7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i159fa2bd7a66408badeaa0faea3b677d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7445253c20dd435886df7adff515242f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e83590d4a854a7190b78c1a5c2d284f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d6381aaa6914a0aa526a6b8b3989a7e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b55dcaca51f44599a00a8fa68d79d85_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib957a62df7f549839a60399d078c4472_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if41b93ee69de4e0d9701c057ae9ab8db_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic35295a277e6424d9f0eb8e2c6404476_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f82a2865f2b492a8c478c3a57f6df30_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i796ef5fe827b4eccb2c3f684dc6db76d_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b687b1f81d948059485e5e2a6425863_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="ib15a63d640244c34a6d0227562acaad5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib37c4b044c234377901beeef0ec945bd_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6845881719c14946a18825ca27e660d9_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i478d2dd73460414f88583f29a46256a5_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38f0432b47e6439c90226e210f3f5025_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id909840ad6bb4ab089bf9cbd591c6393_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31ae9f550b884047875a86b44b481e30_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id293a6a8b52246f59bdad843b0eedcfc_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3f98e4ee19e4429b6719301c1f07c3a_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3c9f00156d0450788ebefaa19e489ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i169899f3ed7e4646b50fcb3a6ea5433a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i516dad7d9d244946b3629a4006f58d73_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie565dceec6384b15bc38825036cc1367_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e8a2cc4f32e492b978886cfa6468d14_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic07137665bed4e8395c06d5d163722d4_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e9ec7b4d1de47779baac1a8003f4ac0_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5611e497378475180730c7bb2d349b0_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98af1fc7fbb546ada30bf032dc682c07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec0a2a9c3a084ecda280560e320b49ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i956ec3fd41944891af79cc5fc668a58d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cah:segment</xbrli:measure></xbrli:unit><xbrli:context id="i3907143d601446b2b2dadc450da37c6e_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5035cf75d04e4c4c800fa6271658ffaf_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d16186a3eb4d6cb347ef265ebd81c2_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22e6eb5fc5b44eb8e366a0e404097eb_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ff998854edd4eda8d8b8b0671924582_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i672ee4b7a6194291882b5780e5e828a0_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i341d682d330c4e5392a574b97873cfbc_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6447be5f30b14c9eae4c5ec00d2365d8_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4bc1df9803142bca96ee5920f3f9477_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i618e7649eb974fa9a8bdda5a0b6c884e_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a603a9a33074afd94135cf3f2682615_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i351ff459d8c147dc85efc9f57fefc562_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a9dbdf0124e48049351c12013836acc_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3403a67c72846a2b090eb4c1dcfe35b_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id84c7d3f10b5448eae225db35d9ff12b_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21a4a9e6c3b742fcb7a36c82c033f21c_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2240c3e8e514deebd1a13337be4bed5_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d7ee7ef7fae4a23a4607553d24f1f27_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94a02c3a95ca45b7a140f7699a115bef_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b2f1f0f8f9e4cdb9a87fac1bfc1dc87_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67c2756a2d8e492a8d27ef7d759a0159_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic482ae4cb0e845e983854f115696e92f_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f48b5e33984bdc8b86b397bfccce23_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b678754b9524d1195c6310b764861aa_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8df2c21ec314065818f504c97c1bc8f_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7d29d41390f4acf84c102913fb223e5_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8216fd9e5c90433ea29335aa86cb447c_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i482f6ccb403f4a52af97d8ca515a61b8_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95d2c4ed996940f9a46e1b79a9311ba9_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i555180dfd31f4d28b52ece1a6f81a588_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97ef54c441584928af5eb60384fe7457_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fc0478dc85442c2942659ad0aeebd71_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i235c9cf737b84394aae05f413fa3c155_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2d75526aa5047f9adcfa5c2aeac6208_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0bce5f6fb544487b4e3560b83f1110a_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46dd8327f8a44abf95b9a0332180575f_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b9e9461ba0a47d18b3547d957221cd6_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i761af129229b4859917784980b5aa533_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83001f54baa54c32ab564685b11c5fd7_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55908a6cac3f444daad213a201d855ec_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99f293e06fa54cba94cd2fe57d28abad_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:SterileSurgicalGownRecallAxis">cah:SterileSurgicalGownRecallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i704d2da68a27491caa5fcefcc86490a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d5964aeb73c4db18da5611b91ef7334_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89a6b93ede39460b8242e3fedc07e841_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57ef56323da34ba69ad0fcaae008d16f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie417bfafb8654792b0622431ec8134ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d0bffbd8bb54efaa2c7c406881f23ab_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if99bd32109874e86a903049a33a5df8d_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib87c6a3a8d094aeaba3759a9a6ff0c4e_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0de7af799774156a7e1dd567937f30d_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fba9c013a7b43dd90febed8d8b6afe3_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia18cb4783d8449c285fe5638df3c4776_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7d0b551d8034adaa39776dff9c6b47b_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1e48cb861974ac9b185da35f6452945_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52a2b1e5f55d48c5a3fbb4e2c6d024d6_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51b81892e14d49f39bb77a27503cd87d_D20190701-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9de38f44efc4734a6acc21a07c418b0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a9264343844c3188592efd3e0a1c18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i130d53f3f6b041848bc6ad14a45add16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdedc1cec79f497e8b28d714bde083dd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia83b442716234d0f8c45c343f0fa6ae7_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95f32f5a14a64f12ade71f4f086f5c9d_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea7a98aa2bac4b76bab476be13a2fb31_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i625efca7a8ef454c8cbb29134f0f0c7a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iac867f2b870144f0baf920261d30f765_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.461%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM184NQ_b474052f-f162-4128-a84e-677841bbcf20">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.923%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6YjUxMjcxYzVlYjcxNDQ2NjhmZmRmMWU3ODlhZDY1YzMvdGFibGVyYW5nZTpiNTEyNzFjNWViNzE0NDY2OGZmZGYxZTc4OWFkNjVjM18wLTAtMS0xLTA_6bd0c712-a791-4745-b5ad-94487adacbdf">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xMjI_5974113b-58e9-40d1-9e10-31e19f27690c">December 31, 2020</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.923%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6ZWY5YjI5NGE4NDg3NDZmOWIwYTdlMDM4Y2Q1ZTE4ZDQvdGFibGVyYW5nZTplZjliMjk0YTg0ODc0NmY5YjBhN2UwMzhjZDVlMThkNF8wLTAtMS0xLTA_7b473323-51f1-40eb-ba53-bcf410066771">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xNTc4_ffac97a4-28ab-4b94-b565-de0f0a90a9a7">1-11373</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xNTc5_fdf7caca-105a-48b7-b469-2f3ffbef91cd">Cardinal Health, Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.282%"><tr><td style="width:1.0%"></td><td style="width:24.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl8wLTAtMS0xLTA_380f828d-4c28-44ee-baf3-13b0dc64fd99">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl8wLTYtMS0xLTA_5dbdd9a0-ec01-4936-a634-6d9c70fc5445">31-0958666</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl8zLTAtMS0xLTA_ed797803-eb11-4dba-bea4-10bef4607820">7000 Cardinal Place</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl8zLTItMS0xLTA_d57f302d-e3fb-410e-b978-35db9c4b91c9">Dublin</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl8zLTQtMS0xLTA_5999803f-ebb5-4b9b-9d93-544eac136817">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl8zLTYtMS0xLTA_14b97211-2d50-43a5-a342-3e33d4e8f3c1">43017</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Zip Code)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl82LTQtMS0xLTA_a7e73169-7ce3-4d95-9cba-603936e7f91a">(614)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl82LTYtMS0xLTA_d14090e1-983a-43a0-b453-90cee731131e">757-5000</ix:nonNumeric></span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.435%"><tr><td style="width:1.0%"></td><td style="width:35.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6YjkwMmY2NGQ1MDcxNDJhZWIwMjg5YjRmMTg0ODY3MWMvdGFibGVyYW5nZTpiOTAyZjY0ZDUwNzE0MmFlYjAyODliNGYxODQ4NjcxY18yLTAtMS0xLTA_7b698113-33c4-4ac0-b746-bba998a9d841">Common shares (without par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6YjkwMmY2NGQ1MDcxNDJhZWIwMjg5YjRmMTg0ODY3MWMvdGFibGVyYW5nZTpiOTAyZjY0ZDUwNzE0MmFlYjAyODliNGYxODQ4NjcxY18yLTEtMS0xLTA_b00f6340-3903-4fb4-9d2d-b26f6926d880">CAH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6YjkwMmY2NGQ1MDcxNDJhZWIwMjg5YjRmMTg0ODY3MWMvdGFibGVyYW5nZTpiOTAyZjY0ZDUwNzE0MmFlYjAyODliNGYxODQ4NjcxY18yLTItMS0xLTA_f9087b94-2cfa-438c-b787-a00a3928a82b">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xNTgw_106b0c96-4c9d-46b4-9ae9-bc8b950ffb93">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xNTgx_d962f212-6d50-450f-a8a0-2022e69c48de">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MWRlZDcxZTZmZjgwNDQ3MDg4N2VjNjI2NWVkNTc2MGEvdGFibGVyYW5nZToxZGVkNzFlNmZmODA0NDcwODg3ZWM2MjY1ZWQ1NzYwYV8wLTAtMS0xLTA_4c0af603-07f2-48a6-a382-3c95011ce66a">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MWRlZDcxZTZmZjgwNDQ3MDg4N2VjNjI2NWVkNTc2MGEvdGFibGVyYW5nZToxZGVkNzFlNmZmODA0NDcwODg3ZWM2MjY1ZWQ1NzYwYV8xLTQtMS0xLTA_1a30c307-20eb-4a88-8da3-1f63dd07e2f0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MWRlZDcxZTZmZjgwNDQ3MDg4N2VjNjI2NWVkNTc2MGEvdGFibGVyYW5nZToxZGVkNzFlNmZmODA0NDcwODg3ZWM2MjY1ZWQ1NzYwYV8yLTQtMS0xLTA_6a1cce77-a526-44d6-813d-c332316f4a14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xNTgy_2b9ac65c-f220-4c7f-a69c-d77d1226be8f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of the registrant&#8217;s common shares, without par value, outstanding as of January&#160;31, 2021, was the following: <ix:nonFraction unitRef="shares" contextRef="i77ba0c60824e4b95b074e0fa4e5f5b85_I20210131" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xNTc2_afde361f-7e47-4aa5-a631-b69551ec9bf7">293,667,560</ix:nonFraction>.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:22pt;font-weight:700;line-height:100%">Cardinal Health</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:100%"> </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:18pt;font-weight:700;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Q2 Fiscal 2021 Form 10-Q                                                                                                                                   </span></div></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:91.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_13">2</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_31">Explanation and Reconciliation of Non-GAAP Financial Measures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_31">18</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_40">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_40">22</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_43">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_43">22</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_46">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_46">23</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_49">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_49">24</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_55">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_55">24</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_61">Financial Statemen</a>ts</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_61">25</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_133">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_133">42</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_136">Form 10-Q Cross Reference Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_136">43</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_139">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_139">44</a></span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">About Cardinal Health</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, Inc. is an Ohio corporation formed in 1979 and is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to fiscal 2021 and fiscal 2020 and to FY21 and FY20 are to the fiscal years ending or ended June&#160;30, 2021 and June 30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2020 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results, trends or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (our &#8220;2020 Form 10-K&#8221;). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the "Overview of Consolidated Results" section of MD&amp;A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the United States Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the &#8220;Explanation and Reconciliation of Non-GAAP Financial Measures&#8221; section following MD&amp;A in this Form 10-Q. </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is concerned with material changes in financial condition and results of operations between the periods specified in our condensed consolidated balance sheets at December&#160;31, 2020 and June&#160;30, 2020, and in our condensed consolidated statements of earnings/(loss) for the three and six months ended December&#160;31, 2020 and 2019. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&amp;A included in our 2020 Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Overview of Consolidated Results</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20201231_g1.jpg" alt="cah-20201231_g1.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2020, revenue increased 5 percent to $41.5 billion and $80.6 billion, respectively, primarily due to sales growth from pharmaceutical distribution and specialty solutions customers.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Operating Earnings/(Loss)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">461</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(163)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,930)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">234</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,070</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,694&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP operating earnings</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">628</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,246</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in GAAP operating earnings during the three months ended December&#160;31, 2020 was primarily due to the beneficial comparison to the prior-year charge in connection with a voluntary recall for certain surgical gowns and a voluntary recall and field actions for surgical procedure packs containing affected gowns (together, the "Recalls").</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had a GAAP operating loss of $163 million and $4.9 billion during the six months ended December&#160;31, 2020 and 2019, respectively, due to $1.02 billion and $5.63&#160;billion of pre-tax charges, respectively, recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. See further description of opioid lawsuits in the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-GAAP operating earnings were negatively impacted by the pandemic associated with the novel strain of coronavirus ("COVID-19") during the three and six months ended December&#160;31, 2020 primarily due to the negative impact from volume declines in our generics program and Nuclear and Precision Health Solutions within the Pharmaceutical segment. Within the Medical segment, higher volumes in our laboratory business, cost savings and a net positive contribution from personal protective equipment ("PPE") partially offset by the adverse impact of reduced surgical products demand resulting from cancelled or deferred elective procedures provided a benefit during the three and six months ended December&#160;31, 2020. The net positive impact of PPE included timing favorability related to our cost mitigation efforts.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP operating earnings were positively impacted during the six months ended December&#160;31, 2020 by higher contribution from branded pharmaceutical sales mix in our Pharmaceutical segment and Medical segment cost-savings measures, including global manufacturing efficiencies.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Diluted EPS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">($ per share)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.99)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.05</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.34&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.60</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.67&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.73)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.66&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transitional tax benefit, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.52&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.26</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("diluted EPS" or "diluted loss per share")</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures." </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">For the six months ended December 31, 2019, GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 294 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the quarter. Year-to-date fiscal 2020 non-GAAP diluted EPS is calculated using a weighted average of 295 million common shares which includes potentially dilutive shares.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Litigation (recoveries)/charges, net, includes a tax benefit recorded during the three months ended December 31, 2020 related to a net operating loss carryback. Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, is currently deductible on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss is being carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act. The total benefit from the net operating loss carryback was $420 million; however, for purposes of Non-GAAP financial measures, we allocated $394 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-insurance pre-tax loss related to opioid litigation claims versus separate tax adjustments. The tax benefit allocated to the separate tax adjustments of $26 million is included in non-GAAP measures. As the fiscal year 2020 federal return is finalized, both the tax benefit and the relative allocation may be adjusted.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP and non-GAAP diluted EPS during the three and six months ended December&#160;31, 2020 were positively impacted due to a tax benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss, as further described in Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements."</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2020, GAAP diluted EPS also increased due to the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factors impacting GAAP operating earnings, partially offset by the tax effect of the </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">charges we recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2020 and 2019, the charges we recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications had a $(2.38) and $(17.49) per share after tax impact on GAAP diluted EPS, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2020, non-GAAP diluted EPS increased 14 percent to $1.74 per share. This increase was primarily due to changes in discrete tax items, including a tax benefit from a net operating loss carryback described above.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the six months ended December&#160;31, 2020, non-GAAP diluted EPS increased 16 percent to $3.26 per share. This increase was primarily due to changes in discrete tax items, including a tax benefit from a net operating loss carryback described above</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, factors impacting non-GAAP operating earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and lower interest expense primarily due to less debt outstanding.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $3.7 billion at December&#160;31, 2020 compared to $2.8 billion at June&#160;30, 2020. During the six months ended December&#160;31, 2020, net cash provided by operating activities was $1.5 billion and we deployed $289 million for cash dividends and $174 million for capital expenditures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Significant Developments in Fiscal 2021 and Trends</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-Tax Loss</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2020, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, is currently deductible on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss is being carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our provision for income taxes during the three months ended December&#160;31, 2020 included a $420 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to file for a federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our condensed consolidated balance sheet at December 31, 2020. We also increased our non-current deferred tax liability by approximately $700 million during the six months ended December 31, 2020 related to this matter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Opioid Lawsuits Development</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general that is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). Negotiations under the Settlement Framework continue. Definitive terms for a settlement continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid lawsuits and settlement negotiations, we recorded pre-tax charges of $1.02&#160;billion and $5.63 billion during the six months ended December&#160;31, 2020 and 2019, respectively, in litigation (recoveries)/charges, net, in the condensed consolidated statements of earnings/(loss). We accrue for contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">No</a><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">te 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effect of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net tax benefits associated with the opioid litigation charges are $35 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million and $469 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision for/(benefit from) income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid accrual during the three months ended September 30, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the six months ended December&#160;31, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent. The inclusion of the relatively lower tax benefit of the current fiscal year charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax expense increased by approximately $150 million during the three months ended December 31, 2020 while the amount of tax benefit increased by approximately $300 million during </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the six months ended December 31, 2020 compared to the tax impacts that would have been recognized without the opioid litigation charge and is expected to significantly increase our provision for income taxes during the remainder of fiscal 2021. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to the Condensed Consolidated Financial Statements&#8221; for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic associated with the novel strain of coronavirus ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic also affected our businesses in a variety of ways beginning in the third quarter of fiscal 2020 and continuing into fiscal 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 had a negative impact on our consolidated operating earnings in the three and six months ended December&#160;31, 2020. As anticipated, Pharmaceutical segment profit was negatively impacted by COVID-19 largely due to volume declines in our generics program and Nuclear and Precision Health Solutions. COVID-19 had a benefit on Medical segment profit with higher volumes in our laboratory business, cost savings and a net positive contribution from personal protective equipment ("PPE") partially offset by the adverse effects of reduced surgical products demand resulting from cancelled or deferred elective medical procedures. The net positive impact of PPE included timing favorability related to our cost mitigation efforts.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that the COVID-19 pandemic will have a further negative impact on fiscal 2021 consolidated operating earnings and Pharmaceutical segment profit. It is possible that political, administrative, legislative, legal or regulatory actions in response to COVID-19, including the possible use of the Defense Production Act in the United States, could create additional supply shortages, disruptions or other uncertainties affecting our Pharmaceutical and Medical segments. We cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. or global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow, and its impact may be greater or less than we anticipate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20201231_g2.jpg" alt="cah-20201231_g2.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20201231_g3.jpg" alt="cah-20201231_g3.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37,236</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,714&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">72,348</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,142&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,310</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,267</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,737&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,615</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77,082&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,541</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,735&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77,076&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment revenue growth was primarily due to sales growth from pharmaceutical distribution and specialty solutions customers, which together increased revenue by $1.5 billion and $3.2 billion during the three and six months ended December&#160;31, 2020, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment revenue increased during the three and six months ended December&#160;31, 2020 primarily within products and distribution, which increased revenue by $231 million and $223 million, respectively, due to a net benefit from COVID-19. The benefit is due to higher volumes in our laboratory business and the positive impact of PPE, partially offset by the adverse impact of reduced surgical products demand resulting from cancelled or deferred elective procedures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold for the three and six months ended December&#160;31, 2020 increased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 percent to $39.8 billion and $77.1 billion, respectively, compared to the respective prior-year periods as a result of the factors affecting the changes in revenue and gross margin. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Gross Margin</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20201231_g4.jpg" alt="cah-20201231_g4.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20201231_g5.jpg" alt="cah-20201231_g5.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,776</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,491</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,393&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin during the three and six months ended December&#160;31, 2020 increased $62 million and $98 million, respectively, compared to the prior-year period, primarily due to the beneficial comparison to the prior-year charge in connection with the Recalls, higher contribution from branded pharmaceutical sales mix and Medical segment cost-savings measures, including global manufacturing efficiencies. COVID-19 negatively impacted gross margin due to volume declines in our generics program and Nuclear and Precision Health Solutions within our Pharmaceutical segment.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin rate declined 3 basis points and 7 basis points during the three and six months ended&#160;December&#160;31, 2020, respectively, mainly due to changes in pharmaceutical distribution product and sales mix. While branded pharmaceutical sales contributed positively to gross margin dollars during the three and six months ended December&#160;31, 2020, they had a dilutive impact on our overall gross margin rate. Gross margin rate year-over-year comparison also benefited from the $56&#160;million charge recognized during the three and six months ended December&#160;31, 2019 in connection with the Recalls.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Distribution, Selling, General and Administrative ("SG&amp;A") Expenses</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A expenses</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,147</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,284</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,270&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2020, SG&amp;A expenses benefited from the year-over-year comparison of a $40&#160;million charge in connection with the Recalls recognized during the three months ended December&#160;31, 2019, partially offset by expenses related to investments in information technology infrastructure.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2020, SG&amp;A expenses increased primarily due to a judicial decision relating to a $41&#160;million assessment on prescription opioid medications that were sold or distributed in New York state in calendar year 2017 and 2018 and expenses related to investments in information technology infrastructure. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on the New York Opioid Stewardship Act. The year-over-year comparison was favorably impacted by the $40&#160;million charge in connection with the Recalls recognized during the six months ended December&#160;31, 2019.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_124">Note 11</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.</span></div><div style="margin-bottom:6pt;text-align:center"><img src="cah-20201231_g6.jpg" alt="cah-20201231_g6.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20201231_g7.jpg" alt="cah-20201231_g7.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">413</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">815</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">466</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">649</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total consolidated operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">461</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(163)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,930)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2020, Pharmaceutical segment profit decreased compared to the prior year periods due to the adverse impact of COVID-19, primarily as a result of volume declines in our generics program and Nuclear and Precision Health Solutions, offset by the impact of higher contribution from branded pharmaceutical sales mix.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment financial results do not include the $1.02 billion and $5.63&#160;billion charges associated with the opioid litigation during the six months ended&#160;December&#160;31, 2020 and 2019, respectively. See the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information. In addition, Pharmaceutical segment financial results do not include the $41&#160;million assessment during the six months ended&#160;December&#160;31, 2020 on prescription opioid medications that were sold or distributed in New York state in calendar year 2017 and 2018. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on the New York Opioid Stewardship Act.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit increased during the three and six months ended&#160;December&#160;31, 2020 due to cost-savings measures, including global manufacturing efficiencies, and COVID-19. The benefit from COVID-19 was a result of higher volumes in our laboratory business, cost savings, and a net positive contribution from PPE, partially offset by the adverse effects of reduced surgical products demand resulting from cancelled or deferred elective procedures. The net positive impact of PPE included timing favorability related to our cost mitigation efforts.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Corporate during the three and six months ended&#160;December&#160;31, 2020&#160;were due to the factors discussed in the Other Components of Consolidated Operating Earnings/(Loss) section that follows. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Components of Consolidated Operating Earnings/(Loss)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to revenue, gross margin and SG&amp;A expenses discussed previously, consolidated operating earnings/(loss) were impacted by the following:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">234</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,070</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,694&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Employee Severance</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and employee severance during both the three and six months ended December&#160;31, 2020 and 2019 was primarily related to implementation of certain enterprise-wide cost-saving measures. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization and Other Acquisition-Related Costs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquisition-related intangible assets was $113 million and $127 million for the three months ended December 31, 2020 and 2019, respectively, and $228 million and $256 million for the six months ended December&#160;31, 2020 and 2019, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation (Recoveries)/Charges, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2020 and 2019, we recognized pre-tax charges of $1.02 billion and $5.63&#160;billion, respectively, associated with certain opioid matters. See the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs we recognized in connection with the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter product liability claims during the three months ended December&#160;31, 2020 and 2019 were $18 million and $17 million, respectively, and $28 million and $62 million during the six months ended December&#160;31, 2020 and 2019, respectively. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three and six months ended December&#160;31, 2020, we recognized a $13 million charge in connection with a civil investigation by the United States Attorney&#8217;s Office for the District of Massachusetts related to discounts and rebates offered or provided to certain Specialty Solutions customers, as described further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of the "Notes to Condensed Consolidated Financial Statements."</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recoveries in class action antitrust lawsuits recognized were $14 million and $16 million during the three and six months ended December&#160;31, 2019, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Earnings/(Loss) Before Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the items discussed above, earnings/(loss) before income taxes were impacted by the following:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income)/Expense, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended&#160;December&#160;31, 2020, other (income)/expense, net was favorable compared to the prior-year period primarily due to increased returns from investments, which offset fluctuations in deferred compensation liabilities that are included within SG&amp;A and discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_106">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" and fluctuations in foreign exchange rates.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest expense during the three and six months ended&#160;December&#160;31, 2020 was primarily due to less debt outstanding.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Provision for/(Benefit from) Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2020 and 2019, the effective tax rate was (47.6) percent and&#160;21.0 percent, respectively. The change in the effective tax rate for the three months ended December&#160;31, 2020 compared to the prior period was primarily due to the $420 million benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss, partially offset by the adverse tax impacts from the opioid litigation charge during the six months ended December&#160;31, 2020, both described below.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the six months ended December&#160;31, 2020 and 2019, the effective tax rate was 259.7&#160;percent and 7.2&#160;percent, respectively. Included in the effective tax rate for the six months ended December&#160;31, 2020 was the $420 million benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss. Included in both the six months ended December 31, 2020 and 2019 were net tax benefits related to the treatment of the tax impacts of opioid litigation charges.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2020, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, is currently deductible on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss is being carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our provision for income taxes during the three months ended December&#160;31, 2020 included a $420 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to file for a federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our condensed consolidated balance sheet at December&#160;31, 2020. We also increased our non-current deferred tax liability by approximately $700 million during the six months ended December&#160;31, 2020 related to this matter.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effect of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $1.02 billion and $5.63&#160;billion pre-tax charges for the opioid litigation during the six months ended December&#160;31, 2020 and 2019, respectively, the net tax benefits are $35 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million and $469 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision for/(benefit from) income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid accrual during the three months ended September 30, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the six months ended December&#160;31, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent. The inclusion of the relatively lower tax benefit of the current fiscal year charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax expense increased by approximately $150 million during the three months ended December&#160;31, 2020 while the amount of tax benefit increased by approximately $300 million during the six months ended December&#160;31, 2020 compared to the tax impacts that would have been recognized without the opioid litigation charge and is expected to significantly increase our provision for income taxes during the remainder of fiscal 2021. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to the Condensed Consolidated Financial Statements&#8221; for additional information.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion; contractual obligations; tax payments; and current and projected debt service requirements, early extinguishment of debt, dividends and share repurchases as well as potential opioid litigation settlement payments associated with the Settlement Framework. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $3.7 billion at December&#160;31, 2020 compared to $2.8 billion at June&#160;30, 2020. At December&#160;31, 2020, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2020 cash from operating cash flow was $1.5 billion, which was driven by timing of payments to vendors, and is partially offset by $289 million paid in dividends and $174 million of capital expenditures. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer payments, inventory purchases and payments to vendors in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and equivalents balance at December&#160;31, 2020 includes $630 million of cash held by subsidiaries outside of the United States. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Financing Arrangements and Financial Instruments</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Credit Facilities and Commercial Paper</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity at December&#160;31, 2020 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;December&#160;31, 2020, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revolving credit and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter through December 2020, a consolidated net leverage ratio of no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021. As of December&#160;31, 2020, we were in compliance with this financial covenant. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At&#160;December&#160;31, 2020, we had total long-term obligations, including the current portion and other short-term borrowings, of&#160;$6.7 billion. During the six months ended December&#160;31, 2020, we early repurchased $40 million of the Floating Rate Notes due 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $2 million of the 2.616% Notes due 2022 with available cash. In connection with the early debt repurchases, we recorded a $1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss on early extinguishment of debt.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Capital Deployment</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with a tax benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss as described further in Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of the "Notes to Condensed Consolidated Financial Statements," we intend to file for a refund of $974 million, which we expect to receive within 12 months. Accordingly, we have recorded a current asset for this amount on our condensed consolidated balance sheet at December&#160;31, 2020. We also increased our non-current deferred tax liability by approximately $700 million during the six months ended December&#160;31, 2020 related to this matter.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Opioid Settlement Framework</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $6.59&#160;billion accrued at December&#160;31, 2020 related to certain opioid litigation, as further described within the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." Negotiations under the Settlement Framework continue regarding, among other things, the amount and timing for payment of the cash component. If a definitive agreement is reached, and subject to participation by states and political subdivisions, we expect the majority of payment amounts to be spread over 18 years. We cannot currently predict when those payments might begin, and it is possible that all or part may ultimately be made over a different time period, or not at all. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures during the six months ended December&#160;31, 2020 and 2019 were $174 million and $149 million, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On each of May 11, 2020, August 6, 2020 and November 5, 2020 our Board of Directors approved a quarterly dividend of $0.4859 per share, or $1.94 per share on an annualized basis, which were paid on July 15, 2020, October 15, 2020 and January 15, 2021 to shareholders of record on July 1, 2020, October 1, 2020 and January 4, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2021, our Board of Directors approved a quarterly dividend of $0.4859 per share, or $1.94 per share on an annualized basis, payable on April 15, 2021 to shareholders of record on April 1, 2021.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Other Items</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A in our 2020 Form 10-K addresses our contractual obligations and off-balance sheet arrangements, as of and for the fiscal year ended June 30, 2020. There have been no subsequent material changes outside the ordinary course of business to those items.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="iac867f2b870144f0baf920261d30f765_28"></div></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is a supplemental disclosure to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheet at June&#160;30, 2020. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2020 Form 10-K and our Form 10-Q for the quarter ended September 30, 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management&#8217;s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Loss Contingencies and Self-Insurance</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review contingencies and self-insurance accruals to determine whether our accruals and related disclosures are adequate. Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or outcomes can occur, assessing contingencies is highly subjective and requires judgments about future events.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#def3c0;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n connection with the opioid litigation as described further in the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A, we recorded pre-tax charges of $1.02&#160;billion and $5.63&#160;billion during the six months ended December 31, 2020 and 2019, respectively. Definitive terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Self-Insurance</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also self-insure </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through a wholly-owned insurance subsidiary</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for employee healthcare, certain product liability matters, auto liability, property and workers' compensation and maintain insurance for losses exceeding certain limits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Self-insurance accruals include an estimate for expected resolution of pending claims, defense costs, administrative fees, claims adjustment costs and an estimate for claims incurred but not reported. For certain types of exposures, we develop the estimate of expected costs to resolve each claim based on specific </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information related to each claim, if available. Other exposure estimates are based on an assessment of outstanding claims, historical analysis and current payment trends. For claims incurred but not reported, the liabilities are calculated and derived in accordance with generally accepted actuarial practices or using an estimated lag period.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:174%">Provision for Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2020, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss  in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, is currently deductible on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss is being carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our provision for income taxes during the three months ended December&#160;31, 2020 included a $420 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to file for a federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our condensed consolidated balance sheet at December&#160;31, 2020. We also increased our non-current deferred tax liability by approximately $700 million during the six months ended December&#160;31, 2020 related to this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the tax law; however, it is possible that the tax authorities could challenge these tax benefits. The actual tax benefit may differ materially from these amounts.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $1.02 billion and $5.63&#160;billion pre-tax charges for the opioid litigation during the six months ended December&#160;31, 2020 and 2019, respectively, the net tax benefits are $35 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million and $469 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision for/(benefit from) income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid accrual during the six months ended December 31, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charges during the three and six months ended December 31, 2020 were included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent. The inclusion of the relatively lower tax benefit of the current fiscal year charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax expense increased by approximately $150 million during the three months ended December 31, 2020 while the amount of tax benefit increased by approximately $300 million during the six months ended December&#160;31, 2020 compared to the tax impacts that would have been recognized without the opioid litigation charge and is expected to significantly increase our provision for income taxes during the remainder of fiscal 2021. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to the Condensed Consolidated Financial Statements&#8221; for additional information.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The "Overview of Consolidated Results" section within MD&amp;A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and, in most cases, determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Exclusions from Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors&#8217; assessment of the business for the reasons identified below:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">LIFO charges and credits</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Surgical gown recall costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes inventory write-offs and certain remediation and supply disruption costs arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">State opioid assessments related to prior fiscal years</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Reversals of these accruals have occurred when the underlying assessments were invalidated by a Court.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Restructuring and employee severance costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because they are not part of the ongoing operations of our underlying business. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Amortization and other acquisition-related costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity&#8217;s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Impairments and gain or loss on disposal of assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.13pt;text-decoration:underline">Litigation recoveries or charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount. During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss. Some pre-tax amounts, which contributed to this loss, relate to litigation charges. As a result, we allocated a portion of the tax benefit to litigation charges. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Transitional tax benefit, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the Tax Cuts and Jobs Act is excluded because it results from the one-time impact of a very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial performance. The transitional tax benefit includes the initial estimate and subsequent adjustments for the re-measurement of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect for each of the items listed above, other than the transitional tax benefit item, is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Definitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth rate calculation:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP operating earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: operating earnings/(loss) excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, and (7) litigation (recoveries)/charges, net. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP earnings before income taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: earnings/(loss) before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, and (8) loss on early extinguishment of debt. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP net earnings attributable to Cardinal Health, Inc.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: net earnings/(loss) attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt, each net of tax, and (9) transitional tax benefit, net. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP effective tax rate: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision for/(benefit from) income taxes adjusted for (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt, and (9) transitional tax benefit, (net) divided by (earnings/(loss) before income taxes adjusted for the first eight items)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliation</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.300%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings/(Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings Growth Rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(Loss) Before Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision for/(Benefit from) Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings/(Loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings/(Loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Growth Rate</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1,2</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Growth Rate</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">461</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">427</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(203)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">629</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">628</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">594</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">514</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transitional tax benefit, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.52&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(163)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(236)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(613)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">376</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,246</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,174</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">960</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.26</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,930)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,065)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,702)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.99)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.67&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,694&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,694&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,193&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.66&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transitional tax benefit, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Attributable to Cardinal Health, Inc.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">2&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six months ended December&#160;31, 2019, GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 294 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period. For the six months ended December&#160;31, 2019, non-GAAP diluted EPS is calculated using a weighted average of 295 million common shares, which includes potentially dilutive shares</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation (recoveries)/charges, net includes pre-tax charges of $1.02 billion and $5.63 billion recorded in the first quarter of fiscal 2021 and 2020, respectively, related to the opioid litigation. For fiscal 2021, the amount of tax expense increased by approximately $150 million during the three months ended December 31, 2020 while the amount of tax benefit increased by approximately $300 million during the six months ended December 31, 2020 compared to the tax impacts that would have been recognized without the opioid litigation charge and is expected to significantly increase the provision for income taxes during the remainder of the fiscal year. The net tax benefits associated with the opioid litigation charges are $35 million and $488 million for fiscal 2021 and 2020, respectively. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Litigation(recoveries)/charges, net also includes a tax benefit recorded during the three months ended December 31, 2020 related to a net operating loss carryback. Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, is currently deductible on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss is being carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The total net benefit was $420 million; however, for purposes of reconciling Non-GAAP financial measures, we allocated $394 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-insurance pre-tax loss related to opioid litigation claims versus separate tax adjustments. The tax benefit allocated to the separate tax adjustments of $26 million is included in non-GAAP measures. As the fiscal year 2020 federal return is finalized, both the tax benefit and the relative allocation may be adjusted. </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span><br/></span></div><div id="iac867f2b870144f0baf920261d30f765_40"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the quantitative and qualitative market risk disclosures included in our&#160;2020&#160;Form 10-K since the end of fiscal&#160;2020&#160;through&#160;December&#160;31, 2020.</span></div><div id="iac867f2b870144f0baf920261d30f765_43"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of December&#160;31, 2020. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of December&#160;31, 2020, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended December&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Implementation of Business Improvement Initiatives</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain business improvement initiatives underway that we expect to affect internal control over financial reporting. As a part of an ongoing effort to optimize and simplify our operating model, we are in the process of transitioning portions of our finance operations to a global professional services firm. Additionally, the Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating information systems. If either of these initiatives are not effectively implemented, or fail to operate as intended, it could adversely affect our internal control over financial reporting.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the proceeding described below, the legal proceedings described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, Melissa Cohen, a purported shareholder, filed an action on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In December 2019 and January 2020, similar complaints were filed in the U.S. District Court for the Southern District of Ohio by purported shareholders, Stanley M. Malone and Michael Splaine, respectively. In January, 2020, the court consolidated the derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. The amended consolidated derivative complaint seeks, among other things, unspecified money damages against the defendants and an award of attorneys' fees. In June 2020, the defendants filed a motion to dismiss the complaint.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the information in this Form 10-Q and the risk factors discussed in "Risk Factors" and other risks discussed in our 2020 Form 10-K and our filings with the SEC since June&#160;30, 2020. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.</span></div><div id="iac867f2b870144f0baf920261d30f765_55"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:14.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased&#160;(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid&#160;per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares<br/>Purchased<br/>as Part of Publicly Announced Programs&#160;(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate<br/>Dollar Value of<br/>Shares That May<br/>Yet be Purchased<br/>Under the Program&#160;(2)<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,538&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.46&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 2020</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.04&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,982</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49.88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">943</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Reflects common shares purchased through a rabbi trust as investments of participants in our Deferred Compensation Plan.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On November 7, 2018, our Board of Directors approved a $1.0 billion share repurchase program that expires on December 31, 2021 and as of December 31, 2020, we have $943 million authorized for share repurchases remaining under this program.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span><br/></span></div><div id="iac867f2b870144f0baf920261d30f765_61"></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Earnings/(Loss)</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMi0xLTEtMS0w_25298851-b43d-425a-b8ac-26cfa28fce46">41,541</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMi0zLTEtMS0w_599dc1c1-d5ea-49e3-b99f-b999cc6faa9f">39,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMi01LTEtMS0w_021e096f-8eb7-4440-aaaf-73c6f0e68422">80,606</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMi03LTEtMS0w_a42c2144-14c5-45a9-8fe9-1a50384193d4">77,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMy0xLTEtMS0w_16fecd0d-4e7c-472d-8114-2ef894d6ee5e">39,765</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMy0zLTEtMS0w_14f38e83-36be-42a2-abd0-6e934ea9517d">38,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMy01LTEtMS0w_a7481e1c-eb59-417a-8f76-ce33b8d4a2e2">77,115</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMy03LTEtMS0w_d3814ab0-e0bc-416c-96f4-dab25287e804">73,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNC0xLTEtMS0w_f9b47339-2a46-44d4-aec4-e00325dbf447">1,776</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNC0zLTEtMS0w_3c2532e1-faa7-4d1c-985b-5bf4d6acb624">1,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNC01LTEtMS0w_a50d7ef2-2281-4729-ae23-4ee3d5cade67">3,491</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNC03LTEtMS0w_399882e0-0f64-4200-9206-a9e7ada02568">3,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution, selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNy0xLTEtMS0w_66b38d36-62fe-4316-8e94-6c984db1fd0d">1,147</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNy0zLTEtMS0w_b017a8c0-73d3-4eb8-9445-18415a3a2dd8">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNy01LTEtMS0w_fb932573-83e2-4cb2-a64e-b0a5f5888351">2,284</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNy03LTEtMS0w_30afedbe-ab76-4d45-9f99-f4d4ef9a4e84">2,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOC0xLTEtMS0w_1d49d59e-d4f6-4531-a0fc-7af0ef528c35">20</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOC0zLTEtMS0w_532b6077-e6f6-481b-a9ce-b8f2e403829d">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOC01LTEtMS0w_a3def86f-b09a-4b55-9e80-4936bb65d333">57</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOC03LTEtMS0w_b417d94f-b1d3-4834-afca-0dd321a4ac89">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOS0xLTEtMS0w_98f02279-0f7a-4d6e-9813-83b65bf36c6f">116</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOS0zLTEtMS0w_d9cf8045-8bdd-46a9-aab1-abd1578f28b4">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOS01LTEtMS0w_b513cf24-776e-43d8-af84-d2683b5e6125">234</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOS03LTEtMS0w_c5c42528-adaf-4117-ab8c-8bf901c0bdb8">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTAtMS0xLTEtMA_017ea4f6-7b9e-4864-842f-ac75983e6e8e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTAtMy0xLTEtMA_5db294a2-f670-40be-863f-f84340cda42d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTAtNS0xLTEtMA_ee813a46-a5aa-4654-9cd4-bdbe3ade0353">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTAtNy0xLTEtMA_54930c21-39e4-4170-8d9f-2b00e17ba8e9">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTEtMS0xLTEtMA_056213ef-62d2-4518-9565-099ea6cfb147">32</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTEtMy0xLTEtMA_87033f3a-f6ec-4463-9bd0-d1ec1fa80baa">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTEtNS0xLTEtMA_d1445ec0-c54b-4e68-bca6-a1a06d513982">1,070</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTEtNy0xLTEtMA_8164fa97-1770-48e1-9329-beddbb7a2558">5,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating earnings/(loss)</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTItMS0xLTEtMA_5cc83a94-de18-4489-a607-2f39e4ae3a3c">461</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTItMy0xLTEtMA_b64ce230-267d-42e9-9e7c-70da5216480a">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTItNS0xLTEtMA_44c7d799-3968-4671-a0c8-4f900e3ffc0c">163</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTItNy0xLTEtMA_4b3caae6-162a-4c95-b59f-8bf13a9ce45d">4,930</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTQtMS0xLTEtMA_b6778388-4ff3-4846-9eb0-a142c144d8ae">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTQtMy0xLTEtMA_88ed116c-ba91-4b2c-a2b5-fd325b7ebce9">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTQtNS0xLTEtMA_acbabe62-4f54-442c-ab66-2fd62372c2f1">19</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTQtNy0xLTEtMA_bd6bf353-6d14-44dc-8996-8affcdd933ab">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTUtMS0xLTEtMA_3bcca4a6-399b-43b3-8007-2da2526b3350">46</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTUtMy0xLTEtMA_d58619d0-fe30-42c1-86a9-74289eb1f05c">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTUtNS0xLTEtMA_737cd494-836e-4ae4-9598-429aaa599571">91</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTUtNy0xLTEtMA_cefbeb2f-9153-499f-a66a-7cbd113b7001">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTYtMS0xLTEtMA_b0b3b784-e3d9-42f3-916f-8753f049c893">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTYtMy0xLTEtMA_aacbbd47-72e0-41e0-bb7f-f610b718da97">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTYtNS0xLTEtMA_37c1445f-af69-4651-a61e-45a6f47601cd">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTYtNy0xLTEtMA_e0a8b30a-55e9-4f19-a3a3-657b74926385">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings/(loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTctMS0xLTEtMA_c48ed16d-a11f-4b1b-867b-59f9290b5550">427</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTctMy0xLTEtMA_cc8fbad7-827e-4518-8cb2-e50f86ec2692">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTctNS0xLTEtMA_4c611f5f-b047-45f9-b49b-27f19ec3866c">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTctNy0xLTEtMA_2979cfaa-2eea-45d5-a070-190c8e8c255e">5,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for/(benefit from) income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTktMS0xLTEtMA_38177116-b29d-4c02-bc35-fbe743b13c8a">203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTktMy0xLTEtMA_0d08e31a-6c21-432a-ad35-0da87a4c5262">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTktNS0xLTEtMA_3cf7f183-6d02-4a2e-b7e3-69e5942863e7">613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTktNy0xLTEtMA_3f9faa73-0a54-4a2e-8534-0181fcdd8b90">364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjAtMS0xLTEtMA_05b749b6-efbb-45e6-a2ac-0b62f1163517">630</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjAtMy0xLTEtMA_ccbff9b9-aad2-4da1-b721-5321e60bad73">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjAtNS0xLTEtMA_45d94a1f-88dd-4849-8417-f554bd7e3e21">377</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjAtNy0xLTEtMA_0ea03550-01f8-431e-ad67-6f6706f833de">4,701</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net earnings attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjUtMS0xLTEtMA_3eb2b372-1c8a-42b5-8109-9067790c4f31">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjUtMy0xLTEtMA_d88656f1-d0de-404f-97cc-c10015089ad9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjUtNS0xLTEtMA_8c9e147f-2d1e-4f92-a344-6b248a79fef6">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjUtNy0xLTEtMA_19e7e849-aaee-45c9-b3cd-e9e6fdb4fcca">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net earnings/(loss) attributable to Cardinal Health, Inc. </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjYtMS0xLTEtMA_9b28f5eb-4bb3-4438-a5dc-ebc1433d96c4">629</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjYtMy0xLTEtMA_f8c42494-9f5c-4f05-adad-e438d75563d0">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjYtNS0xLTEtMA_bf32d39f-2888-4757-9f5a-a51a091a165c">376</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjYtNy0xLTEtMA_ed48cbdf-b16d-486e-83be-7e9b3ca64412">4,702</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(loss) per common share attributable to Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjktMS0xLTEtMA_a292dd8a-5a4f-451c-8371-21242f1331b7">2.14</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjktMy0xLTEtMA_c915b76f-5e07-4f9b-b3e6-2b658311809d">0.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjktNS0xLTEtMA_a3f95be4-e6fc-486e-97d3-92d496c713d3">1.28</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjktNy0xLTEtMA_90030e0c-272e-4268-a823-d1e2b513b489">15.99</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzAtMS0xLTEtMA_94eaf558-d352-405c-8c5d-2921ded0b97b">2.13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzAtMy0xLTEtMA_67ccc16a-b6c4-401f-a3a4-eba37aefb699">0.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzAtNS0xLTEtMA_a17c62f8-48c2-4144-b58c-ef2eb21e3fe3">1.27</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzAtNy0xLTEtMA_3758ae09-ba96-456d-ba1b-521404fe65ab">15.99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzMtMS0xLTEtMA_1704f9c4-97cf-4c41-a2a7-7281a037916b">294</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzMtMy0xLTEtMA_09bcb73d-9c60-44e5-bd44-7a97cf70fc0b">292</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzMtNS0xLTEtMA_1996e7b9-e7fd-4e79-a193-ddf4a069211a">293</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzMtNy0xLTEtMA_38fdc708-b27d-43ac-9b62-45439a13633c">294</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzQtMS0xLTEtMA_da7e3ba7-22f7-4abb-9b53-3939e94f31a4">295</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzQtMy0xLTEtMA_09985a6e-4e31-42f2-993f-2c4f895da606">294</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzQtNS0xLTEtMA_1e781454-f510-4cb0-ba13-d03a3443f663">295</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzQtNy0xLTEtMA_c633cc11-19d0-416e-a16a-685839df02ad">294</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared per common share</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzYtMS0xLTEtMA_08d782e0-ecd0-44a5-9540-1afaa69a41f6">0.4859</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzYtMy0xLTEtMA_87dfb523-0eed-4fc1-b9be-ce7cd2670061">0.4811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="4" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzYtNS0xLTEtMA_8080d569-a904-46fc-adf6-dfeba86bd1c3">0.9718</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="4" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzYtNy0xLTEtMA_d6710252-85d2-4916-ae94-646c4d0b005f">0.9622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income/(Loss)</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMi0xLTEtMS0w_47e22d89-1879-415d-919b-90c4e07189f7">630</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMi0zLTEtMS0w_db68d73c-9c03-4fc6-bb1f-026e95349789">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMi01LTEtMS0w_f1fc5cb8-552c-4966-943c-29ad9d536090">377</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMi03LTEtMS0w_0a2fd817-f00e-4808-ad80-e858cccf8160">4,701</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNS0xLTEtMS0w_4e44391d-4a30-416e-a08f-8ed1b0a0989f">21</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNS0zLTEtMS0w_6ef172e5-8c6c-40b7-acee-5c7fcf9f8d80">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNS01LTEtMS0w_0f4185ac-e9bc-4831-a3a4-b275e9036cfe">33</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNS03LTEtMS0w_445d1159-1e44-406a-8a27-2f5aedac8daf">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain/(loss) on derivative instruments, net of tax</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNy0xLTEtMS0w_614b3d0e-83d1-44d7-9054-684b4d9dd47f">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNy0zLTEtMS0w_cc39116e-af96-4e68-89a5-279def6a3b6b">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNy01LTEtMS0w_14da8600-bb2b-4277-b851-3fd059de887d">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNy03LTEtMS0w_aea7b612-90c6-4197-9464-e274f68b88b6">6</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income/(loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfOC0xLTEtMS0w_2785b137-a168-41d7-9c76-71e9ddf7f0b3">34</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfOC0zLTEtMS0w_dd4a1478-fafd-4a9d-894a-66550d9ca8c1">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfOC01LTEtMS0w_97c10711-7b0d-45d2-8af6-f157b71c8ab3">51</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfOC03LTEtMS0w_57972ed0-e4f8-46ce-9a75-b16a1ecf1c24">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive income/(loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTAtMS0xLTEtMA_839c8f40-7c7f-4d2e-a9a5-5d2a7285d855">664</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTAtMy0xLTEtMA_e9c91b61-0efc-499d-865e-3c9a722400aa">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTAtNS0xLTEtMA_24cca5d6-e30c-4122-85cc-37cc750ea52e">428</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTAtNy0xLTEtMA_a50eb2dd-37d2-49ab-9ab1-e8548e83ca69">4,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTItMS0xLTEtMA_b2728767-d3c8-4bee-a030-2764bd22e450">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTItMy0xLTEtMA_e7206e1c-9b0f-4b06-bc7e-20ccb0425f93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTItNS0xLTEtMA_50c6c1e3-36ab-453f-b601-c72362c3875a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTItNy0xLTEtMA_d9dc5e94-b54c-4af5-b488-a049aee8d43a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total comprehensive income/(loss) attributable to Cardinal Health, Inc. </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTQtMS0xLTEtMA_f07cb22b-b51b-4422-a1c3-52ae29b4c07e">663</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTQtMy0xLTEtMA_b57b9b9d-6876-4a12-b691-06d48e414b88">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTQtNS0xLTEtMA_e20bcdca-0f45-4a3d-8e6d-1e3b5f31b58a">427</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTQtNy0xLTEtMA_2ec5aff7-73c8-4500-9af8-e6a5e0d82e3f">4,726</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMy0xLTEtMS0w_c45d2178-d29a-423b-ac51-5506b005b4de">3,737</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMy0zLTEtMS0w_51345052-4229-452a-97ce-ed10cdabc724">2,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfNC0xLTEtMS0w_9b779b39-c2c7-4cb4-af23-a09801970843">8,728</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfNC0zLTEtMS0w_97a5ce97-1c86-401b-a8de-b2931f99865c">8,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfNS0xLTEtMS0w_12f4e410-6da7-48e9-9943-f5537c70dde5">14,443</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfNS0zLTEtMS0w_c4fd0bea-83af-4034-963a-87bec28a3363">13,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfNy0xLTEtMS0w_7bc2ce45-6576-4285-b9a3-9030e81e0e03">3,205</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfNy0zLTEtMS0w_94fff864-2662-4a71-a3f9-04af904ec748">1,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfOC0xLTEtMS0w_8c3bdf2c-0f38-484e-9646-fe5a0c346a72">30,113</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfOC0zLTEtMS0w_58828c97-b67b-4484-ba53-607f3b56cbe7">25,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTAtMS0xLTEtMA_185bd42d-005b-4cc0-bbe6-103b8093c9c6">2,386</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTAtMy0xLTEtMA_6f4b7320-6dd2-483a-8502-17311b3f2836">2,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTEtMS0xLTEtMA_ee4742f3-3b1e-48a0-89d4-9f8e45d03405">11,102</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTEtMy0xLTEtMA_c1f2466b-4d74-4729-8c22-9c8e4428ea56">11,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTMtMS0xLTEtMA_e9a0de8b-7161-4221-9aea-f42acc7ca306">1,118</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTMtMy0xLTEtMA_56181167-5acf-4eb8-8703-99d57c8b9e52">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTQtMS0xLTEtMA_9405130b-6e12-41d6-975a-37c33c8488d9">44,719</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTQtMy0xLTEtMA_3cc37948-3e36-4f6c-b88f-030d05e0c982">40,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTgtMS0xLTEtMA_148fa4a2-857b-4027-9da3-e9726179fe48">23,235</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTgtMy0xLTEtMA_b7dbc57a-a0fb-48a6-9bfe-63836fcc6721">21,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations and other short-term borrowings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTktMS0xLTEtMA_053e648f-efe8-45d1-9b75-786cf9487f4d">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTktMy0xLTEtMA_e269c532-9d7b-4d30-8f32-52ad94880221">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjAtMS0xLTEtMA_03840fc2-17c0-43df-845d-15a1d04d854f">2,502</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjAtMy0xLTEtMA_b8e7cfbc-3768-4a44-93bc-be3dbe1f81a0">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjEtMS0xLTEtMA_87cd4e36-b8fb-4489-a165-9a63b35f9574">25,750</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjEtMy0xLTEtMA_7adc1b04-adba-4ed3-bbda-405e7264b2fe">23,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjMtMS0xLTEtMA_48d6fe47-17b3-4bfe-a62c-a83407e3ce32">6,720</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjMtMy0xLTEtMA_5a968977-6c86-4bcf-bd38-dd2d91a70430">6,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjQtMS0xLTEtMA_59a77bb4-5b39-4c43-84c5-82ec680e2563">10,274</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjQtMy0xLTEtMA_d6f314c6-180e-4a8b-ac2d-c31d1ab48582">8,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;<ix:nonFraction unitRef="shares" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjgxNmY4YTk0MjQ0YjRkMTE5MTMwMGY1ZmYzMGQ0NWM3XzMyOTg1MzQ4ODM0NTM_0b4cf445-2893-406e-9016-af53c6e3dddc"><ix:nonFraction unitRef="shares" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjgxNmY4YTk0MjQ0YjRkMTE5MTMwMGY1ZmYzMGQ0NWM3XzMyOTg1MzQ4ODM0NTM_66e24bbd-d466-4593-ae38-c4f0858bf472">500</ix:nonFraction></ix:nonFraction> thousand shares, Issued&#8212;<ix:nonFraction unitRef="shares" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjgxNmY4YTk0MjQ0YjRkMTE5MTMwMGY1ZmYzMGQ0NWM3XzMyOTg1MzQ4ODM0NjI_88368891-df3a-49ab-a50c-9163304063a1"><ix:nonFraction unitRef="shares" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjgxNmY4YTk0MjQ0YjRkMTE5MTMwMGY1ZmYzMGQ0NWM3XzMyOTg1MzQ4ODM0NjI_8d5d39cd-6af4-4f5b-b70f-c79887451124">none</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjgtMS0xLTEtMA_8433447c-dd75-4127-8663-bb19643b4e3d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjgtMy0xLTEtMA_551056a7-54ae-4b39-aec9-609ce807a170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;<ix:nonFraction unitRef="shares" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNTc4YTU4YmZjMDQ1OGI5MGQ1YjVkYmM3OGI0ZWRkXzMyOTg1MzQ4ODM2MjA_170b9842-6c1d-43a3-98db-16cfb3027d3e"><ix:nonFraction unitRef="shares" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNTc4YTU4YmZjMDQ1OGI5MGQ1YjVkYmM3OGI0ZWRkXzMyOTg1MzQ4ODM2MjA_ff6f0b38-869d-4b2b-ab6f-d135494b6b38">755</ix:nonFraction></ix:nonFraction> million shares, Issued&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNTc4YTU4YmZjMDQ1OGI5MGQ1YjVkYmM3OGI0ZWRkXzMyOTg1MzQ4ODM2MDQ_1b76026c-ecc6-4878-bc47-0b5dc889a7da"><ix:nonFraction unitRef="shares" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNTc4YTU4YmZjMDQ1OGI5MGQ1YjVkYmM3OGI0ZWRkXzMyOTg1MzQ4ODM2MDQ_70c3dd72-bf06-42c1-b959-9129273dcb08">327</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> and June 30, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzAtMS0xLTEtMA_de131e80-38b3-4852-9f75-42fd7bc93535">2,778</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzAtMy0xLTEtMA_3777223f-da31-4e5a-9495-8651b564a4c1">2,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzEtMS0xLTEtMA_6ad79bec-daf5-4415-b6c3-829db27c9600">1,255</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzEtMy0xLTEtMA_46bac30e-4441-4780-ba37-5a26195b4b15">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares in treasury, at cost: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlZjFiZThiYzA2MzRlM2U4OTcxNDk3M2I1NjhjNTMwXzMyOTg1MzQ4ODM2NTQ_2929e101-f88c-4dd4-9c2d-b7719d850ff3">33</ix:nonFraction> million  </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">shares and <ix:nonFraction unitRef="shares" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlZjFiZThiYzA2MzRlM2U4OTcxNDk3M2I1NjhjNTMwXzMyOTg1MzQ4ODM2NDg_2353fb84-be87-412e-bb57-9cbb41cf61e5">34</ix:nonFraction> million shares at</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> December 31, 2020</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> and June 30, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzItMS0xLTEtMA_5e1eff8b-a737-49cc-96f7-05f03c53de76">2,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzItMy0xLTEtMA_8cc007c0-8761-4cb4-adad-3529c8f85b9a">2,066</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzMtMS0xLTEtMA_91d58854-68a3-4bbe-9408-83aa3c16b2d4">53</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzMtMy0xLTEtMA_d2d39451-ae81-4ee1-94d7-86183e24a691">104</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cardinal Health, Inc. shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzQtMS0xLTEtMA_511d331b-8562-407a-8d7e-c97e6d06f0ec">1,971</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzQtMy0xLTEtMA_604b049f-62e8-4963-8bca-079e39d1b8fa">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzUtMS0xLTEtMA_d255b58d-4d1c-4d17-bad2-136f0b0f03b6">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzUtMy0xLTEtMA_1d71ec0c-0212-4c37-a08b-cba93d0be1b3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzYtMS0xLTEtMA_e342ea57-34fb-45ed-b5b9-a9c228c2d1aa">1,975</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzYtMy0xLTEtMA_7f2708ea-a49f-49c9-ad12-6e9992eec738">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzctMS0xLTEtMA_514a4fcf-a9ee-43ad-acd1-a88f3448251c">44,719</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzctMy0xLTEtMA_0a64aa49-9652-4321-bcb1-1e4a066cb0db">40,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders' Equity</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Shareholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf177919053f4d84b5deede4be106b52_I20200930" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy0xLTEtMS0w_0b099dfb-411c-4eef-a4f6-ff9bcb5e85e4">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf177919053f4d84b5deede4be106b52_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy0zLTEtMS0w_f021a42b-24d4-4f47-bc9b-65bdf23b4eaa">2,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d920529cbde451191352192e3af656c_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy01LTEtMS0w_5adcb09e-34fa-481f-b874-129d7d2ab77d">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3ea5286e8327464ba54819290fd52747_I20200930" decimals="-6" sign="-" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy03LTEtMS0w_e7ec0b27-7d43-4e7d-a48e-517ffa4a7ec2">33</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ea5286e8327464ba54819290fd52747_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy05LTEtMS0w_0715d916-2882-4ae5-b5da-e547338d9c29">2,022</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ae2531be3ff4d52a622e624ada4da07_I20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy0xMS0xLTEtMA_5532ace7-af73-4193-8584-c01b8e534226">87</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf5ab90557c4000a09c6f27f8f43161_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy0xMy0xLTEtMA_537be243-0e58-4f11-bca8-815842b93a6d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i330e68ab5e5340ebadc011e5a0a59586_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy0xNS0xLTEtMA_1ee54e14-6771-4248-a70d-4d5316c3a542">1,425</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNC01LTEtMS0w_9b28f5eb-4bb3-4438-a5dc-ebc1433d96c4">629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866db22bd82141a4a400612301c75ffb_D20201001-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNC0xMy0xLTEtMA_e73d0613-2ce8-407c-a2a1-272bbbc0bbec">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNC0xNS0xLTEtMA_b444b647-462d-4f9f-9e83-00dccf9035ac">630</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNS0xMS0xLTEtMA_2785b137-a168-41d7-9c76-71e9ddf7f0b3">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNS0xNS0xLTEtMA_1089d6d9-f3da-49cd-a956-eb11536d258d">34</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0f0b3868edd4abb9835771227d980e0_D20201001-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNy0xLTEtMS0w_60838326-82ad-4835-a912-4a82e50f0097">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f0b3868edd4abb9835771227d980e0_D20201001-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNy0zLTEtMS0w_32ae3847-7342-4f65-a24f-20a235d79faa">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02b85a2b00dd4f0491c62b22e62fdd52_D20201001-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNy03LTEtMS0w_6de65b8a-e965-4db2-9161-a010518e09da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b85a2b00dd4f0491c62b22e62fdd52_D20201001-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNy05LTEtMS0w_0f4e9602-061c-41c5-b018-9616be0f3177">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNy0xNS0xLTEtMA_f4329832-cda1-4ac7-8247-7e63e7f07ced">30</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief43f820ca8b46dbb807687b9aba78b0_D20201001-20201231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfOS01LTEtMS0w_7347a18b-e122-4145-9f6e-f091162d289e">144</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfOS0xNS0xLTEtMA_57c35d20-ba9b-467b-8179-a34630bb6814">144</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f0b3868edd4abb9835771227d980e0_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTAtMy0xLTEtMzQ5OQ_6b9f2156-a24f-4322-b033-66fc43871390">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief43f820ca8b46dbb807687b9aba78b0_D20201001-20201231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTAtNS0xLTEtMA_3e78a274-3a19-485f-b896-134e00cde9c2">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866db22bd82141a4a400612301c75ffb_D20201001-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTAtMTMtMS0xLTA_26cadf08-b428-4352-ac6d-30c63fc9ed49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTAtMTUtMS0xLTA_a9e7673b-d0d8-42c9-b390-45381204996e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i333fddf2954c4f8f84d124aceab9eb34_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItMS0xLTEtMA_380428a0-87f7-42bc-9c4b-4be7ea456444">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i333fddf2954c4f8f84d124aceab9eb34_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItMy0xLTEtMA_3dd39e3d-27dc-4780-b9ff-404968d72ad2">2,778</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43031c026d442a18ff9382d1b9cffc6_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItNS0xLTEtMA_b32ed5ee-807c-41cf-b6c6-6e1410dd4d83">1,255</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2c921ca8f3fd4b668c26209f32686128_I20201231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItNy0xLTEtMA_217984dc-2ca8-4a3c-968d-1a068af21007">33</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c921ca8f3fd4b668c26209f32686128_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItOS0xLTEtMA_c17aaa45-776a-43cb-9880-18eeeb397309">2,009</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic337060106e84e76a53c24d5a516bded_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItMTEtMS0xLTA_f9d9c4ad-a441-489a-b46f-9883c550b302">53</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531c55176bb64260a4950658a062d0e1_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItMTMtMS0xLTA_c00f07f0-4d8c-4b5e-9466-cd081ced6aaf">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItMTUtMS0xLTA_ba4f5027-1f3f-4923-9809-e69c7425cad9">1,975</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1cd1437e597b4e2682afe89f0b8f38a1_I20190930" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS0xLTEtMS0w_2e1772bc-524f-4f29-9837-412a225b982e">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd1437e597b4e2682afe89f0b8f38a1_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS0zLTEtMS0w_e8167df6-538d-48c1-95c5-8bd604e7fd00">2,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe8fb0429c640549ebd225f00c39fdd_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS01LTEtMS0w_9a362ab7-ab9d-4df7-94d0-87a1b54d3a91">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i90bccc700f344156818dd2a91922ae30_I20190930" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS03LTEtMS0w_60fbf962-bf68-43f3-ab07-4212b5606112">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90bccc700f344156818dd2a91922ae30_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS05LTEtMS0w_5dd22dce-6ba0-41d2-89f9-052842144584">2,039</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08f87960dc81422e8cc8681a4821d475_I20190930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS0xMS0xLTEtMA_ff6fd45a-0b9e-4ba9-9a2c-05665f43e393">101</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3530dfeec0384b169ee4ba603c672780_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS0xMy0xLTEtMA_f12a92ec-237f-4416-b8cf-ef91f462b1db">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c429f356e364a318686f6a96b4c0d70_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS0xNS0xLTEtMA_1c01113f-afaf-41f9-b8f8-0ad121f8e730">903</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMi01LTEtMS0w_75380183-d6c7-4521-b907-d6a48d0659ac">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0d9a0a1c01475c97b8ad225ba6ed8a_D20191001-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMi0xMy0xLTEtMA_be85fbfa-e5f6-43fe-aa22-d5c670c1687f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMi0xNS0xLTEtMA_c82ac67f-e5e4-4809-990b-5045961098cd">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i087a2162c6ab4ee08231b8375275a66f_D20191001-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMy0xMS0xLTEtMA_2e90acb2-fc9d-40e7-abfd-3923234add3a">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMy0xNS0xLTEtMA_aaa6e2f3-6fa9-4588-b592-70779050d0d9">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic709b0f6e31348dc92cb361418750b1a_D20191001-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNS0xLTEtMS0w_17cefcf7-eb8b-45fa-b4fa-e338cfd092a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic709b0f6e31348dc92cb361418750b1a_D20191001-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNS0zLTEtMS0w_3a5daa1c-a30a-421e-a4f0-c737bfa75212">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i356ad0db94fd4af2945d43260c52b004_D20191001-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNS03LTEtMS0w_0b2b78fb-616c-4542-9dc0-3a9b5f906ebe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i356ad0db94fd4af2945d43260c52b004_D20191001-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNS05LTEtMS0w_a8c96be7-cd6e-4f69-bcf8-6e4dabb4fcb0">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNS0xNS0xLTEtMA_89b7fbdf-0ea4-4f3f-87af-8f7b879a9e98">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic709b0f6e31348dc92cb361418750b1a_D20191001-20191231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNi0zLTEtMS0w_8096c90b-b7ba-4ce9-b2aa-a59058028d0a">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i356ad0db94fd4af2945d43260c52b004_D20191001-20191231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNi03LTEtMS0w_f925e0d5-786b-4003-830c-5b29ec375d84">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i356ad0db94fd4af2945d43260c52b004_D20191001-20191231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNi05LTEtMS0w_b596da7b-aaa9-466d-9dc7-cae3e311ecd6">70</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNi0xNS0xLTEtMA_f77d5a77-093f-4b13-85a8-33a343d3d78a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a37151dd9974055b9fd8a3b9f329fda_D20191001-20191231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNy01LTEtMS0w_30b11832-ef18-4460-9a86-5362ed44b659">143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNy0xNS0xLTEtMA_12e04309-4335-4f2d-8d2e-bf2f42bcd1eb">143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a37151dd9974055b9fd8a3b9f329fda_D20191001-20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfOC01LTEtMS0w_e57682cf-698f-4cf5-959b-3bf94c4496d1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0d9a0a1c01475c97b8ad225ba6ed8a_D20191001-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfOC0xMy0xLTEtMA_b8e0e9ca-6d72-4bc4-b2ad-1d1f0a247dc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfOC0xNS0xLTEtMA_5823c5be-e6c7-4681-8deb-0140bc2152dd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ffbcc7b8b47419fafc54db6c65fa67c_I20191231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtMS0xLTEtMA_43fa44b6-5009-4671-a06f-0caf409c41ab">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ffbcc7b8b47419fafc54db6c65fa67c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtMy0xLTEtMA_2570386d-9bb4-4552-9e31-353248b8ec12">2,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961814e0fb934b26a59874c0a47b5c36_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtNS0xLTEtMA_259c1a07-0f77-4d2c-8e9e-ee3dbd524a29">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i34bce33b39294b5990a6d2671d45efc1_I20191231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtNy0xLTEtMA_5dc989c8-12c6-44f1-8ca8-d1ee66d10ad9">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34bce33b39294b5990a6d2671d45efc1_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtOS0xLTEtMA_cad68161-f213-4985-9abf-54fe1ca36e46">2,099</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a67a68103174862933d81e69761227a_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtMTEtMS0xLTA_1d264911-24b7-4828-9d70-0d9da9eb1b6b">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae7680d35a94fe791314d93518ad333_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtMTMtMS0xLTA_f28a690b-c925-42d9-9c0d-133c51c4d8f5">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dfaa9ce43d4c8dbe8e43f793325ab5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtMTUtMS0xLTA_5291704d-6628-485c-8271-4182b2db6059">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc62359854904e73a95bee6e706c2f64_I20200630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy0xLTEtMS0w_63b10f4d-bea4-4144-b9d9-4e3e7f6c756e">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc62359854904e73a95bee6e706c2f64_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy0zLTEtMS0w_d85fe81f-6c99-42d7-9e90-e908f772131d">2,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02eca4589f2a4542b34a4ac4b0e54bbc_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy01LTEtMS0w_141d099c-a70c-4929-a478-0873b75a593e">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i327c9e14b86548eeaa15e0b1195a1713_I20200630" decimals="-6" sign="-" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy03LTEtMS0w_d686c2f8-dd07-4d5c-9a25-1a93eccb40b7">35</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i327c9e14b86548eeaa15e0b1195a1713_I20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy05LTEtMS0w_bd59eb4d-d66c-4dc1-9eea-046469beaa4b">2,066</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d7546c5d1f84a4a8f9ddb1310f520fc_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy0xMS0xLTEtMA_31b275f4-10a8-4a74-9570-05a18bd82340">104</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d7259b2a09452ea238e9d70eb94fcb_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy0xMy0xLTEtMA_d3cd03eb-5b00-4c19-a888-f1372fa44ee9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy0xNS0xLTEtMA_2959b142-0216-4b6d-9a74-43310812bfb3">1,792</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNC01LTEtMS0w_75e0ab69-0e13-49ec-959b-6e7e3705f6be">376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b3c71ac478a4d02806d3987db7fca7c_D20200701-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNC0xMy0xLTEtMA_4e39e17b-ec64-4d7a-8b69-e8c4c8cb263a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNC0xNS0xLTEtMA_c182e57e-e794-4df9-b83c-d279760ddb78">377</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342dbbcc001646b78a3682ec6c4a043a_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNS0xMS0xLTEtMA_6e305aa7-940e-402e-9e3b-54fd79fa96f3">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNS0xNS0xLTEtMA_5bace3b2-df60-46ec-a081-cbafe2229b17">51</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ac4657e05a9499ab00fb27b5751039b_D20200701-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNy0xLTEtMS0w_b8270b07-914b-4bf6-a6f0-3fe19b7207f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ac4657e05a9499ab00fb27b5751039b_D20200701-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNy0zLTEtMS0w_a1c2ca39-0122-4574-9493-cf20659af5b8">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNy03LTEtMS0w_d61bb805-3ab2-4508-b825-c8060436af7a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69b8b80a81a246308be8e9d7ae9fb68e_D20200701-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNy05LTEtMS0w_cdd525f5-4e69-45fb-a8a7-efe9854db8f5">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNy0xNS0xLTEtMA_cbfd2e69-e302-490b-9cc9-20e72685315c">46</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c695c989c1c488a9a822944847a51bb_D20200701-20201231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfOS01LTEtMS0w_ad068914-1f2f-4805-89ab-2b115190f4af">289</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfOS0xNS0xLTEtMA_531e786b-5f5f-4378-aab3-422cce467379">289</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c695c989c1c488a9a822944847a51bb_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTAtNS0xLTEtMA_83d4bd2c-40ea-49ce-8db4-1068e0998a45">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b3c71ac478a4d02806d3987db7fca7c_D20200701-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTAtMTMtMS0xLTA_278a3f9b-428e-412b-97e7-e5caa1091e99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTAtMTUtMS0xLTA_fad3d4f2-07eb-4621-97f0-29dc184d6d19">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i333fddf2954c4f8f84d124aceab9eb34_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItMS0xLTEtMA_f70a6e86-529d-49da-b232-9c8024e09906">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i333fddf2954c4f8f84d124aceab9eb34_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItMy0xLTEtMA_1b00fa32-eff7-448d-bd5e-08d686ad40cf">2,778</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43031c026d442a18ff9382d1b9cffc6_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItNS0xLTEtMA_64014fd8-bf16-484c-b522-5a6212e51531">1,255</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2c921ca8f3fd4b668c26209f32686128_I20201231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItNy0xLTEtMA_21fdd407-3e5b-445e-8c9f-bdc8ddec2499">33</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c921ca8f3fd4b668c26209f32686128_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItOS0xLTEtMA_12fbd443-6735-4d5d-b14f-42f249d697fc">2,009</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic337060106e84e76a53c24d5a516bded_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItMTEtMS0xLTA_23df502c-ff3c-4430-a664-5c573ca30dd2">53</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531c55176bb64260a4950658a062d0e1_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItMTMtMS0xLTA_e676d70f-db1d-4736-84f0-211e95f85cb2">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItMTUtMS0xLTA_93b1a616-807c-46d2-8504-df12c42bdf22">1,975</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2019</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7239edd43644a128d30e8bbd0ab2a9e_I20190630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS0xLTEtMS0w_5eb58318-3122-4c8d-a582-95912b5b4701">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7239edd43644a128d30e8bbd0ab2a9e_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS0zLTEtMS0w_703d6432-fa47-4999-b7da-cf61e0eb3ec0">2,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964a6019a431419c8e09883bc4b9d02c_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS01LTEtMS0w_5f18e710-ef15-41bd-8d74-c456d7e1c354">5,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i41b5d7dfd6a54361850263e4fd529847_I20190630" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS03LTEtMS0w_be41f600-f184-4200-84d8-cac7cdcac69f">28</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b5d7dfd6a54361850263e4fd529847_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS05LTEtMS0w_ce775084-268f-4462-bbd3-475ece6799e8">1,790</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae7a3375f4c4b319354a025e78a9375_I20190630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS0xMS0xLTEtMA_f926453c-eb87-4e32-b340-f41557fb03e4">79</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7285527fa33149449338e908558152ee_I20190630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS0xMy0xLTEtMA_37a5e891-54d3-4fac-bd1d-edd23ba81097">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9263daec240f40e18bbc79b563561d69_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS0xNS0xLTEtMA_34fb0adb-bc99-4c8a-bece-e6dc2b782746">6,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMi01LTEtMS0w_6196a363-b213-4ca9-82e7-0b0439b2d112">4,702</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6044c7ef014ad7b58ff6abb8cf7620_D20190701-20191231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMi0xMy0xLTEtMA_74366959-ec60-4c47-860f-542f8fa4adc8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMi0xNS0xLTEtMA_f25a9773-733b-4e91-8937-a0bd4038468d">4,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdfa6e7ff1fd4ff4894046a2aef75fa0_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMy0xMS0xLTEtMA_77d1216e-a3ba-44ac-bdfc-36fb02144ca7">24</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMy0xNS0xLTEtMA_d6e32505-8167-4d26-9095-232f802e4e1f">24</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i316bc31c1a6f4eb1a59f8bfb2c2df15c_D20190701-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNS0xLTEtMS0w_ab889fbb-2fa6-4252-8d08-04fa31cf4c67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i316bc31c1a6f4eb1a59f8bfb2c2df15c_D20190701-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNS0zLTEtMS0w_64396ad6-168a-43ef-8078-60ae3b69bb25">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4523a176fdd843a1871b85358e66f672_D20190701-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNS03LTEtMS0w_42a82331-a723-4382-8b83-14b5180316fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4523a176fdd843a1871b85358e66f672_D20190701-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNS05LTEtMS0w_ecfd5e0a-69f0-4760-870a-b35dc7f3a992">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNS0xNS0xLTEtMA_69bcbd06-d17e-479e-85c6-14bcee747a8c">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4523a176fdd843a1871b85358e66f672_D20190701-20191231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNi03LTEtMS0w_9fd1accb-5ee7-4ff3-852d-1998ff8fa098">7</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4523a176fdd843a1871b85358e66f672_D20190701-20191231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNi05LTEtMS0w_507bf911-45ae-4bea-8a77-d9cd85557ebd">350</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNi0xNS0xLTEtMA_d102021c-7d99-4714-a596-3f6d2a2a7320">350</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f12e42d72c7409cbec2d494d04aea14_D20190701-20191231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNy01LTEtMS0w_07009b3f-d900-44aa-a060-622dbd56059d">284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNy0xNS0xLTEtMA_2a4d8986-7241-42e4-a248-de680ddd69c3">284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f12e42d72c7409cbec2d494d04aea14_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOC01LTEtMS0w_0450e562-5aeb-4f6c-ab34-4b0c424a115b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6044c7ef014ad7b58ff6abb8cf7620_D20190701-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOC0xMy0xLTEtMA_2f604e33-e854-4b09-b9ef-fe1d142d1f38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOC0xNS0xLTEtMA_538bc6c5-ff86-45da-af6b-70c5d2ccd8e4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ffbcc7b8b47419fafc54db6c65fa67c_I20191231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS0xLTEtMS0w_45844265-c3d4-4bda-9a85-f3ef8c87f001">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ffbcc7b8b47419fafc54db6c65fa67c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS0zLTEtMS0w_6ce1be1e-a4a8-400e-863b-0cab6755b84e">2,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961814e0fb934b26a59874c0a47b5c36_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS01LTEtMS0w_f2e03442-c5f3-44bd-8173-bf4e58c1b4c1">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i34bce33b39294b5990a6d2671d45efc1_I20191231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS03LTEtMS0w_78ca5b74-7d08-4a28-9d14-54e26448cdb8">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34bce33b39294b5990a6d2671d45efc1_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS05LTEtMS0w_a67e1371-52be-4c4c-9869-135d7721bc72">2,099</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a67a68103174862933d81e69761227a_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS0xMS0xLTEtMA_f53c9585-6272-4629-acce-187c40f70509">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae7680d35a94fe791314d93518ad333_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS0xMy0xLTEtMA_d8bcd574-1d5c-4ac6-97f9-2ffdba7b006b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dfaa9ce43d4c8dbe8e43f793325ab5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS0xNS0xLTEtMA_836bd423-6236-4890-be15-feec5020a37e">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMy0xLTEtMS0w_63efd5df-3b5c-479c-b124-280661088817">377</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMy0zLTEtMS0w_1ad69d8a-265a-4dc2-a834-b28567b89a9e">4,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNi0xLTEtMS0w_b3555ad7-4e12-44c6-a616-237ecad8ed52">404</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNi0zLTEtMS0w_46d082e6-7759-433b-9fa5-ef1f50816b57">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfOC0xLTEtMS0w_a1896ab9-59a1-46de-88b4-1c76bf1eba67">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfOC0zLTEtMS0w_cb9aba46-c316-409e-82d9-78c5e8b5cc1f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfOS0xLTEtMS0w_9ab55001-9bfe-4d5b-836f-66187b25ab76">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfOS0zLTEtMS0w_d93e2e25-3b77-4e02-963b-16f751bfd8b9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTAtMS0xLTEtMA_46415682-b3a4-44ba-b02e-2cf50fd33bad">51</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTAtMy0xLTEtMA_037d1587-67aa-4778-93a0-5db916c1b911">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for bad debts</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTItMS0xLTEtMA_286e1185-1b58-4e13-9da1-f5623cc87abd">35</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTItMy0xLTEtMA_4284c4fb-508c-4b82-9976-a11f6fe10fe1">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Increase)/decrease in trade receivables</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTQtMS0xLTEtMA_381396f4-61ba-4e32-b979-84a1400effb0">499</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTQtMy0xLTEtMA_dabe13a6-2a56-4606-b586-b1721fa09345">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTUtMS0xLTEtMA_700988f8-5058-403b-9685-ef2af5b281ff">1,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTUtMy0xLTEtMA_6e033fa0-4fef-436c-957a-3df4503f34fe">991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase/(decrease) in accounts payable</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTYtMS0xLTEtMA_c2a2089a-3621-409c-8f74-7e2c95da5d16">1,861</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTYtMy0xLTEtMA_7ec191ed-eda1-47ba-85e3-f4079fa29135">77</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities and operating items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTctMS0xLTEtMA_b29debfe-d079-4a4d-910f-c0e2ff0ffb27">504</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTctMy0xLTEtMA_96334113-7728-412f-86d3-ae5dbbe70d75">5,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTgtMS0xLTEtMA_1f24f9f6-1f7b-4ec5-852d-37f1808aef71">1,487</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTgtMy0xLTEtMA_462b625f-a095-43a3-86fe-16f2b0623ba7">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of subsidiaries, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjEtMS0xLTEtMA_d8748fe0-44e1-4366-86eb-4bd13032f889">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjEtMy0xLTEtMA_92b77d66-1223-448a-a482-951c161340b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjItMS0xLTEtMA_65999742-1a06-4b30-9f6a-d949205ed1ee">174</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjItMy0xLTEtMA_19b40382-ce74-416a-bab1-a0e481a60b26">149</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjMtMS0xLTEtMA_64c7c407-ec04-4d6a-a0f2-e0f8630466ba">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjMtMy0xLTEtMA_fce92204-dd0a-4653-828f-788bca154400">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from investments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjQtMS0xLTEtMA_e6db36d6-0075-48ba-949e-1084411e7e76">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjQtMy0xLTEtMA_168929fd-afe6-4c0a-81f1-b885cd8f64c4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:zerodash" name="cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjYtMS0xLTEtMA_09ed9d2e-1cc9-45c0-826a-80686baa7740">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjYtMy0xLTEtMA_0f170b31-2f49-4217-a494-dee18dd26771">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjctMS0xLTEtMA_60285dbc-346e-46e0-94ca-9f79e4b42596">191</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjctMy0xLTEtMA_3b828680-58fe-4885-ab5d-8f55da872b18">151</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzAtMS0xLTEtMA_ccfd4dfd-a7f4-4cae-8528-8f6a08e10958">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzAtMy0xLTEtMA_81e380ea-7ddc-4149-a909-9194b113caea">681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of long-term obligations</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzEtMS0xLTEtMA_36fdfee9-3df2-4053-8fc2-c50b44c769d2">49</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzEtMy0xLTEtMA_49b9ed73-c67b-4cac-8fef-25787ceaedb7">793</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net tax withholdings from share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzItMS0xLTEtMA_0300a67a-6042-49a6-a41f-23f4531914c2">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzItMy0xLTEtMA_f12eb40c-5fb0-4dfb-8204-c118363f657d">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends on common shares</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzQtMS0xLTEtMA_e9906218-bc2e-4714-a81c-58d40b9b37e6">289</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzQtMy0xLTEtMA_af0e6f60-2c6c-4b10-98a5-1d74b628b0c9">287</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzUtMS0xLTEtMA_18d912c2-02d8-4333-b54f-5b765d650230">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzUtMy0xLTEtMA_16856b87-b9ab-4cdd-a663-c450e4743845">350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzYtMS0xLTEtMA_b0fde22f-b4e2-4b9c-9ca3-bb99d75ad111">344</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzYtMy0xLTEtMA_9877e529-607e-43f7-88cf-0de6577fadbb">760</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rates changes on cash and equivalents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzgtMS0xLTEtMA_3a815126-f0ad-4ac9-9fac-a40236966fd6">14</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzgtMy0xLTEtMA_752a7433-8831-4baf-b63f-1600c9e2724b">5</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase/(decrease) in cash and equivalents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNDAtMS0xLTEtMA_84784535-18ce-48a0-adc2-3d56318ba424">966</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNDAtMy0xLTEtMA_2da7559e-dcc3-4a57-8732-2ca7f05fd43f">872</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNDEtMS0xLTEtMA_51345052-4229-452a-97ce-ed10cdabc724">2,771</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9263daec240f40e18bbc79b563561d69_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNDEtMy0xLTEtMA_7e1ef14a-000e-480e-bb2e-e95004c555ad">2,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and equivalents at end of period</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNDItMS0xLTEtMA_3667f029-7996-4384-92b5-07d826e7c0a7">3,737</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dfaa9ce43d4c8dbe8e43f793325ab5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNDItMy0xLTEtMA_a975e676-a236-4f7e-ab19-1da9b0f71338">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div id="iac867f2b870144f0baf920261d30f765_82"></div><div style="width:100.000%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84Mi9mcmFnOjVmNjhhNzgxZTUxNzQxYmVhM2ZiMjlkY2EwOWUwODBmL3RleHRyZWdpb246NWY2OGE3ODFlNTE3NDFiZWEzZmIyOWRjYTA5ZTA4MGZfMzI5ODUzNDkwMTQ1OA_13735e2d-b884-41b0-88a1-ea3fff0b0955" escape="true"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84Mi9mcmFnOjVmNjhhNzgxZTUxNzQxYmVhM2ZiMjlkY2EwOWUwODBmL3RleHRyZWdpb246NWY2OGE3ODFlNTE3NDFiZWEzZmIyOWRjYTA5ZTA4MGZfNDU3MA_b5df1fee-dc66-4200-b0c7-936c6ab38744" continuedAt="ifb6496fb889c4c5fa532f43c3d691b47" escape="true"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns is in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2020 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2021 and June&#160;30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic also affected our businesses in a variety of ways beginning in the third quarter of fiscal 2020 and continuing into fiscal 2021. We cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. and global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow. Our estimates, judgments and assumptions related to COVID-19 could ultimately differ over time.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifb6496fb889c4c5fa532f43c3d691b47">Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K").</ix:continuation></span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84Mi9mcmFnOjVmNjhhNzgxZTUxNzQxYmVhM2ZiMjlkY2EwOWUwODBmL3RleHRyZWdpb246NWY2OGE3ODFlNTE3NDFiZWEzZmIyOWRjYTA5ZTA4MGZfMzI5ODUzNDkwMTQ1Nw_e7e1a02e-1d25-4ae6-942c-cd1fa99f87e2" escape="true"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.</span></div></ix:nonNumeric></div></ix:nonNumeric></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RleHRyZWdpb246NGI2OTA2Njc2MWQxNDRkMGJiNmYwZmJiNTk5ZjgzYTVfMTA2Ng_e8a598e6-33a7-4b17-94bb-feb4c20b0f47" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RleHRyZWdpb246NGI2OTA2Njc2MWQxNDRkMGJiNmYwZmJiNTk5ZjgzYTVfMTA2NA_15f164ae-7dfb-4bb8-adc4-83b0ef898287" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmE4MTFlMjlkZDhlZTRkNzA5M2I4NTU1ZGM4NDE0YWE2L3RhYmxlcmFuZ2U6YTgxMWUyOWRkOGVlNGQ3MDkzYjg1NTVkYzg0MTRhYTZfMi0xLTEtMS0w_5855668e-a3e7-4f03-be99-a14c36f41762">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmE4MTFlMjlkZDhlZTRkNzA5M2I4NTU1ZGM4NDE0YWE2L3RhYmxlcmFuZ2U6YTgxMWUyOWRkOGVlNGQ3MDkzYjg1NTVkYzg0MTRhYTZfMi0zLTEtMS0w_6e157480-2dc1-4b17-a179-1e942bf44242">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmE4MTFlMjlkZDhlZTRkNzA5M2I4NTU1ZGM4NDE0YWE2L3RhYmxlcmFuZ2U6YTgxMWUyOWRkOGVlNGQ3MDkzYjg1NTVkYzg0MTRhYTZfMy0xLTEtMS0w_2a4a5c50-9b01-4e14-ba79-4b828b046453">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmE4MTFlMjlkZDhlZTRkNzA5M2I4NTU1ZGM4NDE0YWE2L3RhYmxlcmFuZ2U6YTgxMWUyOWRkOGVlNGQ3MDkzYjg1NTVkYzg0MTRhYTZfMy0zLTEtMS0w_778b9918-7352-47ec-9fb4-489a435a9e5b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmE4MTFlMjlkZDhlZTRkNzA5M2I4NTU1ZGM4NDE0YWE2L3RhYmxlcmFuZ2U6YTgxMWUyOWRkOGVlNGQ3MDkzYjg1NTVkYzg0MTRhYTZfNC0xLTEtMS0w_b9484e85-b3dc-4a30-8d80-bf5e4b332c14">20</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmE4MTFlMjlkZDhlZTRkNzA5M2I4NTU1ZGM4NDE0YWE2L3RhYmxlcmFuZ2U6YTgxMWUyOWRkOGVlNGQ3MDkzYjg1NTVkYzg0MTRhYTZfNC0zLTEtMS0w_3dbed43e-0138-4589-8ebe-fc0fb11ea6b2">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOjlkNzc4MWQwMmY2MDQwNmRhYjA1ZjRkN2E1M2FkOGYwL3RhYmxlcmFuZ2U6OWQ3NzgxZDAyZjYwNDA2ZGFiMDVmNGQ3YTUzYWQ4ZjBfMi0xLTEtMS0w_12bd848a-9c7b-40d4-84da-fd6bedac8995">32</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOjlkNzc4MWQwMmY2MDQwNmRhYjA1ZjRkN2E1M2FkOGYwL3RhYmxlcmFuZ2U6OWQ3NzgxZDAyZjYwNDA2ZGFiMDVmNGQ3YTUzYWQ4ZjBfMi0zLTEtMS0w_6e67740a-bfbb-4bea-b4f1-dd07e1bccdca">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOjlkNzc4MWQwMmY2MDQwNmRhYjA1ZjRkN2E1M2FkOGYwL3RhYmxlcmFuZ2U6OWQ3NzgxZDAyZjYwNDA2ZGFiMDVmNGQ3YTUzYWQ4ZjBfMy0xLTEtMS0w_f5f6088c-7e2a-453e-a021-f25f7a0353b1">25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOjlkNzc4MWQwMmY2MDQwNmRhYjA1ZjRkN2E1M2FkOGYwL3RhYmxlcmFuZ2U6OWQ3NzgxZDAyZjYwNDA2ZGFiMDVmNGQ3YTUzYWQ4ZjBfMy0zLTEtMS0w_6b8b39b7-6ff3-460a-b76f-e520ef3c5698">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOjlkNzc4MWQwMmY2MDQwNmRhYjA1ZjRkN2E1M2FkOGYwL3RhYmxlcmFuZ2U6OWQ3NzgxZDAyZjYwNDA2ZGFiMDVmNGQ3YTUzYWQ4ZjBfNC0xLTEtMS0w_20916a9d-80cc-40b2-9632-736abd02ee95">57</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOjlkNzc4MWQwMmY2MDQwNmRhYjA1ZjRkN2E1M2FkOGYwL3RhYmxlcmFuZ2U6OWQ3NzgxZDAyZjYwNDA2ZGFiMDVmNGQ3YTUzYWQ4ZjBfNC0zLTEtMS0w_60ea036b-0bdd-4719-83e8-12a69ba7990c">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of lease costs associated with vacant facilities, accelerated depreciation, vendor transition fees, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs during both the three and six months ended December&#160;31, 2020 and 2019 were primarily related to implementation of certain enterprise-wide cost-savings measures.</span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RleHRyZWdpb246NGI2OTA2Njc2MWQxNDRkMGJiNmYwZmJiNTk5ZjgzYTVfMTA3MQ_17a53419-3d3e-4ea3-b3fc-75850d72d083" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i715f3cb5de28419892c4abe4c201b08b_I20200630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMS0xLTEtMS0w_7f4675c5-624d-4d2e-b09c-cee692344aa9">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29dfcbbc4b87452b99f5496e7a8ee237_I20200630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMS0zLTEtMS0w_cf8a2bad-ac73-46a1-a931-018abc528625">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMS01LTEtMS0w_02098078-94b6-467c-acc0-64201f8929db">96</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb6bb1cf27c4f7a8d9e429c5c296315_D20200701-20201231" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMi0xLTEtMS0w_fd0a9ed4-510b-4c71-96c6-81071d50d0d9">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaca494a8cb54963b9c8eabe88a49bf4_D20200701-20201231" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMi0zLTEtMS0w_7141d170-95fc-481a-89d1-348e1195a2d8">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMi01LTEtMS0w_7803a793-0440-4825-b69e-992cee0bad6d">41</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cb6bb1cf27c4f7a8d9e429c5c296315_D20200701-20201231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMy0xLTEtMS0w_b77fabb4-c3ff-430d-bd72-36a232ccdfaf">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifaca494a8cb54963b9c8eabe88a49bf4_D20200701-20201231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMy0zLTEtMS0w_5bd3f18f-f5af-46ed-a590-d730c4ef70fe">19</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMy01LTEtMS0w_878bd712-3576-47f1-9183-7bfd44ee4193">53</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23cc7d0aa564d63919be6c6c1cfef81_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfNC0xLTEtMS0w_9c6ad174-207a-416a-8efb-aa2849b7aedb">56</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f208ee71c540dc96e55d1ea0309d92_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfNC0zLTEtMS0w_febdc505-f8f5-4173-89ab-8bb78d5f1e6b">28</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfNC01LTEtMS0w_72d262a3-98b3-40ad-9e51-1ef42fae9656">84</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div id="iac867f2b870144f0baf920261d30f765_88"></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTEyOQ_d499ec34-6557-46bf-a22a-09c3cc445451" continuedAt="ib36fa5f7ab5240fda564323e8bbd2ec4" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTEzNg_031f33ce-4cc5-41ca-aa49-6bcd77231a20" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.482%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98dea8eab827433d8bb7d45c1cfb404b_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMS0xLTEtMS0w_6d83c49d-2287-4a81-9d64-3389283baf2e">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b14c71bbc54f248f49427b82d4c76a_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMS0zLTEtMS0w_93ad5daa-8d64-4441-9973-e2a7c022b983">5,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMS01LTEtMS0w_d844bc90-cf03-4e82-bb31-9ef07457d03b">8,357</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84ce22fc5e7432ea0e7678515ad59b0_D20200701-20201231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMi0xLTEtMS0w_08190193-fde8-4bd0-9d6c-a7c8f411afa6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9662598991e54a289ce467d4c55860b1_D20200701-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMi0zLTEtMS0w_bba06ae2-dc34-4d6b-b2b4-a1cd94177013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMi01LTEtMS0w_a20974ab-d898-4648-8043-e53f9282f1ce">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84ce22fc5e7432ea0e7678515ad59b0_D20200701-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMy0xLTEtMS0w_028cb761-c457-4936-b300-1b70d5ff77c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9662598991e54a289ce467d4c55860b1_D20200701-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMy0zLTEtMS0w_ace2e56b-4595-4cb7-a632-6ed1ef4752d4">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMy01LTEtMS0w_b50fd6e6-7dad-43f4-8bee-f2d8a85531ed">40</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63febb3b06bd4185a6a3f45a6da44204_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfNC0xLTEtMS0w_f27e72e5-8617-4577-9600-167012b30c5f">2,659</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5434fa06a945a9812fd66b941db4b3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfNC0zLTEtMS0w_6f5c7e08-2b97-4a64-9f1b-f4600d065502">5,740</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfNC01LTEtMS0w_5858e7a3-2b56-4bd6-8742-f2bf2da71518">8,399</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="ib36fa5f7ab5240fda564323e8bbd2ec4"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTE0Nw_10c8a59c-0355-4b1e-acfa-62959e72377a" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0576298a2e542fd95ac14b7815c72ea_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMy0xLTEtMS0w_82c86fcc-c35b-4b26-8895-42632e375cbc">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0576298a2e542fd95ac14b7815c72ea_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMy01LTEtMS0w_38238d76-e291-429e-a21b-eb148e2181cb">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfNC0xLTEtMS0w_130ff865-7913-4d67-aedf-20d9e689cc04">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfNC01LTEtMS0w_8978820c-f0cf-45d3-98ca-6efd0bd39e0e">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec244ced74e54c48890cb31ded0bdebf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfNy0xLTEtMS0w_15901ca0-15e3-48ff-9401-01741b9389f0">3,570</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec244ced74e54c48890cb31ded0bdebf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfNy0zLTEtMS0w_30b9f8a3-4665-4089-a9a9-e72cce67ec29">1,978</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec244ced74e54c48890cb31ded0bdebf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfNy01LTEtMS0w_058141b8-c933-4757-b663-be9f91121b98">1,592</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2a7db73217be4f9980a875418215b27c_D20200701-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfNy03LTEtMS0w_9f20391e-e5e4-4d80-a2b0-3b2ca92ab241">13</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3386edf96d3941c387073f4c10dfd3a8_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOC0xLTEtMS0w_77f7350c-ffc3-4bb8-aeb9-0d41215b4296">671</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3386edf96d3941c387073f4c10dfd3a8_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOC0zLTEtMS0w_0aec9d9d-fb56-4652-8468-e7fe9c18b6a1">360</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3386edf96d3941c387073f4c10dfd3a8_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOC01LTEtMS0w_b574895d-e8b0-4c4c-a022-3aae914e06be">311</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i20ba7d43ca1e4e5bad3683d334fed42a_D20200701-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOC03LTEtMS0w_5e32fabf-9a0e-4957-a9b8-c6d5c0993b64">12</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ec4ab4e33146c497406aa05665b794_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOS0xLTEtMS0w_942b0fb8-378e-4ff1-929b-52cc4c20254b">1,612</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ec4ab4e33146c497406aa05665b794_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOS0zLTEtMS0w_6e4de367-389f-43bc-8a9f-7b783f3b50cc">836</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ec4ab4e33146c497406aa05665b794_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOS01LTEtMS0w_c2411600-75fb-4827-8cc4-f926e3ef744e">776</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3be0113a67424f1d89bc62eba84876b6_D20200701-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOS03LTEtMS0w_811c6138-a444-46b0-b5de-bb3e6f31fc43">11</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTAtMS0xLTEtMA_36fc2b9e-8fda-4128-a3e6-a3da8282d15b">5,853</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTAtMy0xLTEtMA_d41ed163-0427-4b4c-a762-4f2006382428">3,174</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTAtNS0xLTEtMA_7ad52785-1c7e-4580-966b-07b4c3abe414">2,679</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTAtNy0xLTEtMA_819f7438-8922-45f6-9ddc-7492f0d51275">12</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTEtMS0xLTEtMA_f8b24703-4004-4827-9565-8430cbe417d8">5,877</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTEtMy0xLTEtMA_34d2a352-00c0-47fd-bfa7-0196f378fcbf">3,174</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTEtNS0xLTEtMA_e1555922-ca37-4039-bdea-b9dc49452240">2,703</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56f4dc613d0944dfb65ad3407fdd7d98_I20200630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMy0xLTEtMS0w_e6fc8ff3-915f-4a0f-982e-15a62ed97905">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56f4dc613d0944dfb65ad3407fdd7d98_I20200630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMy01LTEtMS0w_dc6d9a7c-2fef-47b2-ad8e-54b33a68c5da">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfNC0xLTEtMS0w_72b8885c-477d-4b31-9d81-2363a6726997">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfNC01LTEtMS0w_4b40c765-ce9c-4d07-9f4c-2fd02fe93d58">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036a1401ef2c457fb47d9dd79ed6fc99_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfNy0xLTEtMS0w_1fc28a2e-a577-46bd-b561-5b164cddd9c3">3,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036a1401ef2c457fb47d9dd79ed6fc99_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfNy0zLTEtMS0w_b993081c-1587-4ed8-919c-cfaf8cfd8c6c">1,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036a1401ef2c457fb47d9dd79ed6fc99_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfNy01LTEtMS0w_217b1efc-904d-4d94-81aa-0bb51d1b1e19">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e4b7722d85145d78ebc17885b5a4d24_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfOC0xLTEtMS0w_1953c47a-bcfe-42e1-99fd-4ec01d2caa5c">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e4b7722d85145d78ebc17885b5a4d24_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfOC0zLTEtMS0w_c71b6313-2bc4-4f5b-a45a-b96f01bb8a52">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e4b7722d85145d78ebc17885b5a4d24_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfOC01LTEtMS0w_6c5f0ee9-6325-4f63-a655-6051e25fa6d3">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a47a213956c4b9eb61252e2288e47f9_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfOS0xLTEtMS0w_bf449b0b-d481-48f7-aa6d-994cebb8206d">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a47a213956c4b9eb61252e2288e47f9_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfOS0zLTEtMS0w_05d1c7f1-3e9d-4fd4-9372-5ed290b6cc47">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a47a213956c4b9eb61252e2288e47f9_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfOS01LTEtMS0w_879dd938-49f4-4a53-a6b2-7a007c94fa04">837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMTAtMS0xLTEtMA_e022b3e3-1d9b-487f-a9ef-94c2a9da6941">5,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMTAtMy0xLTEtMA_fd7c161d-b84d-4725-abec-fbb1ac9cbb31">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMTAtNS0xLTEtMA_68e17a15-cb49-4532-a7b3-c77f78dcec60">2,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMTEtMS0xLTEtMA_284eee7a-f4dc-4cad-8fa9-9d356ba8f2d8">5,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMTEtMy0xLTEtMA_4a89cc31-2737-4234-b8d6-35eed67d0d53">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMTEtNS0xLTEtMA_7cac256a-e689-4bea-a645-3e4ea411d03a">2,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfODgy_0a8a1b85-998e-4097-b113-63b135e8efac">113</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfODg5_62935a0d-5336-4cb4-95d6-1535bf871e89">127</ix:nonFraction> million for the three months ended December 31, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfOTQ4_f595b924-9155-4423-b9a5-a4eb475a89aa">228</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfOTU1_c5ce1628-3108-4353-9a08-5819fef95887">256</ix:nonFraction> million for the six months ended December&#160;31, 2020 and 2019, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2021 through 2025 is as follows: $<ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTEwMg_a67aac98-ba06-41f1-9ccc-8bc79de19e58">217</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTEwNg_8fc4c758-71f7-4bc1-81a3-43a4ac57b576">398</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTExMA_ff7b5185-76d9-4084-b571-9856c19e71ff">359</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTExNA_ab7645d2-ca23-4436-b503-3bfce97b4edb">329</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTEyMQ_c7e45ec5-aef1-4363-958e-43b24ff6c416">278</ix:nonFraction> million.</span></div></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMjA0Nw_8ec46927-a08d-4648-8052-64558f94f6ef" continuedAt="ia82ef9bf43d94f6caf8fd27e6c43a914" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Long-Term Obligations and Other Short-Term Borrowings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and June&#160;30, 2020, we had total long-term obligations, including the current portion and other short-term borrowings, of $<ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-8" format="ixt:numdotdecimal" name="cah:TotalLongTermandShortTermObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMTcx_f8abb7ef-f702-41cd-906e-b1f8b41d14b5">6.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-8" format="ixt:numdotdecimal" name="cah:TotalLongTermandShortTermObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMTc4_f9d6fb79-00e9-4805-afff-7bea364a76bf">6.8</ix:nonFraction> billion, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These obligations are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $<ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzI5ODUzNDg4NjY4OA_bcb36f71-c252-42b8-ad39-6d7339f243cc">23.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzI5ODUzNDg4NjY5Ng_0c0376b7-36f5-476e-b797-1a681269967a">21.4</ix:nonFraction> billion at December&#160;31, 2020 and June&#160;30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2020, we early repurchased $<ix:nonFraction unitRef="usd" contextRef="i474cf5f364454a11b22f24b06699e4df_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDUyMg_b9930e4f-4acb-483c-bd5f-78c2b3d39b23">40</ix:nonFraction> million of the Floating Rate Notes due 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="ifb2a9682f8564e3fb789bdc866101ff9_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDUzOA_fadf06c5-25bb-4d2f-b593-c1748b11a1e0">2</ix:nonFraction> million of the 2.616% Notes due 2022. The repurchases were paid for with available cash. In connection with the early debt repurchases, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDIzOQ_37c1445f-af69-4651-a61e-45a6f47601cd">1</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss on early extinguishment of debt during the six months ended December&#160;31, 2020. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we repaid the full principal of the 2.4% Notes due 2019 at maturity for $<ix:nonFraction unitRef="usd" contextRef="i0c200f19e4364602a4c4db803bbe7e50_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDYxOQ_554332fc-2e7e-4d07-a69d-abee8086ed63">450</ix:nonFraction>&#160;million. During the six months ended December 31, 2019, we early repurchased $<ix:nonFraction unitRef="usd" contextRef="i01211baf31064f409c8fa4c5b5b54b09_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDYzMA_73ff5159-b638-41f2-a447-29784801e103">207</ix:nonFraction>&#160;million of the 2.616% Notes due 2022, $<ix:nonFraction unitRef="usd" contextRef="i770887e4d98143a78ad85ee309204ca5_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDYzNA_ad5919ca-bbc7-481f-8cd3-f3ace241b894">10</ix:nonFraction>&#160;million of the 3.2% Notes due 2022, $<ix:nonFraction unitRef="usd" contextRef="iaae728c0a7a4428ab31591199c01df2c_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDYzNw_5144f93d-cc23-4b7a-a71b-32e9e8618315">14</ix:nonFraction>&#160;million of the Floating Rate Notes due 2022, $<ix:nonFraction unitRef="usd" contextRef="i1bea82ad95804e6abff0fd8562560862_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDY0Mg_9ab49f17-c6c1-4b14-b3dc-81830b75d80c">81</ix:nonFraction>&#160;million of the 3.41% Notes due 2027, $<ix:nonFraction unitRef="usd" contextRef="i2763cf8f732c46ac822b3a4e9cc9afce_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDY0Ng_7e95a76b-7ab4-4a76-aa61-ae3b6e82cdc7">6</ix:nonFraction>&#160;million of the 4.6% Notes due 2043,$<ix:nonFraction unitRef="usd" contextRef="i907c1e70968546c7bd30ff773af28457_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDY0OQ_1dfdd934-f0ec-4381-9b50-a858d8b7ff25">2</ix:nonFraction>&#160;million of the 4.9% Notes due 2045, and $<ix:nonFraction unitRef="usd" contextRef="ic9f2efa674d6441590242649316ec9a6_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDY1Mw_59a588d9-e3ca-4bbf-8162-dcc79af2976c">21</ix:nonFraction>&#160;million of the 4.368% Notes due 2047. The repurchases were paid for with available cash and other short-term borrowings. In connection with the early debt repurchases, we recorded a $<ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfOTc3_08b147c4-c064-40e5-9c61-825c1f2d8c3c"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfOTc3_e87b2634-fea3-463b-a792-c370b875021d">4</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss on early extinguishment of debt during the three and six months ended December 31, 2019. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$<ix:nonFraction unitRef="usd" contextRef="i92aefd5c72f64cb89f421ad0100e879f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMTI4NQ_b3b9e3f3-beeb-476b-9dd2-0d72ff183fb3">2.0</ix:nonFraction> billion&#160;commercial paper program backed by a $<ix:nonFraction unitRef="usd" contextRef="ia70ce6414d4f4266bf2f26ca4eafbb15_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMTMyNQ_7a01d479-6afa-4bd4-a14f-8dd9c98ded82">2.0</ix:nonFraction> billion&#160;revolving credit facility. We also have a&#160;$<ix:nonFraction unitRef="usd" contextRef="i91ee5d4795d74c0d97f3782625ff9fd1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMTM3MA_7ad1d2b0-3f59-42eb-a537-4e4ee2b720f6">1.0</ix:nonFraction> billion&#160;committed receivables sales facility. At&#160;December&#160;31, 2020, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2022. CHF was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia82ef9bf43d94f6caf8fd27e6c43a914">Our revolving credit and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter through December 2020, a consolidated net leverage ratio of no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021. As of December&#160;31, 2020, we were in compliance with this financial covenant.</ix:continuation> </span></div><div id="iac867f2b870144f0baf920261d30f765_100"></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzE1Mjk4_bca364ea-15a6-450b-bae9-27b3529046d0" continuedAt="i0f43d6d1ba884f95994c1cb18e0fad36" escape="true"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of <ix:nonNumeric contextRef="ie044a19677f140da979d3894dde5c9de_D20200701-20201231" format="ixt-sec:duryear" name="us-gaap:LongtermPurchaseCommitmentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzI1NA_fba909a0-b642-4a22-abf9-e9b5a175b5e8">10</ix:nonNumeric> years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $<ix:nonFraction unitRef="usd" contextRef="ie044a19677f140da979d3894dde5c9de_D20200701-20201231" decimals="-5" format="ixt:numdotdecimal" name="cah:MaximumQuarterlyPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzQ1NQ_cab72b11-942f-4171-b41d-e46877aa1060">45.6</ix:nonFraction> million to CVS Health for the remainder of the initial term.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $<ix:nonFraction unitRef="usd" contextRef="ib0763235728b4e798df4a93f91297014_I20201231" decimals="-6" format="ixt:numdotdecimal" name="cah:AggregateAnnualAssessment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5MzU2OTc_0b43c45e-0c4e-487e-9a56-6481cbaf06ea">100</ix:nonFraction>&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the U.S. District Court for the Southern District of New York ruled that the OSA was unconstitutional and enjoined its enforcement (the "Ruling"). In April 2019, the State, among other things, amended the OSA so that the assessment would only cover opioid sales in 2017 and 2018, subject to the State's appeal of the Ruling. In September 2020, the U.S. Court of Appeals for the Second Circuit reversed the Ruling and, as a result, New York will likely seek to collect amounts due from distributors and manufacturers for 2017 and 2018. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $<ix:nonFraction unitRef="usd" contextRef="i24af2662052e41a9916032cdb61e8d12_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5MzU3MDQ_b7b4aa79-68aa-44f0-bb2f-73af7ca43634">41</ix:nonFraction>&#160;million for calendar year 2017 and 2018 based on the estimated payment amount, which is our best estimate of the OSA payments probable at December 31, 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i0f43d6d1ba884f95994c1cb18e0fad36" continuedAt="ie7fba41660fe4b4499bcf0e8d4d0ab48"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings/(loss).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately <ix:nonFraction unitRef="number" contextRef="i90dc05ceb60c40f0ac677345f92bae29_I20210201" decimals="0" format="ixt:numdotdecimal" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzQxMzY_ad18c790-4112-4992-beb7-d647d22b3e76">3,300</ix:nonFraction> lawsuits relating to </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="number" contextRef="i38d2978456e542b7b3180f73a3e78c5f_I20210201" decimals="0" format="ixt:numdotdecimal" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzQ2OTk_2762dea4-4de3-446f-8d71-33423e6c7e5c">2,800</ix:nonFraction> of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#8220;MDL&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, <ix:nonFraction unitRef="stateag" contextRef="i90dc05ceb60c40f0ac677345f92bae29_I20210201" decimals="0" name="cah:NumberofStateAttorneysGeneralfilinglawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzU0ODc_17646102-a662-42cc-a43c-71ee0404abe2">25</ix:nonFraction> state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in West Virginia in the Cabell County and City of Huntington cases is scheduled for May 2021 and a trial is scheduled to begin in September 2021 in the case brought by the Ohio Attorney General. Trial dates remain uncertain due in part to uncertainties arising from the COVID-19 pandemic. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). This Settlement Framework is the basis for the ongoing negotiation of definitive terms and documentation. Negotiations under the Settlement Framework continue.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these discussions, we have recorded total pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="i56512e9ae3444aa3993b873d559a9163_D20200701-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5MzU3MTE_b3fea09e-3157-4fff-8452-4328cb7ff292">1.02</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="id328a673f19941118ace9480b141deae_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5MzU3MjE_32d05193-fa88-46a4-82e6-8b427081b660">5.63</ix:nonFraction>&#160;billion in litigation charges/(recoveries), net in the six months ended December 31, 2020 and 2019, respectively. In total, we have $<ix:nonFraction unitRef="usd" contextRef="ia24262f3a922415db5013e0f3ae80122_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationReserve" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5MzU3NzI_7de866c9-a9d2-45ad-8765-16ab5307ea89">6.59</ix:nonFraction>&#160;billion accrued at December 31, 2020, included in deferred income taxes and other liabilities in the condensed consolidated balance sheets, which represents the cash component. We are unable to estimate the range of possible loss associated with these matters. Definitive terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. We continue to </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="ie7fba41660fe4b4499bcf0e8d4d0ab48" continuedAt="i71c8b3c189244b50980014522896990b"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Framework does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private parties had brought approximately <ix:nonFraction unitRef="lawsuit" contextRef="i2a4ad47536df474f94e261a74c430702_I20210201" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5MzU3OTk_75837b26-6fd2-473e-bcc4-b75fa7cb5c3b">423</ix:nonFraction> lawsuits as of February 1, 2021. Of these, <ix:nonFraction unitRef="lawsuit" contextRef="i2b7d20f207654f5896c816a15da9291c_I20210201" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzkzOTU_db70e94d-d0ec-47bc-b2c7-ef2b0f32cf7c">127</ix:nonFraction> are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in these matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Affirmative Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#8220;National Union Fire Insurance&#8221;), seeking a declaration that defense costs are recoverable under our insurance for certain of the lawsuits described above. We have not recorded a receivable for any recoveries related to the litigation against National Union Fire Insurance at December 31, 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these requests. We are unable to predict the outcome of any of these investigations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2021, we are named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="i2b50640db30b49a9aeed0c6c228e045d_D20210201-20210201" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzEwMDcz_069eb644-ed6d-41d8-b8da-5628516080f3">373</ix:nonFraction> product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="i8a7e2cc7591649299a8be4db64de4bf6_D20210201-20210201" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzEwMTk2_52ca27be-a2c7-4836-a580-4cdd3c878986">4,800</ix:nonFraction> plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another <ix:nonFraction unitRef="lawsuit" contextRef="iaf2d67987fbf44f9b89a411201940603_D20210201-20210201" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzEwMzQ1_3c1ddadd-6165-4ec7-821f-5b27d9a1b531">31</ix:nonFraction> lawsuits involving similar claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="i6a938e1fa9214d8cb46bb9c82947ad31_D20210201-20210201" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzEwMzk5_6424b60e-5625-40b6-a0cc-bfd04cdef061">36</ix:nonFraction> plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We continue to vigorously defend ourselves in these lawsuits and are engaged in resolution discussions with certain plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had a total of $<ix:nonFraction unitRef="usd" contextRef="ia0b1626635494e759538b3e69c1d8c44_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzEwNjE0_1d766d54-7802-44b9-98cc-25e824f870f9">508</ix:nonFraction> million net of estimated insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits which are presented on a gross basis in the condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">end of the range to be approximately $<ix:nonFraction unitRef="usd" contextRef="i06d03eb8370c4ad5b575e1b109ddc573_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzExMDI0_4a8c8224-228c-4f28-a86e-e9e21326889e">990</ix:nonFraction> million, net of estimated insurance recoveries.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In November 2020, we filed a motion to dismiss the amended complaint. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Solutions DOJ Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we received investigative demands from the United States Attorney&#8217;s Office for the District of Massachusetts (the "USAO") pertaining to the U.S. federal healthcare fraud and abuse laws. These requests sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with these requests and are engaged in resolution discussions with the USAO. In connection with these discussions, we recorded $<ix:nonFraction unitRef="usd" contextRef="i028cb05d5d774ece897a4eae7abde3c9_D20200701-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5Mzk4NjQ_754b8d83-6922-42d1-8bed-e4ef1226e36b">13</ix:nonFraction> million of expense within litigation charges/(recoveries) on our condensed consolidated statement of operations during the three months ended December&#160;31, 2020. We are not able to estimate a range of reasonably possible additional losses for this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i71c8b3c189244b50980014522896990b" continuedAt="ia5d3bbe3c2514035b5f000034428459b"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. </span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia5d3bbe3c2514035b5f000034428459b">In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#8220;Sartan MDL&#8221;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter. We were also named as a defendant in a Multidistrict Litigation alleging impurities in Zantac and its generic form, ranitidine (the "Zantac MDL"); however, all claims against us in the Zantac MDL have been dismissed, in some cases, with prejudice.</ix:continuation> </span></div><div id="iac867f2b870144f0baf920261d30f765_103"></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzMyOTg1MzQ5MTIyMDQ_e8825dc9-55f3-4f91-9619-d22c0bca6ccc" continuedAt="i8274b0c0f0a34587b7e0f6614c7ea4ac" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of pretax earnings (&#8220;effective tax rate&#8221;) are generally due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2020, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, is currently deductible on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss is being carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our provision for income taxes during the three months ended December&#160;31, 2020 included a $<ix:nonFraction unitRef="usd" contextRef="i87230ed321a245fc91bc68615d9f61a5_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQzOTgwNDY1NDcwOTM_e022fa13-e4cc-4439-88d4-0dbf3d0d36bd">420</ix:nonFraction> million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to file for a federal income tax refund of $<ix:nonFraction unitRef="usd" contextRef="id4465d750964497c99036784264b593a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQzOTgwNDY1NDYxNjI_75570c2b-58a9-47ae-8cca-7b64cf19be1d">974</ix:nonFraction> million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our condensed consolidated balance sheet at December&#160;31, 2020. We also increased our non-current deferred tax liability by approximately $<ix:nonFraction unitRef="usd" contextRef="ic03700ae57af494fb31290e42a1720fd_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzNjEwMTI_1e3efadf-5ccb-47d6-8a22-d75e3bcc0c81">700</ix:nonFraction> million during the six months ended December&#160;31, 2020 related to this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i8274b0c0f0a34587b7e0f6614c7ea4ac" continuedAt="i7f119338b18c4ccd88c13c6e5104da2d"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">challenge these tax benefits. The actual amount of the tax benefit may differ materially from these estimates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $<ix:nonFraction unitRef="usd" contextRef="i56512e9ae3444aa3993b873d559a9163_D20200701-20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYxMDU_db44a638-378d-49b8-b689-a357efe97be1">1.02</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="id328a673f19941118ace9480b141deae_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYwODQ_5ab1155f-43f4-4b04-b08d-94357e0fd089">5.63</ix:nonFraction> billion pre-tax charges for the opioid litigation, during the six months ended December&#160;31, 2020 and 2019, respectively, the net tax benefits are $<ix:nonFraction unitRef="usd" contextRef="i8f1203c9a1ad44c4874a799063ecc408_D20200701-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYwMzE_fc68b125-c974-4a9a-9c9e-41716db01e9d">35</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7325d606c00e4365b83eaf72e2f134be_D20190701-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYwMzk_3a81173d-8464-4019-9053-8e7c9189af9a">488</ix:nonFraction> million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i08769690807c428b9015f5d581f80d13_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYwNzY_4281af6a-c487-469e-aa8f-f4e7e3d3ac20">34</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibbe4dd4c7b6c4b83bbef659b5664d7ff_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYwNTg_09442ce2-2ead-4cf2-9aa1-ee2feaf8088f">469</ix:nonFraction> million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision for/(benefit from) income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid accrual during the six months ended December 31, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the three months ended September 30, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent. The inclusion of the relatively lower tax benefit of the current fiscal year charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax expense increased by approximately $<ix:nonFraction unitRef="usd" contextRef="i2334754903a5458bb5821f0515733377_D20201001-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYxMjQ_ee015cf4-a0ce-4f12-84a9-5bd6620e0c05">150</ix:nonFraction> million during the three months ended December&#160;31, 2020 while the amount of tax benefit increased by approximately $<ix:nonFraction unitRef="usd" contextRef="i56512e9ae3444aa3993b873d559a9163_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzNTAzOTA_84f47c8a-f192-44fa-9b34-0cd3ee868440">300</ix:nonFraction> million during the six months ended December&#160;31, 2020 compared to the tax impacts that would have been recognized without the opioid litigation charge and is expected to significantly increase our provision for income taxes during the remainder of fiscal 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax </span></div></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i7f119338b18c4ccd88c13c6e5104da2d" continuedAt="ide85e0eb9a8d4d20acd37ffb2a4de879"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;December&#160;31, 2020&#160;and&#160;2019, the effective tax rate was&#160;(<ix:nonFraction unitRef="number" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzE0NjM_7d9fb3a8-2762-4f53-b3ee-db5d17bf88e3">47.6</ix:nonFraction>) percent and&#160;<ix:nonFraction unitRef="number" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzE0Nzg_45a1a2f6-172e-4f13-8b97-2a6ef9faa249">21.0</ix:nonFraction>&#160;percent, respectively. The change in the effective tax rate compared to the prior period was primarily due to the $<ix:nonFraction unitRef="usd" contextRef="i87230ed321a245fc91bc68615d9f61a5_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzEwOTk1MTE2MzEzNzkw_e022fa13-e4cc-4439-88d4-0dbf3d0d36bd">420</ix:nonFraction> million benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss, partially offset by the adverse tax impacts of the opioid litigation accrual.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended&#160;December&#160;31, 2020&#160;and&#160;2019, the effective tax rate was <ix:nonFraction unitRef="number" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzE2OTI_cc025117-3733-4070-9c80-3962e5fcc405">259.7</ix:nonFraction>&#160;percent and&#160;<ix:nonFraction unitRef="number" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzE3MDc_ce3484e9-dda3-4895-942f-5dcbb7994767">7.2</ix:nonFraction>&#160;percent, respectively. Included in the effective tax rate for the six months ended December 31, 2020 was the $<ix:nonFraction unitRef="usd" contextRef="i87230ed321a245fc91bc68615d9f61a5_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzNjAxNTE_e022fa13-e4cc-4439-88d4-0dbf3d0d36bd">420</ix:nonFraction> million benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss. Included in both the six months ended December 31, 2020 and 2019 were net tax benefits related to the treatment of the tax impacts of opioid litigation charges. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and June&#160;30, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk3NTA_9a3a8fd5-b4e6-4cfe-b1d1-5dab09263c11">989</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzE5MzE_43a3d081-491f-4ca9-b11b-27b0aa83a444">998</ix:nonFraction> million of unrecognized tax benefits, respectively. The December&#160;31, 2020 and June&#160;30, 2020 balances include $<ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk3NTg_ca93ce37-82ce-4143-8b7d-5509b2fadebb">745</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzIwMTY_af7ca404-bca2-4e89-a82a-b0fc0afd6569">753</ix:nonFraction> million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and June&#160;30, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk3NzQ_d36dd2a1-fc2c-46bc-a991-6342bb3a2c7a">150</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk3NjY_7da4960b-1f15-4a13-a617-e0f4c978e187">146</ix:nonFraction> million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between <ix:nonFraction unitRef="usd" contextRef="i9f1f3a98a99a4d27b6451bfb560ba396_I20201231" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzMwNDM_a75181b8-2bb3-4cfc-81f8-d665e5e745d9">zero</ix:nonFraction> and a net decrease of up to $<ix:nonFraction unitRef="usd" contextRef="i6112186cca62432382db406081a60a17_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzMwNzQ_11c81184-1833-497e-9123-616215fc8f8c">370</ix:nonFraction> million, exclusive of penalties and interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years <ix:nonNumeric contextRef="i888db2833efb4657a6fefd55514539c8_D20201001-20201231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzMzNDY_0dd92d7e-4ce1-4ce9-9284-0eef0bea05dd">2008</ix:nonNumeric> through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, </span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="ide85e0eb9a8d4d20acd37ffb2a4de879"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $<ix:nonFraction unitRef="usd" contextRef="iab7bd98acbea40449f8bd35c7616c720_I20201231" decimals="-6" format="ixt:numdotdecimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk3OTA_56e6477f-a2c2-4eef-b428-70995bf9704e">181</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7f7180f4c5144dceb597f6050eb94368_I20200630" decimals="-6" format="ixt:numdotdecimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk3ODI_d3100ab3-ac64-48eb-a640-4c82d6711ef5">176</ix:nonFraction> million at December&#160;31, 2020 and June&#160;30, 2020, respectively, and is included in other assets in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $<ix:nonFraction unitRef="usd" contextRef="i26e6e263c6fd4a699bb0c1af198967e1_I20200630" decimals="-6" format="ixt:numdotdecimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk4MDI_28c7dee1-e449-4947-b923-849ec5989cc1"><ix:nonFraction unitRef="usd" contextRef="i93d039e782a9419a9742c71dc850ce33_I20201231" decimals="-6" format="ixt:numdotdecimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk4MDI_bbdcd16b-5767-4500-bfa1-7a836111fad6">19</ix:nonFraction></ix:nonFraction> million at both December&#160;31, 2020 and June&#160;30, 2020, and is included in other assets in the condensed consolidated balance sheet.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.</span></div></ix:continuation><div id="iac867f2b870144f0baf920261d30f765_106"></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90ZXh0cmVnaW9uOjk2MzY2ODk3NzUwNzQ3MzhhNGQ3YzIxZmU4ZTc3M2Y0XzMyOTg1MzQ4ODY3ODM_c5794a8c-6613-4105-8ebb-93d022ddfe2b" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90ZXh0cmVnaW9uOjk2MzY2ODk3NzUwNzQ3MzhhNGQ3YzIxZmU4ZTc3M2Y0XzEyNDg_e9ad65e7-cffc-4a31-a9b3-bc06a851d791" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65806b475fdc4876a59494d73901adb7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzMtMS0xLTEtMA_b9fe3d2a-528f-4831-a07f-f1886dab4961">1,920</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i159fa2bd7a66408badeaa0faea3b677d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzMtMy0xLTEtMA_937ee4b7-dd7f-44cc-a5d6-9b312c4b106b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7445253c20dd435886df7adff515242f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzMtNS0xLTEtMA_2337d582-caad-4f06-9431-a78a2f7e897d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e83590d4a854a7190b78c1a5c2d284f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzMtNy0xLTEtMA_02a1b92b-242d-4384-96ad-c963245fa773">1,920</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65806b475fdc4876a59494d73901adb7_I20201231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzUtMS0xLTEtMA_d30084a0-e6a8-48f6-a31a-1b1f92413e34">120</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i159fa2bd7a66408badeaa0faea3b677d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzUtMy0xLTEtMA_41eb4e38-ef3d-466c-9782-eb454c42cd71">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7445253c20dd435886df7adff515242f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzUtNS0xLTEtMA_83abbeeb-9bef-4cc2-a073-8466fad68f36">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e83590d4a854a7190b78c1a5c2d284f_I20201231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzUtNy0xLTEtMA_ddca6df4-b9d3-4c9c-b524-7f050cefb347">120</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65806b475fdc4876a59494d73901adb7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzYtMS0xLTEtMA_37890f9d-3112-4112-af23-d5c2c383594d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i159fa2bd7a66408badeaa0faea3b677d_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzYtMy0xLTEtMA_0f55a28b-b390-469a-8f11-1b2ae9ee711c">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7445253c20dd435886df7adff515242f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzYtNS0xLTEtMA_5a4a3327-219f-48c7-b3d1-b3e12e24555f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e83590d4a854a7190b78c1a5c2d284f_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzYtNy0xLTEtMA_7230ed11-50a8-4f58-9bf5-08606d6bb5f4">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d6381aaa6914a0aa526a6b8b3989a7e_I20200630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzMtMS0xLTEtMA_3d06c298-dde6-4dd3-952c-bca9c5b67689">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b55dcaca51f44599a00a8fa68d79d85_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzMtMy0xLTEtMA_e752bbcb-4436-41be-9496-7620c836d201">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib957a62df7f549839a60399d078c4472_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzMtNS0xLTEtMA_7f4ba0f4-72b5-4423-ad02-942b8c372fcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41b93ee69de4e0d9701c057ae9ab8db_I20200630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzMtNy0xLTEtMA_8a4b11de-e1a1-4610-a7ee-24a2530dedc3">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d6381aaa6914a0aa526a6b8b3989a7e_I20200630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzUtMS0xLTEtMA_093d3254-fa70-4ac6-b400-0049370161a6">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b55dcaca51f44599a00a8fa68d79d85_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzUtMy0xLTEtMA_6c9c6d00-50ad-45dd-8d3d-9705c4d72865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib957a62df7f549839a60399d078c4472_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzUtNS0xLTEtMA_99b3cefc-a52f-4b8a-8cc9-3e22af1ff34e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41b93ee69de4e0d9701c057ae9ab8db_I20200630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzUtNy0xLTEtMA_aab4016c-ac64-4650-9abc-f26a5e27af28">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d6381aaa6914a0aa526a6b8b3989a7e_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzYtMS0xLTEtMA_57db8432-a8ab-4ab6-9f1f-8452b1b2d046">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b55dcaca51f44599a00a8fa68d79d85_I20200630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzYtMy0xLTEtMA_c4536a3f-1932-43f5-8468-47c09d350222">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib957a62df7f549839a60399d078c4472_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzYtNS0xLTEtMA_005018e2-79a0-4ee0-818a-e3eb6e7ae6b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41b93ee69de4e0d9701c057ae9ab8db_I20200630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzYtNy0xLTEtMA_63307f1b-d628-486e-9173-3a36afda320f">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div></ix:nonNumeric></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:nonNumeric contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjUwOTg_f2f24798-4b5d-419f-98cb-0bdfa11691bb" continuedAt="if990b97bfa0c45aa8680f8da9cef7410" escape="true"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and six months ended December&#160;31, 2020 and 2019, there was <ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyNTg_1adb44f1-d4cd-439d-9a61-361b4322e393"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyNTg_3cf8527e-1053-4359-b3a4-b6e1694eb39d"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyNTg_cbda5875-7428-4047-be8b-3bbc92d91203"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyNTg_ea75b992-5092-4a23-ab7a-0596c24e883d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the debt repayment as described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_97">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, two pay-floating interest rate swaps with notional amounts of $<ix:nonFraction unitRef="usd" contextRef="ic35295a277e6424d9f0eb8e2c6404476_I20191231" decimals="-6" format="ixt:numdotdecimal" name="cah:DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzM2Mjk_81f5a1e1-d90a-4296-94b0-e362687345f0">200</ix:nonFraction> million matured in the second quarter of fiscal 2020. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2019, we entered into forward interest rate swaps with a total notional amount of $<ix:nonFraction unitRef="usd" contextRef="i0f82a2865f2b492a8c478c3a57f6df30_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzYwNDczMTM5ODM1OTA_4753b4e1-98a3-4e23-b943-6102c757adea">100</ix:nonFraction>&#160;million to hedge probable, but not firmly committed, future transactions associated with our debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive loss were $<ix:nonFraction unitRef="usd" contextRef="i796ef5fe827b4eccb2c3f684dc6db76d_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjQzNzQ_2d7e2ffa-91e2-4cfe-a41c-7745a6e22dfa">8</ix:nonFraction>&#160;million for the three months ended December&#160;31, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i8b687b1f81d948059485e5e2a6425863_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjQzODI_c6b73cab-7907-45d6-9a20-0bad4ffbcef7">7</ix:nonFraction>&#160;million for the six months ended December&#160;31, 2020, respectively, and immaterial for the three and six months ended December&#160;31, 2019. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and six months ended December&#160;31, 2020 and 2019. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we entered into a &#165;<ix:nonFraction unitRef="jpy" contextRef="ib15a63d640244c34a6d0227562acaad5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzUxMjU_54c6acf6-6e42-4f20-b787-58f523bba8a9">64.0</ix:nonFraction> billion ($<ix:nonFraction unitRef="usd" contextRef="ib15a63d640244c34a6d0227562acaad5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzUxMjk_fe748a37-e20b-4607-96dc-dd0b46d9a8cc">600</ix:nonFraction> million) cross-currency swap maturing in 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly </span></div></div></ix:nonNumeric></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="if990b97bfa0c45aa8680f8da9cef7410"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $<ix:nonFraction unitRef="usd" contextRef="ib37c4b044c234377901beeef0ec945bd_D20201001-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzM4NDgyOTA3Mzc0MjI_98e9e866-6607-41e4-a1e2-68e2202e5987">27</ix:nonFraction>&#160;million loss and a $<ix:nonFraction unitRef="usd" contextRef="i6845881719c14946a18825ca27e660d9_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzM4NDgyOTA3Mzc0MzA_bda6767c-6080-448f-b9c8-90b5853d23fe">1</ix:nonFraction>&#160;million gain during the three months ended December&#160;31, 2020 and 2019, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="i478d2dd73460414f88583f29a46256a5_D20200701-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzYwNDczMTM5OTI3NjA_1417c383-d772-4faa-87e5-53e33a0c0b11">52</ix:nonFraction>&#160;million loss and a $<ix:nonFraction unitRef="usd" contextRef="i38f0432b47e6439c90226e210f3f5025_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzYwNDczMTM5OTI3NzM_cfd5e724-537a-4cb9-9260-5c03806a9ebe">17</ix:nonFraction>&#160;million gain during the six months ended December&#160;31, 2020 and 2019, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $<ix:nonFraction unitRef="usd" contextRef="ib37c4b044c234377901beeef0ec945bd_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjQzOTQ_d35611fd-e50d-446e-b072-24d0c75345da"><ix:nonFraction unitRef="usd" contextRef="i6845881719c14946a18825ca27e660d9_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjQzOTQ_e6b3e0c2-2d0c-4b4f-b835-3c496bb2d9fd">5</ix:nonFraction></ix:nonFraction>&#160;million during the three months ended December&#160;31, 2020 and 2019, and $<ix:nonFraction unitRef="usd" contextRef="i478d2dd73460414f88583f29a46256a5_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjQ4NzA_0b6f74cb-3bd6-45c5-8b50-49deaa7be6bd">10</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i38f0432b47e6439c90226e210f3f5025_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjQ4NzQ_f77b597c-6e5e-413e-9468-1b6ceb81d374">6</ix:nonFraction>&#160;million during the six months ended December&#160;31, 2020 and 2019, respectively. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $<ix:nonFraction unitRef="usd" contextRef="id909840ad6bb4ab089bf9cbd591c6393_D20201001-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzM4NDgyOTA3Mzc1NDA_5cf1dcba-aad2-4ec8-b5e2-b7d765d1913d">4</ix:nonFraction>&#160;million loss and $<ix:nonFraction unitRef="usd" contextRef="i31ae9f550b884047875a86b44b481e30_D20191001-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzM4NDgyOTA3Mzc1NDg_ebc16aea-50bf-4e2b-bd6b-d16879ef50f6">2</ix:nonFraction>&#160;million loss during the three months ended December&#160;31, 2020 and 2019, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="id293a6a8b52246f59bdad843b0eedcfc_D20200701-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzY1NjU_f71cc8cb-38b2-4320-8f12-732da00e9e2e">5</ix:nonFraction> million loss and $<ix:nonFraction unitRef="usd" contextRef="ie3f98e4ee19e4429b6719301c1f07c3a_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzY1NzI_2a1cdd77-4677-4c9c-8331-e0d479dd16ae">7</ix:nonFraction> million loss during the six months ended December&#160;31, 2020 and 2019, respectively. The principal currencies managed through foreign currency contracts are Chinese renminbi, Canadian dollar, Brazilian real and Japanese yen.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at December&#160;31, 2020 and June&#160;30, 2020 approximate fair value due to their short-term maturities.</span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzc0MjU_ae6cbaba-b431-48ae-a989-ae145bc6df54" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c9f00156d0450788ebefaa19e489ed_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90YWJsZTo5OWU4YmYyOWIzMzk0ODYzYjc3MGVmZGMyY2FjMTRlYy90YWJsZXJhbmdlOjk5ZThiZjI5YjMzOTQ4NjNiNzcwZWZkYzJjYWMxNGVjXzEtMS0xLTEtMA_84b89eb4-4510-4b48-892e-ccfb2a38d51b">7,414</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169899f3ed7e4646b50fcb3a6ea5433a_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90YWJsZTo5OWU4YmYyOWIzMzk0ODYzYjc3MGVmZGMyY2FjMTRlYy90YWJsZXJhbmdlOjk5ZThiZjI5YjMzOTQ4NjNiNzcwZWZkYzJjYWMxNGVjXzEtMy0xLTEtMA_b6038863-f233-45c5-946d-38bd7b36d653">7,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90YWJsZTo5OWU4YmYyOWIzMzk0ODYzYjc3MGVmZGMyY2FjMTRlYy90YWJsZXJhbmdlOjk5ZThiZjI5YjMzOTQ4NjNiNzcwZWZkYzJjYWMxNGVjXzItMS0xLTEtMA_0de4d92e-7e11-4f74-b128-e56f03717630">6,733</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90YWJsZTo5OWU4YmYyOWIzMzk0ODYzYjc3MGVmZGMyY2FjMTRlYy90YWJsZXJhbmdlOjk5ZThiZjI5YjMzOTQ4NjNiNzcwZWZkYzJjYWMxNGVjXzItMy0xLTEtMA_cd70e9b2-254f-4378-95fb-ab8be43ed59e">6,775</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div></ix:continuation><div id="iac867f2b870144f0baf920261d30f765_115"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90ZXh0cmVnaW9uOjM3NTdlN2U1MmQ3ZDQwMGJiMzI0MWMzYmY3NmI2ODNjXzc0MA_6530dfcf-9b74-4199-b5dd-bcca36ba8628" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Shareholders' Equity</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2019, we repurchased <ix:nonFraction unitRef="shares" contextRef="i4523a176fdd843a1871b85358e66f672_D20190701-20191231" decimals="-5" format="ixt:numdotdecimal" name="cah:TreasuryStockAcquiredShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90ZXh0cmVnaW9uOjM3NTdlN2U1MmQ3ZDQwMGJiMzI0MWMzYmY3NmI2ODNjXzM4NDgyOTA2OTkwMDI_d2a913e3-c8c5-4135-90af-7320a836eea8">7.3</ix:nonFraction> million common shares having an aggregate cost of $<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90ZXh0cmVnaW9uOjM3NTdlN2U1MmQ3ZDQwMGJiMzI0MWMzYmY3NmI2ODNjXzMyOTg1MzQ4ODU1ODU_3a031054-b493-4f66-ab2e-7291ca8e655f">350</ix:nonFraction> million. The average price paid per common share was $<ix:nonFraction unitRef="usdPerShare" contextRef="i4523a176fdd843a1871b85358e66f672_D20190701-20191231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90ZXh0cmVnaW9uOjM3NTdlN2U1MmQ3ZDQwMGJiMzI0MWMzYmY3NmI2ODNjXzM4NDgyOTA2OTg5ODg_cd95818e-7417-4156-8f61-5e402f820e15">48.00</ix:nonFraction>. These repurchases were made under an accelerated share repurchase ("ASR") program, which began on August 20, 2019 and was completed on December 4, 2019.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded the repurchases with available cash and short-term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90ZXh0cmVnaW9uOjM3NTdlN2U1MmQ3ZDQwMGJiMzI0MWMzYmY3NmI2ODNjXzczOQ_ed5153f4-8734-4887-9ece-605abac3c912" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i516dad7d9d244946b3629a4006f58d73_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzEtMS0xLTEtMA_be52da7d-5c74-4b21-b974-4d1da4bc4e90">92</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie565dceec6384b15bc38825036cc1367_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzEtMy0xLTEtMA_302a31c6-fa84-4ca8-928a-fdd1bfca5e48">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e8a2cc4f32e492b978886cfa6468d14_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzEtNS0xLTEtMA_48c4f0c9-d02a-4f50-99f9-8cefcc92e5d3">104</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic07137665bed4e8395c06d5d163722d4_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzItMS0xLTEtMA_ea99c04f-96de-4143-a2cd-148d9c90cea4">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e9ec7b4d1de47779baac1a8003f4ac0_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzItMy0xLTEtMA_ae1c9ccb-068b-418e-8491-84b23c645d95">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342dbbcc001646b78a3682ec6c4a043a_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzItNS0xLTEtMA_adcefd7d-9c01-412e-827d-53fa1af90dcc">48</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic07137665bed4e8395c06d5d163722d4_D20200701-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzMtMS0xLTEtMA_37916cdd-32af-48f8-b83c-3102821fc24e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e9ec7b4d1de47779baac1a8003f4ac0_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzMtMy0xLTEtMA_dfd33ea3-f664-47c0-a332-8d33b509fa8d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342dbbcc001646b78a3682ec6c4a043a_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzMtNS0xLTEtMA_311785e5-1171-46ad-ba25-afc13ef2b566">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to Cardinal Health, Inc. net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic07137665bed4e8395c06d5d163722d4_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzQtMS0xLTEtMA_a818ef3b-661a-48a9-b447-61823fc2a5b7">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e9ec7b4d1de47779baac1a8003f4ac0_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzQtMy0xLTEtMA_87029f60-7c0d-4af0-9e31-6d9c11eb15f2">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5611e497378475180730c7bb2d349b0_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzQtNS0xLTEtMA_793c6123-c8ce-4be0-9e0d-126349202f24">51</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98af1fc7fbb546ada30bf032dc682c07_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzUtMS0xLTEtMA_e2b4dffe-3bca-4721-8bfc-bdf57ef19a12">59</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec0a2a9c3a084ecda280560e320b49ff_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzUtMy0xLTEtMA_23bd66a1-87bc-4bf2-b7d1-494492bdb1ec">6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i956ec3fd41944891af79cc5fc668a58d_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzUtNS0xLTEtMA_04882224-6f72-4c1e-b4e4-a93acb817d80">53</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div id="iac867f2b870144f0baf920261d30f765_118"></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzMyOTg1MzQ4ODQzNTc_7e343bb3-e0d6-4d47-95b6-1ee135b07457" continuedAt="ic3719ad2a0ab4532a77b40698b02a4a6" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.</span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzU5OQ_db7e8dde-7d74-4052-bc61-ede15913bedc" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTpkODRlM2MwNTkzMmQ0MTMwYmZjYzQ5YzRjNTUzNGI0MS90YWJsZXJhbmdlOmQ4NGUzYzA1OTMyZDQxMzBiZmNjNDljNGM1NTM0YjQxXzItMS0xLTEtMA_70a706f0-49f3-4f20-b0e5-35f1e4a8e37d">294</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTpkODRlM2MwNTkzMmQ0MTMwYmZjYzQ5YzRjNTUzNGI0MS90YWJsZXJhbmdlOmQ4NGUzYzA1OTMyZDQxMzBiZmNjNDljNGM1NTM0YjQxXzItMy0xLTEtMA_8bd50a8c-e848-4b42-ace6-fccc9ef3238c">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTpkODRlM2MwNTkzMmQ0MTMwYmZjYzQ5YzRjNTUzNGI0MS90YWJsZXJhbmdlOmQ4NGUzYzA1OTMyZDQxMzBiZmNjNDljNGM1NTM0YjQxXzQtMS0xLTEtMA_25355634-1d6a-4a83-8c51-dfe1000c6675">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTpkODRlM2MwNTkzMmQ0MTMwYmZjYzQ5YzRjNTUzNGI0MS90YWJsZXJhbmdlOmQ4NGUzYzA1OTMyZDQxMzBiZmNjNDljNGM1NTM0YjQxXzQtMy0xLTEtMA_94542bf7-e915-4236-b762-884a73d321dd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTpkODRlM2MwNTkzMmQ0MTMwYmZjYzQ5YzRjNTUzNGI0MS90YWJsZXJhbmdlOmQ4NGUzYzA1OTMyZDQxMzBiZmNjNDljNGM1NTM0YjQxXzUtMS0xLTEtMA_bdf6a132-1a3e-4b93-a909-67089f894caf">295</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTpkODRlM2MwNTkzMmQ0MTMwYmZjYzQ5YzRjNTUzNGI0MS90YWJsZXJhbmdlOmQ4NGUzYzA1OTMyZDQxMzBiZmNjNDljNGM1NTM0YjQxXzUtMy0xLTEtMA_94a9f698-7078-4d56-bba8-d6ca43b3d218">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTo4ZTlkNTI1OWY3ZjU0NjA2OTIwZDg4MzQ2M2ViMDFiNy90YWJsZXJhbmdlOjhlOWQ1MjU5ZjdmNTQ2MDY5MjBkODgzNDYzZWIwMWI3XzItMS0xLTEtMA_fdf013a8-1bf8-441d-99ce-e823e8ee00b0">293</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTo4ZTlkNTI1OWY3ZjU0NjA2OTIwZDg4MzQ2M2ViMDFiNy90YWJsZXJhbmdlOjhlOWQ1MjU5ZjdmNTQ2MDY5MjBkODgzNDYzZWIwMWI3XzItMy0xLTEtMA_ef0d402f-ce11-4bc6-98a2-cb6f5599963e">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTo4ZTlkNTI1OWY3ZjU0NjA2OTIwZDg4MzQ2M2ViMDFiNy90YWJsZXJhbmdlOjhlOWQ1MjU5ZjdmNTQ2MDY5MjBkODgzNDYzZWIwMWI3XzQtMS0xLTEtMA_35e4fb4d-2cf6-425e-b59f-3bfda24bd811">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTo4ZTlkNTI1OWY3ZjU0NjA2OTIwZDg4MzQ2M2ViMDFiNy90YWJsZXJhbmdlOjhlOWQ1MjU5ZjdmNTQ2MDY5MjBkODgzNDYzZWIwMWI3XzQtMy0xLTEtMA_0bce88ed-7dd0-4a82-a0c3-a80a3d014e37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTo4ZTlkNTI1OWY3ZjU0NjA2OTIwZDg4MzQ2M2ViMDFiNy90YWJsZXJhbmdlOjhlOWQ1MjU5ZjdmNTQ2MDY5MjBkODgzNDYzZWIwMWI3XzUtMS0xLTEtMA_f3bf9004-acfa-4af4-9d4a-816106c07cf2">295</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTo4ZTlkNTI1OWY3ZjU0NjA2OTIwZDg4MzQ2M2ViMDFiNy90YWJsZXJhbmdlOjhlOWQ1MjU5ZjdmNTQ2MDY5MjBkODgzNDYzZWIwMWI3XzUtMy0xLTEtMA_048ca07b-fa85-41ab-8b38-c5302304d795">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="ic3719ad2a0ab4532a77b40698b02a4a6"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were <ix:nonFraction unitRef="shares" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzI5Mw_1735f8be-d686-4e6f-9167-b0fbb4aab5e1"><ix:nonFraction unitRef="shares" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzI5Mw_7e0ca281-a006-4098-b257-65507cbad5eb">4</ix:nonFraction></ix:nonFraction> million for the three and six months ended December&#160;31, 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were <ix:nonFraction unitRef="shares" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzQ5NDc4MDIzMjU5OTY_2d091ae4-b1fe-4d87-b380-fb0b233f4d79">4</ix:nonFraction> million for the three months ended December&#160;31, 2019 and <ix:nonFraction unitRef="shares" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzQ5NDc4MDIzMjU5OTE_d78c8cc8-178e-46f0-8774-b900c173b7c2">6</ix:nonFraction> million for the six months ended December&#160;31, 2019 (<ix:nonFraction unitRef="shares" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="cah:Sharesthatwouldbeantidilutiveasaresultofnetloss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzQ5NDc4MDIzMjU5NzU_5fd3fd75-3ec3-428b-a58e-1f3083612ba9">1</ix:nonFraction> million of which were anti-dilutive as a result of the year-to-date net loss).</span></div></ix:continuation><div id="iac867f2b870144f0baf920261d30f765_124"></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzUwNDg_dc482083-764e-4fed-9a81-000ebf48d8c0" continuedAt="i3097d8aafffc47a88f23f71541098748" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of <ix:nonFraction unitRef="segment" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzEwMQ_83dc1dbc-d4bc-4a1a-8758-5712eecbe9ee"><ix:nonFraction unitRef="segment" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzEwMQ_eade499d-73c4-475b-adc2-4173be26220a">two</ix:nonFraction></ix:nonFraction> operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i3097d8aafffc47a88f23f71541098748" continuedAt="i04aae0c49a904793bb005cd79a52f2a4"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for each reportable segment and disaggregated revenue within our <ix:nonFraction unitRef="segment" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzQzOTgwNDY1MzAwOTA_83dc1dbc-d4bc-4a1a-8758-5712eecbe9ee"><ix:nonFraction unitRef="segment" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzQzOTgwNDY1MzAwOTA_eade499d-73c4-475b-adc2-4173be26220a">two</ix:nonFraction></ix:nonFraction> reportable segments and Corporate:</span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzUwNjU_043337ee-892f-4706-8750-8d40d0f44045" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3907143d601446b2b2dadc450da37c6e_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzItMS0xLTEtMA_47c2797f-88e2-419e-8e5e-3ecdb20d8bd9">37,040</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5035cf75d04e4c4c800fa6271658ffaf_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzItMy0xLTEtMA_46a45316-0e58-46a4-877c-04d21efb2959">35,501</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d16186a3eb4d6cb347ef265ebd81c2_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzMtMS0xLTEtMA_00a90759-48f0-470c-b9e8-91e266236683">196</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22e6eb5fc5b44eb8e366a0e404097eb_D20191001-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzMtMy0xLTEtMA_7b601f34-7032-476f-bd11-df0f26673306">213</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ff998854edd4eda8d8b8b0671924582_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzQtMS0xLTEtMA_91ba1784-7536-4fef-a5af-339810856dd2">37,236</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i672ee4b7a6194291882b5780e5e828a0_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzQtMy0xLTEtMA_3e17b580-3a9e-4165-9c79-0cf0618cd6a9">35,714</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i341d682d330c4e5392a574b97873cfbc_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzUtMS0xLTEtMA_eccd76db-8d83-4d55-a19d-e669166de6ea">3,729</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6447be5f30b14c9eae4c5ec00d2365d8_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzUtMy0xLTEtMA_e956798c-343f-4540-be04-e06a2295d802">3,498</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4bc1df9803142bca96ee5920f3f9477_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzYtMS0xLTEtMA_491c7c26-aecf-4eed-90c2-1a8454ebbcaa">581</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i618e7649eb974fa9a8bdda5a0b6c884e_D20191001-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzYtMy0xLTEtMA_9785df46-858b-488c-ae88-a9658aa67271">525</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a603a9a33074afd94135cf3f2682615_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzctMS0xLTEtMA_bab3e29e-6ea9-4aa1-a99b-add586ce0a4c">4,310</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i351ff459d8c147dc85efc9f57fefc562_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzctMy0xLTEtMA_2caae90d-0ce0-4920-a459-2d36d5a73b0d">4,023</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9dbdf0124e48049351c12013836acc_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzgtMS0xLTEtMA_6a1c2c2a-b214-46e1-b9a8-cb1203597d5b">41,546</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3403a67c72846a2b090eb4c1dcfe35b_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzgtMy0xLTEtMA_4ce5231b-89f1-46db-b0a0-4ae117bee250">39,737</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id84c7d3f10b5448eae225db35d9ff12b_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzktMS0xLTEtMA_c519da6c-a918-4ca0-8846-6cc64b8b232f">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21a4a9e6c3b742fcb7a36c82c033f21c_D20191001-20191231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzktMy0xLTEtMA_b4af66ba-791a-4c0a-84e6-f03714a1baf7">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzEwLTEtMS0xLTA_ff071527-061f-4e88-b6d3-ce2637cc8c5e">41,541</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzEwLTMtMS0xLTA_b868c0b9-5fb7-4c19-bcce-d9c5fdb20019">39,735</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2240c3e8e514deebd1a13337be4bed5_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzItMS0xLTEtMA_fcfdf8a8-d831-4a07-885d-9f5a5a5c86d3">71,956</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7ee7ef7fae4a23a4607553d24f1f27_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzItMy0xLTEtMA_0bfbf872-643e-4ff1-9789-cc826e0d9e1c">68,713</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a02c3a95ca45b7a140f7699a115bef_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzMtMS0xLTEtMA_d0c953dc-c13e-4d94-b956-a49d1626ac0f">392</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2f1f0f8f9e4cdb9a87fac1bfc1dc87_D20190701-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzMtMy0xLTEtMA_83b07a3b-9a1f-484c-bcb2-9ec507e60533">429</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67c2756a2d8e492a8d27ef7d759a0159_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzQtMS0xLTEtMA_e8859a95-25d1-4a18-bf75-91b83e48e83c">72,348</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic482ae4cb0e845e983854f115696e92f_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzQtMy0xLTEtMA_3dc28e95-dbb3-4227-a7f3-1fc6899a61d8">69,142</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f48b5e33984bdc8b86b397bfccce23_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzUtMS0xLTEtMA_19b9778c-4e5d-4eb2-b863-a7c7c9024bea">7,167</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b678754b9524d1195c6310b764861aa_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzUtMy0xLTEtMA_90a2e76c-db76-4da2-97d0-3959ab018cab">6,944</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8df2c21ec314065818f504c97c1bc8f_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzYtMS0xLTEtMA_18a272dc-710e-41f1-a1e6-db2de4046421">1,100</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d29d41390f4acf84c102913fb223e5_D20190701-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzYtMy0xLTEtMA_c47c3675-c8b8-4960-9f7f-4f666e81c705">996</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8216fd9e5c90433ea29335aa86cb447c_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzctMS0xLTEtMA_2613f558-8e8a-405c-ab1f-7bfa51ef2735">8,267</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482f6ccb403f4a52af97d8ca515a61b8_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzctMy0xLTEtMA_cc06872c-0ce4-4a50-82b9-2888cd8f538c">7,940</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d2c4ed996940f9a46e1b79a9311ba9_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzgtMS0xLTEtMA_1d64c796-65aa-44e7-abf4-b668c8480064">80,615</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i555180dfd31f4d28b52ece1a6f81a588_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzgtMy0xLTEtMA_ad1ea73d-f508-4be4-ad43-80c8cce10574">77,082</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97ef54c441584928af5eb60384fe7457_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzktMS0xLTEtMA_56449087-159e-43f2-9cbe-31924a0d835d">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fc0478dc85442c2942659ad0aeebd71_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzktMy0xLTEtMA_32d6c8d3-ad8f-4123-97de-a65f6d6e21b6">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzEwLTEtMS0xLTA_eba8f0fe-d5cb-4c2b-b6eb-6cdb7062bf3d">80,606</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzEwLTMtMS0xLTA_a42c2144-14c5-45a9-8fe9-1a50384193d4">77,076</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><ix:continuation id="i04aae0c49a904793bb005cd79a52f2a4"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzUwNTQ_606c7fa0-0803-480e-8661-8ddb2393a72f" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i235c9cf737b84394aae05f413fa3c155_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzItMS0xLTEtMA_cad52e31-bc0c-489c-b202-b0e52824e953">40,360</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2d75526aa5047f9adcfa5c2aeac6208_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzItMy0xLTEtMA_9f870e31-b28e-48fb-8248-4d8ba68c81fb">38,670</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bce5f6fb544487b4e3560b83f1110a_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzMtMS0xLTEtMA_5481c992-6dc4-495e-8625-c40993a0566c">1,186</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46dd8327f8a44abf95b9a0332180575f_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzMtMy0xLTEtMA_1fad40fe-5c53-4d0b-aca0-1eaa7381708d">1,067</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9dbdf0124e48049351c12013836acc_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzQtMS0xLTEtMA_34fcd773-37a8-4679-9bb4-bb225caee5f8">41,546</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3403a67c72846a2b090eb4c1dcfe35b_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzQtMy0xLTEtMA_ef6c729e-372d-4a8f-9448-29ae6184bb4a">39,737</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id84c7d3f10b5448eae225db35d9ff12b_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzUtMS0xLTEtMA_2b175319-4fe5-4df3-baf0-2578baa3cfa9">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21a4a9e6c3b742fcb7a36c82c033f21c_D20191001-20191231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzUtMy0xLTEtMA_87251c85-ae2d-4484-abed-34d4e996b3fd">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzYtMS0xLTEtMA_0d65eb96-55a9-4ff4-bafd-eb6fb2f0233c">41,541</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzYtMy0xLTEtMA_85a0a73a-4baf-484c-ba2b-be30ce808ea8">39,735</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b9e9461ba0a47d18b3547d957221cd6_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzItMS0xLTEtMA_fb799775-960b-4e99-9c4b-3e0c40073b2e">78,336</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i761af129229b4859917784980b5aa533_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzItMy0xLTEtMA_fda483a6-b0eb-413d-90ad-e2e2518297be">74,980</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83001f54baa54c32ab564685b11c5fd7_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzMtMS0xLTEtMA_65c24f3f-dd2f-4826-acda-fa8b589021da">2,279</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55908a6cac3f444daad213a201d855ec_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzMtMy0xLTEtMA_e67c26dd-b30e-4f0d-8c1f-e256f8254a8d">2,102</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d2c4ed996940f9a46e1b79a9311ba9_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzQtMS0xLTEtMA_f79a4f5c-536a-4ca7-9fdc-baeeac62cfab">80,615</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i555180dfd31f4d28b52ece1a6f81a588_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzQtMy0xLTEtMA_dc6dc3ac-3274-4fd6-bbfd-bbdf37547ca9">77,082</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97ef54c441584928af5eb60384fe7457_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzUtMS0xLTEtMA_55cdd02a-aef0-45f7-a596-c35fe48257f2">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fc0478dc85442c2942659ad0aeebd71_D20190701-20191231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzUtMy0xLTEtMA_48374aa3-9dc9-4104-803d-196f73fa4202">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzYtMS0xLTEtMA_4590d3f2-43e2-4347-887a-00da091472b3">80,606</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzYtMy0xLTEtMA_b3c813cf-a2cc-4b1e-a210-235c95f9ce8f">77,076</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on early extinguishment of debt; and provision for income taxes. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $<ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="cah:ProjectCostsOnInvestmentAndOtherSpending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzQzMTU_51f46904-3055-482f-a65f-9cbe7541d859">6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="cah:ProjectCostsOnInvestmentAndOtherSpending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzEwOTk1MTE2MzI4NTM_4c56e4bd-0c74-4ddd-98ab-a1d830d5c5c6">17</ix:nonFraction> million for the three months ended December&#160;31, 2020 and 2019, and $<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="cah:ProjectCostsOnInvestmentAndOtherSpending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzQzNjU_0653edaa-bd41-461c-8ed0-29fb80acfd11">11</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="cah:ProjectCostsOnInvestmentAndOtherSpending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzQzNzI_58556d51-4b67-4838-93ff-bddab796caef">20</ix:nonFraction> million for the six months ended December&#160;31, 2020 and 2019, respectively.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid litigation as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="i56512e9ae3444aa3993b873d559a9163_D20200701-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzM4NDgyOTA3MDk3NTk_b3fea09e-3157-4fff-8452-4328cb7ff292">1.02</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="id328a673f19941118ace9480b141deae_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzM4NDgyOTA3MDk3Njc_32d05193-fa88-46a4-82e6-8b427081b660">5.63</ix:nonFraction>&#160;billion</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the six months ended December&#160;31, 2020 and 2019, respectively, which were retained at Corporate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the New York Opioid Stewardship Act as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i24af2662052e41a9916032cdb61e8d12_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzMyOTg1MzQ4OTcxNDQ_27d75f4a-6fdb-48ed-a06d-5dda8b472a58">41</ix:nonFraction>&#160;million during the six months ended December&#160;31, 2020, related to calendar year 2017 and 2018 assessments, which was retained at corporate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a voluntary recall for certain surgical gowns and a voluntary recall and field actions for surgical procedure packs containing affected gowns, we recognized a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i99f293e06fa54cba94cd2fe57d28abad_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryRecallExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzMyOTg1MzQ4OTU4OTg_3549363e-22e1-40d7-95c4-93d748ea0f35">96</ix:nonFraction> million during the three and six months ended December&#160;31, 2019 which was retained at Corporate. </span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzUwNjk_c7eb88ca-33c3-44ce-a16c-800121eb8a24" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ff998854edd4eda8d8b8b0671924582_D20201001-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzItMS0xLTEtMA_e4dc2210-ba64-4805-aade-f324ba0189d2">413</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i672ee4b7a6194291882b5780e5e828a0_D20191001-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzItMy0xLTEtMA_ff6bf733-8daa-4fc9-8abf-c7ccab86e4aa">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a603a9a33074afd94135cf3f2682615_D20201001-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzMtMS0xLTEtMA_493724bf-a8d2-42a7-8aa7-6c44c5d90c2e">236</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i351ff459d8c147dc85efc9f57fefc562_D20191001-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzMtMy0xLTEtMA_4cf54cb6-877a-437e-8386-969ccf24f069">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9dbdf0124e48049351c12013836acc_D20201001-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzQtMS0xLTEtMA_ea8835bc-4828-49b3-9689-884a2832bd29">649</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3403a67c72846a2b090eb4c1dcfe35b_D20191001-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzQtMy0xLTEtMA_95f7423a-b0dd-4779-a8cf-7457c9b32c6f">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id84c7d3f10b5448eae225db35d9ff12b_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzUtMS0xLTEtMA_bed417b0-00e6-47bb-8a67-8deabbf94353">188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21a4a9e6c3b742fcb7a36c82c033f21c_D20191001-20191231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzUtMy0xLTEtMA_752c9559-c481-429d-b65c-c5156db3f215">323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzYtMS0xLTEtMA_37d5d55e-da2d-4bc7-9667-a7a611cf7639">461</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzYtMy0xLTEtMA_ba111e5f-06a0-4c76-ac60-31966d4d9ba3">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67c2756a2d8e492a8d27ef7d759a0159_D20200701-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzItMS0xLTEtMA_c01aa255-7114-456c-808f-b807bae09bd8">815</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic482ae4cb0e845e983854f115696e92f_D20190701-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzItMy0xLTEtMA_a6bc19fb-4f49-4bad-9f86-da9519452323">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8216fd9e5c90433ea29335aa86cb447c_D20200701-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzMtMS0xLTEtMA_5a2a8e74-9d4b-4a00-8e40-675ce6b770f6">466</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482f6ccb403f4a52af97d8ca515a61b8_D20190701-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzMtMy0xLTEtMA_7d6f84bd-cc9e-4180-9952-4121834c5c96">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d2c4ed996940f9a46e1b79a9311ba9_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzQtMS0xLTEtMA_98b24c7f-b1dc-4504-aed9-58883766380f">1,281</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i555180dfd31f4d28b52ece1a6f81a588_D20190701-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzQtMy0xLTEtMA_3946cca2-e973-47bd-8b85-4e9e3ec218ad">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97ef54c441584928af5eb60384fe7457_D20200701-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzUtMS0xLTEtMA_5b37ba70-085e-4439-8cab-5511a53d3b59">1,444</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fc0478dc85442c2942659ad0aeebd71_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzUtMy0xLTEtMA_a0142964-e2df-45b2-9939-da7719447539">6,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating loss</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzYtMS0xLTEtMA_49cf5625-009b-4197-996e-6dd1fd29edea">163</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzYtMy0xLTEtMA_bde96e9b-8cb7-47a9-bba3-f5df3b57a49c">4,930</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzUwNjc_44973233-7266-4ce4-9645-22d00fae6be2" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i704d2da68a27491caa5fcefcc86490a6_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzEtMS0xLTEtMA_4e712fd6-2a93-4126-9ef9-14717175fc8a">23,567</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d5964aeb73c4db18da5611b91ef7334_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzEtMy0xLTEtMA_3c487270-5673-4956-8add-873307b060d8">22,398</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a6b93ede39460b8242e3fedc07e841_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzItMS0xLTEtMA_33424899-6126-4499-847c-62357717e8c1">15,259</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ef56323da34ba69ad0fcaae008d16f_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzItMy0xLTEtMA_8f042edf-a737-4d39-87b6-a39406fca9a8">14,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie417bfafb8654792b0622431ec8134ce_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzMtMS0xLTEtMA_43ed4f86-dc6c-42d9-a014-076367ed1def">5,893</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0bffbd8bb54efaa2c7c406881f23ab_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzMtMy0xLTEtMA_65aad398-0486-48e4-9ebb-38df05e2066b">3,677</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzQtMS0xLTEtMA_7507f1a0-c399-4402-b0d0-50acc9b81a30">44,719</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzQtMy0xLTEtMA_7d198f3d-eeff-4b60-9231-497210c37cb7">40,766</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzMyOTg1MzQ4ODU5NDM_da0609ba-9f02-4a8a-9a4e-e9f7d96a6568" escape="true"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzI0MTQ_67c045d8-d338-4bde-b188-34f568c83c0f" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99bd32109874e86a903049a33a5df8d_D20201001-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzItMS0xLTEtMA_f5b5ddc7-ab14-400a-868b-eb622c7725cf">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87c6a3a8d094aeaba3759a9a6ff0c4e_D20191001-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzItMy0xLTEtMA_efda2ce4-5035-4c9e-a624-78d86a0761b0">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0de7af799774156a7e1dd567937f30d_D20201001-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzMtMS0xLTEtMA_e43c478d-3a0d-442a-858b-66f17f699999">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fba9c013a7b43dd90febed8d8b6afe3_D20191001-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzMtMy0xLTEtMA_dc46346a-b7dc-4239-a57f-0cabe9df0b53">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18cb4783d8449c285fe5638df3c4776_D20201001-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzQtMS0xLTEtMA_64d1b575-4c6d-472a-895a-9bb2ce5884af">6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d0b551d8034adaa39776dff9c6b47b_D20191001-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzQtMy0xLTEtMA_4d22c192-fbfe-4ae1-adbb-68bd8b213fee">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzUtMS0xLTEtMA_5bfd7f73-b392-47d5-b180-b571f4e012d5">23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzUtMy0xLTEtMA_25191a0b-331d-497b-8a5e-935c0219d4b3">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzItMS0xLTEtMA_e64a53f7-046c-4529-ad53-c0b196364433">36</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1e48cb861974ac9b185da35f6452945_D20190701-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzItMy0xLTEtMA_90ae39b9-8ad5-47dd-876c-f2dc0b90b359">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzMtMS0xLTEtMA_1198b165-95ef-442e-b410-ad7b393d1dd8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a2b1e5f55d48c5a3fbb4e2c6d024d6_D20190701-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzMtMy0xLTEtMA_6e974791-6e7e-4e5d-8a8f-575f889ffac7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzQtMS0xLTEtMA_45c653eb-5746-48ac-a617-60e5ef1cad3a">15</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b81892e14d49f39bb77a27503cd87d_D20190701-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzQtMy0xLTEtMA_b4734e30-4eb5-4ec7-9568-440d2ad50493">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzUtMS0xLTEtMA_64c91b9a-459e-4b58-8c08-804e367d83aa">51</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzUtMy0xLTEtMA_96734f95-8933-482c-b8d6-d535c055a28c">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $<ix:nonFraction unitRef="usd" contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzI5NA_211ddb01-48c8-4850-b3da-04de2204d56e">3</ix:nonFraction> million for both the three months ended December&#160;31, 2020 and 2019, and $<ix:nonFraction unitRef="usd" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzM2MA_d71f7c38-30c0-4cdb-b30c-044c42feee78">7</ix:nonFraction> million for both the six months ended December&#160;31, 2020 and 2019.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzUyNQ_1c4a16ff-aa81-4cf4-9159-8cf601204a65">three years</ix:nonNumeric>. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzI0MjU_030686c0-72a2-49b8-9061-50edb67b133a" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9de38f44efc4734a6acc21a07c418b0_I20200630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzEtMS0xLTEtMA_6a70c19f-1037-4119-8816-48a3c723f8d6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9de38f44efc4734a6acc21a07c418b0_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzEtMy0xLTEtMA_a6e1553d-2dfd-43c0-864a-fc0a9c06c03e">45.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzItMS0xLTEtMA_9c795559-4dcf-4343-bc07-783337412abc">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzItMy0xLTEtMA_c2d5a2da-2f19-4a0f-8462-669135b37c77">53.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzMtMS0xLTEtMA_e7dedd4c-959d-4e99-9582-2e2c680d0727">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzMtMy0xLTEtMA_93979af1-103e-4a97-b003-ad6d686e7869">49.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzQtMS0xLTEtMA_092c2082-ad1c-417a-9b20-8f636e938791">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzQtMy0xLTEtMA_75575df0-2b83-4efc-ad6b-b9856164cbb5">48.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6a9264343844c3188592efd3e0a1c18_I20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzUtMS0xLTEtMA_5f49bb8b-26ea-4db0-9753-4d50ed8dab32">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6a9264343844c3188592efd3e0a1c18_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzUtMy0xLTEtMA_150208f2-37c5-4ce4-98d9-e2c1443c7b15">48.29</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="id6a9264343844c3188592efd3e0a1c18_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzg3Mg_ff6b4e23-347b-47a2-a423-b546972f1c1e">111</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzk0NQ_5b625245-6d62-449b-9e82-b6cfb3ebd61e">two years</ix:nonNumeric>.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzEwNTk_54e6171f-72e6-4788-a5d0-b76c51444e4a">three years</ix:nonNumeric> and are exercisable for <ix:nonNumeric contextRef="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231" format="ixt-sec:durwordsen" name="cah:ExercisablePeriodOfPlansInYears" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzEwODY_6947fa6c-4742-468c-8d5e-147f1ff001f1">ten years</ix:nonNumeric> from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzI0MzA_6c51a419-e6f9-47dc-b733-317e46322294" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzEtMS0xLTEtMA_4ca75862-acee-4541-aa61-89b14d0a8b41">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzEtMy0xLTEtMA_7209cdb8-5b33-4083-a179-a633b1315101">65.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzItMS0xLTEtMA_8e12909f-dbb0-4105-abab-ffc0d04884c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzItMy0xLTEtMA_de3cd7c3-91d5-4969-8a2d-874b380b8312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzMtMS0xLTEtMA_721e31b9-65fa-46a1-96b6-5c6593643403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzMtMy0xLTEtMA_8823e544-f3ee-4d9f-989d-29edff26e3a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzQtMS0xLTEtMA_9c512cad-e6b6-465c-9ca3-8b32a77763d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzQtMy0xLTEtMA_1b68c22d-10aa-4a7c-bfbc-192056ccefb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzUtMS0xLTEtMA_99f34743-966c-4aa8-b427-f9e9a5c61939">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzUtMy0xLTEtMA_417b2762-ab62-49fb-aa94-351179700314">67.08</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzYtMS0xLTEtMA_eab39eda-26b7-4dbd-9be2-df0c4199c884">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6d8949488e504051b168d44d36fc8172_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzYtMy0xLTEtMA_17c84d7e-7a62-41ab-93b3-3f4aca699c88">67.27</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i130d53f3f6b041848bc6ad14a45add16_I20201231" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzE0NTU_01fc1c78-5995-4957-a005-f0b0055a33b9">0.3</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzE1Mzg_2e7de27e-69a6-4c88-9f2c-418bfcc8ee77">two years</ix:nonNumeric>. </span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="cah:AdditionalStockOptionPlanDataTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzI0NTI_e9c86ba3-1a74-495e-a2af-827e32db0947" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i130d53f3f6b041848bc6ad14a45add16_I20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTo3OGFkM2FjNTI3MmM0NTk2Yjk4MjUyYjUxNzdhZGQyMC90YWJsZXJhbmdlOjc4YWQzYWM1MjcyYzQ1OTZiOTgyNTJiNTE3N2FkZDIwXzEtMS0xLTEtMA_d2ca9b75-b79f-4556-8c9e-84355b810d79">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdedc1cec79f497e8b28d714bde083dd_I20200630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTo3OGFkM2FjNTI3MmM0NTk2Yjk4MjUyYjUxNzdhZGQyMC90YWJsZXJhbmdlOjc4YWQzYWM1MjcyYzQ1OTZiOTgyNTJiNTE3N2FkZDIwXzEtMy0xLTEtMA_b2af43fa-d198-4adf-a909-ce68fe1ddfbf">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i130d53f3f6b041848bc6ad14a45add16_I20201231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTo3OGFkM2FjNTI3MmM0NTk2Yjk4MjUyYjUxNzdhZGQyMC90YWJsZXJhbmdlOjc4YWQzYWM1MjcyYzQ1OTZiOTgyNTJiNTE3N2FkZDIwXzItMS0xLTEtMA_b7c0c4f4-d02a-4f07-b7a7-c0ab3fd21639">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdedc1cec79f497e8b28d714bde083dd_I20200630" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTo3OGFkM2FjNTI3MmM0NTk2Yjk4MjUyYjUxNzdhZGQyMC90YWJsZXJhbmdlOjc4YWQzYWM1MjcyYzQ1OTZiOTgyNTJiNTE3N2FkZDIwXzItMy0xLTEtMA_768bfa35-6a5a-4f53-a644-eefdc5b635cd">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphNDBmMzg5YjExYWM0NjU3YTMxNDFjZTM0YjgwODAxMy90YWJsZXJhbmdlOmE0MGYzODliMTFhYzQ2NTdhMzE0MWNlMzRiODA4MDEzXzEtMS0xLTEtMA_91e0e320-937e-43d1-9153-d4316f8c7215">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52a2b1e5f55d48c5a3fbb4e2c6d024d6_D20190701-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphNDBmMzg5YjExYWM0NjU3YTMxNDFjZTM0YjgwODAxMy90YWJsZXJhbmdlOmE0MGYzODliMTFhYzQ2NTdhMzE0MWNlMzRiODA4MDEzXzEtMy0xLTEtMA_51da4baf-b4da-4e1a-a8b8-40539f24e8b7">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphNDBmMzg5YjExYWM0NjU3YTMxNDFjZTM0YjgwODAxMy90YWJsZXJhbmdlOmE0MGYzODliMTFhYzQ2NTdhMzE0MWNlMzRiODA4MDEzXzItMS0xLTEtMA_2fa5f343-408e-4f2a-b6a4-fef5df231da7">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52a2b1e5f55d48c5a3fbb4e2c6d024d6_D20190701-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphNDBmMzg5YjExYWM0NjU3YTMxNDFjZTM0YjgwODAxMy90YWJsZXJhbmdlOmE0MGYzODliMTFhYzQ2NTdhMzE0MWNlMzRiODA4MDEzXzItMy0xLTEtMA_9f48caa6-3804-419d-87a1-efc3d11e6cf9">5</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a <ix:nonFraction unitRef="number" contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231" decimals="INF" name="cah:VestingPeriodinyearsforShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzMyOTg1MzQ4ODU5MzY_77f40a4e-9b04-43b2-b791-c36411004404">3</ix:nonFraction>-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from <ix:nonFraction unitRef="number" contextRef="ia83b442716234d0f8c45c343f0fa6ae7_D20200701-20201231" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzE4NDQ_e7eb077d-5ed7-4955-bcc4-9425789bbb48">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i95f32f5a14a64f12ade71f4f086f5c9d_D20200701-20201231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzE4NTA_6678e061-e343-4e61-8726-1e97e0f65d96">240</ix:nonFraction> percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzI0NTA_e9d5e729-cbb1-4e54-8c38-e05cf965b8ea" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea7a98aa2bac4b76bab476be13a2fb31_I20200630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzEtMS0xLTEtMA_6e134238-16d1-48e9-8b4a-cffb5a723893">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea7a98aa2bac4b76bab476be13a2fb31_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzEtMy0xLTEtMA_331d965a-4b69-45d6-b4b8-92fb044a74b4">54.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzItMS0xLTEtMA_109de2ab-705f-47ed-9e24-473a3ca78f4d">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzItMy0xLTEtMA_a5b55fe1-f345-4216-ac09-1e4c48980417">55.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzMtMS0xLTEtMA_f4ee5248-283f-4381-813a-25c4adecb454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzMtMy0xLTEtMA_2a54c07f-7038-421e-9f7a-b288027fba88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzQtMS0xLTEtMA_f41f7624-bacf-4370-915b-87f53d7b169c">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzQtMy0xLTEtMA_0537dc28-a160-463f-b95b-f0eefaa9b982">52.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i625efca7a8ef454c8cbb29134f0f0c7a_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzUtMS0xLTEtMA_3befb5e7-bad8-4d08-8745-a5d3a6a5226b">1.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i625efca7a8ef454c8cbb29134f0f0c7a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzUtMy0xLTEtMA_15f6c4b6-8b97-46b1-aabd-eb4ab9ceaf0e">53.89</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i625efca7a8ef454c8cbb29134f0f0c7a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzIyNTk_85fe3f26-aee9-41d6-8e2b-b78c1fb7f127">38</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzIzMzI_f2f058d0-3c9e-4b91-bfc1-6799cd69a270">two years</ix:nonNumeric> if performance goals are achieved.</span></div></div></ix:nonNumeric></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/721371/000119312508230011/dex31.htm">Amended and Restated Articles of Incorporation of Cardinal Health, Inc., as amended (incorporated by reference to Exhibit 3.1 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137120000133/restatedcodeofregulationsn.htm">Cardinal Health, Inc. Restated Code of Regulations (incorporated by reference to Exhibit 3.2 to Cardinal Health&#8217;s Current Report on Form 8-K filed on November </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137120000133/restatedcodeofregulationsn.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137120000133/restatedcodeofregulationsn.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137120000133/restatedcodeofregulationsn.htm">20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137120000133/restatedcodeofregulationsn.htm">, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a21q2_10qx123120xexhibit311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a21q2_10qx123120xexhibit312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a21q2_10qx123120xexhibit321.htm">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a21q2_10qx123120xexhibit991.htm">Statement Regarding Forward-Looking Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Cardinal Health Website</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health&#160;uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when the company posts news releases,&#160;SEC filings and certain other information on its website.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_136"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:27.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-Q Cross Reference Index</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Form 10-Q Cross Reference Index</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I. Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_61">Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_61">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_40">Quantitative and Qualitative Disclosures about Market Risk </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_40">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_43">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_43">22</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II. Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_46">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_46">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_49">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_49">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_55">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_55">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_133">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_133">42</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_139">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iac867f2b870144f0baf920261d30f765_139">44</a></span></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:3.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="iac867f2b870144f0baf920261d30f765_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Information</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.182%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 5, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;MICHAEL C. KAUFMANN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael C. Kaufmann</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;JASON M. HOLLAR</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jason M. Hollar</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a21q2_10qx123120xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i14d2a67cf9b143838a25f2885d949810_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.1</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael C. Kaufmann, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;5, 2021 </font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:470.25pt"><tr><td style="width:1.0pt"></td><td style="width:147.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:319.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; MICHAEL C. KAUFMANN</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael C. Kaufmann</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a21q2_10qx123120xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i532277ca35ee495f8eda2ee501d0668d_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.2</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jason M. Hollar, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;5, 2021 </font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:136.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:372.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> JASON M. HOLLAR</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a21q2_10qx123120xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i24541329b1244e4f81d04e5e49088000_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></td></tr></table></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael C. Kaufmann, Chief Executive Officer of Cardinal Health, Inc. (the &#8220;Company&#8221;) and Jason M. Hollar, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the Periodic Report on Form 10-Q for the quarter ended December 31, 2020 containing the financial statements of the Company (the &#8220;Periodic Report&#8221;), which this statement accompanies, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;5, 2021 </font></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; MICHAEL C. KAUFMANN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael C. Kaufmann</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>a21q2_10qx123120xexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i089afb329dad4ff3b1a3780b983540f0_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Statement Regarding Forward-Looking Information </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this exhibit, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2020 (the &#8220;2020 Form 10-K&#8221;), our quarterly reports on Form 10-Q, including this one, and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from the COVID-19 pandemic, including the possibility that our manufacturing or distribution facilities will be required to cease operations, whether from government regulation in the United States or internationally, or from reduction in available workforce due to illness&#59; the possibility that we could experience significant delays or disruptions in our supply of medical or pharmaceutical products resulting in an inability to fulfill customer demand, whether attributable to the use of the Defense Production Act or otherwise&#59; the risk that we will not be able to offset significant cost increases or that and price increases for these products could result in lost sales or customer losses or disputes&#59; the possibility that reduced demand for elective medical procedures may result in a sustained reduction in demand for our products&#59; and the potential for us to receive negative publicity resulting from prolonged supply shortages or our participation in industry-wide collaboration to increase the supply of personal protective equipment in the United States&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">competitive pressures in the markets in which we operate, including pricing pressures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the pricing of generic pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches&#59;  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">with respect to our distribution services agreements with branded pharmaceutical manufacturers, changes in the amount of service fees we receive or, in cases where part of our compensation under these agreements is based on branded pharmaceutical price appreciation, changes in the frequency or magnitude of such price appreciation&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturer approaches to pricing branded pharmaceutical products and risks related to our compensation under contractual arrangements with manufacturers being set as a percentage of the wholesale acquisition cost of branded pharmaceuticals&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in the timing or frequency of the introduction of branded pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including the risk that the outcome of these lawsuits and investigations could have a material adverse effect on our results of operations, financial condition, cash flows or liquidity&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential damage to our reputation, adverse operational impacts or other effects that may result from the national opioid epidemic, the allegations that have been made about our role in such epidemic and the ongoing unfavorable publicity surrounding the lawsuits and investigations against us&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the ongoing discussions regarding a potential global settlement of certain opioid lawsuits and investigations against us, including the risk that we could fail to reach a final settlement, that any final settlement reached could require us to pay more than we currently anticipate or could have a negative effect on our liquidity or ability to return money to shareholders and the risk that any injunctive or non-monetary remedies we may agree to could have unintended consequences&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the tax benefit from our self-insurance loss claims, including the possibility that we may receive negative or unfavorable publicity or that the IRS may not agree with our underlying assumptions and judgments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential adverse impact to our financial results from enacted and proposed state taxes or other assessments on the sale or distribution of opioid medications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">costs or claims resulting from a quality issue related to the manufacture of some of our sterile surgical gowns, or other potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties related to our Medical segment's Cardinal Health Brand products, including our ability to manage cost, infrastructure and to retain margin or improve its performance&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the realignment of our Medical segment's supply chain and other businesses, including our ability to achieve the expected benefits from such realignment&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to our cost-savings initiatives or IT infrastructure activities, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">manufacturing disruptions, whether due to regulatory action, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of healthcare fraud and abuse laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in hospital buying groups or hospital buying practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks to our business and information and controls systems in the event that business process improvements, infrastructure modernizations or initiatives to use third-party service providers for key systems and processes are not effectively implemented&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, government investigations, shareholder lawsuits or other legal proceedings&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">possible losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain adequate intellectual property protections&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">increased costs for commodities and other materials used in the Medical segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to introduce and market new products and our ability to keep pace with advances in technology&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significant charges to earnings if goodwill or intangible assets become impaired&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to general political, business, industry, regulatory and market conditions&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other factors described in the &#8220;Risk Factors&#8221; section of the 2020 Form 10-K.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; and similar expressions generally identify &#8220;forward-looking statements,&#8221; which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cah-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9f2b874d-aa0f-4f0c-98af-f0bcbd3c3f24,g:771f989f-b1cf-4cd9-b16a-9064b3a47170-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cah="http://www.cardinal.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardinal.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardinal.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEarnings" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquity" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails">
        <link:definition>2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeverance" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance">
        <link:definition>2104102 - Disclosure - Restructuring and Employee Severance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceTables" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables">
        <link:definition>2305301 - Disclosure - Restructuring and Employee Severance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails">
        <link:definition>2406402 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
        <link:definition>2407403 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceNarativeDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails">
        <link:definition>2408404 - Disclosure - Restructuring and Employee Severance Narative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>2109103 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>2310302 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
        <link:definition>2411405 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>2412406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNarrativeDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails">
        <link:definition>2413407 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowings" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings">
        <link:definition>2114104 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsTables" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables">
        <link:definition>2315303 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails">
        <link:definition>2416408 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails">
        <link:definition>2417409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigation" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation">
        <link:definition>2118105 - Disclosure - Commitments, Contingent Liabilities and Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigationDetails" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails">
        <link:definition>2419410 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cardinal.com/role/IncomeTaxes">
        <link:definition>2120106 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2421411 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardinal.com/role/FairValueMeasurements">
        <link:definition>2122107 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables">
        <link:definition>2323304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>2424412 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.cardinal.com/role/FinancialInstruments">
        <link:definition>2125108 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables">
        <link:definition>2326305 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2427413 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
        <link:definition>2428414 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cardinal.com/role/ShareholdersEquity">
        <link:definition>2129109 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.cardinal.com/role/ShareholdersEquityTables">
        <link:definition>2330306 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>2431415 - Disclosure - Shareholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2432416 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthInc" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc">
        <link:definition>2133110 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncTables" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables">
        <link:definition>2334307 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails">
        <link:definition>2435417 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails">
        <link:definition>2436418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.cardinal.com/role/SegmentInformation">
        <link:definition>2137111 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.cardinal.com/role/SegmentInformationTables">
        <link:definition>2338308 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails">
        <link:definition>2439419 - Disclosure - Segment Information (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails">
        <link:definition>2440420 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentProfitbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails">
        <link:definition>2441421 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails">
        <link:definition>2442422 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAssetsbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails">
        <link:definition>2443423 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.cardinal.com/role/ShareBasedCompensation">
        <link:definition>2144112 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables">
        <link:definition>2345309 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>2446424 - Disclosure - Share-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
        <link:definition>2447425 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails">
        <link:definition>2448426 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
        <link:definition>2449427 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
        <link:definition>2450428 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
        <link:definition>2451429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cah_MaximumQuarterlyPayment" abstract="false" name="MaximumQuarterlyPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_SterileSurgicalGownRecallDomain" abstract="true" name="SterileSurgicalGownRecallDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CommittedReceivablesSalesFacilityProgramMember" abstract="true" name="CommittedReceivablesSalesFacilityProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_PatientRecoveryBusinessMember" abstract="true" name="PatientRecoveryBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_PlaintiffTypeDomain" abstract="true" name="PlaintiffTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_ClassActionLawsuitsMember" abstract="true" name="ClassActionLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_NuclearPrecisionHealthServicesMember" abstract="true" name="NuclearPrecisionHealthServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_TaxMattersAgreementDomain" abstract="true" name="TaxMattersAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_LossContingencyLawsuitsNumber" abstract="false" name="LossContingencyLawsuitsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_NetOperatingLossCarrybackAxis" abstract="true" name="NetOperatingLossCarrybackAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_FacilityExitAndOtherCosts" abstract="false" name="FacilityExitAndOtherCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_ProductLiabilityLawsuitsMember" abstract="true" name="ProductLiabilityLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_LawsuitTypeDomain" abstract="true" name="LawsuitTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_AlamedaCountyMember" abstract="true" name="AlamedaCountyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_OpioidLawsuitsMember" abstract="true" name="OpioidLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_FloatingRateNotesdue2022Member" abstract="true" name="FloatingRateNotesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_NarativeAbstract" abstract="true" name="NarativeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_A4.368Notesdue2047Member" abstract="true" name="A4.368Notesdue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_MedicaldistributionandproductsMember" abstract="true" name="MedicaldistributionandproductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_OpioidLawsuitsStateDomain" abstract="true" name="OpioidLawsuitsStateDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_ProjectCostsOnInvestmentAndOtherSpending" abstract="false" name="ProjectCostsOnInvestmentAndOtherSpending" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_TaxMattersAgreementAxis" abstract="true" name="TaxMattersAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_NotesPayableRepurchased" abstract="false" name="NotesPayableRepurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_TotalOpioidLitigationMember" abstract="true" name="TotalOpioidLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_PlaintiffTypeAxis" abstract="true" name="PlaintiffTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_A4.6Notesdue2043Member" abstract="true" name="A4.6Notesdue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_TreasuryStockAcquiredShares" abstract="false" name="TreasuryStockAcquiredShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_VestingPeriodinyearsforShares" abstract="false" name="VestingPeriodinyearsforShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_IPRDTrademarksandOtherMember" abstract="true" name="IPRDTrademarksandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_Purchaseofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Purchaseofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" abstract="false" name="DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" abstract="true" name="LongTermObligationsandOtherShortTermBorrowingsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_DOJInvestigationMember" abstract="true" name="DOJInvestigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" abstract="false" name="EstimatedLiabilityForNewYorkOpioidStewardshipAct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_PrivatePartiesMember" abstract="true" name="PrivatePartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_NetOperatingLossCarrybackMember" abstract="true" name="NetOperatingLossCarrybackMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_GownRecallAxis" abstract="true" name="GownRecallAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_Netproceedstaxwithholdingsfromsharebasedcompensation" abstract="false" name="Netproceedstaxwithholdingsfromsharebasedcompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_SterileSurgicalGownRecallMember" abstract="true" name="SterileSurgicalGownRecallMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CareFusionMember" abstract="true" name="CareFusionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_A4.9Notesdue2045Member" abstract="true" name="A4.9Notesdue2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_TotalLongTermandShortTermObligations" abstract="false" name="TotalLongTermandShortTermObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_GownRecallDomain" abstract="true" name="GownRecallDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_OpioidLitigationDomain" abstract="true" name="OpioidLitigationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CARESActDomain" abstract="true" name="CARESActDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_AdditionalStockOptionPlanDataTableTextBlock" abstract="false" name="AdditionalStockOptionPlanDataTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cah_LawsuitTypeAxis" abstract="true" name="LawsuitTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_OtherJurisdictionsMember" abstract="true" name="OtherJurisdictionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" abstract="false" name="Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CVSHealthMember" abstract="true" name="CVSHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_ShortTermCreditFacilitiesMember" abstract="true" name="ShortTermCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_IndemnificationReceivable" abstract="false" name="IndemnificationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_A3.41Notesdue2027Member" abstract="true" name="A3.41Notesdue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CarryingAmountofLongTermandotherShortTermBorrowings" abstract="false" name="CarryingAmountofLongTermandotherShortTermBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_NumberofStateAttorneysGeneralfilinglawsuits" abstract="false" name="NumberofStateAttorneysGeneralfilinglawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_MedicalMember" abstract="true" name="MedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_SterileSurgicalGownRecallAxis" abstract="true" name="SterileSurgicalGownRecallAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_Amortizationandotheracquisitionrelatedcosts" abstract="false" name="Amortizationandotheracquisitionrelatedcosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" abstract="true" name="SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_A3.2Notesdue2022Member" abstract="true" name="A3.2Notesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_TaxMatterAxis" abstract="true" name="TaxMatterAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" abstract="true" name="SegmentRevenuefromExternalCustomersbyGeographicAreaTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_PharmaceuticalDistributionandSpecialtyMember" abstract="true" name="PharmaceuticalDistributionandSpecialtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_ExercisablePeriodOfPlansInYears" abstract="false" name="ExercisablePeriodOfPlansInYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cah_NewYorkOpioidStewardshipActMember" abstract="true" name="NewYorkOpioidStewardshipActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_TaxMatterDomain" abstract="true" name="TaxMatterDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_A2.616Notesdue2022Member" abstract="true" name="A2.616Notesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" abstract="false" name="Sharesthatwouldbeantidilutiveasaresultofnetloss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cah_TrademarksAndPatentsMember" abstract="true" name="TrademarksAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CardinalHealthAtHomeMember" abstract="true" name="CardinalHealthAtHomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_A2.4Notesdue2020Member" abstract="true" name="A2.4Notesdue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_OpioidLitigationAxis" abstract="true" name="OpioidLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_AggregateAnnualAssessment" abstract="false" name="AggregateAnnualAssessment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cah-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9f2b874d-aa0f-4f0c-98af-f0bcbd3c3f24,g:771f989f-b1cf-4cd9-b16a-9064b3a47170-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_226a9215-ee0a-421c-abe7-fd57162bd17b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_547c28fd-92ac-4b80-a517-b7e54f67955e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_226a9215-ee0a-421c-abe7-fd57162bd17b" xlink:to="loc_us-gaap_OperatingIncomeLoss_547c28fd-92ac-4b80-a517-b7e54f67955e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7b4e4777-31fd-4a01-907a-dbf775d01c3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_226a9215-ee0a-421c-abe7-fd57162bd17b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7b4e4777-31fd-4a01-907a-dbf775d01c3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0d2824f0-4f8e-4502-acdc-5c3a89b3ca73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_226a9215-ee0a-421c-abe7-fd57162bd17b" xlink:to="loc_us-gaap_InterestExpense_0d2824f0-4f8e-4502-acdc-5c3a89b3ca73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0897de60-c2b8-4b29-8a04-b5aeb7ea4b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_226a9215-ee0a-421c-abe7-fd57162bd17b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0897de60-c2b8-4b29-8a04-b5aeb7ea4b94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c25d4860-c413-4f9d-b5de-d310873a8c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6d467241-cf38-4913-8aaa-11dcc8ea94b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c25d4860-c413-4f9d-b5de-d310873a8c8e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6d467241-cf38-4913-8aaa-11dcc8ea94b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4899be18-5d49-46eb-8f1d-ba69a1919d71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c25d4860-c413-4f9d-b5de-d310873a8c8e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4899be18-5d49-46eb-8f1d-ba69a1919d71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_63c10d06-8289-42f6-9b10-92531e62500a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_1b772fd2-6702-45c9-a5a5-99c9c116f4b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_63c10d06-8289-42f6-9b10-92531e62500a" xlink:to="loc_us-gaap_GrossProfit_1b772fd2-6702-45c9-a5a5-99c9c116f4b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_53fbfca2-b27a-46eb-b4ca-c92bf4aab3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_63c10d06-8289-42f6-9b10-92531e62500a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_53fbfca2-b27a-46eb-b4ca-c92bf4aab3b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_7799f112-0192-4160-b308-3f583ea6b7d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_63c10d06-8289-42f6-9b10-92531e62500a" xlink:to="loc_us-gaap_RestructuringCharges_7799f112-0192-4160-b308-3f583ea6b7d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_3ee5a46b-f409-4e4e-9fd7-f982d4500cc5" xlink:href="cah-20201231.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_63c10d06-8289-42f6-9b10-92531e62500a" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_3ee5a46b-f409-4e4e-9fd7-f982d4500cc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b5e696b3-3dee-45b1-a749-36f825255210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_63c10d06-8289-42f6-9b10-92531e62500a" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b5e696b3-3dee-45b1-a749-36f825255210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_3f2e9097-56ae-4f97-8c56-930679f5be54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_63c10d06-8289-42f6-9b10-92531e62500a" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_3f2e9097-56ae-4f97-8c56-930679f5be54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9ab5cb0b-330f-44f7-a7f5-37d0f79eb0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0f4ce878-49c7-413d-b11a-d0c6ae3211df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9ab5cb0b-330f-44f7-a7f5-37d0f79eb0a4" xlink:to="loc_us-gaap_ProfitLoss_0f4ce878-49c7-413d-b11a-d0c6ae3211df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e65a035b-c3da-4893-86eb-a05e04295305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9ab5cb0b-330f-44f7-a7f5-37d0f79eb0a4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e65a035b-c3da-4893-86eb-a05e04295305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_77aed3b1-8573-4e73-afe9-01134ebdd605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_349309e5-abce-4d9d-a4f9-0d03bbef18f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_77aed3b1-8573-4e73-afe9-01134ebdd605" xlink:to="loc_us-gaap_Revenues_349309e5-abce-4d9d-a4f9-0d03bbef18f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b8963260-5bfb-43d3-94a8-e543851f5e33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_77aed3b1-8573-4e73-afe9-01134ebdd605" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b8963260-5bfb-43d3-94a8-e543851f5e33" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_28e368e8-3d32-4426-b92b-e4e361b89f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2ce46640-ce43-44c1-8f1f-3ff93beb87dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_28e368e8-3d32-4426-b92b-e4e361b89f49" xlink:to="loc_us-gaap_ProfitLoss_2ce46640-ce43-44c1-8f1f-3ff93beb87dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_84c281f9-add4-47e0-a20f-d0d02f291128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_28e368e8-3d32-4426-b92b-e4e361b89f49" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_84c281f9-add4-47e0-a20f-d0d02f291128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8411f2f8-ab78-4163-88e5-9617174f40c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e47bd614-3f75-42fe-9766-8dc4f4da4ba3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8411f2f8-ab78-4163-88e5-9617174f40c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e47bd614-3f75-42fe-9766-8dc4f4da4ba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_66238e77-93a9-43b9-8b90-f2d57887cdff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8411f2f8-ab78-4163-88e5-9617174f40c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_66238e77-93a9-43b9-8b90-f2d57887cdff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_61973135-d86b-4dee-8dba-9cb08fd71be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_125d1e07-cd6d-4fb9-836a-c5d58c113ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_61973135-d86b-4dee-8dba-9cb08fd71be3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_125d1e07-cd6d-4fb9-836a-c5d58c113ad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3ba2b62a-fecf-4ba8-a1a0-b94473ef0e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_61973135-d86b-4dee-8dba-9cb08fd71be3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3ba2b62a-fecf-4ba8-a1a0-b94473ef0e14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4246c500-72c7-45c7-a814-65974b8aaa8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7213a971-a384-4237-a9f0-88953f832a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4246c500-72c7-45c7-a814-65974b8aaa8f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7213a971-a384-4237-a9f0-88953f832a8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_2bf8018c-a192-463e-a53f-d8065e5c060d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4246c500-72c7-45c7-a814-65974b8aaa8f" xlink:to="loc_us-gaap_ReceivablesNetCurrent_2bf8018c-a192-463e-a53f-d8065e5c060d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_34fa53d6-d6ed-4fcc-abff-e796aaaf8249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4246c500-72c7-45c7-a814-65974b8aaa8f" xlink:to="loc_us-gaap_InventoryNet_34fa53d6-d6ed-4fcc-abff-e796aaaf8249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_53aaa6f7-d295-4e77-8dc3-41f0d6509042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4246c500-72c7-45c7-a814-65974b8aaa8f" xlink:to="loc_us-gaap_OtherAssetsCurrent_53aaa6f7-d295-4e77-8dc3-41f0d6509042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_166ad2cf-a3ce-4ffc-88ef-30cb8bb0a09b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c5831594-5987-427a-939b-ef610bb840e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_166ad2cf-a3ce-4ffc-88ef-30cb8bb0a09b" xlink:to="loc_us-gaap_AssetsCurrent_c5831594-5987-427a-939b-ef610bb840e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_42e8bba5-df0f-49b2-8ff3-8603e311d868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_166ad2cf-a3ce-4ffc-88ef-30cb8bb0a09b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_42e8bba5-df0f-49b2-8ff3-8603e311d868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_9ea29576-3825-44b7-8855-010b5ce646ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_166ad2cf-a3ce-4ffc-88ef-30cb8bb0a09b" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_9ea29576-3825-44b7-8855-010b5ce646ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_311ee8d2-bd10-4ea7-a59b-05b654e54263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_166ad2cf-a3ce-4ffc-88ef-30cb8bb0a09b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_311ee8d2-bd10-4ea7-a59b-05b654e54263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ce2f7aec-2fc0-46bf-a0b9-4d8cca9a3133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e1715483-4643-49f7-a26d-7492345b266e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ce2f7aec-2fc0-46bf-a0b9-4d8cca9a3133" xlink:to="loc_us-gaap_LiabilitiesCurrent_e1715483-4643-49f7-a26d-7492345b266e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_613f79a4-6161-45c0-a25e-bfd454b933ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ce2f7aec-2fc0-46bf-a0b9-4d8cca9a3133" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_613f79a4-6161-45c0-a25e-bfd454b933ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_c1302530-9fbf-4a55-a557-d8818816b35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ce2f7aec-2fc0-46bf-a0b9-4d8cca9a3133" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_c1302530-9fbf-4a55-a557-d8818816b35e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b74b1d26-5d3b-499b-9340-971de785a8af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ce2f7aec-2fc0-46bf-a0b9-4d8cca9a3133" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b74b1d26-5d3b-499b-9340-971de785a8af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7919cde1-90f6-45c1-a8a2-02a826a85e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6a291d2a-4a1b-43f6-b0d1-70d4823e8fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7919cde1-90f6-45c1-a8a2-02a826a85e83" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6a291d2a-4a1b-43f6-b0d1-70d4823e8fed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a7b01a8d-8c2c-4e7f-8ab6-0eac367391d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7919cde1-90f6-45c1-a8a2-02a826a85e83" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a7b01a8d-8c2c-4e7f-8ab6-0eac367391d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_13064e2c-2749-4d0f-962f-f902c97fcecd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7919cde1-90f6-45c1-a8a2-02a826a85e83" xlink:to="loc_us-gaap_AccountsPayableCurrent_13064e2c-2749-4d0f-962f-f902c97fcecd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_40fe7fc3-35c1-4606-a3fa-a51664c64b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_785def73-4b00-46fa-a7cd-a16a683f5f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_40fe7fc3-35c1-4606-a3fa-a51664c64b1a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_785def73-4b00-46fa-a7cd-a16a683f5f50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_eea91a8b-677b-4cb2-ba14-368e96d9c0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_40fe7fc3-35c1-4606-a3fa-a51664c64b1a" xlink:to="loc_us-gaap_PreferredStockValue_eea91a8b-677b-4cb2-ba14-368e96d9c0d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f9eec29f-cfe4-44e5-9b68-7ecab0793101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_40fe7fc3-35c1-4606-a3fa-a51664c64b1a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f9eec29f-cfe4-44e5-9b68-7ecab0793101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_92111e01-d5d7-4cc3-ad0e-adfdd6ebba32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_40fe7fc3-35c1-4606-a3fa-a51664c64b1a" xlink:to="loc_us-gaap_CommonStockValue_92111e01-d5d7-4cc3-ad0e-adfdd6ebba32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_65e90e7f-ec29-4eba-8ac1-0107f7bdf7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_40fe7fc3-35c1-4606-a3fa-a51664c64b1a" xlink:to="loc_us-gaap_TreasuryStockValue_65e90e7f-ec29-4eba-8ac1-0107f7bdf7fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42c9bf4d-49c3-48d7-9400-b3a59cc10d81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1adcf6b0-0c4f-44a8-bd75-e7ea275891b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42c9bf4d-49c3-48d7-9400-b3a59cc10d81" xlink:to="loc_us-gaap_CommonStockValue_1adcf6b0-0c4f-44a8-bd75-e7ea275891b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cb09ac58-e31e-4cef-8a4c-280f04692e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42c9bf4d-49c3-48d7-9400-b3a59cc10d81" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cb09ac58-e31e-4cef-8a4c-280f04692e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_01a395a5-126e-4e64-b4f8-873177f82a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42c9bf4d-49c3-48d7-9400-b3a59cc10d81" xlink:to="loc_us-gaap_TreasuryStockValue_01a395a5-126e-4e64-b4f8-873177f82a27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_56f8494b-8824-44db-bf51-faf0164962ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42c9bf4d-49c3-48d7-9400-b3a59cc10d81" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_56f8494b-8824-44db-bf51-faf0164962ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_3f596be4-ea00-4520-8035-606edb8c9461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42c9bf4d-49c3-48d7-9400-b3a59cc10d81" xlink:to="loc_us-gaap_MinorityInterest_3f596be4-ea00-4520-8035-606edb8c9461" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_03c4b037-b3e3-48cc-ad74-0d6fb0af4c55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_8278605b-9510-401d-ab96-fbf0ceaa0720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_03c4b037-b3e3-48cc-ad74-0d6fb0af4c55" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_8278605b-9510-401d-ab96-fbf0ceaa0720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_07697b4e-84cc-46bb-b614-e0c40a582159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_03c4b037-b3e3-48cc-ad74-0d6fb0af4c55" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_07697b4e-84cc-46bb-b614-e0c40a582159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_195d515d-e7b8-4a41-b7ac-6b67e872a7ad" xlink:href="cah-20201231.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_03c4b037-b3e3-48cc-ad74-0d6fb0af4c55" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_195d515d-e7b8-4a41-b7ac-6b67e872a7ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_47cedeb5-e9f6-413a-8880-b9817ef54138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_03c4b037-b3e3-48cc-ad74-0d6fb0af4c55" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_47cedeb5-e9f6-413a-8880-b9817ef54138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_66fb73dd-4de9-42ad-a51f-e10305351bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_03c4b037-b3e3-48cc-ad74-0d6fb0af4c55" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_66fb73dd-4de9-42ad-a51f-e10305351bd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_259f9fc8-e40d-4e30-88f2-5a7df1fa42a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b099abc-dfa0-4c1a-8316-2616edf74e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_259f9fc8-e40d-4e30-88f2-5a7df1fa42a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b099abc-dfa0-4c1a-8316-2616edf74e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_279e7543-f396-46cf-af65-00912b4bee20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_259f9fc8-e40d-4e30-88f2-5a7df1fa42a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_279e7543-f396-46cf-af65-00912b4bee20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_00be9152-f664-4ca5-b0d9-6584db7a6fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_259f9fc8-e40d-4e30-88f2-5a7df1fa42a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_00be9152-f664-4ca5-b0d9-6584db7a6fcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7d0da3bf-5258-4478-86d9-f2e4afd2edca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_259f9fc8-e40d-4e30-88f2-5a7df1fa42a9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7d0da3bf-5258-4478-86d9-f2e4afd2edca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e97ea57f-0246-43d0-8cce-90affba7d943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_67232aa9-3e49-44c7-aa55-e9780054b3bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e97ea57f-0246-43d0-8cce-90affba7d943" xlink:to="loc_us-gaap_ProfitLoss_67232aa9-3e49-44c7-aa55-e9780054b3bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_418c23d1-9f70-4f0f-a826-e1861fee91dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e97ea57f-0246-43d0-8cce-90affba7d943" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_418c23d1-9f70-4f0f-a826-e1861fee91dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_fa0f1428-6154-4be2-a089-21e6f4cfe0a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e97ea57f-0246-43d0-8cce-90affba7d943" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_fa0f1428-6154-4be2-a089-21e6f4cfe0a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ec8dccce-58fb-4a35-8222-aec965155f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e97ea57f-0246-43d0-8cce-90affba7d943" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ec8dccce-58fb-4a35-8222-aec965155f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4bc91821-c9a2-4bf0-813b-e675564e2955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e97ea57f-0246-43d0-8cce-90affba7d943" xlink:to="loc_us-gaap_ShareBasedCompensation_4bc91821-c9a2-4bf0-813b-e675564e2955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_c7d35737-309f-4adb-b8bf-b9280209f629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e97ea57f-0246-43d0-8cce-90affba7d943" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_c7d35737-309f-4adb-b8bf-b9280209f629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_4d23efe7-eddd-482b-af71-2e98d4c5731f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e97ea57f-0246-43d0-8cce-90affba7d943" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_4d23efe7-eddd-482b-af71-2e98d4c5731f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c3105ff0-fa72-4a2d-9e28-da40b4d56fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e97ea57f-0246-43d0-8cce-90affba7d943" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c3105ff0-fa72-4a2d-9e28-da40b4d56fd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4c3b3b5e-4c9b-444d-ad42-b9fb427c4fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e97ea57f-0246-43d0-8cce-90affba7d943" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4c3b3b5e-4c9b-444d-ad42-b9fb427c4fea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_8feb685c-4aaa-4ce5-a3a9-c05b0fffcc44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e97ea57f-0246-43d0-8cce-90affba7d943" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_8feb685c-4aaa-4ce5-a3a9-c05b0fffcc44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9d7a2665-ec55-43c3-9539-ce117f38ec20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_53980ca3-97fc-48b2-8ae7-f5b2e7454385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9d7a2665-ec55-43c3-9539-ce117f38ec20" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_53980ca3-97fc-48b2-8ae7-f5b2e7454385" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3a4ff40a-142d-4bf0-a325-cd1cdaf30527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9d7a2665-ec55-43c3-9539-ce117f38ec20" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3a4ff40a-142d-4bf0-a325-cd1cdaf30527" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_d8050785-4925-412f-9838-d1075686a59c" xlink:href="cah-20201231.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9d7a2665-ec55-43c3-9539-ce117f38ec20" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_d8050785-4925-412f-9838-d1075686a59c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_bdfae456-3a64-42b5-a018-37f8ec5c97a4" xlink:href="cah-20201231.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9d7a2665-ec55-43c3-9539-ce117f38ec20" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_bdfae456-3a64-42b5-a018-37f8ec5c97a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_e467c9e3-587c-44a7-8600-4b1aad5ba041" xlink:href="cah-20201231.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9d7a2665-ec55-43c3-9539-ce117f38ec20" xlink:to="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_e467c9e3-587c-44a7-8600-4b1aad5ba041" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeverance"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeveranceTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_4481559a-ecf2-4331-ae40-58756e5a3841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_5d5c86fc-ff5d-43fc-a5b3-9618a7453df2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_4481559a-ecf2-4331-ae40-58756e5a3841" xlink:to="loc_us-gaap_SeveranceCosts1_5d5c86fc-ff5d-43fc-a5b3-9618a7453df2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_912fd586-3838-4206-a111-6f53542163ba" xlink:href="cah-20201231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_4481559a-ecf2-4331-ae40-58756e5a3841" xlink:to="loc_cah_FacilityExitAndOtherCosts_912fd586-3838-4206-a111-6f53542163ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20201231.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="simple" xlink:href="cah-20201231.xsd#LongTermObligationsandOtherShortTermBorrowingsTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20201231.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20201231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20201231.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20201231.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20201231.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5a7df678-a364-4300-82f7-5757107d44fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_dcf44499-e143-420f-8830-1e6730757b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5a7df678-a364-4300-82f7-5757107d44fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_dcf44499-e143-420f-8830-1e6730757b76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bb3e4ab4-41af-4bc2-82bd-325d869534af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5a7df678-a364-4300-82f7-5757107d44fb" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_bb3e4ab4-41af-4bc2-82bd-325d869534af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20201231.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20201231.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_04dd20d1-fb34-46c7-8232-c5349eb9bbb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7e6a9c2f-7885-4ef8-bd99-da3e117051fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_04dd20d1-fb34-46c7-8232-c5349eb9bbb1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7e6a9c2f-7885-4ef8-bd99-da3e117051fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_62fae4b0-2025-4963-97f9-1a1048dfefde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_04dd20d1-fb34-46c7-8232-c5349eb9bbb1" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_62fae4b0-2025-4963-97f9-1a1048dfefde" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformation"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cah-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9f2b874d-aa0f-4f0c-98af-f0bcbd3c3f24,g:771f989f-b1cf-4cd9-b16a-9064b3a47170-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended" id="ia00e57080fe54a909b8438cfc3c37703_CoverPage"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended" id="i1fc6d35f36c04bf0bded7d5b0737e3bd_CondensedConsolidatedStatementsofEarnings"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended" id="i36293d331a4941af84855e8aaacb49db_CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i40411761b1a04fd8875303a6dcb7f984_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ibda0c606a16648efbd76a9184c74ae26_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i1fc4b9b3ebc1440ba7139cdab4442f0e_CondensedConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_9b6467e0-1a97-4d59-8ecd-bb096bc4fef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_CommonStockSharesIssued_9b6467e0-1a97-4d59-8ecd-bb096bc4fef2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e30ba76-91a5-4cc8-b332-30810d3bf927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e30ba76-91a5-4cc8-b332-30810d3bf927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_66a0e276-5002-4b44-b65a-28858d7fa480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_TreasuryStockShares_66a0e276-5002-4b44-b65a-28858d7fa480" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_86ceda50-f70c-4348-8e33-700aaa247e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_TreasuryStockValue_86ceda50-f70c-4348-8e33-700aaa247e5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_46c28eea-55e6-473a-bc7f-3bf26d220d49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_ProfitLoss_46c28eea-55e6-473a-bc7f-3bf26d220d49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_43dcd522-6cf0-4ae0-a114-a26553354598" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_NetIncomeLoss_43dcd522-6cf0-4ae0-a114-a26553354598" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f4f7d007-2e71-44b8-8ecf-64121428f48a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f4f7d007-2e71-44b8-8ecf-64121428f48a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_604d1c90-f059-43cc-b55c-21af3032eabf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_604d1c90-f059-43cc-b55c-21af3032eabf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5dd18a8d-b6ef-4bf2-8b56-106a76fa48ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5dd18a8d-b6ef-4bf2-8b56-106a76fa48ec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8d89b9ee-0528-42ae-86fc-c9b7ed576ecd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8d89b9ee-0528-42ae-86fc-c9b7ed576ecd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_487526d4-6df6-43e7-89a6-29a71971874a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_487526d4-6df6-43e7-89a6-29a71971874a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_3bd7c8ba-221e-4e1b-8f99-03d5774dbbc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_3bd7c8ba-221e-4e1b-8f99-03d5774dbbc4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_7c4ed1d7-a8b5-471d-a5b0-c11bc9303fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_Dividends_7c4ed1d7-a8b5-471d-a5b0-c11bc9303fed" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_51735611-e39f-4712-ba87-3697abdb510e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_StockholdersEquityOther_51735611-e39f-4712-ba87-3697abdb510e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b489bd5a-df1b-4dba-b9d7-2720d0ab7f36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9c310300-b810-4dfc-a4a2-0284f6c1834d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_eee08df9-2540-4098-a929-f66e3d0df558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_a0d763c6-b008-4179-a0be-f789f788ee58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1890b529-c00d-418a-bdd2-f9f1905b2950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1890b529-c00d-418a-bdd2-f9f1905b2950" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1dbbb7c1-0b42-4ecf-8843-3ebd1b86347b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_StatementTable_1dbbb7c1-0b42-4ecf-8843-3ebd1b86347b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_36f58a4d-f550-46fc-86e2-6ed91585c36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1dbbb7c1-0b42-4ecf-8843-3ebd1b86347b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_36f58a4d-f550-46fc-86e2-6ed91585c36c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_36f58a4d-f550-46fc-86e2-6ed91585c36c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_36f58a4d-f550-46fc-86e2-6ed91585c36c" xlink:to="loc_us-gaap_EquityComponentDomain_36f58a4d-f550-46fc-86e2-6ed91585c36c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_36f58a4d-f550-46fc-86e2-6ed91585c36c" xlink:to="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1774f71a-015e-4a3c-89f6-7d67804de58a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:to="loc_us-gaap_CommonStockMember_1774f71a-015e-4a3c-89f6-7d67804de58a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6091f4c3-2ff2-424b-8b89-1387a1ad5420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:to="loc_us-gaap_RetainedEarningsMember_6091f4c3-2ff2-424b-8b89-1387a1ad5420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_56c48de7-cd34-4b36-ab21-ab4ac4f36615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:to="loc_us-gaap_TreasuryStockMember_56c48de7-cd34-4b36-ab21-ab4ac4f36615" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b100e19c-9a97-40bd-ab21-d03d87374018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b100e19c-9a97-40bd-ab21-d03d87374018" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_922585c8-4501-4343-a463-e3f91bc0cc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_922585c8-4501-4343-a463-e3f91bc0cc15" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="if1c3a03eab0b46a38529666ceece96ff_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="ic6f82de2a4854c7ab65a07cba6dc4eb1_BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ic78ec2bf8047431c96ec3adba6a2119e_BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="extended" id="id5dedf1a3acc4ed1b2414566f3163a54_BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeverance"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended" id="ife648a6971554af993179f0262c4567b_RestructuringandEmployeeSeverance"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeveranceTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="extended" id="i4f3981b0ff264a18b07fc52c3d1a0f93_RestructuringandEmployeeSeveranceTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended" id="i9da58645c1604f88a3ce722863ad8687_RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended" id="i920e1bcd30354503a7e1ccd4a3a13120_RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1164faca-4259-4ef4-a592-6bec902f4c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_5855d350-1865-4997-8139-504b6c4af5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1164faca-4259-4ef4-a592-6bec902f4c6f" xlink:to="loc_us-gaap_RestructuringReserveRollForward_5855d350-1865-4997-8139-504b6c4af5ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_843586f3-3114-4186-a5f8-9c6eb23d9d02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_5855d350-1865-4997-8139-504b6c4af5ca" xlink:to="loc_us-gaap_RestructuringReserve_843586f3-3114-4186-a5f8-9c6eb23d9d02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_6ba60779-5535-438a-894f-86c3754a5339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_5855d350-1865-4997-8139-504b6c4af5ca" xlink:to="loc_us-gaap_RestructuringCosts_6ba60779-5535-438a-894f-86c3754a5339" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_c177dd68-c148-4d11-961e-f548deb49e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_5855d350-1865-4997-8139-504b6c4af5ca" xlink:to="loc_us-gaap_PaymentsForRestructuring_c177dd68-c148-4d11-961e-f548deb49e47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7d07a42f-c10b-464b-be3c-a79f80315669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ee85180a-94cb-4d8e-8dfe-efc8ccddd5ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1164faca-4259-4ef4-a592-6bec902f4c6f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ee85180a-94cb-4d8e-8dfe-efc8ccddd5ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_746ec3f7-a9b8-45c8-8659-35593718cad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ee85180a-94cb-4d8e-8dfe-efc8ccddd5ab" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_746ec3f7-a9b8-45c8-8659-35593718cad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_746ec3f7-a9b8-45c8-8659-35593718cad7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_746ec3f7-a9b8-45c8-8659-35593718cad7" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_746ec3f7-a9b8-45c8-8659-35593718cad7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_98d4e799-8990-4899-932b-f96a21490a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_746ec3f7-a9b8-45c8-8659-35593718cad7" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_98d4e799-8990-4899-932b-f96a21490a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_e88e27ea-ded6-4cf7-a70d-7e3087a5c6b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_98d4e799-8990-4899-932b-f96a21490a99" xlink:to="loc_us-gaap_EmployeeSeveranceMember_e88e27ea-ded6-4cf7-a70d-7e3087a5c6b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_14fbdb06-b040-4412-85ed-b1079aac2c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_98d4e799-8990-4899-932b-f96a21490a99" xlink:to="loc_us-gaap_FacilityClosingMember_14fbdb06-b040-4412-85ed-b1079aac2c9d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended" id="ie204feadd0c44334aa0d36f7e359ed05_RestructuringandEmployeeSeveranceNarativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_18957ce5-791e-4ab9-96c6-5763290b6eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_9f1609bf-e61f-49a6-bb15-ac8545e2fd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18957ce5-791e-4ab9-96c6-5763290b6eeb" xlink:to="loc_us-gaap_RestructuringCosts_9f1609bf-e61f-49a6-bb15-ac8545e2fd8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_2e37d45d-9efa-4a8d-9886-a834c98475d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18957ce5-791e-4ab9-96c6-5763290b6eeb" xlink:to="loc_us-gaap_SeveranceCosts1_2e37d45d-9efa-4a8d-9886-a834c98475d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_1b9344a3-0069-4ed3-91c2-c3114f827208" xlink:href="cah-20201231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18957ce5-791e-4ab9-96c6-5763290b6eeb" xlink:to="loc_cah_FacilityExitAndOtherCosts_1b9344a3-0069-4ed3-91c2-c3114f827208" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_957b1a08-48c6-428a-9b80-5e3db1c584a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18957ce5-791e-4ab9-96c6-5763290b6eeb" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_957b1a08-48c6-428a-9b80-5e3db1c584a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a966ea02-e3ba-4b06-be36-a95654024241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_957b1a08-48c6-428a-9b80-5e3db1c584a1" xlink:to="loc_us-gaap_RestructuringPlanAxis_a966ea02-e3ba-4b06-be36-a95654024241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_a966ea02-e3ba-4b06-be36-a95654024241_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_a966ea02-e3ba-4b06-be36-a95654024241" xlink:to="loc_us-gaap_RestructuringPlanDomain_a966ea02-e3ba-4b06-be36-a95654024241_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_eaf91b2b-e588-4aaf-9c8e-308af5fed369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_a966ea02-e3ba-4b06-be36-a95654024241" xlink:to="loc_us-gaap_RestructuringPlanDomain_eaf91b2b-e588-4aaf-9c8e-308af5fed369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_e9f65f63-aaf1-4c1f-b339-f11cfb863928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_957b1a08-48c6-428a-9b80-5e3db1c584a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_e9f65f63-aaf1-4c1f-b339-f11cfb863928" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_e9f65f63-aaf1-4c1f-b339-f11cfb863928_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_e9f65f63-aaf1-4c1f-b339-f11cfb863928" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_e9f65f63-aaf1-4c1f-b339-f11cfb863928_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_472d2e78-3a0f-4626-91f0-439ed2488f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_e9f65f63-aaf1-4c1f-b339-f11cfb863928" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_472d2e78-3a0f-4626-91f0-439ed2488f71" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended" id="iee64e4793be64392a2220b2468e9e9d0_GoodwillandOtherIntangibleAssets"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended" id="i6063161e53b94bb89e2153439523e702_GoodwillandOtherIntangibleAssetsTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended" id="iffd963c6d52b4a59baf48fbe8e5a4c7a_GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_49339e7e-ed8d-4e0b-bbb5-9312750d6bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_01f3ba29-2166-4109-a430-0b24ee09e909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_49339e7e-ed8d-4e0b-bbb5-9312750d6bf7" xlink:to="loc_us-gaap_GoodwillRollForward_01f3ba29-2166-4109-a430-0b24ee09e909" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_34147849-c3b9-46f3-b15f-6060128e4248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_01f3ba29-2166-4109-a430-0b24ee09e909" xlink:to="loc_us-gaap_Goodwill_34147849-c3b9-46f3-b15f-6060128e4248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_fdf0dc58-93b9-4f97-bdcb-7e48dd41fc66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_01f3ba29-2166-4109-a430-0b24ee09e909" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_fdf0dc58-93b9-4f97-bdcb-7e48dd41fc66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_7b0e0688-ae87-4c00-92d8-89dd44890922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_01f3ba29-2166-4109-a430-0b24ee09e909" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_7b0e0688-ae87-4c00-92d8-89dd44890922" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c52b3986-402a-40ad-befa-f1c96ca00e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c65de008-ccc8-4d05-8f77-e98e80253bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_49339e7e-ed8d-4e0b-bbb5-9312750d6bf7" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c65de008-ccc8-4d05-8f77-e98e80253bdc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4df33259-aac1-4df2-acf5-2fcc625d0006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c65de008-ccc8-4d05-8f77-e98e80253bdc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4df33259-aac1-4df2-acf5-2fcc625d0006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4df33259-aac1-4df2-acf5-2fcc625d0006_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4df33259-aac1-4df2-acf5-2fcc625d0006" xlink:to="loc_us-gaap_SegmentDomain_4df33259-aac1-4df2-acf5-2fcc625d0006_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_394e1b4f-b7e7-41b2-9613-39e001b84313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4df33259-aac1-4df2-acf5-2fcc625d0006" xlink:to="loc_us-gaap_SegmentDomain_394e1b4f-b7e7-41b2-9613-39e001b84313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_dd7ee168-cacb-4708-bf47-2559b2adc192" xlink:href="cah-20201231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_394e1b4f-b7e7-41b2-9613-39e001b84313" xlink:to="loc_cah_PharmaceuticalMember_dd7ee168-cacb-4708-bf47-2559b2adc192" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_a182b614-e964-462e-82a9-2b013bb5a156" xlink:href="cah-20201231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_394e1b4f-b7e7-41b2-9613-39e001b84313" xlink:to="loc_cah_MedicalMember_a182b614-e964-462e-82a9-2b013bb5a156" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i3613a69252974f9cb3e1f14676036d4c_GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_36050c4b-996c-47e2-93c6-6c416c7710c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_151b0133-c9c3-4eab-a646-c489e77eab1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_36050c4b-996c-47e2-93c6-6c416c7710c4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_151b0133-c9c3-4eab-a646-c489e77eab1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_85ae8069-632d-438c-a92d-539e20cccd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_36050c4b-996c-47e2-93c6-6c416c7710c4" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_85ae8069-632d-438c-a92d-539e20cccd8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04fabc7f-b418-4f63-bdf8-31e472959311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_85ae8069-632d-438c-a92d-539e20cccd8b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04fabc7f-b418-4f63-bdf8-31e472959311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_04fabc7f-b418-4f63-bdf8-31e472959311_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04fabc7f-b418-4f63-bdf8-31e472959311" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_04fabc7f-b418-4f63-bdf8-31e472959311_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1e53939f-fd3f-4073-aa50-afbb25ba7ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04fabc7f-b418-4f63-bdf8-31e472959311" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1e53939f-fd3f-4073-aa50-afbb25ba7ee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_ed09b6e3-2022-422e-8be4-6a34d9e7dc9e" xlink:href="cah-20201231.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1e53939f-fd3f-4073-aa50-afbb25ba7ee3" xlink:to="loc_cah_IPRDTrademarksandOtherMember_ed09b6e3-2022-422e-8be4-6a34d9e7dc9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590e0046-446a-43dc-b38c-cec240c16ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a44a4f02-1498-46b5-9bf0-d1735b8d669a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590e0046-446a-43dc-b38c-cec240c16ba6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a44a4f02-1498-46b5-9bf0-d1735b8d669a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_751522dc-5183-4661-8bbb-726bdd6815f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590e0046-446a-43dc-b38c-cec240c16ba6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_751522dc-5183-4661-8bbb-726bdd6815f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fea9dfd5-4b44-4012-9bb3-80030082db7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590e0046-446a-43dc-b38c-cec240c16ba6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fea9dfd5-4b44-4012-9bb3-80030082db7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_7f2c2dc8-9e97-4289-8988-97b4c599878e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590e0046-446a-43dc-b38c-cec240c16ba6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_7f2c2dc8-9e97-4289-8988-97b4c599878e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6fab6747-58be-44bf-a439-5d4654a31664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590e0046-446a-43dc-b38c-cec240c16ba6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6fab6747-58be-44bf-a439-5d4654a31664" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63313176-31cf-4086-9e72-fe14f971cc21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6fab6747-58be-44bf-a439-5d4654a31664" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63313176-31cf-4086-9e72-fe14f971cc21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_63313176-31cf-4086-9e72-fe14f971cc21_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63313176-31cf-4086-9e72-fe14f971cc21" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_63313176-31cf-4086-9e72-fe14f971cc21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03e383ca-eca1-4c20-83fa-51c4cefea05a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63313176-31cf-4086-9e72-fe14f971cc21" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03e383ca-eca1-4c20-83fa-51c4cefea05a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_e5ed671d-d588-470e-824f-daceabce2b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03e383ca-eca1-4c20-83fa-51c4cefea05a" xlink:to="loc_us-gaap_CustomerRelationshipsMember_e5ed671d-d588-470e-824f-daceabce2b43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_0c5cb199-ab86-4059-b2aa-e9c2b88cd891" xlink:href="cah-20201231.xsd#cah_TrademarksAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03e383ca-eca1-4c20-83fa-51c4cefea05a" xlink:to="loc_cah_TrademarksAndPatentsMember_0c5cb199-ab86-4059-b2aa-e9c2b88cd891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_2c28d70a-882b-42f9-9352-389c9001187f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03e383ca-eca1-4c20-83fa-51c4cefea05a" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_2c28d70a-882b-42f9-9352-389c9001187f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended" id="ic5fc4ce281724b8494c490ff2c2d2de5_GoodwillandOtherIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f0de954b-b7e0-4e02-9f12-6dcfebaa6dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_63e5ebff-f9b2-40f4-8b71-3a2b216a4e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f0de954b-b7e0-4e02-9f12-6dcfebaa6dcb" xlink:to="loc_us-gaap_Goodwill_63e5ebff-f9b2-40f4-8b71-3a2b216a4e9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b593c014-1beb-4dbb-9aa8-678421b30667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f0de954b-b7e0-4e02-9f12-6dcfebaa6dcb" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b593c014-1beb-4dbb-9aa8-678421b30667" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c405055d-0aeb-435c-9d7c-b2eb133e6036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b593c014-1beb-4dbb-9aa8-678421b30667" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c405055d-0aeb-435c-9d7c-b2eb133e6036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c405055d-0aeb-435c-9d7c-b2eb133e6036_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c405055d-0aeb-435c-9d7c-b2eb133e6036" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c405055d-0aeb-435c-9d7c-b2eb133e6036_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42ce7373-8150-4843-bd70-05820dec8be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c405055d-0aeb-435c-9d7c-b2eb133e6036" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42ce7373-8150-4843-bd70-05820dec8be0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_cb7f75e2-0cf2-4004-902e-c6ac1ffef87d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b593c014-1beb-4dbb-9aa8-678421b30667" xlink:to="loc_srt_ConsolidationItemsAxis_cb7f75e2-0cf2-4004-902e-c6ac1ffef87d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cb7f75e2-0cf2-4004-902e-c6ac1ffef87d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_cb7f75e2-0cf2-4004-902e-c6ac1ffef87d" xlink:to="loc_srt_ConsolidationItemsDomain_cb7f75e2-0cf2-4004-902e-c6ac1ffef87d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ccfb0389-9314-42ac-b1df-5d9cf585fde6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_cb7f75e2-0cf2-4004-902e-c6ac1ffef87d" xlink:to="loc_srt_ConsolidationItemsDomain_ccfb0389-9314-42ac-b1df-5d9cf585fde6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dc5cabd4-041e-424e-97d5-9db3c53b1de2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b593c014-1beb-4dbb-9aa8-678421b30667" xlink:to="loc_srt_RangeAxis_dc5cabd4-041e-424e-97d5-9db3c53b1de2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dc5cabd4-041e-424e-97d5-9db3c53b1de2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dc5cabd4-041e-424e-97d5-9db3c53b1de2" xlink:to="loc_srt_RangeMember_dc5cabd4-041e-424e-97d5-9db3c53b1de2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6ff8ba7f-705c-4512-a334-40ac68745583" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dc5cabd4-041e-424e-97d5-9db3c53b1de2" xlink:to="loc_srt_RangeMember_6ff8ba7f-705c-4512-a334-40ac68745583" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20201231.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended" id="i28002934b3a84e3f9f87b60dc53c700a_LongTermObligationsandOtherShortTermBorrowings"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="simple" xlink:href="cah-20201231.xsd#LongTermObligationsandOtherShortTermBorrowingsTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="extended" id="i98675db637744428892b10301b0f04ef_LongTermObligationsandOtherShortTermBorrowingsTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended" id="ib79031c1ed494187ae706984128150d4_LongTermObligationsandOtherShortTermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_d9cdc18f-721a-4e56-8ad6-a2412b1650a1" xlink:href="cah-20201231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:to="loc_cah_TotalLongTermandShortTermObligations_d9cdc18f-721a-4e56-8ad6-a2412b1650a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c5e855b8-3b88-4393-a607-102f40090b60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c5e855b8-3b88-4393-a607-102f40090b60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NotesPayableRepurchased_4bab324c-ead2-4d85-ae67-42f4e7c721dc" xlink:href="cah-20201231.xsd#cah_NotesPayableRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:to="loc_cah_NotesPayableRepurchased_4bab324c-ead2-4d85-ae67-42f4e7c721dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9280e304-967d-4696-92a1-fa3f11f8ad68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9280e304-967d-4696-92a1-fa3f11f8ad68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_76b4f68a-12e7-4446-818d-504d3a32202d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_76b4f68a-12e7-4446-818d-504d3a32202d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_25cfb98e-3f50-4caf-87a8-e91444ee2ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:to="loc_us-gaap_DebtInstrumentTable_25cfb98e-3f50-4caf-87a8-e91444ee2ef0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aa834377-cc25-4038-8a46-1e6a8dcd1710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_25cfb98e-3f50-4caf-87a8-e91444ee2ef0" xlink:to="loc_us-gaap_DebtInstrumentAxis_aa834377-cc25-4038-8a46-1e6a8dcd1710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aa834377-cc25-4038-8a46-1e6a8dcd1710_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_aa834377-cc25-4038-8a46-1e6a8dcd1710" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aa834377-cc25-4038-8a46-1e6a8dcd1710_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_aa834377-cc25-4038-8a46-1e6a8dcd1710" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.4Notesdue2020Member_108a7218-b3e1-4b53-8f24-e59257d4baa5" xlink:href="cah-20201231.xsd#cah_A2.4Notesdue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A2.4Notesdue2020Member_108a7218-b3e1-4b53-8f24-e59257d4baa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_21196fb3-a80a-41bc-a0fe-e5573e9fdb16" xlink:href="cah-20201231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A2.616Notesdue2022Member_21196fb3-a80a-41bc-a0fe-e5573e9fdb16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.41Notesdue2027Member_7dc9404b-ddb6-49e3-9a1d-7636b4c69455" xlink:href="cah-20201231.xsd#cah_A3.41Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A3.41Notesdue2027Member_7dc9404b-ddb6-49e3-9a1d-7636b4c69455" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_b2e12deb-c5b4-455a-8c94-fe3afb91ef1b" xlink:href="cah-20201231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_b2e12deb-c5b4-455a-8c94-fe3afb91ef1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.6Notesdue2043Member_bb76d2a4-fc96-48b6-b6dc-3ce2d37394e4" xlink:href="cah-20201231.xsd#cah_A4.6Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A4.6Notesdue2043Member_bb76d2a4-fc96-48b6-b6dc-3ce2d37394e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.9Notesdue2045Member_03b6b504-c526-48f2-b07a-f3b4b42dd2e2" xlink:href="cah-20201231.xsd#cah_A4.9Notesdue2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A4.9Notesdue2045Member_03b6b504-c526-48f2-b07a-f3b4b42dd2e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.368Notesdue2047Member_a738a078-f395-4f6f-8a96-41e7de798afd" xlink:href="cah-20201231.xsd#cah_A4.368Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A4.368Notesdue2047Member_a738a078-f395-4f6f-8a96-41e7de798afd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_00cc78c3-ecb5-497c-8932-3f25c2cab788" xlink:href="cah-20201231.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_FloatingRateNotesdue2022Member_00cc78c3-ecb5-497c-8932-3f25c2cab788" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.2Notesdue2022Member_95d4873a-7351-4b8d-8a95-f73ae2da4cb6" xlink:href="cah-20201231.xsd#cah_A3.2Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A3.2Notesdue2022Member_95d4873a-7351-4b8d-8a95-f73ae2da4cb6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_176629cb-33d1-4aa6-8400-7f5251e54bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_25cfb98e-3f50-4caf-87a8-e91444ee2ef0" xlink:to="loc_us-gaap_CreditFacilityAxis_176629cb-33d1-4aa6-8400-7f5251e54bdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_176629cb-33d1-4aa6-8400-7f5251e54bdb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_176629cb-33d1-4aa6-8400-7f5251e54bdb" xlink:to="loc_us-gaap_CreditFacilityDomain_176629cb-33d1-4aa6-8400-7f5251e54bdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cd36c239-d7f6-436c-a5c0-e6479c0ea1fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_176629cb-33d1-4aa6-8400-7f5251e54bdb" xlink:to="loc_us-gaap_CreditFacilityDomain_cd36c239-d7f6-436c-a5c0-e6479c0ea1fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_14cc7717-a9ff-4da0-a610-3a130f6b8786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cd36c239-d7f6-436c-a5c0-e6479c0ea1fe" xlink:to="loc_us-gaap_CommercialPaperMember_14cc7717-a9ff-4da0-a610-3a130f6b8786" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_b75f64fb-f415-4543-ac81-2885e4b907c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cd36c239-d7f6-436c-a5c0-e6479c0ea1fe" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_b75f64fb-f415-4543-ac81-2885e4b907c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_873999fc-a1ac-445b-a06c-195a85673383" xlink:href="cah-20201231.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cd36c239-d7f6-436c-a5c0-e6479c0ea1fe" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_873999fc-a1ac-445b-a06c-195a85673383" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_a681bddd-fdd1-4402-a5dc-ebafc50e1b71" xlink:href="cah-20201231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cd36c239-d7f6-436c-a5c0-e6479c0ea1fe" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_a681bddd-fdd1-4402-a5dc-ebafc50e1b71" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended" id="i378fb3729c8f47e3a246e9925cda3304_LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cff9c8d6-c738-4c2a-bbe1-878ea4a9b299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_2b715a86-b2f0-4233-81d5-406be58fc24d" xlink:href="cah-20201231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cff9c8d6-c738-4c2a-bbe1-878ea4a9b299" xlink:to="loc_cah_TotalLongTermandShortTermObligations_2b715a86-b2f0-4233-81d5-406be58fc24d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7de65fc4-7fcd-42c6-9b1d-51393afdf2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cff9c8d6-c738-4c2a-bbe1-878ea4a9b299" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7de65fc4-7fcd-42c6-9b1d-51393afdf2a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_abf34b70-6552-462f-bd49-77dc63ffc3f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cff9c8d6-c738-4c2a-bbe1-878ea4a9b299" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_abf34b70-6552-462f-bd49-77dc63ffc3f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4b2c9cb1-ae43-412e-a849-3e058db913ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cff9c8d6-c738-4c2a-bbe1-878ea4a9b299" xlink:to="loc_us-gaap_DebtInstrumentTable_4b2c9cb1-ae43-412e-a849-3e058db913ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c8b23d14-a603-4cda-9797-4d4215038ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4b2c9cb1-ae43-412e-a849-3e058db913ab" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c8b23d14-a603-4cda-9797-4d4215038ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c8b23d14-a603-4cda-9797-4d4215038ae1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c8b23d14-a603-4cda-9797-4d4215038ae1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c8b23d14-a603-4cda-9797-4d4215038ae1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_36482b49-6cbd-4b08-9fac-759293a0dd8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c8b23d14-a603-4cda-9797-4d4215038ae1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_36482b49-6cbd-4b08-9fac-759293a0dd8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f3a2af4a-fa68-467f-aa95-00862375282b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4b2c9cb1-ae43-412e-a849-3e058db913ab" xlink:to="loc_us-gaap_DebtInstrumentAxis_f3a2af4a-fa68-467f-aa95-00862375282b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f3a2af4a-fa68-467f-aa95-00862375282b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f3a2af4a-fa68-467f-aa95-00862375282b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f3a2af4a-fa68-467f-aa95-00862375282b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f3a2af4a-fa68-467f-aa95-00862375282b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.4Notesdue2020Member_882cbb14-7bd7-4c4d-8155-4072ea5c21fd" xlink:href="cah-20201231.xsd#cah_A2.4Notesdue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A2.4Notesdue2020Member_882cbb14-7bd7-4c4d-8155-4072ea5c21fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_b7dceaf4-7b1b-453f-85a0-054363ee46a2" xlink:href="cah-20201231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A2.616Notesdue2022Member_b7dceaf4-7b1b-453f-85a0-054363ee46a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.2Notesdue2022Member_a4f744a1-8936-489f-92c5-2b9cd1ffffd0" xlink:href="cah-20201231.xsd#cah_A3.2Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A3.2Notesdue2022Member_a4f744a1-8936-489f-92c5-2b9cd1ffffd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_3bfa977a-b98e-41f4-9f8e-715d43bd7c53" xlink:href="cah-20201231.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_FloatingRateNotesdue2022Member_3bfa977a-b98e-41f4-9f8e-715d43bd7c53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.41Notesdue2027Member_55893ea5-dc7b-450d-bf19-a663464fdea5" xlink:href="cah-20201231.xsd#cah_A3.41Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A3.41Notesdue2027Member_55893ea5-dc7b-450d-bf19-a663464fdea5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.6Notesdue2043Member_e7fc9c05-6e6f-47e8-878d-447bdc62b3b4" xlink:href="cah-20201231.xsd#cah_A4.6Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A4.6Notesdue2043Member_e7fc9c05-6e6f-47e8-878d-447bdc62b3b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.9Notesdue2045Member_a276d7aa-4f08-4157-a3fa-279d8da33763" xlink:href="cah-20201231.xsd#cah_A4.9Notesdue2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A4.9Notesdue2045Member_a276d7aa-4f08-4157-a3fa-279d8da33763" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.368Notesdue2047Member_bada04cc-cca6-4615-923c-93bdf7537ae4" xlink:href="cah-20201231.xsd#cah_A4.368Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A4.368Notesdue2047Member_bada04cc-cca6-4615-923c-93bdf7537ae4" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20201231.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended" id="i42a4a1921abf442ab5f5417bec1053fc_CommitmentsContingentLiabilitiesandLitigation"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended" id="iaf7c5e723fac4cdcad0015af188eb38a_CommitmentsContingentLiabilitiesandLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7349f615-6d0a-4314-9b14-75be63ae426f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_InventoryNet_7349f615-6d0a-4314-9b14-75be63ae426f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_b8785f9b-6b6a-443e-8351-14583ca33585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_b8785f9b-6b6a-443e-8351-14583ca33585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaximumQuarterlyPayment_6e451910-3dac-408a-bf14-ca29fa7b2f02" xlink:href="cah-20201231.xsd#cah_MaximumQuarterlyPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_cah_MaximumQuarterlyPayment_6e451910-3dac-408a-bf14-ca29fa7b2f02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_9268ce21-2ea9-4dde-b5f8-14a592958a2b" xlink:href="cah-20201231.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_cah_LossContingencyLawsuitsNumber_9268ce21-2ea9-4dde-b5f8-14a592958a2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_84b2afd7-df71-4885-9718-931d0f55b721" xlink:href="cah-20201231.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_84b2afd7-df71-4885-9718-931d0f55b721" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_7116ae63-92e0-4fca-8c40-39df31931944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_7116ae63-92e0-4fca-8c40-39df31931944" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_fa9cd899-604d-4a21-9296-b5cca5e7bcd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_LitigationReserve_fa9cd899-604d-4a21-9296-b5cca5e7bcd5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_e5907323-b302-4c0b-b7d2-e311e21ca52b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_e5907323-b302-4c0b-b7d2-e311e21ca52b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_1796696a-49b0-4895-a59c-6e562660f918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_1796696a-49b0-4895-a59c-6e562660f918" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_437d9a6c-ec1d-4635-b68c-414d3486ffdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_437d9a6c-ec1d-4635-b68c-414d3486ffdb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRecallExpense_28be8af9-278b-483b-9ea3-8e4e88f34ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRecallExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_InventoryRecallExpense_28be8af9-278b-483b-9ea3-8e4e88f34ac0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_92dceba4-fda3-418c-95d8-c591201f6c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_92dceba4-fda3-418c-95d8-c591201f6c26" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_92cd238d-8074-4870-9901-647d72510ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_92cd238d-8074-4870-9901-647d72510ed3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2d6cfe63-06da-4b19-a7ae-06824af115b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2d6cfe63-06da-4b19-a7ae-06824af115b7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_1bb25315-1fa0-4645-b163-e64bd4ce31a3" xlink:href="cah-20201231.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_1bb25315-1fa0-4645-b163-e64bd4ce31a3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_b9cfe3e1-91d2-4924-9029-dce82eca081a" xlink:href="cah-20201231.xsd#cah_AggregateAnnualAssessment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_cah_AggregateAnnualAssessment_b9cfe3e1-91d2-4924-9029-dce82eca081a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallAxis_3f0eb5e7-01eb-4197-a33d-fb60748fc66b" xlink:href="cah-20201231.xsd#cah_GownRecallAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_cah_GownRecallAxis_3f0eb5e7-01eb-4197-a33d-fb60748fc66b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallDomain_3f0eb5e7-01eb-4197-a33d-fb60748fc66b_default" xlink:href="cah-20201231.xsd#cah_GownRecallDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_GownRecallAxis_3f0eb5e7-01eb-4197-a33d-fb60748fc66b" xlink:to="loc_cah_GownRecallDomain_3f0eb5e7-01eb-4197-a33d-fb60748fc66b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallDomain_105b87b8-eb0c-4786-891e-bd57875b0fb5" xlink:href="cah-20201231.xsd#cah_GownRecallDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_GownRecallAxis_3f0eb5e7-01eb-4197-a33d-fb60748fc66b" xlink:to="loc_cah_GownRecallDomain_105b87b8-eb0c-4786-891e-bd57875b0fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_eef4b198-0f52-42a1-b716-f163adc0be56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_eef4b198-0f52-42a1-b716-f163adc0be56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_eef4b198-0f52-42a1-b716-f163adc0be56_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_eef4b198-0f52-42a1-b716-f163adc0be56" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_eef4b198-0f52-42a1-b716-f163adc0be56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_921e041d-bd89-4db8-86a2-1f4c6aaf7766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_eef4b198-0f52-42a1-b716-f163adc0be56" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_921e041d-bd89-4db8-86a2-1f4c6aaf7766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7f7eb287-2b37-4a70-879a-5d24abb20c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7f7eb287-2b37-4a70-879a-5d24abb20c72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7f7eb287-2b37-4a70-879a-5d24abb20c72_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7f7eb287-2b37-4a70-879a-5d24abb20c72" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7f7eb287-2b37-4a70-879a-5d24abb20c72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_929e22ab-d905-46a5-911d-cc2ecf1b18fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7f7eb287-2b37-4a70-879a-5d24abb20c72" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_929e22ab-d905-46a5-911d-cc2ecf1b18fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_69df9ede-9085-48d6-8bf9-9f60bc950ef7" xlink:href="cah-20201231.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_cah_OpioidLitigationAxis_69df9ede-9085-48d6-8bf9-9f60bc950ef7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_69df9ede-9085-48d6-8bf9-9f60bc950ef7_default" xlink:href="cah-20201231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_69df9ede-9085-48d6-8bf9-9f60bc950ef7" xlink:to="loc_cah_OpioidLitigationDomain_69df9ede-9085-48d6-8bf9-9f60bc950ef7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_d99419c8-9406-4f23-a774-fe7c3dd6c0bd" xlink:href="cah-20201231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_69df9ede-9085-48d6-8bf9-9f60bc950ef7" xlink:to="loc_cah_OpioidLitigationDomain_d99419c8-9406-4f23-a774-fe7c3dd6c0bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_0afee6fb-67a2-4508-af3f-288f2d62ebcf" xlink:href="cah-20201231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_d99419c8-9406-4f23-a774-fe7c3dd6c0bd" xlink:to="loc_cah_TotalOpioidLitigationMember_0afee6fb-67a2-4508-af3f-288f2d62ebcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_d3373953-4564-486e-acac-21201506830c" xlink:href="cah-20201231.xsd#cah_LawsuitTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_cah_LawsuitTypeAxis_d3373953-4564-486e-acac-21201506830c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_d3373953-4564-486e-acac-21201506830c_default" xlink:href="cah-20201231.xsd#cah_LawsuitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_LawsuitTypeAxis_d3373953-4564-486e-acac-21201506830c" xlink:to="loc_cah_LawsuitTypeDomain_d3373953-4564-486e-acac-21201506830c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_9c4228bc-01a7-418a-aa50-6d6533466441" xlink:href="cah-20201231.xsd#cah_LawsuitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_LawsuitTypeAxis_d3373953-4564-486e-acac-21201506830c" xlink:to="loc_cah_LawsuitTypeDomain_9c4228bc-01a7-418a-aa50-6d6533466441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_6500cc89-4353-4d33-9a89-c32ce45a67d1" xlink:href="cah-20201231.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LawsuitTypeDomain_9c4228bc-01a7-418a-aa50-6d6533466441" xlink:to="loc_cah_ClassActionLawsuitsMember_6500cc89-4353-4d33-9a89-c32ce45a67d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_98457a1b-5268-480e-9042-527975a06e5c" xlink:href="cah-20201231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LawsuitTypeDomain_9c4228bc-01a7-418a-aa50-6d6533466441" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_98457a1b-5268-480e-9042-527975a06e5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_d910f55a-0632-495b-8f60-99b169e7589d" xlink:href="cah-20201231.xsd#cah_PlaintiffTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_cah_PlaintiffTypeAxis_d910f55a-0632-495b-8f60-99b169e7589d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_d910f55a-0632-495b-8f60-99b169e7589d_default" xlink:href="cah-20201231.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_PlaintiffTypeAxis_d910f55a-0632-495b-8f60-99b169e7589d" xlink:to="loc_cah_PlaintiffTypeDomain_d910f55a-0632-495b-8f60-99b169e7589d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_9da79e18-411c-4169-9ffd-80619f369192" xlink:href="cah-20201231.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_PlaintiffTypeAxis_d910f55a-0632-495b-8f60-99b169e7589d" xlink:to="loc_cah_PlaintiffTypeDomain_9da79e18-411c-4169-9ffd-80619f369192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_36d82d12-74a1-4ce2-a502-6270a618ca17" xlink:href="cah-20201231.xsd#cah_PrivatePartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PlaintiffTypeDomain_9da79e18-411c-4169-9ffd-80619f369192" xlink:to="loc_cah_PrivatePartiesMember_36d82d12-74a1-4ce2-a502-6270a618ca17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_54bc3912-926b-417d-b908-118eecec2b09" xlink:href="cah-20201231.xsd#cah_TaxMattersAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_cah_TaxMattersAgreementAxis_54bc3912-926b-417d-b908-118eecec2b09" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_54bc3912-926b-417d-b908-118eecec2b09_default" xlink:href="cah-20201231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMattersAgreementAxis_54bc3912-926b-417d-b908-118eecec2b09" xlink:to="loc_cah_TaxMattersAgreementDomain_54bc3912-926b-417d-b908-118eecec2b09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_c078da48-fe27-4e7c-817e-1e2672b58f42" xlink:href="cah-20201231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMattersAgreementAxis_54bc3912-926b-417d-b908-118eecec2b09" xlink:to="loc_cah_TaxMattersAgreementDomain_c078da48-fe27-4e7c-817e-1e2672b58f42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_40045b92-51b1-4d80-a89b-d98d8f8e04ab" xlink:href="cah-20201231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMattersAgreementDomain_c078da48-fe27-4e7c-817e-1e2672b58f42" xlink:to="loc_cah_TotalOpioidLitigationMember_40045b92-51b1-4d80-a89b-d98d8f8e04ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5af356ad-f6aa-4355-b914-360cf96b8be1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_srt_StatementGeographicalAxis_5af356ad-f6aa-4355-b914-360cf96b8be1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5af356ad-f6aa-4355-b914-360cf96b8be1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5af356ad-f6aa-4355-b914-360cf96b8be1" xlink:to="loc_srt_SegmentGeographicalDomain_5af356ad-f6aa-4355-b914-360cf96b8be1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e0c509f9-99e2-403d-98bd-485bc9e5409e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5af356ad-f6aa-4355-b914-360cf96b8be1" xlink:to="loc_srt_SegmentGeographicalDomain_e0c509f9-99e2-403d-98bd-485bc9e5409e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_09c5a03c-5676-48ef-a703-d25558347ba8" xlink:href="cah-20201231.xsd#cah_AlamedaCountyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e0c509f9-99e2-403d-98bd-485bc9e5409e" xlink:to="loc_cah_AlamedaCountyMember_09c5a03c-5676-48ef-a703-d25558347ba8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_241d5289-7933-48da-911e-73d35f68ed78" xlink:href="cah-20201231.xsd#cah_OtherJurisdictionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e0c509f9-99e2-403d-98bd-485bc9e5409e" xlink:to="loc_cah_OtherJurisdictionsMember_241d5289-7933-48da-911e-73d35f68ed78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1e4ca531-f190-44a1-ac4b-727fee485b0b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_srt_RangeAxis_1e4ca531-f190-44a1-ac4b-727fee485b0b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1e4ca531-f190-44a1-ac4b-727fee485b0b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1e4ca531-f190-44a1-ac4b-727fee485b0b" xlink:to="loc_srt_RangeMember_1e4ca531-f190-44a1-ac4b-727fee485b0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3a957210-8616-4762-aabe-153cba185947" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1e4ca531-f190-44a1-ac4b-727fee485b0b" xlink:to="loc_srt_RangeMember_3a957210-8616-4762-aabe-153cba185947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_09631f5e-3b73-4dce-843e-d2d590ecc6d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3a957210-8616-4762-aabe-153cba185947" xlink:to="loc_srt_MinimumMember_09631f5e-3b73-4dce-843e-d2d590ecc6d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b9de9871-0e21-4011-9719-a3488fc47147" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3a957210-8616-4762-aabe-153cba185947" xlink:to="loc_srt_MaximumMember_b9de9871-0e21-4011-9719-a3488fc47147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8f0612b0-6f2e-45b5-a418-4de4d5bbb99f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8f0612b0-6f2e-45b5-a418-4de4d5bbb99f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_8f0612b0-6f2e-45b5-a418-4de4d5bbb99f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8f0612b0-6f2e-45b5-a418-4de4d5bbb99f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_8f0612b0-6f2e-45b5-a418-4de4d5bbb99f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b97b63a8-2d97-47d2-baf9-ca0d7b09c0eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8f0612b0-6f2e-45b5-a418-4de4d5bbb99f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b97b63a8-2d97-47d2-baf9-ca0d7b09c0eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_5c64932c-1cbe-4c97-9cd2-7837f999a9c2" xlink:href="cah-20201231.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b97b63a8-2d97-47d2-baf9-ca0d7b09c0eb" xlink:to="loc_cah_OpioidLawsuitsMember_5c64932c-1cbe-4c97-9cd2-7837f999a9c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_4cbaa6d2-9c34-4f37-bb97-dd1d21334e06" xlink:href="cah-20201231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b97b63a8-2d97-47d2-baf9-ca0d7b09c0eb" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_4cbaa6d2-9c34-4f37-bb97-dd1d21334e06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7d085ccc-2ed9-4361-80b2-9cb52da3c880" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_srt_MajorCustomersAxis_7d085ccc-2ed9-4361-80b2-9cb52da3c880" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7d085ccc-2ed9-4361-80b2-9cb52da3c880_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7d085ccc-2ed9-4361-80b2-9cb52da3c880" xlink:to="loc_srt_NameOfMajorCustomerDomain_7d085ccc-2ed9-4361-80b2-9cb52da3c880_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1350d850-46be-492a-a6a0-83534552d924" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7d085ccc-2ed9-4361-80b2-9cb52da3c880" xlink:to="loc_srt_NameOfMajorCustomerDomain_1350d850-46be-492a-a6a0-83534552d924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_489b640c-0879-4a1d-bdb5-8a95b59007bf" xlink:href="cah-20201231.xsd#cah_CVSHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1350d850-46be-492a-a6a0-83534552d924" xlink:to="loc_cah_CVSHealthMember_489b640c-0879-4a1d-bdb5-8a95b59007bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c683c0fb-5e0e-4f90-b542-627da018fa18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_srt_LitigationCaseAxis_c683c0fb-5e0e-4f90-b542-627da018fa18" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c683c0fb-5e0e-4f90-b542-627da018fa18_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c683c0fb-5e0e-4f90-b542-627da018fa18" xlink:to="loc_srt_LitigationCaseTypeDomain_c683c0fb-5e0e-4f90-b542-627da018fa18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c683c0fb-5e0e-4f90-b542-627da018fa18" xlink:to="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateDomain_4932613e-2ff4-4a85-be25-0621967c4cd2" xlink:href="cah-20201231.xsd#cah_OpioidLawsuitsStateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:to="loc_cah_OpioidLawsuitsStateDomain_4932613e-2ff4-4a85-be25-0621967c4cd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_0a80d09f-0953-44c5-8c55-b661c6ae89e9" xlink:href="cah-20201231.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:to="loc_cah_OpioidLawsuitsMember_0a80d09f-0953-44c5-8c55-b661c6ae89e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_f0e91e28-840f-44ae-9bc6-fd98ef1572c1" xlink:href="cah-20201231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_f0e91e28-840f-44ae-9bc6-fd98ef1572c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_ff9e7e2e-60cb-40ab-a23d-c901a8fddf53" xlink:href="cah-20201231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_ff9e7e2e-60cb-40ab-a23d-c901a8fddf53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember_0c66d30f-1e83-4adb-b647-56861df4d186" xlink:href="cah-20201231.xsd#cah_DOJInvestigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:to="loc_cah_DOJInvestigationMember_0c66d30f-1e83-4adb-b647-56861df4d186" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4ae1e31c-f1c1-4540-9468-d66f5440dcc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4ae1e31c-f1c1-4540-9468-d66f5440dcc1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4ae1e31c-f1c1-4540-9468-d66f5440dcc1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4ae1e31c-f1c1-4540-9468-d66f5440dcc1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4ae1e31c-f1c1-4540-9468-d66f5440dcc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0bd43821-76f3-44cb-862c-afdd6f31d1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4ae1e31c-f1c1-4540-9468-d66f5440dcc1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0bd43821-76f3-44cb-862c-afdd6f31d1eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5edf83de-26f3-4fe8-b171-890f1c3768b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0bd43821-76f3-44cb-862c-afdd6f31d1eb" xlink:to="loc_us-gaap_SubsequentEventMember_5edf83de-26f3-4fe8-b171-890f1c3768b2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended" id="idee8c7eaab234d8a8706c677c209fb5d_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="ie457424bc779472f9b5b3d7805f8fbf0_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_f23ed0fa-97ae-440d-babf-e6c6ae5a6e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_LitigationReserve_f23ed0fa-97ae-440d-babf-e6c6ae5a6e2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_04986809-728c-4ffe-a233-5d7fca68db2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_04986809-728c-4ffe-a233-5d7fca68db2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e34ce24a-bbac-4149-89a6-bdc304d03bc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e34ce24a-bbac-4149-89a6-bdc304d03bc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b08cd7f6-2108-4afe-9583-2fb06540db4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b08cd7f6-2108-4afe-9583-2fb06540db4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ab6c138c-df88-45f2-9473-1d36e896087a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ab6c138c-df88-45f2-9473-1d36e896087a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_10cac8ab-4374-4d7f-9cfa-f05ef1331959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_10cac8ab-4374-4d7f-9cfa-f05ef1331959" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_5a2b9cbd-6c92-4e41-bcbc-bad08fffbace" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_OpenTaxYear_5a2b9cbd-6c92-4e41-bcbc-bad08fffbace" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_cd5d6157-4821-4ba1-84c9-6c6582995bb6" xlink:href="cah-20201231.xsd#cah_IndemnificationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_cah_IndemnificationReceivable_cd5d6157-4821-4ba1-84c9-6c6582995bb6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ed4cf63-ba29-49cf-acad-bfceff5fad28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ed4cf63-ba29-49cf-acad-bfceff5fad28" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_a97f1439-62f4-4c16-acbf-68fe9c61e366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_LitigationSettlementExpense_a97f1439-62f4-4c16-acbf-68fe9c61e366" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8c33e9c5-4232-43f2-832d-f27726ff3649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8c33e9c5-4232-43f2-832d-f27726ff3649" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_25135d1a-886e-47e5-aa54-420fca8a86b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_IncomeTaxReceivable_25135d1a-886e-47e5-aa54-420fca8a86b6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_708ca2fd-da47-4397-a8d3-05f846526099" xlink:href="cah-20201231.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_cah_OpioidLitigationAxis_708ca2fd-da47-4397-a8d3-05f846526099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_708ca2fd-da47-4397-a8d3-05f846526099_default" xlink:href="cah-20201231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_708ca2fd-da47-4397-a8d3-05f846526099" xlink:to="loc_cah_OpioidLitigationDomain_708ca2fd-da47-4397-a8d3-05f846526099_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_8b809382-e68e-4ef9-91e9-28dddf7cb467" xlink:href="cah-20201231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_708ca2fd-da47-4397-a8d3-05f846526099" xlink:to="loc_cah_OpioidLitigationDomain_8b809382-e68e-4ef9-91e9-28dddf7cb467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_843f12e0-1d1b-4fa9-888f-81d4f8ceaf45" xlink:href="cah-20201231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_8b809382-e68e-4ef9-91e9-28dddf7cb467" xlink:to="loc_cah_TotalOpioidLitigationMember_843f12e0-1d1b-4fa9-888f-81d4f8ceaf45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_af547712-8dff-42c7-8eef-baf214d7bc2c" xlink:href="cah-20201231.xsd#cah_TaxMatterAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_cah_TaxMatterAxis_af547712-8dff-42c7-8eef-baf214d7bc2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_af547712-8dff-42c7-8eef-baf214d7bc2c_default" xlink:href="cah-20201231.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMatterAxis_af547712-8dff-42c7-8eef-baf214d7bc2c" xlink:to="loc_cah_TaxMatterDomain_af547712-8dff-42c7-8eef-baf214d7bc2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_59d002ea-3585-4d8d-95f0-1d6393b25d4d" xlink:href="cah-20201231.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMatterAxis_af547712-8dff-42c7-8eef-baf214d7bc2c" xlink:to="loc_cah_TaxMatterDomain_59d002ea-3585-4d8d-95f0-1d6393b25d4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_b4f96812-b04f-47fa-b1fe-c339d9f482fe" xlink:href="cah-20201231.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_59d002ea-3585-4d8d-95f0-1d6393b25d4d" xlink:to="loc_cah_PatientRecoveryBusinessMember_b4f96812-b04f-47fa-b1fe-c339d9f482fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_bf6e6611-f396-4361-accd-4f04bc7dbd34" xlink:href="cah-20201231.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_59d002ea-3585-4d8d-95f0-1d6393b25d4d" xlink:to="loc_cah_CareFusionMember_bf6e6611-f396-4361-accd-4f04bc7dbd34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ae59cfae-9e3d-4cf0-b962-032dbd5269ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ae59cfae-9e3d-4cf0-b962-032dbd5269ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae59cfae-9e3d-4cf0-b962-032dbd5269ff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ae59cfae-9e3d-4cf0-b962-032dbd5269ff" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae59cfae-9e3d-4cf0-b962-032dbd5269ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a2270a6-3b9b-45d6-8181-375a2ef23dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ae59cfae-9e3d-4cf0-b962-032dbd5269ff" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a2270a6-3b9b-45d6-8181-375a2ef23dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_6755f5df-1a5d-4ae2-aa2f-967b7847ff47" xlink:href="cah-20201231.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a2270a6-3b9b-45d6-8181-375a2ef23dc9" xlink:to="loc_cah_PatientRecoveryBusinessMember_6755f5df-1a5d-4ae2-aa2f-967b7847ff47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_0e522e0f-667c-4ff4-983e-c50f1aa78855" xlink:href="cah-20201231.xsd#cah_TaxMattersAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_cah_TaxMattersAgreementAxis_0e522e0f-667c-4ff4-983e-c50f1aa78855" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_0e522e0f-667c-4ff4-983e-c50f1aa78855_default" xlink:href="cah-20201231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMattersAgreementAxis_0e522e0f-667c-4ff4-983e-c50f1aa78855" xlink:to="loc_cah_TaxMattersAgreementDomain_0e522e0f-667c-4ff4-983e-c50f1aa78855_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_c20249a3-65c2-4242-bb0a-77d9d5840ca3" xlink:href="cah-20201231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMattersAgreementAxis_0e522e0f-667c-4ff4-983e-c50f1aa78855" xlink:to="loc_cah_TaxMattersAgreementDomain_c20249a3-65c2-4242-bb0a-77d9d5840ca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_dfebc0ff-b274-4419-850d-19f4c45352d0" xlink:href="cah-20201231.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMattersAgreementDomain_c20249a3-65c2-4242-bb0a-77d9d5840ca3" xlink:to="loc_cah_CareFusionMember_dfebc0ff-b274-4419-850d-19f4c45352d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_830b2da2-d0bc-4861-a44f-a33ec3d563b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_830b2da2-d0bc-4861-a44f-a33ec3d563b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_830b2da2-d0bc-4861-a44f-a33ec3d563b9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_830b2da2-d0bc-4861-a44f-a33ec3d563b9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_830b2da2-d0bc-4861-a44f-a33ec3d563b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ce163380-fb37-4681-b002-d25e04a5e781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_830b2da2-d0bc-4861-a44f-a33ec3d563b9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ce163380-fb37-4681-b002-d25e04a5e781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_0b2b8ba0-052b-47f1-b016-2dfe72aded49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ce163380-fb37-4681-b002-d25e04a5e781" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_0b2b8ba0-052b-47f1-b016-2dfe72aded49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd1a5ea8-7d5d-4e5a-9efa-92734c915abe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_srt_RangeAxis_fd1a5ea8-7d5d-4e5a-9efa-92734c915abe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd1a5ea8-7d5d-4e5a-9efa-92734c915abe_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fd1a5ea8-7d5d-4e5a-9efa-92734c915abe" xlink:to="loc_srt_RangeMember_fd1a5ea8-7d5d-4e5a-9efa-92734c915abe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_836ccfd5-98c5-472c-9af1-8a727075ad1e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fd1a5ea8-7d5d-4e5a-9efa-92734c915abe" xlink:to="loc_srt_RangeMember_836ccfd5-98c5-472c-9af1-8a727075ad1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4ef5f16d-90d1-4dd5-9ac7-61a509b56e19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_836ccfd5-98c5-472c-9af1-8a727075ad1e" xlink:to="loc_srt_MinimumMember_4ef5f16d-90d1-4dd5-9ac7-61a509b56e19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a06a03cc-c5cd-4d54-92bf-e75f744a3aa6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_836ccfd5-98c5-472c-9af1-8a727075ad1e" xlink:to="loc_srt_MaximumMember_a06a03cc-c5cd-4d54-92bf-e75f744a3aa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis_6083ab62-caf1-49ec-b4f0-d491f7f096ff" xlink:href="cah-20201231.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_cah_NetOperatingLossCarrybackAxis_6083ab62-caf1-49ec-b4f0-d491f7f096ff" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_6083ab62-caf1-49ec-b4f0-d491f7f096ff_default" xlink:href="cah-20201231.xsd#cah_CARESActDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_6083ab62-caf1-49ec-b4f0-d491f7f096ff" xlink:to="loc_cah_CARESActDomain_6083ab62-caf1-49ec-b4f0-d491f7f096ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_62956ba0-a52d-42cf-bd03-24c209196860" xlink:href="cah-20201231.xsd#cah_CARESActDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_6083ab62-caf1-49ec-b4f0-d491f7f096ff" xlink:to="loc_cah_CARESActDomain_62956ba0-a52d-42cf-bd03-24c209196860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackMember_9aa7e8d5-2a19-479b-8796-bcf8ccaa8e69" xlink:href="cah-20201231.xsd#cah_NetOperatingLossCarrybackMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CARESActDomain_62956ba0-a52d-42cf-bd03-24c209196860" xlink:to="loc_cah_NetOperatingLossCarrybackMember_9aa7e8d5-2a19-479b-8796-bcf8ccaa8e69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_06d935f0-9392-4702-80af-e00fa753280e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_srt_StatementScenarioAxis_06d935f0-9392-4702-80af-e00fa753280e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_06d935f0-9392-4702-80af-e00fa753280e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_06d935f0-9392-4702-80af-e00fa753280e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_06d935f0-9392-4702-80af-e00fa753280e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f6708300-03bd-4693-ae9c-59907efa118c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_06d935f0-9392-4702-80af-e00fa753280e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f6708300-03bd-4693-ae9c-59907efa118c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0cbe1aa2-a07f-4d8a-a1b3-1dc23c599f4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f6708300-03bd-4693-ae9c-59907efa118c" xlink:to="loc_srt_ScenarioForecastMember_0cbe1aa2-a07f-4d8a-a1b3-1dc23c599f4e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20201231.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended" id="ifad1c68c3c0b4ac293e584cb1c90cf28_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20201231.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i9dd9b991358b46e1bcfbf5f7bb9f8dbe_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="i64a54b294eea478b838ea81b5a694e56_FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24dcedc2-b99d-4be8-9ecb-f4acc61ce769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9068d72-9c69-44b8-b04a-ba0b3de69f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24dcedc2-b99d-4be8-9ecb-f4acc61ce769" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9068d72-9c69-44b8-b04a-ba0b3de69f16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a2b86b01-ea7d-4902-9145-3af49a5eaece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9068d72-9c69-44b8-b04a-ba0b3de69f16" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a2b86b01-ea7d-4902-9145-3af49a5eaece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_58113f82-d7cc-47bf-a453-5aec6422a7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9068d72-9c69-44b8-b04a-ba0b3de69f16" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_58113f82-d7cc-47bf-a453-5aec6422a7af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_c2ba3ece-559b-4ef6-a050-39b259cfab6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9068d72-9c69-44b8-b04a-ba0b3de69f16" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_c2ba3ece-559b-4ef6-a050-39b259cfab6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_8512f008-a128-4176-81f4-e1fbe821335f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24dcedc2-b99d-4be8-9ecb-f4acc61ce769" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_8512f008-a128-4176-81f4-e1fbe821335f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_90c8aeae-ff7b-4f6d-8355-8d13bf1447dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24dcedc2-b99d-4be8-9ecb-f4acc61ce769" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_90c8aeae-ff7b-4f6d-8355-8d13bf1447dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0bfb8ff7-e5d3-46bf-a7c4-ff847edff2b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_90c8aeae-ff7b-4f6d-8355-8d13bf1447dc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0bfb8ff7-e5d3-46bf-a7c4-ff847edff2b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0bfb8ff7-e5d3-46bf-a7c4-ff847edff2b8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0bfb8ff7-e5d3-46bf-a7c4-ff847edff2b8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0bfb8ff7-e5d3-46bf-a7c4-ff847edff2b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3a58c44c-85b7-49fc-8223-3458b0cbe650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0bfb8ff7-e5d3-46bf-a7c4-ff847edff2b8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3a58c44c-85b7-49fc-8223-3458b0cbe650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b90c8b4a-dc25-43a9-b0af-4175b5a8cc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3a58c44c-85b7-49fc-8223-3458b0cbe650" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b90c8b4a-dc25-43a9-b0af-4175b5a8cc49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d00e7644-dd35-4c94-b2c6-0d81a039c3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_90c8aeae-ff7b-4f6d-8355-8d13bf1447dc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d00e7644-dd35-4c94-b2c6-0d81a039c3b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d00e7644-dd35-4c94-b2c6-0d81a039c3b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d00e7644-dd35-4c94-b2c6-0d81a039c3b4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d00e7644-dd35-4c94-b2c6-0d81a039c3b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_00afc706-3b81-484b-9488-f6732933aaae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d00e7644-dd35-4c94-b2c6-0d81a039c3b4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_00afc706-3b81-484b-9488-f6732933aaae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_60be4cd9-cdcc-448e-ba2d-8324e737c505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_00afc706-3b81-484b-9488-f6732933aaae" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_60be4cd9-cdcc-448e-ba2d-8324e737c505" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1a104975-4ee6-4518-b44b-2ccb1952c5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_00afc706-3b81-484b-9488-f6732933aaae" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1a104975-4ee6-4518-b44b-2ccb1952c5b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4c8261ff-6b16-4ae6-9564-d093b79d9822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_00afc706-3b81-484b-9488-f6732933aaae" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4c8261ff-6b16-4ae6-9564-d093b79d9822" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20201231.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended" id="i5306ccf1278246f09936eeca270e9b1a_FinancialInstruments"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20201231.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended" id="i86daec1dd46f452aa23d7325cd7bd49f_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i77ecd1b7ce414663bef1f187c25a2dc0_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_5cfb9692-552c-45d4-afe2-44d04e3cbea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_5cfb9692-552c-45d4-afe2-44d04e3cbea7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_991a3364-10de-49e6-9c93-ba4d70634421" xlink:href="cah-20201231.xsd#cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_991a3364-10de-49e6-9c93-ba4d70634421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_e24f7918-639d-494a-9ea5-242fd9d2c1af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_e24f7918-639d-494a-9ea5-242fd9d2c1af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_0c33c237-1838-41ab-93a5-099d67c38cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_0c33c237-1838-41ab-93a5-099d67c38cfe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b5e85ab4-5d00-4a1c-84fe-bbf61a035226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b5e85ab4-5d00-4a1c-84fe-bbf61a035226" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_3e0c900d-c096-445a-b862-538b6799536c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_3e0c900d-c096-445a-b862-538b6799536c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_97896363-5adc-48b8-bfbc-8bebe3d3cd1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_97896363-5adc-48b8-bfbc-8bebe3d3cd1a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_76605c40-3b33-4b92-b17f-266acf05b705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_76605c40-3b33-4b92-b17f-266acf05b705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_76605c40-3b33-4b92-b17f-266acf05b705_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_76605c40-3b33-4b92-b17f-266acf05b705" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_76605c40-3b33-4b92-b17f-266acf05b705_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_63653785-3c02-4c8e-b41f-a8f9098e116a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_76605c40-3b33-4b92-b17f-266acf05b705" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_63653785-3c02-4c8e-b41f-a8f9098e116a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_a98d3b47-0193-4eb6-a041-3fb9ca5596ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_63653785-3c02-4c8e-b41f-a8f9098e116a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_a98d3b47-0193-4eb6-a041-3fb9ca5596ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fee8686-657a-4ccf-abb3-c3953b480efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fee8686-657a-4ccf-abb3-c3953b480efa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6fee8686-657a-4ccf-abb3-c3953b480efa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fee8686-657a-4ccf-abb3-c3953b480efa" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6fee8686-657a-4ccf-abb3-c3953b480efa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8c6aea07-eb3c-4ac1-ba2c-f509f2d2b3c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fee8686-657a-4ccf-abb3-c3953b480efa" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8c6aea07-eb3c-4ac1-ba2c-f509f2d2b3c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ac443bf6-53cd-4b94-8ee3-a0a6c45ade65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8c6aea07-eb3c-4ac1-ba2c-f509f2d2b3c8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ac443bf6-53cd-4b94-8ee3-a0a6c45ade65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_769f89db-3024-48ef-82c5-6f6022f95304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:to="loc_us-gaap_HedgingDesignationAxis_769f89db-3024-48ef-82c5-6f6022f95304" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_769f89db-3024-48ef-82c5-6f6022f95304_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_769f89db-3024-48ef-82c5-6f6022f95304" xlink:to="loc_us-gaap_HedgingDesignationDomain_769f89db-3024-48ef-82c5-6f6022f95304_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0b5f79a0-c291-4392-8dbb-55c78f52b634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_769f89db-3024-48ef-82c5-6f6022f95304" xlink:to="loc_us-gaap_HedgingDesignationDomain_0b5f79a0-c291-4392-8dbb-55c78f52b634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_26bb7a9f-d090-405b-a1c2-3d0d42ce85e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_0b5f79a0-c291-4392-8dbb-55c78f52b634" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_26bb7a9f-d090-405b-a1c2-3d0d42ce85e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5dc6d181-f364-4a14-8563-b121676189ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_0b5f79a0-c291-4392-8dbb-55c78f52b634" xlink:to="loc_us-gaap_NondesignatedMember_5dc6d181-f364-4a14-8563-b121676189ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e2febfb8-19c6-4046-bb75-02a9f85ae5f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e2febfb8-19c6-4046-bb75-02a9f85ae5f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e2febfb8-19c6-4046-bb75-02a9f85ae5f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e2febfb8-19c6-4046-bb75-02a9f85ae5f4" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e2febfb8-19c6-4046-bb75-02a9f85ae5f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_31008797-ac06-4e7d-a2d6-9dca64881d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e2febfb8-19c6-4046-bb75-02a9f85ae5f4" xlink:to="loc_us-gaap_HedgingRelationshipDomain_31008797-ac06-4e7d-a2d6-9dca64881d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_840a39dc-6e02-4a8f-b059-12c7c45860b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_31008797-ac06-4e7d-a2d6-9dca64881d06" xlink:to="loc_us-gaap_FairValueHedgingMember_840a39dc-6e02-4a8f-b059-12c7c45860b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cd8ccc6a-43ea-487b-a67d-8caf9bc81683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cd8ccc6a-43ea-487b-a67d-8caf9bc81683" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cd8ccc6a-43ea-487b-a67d-8caf9bc81683_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cd8ccc6a-43ea-487b-a67d-8caf9bc81683" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cd8ccc6a-43ea-487b-a67d-8caf9bc81683_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0c438365-4788-44bc-8d06-736833855148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cd8ccc6a-43ea-487b-a67d-8caf9bc81683" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0c438365-4788-44bc-8d06-736833855148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_23a53e0f-ded2-497b-9b37-13f24ff6175d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c438365-4788-44bc-8d06-736833855148" xlink:to="loc_us-gaap_CashFlowHedgingMember_23a53e0f-ded2-497b-9b37-13f24ff6175d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5bcb88f4-3024-411a-a174-f4d2d33068e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c438365-4788-44bc-8d06-736833855148" xlink:to="loc_us-gaap_InterestRateSwapMember_5bcb88f4-3024-411a-a174-f4d2d33068e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_5ab7eb9e-02d9-4dcc-ace2-e7aa15724b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c438365-4788-44bc-8d06-736833855148" xlink:to="loc_us-gaap_CurrencySwapMember_5ab7eb9e-02d9-4dcc-ace2-e7aa15724b46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a3a8fe01-3fdc-485c-a24e-13df4cdf62ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c438365-4788-44bc-8d06-736833855148" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a3a8fe01-3fdc-485c-a24e-13df4cdf62ca" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended" id="i2347cd9088c4494c812bc057729ec748_FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10ea53ee-a41b-492e-a6ec-8ee72fa12c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_d66bcc5c-8cf2-495e-b1e6-5b42ca69c3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10ea53ee-a41b-492e-a6ec-8ee72fa12c6f" xlink:to="loc_us-gaap_DebtInstrumentFairValue_d66bcc5c-8cf2-495e-b1e6-5b42ca69c3b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_017c99af-33c7-4de5-b37b-40bb2c000044" xlink:href="cah-20201231.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10ea53ee-a41b-492e-a6ec-8ee72fa12c6f" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_017c99af-33c7-4de5-b37b-40bb2c000044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3802f513-5bd8-49ca-87b2-e53a7df0b99a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10ea53ee-a41b-492e-a6ec-8ee72fa12c6f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3802f513-5bd8-49ca-87b2-e53a7df0b99a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94175aae-439e-48d8-bbde-de723a3a59d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3802f513-5bd8-49ca-87b2-e53a7df0b99a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94175aae-439e-48d8-bbde-de723a3a59d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94175aae-439e-48d8-bbde-de723a3a59d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94175aae-439e-48d8-bbde-de723a3a59d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94175aae-439e-48d8-bbde-de723a3a59d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b0c967f-d2b5-4141-b3c0-1ce3d6fddd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94175aae-439e-48d8-bbde-de723a3a59d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b0c967f-d2b5-4141-b3c0-1ce3d6fddd2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_44b496c5-26ae-4a10-9338-02ee281dcfb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b0c967f-d2b5-4141-b3c0-1ce3d6fddd2a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_44b496c5-26ae-4a10-9338-02ee281dcfb0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended" id="icc28844a640b4a7bbf97d7682c3e72f7_ShareholdersEquity"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended" id="i2cfce66f2fe848d5b6f3f532057382fe_ShareholdersEquityTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" id="i6a7c11c7dc014df0a1ae4de21021b4d5_ShareholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3a6ddd17-53f6-4574-a178-90a9f1254dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_87c88711-60e3-4dfb-9f0e-68ec0f979869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3a6ddd17-53f6-4574-a178-90a9f1254dd1" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_87c88711-60e3-4dfb-9f0e-68ec0f979869" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2c7b4c4a-97c0-4a20-9724-0957d63d216c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3a6ddd17-53f6-4574-a178-90a9f1254dd1" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2c7b4c4a-97c0-4a20-9724-0957d63d216c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_69ce5025-f9c0-48eb-ae81-56c76608cb4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3a6ddd17-53f6-4574-a178-90a9f1254dd1" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_69ce5025-f9c0-48eb-ae81-56c76608cb4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TreasuryStockAcquiredShares_ba66d9d1-20e3-4351-abab-7234f5b06332" xlink:href="cah-20201231.xsd#cah_TreasuryStockAcquiredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3a6ddd17-53f6-4574-a178-90a9f1254dd1" xlink:to="loc_cah_TreasuryStockAcquiredShares_ba66d9d1-20e3-4351-abab-7234f5b06332" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e9e7b0ad-4a0d-4a80-b529-e784c7cbb6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3a6ddd17-53f6-4574-a178-90a9f1254dd1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e9e7b0ad-4a0d-4a80-b529-e784c7cbb6f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cb7ef88b-35be-43a2-848e-6199504ea858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9e7b0ad-4a0d-4a80-b529-e784c7cbb6f5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cb7ef88b-35be-43a2-848e-6199504ea858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cb7ef88b-35be-43a2-848e-6199504ea858_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cb7ef88b-35be-43a2-848e-6199504ea858" xlink:to="loc_us-gaap_EquityComponentDomain_cb7ef88b-35be-43a2-848e-6199504ea858_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ef38c985-c98a-4d5b-ba7c-c5aa5b750d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cb7ef88b-35be-43a2-848e-6199504ea858" xlink:to="loc_us-gaap_EquityComponentDomain_ef38c985-c98a-4d5b-ba7c-c5aa5b750d7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_346f2b04-a40f-482a-a6a2-9582ba014977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ef38c985-c98a-4d5b-ba7c-c5aa5b750d7b" xlink:to="loc_us-gaap_TreasuryStockMember_346f2b04-a40f-482a-a6a2-9582ba014977" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i4c40dde615ea430ca1bd15fb3c6fd8d7_ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_9a4bd75b-5eb8-4500-9489-3c233eea2cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d7d90dc8-ed06-42e4-99a8-43d3969118e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_9a4bd75b-5eb8-4500-9489-3c233eea2cdd" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d7d90dc8-ed06-42e4-99a8-43d3969118e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cac3c361-ff8d-46ee-ad26-09b0ff09194e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d7d90dc8-ed06-42e4-99a8-43d3969118e7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cac3c361-ff8d-46ee-ad26-09b0ff09194e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2b71ba5c-831f-46d9-a096-29a4f1b2f782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d7d90dc8-ed06-42e4-99a8-43d3969118e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2b71ba5c-831f-46d9-a096-29a4f1b2f782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_35dd5e7b-f5dd-4563-9f5c-50696bdd7f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d7d90dc8-ed06-42e4-99a8-43d3969118e7" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_35dd5e7b-f5dd-4563-9f5c-50696bdd7f94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7849e84f-609f-4933-b7f8-88cdf672f30f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d7d90dc8-ed06-42e4-99a8-43d3969118e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7849e84f-609f-4933-b7f8-88cdf672f30f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_382515b5-a09b-47bd-be10-f955286e6f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_14161c0e-f478-4aa6-b459-d8ddbe077c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_9a4bd75b-5eb8-4500-9489-3c233eea2cdd" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_14161c0e-f478-4aa6-b459-d8ddbe077c9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e54e3acd-c2ba-4299-a584-d119f22a2c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_14161c0e-f478-4aa6-b459-d8ddbe077c9c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e54e3acd-c2ba-4299-a584-d119f22a2c59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e54e3acd-c2ba-4299-a584-d119f22a2c59_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e54e3acd-c2ba-4299-a584-d119f22a2c59" xlink:to="loc_us-gaap_EquityComponentDomain_e54e3acd-c2ba-4299-a584-d119f22a2c59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e51dd659-1890-4f14-b760-63a03695af3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e54e3acd-c2ba-4299-a584-d119f22a2c59" xlink:to="loc_us-gaap_EquityComponentDomain_e51dd659-1890-4f14-b760-63a03695af3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_7bea01f1-91fa-470b-a114-95c2535c03d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e51dd659-1890-4f14-b760-63a03695af3c" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_7bea01f1-91fa-470b-a114-95c2535c03d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_ecb8d374-9ca1-45bd-ade6-8d0f42dc9960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e51dd659-1890-4f14-b760-63a03695af3c" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_ecb8d374-9ca1-45bd-ade6-8d0f42dc9960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6ce12696-efb7-4b5d-ae87-fb1db6d63517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e51dd659-1890-4f14-b760-63a03695af3c" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6ce12696-efb7-4b5d-ae87-fb1db6d63517" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e039e602-f5f1-482a-bf0b-bba3e3b1e438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e51dd659-1890-4f14-b760-63a03695af3c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e039e602-f5f1-482a-bf0b-bba3e3b1e438" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20201231.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended" id="i68df5a94167541f09432624f32c05691_EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20201231.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended" id="ib22261c4aaba463cb9f1ac31cf165042_EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended" id="if2720deeba7140cba25d4e13bf5441b0_EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended" id="i303afdda56594e6c8941aa45e9dae49f_EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformation"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended" id="i0558b7f76e824debaa57937fe24dab8a_SegmentInformation"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended" id="ib29368a0d12742268661c266bca10fd4_SegmentInformationTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" id="i8011303972eb4e358ec79f4e76119818_SegmentInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_455543ac-3e12-4081-a882-856aec4ca96f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_455543ac-3e12-4081-a882-856aec4ca96f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRecallExpense_5ca8255d-6592-4c36-b11b-f25b69893568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRecallExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:to="loc_us-gaap_InventoryRecallExpense_5ca8255d-6592-4c36-b11b-f25b69893568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_73c7a18e-4d10-4b17-a51b-c472a7b185a9" xlink:href="cah-20201231.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_73c7a18e-4d10-4b17-a51b-c472a7b185a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_47183577-ae77-45ba-bf7e-54344354f761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:to="loc_us-gaap_NumberOfReportableSegments_47183577-ae77-45ba-bf7e-54344354f761" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cab1f182-6947-413e-876b-d2461b34a36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cab1f182-6947-413e-876b-d2461b34a36c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_fe2338c7-9ae7-42b9-a0cc-92d51fddbd29" xlink:href="cah-20201231.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_fe2338c7-9ae7-42b9-a0cc-92d51fddbd29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4958e427-239f-4cee-bb80-8fadba51fa21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4958e427-239f-4cee-bb80-8fadba51fa21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallAxis_d2e25efc-2eea-4bd9-9b28-35804b17629c" xlink:href="cah-20201231.xsd#cah_SterileSurgicalGownRecallAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4958e427-239f-4cee-bb80-8fadba51fa21" xlink:to="loc_cah_SterileSurgicalGownRecallAxis_d2e25efc-2eea-4bd9-9b28-35804b17629c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallDomain_d2e25efc-2eea-4bd9-9b28-35804b17629c_default" xlink:href="cah-20201231.xsd#cah_SterileSurgicalGownRecallDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_SterileSurgicalGownRecallAxis_d2e25efc-2eea-4bd9-9b28-35804b17629c" xlink:to="loc_cah_SterileSurgicalGownRecallDomain_d2e25efc-2eea-4bd9-9b28-35804b17629c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallDomain_03412e80-d084-4dd3-8962-82dd53877120" xlink:href="cah-20201231.xsd#cah_SterileSurgicalGownRecallDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_SterileSurgicalGownRecallAxis_d2e25efc-2eea-4bd9-9b28-35804b17629c" xlink:to="loc_cah_SterileSurgicalGownRecallDomain_03412e80-d084-4dd3-8962-82dd53877120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallMember_1f5c5be6-95ec-426a-8744-2f50e3b63e67" xlink:href="cah-20201231.xsd#cah_SterileSurgicalGownRecallMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_SterileSurgicalGownRecallDomain_03412e80-d084-4dd3-8962-82dd53877120" xlink:to="loc_cah_SterileSurgicalGownRecallMember_1f5c5be6-95ec-426a-8744-2f50e3b63e67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_0cf927f5-8f91-49d4-b88a-d0629bbbe511" xlink:href="cah-20201231.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4958e427-239f-4cee-bb80-8fadba51fa21" xlink:to="loc_cah_OpioidLitigationAxis_0cf927f5-8f91-49d4-b88a-d0629bbbe511" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_0cf927f5-8f91-49d4-b88a-d0629bbbe511_default" xlink:href="cah-20201231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_0cf927f5-8f91-49d4-b88a-d0629bbbe511" xlink:to="loc_cah_OpioidLitigationDomain_0cf927f5-8f91-49d4-b88a-d0629bbbe511_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_124afb24-606c-4db7-83ef-e770577104e7" xlink:href="cah-20201231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_0cf927f5-8f91-49d4-b88a-d0629bbbe511" xlink:to="loc_cah_OpioidLitigationDomain_124afb24-606c-4db7-83ef-e770577104e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_37b15193-4650-49cd-8367-cc4e821fd4d5" xlink:href="cah-20201231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_124afb24-606c-4db7-83ef-e770577104e7" xlink:to="loc_cah_TotalOpioidLitigationMember_37b15193-4650-49cd-8367-cc4e821fd4d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_1daa4ec4-e374-4d5a-8a72-58b158c8690d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4958e427-239f-4cee-bb80-8fadba51fa21" xlink:to="loc_srt_LitigationCaseAxis_1daa4ec4-e374-4d5a-8a72-58b158c8690d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1daa4ec4-e374-4d5a-8a72-58b158c8690d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_1daa4ec4-e374-4d5a-8a72-58b158c8690d" xlink:to="loc_srt_LitigationCaseTypeDomain_1daa4ec4-e374-4d5a-8a72-58b158c8690d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ef59c5b6-f714-477d-9831-39197b32de9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_1daa4ec4-e374-4d5a-8a72-58b158c8690d" xlink:to="loc_srt_LitigationCaseTypeDomain_ef59c5b6-f714-477d-9831-39197b32de9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_31b06e32-44ac-4488-8b5e-20ba68fa3c24" xlink:href="cah-20201231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ef59c5b6-f714-477d-9831-39197b32de9e" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_31b06e32-44ac-4488-8b5e-20ba68fa3c24" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended" id="if98695689cb34eb59b77d9de55391e3a_SegmentInformationRevenuebyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_6c68d173-05ea-4d31-9fc8-cbbf265c1fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5a266db7-9350-4733-879b-c54b835c9037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6c68d173-05ea-4d31-9fc8-cbbf265c1fec" xlink:to="loc_us-gaap_Revenues_5a266db7-9350-4733-879b-c54b835c9037" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_fddf6739-b3f9-48be-9d9b-e4158afb2614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6c68d173-05ea-4d31-9fc8-cbbf265c1fec" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_fddf6739-b3f9-48be-9d9b-e4158afb2614" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_5907dc93-8cf3-4638-ba8e-060f0c565d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_fddf6739-b3f9-48be-9d9b-e4158afb2614" xlink:to="loc_us-gaap_SubsegmentsAxis_5907dc93-8cf3-4638-ba8e-060f0c565d3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_5907dc93-8cf3-4638-ba8e-060f0c565d3b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_5907dc93-8cf3-4638-ba8e-060f0c565d3b" xlink:to="loc_us-gaap_SubsegmentsDomain_5907dc93-8cf3-4638-ba8e-060f0c565d3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_59412381-ba36-4375-ac04-4d4ea12d7f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_5907dc93-8cf3-4638-ba8e-060f0c565d3b" xlink:to="loc_us-gaap_SubsegmentsDomain_59412381-ba36-4375-ac04-4d4ea12d7f1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_6c5d3135-e005-4ee5-a8cd-ac495c7657ed" xlink:href="cah-20201231.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_59412381-ba36-4375-ac04-4d4ea12d7f1e" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_6c5d3135-e005-4ee5-a8cd-ac495c7657ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_5c9eebd5-a84c-409b-a952-c5d71891b938" xlink:href="cah-20201231.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_59412381-ba36-4375-ac04-4d4ea12d7f1e" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_5c9eebd5-a84c-409b-a952-c5d71891b938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_89bd1d17-d40f-4873-b640-4dd589d5dccc" xlink:href="cah-20201231.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_59412381-ba36-4375-ac04-4d4ea12d7f1e" xlink:to="loc_cah_MedicaldistributionandproductsMember_89bd1d17-d40f-4873-b640-4dd589d5dccc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember_0ca9cae8-60ee-4468-ab6d-be384b10f157" xlink:href="cah-20201231.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_59412381-ba36-4375-ac04-4d4ea12d7f1e" xlink:to="loc_cah_CardinalHealthAtHomeMember_0ca9cae8-60ee-4468-ab6d-be384b10f157" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_80f0c904-205c-4af9-899f-cdc0fb044113" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_fddf6739-b3f9-48be-9d9b-e4158afb2614" xlink:to="loc_srt_ConsolidationItemsAxis_80f0c904-205c-4af9-899f-cdc0fb044113" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_80f0c904-205c-4af9-899f-cdc0fb044113_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_80f0c904-205c-4af9-899f-cdc0fb044113" xlink:to="loc_srt_ConsolidationItemsDomain_80f0c904-205c-4af9-899f-cdc0fb044113_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_0f884f0b-4c0a-4fc8-8007-b2fafc206275" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_80f0c904-205c-4af9-899f-cdc0fb044113" xlink:to="loc_srt_ConsolidationItemsDomain_0f884f0b-4c0a-4fc8-8007-b2fafc206275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d2d4e108-ef29-461a-9756-f84baabbb569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_0f884f0b-4c0a-4fc8-8007-b2fafc206275" xlink:to="loc_us-gaap_OperatingSegmentsMember_d2d4e108-ef29-461a-9756-f84baabbb569" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_8ad66b48-d72a-4fc1-970c-a80de51b8f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_0f884f0b-4c0a-4fc8-8007-b2fafc206275" xlink:to="loc_us-gaap_CorporateNonSegmentMember_8ad66b48-d72a-4fc1-970c-a80de51b8f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_004f8f52-97fc-4907-808d-d9f902b74d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_fddf6739-b3f9-48be-9d9b-e4158afb2614" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_004f8f52-97fc-4907-808d-d9f902b74d48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_004f8f52-97fc-4907-808d-d9f902b74d48_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_004f8f52-97fc-4907-808d-d9f902b74d48" xlink:to="loc_us-gaap_SegmentDomain_004f8f52-97fc-4907-808d-d9f902b74d48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_15e98bdb-d83e-496f-85b1-4aa458fb1c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_004f8f52-97fc-4907-808d-d9f902b74d48" xlink:to="loc_us-gaap_SegmentDomain_15e98bdb-d83e-496f-85b1-4aa458fb1c2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_ccceb31b-42bb-4078-83dd-77d31108e76f" xlink:href="cah-20201231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_15e98bdb-d83e-496f-85b1-4aa458fb1c2b" xlink:to="loc_cah_PharmaceuticalMember_ccceb31b-42bb-4078-83dd-77d31108e76f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_258ed645-7110-48a7-b0e6-d9eabe56a36c" xlink:href="cah-20201231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_15e98bdb-d83e-496f-85b1-4aa458fb1c2b" xlink:to="loc_cah_MedicalMember_258ed645-7110-48a7-b0e6-d9eabe56a36c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended" id="ib0c7b83100414a7cbe7d9e391f202d96_SegmentInformationSegmentProfitbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_a4d03f49-7124-4e48-927d-ad0f808b4c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d8d225e5-1674-4590-855d-00feef9626a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_a4d03f49-7124-4e48-927d-ad0f808b4c88" xlink:to="loc_us-gaap_OperatingIncomeLoss_d8d225e5-1674-4590-855d-00feef9626a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_46a68c78-fd76-465d-9b21-29169a49a07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_a4d03f49-7124-4e48-927d-ad0f808b4c88" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_46a68c78-fd76-465d-9b21-29169a49a07b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_249217cb-8bd9-4532-bd06-74832f1e92b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_46a68c78-fd76-465d-9b21-29169a49a07b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_249217cb-8bd9-4532-bd06-74832f1e92b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_249217cb-8bd9-4532-bd06-74832f1e92b6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_249217cb-8bd9-4532-bd06-74832f1e92b6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_249217cb-8bd9-4532-bd06-74832f1e92b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_88ea188c-6fe8-4263-acfd-8419663c8b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_249217cb-8bd9-4532-bd06-74832f1e92b6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_88ea188c-6fe8-4263-acfd-8419663c8b95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_55da60d1-1ee8-44d8-abc7-2abf58106660" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_46a68c78-fd76-465d-9b21-29169a49a07b" xlink:to="loc_srt_ConsolidationItemsAxis_55da60d1-1ee8-44d8-abc7-2abf58106660" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_55da60d1-1ee8-44d8-abc7-2abf58106660_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_55da60d1-1ee8-44d8-abc7-2abf58106660" xlink:to="loc_srt_ConsolidationItemsDomain_55da60d1-1ee8-44d8-abc7-2abf58106660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b22923ee-3408-4fbd-aacf-a6aa682c9ec2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_55da60d1-1ee8-44d8-abc7-2abf58106660" xlink:to="loc_srt_ConsolidationItemsDomain_b22923ee-3408-4fbd-aacf-a6aa682c9ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_1dca9e5d-b654-456f-b6c7-4d4724b810d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_b22923ee-3408-4fbd-aacf-a6aa682c9ec2" xlink:to="loc_us-gaap_OperatingSegmentsMember_1dca9e5d-b654-456f-b6c7-4d4724b810d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e7e969e9-206a-4fc1-8eef-376de8372679" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_b22923ee-3408-4fbd-aacf-a6aa682c9ec2" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e7e969e9-206a-4fc1-8eef-376de8372679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_328296e4-3a0a-4299-9fd7-6dfacea92ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_46a68c78-fd76-465d-9b21-29169a49a07b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_328296e4-3a0a-4299-9fd7-6dfacea92ce2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_328296e4-3a0a-4299-9fd7-6dfacea92ce2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_328296e4-3a0a-4299-9fd7-6dfacea92ce2" xlink:to="loc_us-gaap_SegmentDomain_328296e4-3a0a-4299-9fd7-6dfacea92ce2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_794b7718-221e-48a8-8841-8ab82bd1d5dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_328296e4-3a0a-4299-9fd7-6dfacea92ce2" xlink:to="loc_us-gaap_SegmentDomain_794b7718-221e-48a8-8841-8ab82bd1d5dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_e6e4a968-4131-41c3-9983-59bb659d5749" xlink:href="cah-20201231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_794b7718-221e-48a8-8841-8ab82bd1d5dd" xlink:to="loc_cah_PharmaceuticalMember_e6e4a968-4131-41c3-9983-59bb659d5749" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_42763e86-bff6-4a2d-bfcf-ade70b92d641" xlink:href="cah-20201231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_794b7718-221e-48a8-8841-8ab82bd1d5dd" xlink:to="loc_cah_MedicalMember_42763e86-bff6-4a2d-bfcf-ade70b92d641" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended" id="i9007cacc0ab641e58809f3d9ab654435_SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_13650887-ace5-49a0-9524-bbdf8ba98f3c" xlink:href="cah-20201231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c39f78c4-6ce6-4bc9-b501-2c736e20c4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_13650887-ace5-49a0-9524-bbdf8ba98f3c" xlink:to="loc_us-gaap_Revenues_c39f78c4-6ce6-4bc9-b501-2c736e20c4bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_f124fa53-9fac-4352-bf1b-6ffca2f4dbc5" xlink:href="cah-20201231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_13650887-ace5-49a0-9524-bbdf8ba98f3c" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_f124fa53-9fac-4352-bf1b-6ffca2f4dbc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_7401b809-3b63-4934-8a87-315ba08058ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_f124fa53-9fac-4352-bf1b-6ffca2f4dbc5" xlink:to="loc_srt_ConsolidationItemsAxis_7401b809-3b63-4934-8a87-315ba08058ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7401b809-3b63-4934-8a87-315ba08058ea_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_7401b809-3b63-4934-8a87-315ba08058ea" xlink:to="loc_srt_ConsolidationItemsDomain_7401b809-3b63-4934-8a87-315ba08058ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_57daead9-58d5-4ec0-8518-f3ee4de07c85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_7401b809-3b63-4934-8a87-315ba08058ea" xlink:to="loc_srt_ConsolidationItemsDomain_57daead9-58d5-4ec0-8518-f3ee4de07c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4c3f42f7-b701-419a-a45a-ff6c7c6633d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_57daead9-58d5-4ec0-8518-f3ee4de07c85" xlink:to="loc_us-gaap_OperatingSegmentsMember_4c3f42f7-b701-419a-a45a-ff6c7c6633d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_37f972d4-cbe3-415c-8cb1-894410271417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_57daead9-58d5-4ec0-8518-f3ee4de07c85" xlink:to="loc_us-gaap_CorporateNonSegmentMember_37f972d4-cbe3-415c-8cb1-894410271417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_21982595-9d9c-4f3a-8ac4-b34f58cadb65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_f124fa53-9fac-4352-bf1b-6ffca2f4dbc5" xlink:to="loc_srt_StatementGeographicalAxis_21982595-9d9c-4f3a-8ac4-b34f58cadb65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_21982595-9d9c-4f3a-8ac4-b34f58cadb65_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_21982595-9d9c-4f3a-8ac4-b34f58cadb65" xlink:to="loc_srt_SegmentGeographicalDomain_21982595-9d9c-4f3a-8ac4-b34f58cadb65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4c8b5180-8125-48a5-b8a7-0f6f1f858e05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_21982595-9d9c-4f3a-8ac4-b34f58cadb65" xlink:to="loc_srt_SegmentGeographicalDomain_4c8b5180-8125-48a5-b8a7-0f6f1f858e05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_632e9983-9501-4618-9f70-7ce718ee227d" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4c8b5180-8125-48a5-b8a7-0f6f1f858e05" xlink:to="loc_country_US_632e9983-9501-4618-9f70-7ce718ee227d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_609d36fc-fd70-4dba-a9d6-e9db9ec26538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4c8b5180-8125-48a5-b8a7-0f6f1f858e05" xlink:to="loc_us-gaap_NonUsMember_609d36fc-fd70-4dba-a9d6-e9db9ec26538" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended" id="i3283014a13c14d1dbc2d13e0776ba28a_SegmentInformationAssetsbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_748365ea-b8fe-426b-acc1-e571d8a96ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_be5d3d82-e591-486c-bcd0-42d11172a435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_748365ea-b8fe-426b-acc1-e571d8a96ea9" xlink:to="loc_us-gaap_Assets_be5d3d82-e591-486c-bcd0-42d11172a435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6193001b-d7a4-47e9-8490-9c5e73d34669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_748365ea-b8fe-426b-acc1-e571d8a96ea9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6193001b-d7a4-47e9-8490-9c5e73d34669" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f18703e7-5192-49df-aa24-7547952a53b2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6193001b-d7a4-47e9-8490-9c5e73d34669" xlink:to="loc_srt_ConsolidationItemsAxis_f18703e7-5192-49df-aa24-7547952a53b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f18703e7-5192-49df-aa24-7547952a53b2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_f18703e7-5192-49df-aa24-7547952a53b2" xlink:to="loc_srt_ConsolidationItemsDomain_f18703e7-5192-49df-aa24-7547952a53b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_848d4559-ec70-4dc4-b764-d0ee4e8dec65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_f18703e7-5192-49df-aa24-7547952a53b2" xlink:to="loc_srt_ConsolidationItemsDomain_848d4559-ec70-4dc4-b764-d0ee4e8dec65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f7683759-c435-4754-a6b6-ac4541f34096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_848d4559-ec70-4dc4-b764-d0ee4e8dec65" xlink:to="loc_us-gaap_OperatingSegmentsMember_f7683759-c435-4754-a6b6-ac4541f34096" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_5def9d32-b302-43a7-b82c-68336f79fe35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_848d4559-ec70-4dc4-b764-d0ee4e8dec65" xlink:to="loc_us-gaap_CorporateNonSegmentMember_5def9d32-b302-43a7-b82c-68336f79fe35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ce44e7e9-9b77-4ceb-a4b0-1434bdf5bcc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6193001b-d7a4-47e9-8490-9c5e73d34669" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ce44e7e9-9b77-4ceb-a4b0-1434bdf5bcc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ce44e7e9-9b77-4ceb-a4b0-1434bdf5bcc2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ce44e7e9-9b77-4ceb-a4b0-1434bdf5bcc2" xlink:to="loc_us-gaap_SegmentDomain_ce44e7e9-9b77-4ceb-a4b0-1434bdf5bcc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cf74f607-beed-475a-930f-24be8ff109e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ce44e7e9-9b77-4ceb-a4b0-1434bdf5bcc2" xlink:to="loc_us-gaap_SegmentDomain_cf74f607-beed-475a-930f-24be8ff109e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_594e74c9-253b-4a23-9665-9b61425c26a1" xlink:href="cah-20201231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cf74f607-beed-475a-930f-24be8ff109e8" xlink:to="loc_cah_PharmaceuticalMember_594e74c9-253b-4a23-9665-9b61425c26a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_8b10ffc0-327e-4b46-a397-3f01183df906" xlink:href="cah-20201231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cf74f607-beed-475a-930f-24be8ff109e8" xlink:to="loc_cah_MedicalMember_8b10ffc0-327e-4b46-a397-3f01183df906" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended" id="i312085a45b5e43ebaf2ae1c4faefb082_ShareBasedCompensation"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended" id="ie33dce54bb384e53bd52a20bc51ab27e_ShareBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="i12360298f8f841b289b74f92141fd142_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_c25ed4dd-544d-43fd-8155-27e479e48e4b" xlink:href="cah-20201231.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_cah_VestingPeriodinyearsforShares_c25ed4dd-544d-43fd-8155-27e479e48e4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_66e81a5a-7d19-4e05-a90c-c91b08f635fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_66e81a5a-7d19-4e05-a90c-c91b08f635fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25af8b11-c5f7-4c55-b420-cef658299bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25af8b11-c5f7-4c55-b420-cef658299bea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6c546d2b-9e91-4230-a29a-965320b817d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6c546d2b-9e91-4230-a29a-965320b817d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c013562c-6398-4bf1-8946-d49cd9f94fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c013562c-6398-4bf1-8946-d49cd9f94fd0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears_b1b2cf7d-0c36-4d2a-8b22-6408183134e6" xlink:href="cah-20201231.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_cah_ExercisablePeriodOfPlansInYears_b1b2cf7d-0c36-4d2a-8b22-6408183134e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d57eaf83-2519-45c3-924f-9cc989dbddd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d57eaf83-2519-45c3-924f-9cc989dbddd8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d568400-c84a-45ff-b5d6-0ffd455a68cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d568400-c84a-45ff-b5d6-0ffd455a68cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1b446e21-ecbf-4362-9fef-1c2f11d78093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d568400-c84a-45ff-b5d6-0ffd455a68cd" xlink:to="loc_us-gaap_AwardTypeAxis_1b446e21-ecbf-4362-9fef-1c2f11d78093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b446e21-ecbf-4362-9fef-1c2f11d78093_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1b446e21-ecbf-4362-9fef-1c2f11d78093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b446e21-ecbf-4362-9fef-1c2f11d78093_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bc96c5d-dcee-45aa-8ac1-7cec41f64975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1b446e21-ecbf-4362-9fef-1c2f11d78093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bc96c5d-dcee-45aa-8ac1-7cec41f64975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b0a32cee-bd23-4156-bbf0-3006940b6a03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bc96c5d-dcee-45aa-8ac1-7cec41f64975" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b0a32cee-bd23-4156-bbf0-3006940b6a03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8fa14ad3-cd55-4ceb-ba08-7b02946ed2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bc96c5d-dcee-45aa-8ac1-7cec41f64975" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8fa14ad3-cd55-4ceb-ba08-7b02946ed2c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4a7aec2e-68d3-4d23-be10-84fc8fad13a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bc96c5d-dcee-45aa-8ac1-7cec41f64975" xlink:to="loc_us-gaap_PerformanceSharesMember_4a7aec2e-68d3-4d23-be10-84fc8fad13a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb7ac1a3-39cc-4338-944f-0b7a305a3cdd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d568400-c84a-45ff-b5d6-0ffd455a68cd" xlink:to="loc_srt_RangeAxis_cb7ac1a3-39cc-4338-944f-0b7a305a3cdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb7ac1a3-39cc-4338-944f-0b7a305a3cdd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cb7ac1a3-39cc-4338-944f-0b7a305a3cdd" xlink:to="loc_srt_RangeMember_cb7ac1a3-39cc-4338-944f-0b7a305a3cdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b9b78ab9-dfaf-4d7e-8e25-67df49dc0217" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cb7ac1a3-39cc-4338-944f-0b7a305a3cdd" xlink:to="loc_srt_RangeMember_b9b78ab9-dfaf-4d7e-8e25-67df49dc0217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_266c0723-c3f0-4fc0-bf8a-7ed303a6bd8e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b9b78ab9-dfaf-4d7e-8e25-67df49dc0217" xlink:to="loc_srt_MinimumMember_266c0723-c3f0-4fc0-bf8a-7ed303a6bd8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e876c279-d234-4ee7-98f8-626d7fa3c728" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b9b78ab9-dfaf-4d7e-8e25-67df49dc0217" xlink:to="loc_srt_MaximumMember_e876c279-d234-4ee7-98f8-626d7fa3c728" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended" id="i28ee2d642c5d4ef8a398d3aa88d29d51_ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ff30acc-7e83-4cc2-ac02-fcbc3471d227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a4d23fdc-72b3-4441-9e25-19f980e2d891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ff30acc-7e83-4cc2-ac02-fcbc3471d227" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a4d23fdc-72b3-4441-9e25-19f980e2d891" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6512ab4-4bc2-4e77-92d8-919f6fd5269b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ff30acc-7e83-4cc2-ac02-fcbc3471d227" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6512ab4-4bc2-4e77-92d8-919f6fd5269b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d1ee8413-326d-4f38-b1e4-4159974be8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6512ab4-4bc2-4e77-92d8-919f6fd5269b" xlink:to="loc_us-gaap_AwardTypeAxis_d1ee8413-326d-4f38-b1e4-4159974be8d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1ee8413-326d-4f38-b1e4-4159974be8d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d1ee8413-326d-4f38-b1e4-4159974be8d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1ee8413-326d-4f38-b1e4-4159974be8d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84084441-6b65-4265-8045-d9ccbd406ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d1ee8413-326d-4f38-b1e4-4159974be8d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84084441-6b65-4265-8045-d9ccbd406ea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f3d06c01-1c2e-4050-983c-2b34a7b59cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84084441-6b65-4265-8045-d9ccbd406ea1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f3d06c01-1c2e-4050-983c-2b34a7b59cb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f853f077-6be9-4151-8a5c-3adf6802a9a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84084441-6b65-4265-8045-d9ccbd406ea1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f853f077-6be9-4151-8a5c-3adf6802a9a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a0080851-a919-4e79-984e-878b751cb2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84084441-6b65-4265-8045-d9ccbd406ea1" xlink:to="loc_us-gaap_PerformanceSharesMember_a0080851-a919-4e79-984e-878b751cb2cc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended" id="i46f5d97d89ca4e979ddccd95f6c56e71_ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended" id="i25af1a6b79604c3797f689fee49329d1_ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_46b953aa-be55-4d7e-b9aa-116a323de098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_46b953aa-be55-4d7e-b9aa-116a323de098" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0376c80f-c248-4b54-acf6-44fc4f7f88ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0376c80f-c248-4b54-acf6-44fc4f7f88ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c276f266-123f-4b2b-a933-f1d9cc980b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c276f266-123f-4b2b-a933-f1d9cc980b5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ebef7b7f-466b-4179-ae3e-b4aa7fb81a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ebef7b7f-466b-4179-ae3e-b4aa7fb81a5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2ca16edf-880c-4b7f-9abe-ad07120e767c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2ca16edf-880c-4b7f-9abe-ad07120e767c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a09f2b3-4fa3-43bf-81c9-376c8437fbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a09f2b3-4fa3-43bf-81c9-376c8437fbf5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1dbea628-284f-4606-aae5-b934f37d6dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a09f2b3-4fa3-43bf-81c9-376c8437fbf5" xlink:to="loc_us-gaap_AwardTypeAxis_1dbea628-284f-4606-aae5-b934f37d6dd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dbea628-284f-4606-aae5-b934f37d6dd1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1dbea628-284f-4606-aae5-b934f37d6dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1dbea628-284f-4606-aae5-b934f37d6dd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbdb8b92-374e-498a-89d3-c4d1a6553ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1dbea628-284f-4606-aae5-b934f37d6dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbdb8b92-374e-498a-89d3-c4d1a6553ff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e9a70202-7e54-468b-80c8-a8494a7e7afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbdb8b92-374e-498a-89d3-c4d1a6553ff9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e9a70202-7e54-468b-80c8-a8494a7e7afa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended" id="i78820c5f501f40419533aed21de1f134_ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a35c354e-3d55-4a19-8546-fa94df13225e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f67d6aae-3ff7-409a-8979-b604a152bbf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a35c354e-3d55-4a19-8546-fa94df13225e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f67d6aae-3ff7-409a-8979-b604a152bbf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_04bbb812-6631-474e-b71f-996a3e9f8975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a35c354e-3d55-4a19-8546-fa94df13225e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_04bbb812-6631-474e-b71f-996a3e9f8975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04b03792-7c50-4779-8bb6-3e302b80d059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a35c354e-3d55-4a19-8546-fa94df13225e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04b03792-7c50-4779-8bb6-3e302b80d059" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a6db5ba-2314-45b8-8207-472dfdb46b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04b03792-7c50-4779-8bb6-3e302b80d059" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a6db5ba-2314-45b8-8207-472dfdb46b89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ebda9286-bda0-4525-9b63-a8c08c688166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04b03792-7c50-4779-8bb6-3e302b80d059" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ebda9286-bda0-4525-9b63-a8c08c688166" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a5b058bc-9c9e-4a69-810e-0c80cb172298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04b03792-7c50-4779-8bb6-3e302b80d059" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a5b058bc-9c9e-4a69-810e-0c80cb172298" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bd9eae2f-6181-4419-9162-9cc75f124db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04b03792-7c50-4779-8bb6-3e302b80d059" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bd9eae2f-6181-4419-9162-9cc75f124db0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d7dee0c-058a-4521-9cea-0e8ab307d4f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c183287-2781-4f3a-9f14-85b2bc321625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a35c354e-3d55-4a19-8546-fa94df13225e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c183287-2781-4f3a-9f14-85b2bc321625" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e44247e6-8e17-48e5-97ea-d208893d176a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c183287-2781-4f3a-9f14-85b2bc321625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e44247e6-8e17-48e5-97ea-d208893d176a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1b17a31e-549f-4ffe-9bf1-a944177d512c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c183287-2781-4f3a-9f14-85b2bc321625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1b17a31e-549f-4ffe-9bf1-a944177d512c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4cb7ed11-54b1-4bba-ae00-833e2881222c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c183287-2781-4f3a-9f14-85b2bc321625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4cb7ed11-54b1-4bba-ae00-833e2881222c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e8ce3583-4644-46b2-adcf-195503692a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c183287-2781-4f3a-9f14-85b2bc321625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e8ce3583-4644-46b2-adcf-195503692a5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2613e007-5caf-49fe-909d-5e006075bee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bb81561-4e65-4547-88c8-764208fc8425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a35c354e-3d55-4a19-8546-fa94df13225e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bb81561-4e65-4547-88c8-764208fc8425" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ea7becfe-d4eb-47a6-9136-9172d11da95f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bb81561-4e65-4547-88c8-764208fc8425" xlink:to="loc_us-gaap_AwardTypeAxis_ea7becfe-d4eb-47a6-9136-9172d11da95f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea7becfe-d4eb-47a6-9136-9172d11da95f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ea7becfe-d4eb-47a6-9136-9172d11da95f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea7becfe-d4eb-47a6-9136-9172d11da95f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87624f97-9b71-4ac5-a435-d054a6eadf8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ea7becfe-d4eb-47a6-9136-9172d11da95f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87624f97-9b71-4ac5-a435-d054a6eadf8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d684f903-5a61-4846-8b62-13166cd11c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87624f97-9b71-4ac5-a435-d054a6eadf8e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d684f903-5a61-4846-8b62-13166cd11c6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b1826bd1-e993-422d-844e-4a4e174fd8af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87624f97-9b71-4ac5-a435-d054a6eadf8e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b1826bd1-e993-422d-844e-4a4e174fd8af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended" id="i0b931445aa8b40bcbeea2034e7eb365d_ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_81156bd0-e8a8-4418-8c9f-3905151528cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_81156bd0-e8a8-4418-8c9f-3905151528cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1261bb1b-d3d4-4285-a19b-3a9e12899124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1261bb1b-d3d4-4285-a19b-3a9e12899124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ddc9cf19-0839-4621-adb4-baa91bc0e43b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1261bb1b-d3d4-4285-a19b-3a9e12899124" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ddc9cf19-0839-4621-adb4-baa91bc0e43b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51801b57-af3e-4443-a62b-2648b5725321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1261bb1b-d3d4-4285-a19b-3a9e12899124" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51801b57-af3e-4443-a62b-2648b5725321" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d7bc70af-0bd1-45ec-b364-5bc1c2079113" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1261bb1b-d3d4-4285-a19b-3a9e12899124" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d7bc70af-0bd1-45ec-b364-5bc1c2079113" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_58d7f111-7bc4-436b-b550-e1086eb3b060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1261bb1b-d3d4-4285-a19b-3a9e12899124" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_58d7f111-7bc4-436b-b550-e1086eb3b060" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd873cf3-63f6-455a-9465-c17a8e89c04e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4430727-fa5d-4fd4-9ae1-4041f47fbc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4430727-fa5d-4fd4-9ae1-4041f47fbc1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5ebb5635-06b5-4b49-b744-18b4d4e06bfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4430727-fa5d-4fd4-9ae1-4041f47fbc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5ebb5635-06b5-4b49-b744-18b4d4e06bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e3bedb53-9121-4cf8-9304-d5015e65ba9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4430727-fa5d-4fd4-9ae1-4041f47fbc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e3bedb53-9121-4cf8-9304-d5015e65ba9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e872caf6-9dda-45ab-871e-85e5f87ff5e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4430727-fa5d-4fd4-9ae1-4041f47fbc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e872caf6-9dda-45ab-871e-85e5f87ff5e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab9bb91b-3f8f-4d59-baaf-8a0025fb8561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4430727-fa5d-4fd4-9ae1-4041f47fbc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab9bb91b-3f8f-4d59-baaf-8a0025fb8561" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_732c5b2e-f7e8-4ae7-9f34-e588626f8755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fc253800-013b-4a02-8b58-e4961220517d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fc253800-013b-4a02-8b58-e4961220517d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5168c547-9a8e-4a5b-8f5a-bb8fe9b08cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5168c547-9a8e-4a5b-8f5a-bb8fe9b08cf8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_df3e0163-6e8f-4e2a-b5ae-a73219b262b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_df3e0163-6e8f-4e2a-b5ae-a73219b262b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e50f003-9028-473e-acdc-aab04ca1a114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e50f003-9028-473e-acdc-aab04ca1a114" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_01c4decb-2ca4-4c76-9755-4d6b7b0178e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e50f003-9028-473e-acdc-aab04ca1a114" xlink:to="loc_us-gaap_AwardTypeAxis_01c4decb-2ca4-4c76-9755-4d6b7b0178e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01c4decb-2ca4-4c76-9755-4d6b7b0178e2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_01c4decb-2ca4-4c76-9755-4d6b7b0178e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01c4decb-2ca4-4c76-9755-4d6b7b0178e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_073ff669-34b8-4c75-8aac-1334c384a807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_01c4decb-2ca4-4c76-9755-4d6b7b0178e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_073ff669-34b8-4c75-8aac-1334c384a807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_84756d35-2e40-4717-80ce-6738e32b8ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_073ff669-34b8-4c75-8aac-1334c384a807" xlink:to="loc_us-gaap_PerformanceSharesMember_84756d35-2e40-4717-80ce-6738e32b8ea6" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cah-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9f2b874d-aa0f-4f0c-98af-f0bcbd3c3f24,g:771f989f-b1cf-4cd9-b16a-9064b3a47170-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cah_A2.4Notesdue2020Member_00983987-813b-44aa-bb77-e48ca22649c0_terseLabel_en-US" xlink:label="lab_cah_A2.4Notesdue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.4% Notes due 2020 [Member]</link:label>
    <link:label id="lab_cah_A2.4Notesdue2020Member_label_en-US" xlink:label="lab_cah_A2.4Notesdue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.4% Notes due 2020 [Member]</link:label>
    <link:label id="lab_cah_A2.4Notesdue2020Member_documentation_en-US" xlink:label="lab_cah_A2.4Notesdue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.4% Notes due 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.4Notesdue2020Member" xlink:href="cah-20201231.xsd#cah_A2.4Notesdue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A2.4Notesdue2020Member" xlink:to="lab_cah_A2.4Notesdue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_94a3cab4-a7c2-44d7-a6d9-6d6c3894e57f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1dcc046d-862f-4384-aaf4-bf8951acdeb6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4cb9435c-f4b6-49e5-a04b-938a0dcefbd3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of outstanding options at period end</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e5fbdb8b-cde7-4cc4-abfe-68899fbdadee_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A4.9Notesdue2045Member_3471a171-ef15-49d1-9b4d-15b2304b8ca4_terseLabel_en-US" xlink:label="lab_cah_A4.9Notesdue2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.9% Notes due 2045 [Member]</link:label>
    <link:label id="lab_cah_A4.9Notesdue2045Member_label_en-US" xlink:label="lab_cah_A4.9Notesdue2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.9% Notes due 2045 [Member]</link:label>
    <link:label id="lab_cah_A4.9Notesdue2045Member_documentation_en-US" xlink:label="lab_cah_A4.9Notesdue2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.9% Notes due 2045</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.9Notesdue2045Member" xlink:href="cah-20201231.xsd#cah_A4.9Notesdue2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A4.9Notesdue2045Member" xlink:to="lab_cah_A4.9Notesdue2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9c68559f-fc0b-42ff-b8bb-43f9d654421c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, without par value:</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0acd8261-cad2-4699-bacf-3e01870b949c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f7731fba-62eb-444d-b0fc-d05189a4aba7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, Contingent Liabilities and Litigation</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_98168a87-a9cb-4996-ad9e-4fb40090d3e7_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_779e9471-5908-42db-8641-5cc4ded32e48_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_353c84ad-8f6a-4178-bddf-73fac948649b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes and other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_18f6951c-2b57-474e-98a8-38c579518599_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Reportable Segment</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_c2a334c4-59e5-4fca-9fd2-d7621e3a8b4b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_22a52d62-9a23-4439-b4ec-7f36426c57f8_terseLabel_en-US" xlink:label="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_label_en-US" xlink:label="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_documentation_en-US" xlink:label="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares that would be antidilutive as a result of net loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:href="cah-20201231.xsd#cah_Sharesthatwouldbeantidilutiveasaresultofnetloss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:to="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7671616f-db3f-41d5-ab9e-4e69262fef51_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain/(loss) on derivative instruments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_df7f39d7-d2a8-41a2-9148-26288f3b8aac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_56a9f265-90c0-494f-ac6f-9b78837a44a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7e6e2b10-8a5f-47c7-a76d-4f295e7176db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2ee5adc5-bacc-4b19-939d-40679158e0cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalMember_b1b0e5f9-d024-434a-b1ee-3578a01b5369_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_label_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Member</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember" xlink:href="cah-20201231.xsd#cah_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalMember" xlink:to="lab_cah_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_3c160b5b-2338-488d-9c17-210ed65a1745_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_label_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_documentation_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:href="cah-20201231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:to="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4646b0ae-cbb6-4b16-949d-2dcd5dc19a62_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c077c37-4926-4171-8134-9133c3ee065c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_663d1451-ba64-4539-af87-b34706b34631_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_af7db28d-7271-4992-8d7a-1a6000fa60c6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e3c3e0b6-7768-4e20-800a-19ac05ac1a76_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_b9734527-e21d-4320-98bb-0eb69f2c42c0_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_a5372495-51ab-4dbf-bc5f-7eff3f36828e_terseLabel_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_label_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_documentation_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares" xlink:href="cah-20201231.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_VestingPeriodinyearsforShares" xlink:to="lab_cah_VestingPeriodinyearsforShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e18d474e-fd08-45ef-bd66-1ccfb5752ef3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6ecbdeab-4866-43a2-974d-a3c22ed27a3d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_3903599f-a0cc-43e9-b46e-d39326461fc2_terseLabel_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_label_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember" xlink:href="cah-20201231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProductLiabilityLawsuitsMember" xlink:to="lab_cah_ProductLiabilityLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3a12d213-94cc-48cc-b640-ff924c5a9498_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ClassActionLawsuitsMember_dc74229d-5497-43de-bafa-058f72281248_terseLabel_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_label_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember" xlink:href="cah-20201231.xsd#cah_ClassActionLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ClassActionLawsuitsMember" xlink:to="lab_cah_ClassActionLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_05e3e28d-6fc2-4abf-b3ee-f3c61f7faa64_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_1f4e689c-6ea1-4bd8-8c95-04f22ee48779_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_2eb8c2a0-35af-4eb5-9eac-2ac1c5d622e2_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Unit</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b5ac8a53-cc9d-4497-a8dc-44a80b02eccc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d986ec44-c816-49e4-8c5f-4447a37e2328_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_fe04b9fe-4800-4a01-84c7-fd587d85e7e9_terseLabel_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_label_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_documentation_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:href="cah-20201231.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:to="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_6f81fea4-6042-4331-8af2-abd993048aa0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_2c713a87-281d-44fb-89fc-41909febb2e2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_95d82690-7e3e-4d9b-8006-8ab686721439_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73266df6-8d4a-450b-8a0b-5292ec395f0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7feef464-c08a-4d84-b3dc-8abe072e040e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9a47d5d0-d0d7-4ac6-8c63-16ded6c0e3b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e835e930-0028-411a-be1e-ff083fd54d89_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1a57b0fe-36f1-4a4e-8473-075d2e55bd2a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_bbd1340d-c594-4eb4-8b07-5fb25e29aed0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_475b5b74-41dd-43e5-89c2-caab231e7d3c_terseLabel_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_label_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_documentation_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember" xlink:href="cah-20201231.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NuclearPrecisionHealthServicesMember" xlink:to="lab_cah_NuclearPrecisionHealthServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_8c13b8c1-a956-489e-a073-65ee8ee53efd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_76701cad-c281-458d-9664-7e3e748d5081_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_fd6042bd-9295-43cf-b85e-77a827c3500f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_b24f3f85-f377-4949-91fd-48f04f201dc9_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_5e31befe-5aa7-445e-b610-c5489b871097_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_2f6f2578-46d2-4482-bdf3-295cb91e9937_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0452a94f-e1b1-468a-8027-1506a74f0bef_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_43b7cc88-7c49-437c-992f-7cd0069fc70e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a1a6abee-2f1c-461a-91c1-cd128f3cff05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_cddad42d-2cf6-494c-b433-c3750a17b53f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_138d9609-3e4c-4c67-9f48-1db1e9d3537a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_d642c08b-6581-4485-8848-bfe393b4042a_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_4d6153db-9058-4296-baf8-a3b235b1cf50_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_7f145009-89db-424e-a47b-cd5ef4845d83_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SterileSurgicalGownRecallAxis_a824bbf3-9e69-49a8-8deb-51f4685e9498_terseLabel_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Axis]</link:label>
    <link:label id="lab_cah_SterileSurgicalGownRecallAxis_label_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Axis]</link:label>
    <link:label id="lab_cah_SterileSurgicalGownRecallAxis_documentation_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Axis] [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallAxis" xlink:href="cah-20201231.xsd#cah_SterileSurgicalGownRecallAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SterileSurgicalGownRecallAxis" xlink:to="lab_cah_SterileSurgicalGownRecallAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_b8f3090a-3150-4aa7-91a5-b6448d161558_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_46295f90-98b0-4418-91e6-7308764ac062_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized&#8212;500 thousand shares, Issued&#8212;none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_95038f1e-236f-47b2-b097-1ab04970549b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_a3c0cc35-b5f4-4327-88b5-766c6e420fcb_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7d509a97-a1f5-48c9-b890-7f1f369d9065_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1253f051-ca48-4119-839f-bb7cedba845b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GownRecallDomain_f654d4a7-7540-4d0e-951d-c8f94fd79dd2_terseLabel_en-US" xlink:label="lab_cah_GownRecallDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gown Recall [Domain]</link:label>
    <link:label id="lab_cah_GownRecallDomain_label_en-US" xlink:label="lab_cah_GownRecallDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gown Recall [Domain]</link:label>
    <link:label id="lab_cah_GownRecallDomain_documentation_en-US" xlink:label="lab_cah_GownRecallDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Gown Recall [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallDomain" xlink:href="cah-20201231.xsd#cah_GownRecallDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GownRecallDomain" xlink:to="lab_cah_GownRecallDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_425585ba-6ce8-4c8e-929d-b13e45beb4e8_terseLabel_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_label_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_documentation_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:href="cah-20201231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:to="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_fa45bae8-4a23-4464-8d43-8138af4ed86a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_2865968b-f7c5-430d-935b-d87c24225b27_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_7d9568e5-39be-479d-b828-983132227929_terseLabel_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project costs on investment and other spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_label_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_documentation_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:href="cah-20201231.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:to="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalMember_6e79b5d3-950d-470b-a1f7-794760e405f5_terseLabel_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical</link:label>
    <link:label id="lab_cah_MedicalMember_label_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Member</link:label>
    <link:label id="lab_cah_MedicalMember_documentation_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember" xlink:href="cah-20201231.xsd#cah_MedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalMember" xlink:to="lab_cah_MedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_b818fd33-930f-45d5-b4cd-df41c6ecdebf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_62511297-b0c0-4d78-b6b4-4aaaee9cfecb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_e3f53627-10eb-47da-b153-219742333b90_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_1fbc2f5a-b235-44ed-b9cd-3e2fd8af5a1a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DOJInvestigationMember_9d964082-57ba-4dce-be4c-2d7168b1b409_terseLabel_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation [Member]</link:label>
    <link:label id="lab_cah_DOJInvestigationMember_label_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation [Member]</link:label>
    <link:label id="lab_cah_DOJInvestigationMember_documentation_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember" xlink:href="cah-20201231.xsd#cah_DOJInvestigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DOJInvestigationMember" xlink:to="lab_cah_DOJInvestigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IndemnificationReceivable_3c2eb0d5-f820-429d-a5a6-d4b2d63d064e_terseLabel_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_label_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_documentation_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable" xlink:href="cah-20201231.xsd#cah_IndemnificationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IndemnificationReceivable" xlink:to="lab_cah_IndemnificationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_c8cdd44b-48b2-4366-ac6a-ef88f3399db4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_782fca25-608c-4db0-80ab-0d1ed903e2e3_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_fa103eb6-b89a-4131-a145-c52edc96274a_terseLabel_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_label_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_documentation_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:href="cah-20201231.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:to="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_97a999a4-14d1-4b87-a794-b7c6529211df_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_ae711c77-8875-4f2e-b68d-4772d8976a71_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeDomain_4f4c81d4-231e-492c-8e63-011c8964d512_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_label_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain" xlink:href="cah-20201231.xsd#cah_PlaintiffTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeDomain" xlink:to="lab_cah_PlaintiffTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2e503527-b836-458c-9d4d-8a4056646a9b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_869371bc-73a8-4dcf-b2e7-6a3d754ff708_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_be60493b-64dc-4f72-9a7b-3b632a182c47_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_7d6e9a5e-aeb4-4f29-a29f-61a96e9c8fc0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_a38a977b-fdd9-465d-9aa5-93338719adc0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8721d525-ce42-45ad-9c85-862739423c88_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_ad7a9b58-5857-4d69-8360-04e544299ab9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c7e43278-e96a-4331-b930-a1ee6cd1b641_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_534f2481-d913-4abf-ac80-058ae4593217_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_39a0a9d2-2d36-458e-aca2-fcd6ba42ca1f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_92647ad2-f26e-4d15-b701-a3769363d2f9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A4.368Notesdue2047Member_b93d0162-f44c-4d6f-aa17-6058a5bca728_terseLabel_en-US" xlink:label="lab_cah_A4.368Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.368% Notes due 2047 [Member]</link:label>
    <link:label id="lab_cah_A4.368Notesdue2047Member_label_en-US" xlink:label="lab_cah_A4.368Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.368% Notes due 2047 [Member]</link:label>
    <link:label id="lab_cah_A4.368Notesdue2047Member_documentation_en-US" xlink:label="lab_cah_A4.368Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.368% Notes due 2047</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.368Notesdue2047Member" xlink:href="cah-20201231.xsd#cah_A4.368Notesdue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A4.368Notesdue2047Member" xlink:to="lab_cah_A4.368Notesdue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_7ea83ca5-70e4-48de-bb39-bf2247bec356_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6410a0e3-8735-454d-a636-1c7b41f7389e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A2.616Notesdue2022Member_27e499c3-7548-481f-8a62-fe572030cf18_terseLabel_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_label_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_documentation_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member" xlink:href="cah-20201231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A2.616Notesdue2022Member" xlink:to="lab_cah_A2.616Notesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_386dd155-4aaa-454d-a2a0-b131e378f488_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c64403c-588e-4d55-8c28-97544cc48e47_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_63cecf32-ff7a-47b3-840a-c679facd2557_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_7bebd03d-a16a-4333-8a2e-ab3cf230d38d_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from sales of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20201231.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_070f69d7-182f-42a3-806e-f64208193970_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_c77f6533-7f77-4c50-9b25-70cdc5c009d4_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_94201a74-2c8c-4a31-ba3f-6e6cf553d50c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_c95bebc0-446b-4119-a272-8e25ad56b384_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f24255c-6631-4b3a-93c8-6420436137e2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e54abc0b-8bc7-444c-81cf-a4fc9907e464_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_339d3f5c-154d-4ef6-8c07-2740ff8a05ba_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6e179c3c-57b3-4949-aca8-6772ef9f20a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_c8cf8291-50c9-4ff8-a750-13965a83b671_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_6cc392da-b621-41ec-a1b6-425c13c9a089_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_da5476b1-ac41-4e38-87bd-599e3610f8ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0fe39e68-3c55-4398-8c4c-04fcc9a94bcd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_a3dfbeb5-8d85-40f7-9102-70632d0ea870_terseLabel_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_label_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_documentation_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts" xlink:href="cah-20201231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FacilityExitAndOtherCosts" xlink:to="lab_cah_FacilityExitAndOtherCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4b610329-840e-42a1-b2f8-3c293d8117bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a1896082-59a4-4683-9380-21fb8d57dcac_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_3cd8893a-0b12-46f9-9757-a9fea379a709_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_870543e0-3588-438c-8430-2b4a5f55da6e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NetOperatingLossCarrybackMember_19d5719d-f6d0-4b01-afe8-d8963fe81372_terseLabel_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Member]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackMember_label_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Member]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackMember_documentation_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackMember" xlink:href="cah-20201231.xsd#cah_NetOperatingLossCarrybackMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NetOperatingLossCarrybackMember" xlink:to="lab_cah_NetOperatingLossCarrybackMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8d77b58b-3116-4b55-ad0c-4cd9ffa1c6b2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock options, restricted share units, and performance share units (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_fe458cd4-e9a1-42cf-939e-cac452732f30_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates changes on cash and equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_796b899b-6100-411d-bd1e-d43e091d7ee8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2881d95c-d6c3-480f-9862-41cbaeddc89c_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_25678530-df27-4bc6-8035-405ab3fae5f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_a3bee232-18ef-42db-97e6-fe09ed3d5204_terseLabel_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_label_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_documentation_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:href="cah-20201231.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:to="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_884ffd2c-af71-4c24-8781-03448a64f932_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired, average price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_23b02827-8f33-4727-8eb0-5cbb355d7846_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5357a67e-ac8b-4b54-a7dd-c4bc71a28755_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6bff378d-cd26-4c8b-870d-1ed741332ff9_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution, selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c46bae2b-adf7-4153-947f-6ba97af38894_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_7f39ec77-3510-4f51-b519-39c98f979933_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_b1df7efd-d663-437e-a72d-a349ff16e480_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9cffa4a5-a07c-4b22-8a57-1e81987afa0a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_7b00a25b-14cd-446a-9a01-fa66b3c140ea_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e3a94854-8a44-4e11-97c5-547b354b6d71_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_dd534f95-5582-4db1-821b-700c755b9fde_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ba09bfdc-fb8c-469d-a9fd-1b3b7a535bce_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_cb5f039f-cd15-436f-95f0-556522f87248_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_2f7e74fe-9ef3-4163-b5bf-6ef5d16da362_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00207c94-18a1-4ebe-9729-87172b885401_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a3bbcfed-6da7-437d-aa0e-8d1911823099_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_65ddd32a-6fea-44f0-9ce5-da5b398ab2c0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0a40f4f9-fccf-4e01-98e5-d31391bd3af0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_b56bf71c-7268-4592-af14-c6b6aa1d5fa8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_6351087b-36e2-442b-afdb-94e7a342bf41_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_9d754d60-76ce-4272-a17e-8f75629da83a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e4cc3d30-dd75-449a-b2c2-54c9bc979161_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_a38a02ed-0b43-43d9-8ff3-8aa76d0945d1_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4df41088-241f-4dc9-bbfc-ea3aa4e71892_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_7e6caca2-32ee-4269-b0b6-ee3e41a32279_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_602a2cab-0e17-4e3a-a085-a863a92f4af9_terseLabel_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_label_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_documentation_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term credit facilities and an unsecured line of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember" xlink:href="cah-20201231.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShortTermCreditFacilitiesMember" xlink:to="lab_cah_ShortTermCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLocationDomain_cbe52fee-eace-44ac-908f-84ea07011669_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income Location [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLocationDomain_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_50ed63ee-612a-468a-bbcc-19b39671a784_terseLabel_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount</link:label>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_label_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount</link:label>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_documentation_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" xlink:href="cah-20201231.xsd#cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" xlink:to="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ae045f32-8a09-4cdb-a36b-3494133d9d78_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8703734d-5436-44d8-afcb-8f6194d4800f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_e0032f06-7532-4525-82a5-4fbdc0c09b7f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cb44a696-80ef-4d0d-8635-ec52d5d778c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc40653d-74fc-4a14-a3c0-7bc142f45744_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_e860d415-5159-4d87-9dbf-c93d6f23bffe_terseLabel_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_label_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_documentation_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:href="cah-20201231.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:to="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_121fa9ad-d399-43d0-83b7-988d223766cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(decrease) in accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e9850b59-c19d-486f-bca3-4557d71c830d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_53ed3f25-7480-42ff-8814-bda0d215c92b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_540aee06-aaf2-4f33-ab2c-e7d02069edca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities and operating items, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_f8a19de9-9be7-4162-8f84-63a4ef6c47f8_terseLabel_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_label_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_documentation_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:href="cah-20201231.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:to="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_18e28a1a-f2fd-48dc-b09b-af15b504bd1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_6c41f135-5cbb-4084-b95b-73903eab784d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_a06aa9bb-8d20-4ca5-aa7d-c7c3b0cc27c3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_aab6d070-3b3a-470c-9e75-b1be215b30bb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_217ed31f-2903-4806-820e-6ff65fcd661b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8e88295d-a520-43ae-a969-e1cb14bf86a5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9e132b33-250c-43e7-a736-b0e7ff7590c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_6039efef-dfda-4965-ad1a-e85731b855b8_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TrademarksAndPatentsMember_bb3a3197-c32c-4706-a3cf-29ffa13c8911_terseLabel_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks, trade names and patents</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_label_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks And Patents Member</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_documentation_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember" xlink:href="cah-20201231.xsd#cah_TrademarksAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TrademarksAndPatentsMember" xlink:to="lab_cah_TrademarksAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A4.6Notesdue2043Member_9d07909e-4208-4293-8e02-1edc43ea4532_terseLabel_en-US" xlink:label="lab_cah_A4.6Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.6% Notes due 2043 [Member]</link:label>
    <link:label id="lab_cah_A4.6Notesdue2043Member_label_en-US" xlink:label="lab_cah_A4.6Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.6% Notes due 2043 [Member]</link:label>
    <link:label id="lab_cah_A4.6Notesdue2043Member_documentation_en-US" xlink:label="lab_cah_A4.6Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.6% Notes due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.6Notesdue2043Member" xlink:href="cah-20201231.xsd#cah_A4.6Notesdue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A4.6Notesdue2043Member" xlink:to="lab_cah_A4.6Notesdue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_2e1e4f22-f894-43ed-a0bd-bb65c9706110_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_7e3aec81-1c97-4074-81d3-5de89e0c6fea_terseLabel_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_label_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_documentation_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations" xlink:href="cah-20201231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalLongTermandShortTermObligations" xlink:to="lab_cah_TotalLongTermandShortTermObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_3695e315-7566-423b-a979-4a13bc46e86d_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_706f4230-e150-423f-90a0-676cd389ed2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_1f616599-b6b6-4189-ae2d-0084f7f02aa9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReceivable" xlink:to="lab_us-gaap_IncomeTaxReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CARESActDomain_58a10fc3-686f-4e1d-9849-b80e789f89fd_terseLabel_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Domain]</link:label>
    <link:label id="lab_cah_CARESActDomain_label_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act [Domain]</link:label>
    <link:label id="lab_cah_CARESActDomain_documentation_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain" xlink:href="cah-20201231.xsd#cah_CARESActDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CARESActDomain" xlink:to="lab_cah_CARESActDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_85754536-7a55-4eb9-b65b-396c0af10118_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_1b73fe64-d737-4ec7-aa30-7b22102eeeda_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_346aefc4-50b1-4f71-8f79-e0b3ccf79c84_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c502894-2589-4e8f-ac81-a9e1e1e534a0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_eab1beae-353e-4595-b019-1ca75fa8c408_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of subsidiaries, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3dbcd819-efb9-4f0c-a93c-57a7b99e7b2a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_06389e0e-cc5a-425c-b5b4-bf399bee9b99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Restricted Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_ed956e24-fe8e-40ed-89b5-b4179a8077d6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NotesPayableRepurchased_aa1e4d25-9428-495b-a6ad-07d46aadb6ec_terseLabel_en-US" xlink:label="lab_cah_NotesPayableRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable Repurchased</link:label>
    <link:label id="lab_cah_NotesPayableRepurchased_label_en-US" xlink:label="lab_cah_NotesPayableRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable Repurchased</link:label>
    <link:label id="lab_cah_NotesPayableRepurchased_documentation_en-US" xlink:label="lab_cah_NotesPayableRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount of Notes Payable Repurchased during the year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NotesPayableRepurchased" xlink:href="cah-20201231.xsd#cah_NotesPayableRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NotesPayableRepurchased" xlink:to="lab_cah_NotesPayableRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_89de61bc-8d1b-49c0-b833-ba070641a6d3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_9f6eaf79-2200-49fa-8d9e-fb4a96bd4da9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations and other short-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_9773e1be-fe84-4601-9b19-be06d118817d_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_11f3fac4-0fac-476f-a05a-de25deb332c4_terseLabel_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D, trademarks and other</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_label_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D,TrademarksandOther [Member]</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_documentation_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember" xlink:href="cah-20201231.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IPRDTrademarksandOtherMember" xlink:to="lab_cah_IPRDTrademarksandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ec3c335f-c3a9-4bc7-b0cf-b4616f890df1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5c90618d-1263-4871-add9-6b7af583dc2c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4438809d-3b67-44d7-bccc-3ce5411b1aa2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_337e940c-ce75-4aef-b4ee-27f3eb8429e5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4949b44-d86d-4f56-ab0c-d20717164e1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_60f5b410-3c21-48da-9f50-81b896aaf076_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SterileSurgicalGownRecallMember_20cc54a5-460b-49a8-80e8-c4bdf308617d_terseLabel_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Member]</link:label>
    <link:label id="lab_cah_SterileSurgicalGownRecallMember_label_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Member]</link:label>
    <link:label id="lab_cah_SterileSurgicalGownRecallMember_documentation_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallMember" xlink:href="cah-20201231.xsd#cah_SterileSurgicalGownRecallMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SterileSurgicalGownRecallMember" xlink:to="lab_cah_SterileSurgicalGownRecallMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_b5739981-6843-45fd-a7a3-0fd4d95c377d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b43422c6-a152-4482-924d-9c55e4ed764b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_af7937ae-cd65-4dc0-98d9-eee176f7e156_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_c39d40cf-f86b-4c66-9d09-251df1c0b5d2_terseLabel_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_label_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_documentation_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember" xlink:href="cah-20201231.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicaldistributionandproductsMember" xlink:to="lab_cah_MedicaldistributionandproductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_731cb017-fb22-4836-a25a-1b0039bbfbaa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterDomain_13f91cd9-9f81-4564-a658-0636115887ca_terseLabel_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_label_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_documentation_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain" xlink:href="cah-20201231.xsd#cah_TaxMatterDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterDomain" xlink:to="lab_cah_TaxMatterDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_0a06ba25-4b02-46d1-ae2d-071a1b928d41_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_d140921e-9d05-4b47-9a2c-4d3a95f55056_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_f55196b8-9109-4284-94ba-3190a0e6c3b9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_274e5b5a-013d-4b16-9fbd-468df97742ad_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_84053072-0db5-47f2-a615-48a694b9e53b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_a746b981-c637-4ab7-9e8e-76788a612360_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Performance Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_e3fd78a8-c754-47d1-81cd-372f7779f92d_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a34b70fc-47f9-4fb5-b8b3-955e093eec73_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_649046a9-ffde-46c3-be41-4718accc431a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_cf435041-d39a-449c-b3f7-ae4dba18e37f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GownRecallAxis_9b0cd6bf-d3d1-4013-98f2-4148131e645d_terseLabel_en-US" xlink:label="lab_cah_GownRecallAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gown Recall [Axis]</link:label>
    <link:label id="lab_cah_GownRecallAxis_label_en-US" xlink:label="lab_cah_GownRecallAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gown Recall [Axis]</link:label>
    <link:label id="lab_cah_GownRecallAxis_documentation_en-US" xlink:label="lab_cah_GownRecallAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gown Recall [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallAxis" xlink:href="cah-20201231.xsd#cah_GownRecallAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GownRecallAxis" xlink:to="lab_cah_GownRecallAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_f1934bbd-3856-4921-920b-62030607ec6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ea42de29-f7d6-4f82-b717-8b7332e8ff3d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FloatingRateNotesdue2022Member_049b1f1d-03f7-478d-aff2-b16a5900c022_terseLabel_en-US" xlink:label="lab_cah_FloatingRateNotesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_FloatingRateNotesdue2022Member_label_en-US" xlink:label="lab_cah_FloatingRateNotesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_FloatingRateNotesdue2022Member_documentation_en-US" xlink:label="lab_cah_FloatingRateNotesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member" xlink:href="cah-20201231.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FloatingRateNotesdue2022Member" xlink:to="lab_cah_FloatingRateNotesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_32bbf097-9b42-4d73-9b21-e8a6f481c03a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_8407cfb7-244e-4577-a116-e51e36f116ca_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsStateDomain_38368cb8-3bf8-465d-9777-ec09f95f29fa_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsStateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State [Domain]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsStateDomain_label_en-US" xlink:label="lab_cah_OpioidLawsuitsStateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State [Domain]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsStateDomain_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsStateDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State and Political Subdivisions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateDomain" xlink:href="cah-20201231.xsd#cah_OpioidLawsuitsStateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsStateDomain" xlink:to="lab_cah_OpioidLawsuitsStateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_725d4a31-f6ba-44fb-9a9f-0275f5364cfd_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_dab16ba6-6d5f-46a7-b742-c891bf8093c6_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_068c99bf-cc63-4633-a3aa-5f369ae97d93_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_3cb80d6e-204e-4ebd-b33b-0c9f0260f86c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MaximumQuarterlyPayment_17c6ad83-0097-422d-8bba-48908d76cc22_terseLabel_en-US" xlink:label="lab_cah_MaximumQuarterlyPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum quarterly payment</link:label>
    <link:label id="lab_cah_MaximumQuarterlyPayment_label_en-US" xlink:label="lab_cah_MaximumQuarterlyPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Quarterly Payment</link:label>
    <link:label id="lab_cah_MaximumQuarterlyPayment_documentation_en-US" xlink:label="lab_cah_MaximumQuarterlyPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaximumQuarterlyPayment" xlink:href="cah-20201231.xsd#cah_MaximumQuarterlyPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MaximumQuarterlyPayment" xlink:to="lab_cah_MaximumQuarterlyPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b2e563e-c91e-4c4d-9d3f-fff2e92cfa70_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_73ac4373-afc7-4a8f-bd49-4f9c380c4f2e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_6a2e0ae6-6a2b-4b73-9e5f-9f78b0f61111_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OtherJurisdictionsMember_5f32b36d-ca6d-40de-959d-a5ec7a842299_terseLabel_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_label_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_documentation_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember" xlink:href="cah-20201231.xsd#cah_OtherJurisdictionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OtherJurisdictionsMember" xlink:to="lab_cah_OtherJurisdictionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_21710f96-442c-4ca8-a21a-5a38e20bc3a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Share-based Compensation Expense by Type of Award</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRecallExpense_a587f0dc-046a-40cf-b5b0-9980f1ec5006_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRecallExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Recall Expense</link:label>
    <link:label id="lab_us-gaap_InventoryRecallExpense_label_en-US" xlink:label="lab_us-gaap_InventoryRecallExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Recall Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRecallExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRecallExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRecallExpense" xlink:to="lab_us-gaap_InventoryRecallExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_617d0c49-fc6f-464e-9d36-cbb6ac724417_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ec93746d-bc83-4d53-9484-d0d435b2c908_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_79518959-8e29-4a14-96d2-f5ae9a6665bb_terseLabel_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_label_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_documentation_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:href="cah-20201231.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:to="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_1b5a259d-1dc8-4ec8-9070-d9533f81c288_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeDomain_f66a8a30-33a5-4c59-ab11-c7471d55631d_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Domain]</link:label>
    <link:label id="lab_cah_LawsuitTypeDomain_label_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Domain]</link:label>
    <link:label id="lab_cah_LawsuitTypeDomain_documentation_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain" xlink:href="cah-20201231.xsd#cah_LawsuitTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeDomain" xlink:to="lab_cah_LawsuitTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_a64b860d-1741-492a-9a05-6942df05290c_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationDomain_0b37ba35-c212-45f0-9383-7705bd6c3382_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_label_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_documentation_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain" xlink:href="cah-20201231.xsd#cah_OpioidLitigationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationDomain" xlink:to="lab_cah_OpioidLitigationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8fd25eeb-24f1-4bef-8a53-4e1776cd1ac9_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_9ce106eb-8a7b-4e1c-b44b-37c190977229_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_c091ad20-013a-4bee-bd0b-580ea7a8d4cf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_d189045e-9923-4f2d-a149-8b676869c5ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_bb7640b8-377d-4777-a128-71526d814e8e_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_142e97dc-38fc-4c19-96e2-0ffa46a1fecf_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CareFusionMember_35deac56-7501-4226-bb81-648c32428673_terseLabel_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_label_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_documentation_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember" xlink:href="cah-20201231.xsd#cah_CareFusionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CareFusionMember" xlink:to="lab_cah_CareFusionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_e91ed5a4-5c23-49de-a287-37cebc671485_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d1a4f267-8d47-4e89-9375-e9bd45c4eb74_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_afcaee5d-63a3-4cad-b582-2d68c1c2782a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_b6788c70-0496-4a30-bffd-dabdca4846de_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_6b6b9d1e-6655-4008-a6df-63719b0f6819_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_35d1531d-fc82-4314-8cf4-8969c776f67a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e05eddc-eaf7-412d-aeb1-3c70f4413ae5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_d9e3a479-ade5-4261-bffe-04a96fc302f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c255f066-6b1e-4482-85db-c333f92cd57c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_e046ccc9-4772-40ed-bd4d-bc9a862dac34_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_730c61a9-5333-42d3-bc4e-f03b6d318b66_terseLabel_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business</link:label>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_label_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_documentation_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember" xlink:href="cah-20201231.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PatientRecoveryBusinessMember" xlink:to="lab_cah_PatientRecoveryBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c38dea51-385f-46e6-8250-da63124acb2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net earnings attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_84853ce8-1eb7-417c-ad3e-a43784a4f28e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b1c8f483-4344-4459-8852-0b4a75cb57f8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_f57f3144-6120-4b66-8602-44d0abb8247d_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5f54de6f-8278-4c34-8a04-773d5c46b8c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_b8a3d20b-2b6e-428f-8abe-05fb595cb4e4_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_label_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:href="cah-20201231.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:to="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1914a9ff-c6ce-4659-b2c7-bba34849d750_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_770d637b-bae1-4ac8-93f7-8c3b298b4188_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fb686868-387b-4f80-9bd7-7a7d9b5ce86a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8b6de8b8-9cbc-4ec9-b78c-c018bc907b5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Transactions Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_80e8aeef-35ee-493c-8e87-5e6c53f71032_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a8a4bb97-cf76-4e5f-8d92-84888c6b1e92_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Amortization Period (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_67a5efdd-b43d-41ab-8c15-23fce9584cb3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e1494eed-a239-41cb-8145-58fa44fc2e30_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Remainder of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_66035462-5fb1-4853-a46b-17c0a7df5b38_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_2a083b4d-212d-4d72-a193-eab347e95728_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_538a0f57-c671-4115-886a-0c2ec26a55ef_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_806779ba-e9f1-4814-a72d-dcac330a7087_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_d4b9402b-6b5f-477f-bf7a-2c4554e9106f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_7f70faf4-114b-4580-8a5e-8d47581f3918_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_af844ca8-4cab-4b43-8de9-cee672a83f4e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_b972c7d5-cb2f-4145-b226-88aac5bfb957_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_a4e8fe98-bec1-4478-a93e-39cbe1ab635e_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Profit by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c6887e8-43f1-4505-9cf8-f9161900797d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Common Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a87aea12-2c31-4c01-9266-7f28864723b6_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_deca51ef-7964-4a7e-84d6-186de4811164_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_bc18a88d-a4c3-4472-96e4-3474821b36a1_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated range of decrease in unrecognized tax benefits within the next 12 months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_9f02c171-0916-43a0-a8f9-f5eab82c14cf_terseLabel_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_label_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_documentation_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember" xlink:href="cah-20201231.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CardinalHealthAtHomeMember" xlink:to="lab_cah_CardinalHealthAtHomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenTaxYear_ce8f87aa-40c1-4cca-9e81-3d81b077009d_terseLabel_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:label id="lab_us-gaap_OpenTaxYear_label_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_3a4031f0-cff3-4357-a8ac-eb17c0f34e66_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_ea79b0bc-435c-4d05-b545-6ac584def1ce_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_206678ef-6ad9-4e5e-98ae-4129170f4d2d_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_82bfd264-d44b-4103-bbd7-859a50a64791_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1f11c831-87ef-4b59-aca1-1efc6fa74430_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLocationAxis_abc63ff2-5ded-4f9e-a664-f8f0ea76f480_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income Location [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLocationAxis_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_ce5be44e-17aa-492a-9767-5e5751910054_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_2f4acbad-4cc1-4e1e-a6c6-cb8497684d40_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_e29acef5-7943-4dfc-acbc-83e1455d4e7c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6168ff45-4781-44ab-bb2d-9c212c6f9a30_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_4f1ab1ed-8eaa-4de0-ad39-226d0bd13f87_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_0de65d3f-c0b7-4d79-8f26-2ef3f7d9b3a2_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_5e72a8a2-45d6-4058-9e3d-7a7b640f3937_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain/(Loss) on Derivatives, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_a24e69e8-ecc1-4136-8849-24bf8018fd1e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_dbf068ac-58be-4cd7-bbe5-846ab9e5d07d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and other adjustments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_e3e95ed0-200a-4681-8d0a-f8c9594df68b_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_fead03e7-08b2-4596-80ef-2fbe4cd2508e_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_926a4bdd-50b0-4701-ac6a-b78e55420700_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_dda3998b-531c-4eae-a6a3-5b866608692d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_67ac2b1c-3ece-4742-ae69-7dd2132b1c12_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalOpioidLitigationMember_ea95ee8c-7654-4453-b00b-0f1493273fbf_terseLabel_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_label_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_documentation_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember" xlink:href="cah-20201231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalOpioidLitigationMember" xlink:to="lab_cah_TotalOpioidLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_9ff4d026-c50d-4ca4-9040-a5a904a7f7f4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per common share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2550eb28-b6b8-41ff-91ca-195c17d65979_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0dcda614-dd32-4198-847b-1fe74a4d1866_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_a2383feb-8b09-4b58-a963-5fbc84054f56_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_ca2da7f1-4f22-457c-ad57-1697511d30b7_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_67c01e04-54a7-4fd0-aa13-d4ee8a39fda1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_7de6440b-fe24-4d18-839e-a379d6c5b76b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_1cfa50a0-66b1-4138-abac-c2725a056edf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase)/decrease in trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeAxis_a3b84be0-0aae-4866-b063-5b031151f372_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_label_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_documentation_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis" xlink:href="cah-20201231.xsd#cah_LawsuitTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeAxis" xlink:to="lab_cah_LawsuitTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2505300c-4196-4638-a913-163b5aae8a79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_c70e9030-5ac7-4ba3-af36-93f6ebb89316_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_ae8340f7-0582-4ae8-a2be-781e6aab0015_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_04e6729a-ae00-4113-a19a-6c616eadfa22_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a93d17a1-0a28-4c9f-98c2-c9a09f905f91_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_c5c6c24f-b7c2-4a98-8cd3-8b0c348f8560_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_96ae6fc0-041d-435f-8baf-327ea0d6ebc2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f4fba341-2cf1-4c22-b577-1f9ac15c8eec_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_44e3bb59-87f4-4292-a9ed-1cf56fdbd0be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a59880fc-a966-4f95-a440-4cec257e15ce_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_28db4535-e096-4e61-ad0b-526fc2e3a143_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_30592e1c-ad52-4f4a-9610-106261363eea_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_d2d74d4f-03ee-4b99-a2d3-5e6d342e62f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_549396af-1336-40a0-ba04-3f28b3dc1dc2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_20bb2f9b-99fa-4eae-a4a5-434e278fd638_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_50cc5e5e-3d66-4301-b842-073b746a3e51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SterileSurgicalGownRecallDomain_50c51418-b0e5-4213-beca-9c2f7b7537b2_terseLabel_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Domain]</link:label>
    <link:label id="lab_cah_SterileSurgicalGownRecallDomain_label_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Domain]</link:label>
    <link:label id="lab_cah_SterileSurgicalGownRecallDomain_documentation_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Sterile Surgical Gown Recall [Axis] [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallDomain" xlink:href="cah-20201231.xsd#cah_SterileSurgicalGownRecallDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SterileSurgicalGownRecallDomain" xlink:to="lab_cah_SterileSurgicalGownRecallDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b9531960-f93a-48ab-a203-3d620ffe0d5e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_ef998853-6aa6-4778-a895-8aad588c0297_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b762fed0-a5c8-4d87-a18f-5be3fd574bf5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_7398524a-db13-4276-9162-cf194f9d2575_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_3d6b8088-50a1-469d-b451-2f49e577b8c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized&#8212;755 million shares, Issued&#8212;327 million shares at December 31, 2020 and June 30, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_068c366c-4252-43c5-84c7-72965ea5079d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c145046b-6d26-45c8-af43-f638ae463c3c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b884395-e0b8-416d-be50-7b48e44bc388_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_124cd214-2a56-4b44-be37-43cb29bce44d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_04ad26b0-b541-4766-8c79-b39b2790a96b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_8746cd32-71be-4e76-8ecd-526e9fbde3a8_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f339d35a-ad04-48e3-b288-12da2b78f13e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of exercisable options at period end</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_8bbc364b-99a8-43a0-bf9a-cb1bb5ae77bc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6a2c2dce-c7cc-41fe-915b-52351ef8c4e5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_c7d85335-fc8f-4fc7-b8ff-50eeaa84c78e_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_label_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_documentation_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:href="cah-20201231.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:to="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_07f01b45-f126-403d-88ab-c72b004e3650_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_3003f3b6-38e2-449d-82ba-4ee4ca2a6f13_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0a58f400-8cff-4694-8aa1-3b572509e841_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_586dd783-d7db-4f10-8357-1baa449eaaf6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_628ea152-4636-4c7c-9b43-35004e56ca68_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_6f282b7e-c4c0-44d5-be49-5685359b44fd_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1a374fdc-6933-4dfe-9121-0987b0ff7b72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2abc026e-4e27-4521-b03d-72bbb413175e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target performance goal (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c8ca781c-1f58-4b6b-8114-8caa6aa222cc_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1cf56a8a-9820-4b24-90ca-e862d1cfd574_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1fad9ffa-4c10-4871-8a59-f7f73c75569d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_349d4dab-1fba-4153-b80a-24c14ff722da_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a07c980c-6578-43eb-9a9f-2bad62a03290_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6ddf1c84-fcd5-43c8-a351-5b51e12613b6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_227f4df1-a632-4db6-a5dc-995458599ff3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_97dbb886-15bd-40ca-af46-93bb26b1f048_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_300166e7-8ab4-45a1-b92c-f538ff9a9063_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_64449c5a-f75c-4042-a53f-3f769e7c99b9_terseLabel_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Axis]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_label_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Axis]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_documentation_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis" xlink:href="cah-20201231.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NetOperatingLossCarrybackAxis" xlink:to="lab_cah_NetOperatingLossCarrybackAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_38c395af-ded5-483d-ae1a-0a4a93014125_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_062c605d-8c4d-4797-86ef-d499a2c08c25_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1dc0ddcc-f532-4ad6-a8f6-5150d8c578cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_85002812-f22a-4543-bdd8-8c84a9868523_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cardinal Health, Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_10a8088c-9c78-4c79-8cf3-0faed99f9f51_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CVSHealthMember_9ae4ac0b-1a76-45fb-98cb-ce351ca57dad_terseLabel_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health</link:label>
    <link:label id="lab_cah_CVSHealthMember_label_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:label id="lab_cah_CVSHealthMember_documentation_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember" xlink:href="cah-20201231.xsd#cah_CVSHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CVSHealthMember" xlink:to="lab_cah_CVSHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_11345af7-bbb9-41eb-970d-44604d011650_terseLabel_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_label_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_documentation_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember" xlink:href="cah-20201231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NewYorkOpioidStewardshipActMember" xlink:to="lab_cah_NewYorkOpioidStewardshipActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_76535bde-6a14-4a56-a6bc-fe78a1132db9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_a23db486-3b4e-4238-a405-7211456868a8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_946fb5b0-d734-45ec-a37c-a3669cb09ba5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_ff7e6563-328b-40c9-b6d8-5c3ef13184cc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ad3cbfae-2b0d-44b0-a6e2-4f1ee085bf16_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_eb4d3459-dac9-4ff2-afa0-14e90c46ccfb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_3ace48ee-b719-41ce-a638-b04fdb921211_terseLabel_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable period of plans (in years)</link:label>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_label_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable period of plans, in years</link:label>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_documentation_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The instrument's contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears" xlink:href="cah-20201231.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ExercisablePeriodOfPlansInYears" xlink:to="lab_cah_ExercisablePeriodOfPlansInYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f7b0b387-0be1-48d4-82c8-7ff81dfb2fa3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_1f089ef9-2565-401d-835f-85c41629f4f9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3326f32e-5b08-49b8-8c53-b2047f99bc48_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a82a9ac3-369f-4462-8d96-221b902ebdd1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ec3355c4-09b6-4da9-bc36-f5b13baca207_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_acafc300-3cea-4540-b9a4-7989a0a6c5d8_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1a9c9258-cc7b-4a81-9359-b0533564c269_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_1e28ef81-9de4-4491-8dd0-1959dae0c4e6_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_1d2f41ef-4510-4eb9-b926-dff3b9be6195_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7318270f-88ac-43fe-8040-1fde9e2079bf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_21cda1d4-2933-48b5-8113-519d982f162a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_741c9228-3d8e-4d8b-9b15-30ca1a507d47_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_1b0531f1-dca1-4719-8fc5-e81b1bf7f16c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ca3fec98-78b2-4b90-a6bd-eed557096a34_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_53e62ef7-1855-443d-82ed-d4b2a9819f58_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss) attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4163427c-eb2e-4c79-9a33-ad7a8b7304c1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c9762edc-35aa-4658-b748-667d6b9b0f55_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bc131bba-ac8c-4680-b651-d297f3ddeef6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_88f23a29-9e78-41f8-9050-b99774c6bdd5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_c6969845-7251-4131-8b4a-a69821d36611_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f5a4bb87-1270-4a05-bc26-aef083041338_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f877621a-c639-485f-90a7-f15106f8209d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_cb60127e-6e7f-4ebe-bad3-0cef786d5766_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_24411568-2e91-4113-ad99-e7c78616ca94_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_cde0e0ba-f611-4fdc-9fec-f0f1b7e63ce6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_9f61f1c7-5b6b-4892-beb4-d4a66ae9e626_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d2ed08ce-1062-47cf-9aa2-505b00171509_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fbc3b232-bb56-4c00-b8c4-dd66393d781e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_78b3f9fc-efb0-4c15-86d1-8b606f1857ed_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology and other</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_08a673f3-00ce-40ca-860d-44e0c33df24d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TreasuryStockAcquiredShares_992fb802-4f11-4744-b2f6-3b9aaa81d6e6_terseLabel_en-US" xlink:label="lab_cah_TreasuryStockAcquiredShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired Shares</link:label>
    <link:label id="lab_cah_TreasuryStockAcquiredShares_label_en-US" xlink:label="lab_cah_TreasuryStockAcquiredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired Shares</link:label>
    <link:label id="lab_cah_TreasuryStockAcquiredShares_documentation_en-US" xlink:label="lab_cah_TreasuryStockAcquiredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TreasuryStockAcquiredShares" xlink:href="cah-20201231.xsd#cah_TreasuryStockAcquiredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TreasuryStockAcquiredShares" xlink:to="lab_cah_TreasuryStockAcquiredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_bccaee3f-2bfd-47e2-9cda-a16de572f252_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeAxis_7aa92a94-a8b0-4c07-a810-88f2f8f9f95e_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_label_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis" xlink:href="cah-20201231.xsd#cah_PlaintiffTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeAxis" xlink:to="lab_cah_PlaintiffTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_d7523aec-c8ec-4197-b8c7-f82ddedd1506_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation (recoveries)/charges, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_fd690658-c5f5-4101-8097-4df8a6612fe3_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NarativeAbstract_b0c7d2fc-7dc6-4003-bb7c-e5f2a7e6e046_terseLabel_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:label id="lab_cah_NarativeAbstract_label_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:label id="lab_cah_NarativeAbstract_documentation_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NarativeAbstract" xlink:href="cah-20201231.xsd#cah_NarativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NarativeAbstract" xlink:to="lab_cah_NarativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A3.41Notesdue2027Member_09325709-ea5b-493c-8110-513770b5df0d_terseLabel_en-US" xlink:label="lab_cah_A3.41Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.41% Notes due 2027 [Member]</link:label>
    <link:label id="lab_cah_A3.41Notesdue2027Member_label_en-US" xlink:label="lab_cah_A3.41Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.41% Notes due 2027 [Member]</link:label>
    <link:label id="lab_cah_A3.41Notesdue2027Member_documentation_en-US" xlink:label="lab_cah_A3.41Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.41% Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.41Notesdue2027Member" xlink:href="cah-20201231.xsd#cah_A3.41Notesdue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A3.41Notesdue2027Member" xlink:to="lab_cah_A3.41Notesdue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_ab51d16f-3c28-43b9-b5fc-d3d9bca753d8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_cd2ea144-ef81-4abd-a9b9-35d983fd960b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_31d58550-143a-406d-9737-422c14c46464_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterAxis_3593bc07-1e27-49c7-8243-ecaafad64ff0_terseLabel_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_label_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_documentation_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis" xlink:href="cah-20201231.xsd#cah_TaxMatterAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterAxis" xlink:to="lab_cah_TaxMatterAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsMember_3533fab7-ef6c-49b8-9d86-59cadda48dd1_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_label_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember" xlink:href="cah-20201231.xsd#cah_OpioidLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsMember" xlink:to="lab_cah_OpioidLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AlamedaCountyMember_266d8437-2e7c-4e00-8ff9-a18d7d30ca9d_terseLabel_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_label_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_documentation_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember" xlink:href="cah-20201231.xsd#cah_AlamedaCountyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AlamedaCountyMember" xlink:to="lab_cah_AlamedaCountyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PrivatePartiesMember_fabab8be-4694-478f-85b4-657e88796255_terseLabel_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_label_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_documentation_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember" xlink:href="cah-20201231.xsd#cah_PrivatePartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PrivatePartiesMember" xlink:to="lab_cah_PrivatePartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_93fdd36f-93a2-43fa-b659-820990a56539_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Loss [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_575d9081-cd80-487e-8684-e0ec56c38b81_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_74e3441e-9864-4f7f-b1de-cd2e21afea6c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_02ef4d48-bd86-4d55-a47f-5307f113ab56_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_dcbb4b74-b989-480b-bfde-b42b0fb76486_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81d350c7-c5ce-46e8-a5f6-30ca588a65cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_75c2b669-1aab-4586-942c-f58e538de385_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_bee5a869-b11e-401a-a838-38955fbc35ee_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_2bc65676-f106-4928-8cb1-0011664a9423_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6a0e38d2-8f99-4ce0-a327-3ae9f28d0f95_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c9f7939b-831f-408c-a432-048e5e85b25a_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_270c8226-51e0-4750-ad00-1eb6f1f954f0_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationAxis_81cbf882-d280-459f-a08e-3aa171cf5c80_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_label_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_documentation_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis" xlink:href="cah-20201231.xsd#cah_OpioidLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationAxis" xlink:to="lab_cah_OpioidLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_07433857-0117-4ef9-9a6e-b878ca25c3cb_terseLabel_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Data Related to Stock Option Activity</link:label>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_label_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock Option Plan Data [Table Text Block]</link:label>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_documentation_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A disclosure of additional data related to all stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:href="cah-20201231.xsd#cah_AdditionalStockOptionPlanDataTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:to="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_b724f032-590e-4413-8a49-bf56ea6e10f5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8289b6e3-a70d-4eb8-9ed8-e304866fe3ec_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, without par value:</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6b6e7117-589c-448c-bd4f-ee0c59bc36e4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5e43eece-5915-4872-959a-0394552827fd_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_2bcec2b7-cf9c-47ae-b1e0-d134fd530989_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_832cdf02-0d13-42d5-ab19-8d570d9a3bb6_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_52dfe853-0c25-4675-a4ca-fda30e1943d7_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ddffaf6a-8944-4f0e-af1e-d8da7d3e6c83_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AggregateAnnualAssessment_fe2d8618-37dc-4127-989d-c469b31b213f_terseLabel_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_label_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_documentation_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment" xlink:href="cah-20201231.xsd#cah_AggregateAnnualAssessment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AggregateAnnualAssessment" xlink:to="lab_cah_AggregateAnnualAssessment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_b7600c36-4f95-4ba4-b8ee-e42e0da7f0b2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_e592087c-34a1-4797-bde8-90f605d1c1fc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee- Related Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_3a6109f1-cfef-4415-89ea-1c1e4c3ee231_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_021edad1-5e31-4ae7-8152-3c22ab0c6c97_negatedLabel_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow from purchases of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20201231.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f8b986bf-1b47-4abd-9e09-944b47f1c105_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1f5ed2b-0d25-4d43-b26b-8c5ff628c81b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3baf47e4-12ca-4e07-8ddf-8bb157b77cfb_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f648fccf-5438-43e9-bcdc-935643411f4f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year One</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_9238c0b1-d589-4235-aeb1-ada7b313193c_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_7ead106e-3cc4-44cf-82d0-cc7299ef2710_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_bef75154-4eb0-47a4-9b0a-5662d767f667_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for/(benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d9ff9162-2f4e-4514-8d83-6b4c1e7db3b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_0729ab59-dd21-4dc2-bab7-68451b496419_verboseLabel_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_label_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_documentation_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber" xlink:href="cah-20201231.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LossContingencyLawsuitsNumber" xlink:to="lab_cah_LossContingencyLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a2f5ee80-f2bb-44b9-bef8-e727b53f8170_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments and (gain)/loss on disposal of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a60ed79e-af7f-41ae-8ab8-8f32325b3311_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_57f8763f-ae55-46ea-b799-c96c68b93cb8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a369bdd1-fecf-4d58-a8c8-82ff992b111d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_44c60635-16de-4875-8659-9d1aaf907cbb_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4ecc7700-67f5-4c83-b47f-42c0c7b1a54d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_8bb20ae6-a25c-414e-9d72-ffed6eabd356_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_label_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_documentation_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:href="cah-20201231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:to="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_d51a6c11-cadb-4076-9def-f7b8443e918b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f0d23518-6208-4701-9e48-a711f6e5283d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c2dc728a-f26f-413e-9dc7-cd273a1c3ae2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_27f557d8-cadf-46ba-924a-f31158e33457_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e595229b-f802-4505-9176-7ecfc61b525c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_de4c94cb-cc62-40fb-b97d-4990fb098d38_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1b2ce3a4-efe6-443e-8f61-976e88786805_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_c817da89-ea9c-4dd2-a7fc-17fa914d15ff_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6a04facf-a3bb-43e7-bb7a-481d1cb68150_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_faf901c1-4593-4338-b67f-d85953c0474f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d857b8e7-ee0b-4cbc-a165-1c072673b5ed_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_97410b01-9bf3-4255-95b5-672be4aa5633_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c12bbbe3-bf08-4dd4-b021-d6ff97b99d5f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_5f153fb5-96a6-42c5-baa9-56d28becdda8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f7c4bdb1-95e7-4cae-be41-5d3cc2a906d2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a8575648-f50c-4b3d-ad11-1034db078fdb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e30475df-a8ba-49b8-8345-245de8800dde_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_263bb184-7d5f-4169-9c7b-90e24669ae90_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b3df27a-ce88-4c66-87a0-a0ae2bd5d832_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8c336770-80e5-41cd-b146-658c1bc73108_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d366191-3d1f-4de6-ad33-cbf29009cb27_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bfe2c60c-a90a-497c-a877-9314a673cd69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ddb9f5de-a2a0-4c06-9172-1bfcf8cf106a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a70e49a9-678c-4a60-8c53-bcd996a37f18_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_eb2738a4-1c2a-41c9-88d1-06044c3e96f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_75496f54-6de3-4e95-a717-6ea8c1acca31_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMattersAgreementDomain_963e6a1a-1d17-4f34-b117-6dbde35c6b58_terseLabel_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_label_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_documentation_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matters Agreement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain" xlink:href="cah-20201231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMattersAgreementDomain" xlink:to="lab_cah_TaxMattersAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_911cb4a7-ba84-41c2-be44-105dc152a875_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares in treasury, at cost: 33 million shares and 34 million shares at December 31, 2020 and June 30, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_f746dd69-727b-4867-bcc7-007150444f2d_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_7a6ce88a-9a84-4046-b45b-13cc448d576d_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMattersAgreementAxis_078a4790-ee0f-4d17-aab7-2abe340f13e4_terseLabel_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementAxis_label_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementAxis_documentation_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis" xlink:href="cah-20201231.xsd#cah_TaxMattersAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMattersAgreementAxis" xlink:to="lab_cah_TaxMattersAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_2d0a4b0e-f620-465d-9f23-b4fa1e87804c_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_25d3d522-a76c-442b-851c-dfb84dc88a4a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A3.2Notesdue2022Member_8b05c2e3-f6c2-4666-9628-6c7d2852defe_terseLabel_en-US" xlink:label="lab_cah_A3.2Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.2% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A3.2Notesdue2022Member_label_en-US" xlink:label="lab_cah_A3.2Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.2% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A3.2Notesdue2022Member_documentation_en-US" xlink:label="lab_cah_A3.2Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.2% Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.2Notesdue2022Member" xlink:href="cah-20201231.xsd#cah_A3.2Notesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A3.2Notesdue2022Member" xlink:to="lab_cah_A3.2Notesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_ca3a5252-ef1b-4c24-80c3-de162567a7a8_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b1cbfcdb-f01b-45ae-a45c-6b59fd06129e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6db0b44b-278e-4243-960a-86529bb9f5aa_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_18733aa1-38c8-41d5-ab01-66f1a4c2cc82_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_31f8a27c-c821-4667-b35b-2cd5d729e78e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cf588d4e-675f-408e-95cf-5782e79f4e5c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Financial Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3f519eb5-8bf0-47ab-a4b0-81d276d71b82_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_80057800-ca5f-4dd3-84da-d49308a23fbf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(loss) per common share attributable to Cardinal Health, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_137f901c-407f-4ec5-85de-05f513ebb6d9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cah-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9f2b874d-aa0f-4f0c-98af-f0bcbd3c3f24,g:771f989f-b1cf-4cd9-b16a-9064b3a47170-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_69e14898-2327-4fa6-917e-e585c98dc1b7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_DocumentType_69e14898-2327-4fa6-917e-e585c98dc1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_978b3823-dc91-4605-8934-e3d3990e5429" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_DocumentQuarterlyReport_978b3823-dc91-4605-8934-e3d3990e5429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7dbc318b-38d5-44cf-accb-b1b5dd929ef6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_DocumentPeriodEndDate_7dbc318b-38d5-44cf-accb-b1b5dd929ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d9455ecc-3c50-40e3-8eed-6abea347facc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_DocumentTransitionReport_d9455ecc-3c50-40e3-8eed-6abea347facc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e448acf9-d4e7-4914-a3e3-16a420b677aa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityFileNumber_e448acf9-d4e7-4914-a3e3-16a420b677aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bdd78a24-b21c-4423-b6fd-54fbc053d202" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityRegistrantName_bdd78a24-b21c-4423-b6fd-54fbc053d202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_29821412-2542-43e3-9d86-736fd2966ac0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityCentralIndexKey_29821412-2542-43e3-9d86-736fd2966ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_83b0c268-6165-4d67-a23c-3a56b3e8def8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_CurrentFiscalYearEndDate_83b0c268-6165-4d67-a23c-3a56b3e8def8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_aff81b5b-0ec5-4618-8efb-b9a22dda9d7c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_DocumentFiscalYearFocus_aff81b5b-0ec5-4618-8efb-b9a22dda9d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_fe6609b8-8b5f-4446-a701-0bb388314ed1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_DocumentFiscalPeriodFocus_fe6609b8-8b5f-4446-a701-0bb388314ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d1085c89-57b2-46f3-a9ea-3e0df49ec1a4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_AmendmentFlag_d1085c89-57b2-46f3-a9ea-3e0df49ec1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cabd283c-2502-4355-b9d1-350f8c044b14" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cabd283c-2502-4355-b9d1-350f8c044b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7b82b90b-8914-4d66-9120-4c6ab8f0360f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityTaxIdentificationNumber_7b82b90b-8914-4d66-9120-4c6ab8f0360f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8c0f16b5-1b6b-4a4a-8f0c-3fc5df8e792a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityAddressAddressLine1_8c0f16b5-1b6b-4a4a-8f0c-3fc5df8e792a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_abd4fc50-79b7-47ae-8012-71a45be7a3c0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityAddressCityOrTown_abd4fc50-79b7-47ae-8012-71a45be7a3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2a0a8751-cfd6-4ad0-ac80-0245d5288add" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityAddressStateOrProvince_2a0a8751-cfd6-4ad0-ac80-0245d5288add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4812efd9-253c-47c1-8442-6da0076465fd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityAddressPostalZipCode_4812efd9-253c-47c1-8442-6da0076465fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_349d50ed-5249-47ed-8668-62bbd487c73b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_CityAreaCode_349d50ed-5249-47ed-8668-62bbd487c73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bb1c6bd2-666f-4518-aa93-5d21282571d6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_LocalPhoneNumber_bb1c6bd2-666f-4518-aa93-5d21282571d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f1ab2225-60de-45a1-a53f-4c681d7da048" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_Security12bTitle_f1ab2225-60de-45a1-a53f-4c681d7da048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9c304b87-acfb-4335-b327-e3b30a4d70be" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_TradingSymbol_9c304b87-acfb-4335-b327-e3b30a4d70be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_14a7c09c-a7ef-4cbf-8f45-956196e0153e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_SecurityExchangeName_14a7c09c-a7ef-4cbf-8f45-956196e0153e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_94c46e93-e0ef-4685-8ba2-6f9582a2abf6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityCurrentReportingStatus_94c46e93-e0ef-4685-8ba2-6f9582a2abf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_de06de79-7c6b-44f4-bed4-a56c10e6e36c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityInteractiveDataCurrent_de06de79-7c6b-44f4-bed4-a56c10e6e36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a17a7f52-bd45-4185-9fbb-a8d4367130e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityFilerCategory_a17a7f52-bd45-4185-9fbb-a8d4367130e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6bc80ded-5024-46dd-ab89-69ad9fb1c749" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntitySmallBusiness_6bc80ded-5024-46dd-ab89-69ad9fb1c749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9bba2801-8a8e-4ada-907f-9a9cad8207bf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityEmergingGrowthCompany_9bba2801-8a8e-4ada-907f-9a9cad8207bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8946ec08-6084-41e6-b35e-b979a1b05468" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityShellCompany_8946ec08-6084-41e6-b35e-b979a1b05468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_03de084e-a3ad-4c52-943c-dade6ed6d16f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_649a14ef-9cab-4856-8236-36faa08091eb" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_03de084e-a3ad-4c52-943c-dade6ed6d16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2ceb079c-b3c8-4ad9-8134-ef622ba91ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_Revenues_2ceb079c-b3c8-4ad9-8134-ef622ba91ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a99a8cc7-4480-4258-996b-a6ad615fb9f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a99a8cc7-4480-4258-996b-a6ad615fb9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f4fc8be2-b093-46f8-9762-2dadf6ce3b87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_GrossProfit_f4fc8be2-b093-46f8-9762-2dadf6ce3b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ce1c4ea6-800c-4be8-972e-1f431e274e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ce1c4ea6-800c-4be8-972e-1f431e274e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_62905f4b-cc17-4ae7-8d1e-fa018dc8c041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ce1c4ea6-800c-4be8-972e-1f431e274e7f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_62905f4b-cc17-4ae7-8d1e-fa018dc8c041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_804eb0f1-d25b-482c-80b8-24de9cbfc716" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ce1c4ea6-800c-4be8-972e-1f431e274e7f" xlink:to="loc_us-gaap_RestructuringCharges_804eb0f1-d25b-482c-80b8-24de9cbfc716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_eb8429ae-00e5-493b-b9ea-977900442227" xlink:href="cah-20201231.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ce1c4ea6-800c-4be8-972e-1f431e274e7f" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_eb8429ae-00e5-493b-b9ea-977900442227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b101809c-1d31-49ad-b29d-47be24c1a9b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ce1c4ea6-800c-4be8-972e-1f431e274e7f" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b101809c-1d31-49ad-b29d-47be24c1a9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_abf04b54-7108-4581-9cfd-197c18577e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ce1c4ea6-800c-4be8-972e-1f431e274e7f" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_abf04b54-7108-4581-9cfd-197c18577e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_243b4dee-ff26-45ea-84ed-54dc46831154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_OperatingIncomeLoss_243b4dee-ff26-45ea-84ed-54dc46831154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_af2bd52c-0869-46e1-b7ce-4fbd4c2952d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_af2bd52c-0869-46e1-b7ce-4fbd4c2952d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_31b7f8e1-1545-44bf-a6c3-2bebee8b2314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_InterestExpense_31b7f8e1-1545-44bf-a6c3-2bebee8b2314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_09365532-dae8-41d5-8445-8a566ec8650a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_09365532-dae8-41d5-8445-8a566ec8650a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3e5f977a-bfb7-4fcc-a941-8c2105ac042e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3e5f977a-bfb7-4fcc-a941-8c2105ac042e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a2f87291-e40f-43dc-b6e1-a8a9098c0e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a2f87291-e40f-43dc-b6e1-a8a9098c0e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1ad42cb5-e247-4d6e-817c-832c7f630a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_ProfitLoss_1ad42cb5-e247-4d6e-817c-832c7f630a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a9a09c8d-f184-43f7-8a42-a70a3fa327f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a9a09c8d-f184-43f7-8a42-a70a3fa327f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a21e90e-ce8a-41b7-ae9c-fefc53e9fca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_NetIncomeLoss_1a21e90e-ce8a-41b7-ae9c-fefc53e9fca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_0eff9a6d-7f65-4fb0-a7fc-69fe65e9c7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_0eff9a6d-7f65-4fb0-a7fc-69fe65e9c7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_4f5c6ecd-fee1-4d5e-b1a1-685f2ab55d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0eff9a6d-7f65-4fb0-a7fc-69fe65e9c7c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_4f5c6ecd-fee1-4d5e-b1a1-685f2ab55d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_324b801f-a263-4f36-b487-b768d6c58a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0eff9a6d-7f65-4fb0-a7fc-69fe65e9c7c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_324b801f-a263-4f36-b487-b768d6c58a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_197d1242-2451-4d73-82ff-39dcf9b0b9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_197d1242-2451-4d73-82ff-39dcf9b0b9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e9ac986d-5540-4795-b002-604e2fb7cd1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e9ac986d-5540-4795-b002-604e2fb7cd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_599d038f-f649-43da-8ea4-65b7d548f220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e9ac986d-5540-4795-b002-604e2fb7cd1c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_599d038f-f649-43da-8ea4-65b7d548f220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c68320f0-52e2-4b6e-8cbf-e750a7700180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e9ac986d-5540-4795-b002-604e2fb7cd1c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c68320f0-52e2-4b6e-8cbf-e750a7700180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_d293ccb1-be77-468d-a9e0-0f61a7ada408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_672f0793-a204-4059-a8d2-d877729ecfb5" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_d293ccb1-be77-468d-a9e0-0f61a7ada408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9cd5a6c3-acf6-446f-a89c-3d7e27f655cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a41c276d-9445-4764-8040-d28567c23761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9cd5a6c3-acf6-446f-a89c-3d7e27f655cc" xlink:to="loc_us-gaap_ProfitLoss_a41c276d-9445-4764-8040-d28567c23761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cace1c5d-b1f6-4989-aa09-a6c707d02e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9cd5a6c3-acf6-446f-a89c-3d7e27f655cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cace1c5d-b1f6-4989-aa09-a6c707d02e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_51fede3a-e8b9-46f4-97cb-194440e72dda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cace1c5d-b1f6-4989-aa09-a6c707d02e56" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_51fede3a-e8b9-46f4-97cb-194440e72dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2646de9e-9965-4f0a-85c6-14684fd8450f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cace1c5d-b1f6-4989-aa09-a6c707d02e56" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2646de9e-9965-4f0a-85c6-14684fd8450f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f709575e-dfa0-4202-a73d-638893c4918e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cace1c5d-b1f6-4989-aa09-a6c707d02e56" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f709575e-dfa0-4202-a73d-638893c4918e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_65c9d808-d9c6-4c54-9f11-d64d5165e802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9cd5a6c3-acf6-446f-a89c-3d7e27f655cc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_65c9d808-d9c6-4c54-9f11-d64d5165e802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7f6a098a-71f3-4ee8-91b2-55782e832950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9cd5a6c3-acf6-446f-a89c-3d7e27f655cc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7f6a098a-71f3-4ee8-91b2-55782e832950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ee961041-56bb-4099-b0e9-d1316448d114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9cd5a6c3-acf6-446f-a89c-3d7e27f655cc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ee961041-56bb-4099-b0e9-d1316448d114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_65a8f39f-e43f-412b-a93a-15de53231e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5a6cf9fd-90cf-48ef-8f3a-b586e4d2d661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_65a8f39f-e43f-412b-a93a-15de53231e86" xlink:to="loc_us-gaap_AssetsAbstract_5a6cf9fd-90cf-48ef-8f3a-b586e4d2d661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5c8b4523-ea29-4ac1-8cc6-6f2efe601766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5a6cf9fd-90cf-48ef-8f3a-b586e4d2d661" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5c8b4523-ea29-4ac1-8cc6-6f2efe601766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11501641-5bb1-447d-ae62-658799a77ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c8b4523-ea29-4ac1-8cc6-6f2efe601766" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11501641-5bb1-447d-ae62-658799a77ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_51fa9eb1-c62d-45b3-9c21-88f83a849484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c8b4523-ea29-4ac1-8cc6-6f2efe601766" xlink:to="loc_us-gaap_ReceivablesNetCurrent_51fa9eb1-c62d-45b3-9c21-88f83a849484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_66f1046d-3e26-4863-9bc9-df9a30cb08d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c8b4523-ea29-4ac1-8cc6-6f2efe601766" xlink:to="loc_us-gaap_InventoryNet_66f1046d-3e26-4863-9bc9-df9a30cb08d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_6e2a4026-2acd-4ad9-a40b-b792f3360177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c8b4523-ea29-4ac1-8cc6-6f2efe601766" xlink:to="loc_us-gaap_OtherAssetsCurrent_6e2a4026-2acd-4ad9-a40b-b792f3360177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_177ea4cc-c0e9-4893-9985-be3bdec0773c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c8b4523-ea29-4ac1-8cc6-6f2efe601766" xlink:to="loc_us-gaap_AssetsCurrent_177ea4cc-c0e9-4893-9985-be3bdec0773c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b442eb1f-f384-4aa7-9862-1812431b47d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5a6cf9fd-90cf-48ef-8f3a-b586e4d2d661" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b442eb1f-f384-4aa7-9862-1812431b47d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_ae14fdaa-70f6-469b-b79d-1acbda670bae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5a6cf9fd-90cf-48ef-8f3a-b586e4d2d661" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_ae14fdaa-70f6-469b-b79d-1acbda670bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_33b68f17-b756-4659-8a49-704bb9d65462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5a6cf9fd-90cf-48ef-8f3a-b586e4d2d661" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_33b68f17-b756-4659-8a49-704bb9d65462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d8ef22bd-8f1d-427a-8a29-4c8d8bf0b92a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5a6cf9fd-90cf-48ef-8f3a-b586e4d2d661" xlink:to="loc_us-gaap_Assets_d8ef22bd-8f1d-427a-8a29-4c8d8bf0b92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ab66e198-a49f-4a0e-ba81-174d879a0ba4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_65a8f39f-e43f-412b-a93a-15de53231e86" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ab66e198-a49f-4a0e-ba81-174d879a0ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_534d16ab-f41c-4c19-907a-e748888e476a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ab66e198-a49f-4a0e-ba81-174d879a0ba4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_534d16ab-f41c-4c19-907a-e748888e476a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1599cb0b-9a05-4462-a661-d821a254dfe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_534d16ab-f41c-4c19-907a-e748888e476a" xlink:to="loc_us-gaap_AccountsPayableCurrent_1599cb0b-9a05-4462-a661-d821a254dfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_c4ef4ba4-6944-4b6c-85a0-71270aa10e78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_534d16ab-f41c-4c19-907a-e748888e476a" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_c4ef4ba4-6944-4b6c-85a0-71270aa10e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d2efc5c8-fc0f-4cc7-a988-eda75312db19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_534d16ab-f41c-4c19-907a-e748888e476a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d2efc5c8-fc0f-4cc7-a988-eda75312db19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e2efab7d-d38c-4069-bc08-b83cd41cbf55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_534d16ab-f41c-4c19-907a-e748888e476a" xlink:to="loc_us-gaap_LiabilitiesCurrent_e2efab7d-d38c-4069-bc08-b83cd41cbf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_afc5f850-6249-4286-a550-aeca76166bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ab66e198-a49f-4a0e-ba81-174d879a0ba4" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_afc5f850-6249-4286-a550-aeca76166bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_16016c40-adc7-4c52-9946-ec8832fb40ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ab66e198-a49f-4a0e-ba81-174d879a0ba4" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_16016c40-adc7-4c52-9946-ec8832fb40ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_aaa54fc9-b936-4e47-8a02-bbde7b2b7ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ab66e198-a49f-4a0e-ba81-174d879a0ba4" xlink:to="loc_us-gaap_StockholdersEquityAbstract_aaa54fc9-b936-4e47-8a02-bbde7b2b7ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_c0711087-7768-4065-8461-6a0354155bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa54fc9-b936-4e47-8a02-bbde7b2b7ddb" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_c0711087-7768-4065-8461-6a0354155bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6f6e5c0b-02aa-479e-996f-edaa2fd40a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_c0711087-7768-4065-8461-6a0354155bc7" xlink:to="loc_us-gaap_PreferredStockValue_6f6e5c0b-02aa-479e-996f-edaa2fd40a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1a8adeb3-fb62-492f-88f4-51fb49e24971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa54fc9-b936-4e47-8a02-bbde7b2b7ddb" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1a8adeb3-fb62-492f-88f4-51fb49e24971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_91e0b7e6-52a9-4d84-a949-44d3c0dd882c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1a8adeb3-fb62-492f-88f4-51fb49e24971" xlink:to="loc_us-gaap_CommonStockValue_91e0b7e6-52a9-4d84-a949-44d3c0dd882c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7393b9ed-a564-49d8-8e2c-b153d778d39b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa54fc9-b936-4e47-8a02-bbde7b2b7ddb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7393b9ed-a564-49d8-8e2c-b153d778d39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_1e94fb0f-827f-4b3c-86bf-a05a11470f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa54fc9-b936-4e47-8a02-bbde7b2b7ddb" xlink:to="loc_us-gaap_TreasuryStockValue_1e94fb0f-827f-4b3c-86bf-a05a11470f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2bb68d92-618e-439b-aefb-0e96354c8914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa54fc9-b936-4e47-8a02-bbde7b2b7ddb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2bb68d92-618e-439b-aefb-0e96354c8914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3e07b768-2a89-4d29-8334-87cffa4e6457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa54fc9-b936-4e47-8a02-bbde7b2b7ddb" xlink:to="loc_us-gaap_StockholdersEquity_3e07b768-2a89-4d29-8334-87cffa4e6457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_cf952c8b-337d-490d-9c0b-0db0c5036db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa54fc9-b936-4e47-8a02-bbde7b2b7ddb" xlink:to="loc_us-gaap_MinorityInterest_cf952c8b-337d-490d-9c0b-0db0c5036db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f9b53735-dcf0-4d03-bc1f-8b8c8f99cd7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aaa54fc9-b936-4e47-8a02-bbde7b2b7ddb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f9b53735-dcf0-4d03-bc1f-8b8c8f99cd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3238c179-706d-4267-8163-053ecb7b074f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ab66e198-a49f-4a0e-ba81-174d879a0ba4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3238c179-706d-4267-8163-053ecb7b074f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_801c4341-4427-4d00-b5d8-e736ab23b5f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_65a8f39f-e43f-412b-a93a-15de53231e86" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_801c4341-4427-4d00-b5d8-e736ab23b5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_63f878ac-1052-4d18-af0d-178acce60296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_65a8f39f-e43f-412b-a93a-15de53231e86" xlink:to="loc_us-gaap_PreferredStockSharesIssued_63f878ac-1052-4d18-af0d-178acce60296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2040c894-6165-4825-95e5-a37cf78469c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_65a8f39f-e43f-412b-a93a-15de53231e86" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2040c894-6165-4825-95e5-a37cf78469c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_03e37c94-09a0-4e7c-85a3-080224d7dac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_65a8f39f-e43f-412b-a93a-15de53231e86" xlink:to="loc_us-gaap_CommonStockSharesIssued_03e37c94-09a0-4e7c-85a3-080224d7dac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_039dc963-62ef-4311-aff4-946bc5c470a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_65a8f39f-e43f-412b-a93a-15de53231e86" xlink:to="loc_us-gaap_TreasuryStockShares_039dc963-62ef-4311-aff4-946bc5c470a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ef71d78e-62df-4c0d-a9de-000f46f64f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3dd7a0a0-505a-434a-b236-4bce4e14d691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ef71d78e-62df-4c0d-a9de-000f46f64f18" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3dd7a0a0-505a-434a-b236-4bce4e14d691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4761d3b8-391a-4e1d-8589-f33524dff21c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ef71d78e-62df-4c0d-a9de-000f46f64f18" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4761d3b8-391a-4e1d-8589-f33524dff21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fe4890fb-13bc-4117-8392-bac1576b4221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ef71d78e-62df-4c0d-a9de-000f46f64f18" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fe4890fb-13bc-4117-8392-bac1576b4221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_25751ece-078f-4bb5-a202-b2bfdba38909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ef71d78e-62df-4c0d-a9de-000f46f64f18" xlink:to="loc_us-gaap_CommonStockSharesIssued_25751ece-078f-4bb5-a202-b2bfdba38909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_a0de2fb2-52ab-4d61-8c8a-f352f1f9adac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ef71d78e-62df-4c0d-a9de-000f46f64f18" xlink:to="loc_us-gaap_TreasuryStockShares_a0de2fb2-52ab-4d61-8c8a-f352f1f9adac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e993c276-01bc-408c-a97c-ecfa9ff505b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1dbbb7c1-0b42-4ecf-8843-3ebd1b86347b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e993c276-01bc-408c-a97c-ecfa9ff505b2" xlink:to="loc_us-gaap_StatementTable_1dbbb7c1-0b42-4ecf-8843-3ebd1b86347b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_36f58a4d-f550-46fc-86e2-6ed91585c36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1dbbb7c1-0b42-4ecf-8843-3ebd1b86347b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_36f58a4d-f550-46fc-86e2-6ed91585c36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_36f58a4d-f550-46fc-86e2-6ed91585c36c" xlink:to="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1774f71a-015e-4a3c-89f6-7d67804de58a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:to="loc_us-gaap_CommonStockMember_1774f71a-015e-4a3c-89f6-7d67804de58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6091f4c3-2ff2-424b-8b89-1387a1ad5420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:to="loc_us-gaap_RetainedEarningsMember_6091f4c3-2ff2-424b-8b89-1387a1ad5420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_56c48de7-cd34-4b36-ab21-ab4ac4f36615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:to="loc_us-gaap_TreasuryStockMember_56c48de7-cd34-4b36-ab21-ab4ac4f36615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b100e19c-9a97-40bd-ab21-d03d87374018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b100e19c-9a97-40bd-ab21-d03d87374018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_922585c8-4501-4343-a463-e3f91bc0cc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_941f0f1e-1943-4a76-bce0-12af560a629f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_922585c8-4501-4343-a463-e3f91bc0cc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1dbbb7c1-0b42-4ecf-8843-3ebd1b86347b" xlink:to="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_9b6467e0-1a97-4d59-8ecd-bb096bc4fef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_CommonStockSharesIssued_9b6467e0-1a97-4d59-8ecd-bb096bc4fef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e30ba76-91a5-4cc8-b332-30810d3bf927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e30ba76-91a5-4cc8-b332-30810d3bf927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_66a0e276-5002-4b44-b65a-28858d7fa480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_TreasuryStockShares_66a0e276-5002-4b44-b65a-28858d7fa480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_86ceda50-f70c-4348-8e33-700aaa247e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_TreasuryStockValue_86ceda50-f70c-4348-8e33-700aaa247e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_46c28eea-55e6-473a-bc7f-3bf26d220d49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_ProfitLoss_46c28eea-55e6-473a-bc7f-3bf26d220d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_43dcd522-6cf0-4ae0-a114-a26553354598" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_NetIncomeLoss_43dcd522-6cf0-4ae0-a114-a26553354598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f4f7d007-2e71-44b8-8ecf-64121428f48a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f4f7d007-2e71-44b8-8ecf-64121428f48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_604d1c90-f059-43cc-b55c-21af3032eabf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_604d1c90-f059-43cc-b55c-21af3032eabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5dd18a8d-b6ef-4bf2-8b56-106a76fa48ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5dd18a8d-b6ef-4bf2-8b56-106a76fa48ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8d89b9ee-0528-42ae-86fc-c9b7ed576ecd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8d89b9ee-0528-42ae-86fc-c9b7ed576ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_487526d4-6df6-43e7-89a6-29a71971874a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_487526d4-6df6-43e7-89a6-29a71971874a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_3bd7c8ba-221e-4e1b-8f99-03d5774dbbc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_3bd7c8ba-221e-4e1b-8f99-03d5774dbbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_7c4ed1d7-a8b5-471d-a5b0-c11bc9303fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_Dividends_7c4ed1d7-a8b5-471d-a5b0-c11bc9303fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_51735611-e39f-4712-ba87-3697abdb510e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_StockholdersEquityOther_51735611-e39f-4712-ba87-3697abdb510e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b489bd5a-df1b-4dba-b9d7-2720d0ab7f36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_CommonStockSharesIssued_b489bd5a-df1b-4dba-b9d7-2720d0ab7f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9c310300-b810-4dfc-a4a2-0284f6c1834d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9c310300-b810-4dfc-a4a2-0284f6c1834d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_eee08df9-2540-4098-a929-f66e3d0df558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_TreasuryStockShares_eee08df9-2540-4098-a929-f66e3d0df558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_a0d763c6-b008-4179-a0be-f789f788ee58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_TreasuryStockValue_a0d763c6-b008-4179-a0be-f789f788ee58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1890b529-c00d-418a-bdd2-f9f1905b2950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_951ca9a4-cd71-4535-ba7e-0ddc5a1b2efb" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1890b529-c00d-418a-bdd2-f9f1905b2950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20201231.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3a7d5bca-b424-4865-8a7a-9b05f91b6f28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c40ade62-e319-4347-9ac8-572d22d5a16c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a7d5bca-b424-4865-8a7a-9b05f91b6f28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c40ade62-e319-4347-9ac8-572d22d5a16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6f842d25-0ded-40c1-9c40-f76fd6039203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c40ade62-e319-4347-9ac8-572d22d5a16c" xlink:to="loc_us-gaap_ProfitLoss_6f842d25-0ded-40c1-9c40-f76fd6039203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_982641bc-1a02-4c65-8ce4-e45a43211f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c40ade62-e319-4347-9ac8-572d22d5a16c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_982641bc-1a02-4c65-8ce4-e45a43211f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3902d7f0-1992-4265-9ae5-eb4d0a45f96c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_982641bc-1a02-4c65-8ce4-e45a43211f07" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3902d7f0-1992-4265-9ae5-eb4d0a45f96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b2696b9f-43a5-4dfb-8c20-f716a9f211a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_982641bc-1a02-4c65-8ce4-e45a43211f07" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b2696b9f-43a5-4dfb-8c20-f716a9f211a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_909b38d6-33dd-44fc-a501-748269fe231b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_982641bc-1a02-4c65-8ce4-e45a43211f07" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_909b38d6-33dd-44fc-a501-748269fe231b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_adef68ca-155e-4067-9f39-bb53d51c7450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_982641bc-1a02-4c65-8ce4-e45a43211f07" xlink:to="loc_us-gaap_ShareBasedCompensation_adef68ca-155e-4067-9f39-bb53d51c7450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_506efcc2-919c-4a81-94dd-c6e215d1f149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_982641bc-1a02-4c65-8ce4-e45a43211f07" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_506efcc2-919c-4a81-94dd-c6e215d1f149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78d98b6f-ef88-4795-84bf-fac201717d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_982641bc-1a02-4c65-8ce4-e45a43211f07" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78d98b6f-ef88-4795-84bf-fac201717d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_2e4e4d65-3ee8-49fa-8db5-188986ec70a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78d98b6f-ef88-4795-84bf-fac201717d33" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_2e4e4d65-3ee8-49fa-8db5-188986ec70a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_33ec5412-8026-471c-9c41-cfba12ccbe9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78d98b6f-ef88-4795-84bf-fac201717d33" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_33ec5412-8026-471c-9c41-cfba12ccbe9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_529de6fe-4461-4d53-8ad1-7eec9e5dbcb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78d98b6f-ef88-4795-84bf-fac201717d33" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_529de6fe-4461-4d53-8ad1-7eec9e5dbcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_ee7be053-58e3-4e9a-a49e-2a806317badf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78d98b6f-ef88-4795-84bf-fac201717d33" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_ee7be053-58e3-4e9a-a49e-2a806317badf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65feccfc-2ad6-4f9b-aac1-5b940d872c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c40ade62-e319-4347-9ac8-572d22d5a16c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65feccfc-2ad6-4f9b-aac1-5b940d872c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02282e40-7622-490b-80df-e55a0d8e4f60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a7d5bca-b424-4865-8a7a-9b05f91b6f28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02282e40-7622-490b-80df-e55a0d8e4f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_34a10a59-2f5a-4183-8ec8-7d9e4f03c159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02282e40-7622-490b-80df-e55a0d8e4f60" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_34a10a59-2f5a-4183-8ec8-7d9e4f03c159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0012ac33-dd1e-41ff-8811-1ea1d2095784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02282e40-7622-490b-80df-e55a0d8e4f60" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0012ac33-dd1e-41ff-8811-1ea1d2095784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_8065f1d6-5217-408f-b9ce-5ada8c4f4784" xlink:href="cah-20201231.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02282e40-7622-490b-80df-e55a0d8e4f60" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_8065f1d6-5217-408f-b9ce-5ada8c4f4784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_ad474559-d27e-413c-8f25-418fbfff9b3c" xlink:href="cah-20201231.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02282e40-7622-490b-80df-e55a0d8e4f60" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_ad474559-d27e-413c-8f25-418fbfff9b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_eb2cb7ab-9d28-41e8-87ab-17f1c2b9c1ac" xlink:href="cah-20201231.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02282e40-7622-490b-80df-e55a0d8e4f60" xlink:to="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_eb2cb7ab-9d28-41e8-87ab-17f1c2b9c1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e77a839-496a-4a77-9bf2-7737f78109d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02282e40-7622-490b-80df-e55a0d8e4f60" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9e77a839-496a-4a77-9bf2-7737f78109d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1f5d67a1-a0eb-437e-a024-fb63551affed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a7d5bca-b424-4865-8a7a-9b05f91b6f28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1f5d67a1-a0eb-437e-a024-fb63551affed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_77f8be01-b8ac-457e-859e-9bb3db3e4850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1f5d67a1-a0eb-437e-a024-fb63551affed" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_77f8be01-b8ac-457e-859e-9bb3db3e4850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8fa9ae72-b734-4b04-946f-2a4f37c125ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1f5d67a1-a0eb-437e-a024-fb63551affed" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8fa9ae72-b734-4b04-946f-2a4f37c125ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_02a66215-479f-4d8e-8780-a1d7e1cb6a16" xlink:href="cah-20201231.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1f5d67a1-a0eb-437e-a024-fb63551affed" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_02a66215-479f-4d8e-8780-a1d7e1cb6a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_51bc1199-9192-4923-be10-7713f3beb54f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1f5d67a1-a0eb-437e-a024-fb63551affed" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_51bc1199-9192-4923-be10-7713f3beb54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e98d7b39-8d74-4aac-ad25-7d172b571009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1f5d67a1-a0eb-437e-a024-fb63551affed" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e98d7b39-8d74-4aac-ad25-7d172b571009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cfd97ca8-3b52-4b42-8e15-52af985e3ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1f5d67a1-a0eb-437e-a024-fb63551affed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cfd97ca8-3b52-4b42-8e15-52af985e3ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6a7d33d9-d6cf-460f-96e3-ae7411dab945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a7d5bca-b424-4865-8a7a-9b05f91b6f28" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6a7d33d9-d6cf-460f-96e3-ae7411dab945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9e3c0714-379d-4079-aae5-85694c77293e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a7d5bca-b424-4865-8a7a-9b05f91b6f28" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9e3c0714-379d-4079-aae5-85694c77293e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3d1db0e-1bde-4bff-8553-e9c1212df47a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a7d5bca-b424-4865-8a7a-9b05f91b6f28" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3d1db0e-1bde-4bff-8553-e9c1212df47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e929b7bb-57fd-4293-8b0b-b9ef0f7f8f5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a7d5bca-b424-4865-8a7a-9b05f91b6f28" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e929b7bb-57fd-4293-8b0b-b9ef0f7f8f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_09e8ac13-3b5d-4c7d-bbd7-7763ff0b4d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_c9a15fda-1ef0-4dd8-91c0-c4679a1c5e5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_09e8ac13-3b5d-4c7d-bbd7-7763ff0b4d6c" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_c9a15fda-1ef0-4dd8-91c0-c4679a1c5e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ab148369-f6af-45d4-b797-726424ff412a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5e1898c0-e844-40ad-a7c7-e6db91d86a87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ab148369-f6af-45d4-b797-726424ff412a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5e1898c0-e844-40ad-a7c7-e6db91d86a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_eb34c6ec-bfcd-4928-93fa-d871e61fdee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ab148369-f6af-45d4-b797-726424ff412a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_eb34c6ec-bfcd-4928-93fa-d871e61fdee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6ffaac80-96c0-43a1-b2d3-343de763f889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeverance"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_7b09e425-696f-429c-a7e0-6c29a055fd9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_8dde188d-f2fb-471e-94d4-289ccf5195fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_7b09e425-696f-429c-a7e0-6c29a055fd9e" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_8dde188d-f2fb-471e-94d4-289ccf5195fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeveranceTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_db5b7c63-5f91-433e-b44e-3c625d7d1c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_bd3ecfe0-6839-445e-bce5-39c3a8463f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_db5b7c63-5f91-433e-b44e-3c625d7d1c45" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_bd3ecfe0-6839-445e-bce5-39c3a8463f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_3b802d00-3766-4d58-89c8-98e22226db72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_db5b7c63-5f91-433e-b44e-3c625d7d1c45" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_3b802d00-3766-4d58-89c8-98e22226db72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_7ee3f0a4-de88-4b16-ade5-ebfed972e397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_a6874031-fecb-4653-9dc4-155b8d7b5433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_7ee3f0a4-de88-4b16-ade5-ebfed972e397" xlink:to="loc_us-gaap_SeveranceCosts1_a6874031-fecb-4653-9dc4-155b8d7b5433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_7479a438-887d-44cb-a4e5-73c6792cc4b7" xlink:href="cah-20201231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_7ee3f0a4-de88-4b16-ade5-ebfed972e397" xlink:to="loc_cah_FacilityExitAndOtherCosts_7479a438-887d-44cb-a4e5-73c6792cc4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_dde2ce40-41ec-4924-95a5-f4be5b5b6801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_7ee3f0a4-de88-4b16-ade5-ebfed972e397" xlink:to="loc_us-gaap_RestructuringCharges_dde2ce40-41ec-4924-95a5-f4be5b5b6801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_fe20d415-36e9-478d-8268-ecb682b7dcd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ee85180a-94cb-4d8e-8dfe-efc8ccddd5ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_fe20d415-36e9-478d-8268-ecb682b7dcd1" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ee85180a-94cb-4d8e-8dfe-efc8ccddd5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_746ec3f7-a9b8-45c8-8659-35593718cad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ee85180a-94cb-4d8e-8dfe-efc8ccddd5ab" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_746ec3f7-a9b8-45c8-8659-35593718cad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_98d4e799-8990-4899-932b-f96a21490a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_746ec3f7-a9b8-45c8-8659-35593718cad7" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_98d4e799-8990-4899-932b-f96a21490a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_e88e27ea-ded6-4cf7-a70d-7e3087a5c6b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_98d4e799-8990-4899-932b-f96a21490a99" xlink:to="loc_us-gaap_EmployeeSeveranceMember_e88e27ea-ded6-4cf7-a70d-7e3087a5c6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_14fbdb06-b040-4412-85ed-b1079aac2c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_98d4e799-8990-4899-932b-f96a21490a99" xlink:to="loc_us-gaap_FacilityClosingMember_14fbdb06-b040-4412-85ed-b1079aac2c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1164faca-4259-4ef4-a592-6bec902f4c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ee85180a-94cb-4d8e-8dfe-efc8ccddd5ab" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1164faca-4259-4ef4-a592-6bec902f4c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_5855d350-1865-4997-8139-504b6c4af5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1164faca-4259-4ef4-a592-6bec902f4c6f" xlink:to="loc_us-gaap_RestructuringReserveRollForward_5855d350-1865-4997-8139-504b6c4af5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_843586f3-3114-4186-a5f8-9c6eb23d9d02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_5855d350-1865-4997-8139-504b6c4af5ca" xlink:to="loc_us-gaap_RestructuringReserve_843586f3-3114-4186-a5f8-9c6eb23d9d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_6ba60779-5535-438a-894f-86c3754a5339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_5855d350-1865-4997-8139-504b6c4af5ca" xlink:to="loc_us-gaap_RestructuringCosts_6ba60779-5535-438a-894f-86c3754a5339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_c177dd68-c148-4d11-961e-f548deb49e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_5855d350-1865-4997-8139-504b6c4af5ca" xlink:to="loc_us-gaap_PaymentsForRestructuring_c177dd68-c148-4d11-961e-f548deb49e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7d07a42f-c10b-464b-be3c-a79f80315669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_5855d350-1865-4997-8139-504b6c4af5ca" xlink:to="loc_us-gaap_RestructuringReserve_7d07a42f-c10b-464b-be3c-a79f80315669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_NarativeAbstract_2b2f139c-7838-40a4-b19a-0f364a7f82d2" xlink:href="cah-20201231.xsd#cah_NarativeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_957b1a08-48c6-428a-9b80-5e3db1c584a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_NarativeAbstract_2b2f139c-7838-40a4-b19a-0f364a7f82d2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_957b1a08-48c6-428a-9b80-5e3db1c584a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a966ea02-e3ba-4b06-be36-a95654024241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_957b1a08-48c6-428a-9b80-5e3db1c584a1" xlink:to="loc_us-gaap_RestructuringPlanAxis_a966ea02-e3ba-4b06-be36-a95654024241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_eaf91b2b-e588-4aaf-9c8e-308af5fed369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_a966ea02-e3ba-4b06-be36-a95654024241" xlink:to="loc_us-gaap_RestructuringPlanDomain_eaf91b2b-e588-4aaf-9c8e-308af5fed369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_e9f65f63-aaf1-4c1f-b339-f11cfb863928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_957b1a08-48c6-428a-9b80-5e3db1c584a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_e9f65f63-aaf1-4c1f-b339-f11cfb863928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_472d2e78-3a0f-4626-91f0-439ed2488f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_e9f65f63-aaf1-4c1f-b339-f11cfb863928" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_472d2e78-3a0f-4626-91f0-439ed2488f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_18957ce5-791e-4ab9-96c6-5763290b6eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_957b1a08-48c6-428a-9b80-5e3db1c584a1" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_18957ce5-791e-4ab9-96c6-5763290b6eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_9f1609bf-e61f-49a6-bb15-ac8545e2fd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18957ce5-791e-4ab9-96c6-5763290b6eeb" xlink:to="loc_us-gaap_RestructuringCosts_9f1609bf-e61f-49a6-bb15-ac8545e2fd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_2e37d45d-9efa-4a8d-9886-a834c98475d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18957ce5-791e-4ab9-96c6-5763290b6eeb" xlink:to="loc_us-gaap_SeveranceCosts1_2e37d45d-9efa-4a8d-9886-a834c98475d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_1b9344a3-0069-4ed3-91c2-c3114f827208" xlink:href="cah-20201231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_18957ce5-791e-4ab9-96c6-5763290b6eeb" xlink:to="loc_cah_FacilityExitAndOtherCosts_1b9344a3-0069-4ed3-91c2-c3114f827208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_af7eac94-1e32-4c3e-9584-d4e41c7b571b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e50e0493-1215-4909-84cc-7b655349bf3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_af7eac94-1e32-4c3e-9584-d4e41c7b571b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e50e0493-1215-4909-84cc-7b655349bf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b226d536-aa2d-4453-b6e3-6451c163cc45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_bc7453b1-0539-40c9-a3ef-9cdc3dcdffb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b226d536-aa2d-4453-b6e3-6451c163cc45" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_bc7453b1-0539-40c9-a3ef-9cdc3dcdffb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_aba973e1-20bc-4a8d-b07d-8f7aa3108015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b226d536-aa2d-4453-b6e3-6451c163cc45" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_aba973e1-20bc-4a8d-b07d-8f7aa3108015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a77d298e-9677-46cf-ac9e-5790194953c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c65de008-ccc8-4d05-8f77-e98e80253bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a77d298e-9677-46cf-ac9e-5790194953c6" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c65de008-ccc8-4d05-8f77-e98e80253bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4df33259-aac1-4df2-acf5-2fcc625d0006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c65de008-ccc8-4d05-8f77-e98e80253bdc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4df33259-aac1-4df2-acf5-2fcc625d0006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_394e1b4f-b7e7-41b2-9613-39e001b84313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4df33259-aac1-4df2-acf5-2fcc625d0006" xlink:to="loc_us-gaap_SegmentDomain_394e1b4f-b7e7-41b2-9613-39e001b84313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_dd7ee168-cacb-4708-bf47-2559b2adc192" xlink:href="cah-20201231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_394e1b4f-b7e7-41b2-9613-39e001b84313" xlink:to="loc_cah_PharmaceuticalMember_dd7ee168-cacb-4708-bf47-2559b2adc192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_a182b614-e964-462e-82a9-2b013bb5a156" xlink:href="cah-20201231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_394e1b4f-b7e7-41b2-9613-39e001b84313" xlink:to="loc_cah_MedicalMember_a182b614-e964-462e-82a9-2b013bb5a156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_49339e7e-ed8d-4e0b-bbb5-9312750d6bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c65de008-ccc8-4d05-8f77-e98e80253bdc" xlink:to="loc_us-gaap_GoodwillLineItems_49339e7e-ed8d-4e0b-bbb5-9312750d6bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_01f3ba29-2166-4109-a430-0b24ee09e909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_49339e7e-ed8d-4e0b-bbb5-9312750d6bf7" xlink:to="loc_us-gaap_GoodwillRollForward_01f3ba29-2166-4109-a430-0b24ee09e909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_34147849-c3b9-46f3-b15f-6060128e4248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_01f3ba29-2166-4109-a430-0b24ee09e909" xlink:to="loc_us-gaap_Goodwill_34147849-c3b9-46f3-b15f-6060128e4248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_fdf0dc58-93b9-4f97-bdcb-7e48dd41fc66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_01f3ba29-2166-4109-a430-0b24ee09e909" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_fdf0dc58-93b9-4f97-bdcb-7e48dd41fc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_7b0e0688-ae87-4c00-92d8-89dd44890922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_01f3ba29-2166-4109-a430-0b24ee09e909" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_7b0e0688-ae87-4c00-92d8-89dd44890922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c52b3986-402a-40ad-befa-f1c96ca00e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_01f3ba29-2166-4109-a430-0b24ee09e909" xlink:to="loc_us-gaap_Goodwill_c52b3986-402a-40ad-befa-f1c96ca00e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b463c28b-0b0a-4a4f-a92f-3df60c523497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_85ae8069-632d-438c-a92d-539e20cccd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b463c28b-0b0a-4a4f-a92f-3df60c523497" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_85ae8069-632d-438c-a92d-539e20cccd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04fabc7f-b418-4f63-bdf8-31e472959311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_85ae8069-632d-438c-a92d-539e20cccd8b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04fabc7f-b418-4f63-bdf8-31e472959311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1e53939f-fd3f-4073-aa50-afbb25ba7ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_04fabc7f-b418-4f63-bdf8-31e472959311" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1e53939f-fd3f-4073-aa50-afbb25ba7ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_ed09b6e3-2022-422e-8be4-6a34d9e7dc9e" xlink:href="cah-20201231.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1e53939f-fd3f-4073-aa50-afbb25ba7ee3" xlink:to="loc_cah_IPRDTrademarksandOtherMember_ed09b6e3-2022-422e-8be4-6a34d9e7dc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_36050c4b-996c-47e2-93c6-6c416c7710c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_85ae8069-632d-438c-a92d-539e20cccd8b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_36050c4b-996c-47e2-93c6-6c416c7710c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_151b0133-c9c3-4eab-a646-c489e77eab1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_36050c4b-996c-47e2-93c6-6c416c7710c4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_151b0133-c9c3-4eab-a646-c489e77eab1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6fab6747-58be-44bf-a439-5d4654a31664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b463c28b-0b0a-4a4f-a92f-3df60c523497" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6fab6747-58be-44bf-a439-5d4654a31664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63313176-31cf-4086-9e72-fe14f971cc21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6fab6747-58be-44bf-a439-5d4654a31664" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63313176-31cf-4086-9e72-fe14f971cc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03e383ca-eca1-4c20-83fa-51c4cefea05a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63313176-31cf-4086-9e72-fe14f971cc21" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03e383ca-eca1-4c20-83fa-51c4cefea05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_e5ed671d-d588-470e-824f-daceabce2b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03e383ca-eca1-4c20-83fa-51c4cefea05a" xlink:to="loc_us-gaap_CustomerRelationshipsMember_e5ed671d-d588-470e-824f-daceabce2b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_0c5cb199-ab86-4059-b2aa-e9c2b88cd891" xlink:href="cah-20201231.xsd#cah_TrademarksAndPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03e383ca-eca1-4c20-83fa-51c4cefea05a" xlink:to="loc_cah_TrademarksAndPatentsMember_0c5cb199-ab86-4059-b2aa-e9c2b88cd891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_2c28d70a-882b-42f9-9352-389c9001187f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03e383ca-eca1-4c20-83fa-51c4cefea05a" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_2c28d70a-882b-42f9-9352-389c9001187f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590e0046-446a-43dc-b38c-cec240c16ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6fab6747-58be-44bf-a439-5d4654a31664" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590e0046-446a-43dc-b38c-cec240c16ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a44a4f02-1498-46b5-9bf0-d1735b8d669a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590e0046-446a-43dc-b38c-cec240c16ba6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a44a4f02-1498-46b5-9bf0-d1735b8d669a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_751522dc-5183-4661-8bbb-726bdd6815f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590e0046-446a-43dc-b38c-cec240c16ba6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_751522dc-5183-4661-8bbb-726bdd6815f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fea9dfd5-4b44-4012-9bb3-80030082db7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590e0046-446a-43dc-b38c-cec240c16ba6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fea9dfd5-4b44-4012-9bb3-80030082db7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_7f2c2dc8-9e97-4289-8988-97b4c599878e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_590e0046-446a-43dc-b38c-cec240c16ba6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_7f2c2dc8-9e97-4289-8988-97b4c599878e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_49bd4747-166f-4f51-bf3a-1671fbe05dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b463c28b-0b0a-4a4f-a92f-3df60c523497" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_49bd4747-166f-4f51-bf3a-1671fbe05dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ec5e490f-3e01-4198-a5b2-65d96177e283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b463c28b-0b0a-4a4f-a92f-3df60c523497" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ec5e490f-3e01-4198-a5b2-65d96177e283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf3adae-5e3d-40ad-b332-a30e96fbe5a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b593c014-1beb-4dbb-9aa8-678421b30667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf3adae-5e3d-40ad-b332-a30e96fbe5a4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b593c014-1beb-4dbb-9aa8-678421b30667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c405055d-0aeb-435c-9d7c-b2eb133e6036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b593c014-1beb-4dbb-9aa8-678421b30667" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c405055d-0aeb-435c-9d7c-b2eb133e6036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42ce7373-8150-4843-bd70-05820dec8be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c405055d-0aeb-435c-9d7c-b2eb133e6036" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42ce7373-8150-4843-bd70-05820dec8be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_cb7f75e2-0cf2-4004-902e-c6ac1ffef87d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b593c014-1beb-4dbb-9aa8-678421b30667" xlink:to="loc_srt_ConsolidationItemsAxis_cb7f75e2-0cf2-4004-902e-c6ac1ffef87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ccfb0389-9314-42ac-b1df-5d9cf585fde6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_cb7f75e2-0cf2-4004-902e-c6ac1ffef87d" xlink:to="loc_srt_ConsolidationItemsDomain_ccfb0389-9314-42ac-b1df-5d9cf585fde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dc5cabd4-041e-424e-97d5-9db3c53b1de2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b593c014-1beb-4dbb-9aa8-678421b30667" xlink:to="loc_srt_RangeAxis_dc5cabd4-041e-424e-97d5-9db3c53b1de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6ff8ba7f-705c-4512-a334-40ac68745583" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dc5cabd4-041e-424e-97d5-9db3c53b1de2" xlink:to="loc_srt_RangeMember_6ff8ba7f-705c-4512-a334-40ac68745583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f0de954b-b7e0-4e02-9f12-6dcfebaa6dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b593c014-1beb-4dbb-9aa8-678421b30667" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f0de954b-b7e0-4e02-9f12-6dcfebaa6dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_63e5ebff-f9b2-40f4-8b71-3a2b216a4e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f0de954b-b7e0-4e02-9f12-6dcfebaa6dcb" xlink:to="loc_us-gaap_Goodwill_63e5ebff-f9b2-40f4-8b71-3a2b216a4e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_efb570db-3dd1-4532-a576-e2a9b6f94452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf3adae-5e3d-40ad-b332-a30e96fbe5a4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_efb570db-3dd1-4532-a576-e2a9b6f94452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2fe9e2e4-d344-4119-9902-bce79ea19d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf3adae-5e3d-40ad-b332-a30e96fbe5a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2fe9e2e4-d344-4119-9902-bce79ea19d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c3c7b8b6-0ddf-46a1-8b15-e457d5505f78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf3adae-5e3d-40ad-b332-a30e96fbe5a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c3c7b8b6-0ddf-46a1-8b15-e457d5505f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c72e5064-70b5-48e7-9521-65374f141ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf3adae-5e3d-40ad-b332-a30e96fbe5a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c72e5064-70b5-48e7-9521-65374f141ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_21213c07-7f56-4a3b-bc98-99bb1eeceb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf3adae-5e3d-40ad-b332-a30e96fbe5a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_21213c07-7f56-4a3b-bc98-99bb1eeceb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8aa8f15a-550f-4120-882a-04794624abe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cdf3adae-5e3d-40ad-b332-a30e96fbe5a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8aa8f15a-550f-4120-882a-04794624abe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20201231.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_54501e95-a2f5-434d-89b0-99a572c4f16e" xlink:href="cah-20201231.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_d5c31724-9e8b-4db0-993c-28f6af2c8113" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_54501e95-a2f5-434d-89b0-99a572c4f16e" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_d5c31724-9e8b-4db0-993c-28f6af2c8113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="simple" xlink:href="cah-20201231.xsd#LongTermObligationsandOtherShortTermBorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_de9f4b05-db86-4c48-a78f-89ae82d4eac1" xlink:href="cah-20201231.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_cd38b70b-9167-4289-b5ca-1ab7bf26682b" xlink:href="cah-20201231.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_25cfb98e-3f50-4caf-87a8-e91444ee2ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_cd38b70b-9167-4289-b5ca-1ab7bf26682b" xlink:to="loc_us-gaap_DebtInstrumentTable_25cfb98e-3f50-4caf-87a8-e91444ee2ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aa834377-cc25-4038-8a46-1e6a8dcd1710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25cfb98e-3f50-4caf-87a8-e91444ee2ef0" xlink:to="loc_us-gaap_DebtInstrumentAxis_aa834377-cc25-4038-8a46-1e6a8dcd1710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_aa834377-cc25-4038-8a46-1e6a8dcd1710" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.4Notesdue2020Member_108a7218-b3e1-4b53-8f24-e59257d4baa5" xlink:href="cah-20201231.xsd#cah_A2.4Notesdue2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A2.4Notesdue2020Member_108a7218-b3e1-4b53-8f24-e59257d4baa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_21196fb3-a80a-41bc-a0fe-e5573e9fdb16" xlink:href="cah-20201231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A2.616Notesdue2022Member_21196fb3-a80a-41bc-a0fe-e5573e9fdb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.41Notesdue2027Member_7dc9404b-ddb6-49e3-9a1d-7636b4c69455" xlink:href="cah-20201231.xsd#cah_A3.41Notesdue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A3.41Notesdue2027Member_7dc9404b-ddb6-49e3-9a1d-7636b4c69455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_b2e12deb-c5b4-455a-8c94-fe3afb91ef1b" xlink:href="cah-20201231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_b2e12deb-c5b4-455a-8c94-fe3afb91ef1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.6Notesdue2043Member_bb76d2a4-fc96-48b6-b6dc-3ce2d37394e4" xlink:href="cah-20201231.xsd#cah_A4.6Notesdue2043Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A4.6Notesdue2043Member_bb76d2a4-fc96-48b6-b6dc-3ce2d37394e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.9Notesdue2045Member_03b6b504-c526-48f2-b07a-f3b4b42dd2e2" xlink:href="cah-20201231.xsd#cah_A4.9Notesdue2045Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A4.9Notesdue2045Member_03b6b504-c526-48f2-b07a-f3b4b42dd2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.368Notesdue2047Member_a738a078-f395-4f6f-8a96-41e7de798afd" xlink:href="cah-20201231.xsd#cah_A4.368Notesdue2047Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A4.368Notesdue2047Member_a738a078-f395-4f6f-8a96-41e7de798afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_00cc78c3-ecb5-497c-8932-3f25c2cab788" xlink:href="cah-20201231.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_FloatingRateNotesdue2022Member_00cc78c3-ecb5-497c-8932-3f25c2cab788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.2Notesdue2022Member_95d4873a-7351-4b8d-8a95-f73ae2da4cb6" xlink:href="cah-20201231.xsd#cah_A3.2Notesdue2022Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93fe64b0-4c8c-4c9d-80e7-c4a59dbc4f6a" xlink:to="loc_cah_A3.2Notesdue2022Member_95d4873a-7351-4b8d-8a95-f73ae2da4cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_176629cb-33d1-4aa6-8400-7f5251e54bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25cfb98e-3f50-4caf-87a8-e91444ee2ef0" xlink:to="loc_us-gaap_CreditFacilityAxis_176629cb-33d1-4aa6-8400-7f5251e54bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cd36c239-d7f6-436c-a5c0-e6479c0ea1fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_176629cb-33d1-4aa6-8400-7f5251e54bdb" xlink:to="loc_us-gaap_CreditFacilityDomain_cd36c239-d7f6-436c-a5c0-e6479c0ea1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_14cc7717-a9ff-4da0-a610-3a130f6b8786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cd36c239-d7f6-436c-a5c0-e6479c0ea1fe" xlink:to="loc_us-gaap_CommercialPaperMember_14cc7717-a9ff-4da0-a610-3a130f6b8786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_b75f64fb-f415-4543-ac81-2885e4b907c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cd36c239-d7f6-436c-a5c0-e6479c0ea1fe" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_b75f64fb-f415-4543-ac81-2885e4b907c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_873999fc-a1ac-445b-a06c-195a85673383" xlink:href="cah-20201231.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cd36c239-d7f6-436c-a5c0-e6479c0ea1fe" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_873999fc-a1ac-445b-a06c-195a85673383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_a681bddd-fdd1-4402-a5dc-ebafc50e1b71" xlink:href="cah-20201231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cd36c239-d7f6-436c-a5c0-e6479c0ea1fe" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_a681bddd-fdd1-4402-a5dc-ebafc50e1b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25cfb98e-3f50-4caf-87a8-e91444ee2ef0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_d9cdc18f-721a-4e56-8ad6-a2412b1650a1" xlink:href="cah-20201231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:to="loc_cah_TotalLongTermandShortTermObligations_d9cdc18f-721a-4e56-8ad6-a2412b1650a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c5e855b8-3b88-4393-a607-102f40090b60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c5e855b8-3b88-4393-a607-102f40090b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NotesPayableRepurchased_4bab324c-ead2-4d85-ae67-42f4e7c721dc" xlink:href="cah-20201231.xsd#cah_NotesPayableRepurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:to="loc_cah_NotesPayableRepurchased_4bab324c-ead2-4d85-ae67-42f4e7c721dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9280e304-967d-4696-92a1-fa3f11f8ad68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9280e304-967d-4696-92a1-fa3f11f8ad68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_76b4f68a-12e7-4446-818d-504d3a32202d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b63ada32-a41f-45b0-a896-4347611eb960" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_76b4f68a-12e7-4446-818d-504d3a32202d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4d79d634-d6c1-4634-b385-a08b7d81bbcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4b2c9cb1-ae43-412e-a849-3e058db913ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4d79d634-d6c1-4634-b385-a08b7d81bbcc" xlink:to="loc_us-gaap_DebtInstrumentTable_4b2c9cb1-ae43-412e-a849-3e058db913ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c8b23d14-a603-4cda-9797-4d4215038ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4b2c9cb1-ae43-412e-a849-3e058db913ab" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c8b23d14-a603-4cda-9797-4d4215038ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_36482b49-6cbd-4b08-9fac-759293a0dd8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c8b23d14-a603-4cda-9797-4d4215038ae1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_36482b49-6cbd-4b08-9fac-759293a0dd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f3a2af4a-fa68-467f-aa95-00862375282b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4b2c9cb1-ae43-412e-a849-3e058db913ab" xlink:to="loc_us-gaap_DebtInstrumentAxis_f3a2af4a-fa68-467f-aa95-00862375282b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f3a2af4a-fa68-467f-aa95-00862375282b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.4Notesdue2020Member_882cbb14-7bd7-4c4d-8155-4072ea5c21fd" xlink:href="cah-20201231.xsd#cah_A2.4Notesdue2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A2.4Notesdue2020Member_882cbb14-7bd7-4c4d-8155-4072ea5c21fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_b7dceaf4-7b1b-453f-85a0-054363ee46a2" xlink:href="cah-20201231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A2.616Notesdue2022Member_b7dceaf4-7b1b-453f-85a0-054363ee46a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.2Notesdue2022Member_a4f744a1-8936-489f-92c5-2b9cd1ffffd0" xlink:href="cah-20201231.xsd#cah_A3.2Notesdue2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A3.2Notesdue2022Member_a4f744a1-8936-489f-92c5-2b9cd1ffffd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_3bfa977a-b98e-41f4-9f8e-715d43bd7c53" xlink:href="cah-20201231.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_FloatingRateNotesdue2022Member_3bfa977a-b98e-41f4-9f8e-715d43bd7c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.41Notesdue2027Member_55893ea5-dc7b-450d-bf19-a663464fdea5" xlink:href="cah-20201231.xsd#cah_A3.41Notesdue2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A3.41Notesdue2027Member_55893ea5-dc7b-450d-bf19-a663464fdea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.6Notesdue2043Member_e7fc9c05-6e6f-47e8-878d-447bdc62b3b4" xlink:href="cah-20201231.xsd#cah_A4.6Notesdue2043Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A4.6Notesdue2043Member_e7fc9c05-6e6f-47e8-878d-447bdc62b3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.9Notesdue2045Member_a276d7aa-4f08-4157-a3fa-279d8da33763" xlink:href="cah-20201231.xsd#cah_A4.9Notesdue2045Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A4.9Notesdue2045Member_a276d7aa-4f08-4157-a3fa-279d8da33763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.368Notesdue2047Member_bada04cc-cca6-4615-923c-93bdf7537ae4" xlink:href="cah-20201231.xsd#cah_A4.368Notesdue2047Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0a579510-bcbc-47a3-a066-87cf8f1258d9" xlink:to="loc_cah_A4.368Notesdue2047Member_bada04cc-cca6-4615-923c-93bdf7537ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cff9c8d6-c738-4c2a-bbe1-878ea4a9b299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4b2c9cb1-ae43-412e-a849-3e058db913ab" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cff9c8d6-c738-4c2a-bbe1-878ea4a9b299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_2b715a86-b2f0-4233-81d5-406be58fc24d" xlink:href="cah-20201231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cff9c8d6-c738-4c2a-bbe1-878ea4a9b299" xlink:to="loc_cah_TotalLongTermandShortTermObligations_2b715a86-b2f0-4233-81d5-406be58fc24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7de65fc4-7fcd-42c6-9b1d-51393afdf2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cff9c8d6-c738-4c2a-bbe1-878ea4a9b299" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7de65fc4-7fcd-42c6-9b1d-51393afdf2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_abf34b70-6552-462f-bd49-77dc63ffc3f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cff9c8d6-c738-4c2a-bbe1-878ea4a9b299" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_abf34b70-6552-462f-bd49-77dc63ffc3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20201231.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2aaa94d-e735-4c37-b960-e3fa82c0cbe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_eef6adc9-e9cf-493f-9b65-419a0a601363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2aaa94d-e735-4c37-b960-e3fa82c0cbe3" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_eef6adc9-e9cf-493f-9b65-419a0a601363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2146d844-4878-4b74-aa60-0f99ed7b593d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2146d844-4878-4b74-aa60-0f99ed7b593d" xlink:to="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallAxis_3f0eb5e7-01eb-4197-a33d-fb60748fc66b" xlink:href="cah-20201231.xsd#cah_GownRecallAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_cah_GownRecallAxis_3f0eb5e7-01eb-4197-a33d-fb60748fc66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallDomain_105b87b8-eb0c-4786-891e-bd57875b0fb5" xlink:href="cah-20201231.xsd#cah_GownRecallDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GownRecallAxis_3f0eb5e7-01eb-4197-a33d-fb60748fc66b" xlink:to="loc_cah_GownRecallDomain_105b87b8-eb0c-4786-891e-bd57875b0fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_eef4b198-0f52-42a1-b716-f163adc0be56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_eef4b198-0f52-42a1-b716-f163adc0be56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_921e041d-bd89-4db8-86a2-1f4c6aaf7766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_eef4b198-0f52-42a1-b716-f163adc0be56" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_921e041d-bd89-4db8-86a2-1f4c6aaf7766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7f7eb287-2b37-4a70-879a-5d24abb20c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7f7eb287-2b37-4a70-879a-5d24abb20c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_929e22ab-d905-46a5-911d-cc2ecf1b18fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7f7eb287-2b37-4a70-879a-5d24abb20c72" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_929e22ab-d905-46a5-911d-cc2ecf1b18fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_69df9ede-9085-48d6-8bf9-9f60bc950ef7" xlink:href="cah-20201231.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_cah_OpioidLitigationAxis_69df9ede-9085-48d6-8bf9-9f60bc950ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_d99419c8-9406-4f23-a774-fe7c3dd6c0bd" xlink:href="cah-20201231.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_69df9ede-9085-48d6-8bf9-9f60bc950ef7" xlink:to="loc_cah_OpioidLitigationDomain_d99419c8-9406-4f23-a774-fe7c3dd6c0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_0afee6fb-67a2-4508-af3f-288f2d62ebcf" xlink:href="cah-20201231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_d99419c8-9406-4f23-a774-fe7c3dd6c0bd" xlink:to="loc_cah_TotalOpioidLitigationMember_0afee6fb-67a2-4508-af3f-288f2d62ebcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_d3373953-4564-486e-acac-21201506830c" xlink:href="cah-20201231.xsd#cah_LawsuitTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_cah_LawsuitTypeAxis_d3373953-4564-486e-acac-21201506830c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_9c4228bc-01a7-418a-aa50-6d6533466441" xlink:href="cah-20201231.xsd#cah_LawsuitTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeAxis_d3373953-4564-486e-acac-21201506830c" xlink:to="loc_cah_LawsuitTypeDomain_9c4228bc-01a7-418a-aa50-6d6533466441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_6500cc89-4353-4d33-9a89-c32ce45a67d1" xlink:href="cah-20201231.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeDomain_9c4228bc-01a7-418a-aa50-6d6533466441" xlink:to="loc_cah_ClassActionLawsuitsMember_6500cc89-4353-4d33-9a89-c32ce45a67d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_98457a1b-5268-480e-9042-527975a06e5c" xlink:href="cah-20201231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeDomain_9c4228bc-01a7-418a-aa50-6d6533466441" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_98457a1b-5268-480e-9042-527975a06e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_d910f55a-0632-495b-8f60-99b169e7589d" xlink:href="cah-20201231.xsd#cah_PlaintiffTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_cah_PlaintiffTypeAxis_d910f55a-0632-495b-8f60-99b169e7589d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_9da79e18-411c-4169-9ffd-80619f369192" xlink:href="cah-20201231.xsd#cah_PlaintiffTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeAxis_d910f55a-0632-495b-8f60-99b169e7589d" xlink:to="loc_cah_PlaintiffTypeDomain_9da79e18-411c-4169-9ffd-80619f369192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_36d82d12-74a1-4ce2-a502-6270a618ca17" xlink:href="cah-20201231.xsd#cah_PrivatePartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeDomain_9da79e18-411c-4169-9ffd-80619f369192" xlink:to="loc_cah_PrivatePartiesMember_36d82d12-74a1-4ce2-a502-6270a618ca17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_54bc3912-926b-417d-b908-118eecec2b09" xlink:href="cah-20201231.xsd#cah_TaxMattersAgreementAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_cah_TaxMattersAgreementAxis_54bc3912-926b-417d-b908-118eecec2b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_c078da48-fe27-4e7c-817e-1e2672b58f42" xlink:href="cah-20201231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementAxis_54bc3912-926b-417d-b908-118eecec2b09" xlink:to="loc_cah_TaxMattersAgreementDomain_c078da48-fe27-4e7c-817e-1e2672b58f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_40045b92-51b1-4d80-a89b-d98d8f8e04ab" xlink:href="cah-20201231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementDomain_c078da48-fe27-4e7c-817e-1e2672b58f42" xlink:to="loc_cah_TotalOpioidLitigationMember_40045b92-51b1-4d80-a89b-d98d8f8e04ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5af356ad-f6aa-4355-b914-360cf96b8be1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_srt_StatementGeographicalAxis_5af356ad-f6aa-4355-b914-360cf96b8be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e0c509f9-99e2-403d-98bd-485bc9e5409e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5af356ad-f6aa-4355-b914-360cf96b8be1" xlink:to="loc_srt_SegmentGeographicalDomain_e0c509f9-99e2-403d-98bd-485bc9e5409e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_09c5a03c-5676-48ef-a703-d25558347ba8" xlink:href="cah-20201231.xsd#cah_AlamedaCountyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e0c509f9-99e2-403d-98bd-485bc9e5409e" xlink:to="loc_cah_AlamedaCountyMember_09c5a03c-5676-48ef-a703-d25558347ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_241d5289-7933-48da-911e-73d35f68ed78" xlink:href="cah-20201231.xsd#cah_OtherJurisdictionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e0c509f9-99e2-403d-98bd-485bc9e5409e" xlink:to="loc_cah_OtherJurisdictionsMember_241d5289-7933-48da-911e-73d35f68ed78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1e4ca531-f190-44a1-ac4b-727fee485b0b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_srt_RangeAxis_1e4ca531-f190-44a1-ac4b-727fee485b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3a957210-8616-4762-aabe-153cba185947" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1e4ca531-f190-44a1-ac4b-727fee485b0b" xlink:to="loc_srt_RangeMember_3a957210-8616-4762-aabe-153cba185947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_09631f5e-3b73-4dce-843e-d2d590ecc6d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3a957210-8616-4762-aabe-153cba185947" xlink:to="loc_srt_MinimumMember_09631f5e-3b73-4dce-843e-d2d590ecc6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b9de9871-0e21-4011-9719-a3488fc47147" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3a957210-8616-4762-aabe-153cba185947" xlink:to="loc_srt_MaximumMember_b9de9871-0e21-4011-9719-a3488fc47147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8f0612b0-6f2e-45b5-a418-4de4d5bbb99f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8f0612b0-6f2e-45b5-a418-4de4d5bbb99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b97b63a8-2d97-47d2-baf9-ca0d7b09c0eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8f0612b0-6f2e-45b5-a418-4de4d5bbb99f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b97b63a8-2d97-47d2-baf9-ca0d7b09c0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_5c64932c-1cbe-4c97-9cd2-7837f999a9c2" xlink:href="cah-20201231.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b97b63a8-2d97-47d2-baf9-ca0d7b09c0eb" xlink:to="loc_cah_OpioidLawsuitsMember_5c64932c-1cbe-4c97-9cd2-7837f999a9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_4cbaa6d2-9c34-4f37-bb97-dd1d21334e06" xlink:href="cah-20201231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b97b63a8-2d97-47d2-baf9-ca0d7b09c0eb" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_4cbaa6d2-9c34-4f37-bb97-dd1d21334e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7d085ccc-2ed9-4361-80b2-9cb52da3c880" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_srt_MajorCustomersAxis_7d085ccc-2ed9-4361-80b2-9cb52da3c880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1350d850-46be-492a-a6a0-83534552d924" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7d085ccc-2ed9-4361-80b2-9cb52da3c880" xlink:to="loc_srt_NameOfMajorCustomerDomain_1350d850-46be-492a-a6a0-83534552d924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_489b640c-0879-4a1d-bdb5-8a95b59007bf" xlink:href="cah-20201231.xsd#cah_CVSHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1350d850-46be-492a-a6a0-83534552d924" xlink:to="loc_cah_CVSHealthMember_489b640c-0879-4a1d-bdb5-8a95b59007bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c683c0fb-5e0e-4f90-b542-627da018fa18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_srt_LitigationCaseAxis_c683c0fb-5e0e-4f90-b542-627da018fa18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c683c0fb-5e0e-4f90-b542-627da018fa18" xlink:to="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateDomain_4932613e-2ff4-4a85-be25-0621967c4cd2" xlink:href="cah-20201231.xsd#cah_OpioidLawsuitsStateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:to="loc_cah_OpioidLawsuitsStateDomain_4932613e-2ff4-4a85-be25-0621967c4cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_0a80d09f-0953-44c5-8c55-b661c6ae89e9" xlink:href="cah-20201231.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:to="loc_cah_OpioidLawsuitsMember_0a80d09f-0953-44c5-8c55-b661c6ae89e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_f0e91e28-840f-44ae-9bc6-fd98ef1572c1" xlink:href="cah-20201231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_f0e91e28-840f-44ae-9bc6-fd98ef1572c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_ff9e7e2e-60cb-40ab-a23d-c901a8fddf53" xlink:href="cah-20201231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_ff9e7e2e-60cb-40ab-a23d-c901a8fddf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember_0c66d30f-1e83-4adb-b647-56861df4d186" xlink:href="cah-20201231.xsd#cah_DOJInvestigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_3870b641-5cc1-4dad-8e26-38de67e631d2" xlink:to="loc_cah_DOJInvestigationMember_0c66d30f-1e83-4adb-b647-56861df4d186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4ae1e31c-f1c1-4540-9468-d66f5440dcc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4ae1e31c-f1c1-4540-9468-d66f5440dcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0bd43821-76f3-44cb-862c-afdd6f31d1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4ae1e31c-f1c1-4540-9468-d66f5440dcc1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0bd43821-76f3-44cb-862c-afdd6f31d1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5edf83de-26f3-4fe8-b171-890f1c3768b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0bd43821-76f3-44cb-862c-afdd6f31d1eb" xlink:to="loc_us-gaap_SubsequentEventMember_5edf83de-26f3-4fe8-b171-890f1c3768b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8be895f8-2f4f-48f4-a8a9-9e67efe302f5" xlink:to="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7349f615-6d0a-4314-9b14-75be63ae426f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_InventoryNet_7349f615-6d0a-4314-9b14-75be63ae426f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_b8785f9b-6b6a-443e-8351-14583ca33585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_b8785f9b-6b6a-443e-8351-14583ca33585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaximumQuarterlyPayment_6e451910-3dac-408a-bf14-ca29fa7b2f02" xlink:href="cah-20201231.xsd#cah_MaximumQuarterlyPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_cah_MaximumQuarterlyPayment_6e451910-3dac-408a-bf14-ca29fa7b2f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_9268ce21-2ea9-4dde-b5f8-14a592958a2b" xlink:href="cah-20201231.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_cah_LossContingencyLawsuitsNumber_9268ce21-2ea9-4dde-b5f8-14a592958a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_84b2afd7-df71-4885-9718-931d0f55b721" xlink:href="cah-20201231.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_84b2afd7-df71-4885-9718-931d0f55b721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_7116ae63-92e0-4fca-8c40-39df31931944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_7116ae63-92e0-4fca-8c40-39df31931944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_fa9cd899-604d-4a21-9296-b5cca5e7bcd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_LitigationReserve_fa9cd899-604d-4a21-9296-b5cca5e7bcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_e5907323-b302-4c0b-b7d2-e311e21ca52b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_e5907323-b302-4c0b-b7d2-e311e21ca52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_1796696a-49b0-4895-a59c-6e562660f918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_1796696a-49b0-4895-a59c-6e562660f918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_437d9a6c-ec1d-4635-b68c-414d3486ffdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_437d9a6c-ec1d-4635-b68c-414d3486ffdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRecallExpense_28be8af9-278b-483b-9ea3-8e4e88f34ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRecallExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_InventoryRecallExpense_28be8af9-278b-483b-9ea3-8e4e88f34ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_92dceba4-fda3-418c-95d8-c591201f6c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_92dceba4-fda3-418c-95d8-c591201f6c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_92cd238d-8074-4870-9901-647d72510ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_92cd238d-8074-4870-9901-647d72510ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2d6cfe63-06da-4b19-a7ae-06824af115b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2d6cfe63-06da-4b19-a7ae-06824af115b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_1bb25315-1fa0-4645-b163-e64bd4ce31a3" xlink:href="cah-20201231.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_1bb25315-1fa0-4645-b163-e64bd4ce31a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_b9cfe3e1-91d2-4924-9029-dce82eca081a" xlink:href="cah-20201231.xsd#cah_AggregateAnnualAssessment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_190133de-ce56-48c9-91e8-d689465828a9" xlink:to="loc_cah_AggregateAnnualAssessment_b9cfe3e1-91d2-4924-9029-dce82eca081a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_325c63d6-0fa6-4807-88c7-341876ad137f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f116803f-0e68-4f30-bd4b-d1ae30a8d68c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_325c63d6-0fa6-4807-88c7-341876ad137f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f116803f-0e68-4f30-bd4b-d1ae30a8d68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c3d17ec8-d776-4af7-8e33-fe52397b0274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c3d17ec8-d776-4af7-8e33-fe52397b0274" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_708ca2fd-da47-4397-a8d3-05f846526099" xlink:href="cah-20201231.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_cah_OpioidLitigationAxis_708ca2fd-da47-4397-a8d3-05f846526099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_8b809382-e68e-4ef9-91e9-28dddf7cb467" xlink:href="cah-20201231.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_708ca2fd-da47-4397-a8d3-05f846526099" xlink:to="loc_cah_OpioidLitigationDomain_8b809382-e68e-4ef9-91e9-28dddf7cb467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_843f12e0-1d1b-4fa9-888f-81d4f8ceaf45" xlink:href="cah-20201231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_8b809382-e68e-4ef9-91e9-28dddf7cb467" xlink:to="loc_cah_TotalOpioidLitigationMember_843f12e0-1d1b-4fa9-888f-81d4f8ceaf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_af547712-8dff-42c7-8eef-baf214d7bc2c" xlink:href="cah-20201231.xsd#cah_TaxMatterAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_cah_TaxMatterAxis_af547712-8dff-42c7-8eef-baf214d7bc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_59d002ea-3585-4d8d-95f0-1d6393b25d4d" xlink:href="cah-20201231.xsd#cah_TaxMatterDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterAxis_af547712-8dff-42c7-8eef-baf214d7bc2c" xlink:to="loc_cah_TaxMatterDomain_59d002ea-3585-4d8d-95f0-1d6393b25d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_b4f96812-b04f-47fa-b1fe-c339d9f482fe" xlink:href="cah-20201231.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_59d002ea-3585-4d8d-95f0-1d6393b25d4d" xlink:to="loc_cah_PatientRecoveryBusinessMember_b4f96812-b04f-47fa-b1fe-c339d9f482fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_bf6e6611-f396-4361-accd-4f04bc7dbd34" xlink:href="cah-20201231.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_59d002ea-3585-4d8d-95f0-1d6393b25d4d" xlink:to="loc_cah_CareFusionMember_bf6e6611-f396-4361-accd-4f04bc7dbd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ae59cfae-9e3d-4cf0-b962-032dbd5269ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ae59cfae-9e3d-4cf0-b962-032dbd5269ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a2270a6-3b9b-45d6-8181-375a2ef23dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ae59cfae-9e3d-4cf0-b962-032dbd5269ff" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a2270a6-3b9b-45d6-8181-375a2ef23dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_6755f5df-1a5d-4ae2-aa2f-967b7847ff47" xlink:href="cah-20201231.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a2270a6-3b9b-45d6-8181-375a2ef23dc9" xlink:to="loc_cah_PatientRecoveryBusinessMember_6755f5df-1a5d-4ae2-aa2f-967b7847ff47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_0e522e0f-667c-4ff4-983e-c50f1aa78855" xlink:href="cah-20201231.xsd#cah_TaxMattersAgreementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_cah_TaxMattersAgreementAxis_0e522e0f-667c-4ff4-983e-c50f1aa78855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_c20249a3-65c2-4242-bb0a-77d9d5840ca3" xlink:href="cah-20201231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementAxis_0e522e0f-667c-4ff4-983e-c50f1aa78855" xlink:to="loc_cah_TaxMattersAgreementDomain_c20249a3-65c2-4242-bb0a-77d9d5840ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_dfebc0ff-b274-4419-850d-19f4c45352d0" xlink:href="cah-20201231.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementDomain_c20249a3-65c2-4242-bb0a-77d9d5840ca3" xlink:to="loc_cah_CareFusionMember_dfebc0ff-b274-4419-850d-19f4c45352d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_830b2da2-d0bc-4861-a44f-a33ec3d563b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_830b2da2-d0bc-4861-a44f-a33ec3d563b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ce163380-fb37-4681-b002-d25e04a5e781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_830b2da2-d0bc-4861-a44f-a33ec3d563b9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ce163380-fb37-4681-b002-d25e04a5e781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_0b2b8ba0-052b-47f1-b016-2dfe72aded49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ce163380-fb37-4681-b002-d25e04a5e781" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_0b2b8ba0-052b-47f1-b016-2dfe72aded49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd1a5ea8-7d5d-4e5a-9efa-92734c915abe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_srt_RangeAxis_fd1a5ea8-7d5d-4e5a-9efa-92734c915abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_836ccfd5-98c5-472c-9af1-8a727075ad1e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fd1a5ea8-7d5d-4e5a-9efa-92734c915abe" xlink:to="loc_srt_RangeMember_836ccfd5-98c5-472c-9af1-8a727075ad1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4ef5f16d-90d1-4dd5-9ac7-61a509b56e19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_836ccfd5-98c5-472c-9af1-8a727075ad1e" xlink:to="loc_srt_MinimumMember_4ef5f16d-90d1-4dd5-9ac7-61a509b56e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a06a03cc-c5cd-4d54-92bf-e75f744a3aa6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_836ccfd5-98c5-472c-9af1-8a727075ad1e" xlink:to="loc_srt_MaximumMember_a06a03cc-c5cd-4d54-92bf-e75f744a3aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis_6083ab62-caf1-49ec-b4f0-d491f7f096ff" xlink:href="cah-20201231.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_cah_NetOperatingLossCarrybackAxis_6083ab62-caf1-49ec-b4f0-d491f7f096ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_62956ba0-a52d-42cf-bd03-24c209196860" xlink:href="cah-20201231.xsd#cah_CARESActDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_6083ab62-caf1-49ec-b4f0-d491f7f096ff" xlink:to="loc_cah_CARESActDomain_62956ba0-a52d-42cf-bd03-24c209196860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackMember_9aa7e8d5-2a19-479b-8796-bcf8ccaa8e69" xlink:href="cah-20201231.xsd#cah_NetOperatingLossCarrybackMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CARESActDomain_62956ba0-a52d-42cf-bd03-24c209196860" xlink:to="loc_cah_NetOperatingLossCarrybackMember_9aa7e8d5-2a19-479b-8796-bcf8ccaa8e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_06d935f0-9392-4702-80af-e00fa753280e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_srt_StatementScenarioAxis_06d935f0-9392-4702-80af-e00fa753280e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f6708300-03bd-4693-ae9c-59907efa118c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_06d935f0-9392-4702-80af-e00fa753280e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f6708300-03bd-4693-ae9c-59907efa118c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0cbe1aa2-a07f-4d8a-a1b3-1dc23c599f4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f6708300-03bd-4693-ae9c-59907efa118c" xlink:to="loc_srt_ScenarioForecastMember_0cbe1aa2-a07f-4d8a-a1b3-1dc23c599f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7ec86da2-576f-494f-bfc4-03ea0bc81385" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_f23ed0fa-97ae-440d-babf-e6c6ae5a6e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_LitigationReserve_f23ed0fa-97ae-440d-babf-e6c6ae5a6e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_04986809-728c-4ffe-a233-5d7fca68db2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_04986809-728c-4ffe-a233-5d7fca68db2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e34ce24a-bbac-4149-89a6-bdc304d03bc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e34ce24a-bbac-4149-89a6-bdc304d03bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b08cd7f6-2108-4afe-9583-2fb06540db4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b08cd7f6-2108-4afe-9583-2fb06540db4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ab6c138c-df88-45f2-9473-1d36e896087a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ab6c138c-df88-45f2-9473-1d36e896087a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_10cac8ab-4374-4d7f-9cfa-f05ef1331959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_10cac8ab-4374-4d7f-9cfa-f05ef1331959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_5a2b9cbd-6c92-4e41-bcbc-bad08fffbace" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_OpenTaxYear_5a2b9cbd-6c92-4e41-bcbc-bad08fffbace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_cd5d6157-4821-4ba1-84c9-6c6582995bb6" xlink:href="cah-20201231.xsd#cah_IndemnificationReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_cah_IndemnificationReceivable_cd5d6157-4821-4ba1-84c9-6c6582995bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ed4cf63-ba29-49cf-acad-bfceff5fad28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ed4cf63-ba29-49cf-acad-bfceff5fad28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_a97f1439-62f4-4c16-acbf-68fe9c61e366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_LitigationSettlementExpense_a97f1439-62f4-4c16-acbf-68fe9c61e366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8c33e9c5-4232-43f2-832d-f27726ff3649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8c33e9c5-4232-43f2-832d-f27726ff3649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_25135d1a-886e-47e5-aa54-420fca8a86b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_aa0dc773-5330-432c-970f-3db9505727f7" xlink:to="loc_us-gaap_IncomeTaxReceivable_25135d1a-886e-47e5-aa54-420fca8a86b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20201231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_367143bb-e5d3-46bb-a132-c4f00305b721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_daa48335-dd42-4578-837c-e84dedbad7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_367143bb-e5d3-46bb-a132-c4f00305b721" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_daa48335-dd42-4578-837c-e84dedbad7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20201231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0f217242-ac17-4e9c-899b-d60c6ef90031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0362cf43-43e9-4674-81d2-a83720fc79a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0f217242-ac17-4e9c-899b-d60c6ef90031" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0362cf43-43e9-4674-81d2-a83720fc79a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a4df67d4-40d4-46c6-a4a8-57ef1a9c9739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_90c8aeae-ff7b-4f6d-8355-8d13bf1447dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a4df67d4-40d4-46c6-a4a8-57ef1a9c9739" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_90c8aeae-ff7b-4f6d-8355-8d13bf1447dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0bfb8ff7-e5d3-46bf-a7c4-ff847edff2b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_90c8aeae-ff7b-4f6d-8355-8d13bf1447dc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0bfb8ff7-e5d3-46bf-a7c4-ff847edff2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3a58c44c-85b7-49fc-8223-3458b0cbe650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0bfb8ff7-e5d3-46bf-a7c4-ff847edff2b8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3a58c44c-85b7-49fc-8223-3458b0cbe650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b90c8b4a-dc25-43a9-b0af-4175b5a8cc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3a58c44c-85b7-49fc-8223-3458b0cbe650" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b90c8b4a-dc25-43a9-b0af-4175b5a8cc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d00e7644-dd35-4c94-b2c6-0d81a039c3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_90c8aeae-ff7b-4f6d-8355-8d13bf1447dc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d00e7644-dd35-4c94-b2c6-0d81a039c3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_00afc706-3b81-484b-9488-f6732933aaae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d00e7644-dd35-4c94-b2c6-0d81a039c3b4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_00afc706-3b81-484b-9488-f6732933aaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_60be4cd9-cdcc-448e-ba2d-8324e737c505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_00afc706-3b81-484b-9488-f6732933aaae" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_60be4cd9-cdcc-448e-ba2d-8324e737c505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1a104975-4ee6-4518-b44b-2ccb1952c5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_00afc706-3b81-484b-9488-f6732933aaae" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1a104975-4ee6-4518-b44b-2ccb1952c5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4c8261ff-6b16-4ae6-9564-d093b79d9822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_00afc706-3b81-484b-9488-f6732933aaae" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4c8261ff-6b16-4ae6-9564-d093b79d9822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24dcedc2-b99d-4be8-9ecb-f4acc61ce769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_90c8aeae-ff7b-4f6d-8355-8d13bf1447dc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24dcedc2-b99d-4be8-9ecb-f4acc61ce769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9068d72-9c69-44b8-b04a-ba0b3de69f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24dcedc2-b99d-4be8-9ecb-f4acc61ce769" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9068d72-9c69-44b8-b04a-ba0b3de69f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a2b86b01-ea7d-4902-9145-3af49a5eaece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9068d72-9c69-44b8-b04a-ba0b3de69f16" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a2b86b01-ea7d-4902-9145-3af49a5eaece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_58113f82-d7cc-47bf-a453-5aec6422a7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9068d72-9c69-44b8-b04a-ba0b3de69f16" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_58113f82-d7cc-47bf-a453-5aec6422a7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_c2ba3ece-559b-4ef6-a050-39b259cfab6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b9068d72-9c69-44b8-b04a-ba0b3de69f16" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_c2ba3ece-559b-4ef6-a050-39b259cfab6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_8512f008-a128-4176-81f4-e1fbe821335f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24dcedc2-b99d-4be8-9ecb-f4acc61ce769" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_8512f008-a128-4176-81f4-e1fbe821335f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20201231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_65b3863c-f9a3-4e2e-b7d2-406fde589e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2796cf25-0801-43be-837d-8005a80d470c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_65b3863c-f9a3-4e2e-b7d2-406fde589e47" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2796cf25-0801-43be-837d-8005a80d470c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20201231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_246449fe-3bea-4b16-af78-b1e491652a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_b56d5991-448f-4036-9570-e35433bb3267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_246449fe-3bea-4b16-af78-b1e491652a4a" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_b56d5991-448f-4036-9570-e35433bb3267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0cb6c484-b570-481e-9d09-f9911d5791c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0cb6c484-b570-481e-9d09-f9911d5791c3" xlink:to="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_76605c40-3b33-4b92-b17f-266acf05b705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_76605c40-3b33-4b92-b17f-266acf05b705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_63653785-3c02-4c8e-b41f-a8f9098e116a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_76605c40-3b33-4b92-b17f-266acf05b705" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_63653785-3c02-4c8e-b41f-a8f9098e116a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_a98d3b47-0193-4eb6-a041-3fb9ca5596ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_63653785-3c02-4c8e-b41f-a8f9098e116a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_a98d3b47-0193-4eb6-a041-3fb9ca5596ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fee8686-657a-4ccf-abb3-c3953b480efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fee8686-657a-4ccf-abb3-c3953b480efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8c6aea07-eb3c-4ac1-ba2c-f509f2d2b3c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fee8686-657a-4ccf-abb3-c3953b480efa" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8c6aea07-eb3c-4ac1-ba2c-f509f2d2b3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ac443bf6-53cd-4b94-8ee3-a0a6c45ade65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8c6aea07-eb3c-4ac1-ba2c-f509f2d2b3c8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ac443bf6-53cd-4b94-8ee3-a0a6c45ade65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_769f89db-3024-48ef-82c5-6f6022f95304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:to="loc_us-gaap_HedgingDesignationAxis_769f89db-3024-48ef-82c5-6f6022f95304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0b5f79a0-c291-4392-8dbb-55c78f52b634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_769f89db-3024-48ef-82c5-6f6022f95304" xlink:to="loc_us-gaap_HedgingDesignationDomain_0b5f79a0-c291-4392-8dbb-55c78f52b634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_26bb7a9f-d090-405b-a1c2-3d0d42ce85e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_0b5f79a0-c291-4392-8dbb-55c78f52b634" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_26bb7a9f-d090-405b-a1c2-3d0d42ce85e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5dc6d181-f364-4a14-8563-b121676189ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_0b5f79a0-c291-4392-8dbb-55c78f52b634" xlink:to="loc_us-gaap_NondesignatedMember_5dc6d181-f364-4a14-8563-b121676189ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e2febfb8-19c6-4046-bb75-02a9f85ae5f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e2febfb8-19c6-4046-bb75-02a9f85ae5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_31008797-ac06-4e7d-a2d6-9dca64881d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e2febfb8-19c6-4046-bb75-02a9f85ae5f4" xlink:to="loc_us-gaap_HedgingRelationshipDomain_31008797-ac06-4e7d-a2d6-9dca64881d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_840a39dc-6e02-4a8f-b059-12c7c45860b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_31008797-ac06-4e7d-a2d6-9dca64881d06" xlink:to="loc_us-gaap_FairValueHedgingMember_840a39dc-6e02-4a8f-b059-12c7c45860b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cd8ccc6a-43ea-487b-a67d-8caf9bc81683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cd8ccc6a-43ea-487b-a67d-8caf9bc81683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0c438365-4788-44bc-8d06-736833855148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cd8ccc6a-43ea-487b-a67d-8caf9bc81683" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0c438365-4788-44bc-8d06-736833855148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_23a53e0f-ded2-497b-9b37-13f24ff6175d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c438365-4788-44bc-8d06-736833855148" xlink:to="loc_us-gaap_CashFlowHedgingMember_23a53e0f-ded2-497b-9b37-13f24ff6175d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5bcb88f4-3024-411a-a174-f4d2d33068e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c438365-4788-44bc-8d06-736833855148" xlink:to="loc_us-gaap_InterestRateSwapMember_5bcb88f4-3024-411a-a174-f4d2d33068e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_5ab7eb9e-02d9-4dcc-ace2-e7aa15724b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c438365-4788-44bc-8d06-736833855148" xlink:to="loc_us-gaap_CurrencySwapMember_5ab7eb9e-02d9-4dcc-ace2-e7aa15724b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a3a8fe01-3fdc-485c-a24e-13df4cdf62ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c438365-4788-44bc-8d06-736833855148" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a3a8fe01-3fdc-485c-a24e-13df4cdf62ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dfc55ea0-77f4-4f1b-a331-bb7de1eb778c" xlink:to="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_5cfb9692-552c-45d4-afe2-44d04e3cbea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_5cfb9692-552c-45d4-afe2-44d04e3cbea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_991a3364-10de-49e6-9c93-ba4d70634421" xlink:href="cah-20201231.xsd#cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_991a3364-10de-49e6-9c93-ba4d70634421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_e24f7918-639d-494a-9ea5-242fd9d2c1af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_e24f7918-639d-494a-9ea5-242fd9d2c1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_0c33c237-1838-41ab-93a5-099d67c38cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_0c33c237-1838-41ab-93a5-099d67c38cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b5e85ab4-5d00-4a1c-84fe-bbf61a035226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b5e85ab4-5d00-4a1c-84fe-bbf61a035226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_3e0c900d-c096-445a-b862-538b6799536c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_3e0c900d-c096-445a-b862-538b6799536c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_97896363-5adc-48b8-bfbc-8bebe3d3cd1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f4a004e4-4323-497e-9515-f496a27be470" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_97896363-5adc-48b8-bfbc-8bebe3d3cd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a10e1a30-7eaf-463b-bcba-fd6faef07c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3802f513-5bd8-49ca-87b2-e53a7df0b99a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a10e1a30-7eaf-463b-bcba-fd6faef07c09" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3802f513-5bd8-49ca-87b2-e53a7df0b99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94175aae-439e-48d8-bbde-de723a3a59d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3802f513-5bd8-49ca-87b2-e53a7df0b99a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94175aae-439e-48d8-bbde-de723a3a59d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b0c967f-d2b5-4141-b3c0-1ce3d6fddd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_94175aae-439e-48d8-bbde-de723a3a59d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b0c967f-d2b5-4141-b3c0-1ce3d6fddd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_44b496c5-26ae-4a10-9338-02ee281dcfb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b0c967f-d2b5-4141-b3c0-1ce3d6fddd2a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_44b496c5-26ae-4a10-9338-02ee281dcfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10ea53ee-a41b-492e-a6ec-8ee72fa12c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3802f513-5bd8-49ca-87b2-e53a7df0b99a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10ea53ee-a41b-492e-a6ec-8ee72fa12c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_d66bcc5c-8cf2-495e-b1e6-5b42ca69c3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10ea53ee-a41b-492e-a6ec-8ee72fa12c6f" xlink:to="loc_us-gaap_DebtInstrumentFairValue_d66bcc5c-8cf2-495e-b1e6-5b42ca69c3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_017c99af-33c7-4de5-b37b-40bb2c000044" xlink:href="cah-20201231.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10ea53ee-a41b-492e-a6ec-8ee72fa12c6f" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_017c99af-33c7-4de5-b37b-40bb2c000044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9ba34f55-eb8f-4bb4-a376-bdff4faafb44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_52912de4-754d-491d-9410-4f3b71b349bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9ba34f55-eb8f-4bb4-a376-bdff4faafb44" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_52912de4-754d-491d-9410-4f3b71b349bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_47e021bb-2dfa-4b96-b2f0-5044cbda3c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d408c897-860c-4b22-aca8-9f92d94d5b45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_47e021bb-2dfa-4b96-b2f0-5044cbda3c2f" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d408c897-860c-4b22-aca8-9f92d94d5b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fe31ba0d-59e3-4daf-a38c-03c1d9f94bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e9e7b0ad-4a0d-4a80-b529-e784c7cbb6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fe31ba0d-59e3-4daf-a38c-03c1d9f94bb4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e9e7b0ad-4a0d-4a80-b529-e784c7cbb6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cb7ef88b-35be-43a2-848e-6199504ea858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9e7b0ad-4a0d-4a80-b529-e784c7cbb6f5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cb7ef88b-35be-43a2-848e-6199504ea858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ef38c985-c98a-4d5b-ba7c-c5aa5b750d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cb7ef88b-35be-43a2-848e-6199504ea858" xlink:to="loc_us-gaap_EquityComponentDomain_ef38c985-c98a-4d5b-ba7c-c5aa5b750d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_346f2b04-a40f-482a-a6a2-9582ba014977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ef38c985-c98a-4d5b-ba7c-c5aa5b750d7b" xlink:to="loc_us-gaap_TreasuryStockMember_346f2b04-a40f-482a-a6a2-9582ba014977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3a6ddd17-53f6-4574-a178-90a9f1254dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9e7b0ad-4a0d-4a80-b529-e784c7cbb6f5" xlink:to="loc_us-gaap_ClassOfStockLineItems_3a6ddd17-53f6-4574-a178-90a9f1254dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_87c88711-60e3-4dfb-9f0e-68ec0f979869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3a6ddd17-53f6-4574-a178-90a9f1254dd1" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_87c88711-60e3-4dfb-9f0e-68ec0f979869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2c7b4c4a-97c0-4a20-9724-0957d63d216c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3a6ddd17-53f6-4574-a178-90a9f1254dd1" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2c7b4c4a-97c0-4a20-9724-0957d63d216c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_69ce5025-f9c0-48eb-ae81-56c76608cb4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3a6ddd17-53f6-4574-a178-90a9f1254dd1" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_69ce5025-f9c0-48eb-ae81-56c76608cb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TreasuryStockAcquiredShares_ba66d9d1-20e3-4351-abab-7234f5b06332" xlink:href="cah-20201231.xsd#cah_TreasuryStockAcquiredShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3a6ddd17-53f6-4574-a178-90a9f1254dd1" xlink:to="loc_cah_TreasuryStockAcquiredShares_ba66d9d1-20e3-4351-abab-7234f5b06332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e0e3a30a-5b8b-4252-bcfc-bfeb762dcf15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_14161c0e-f478-4aa6-b459-d8ddbe077c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e0e3a30a-5b8b-4252-bcfc-bfeb762dcf15" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_14161c0e-f478-4aa6-b459-d8ddbe077c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e54e3acd-c2ba-4299-a584-d119f22a2c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_14161c0e-f478-4aa6-b459-d8ddbe077c9c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e54e3acd-c2ba-4299-a584-d119f22a2c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e51dd659-1890-4f14-b760-63a03695af3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e54e3acd-c2ba-4299-a584-d119f22a2c59" xlink:to="loc_us-gaap_EquityComponentDomain_e51dd659-1890-4f14-b760-63a03695af3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_7bea01f1-91fa-470b-a114-95c2535c03d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e51dd659-1890-4f14-b760-63a03695af3c" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_7bea01f1-91fa-470b-a114-95c2535c03d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_ecb8d374-9ca1-45bd-ade6-8d0f42dc9960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e51dd659-1890-4f14-b760-63a03695af3c" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_ecb8d374-9ca1-45bd-ade6-8d0f42dc9960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6ce12696-efb7-4b5d-ae87-fb1db6d63517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e51dd659-1890-4f14-b760-63a03695af3c" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6ce12696-efb7-4b5d-ae87-fb1db6d63517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e039e602-f5f1-482a-bf0b-bba3e3b1e438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e51dd659-1890-4f14-b760-63a03695af3c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e039e602-f5f1-482a-bf0b-bba3e3b1e438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_9a4bd75b-5eb8-4500-9489-3c233eea2cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_14161c0e-f478-4aa6-b459-d8ddbe077c9c" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_9a4bd75b-5eb8-4500-9489-3c233eea2cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d7d90dc8-ed06-42e4-99a8-43d3969118e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_9a4bd75b-5eb8-4500-9489-3c233eea2cdd" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d7d90dc8-ed06-42e4-99a8-43d3969118e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cac3c361-ff8d-46ee-ad26-09b0ff09194e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d7d90dc8-ed06-42e4-99a8-43d3969118e7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cac3c361-ff8d-46ee-ad26-09b0ff09194e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2b71ba5c-831f-46d9-a096-29a4f1b2f782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d7d90dc8-ed06-42e4-99a8-43d3969118e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2b71ba5c-831f-46d9-a096-29a4f1b2f782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_35dd5e7b-f5dd-4563-9f5c-50696bdd7f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d7d90dc8-ed06-42e4-99a8-43d3969118e7" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_35dd5e7b-f5dd-4563-9f5c-50696bdd7f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7849e84f-609f-4933-b7f8-88cdf672f30f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d7d90dc8-ed06-42e4-99a8-43d3969118e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7849e84f-609f-4933-b7f8-88cdf672f30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_382515b5-a09b-47bd-be10-f955286e6f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d7d90dc8-ed06-42e4-99a8-43d3969118e7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_382515b5-a09b-47bd-be10-f955286e6f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20201231.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f5e8f856-1d85-4994-8493-645d56431505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7903a961-3ce2-42f3-bca2-ea4b0e28c672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f5e8f856-1d85-4994-8493-645d56431505" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7903a961-3ce2-42f3-bca2-ea4b0e28c672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20201231.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_392dc13b-42ce-4176-90bf-09e5f1c1110d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_2f13268e-93bb-4727-827e-ca9d1edcb152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_392dc13b-42ce-4176-90bf-09e5f1c1110d" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_2f13268e-93bb-4727-827e-ca9d1edcb152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_375c31f5-b7df-4ffa-8d41-420a36ade996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c702dafb-2df8-4de1-b0c1-69d57787983b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_375c31f5-b7df-4ffa-8d41-420a36ade996" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c702dafb-2df8-4de1-b0c1-69d57787983b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_a2d506ee-73a6-4b0f-9e0d-bf3ba328c774" xlink:href="cah-20201231.xsd#cah_Sharesthatwouldbeantidilutiveasaresultofnetloss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_375c31f5-b7df-4ffa-8d41-420a36ade996" xlink:to="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_a2d506ee-73a6-4b0f-9e0d-bf3ba328c774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0498ad75-3e9a-4978-bb3d-f2584c88b17f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_55a4cd54-84f4-44f4-b6f8-89cd5068cfdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0498ad75-3e9a-4978-bb3d-f2584c88b17f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_55a4cd54-84f4-44f4-b6f8-89cd5068cfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_10dc9b68-eff7-44e7-992d-a9b09c2cbef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0498ad75-3e9a-4978-bb3d-f2584c88b17f" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_10dc9b68-eff7-44e7-992d-a9b09c2cbef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5509547c-4813-4d57-9bfb-02981e23a5dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_10dc9b68-eff7-44e7-992d-a9b09c2cbef0" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5509547c-4813-4d57-9bfb-02981e23a5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d4344f2-f831-4b8a-a04b-b71be9b9bfb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0498ad75-3e9a-4978-bb3d-f2584c88b17f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d4344f2-f831-4b8a-a04b-b71be9b9bfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_64eb475d-1862-4d32-9cc5-d2a3c893fb53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_62799f1a-850b-4ae2-985c-082426246b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_64eb475d-1862-4d32-9cc5-d2a3c893fb53" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_62799f1a-850b-4ae2-985c-082426246b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c0b3d17b-9193-43fb-966c-b50415027945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_ed674a81-f3ea-4c3a-8963-a2ba591c86e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b3d17b-9193-43fb-966c-b50415027945" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_ed674a81-f3ea-4c3a-8963-a2ba591c86e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_1fe70515-db4e-4543-b16c-d91e3fba7fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b3d17b-9193-43fb-966c-b50415027945" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_1fe70515-db4e-4543-b16c-d91e3fba7fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_4133e643-52e3-435c-a719-522140cdba7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b3d17b-9193-43fb-966c-b50415027945" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_4133e643-52e3-435c-a719-522140cdba7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_d15130aa-c3e8-4cc9-a5ec-8507dbc8a4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c0b3d17b-9193-43fb-966c-b50415027945" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_d15130aa-c3e8-4cc9-a5ec-8507dbc8a4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a4b534de-4d2b-4c76-877c-0090d7db4dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4958e427-239f-4cee-bb80-8fadba51fa21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a4b534de-4d2b-4c76-877c-0090d7db4dbb" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4958e427-239f-4cee-bb80-8fadba51fa21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallAxis_d2e25efc-2eea-4bd9-9b28-35804b17629c" xlink:href="cah-20201231.xsd#cah_SterileSurgicalGownRecallAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4958e427-239f-4cee-bb80-8fadba51fa21" xlink:to="loc_cah_SterileSurgicalGownRecallAxis_d2e25efc-2eea-4bd9-9b28-35804b17629c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallDomain_03412e80-d084-4dd3-8962-82dd53877120" xlink:href="cah-20201231.xsd#cah_SterileSurgicalGownRecallDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SterileSurgicalGownRecallAxis_d2e25efc-2eea-4bd9-9b28-35804b17629c" xlink:to="loc_cah_SterileSurgicalGownRecallDomain_03412e80-d084-4dd3-8962-82dd53877120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallMember_1f5c5be6-95ec-426a-8744-2f50e3b63e67" xlink:href="cah-20201231.xsd#cah_SterileSurgicalGownRecallMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SterileSurgicalGownRecallDomain_03412e80-d084-4dd3-8962-82dd53877120" xlink:to="loc_cah_SterileSurgicalGownRecallMember_1f5c5be6-95ec-426a-8744-2f50e3b63e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_0cf927f5-8f91-49d4-b88a-d0629bbbe511" xlink:href="cah-20201231.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4958e427-239f-4cee-bb80-8fadba51fa21" xlink:to="loc_cah_OpioidLitigationAxis_0cf927f5-8f91-49d4-b88a-d0629bbbe511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_124afb24-606c-4db7-83ef-e770577104e7" xlink:href="cah-20201231.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_0cf927f5-8f91-49d4-b88a-d0629bbbe511" xlink:to="loc_cah_OpioidLitigationDomain_124afb24-606c-4db7-83ef-e770577104e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_37b15193-4650-49cd-8367-cc4e821fd4d5" xlink:href="cah-20201231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_124afb24-606c-4db7-83ef-e770577104e7" xlink:to="loc_cah_TotalOpioidLitigationMember_37b15193-4650-49cd-8367-cc4e821fd4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_1daa4ec4-e374-4d5a-8a72-58b158c8690d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4958e427-239f-4cee-bb80-8fadba51fa21" xlink:to="loc_srt_LitigationCaseAxis_1daa4ec4-e374-4d5a-8a72-58b158c8690d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ef59c5b6-f714-477d-9831-39197b32de9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_1daa4ec4-e374-4d5a-8a72-58b158c8690d" xlink:to="loc_srt_LitigationCaseTypeDomain_ef59c5b6-f714-477d-9831-39197b32de9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_31b06e32-44ac-4488-8b5e-20ba68fa3c24" xlink:href="cah-20201231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ef59c5b6-f714-477d-9831-39197b32de9e" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_31b06e32-44ac-4488-8b5e-20ba68fa3c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4958e427-239f-4cee-bb80-8fadba51fa21" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_455543ac-3e12-4081-a882-856aec4ca96f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_455543ac-3e12-4081-a882-856aec4ca96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRecallExpense_5ca8255d-6592-4c36-b11b-f25b69893568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRecallExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:to="loc_us-gaap_InventoryRecallExpense_5ca8255d-6592-4c36-b11b-f25b69893568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_73c7a18e-4d10-4b17-a51b-c472a7b185a9" xlink:href="cah-20201231.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_73c7a18e-4d10-4b17-a51b-c472a7b185a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_47183577-ae77-45ba-bf7e-54344354f761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:to="loc_us-gaap_NumberOfReportableSegments_47183577-ae77-45ba-bf7e-54344354f761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cab1f182-6947-413e-876b-d2461b34a36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cab1f182-6947-413e-876b-d2461b34a36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_fe2338c7-9ae7-42b9-a0cc-92d51fddbd29" xlink:href="cah-20201231.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_08e264be-d88a-469f-b244-d03f8abfea5b" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_fe2338c7-9ae7-42b9-a0cc-92d51fddbd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ff2d16fd-12dd-4c85-bd3e-bfd833d1e212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a4b534de-4d2b-4c76-877c-0090d7db4dbb" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ff2d16fd-12dd-4c85-bd3e-bfd833d1e212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_ff39ce68-1dd8-4524-83d5-e19e2c8a5880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a4b534de-4d2b-4c76-877c-0090d7db4dbb" xlink:to="loc_us-gaap_NumberOfReportableSegments_ff39ce68-1dd8-4524-83d5-e19e2c8a5880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_32cad75f-70fd-4eb7-a82a-c3ac22708a7a" xlink:href="cah-20201231.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a4b534de-4d2b-4c76-877c-0090d7db4dbb" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_32cad75f-70fd-4eb7-a82a-c3ac22708a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_42cab08e-0e29-40b2-a5ac-323adc36584f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_fddf6739-b3f9-48be-9d9b-e4158afb2614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_42cab08e-0e29-40b2-a5ac-323adc36584f" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_fddf6739-b3f9-48be-9d9b-e4158afb2614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_5907dc93-8cf3-4638-ba8e-060f0c565d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_fddf6739-b3f9-48be-9d9b-e4158afb2614" xlink:to="loc_us-gaap_SubsegmentsAxis_5907dc93-8cf3-4638-ba8e-060f0c565d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_59412381-ba36-4375-ac04-4d4ea12d7f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_5907dc93-8cf3-4638-ba8e-060f0c565d3b" xlink:to="loc_us-gaap_SubsegmentsDomain_59412381-ba36-4375-ac04-4d4ea12d7f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_6c5d3135-e005-4ee5-a8cd-ac495c7657ed" xlink:href="cah-20201231.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_59412381-ba36-4375-ac04-4d4ea12d7f1e" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_6c5d3135-e005-4ee5-a8cd-ac495c7657ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_5c9eebd5-a84c-409b-a952-c5d71891b938" xlink:href="cah-20201231.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_59412381-ba36-4375-ac04-4d4ea12d7f1e" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_5c9eebd5-a84c-409b-a952-c5d71891b938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_89bd1d17-d40f-4873-b640-4dd589d5dccc" xlink:href="cah-20201231.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_59412381-ba36-4375-ac04-4d4ea12d7f1e" xlink:to="loc_cah_MedicaldistributionandproductsMember_89bd1d17-d40f-4873-b640-4dd589d5dccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember_0ca9cae8-60ee-4468-ab6d-be384b10f157" xlink:href="cah-20201231.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_59412381-ba36-4375-ac04-4d4ea12d7f1e" xlink:to="loc_cah_CardinalHealthAtHomeMember_0ca9cae8-60ee-4468-ab6d-be384b10f157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_80f0c904-205c-4af9-899f-cdc0fb044113" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_fddf6739-b3f9-48be-9d9b-e4158afb2614" xlink:to="loc_srt_ConsolidationItemsAxis_80f0c904-205c-4af9-899f-cdc0fb044113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_0f884f0b-4c0a-4fc8-8007-b2fafc206275" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_80f0c904-205c-4af9-899f-cdc0fb044113" xlink:to="loc_srt_ConsolidationItemsDomain_0f884f0b-4c0a-4fc8-8007-b2fafc206275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d2d4e108-ef29-461a-9756-f84baabbb569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_0f884f0b-4c0a-4fc8-8007-b2fafc206275" xlink:to="loc_us-gaap_OperatingSegmentsMember_d2d4e108-ef29-461a-9756-f84baabbb569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_8ad66b48-d72a-4fc1-970c-a80de51b8f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_0f884f0b-4c0a-4fc8-8007-b2fafc206275" xlink:to="loc_us-gaap_CorporateNonSegmentMember_8ad66b48-d72a-4fc1-970c-a80de51b8f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_004f8f52-97fc-4907-808d-d9f902b74d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_fddf6739-b3f9-48be-9d9b-e4158afb2614" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_004f8f52-97fc-4907-808d-d9f902b74d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_15e98bdb-d83e-496f-85b1-4aa458fb1c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_004f8f52-97fc-4907-808d-d9f902b74d48" xlink:to="loc_us-gaap_SegmentDomain_15e98bdb-d83e-496f-85b1-4aa458fb1c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_ccceb31b-42bb-4078-83dd-77d31108e76f" xlink:href="cah-20201231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_15e98bdb-d83e-496f-85b1-4aa458fb1c2b" xlink:to="loc_cah_PharmaceuticalMember_ccceb31b-42bb-4078-83dd-77d31108e76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_258ed645-7110-48a7-b0e6-d9eabe56a36c" xlink:href="cah-20201231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_15e98bdb-d83e-496f-85b1-4aa458fb1c2b" xlink:to="loc_cah_MedicalMember_258ed645-7110-48a7-b0e6-d9eabe56a36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_6c68d173-05ea-4d31-9fc8-cbbf265c1fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_fddf6739-b3f9-48be-9d9b-e4158afb2614" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_6c68d173-05ea-4d31-9fc8-cbbf265c1fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5a266db7-9350-4733-879b-c54b835c9037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6c68d173-05ea-4d31-9fc8-cbbf265c1fec" xlink:to="loc_us-gaap_Revenues_5a266db7-9350-4733-879b-c54b835c9037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4133eade-3a9e-4fa2-bb9a-624de5c2dcb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_46a68c78-fd76-465d-9b21-29169a49a07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4133eade-3a9e-4fa2-bb9a-624de5c2dcb9" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_46a68c78-fd76-465d-9b21-29169a49a07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_249217cb-8bd9-4532-bd06-74832f1e92b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_46a68c78-fd76-465d-9b21-29169a49a07b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_249217cb-8bd9-4532-bd06-74832f1e92b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_88ea188c-6fe8-4263-acfd-8419663c8b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_249217cb-8bd9-4532-bd06-74832f1e92b6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_88ea188c-6fe8-4263-acfd-8419663c8b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_55da60d1-1ee8-44d8-abc7-2abf58106660" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_46a68c78-fd76-465d-9b21-29169a49a07b" xlink:to="loc_srt_ConsolidationItemsAxis_55da60d1-1ee8-44d8-abc7-2abf58106660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b22923ee-3408-4fbd-aacf-a6aa682c9ec2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_55da60d1-1ee8-44d8-abc7-2abf58106660" xlink:to="loc_srt_ConsolidationItemsDomain_b22923ee-3408-4fbd-aacf-a6aa682c9ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_1dca9e5d-b654-456f-b6c7-4d4724b810d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_b22923ee-3408-4fbd-aacf-a6aa682c9ec2" xlink:to="loc_us-gaap_OperatingSegmentsMember_1dca9e5d-b654-456f-b6c7-4d4724b810d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e7e969e9-206a-4fc1-8eef-376de8372679" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_b22923ee-3408-4fbd-aacf-a6aa682c9ec2" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e7e969e9-206a-4fc1-8eef-376de8372679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_328296e4-3a0a-4299-9fd7-6dfacea92ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_46a68c78-fd76-465d-9b21-29169a49a07b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_328296e4-3a0a-4299-9fd7-6dfacea92ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_794b7718-221e-48a8-8841-8ab82bd1d5dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_328296e4-3a0a-4299-9fd7-6dfacea92ce2" xlink:to="loc_us-gaap_SegmentDomain_794b7718-221e-48a8-8841-8ab82bd1d5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_e6e4a968-4131-41c3-9983-59bb659d5749" xlink:href="cah-20201231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_794b7718-221e-48a8-8841-8ab82bd1d5dd" xlink:to="loc_cah_PharmaceuticalMember_e6e4a968-4131-41c3-9983-59bb659d5749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_42763e86-bff6-4a2d-bfcf-ade70b92d641" xlink:href="cah-20201231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_794b7718-221e-48a8-8841-8ab82bd1d5dd" xlink:to="loc_cah_MedicalMember_42763e86-bff6-4a2d-bfcf-ade70b92d641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_a4d03f49-7124-4e48-927d-ad0f808b4c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_46a68c78-fd76-465d-9b21-29169a49a07b" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_a4d03f49-7124-4e48-927d-ad0f808b4c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d8d225e5-1674-4590-855d-00feef9626a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_a4d03f49-7124-4e48-927d-ad0f808b4c88" xlink:to="loc_us-gaap_OperatingIncomeLoss_d8d225e5-1674-4590-855d-00feef9626a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d0d13712-8a4d-49a0-8b3d-a179c8e75185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_f124fa53-9fac-4352-bf1b-6ffca2f4dbc5" xlink:href="cah-20201231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d0d13712-8a4d-49a0-8b3d-a179c8e75185" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_f124fa53-9fac-4352-bf1b-6ffca2f4dbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_7401b809-3b63-4934-8a87-315ba08058ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_f124fa53-9fac-4352-bf1b-6ffca2f4dbc5" xlink:to="loc_srt_ConsolidationItemsAxis_7401b809-3b63-4934-8a87-315ba08058ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_57daead9-58d5-4ec0-8518-f3ee4de07c85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_7401b809-3b63-4934-8a87-315ba08058ea" xlink:to="loc_srt_ConsolidationItemsDomain_57daead9-58d5-4ec0-8518-f3ee4de07c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4c3f42f7-b701-419a-a45a-ff6c7c6633d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_57daead9-58d5-4ec0-8518-f3ee4de07c85" xlink:to="loc_us-gaap_OperatingSegmentsMember_4c3f42f7-b701-419a-a45a-ff6c7c6633d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_37f972d4-cbe3-415c-8cb1-894410271417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_57daead9-58d5-4ec0-8518-f3ee4de07c85" xlink:to="loc_us-gaap_CorporateNonSegmentMember_37f972d4-cbe3-415c-8cb1-894410271417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_21982595-9d9c-4f3a-8ac4-b34f58cadb65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_f124fa53-9fac-4352-bf1b-6ffca2f4dbc5" xlink:to="loc_srt_StatementGeographicalAxis_21982595-9d9c-4f3a-8ac4-b34f58cadb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4c8b5180-8125-48a5-b8a7-0f6f1f858e05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_21982595-9d9c-4f3a-8ac4-b34f58cadb65" xlink:to="loc_srt_SegmentGeographicalDomain_4c8b5180-8125-48a5-b8a7-0f6f1f858e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_632e9983-9501-4618-9f70-7ce718ee227d" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4c8b5180-8125-48a5-b8a7-0f6f1f858e05" xlink:to="loc_country_US_632e9983-9501-4618-9f70-7ce718ee227d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_609d36fc-fd70-4dba-a9d6-e9db9ec26538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4c8b5180-8125-48a5-b8a7-0f6f1f858e05" xlink:to="loc_us-gaap_NonUsMember_609d36fc-fd70-4dba-a9d6-e9db9ec26538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_13650887-ace5-49a0-9524-bbdf8ba98f3c" xlink:href="cah-20201231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_f124fa53-9fac-4352-bf1b-6ffca2f4dbc5" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_13650887-ace5-49a0-9524-bbdf8ba98f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c39f78c4-6ce6-4bc9-b501-2c736e20c4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_13650887-ace5-49a0-9524-bbdf8ba98f3c" xlink:to="loc_us-gaap_Revenues_c39f78c4-6ce6-4bc9-b501-2c736e20c4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b455777d-4260-4dec-8408-f2e0e1a01b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6193001b-d7a4-47e9-8490-9c5e73d34669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b455777d-4260-4dec-8408-f2e0e1a01b34" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6193001b-d7a4-47e9-8490-9c5e73d34669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f18703e7-5192-49df-aa24-7547952a53b2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6193001b-d7a4-47e9-8490-9c5e73d34669" xlink:to="loc_srt_ConsolidationItemsAxis_f18703e7-5192-49df-aa24-7547952a53b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_848d4559-ec70-4dc4-b764-d0ee4e8dec65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_f18703e7-5192-49df-aa24-7547952a53b2" xlink:to="loc_srt_ConsolidationItemsDomain_848d4559-ec70-4dc4-b764-d0ee4e8dec65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f7683759-c435-4754-a6b6-ac4541f34096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_848d4559-ec70-4dc4-b764-d0ee4e8dec65" xlink:to="loc_us-gaap_OperatingSegmentsMember_f7683759-c435-4754-a6b6-ac4541f34096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_5def9d32-b302-43a7-b82c-68336f79fe35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_848d4559-ec70-4dc4-b764-d0ee4e8dec65" xlink:to="loc_us-gaap_CorporateNonSegmentMember_5def9d32-b302-43a7-b82c-68336f79fe35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ce44e7e9-9b77-4ceb-a4b0-1434bdf5bcc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6193001b-d7a4-47e9-8490-9c5e73d34669" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ce44e7e9-9b77-4ceb-a4b0-1434bdf5bcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cf74f607-beed-475a-930f-24be8ff109e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ce44e7e9-9b77-4ceb-a4b0-1434bdf5bcc2" xlink:to="loc_us-gaap_SegmentDomain_cf74f607-beed-475a-930f-24be8ff109e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_594e74c9-253b-4a23-9665-9b61425c26a1" xlink:href="cah-20201231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cf74f607-beed-475a-930f-24be8ff109e8" xlink:to="loc_cah_PharmaceuticalMember_594e74c9-253b-4a23-9665-9b61425c26a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_8b10ffc0-327e-4b46-a397-3f01183df906" xlink:href="cah-20201231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cf74f607-beed-475a-930f-24be8ff109e8" xlink:to="loc_cah_MedicalMember_8b10ffc0-327e-4b46-a397-3f01183df906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_748365ea-b8fe-426b-acc1-e571d8a96ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6193001b-d7a4-47e9-8490-9c5e73d34669" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_748365ea-b8fe-426b-acc1-e571d8a96ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_be5d3d82-e591-486c-bcd0-42d11172a435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_748365ea-b8fe-426b-acc1-e571d8a96ea9" xlink:to="loc_us-gaap_Assets_be5d3d82-e591-486c-bcd0-42d11172a435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ad2bdf1-23a0-4a95-8f49-304acf90fda3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e0400223-7dc8-45c6-bc78-f5ce688382af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ad2bdf1-23a0-4a95-8f49-304acf90fda3" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e0400223-7dc8-45c6-bc78-f5ce688382af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_982f7ac5-8957-45a3-a155-7b8eb1e881d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_f105acb1-1046-4e55-8a2d-17a54a59ad60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_982f7ac5-8957-45a3-a155-7b8eb1e881d0" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_f105acb1-1046-4e55-8a2d-17a54a59ad60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_498950d8-8461-4adf-ab5e-f46651a81be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_982f7ac5-8957-45a3-a155-7b8eb1e881d0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_498950d8-8461-4adf-ab5e-f46651a81be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AdditionalStockOptionPlanDataTableTextBlock_514557f2-4ec7-4ef0-8611-7cdce49d23ab" xlink:href="cah-20201231.xsd#cah_AdditionalStockOptionPlanDataTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_982f7ac5-8957-45a3-a155-7b8eb1e881d0" xlink:to="loc_cah_AdditionalStockOptionPlanDataTableTextBlock_514557f2-4ec7-4ef0-8611-7cdce49d23ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_791e7003-c4bf-4048-b804-e52dab20f90a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_982f7ac5-8957-45a3-a155-7b8eb1e881d0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_791e7003-c4bf-4048-b804-e52dab20f90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_738a58b9-e756-416c-9644-883b73588102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_982f7ac5-8957-45a3-a155-7b8eb1e881d0" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_738a58b9-e756-416c-9644-883b73588102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a950880c-958d-434c-83ee-96f0b30d033f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d568400-c84a-45ff-b5d6-0ffd455a68cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a950880c-958d-434c-83ee-96f0b30d033f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d568400-c84a-45ff-b5d6-0ffd455a68cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1b446e21-ecbf-4362-9fef-1c2f11d78093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d568400-c84a-45ff-b5d6-0ffd455a68cd" xlink:to="loc_us-gaap_AwardTypeAxis_1b446e21-ecbf-4362-9fef-1c2f11d78093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bc96c5d-dcee-45aa-8ac1-7cec41f64975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1b446e21-ecbf-4362-9fef-1c2f11d78093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bc96c5d-dcee-45aa-8ac1-7cec41f64975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b0a32cee-bd23-4156-bbf0-3006940b6a03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bc96c5d-dcee-45aa-8ac1-7cec41f64975" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b0a32cee-bd23-4156-bbf0-3006940b6a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8fa14ad3-cd55-4ceb-ba08-7b02946ed2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bc96c5d-dcee-45aa-8ac1-7cec41f64975" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8fa14ad3-cd55-4ceb-ba08-7b02946ed2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4a7aec2e-68d3-4d23-be10-84fc8fad13a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bc96c5d-dcee-45aa-8ac1-7cec41f64975" xlink:to="loc_us-gaap_PerformanceSharesMember_4a7aec2e-68d3-4d23-be10-84fc8fad13a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb7ac1a3-39cc-4338-944f-0b7a305a3cdd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d568400-c84a-45ff-b5d6-0ffd455a68cd" xlink:to="loc_srt_RangeAxis_cb7ac1a3-39cc-4338-944f-0b7a305a3cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b9b78ab9-dfaf-4d7e-8e25-67df49dc0217" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cb7ac1a3-39cc-4338-944f-0b7a305a3cdd" xlink:to="loc_srt_RangeMember_b9b78ab9-dfaf-4d7e-8e25-67df49dc0217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_266c0723-c3f0-4fc0-bf8a-7ed303a6bd8e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b9b78ab9-dfaf-4d7e-8e25-67df49dc0217" xlink:to="loc_srt_MinimumMember_266c0723-c3f0-4fc0-bf8a-7ed303a6bd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e876c279-d234-4ee7-98f8-626d7fa3c728" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b9b78ab9-dfaf-4d7e-8e25-67df49dc0217" xlink:to="loc_srt_MaximumMember_e876c279-d234-4ee7-98f8-626d7fa3c728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d568400-c84a-45ff-b5d6-0ffd455a68cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_c25ed4dd-544d-43fd-8155-27e479e48e4b" xlink:href="cah-20201231.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_cah_VestingPeriodinyearsforShares_c25ed4dd-544d-43fd-8155-27e479e48e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_66e81a5a-7d19-4e05-a90c-c91b08f635fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_66e81a5a-7d19-4e05-a90c-c91b08f635fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25af8b11-c5f7-4c55-b420-cef658299bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25af8b11-c5f7-4c55-b420-cef658299bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6c546d2b-9e91-4230-a29a-965320b817d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6c546d2b-9e91-4230-a29a-965320b817d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c013562c-6398-4bf1-8946-d49cd9f94fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c013562c-6398-4bf1-8946-d49cd9f94fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears_b1b2cf7d-0c36-4d2a-8b22-6408183134e6" xlink:href="cah-20201231.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_cah_ExercisablePeriodOfPlansInYears_b1b2cf7d-0c36-4d2a-8b22-6408183134e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d57eaf83-2519-45c3-924f-9cc989dbddd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_277a05fa-d970-46c0-853f-4befe9ba359f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d57eaf83-2519-45c3-924f-9cc989dbddd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eb4a0480-5897-4728-bd88-7adee84d0d49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6512ab4-4bc2-4e77-92d8-919f6fd5269b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eb4a0480-5897-4728-bd88-7adee84d0d49" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6512ab4-4bc2-4e77-92d8-919f6fd5269b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d1ee8413-326d-4f38-b1e4-4159974be8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6512ab4-4bc2-4e77-92d8-919f6fd5269b" xlink:to="loc_us-gaap_AwardTypeAxis_d1ee8413-326d-4f38-b1e4-4159974be8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84084441-6b65-4265-8045-d9ccbd406ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d1ee8413-326d-4f38-b1e4-4159974be8d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84084441-6b65-4265-8045-d9ccbd406ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f3d06c01-1c2e-4050-983c-2b34a7b59cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84084441-6b65-4265-8045-d9ccbd406ea1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f3d06c01-1c2e-4050-983c-2b34a7b59cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f853f077-6be9-4151-8a5c-3adf6802a9a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84084441-6b65-4265-8045-d9ccbd406ea1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f853f077-6be9-4151-8a5c-3adf6802a9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a0080851-a919-4e79-984e-878b751cb2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84084441-6b65-4265-8045-d9ccbd406ea1" xlink:to="loc_us-gaap_PerformanceSharesMember_a0080851-a919-4e79-984e-878b751cb2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ff30acc-7e83-4cc2-ac02-fcbc3471d227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6512ab4-4bc2-4e77-92d8-919f6fd5269b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ff30acc-7e83-4cc2-ac02-fcbc3471d227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a4d23fdc-72b3-4441-9e25-19f980e2d891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ff30acc-7e83-4cc2-ac02-fcbc3471d227" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a4d23fdc-72b3-4441-9e25-19f980e2d891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df82e864-afcb-45e4-8301-507c1662b376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca39290b-0014-49f6-9d38-08db3855b09f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df82e864-afcb-45e4-8301-507c1662b376" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca39290b-0014-49f6-9d38-08db3855b09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3419542e-13a2-4dbd-8fe5-05d670ab4eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca39290b-0014-49f6-9d38-08db3855b09f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3419542e-13a2-4dbd-8fe5-05d670ab4eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5d9e4f18-2567-4806-bdc4-1af9474096bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca39290b-0014-49f6-9d38-08db3855b09f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5d9e4f18-2567-4806-bdc4-1af9474096bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_59c2163b-9f3a-4e34-872e-791445b4e0c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca39290b-0014-49f6-9d38-08db3855b09f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_59c2163b-9f3a-4e34-872e-791445b4e0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_17f06195-d70f-49ec-a47b-cdb0ce5e89c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca39290b-0014-49f6-9d38-08db3855b09f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_17f06195-d70f-49ec-a47b-cdb0ce5e89c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19a7751e-006c-4a02-8331-20472ab346b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca39290b-0014-49f6-9d38-08db3855b09f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19a7751e-006c-4a02-8331-20472ab346b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2f7a31f4-c3ec-4496-a3ad-3b59edc6c17a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df82e864-afcb-45e4-8301-507c1662b376" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2f7a31f4-c3ec-4496-a3ad-3b59edc6c17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2691a66e-8ba7-4a90-b74d-009e9e24a67c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df82e864-afcb-45e4-8301-507c1662b376" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2691a66e-8ba7-4a90-b74d-009e9e24a67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_04ec6ca1-fc83-4eff-a754-c6452cb8d392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2691a66e-8ba7-4a90-b74d-009e9e24a67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_04ec6ca1-fc83-4eff-a754-c6452cb8d392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d77bca11-de6f-4f8a-ae5c-6f0072dea947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2691a66e-8ba7-4a90-b74d-009e9e24a67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d77bca11-de6f-4f8a-ae5c-6f0072dea947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3ee70855-d669-4d1b-aa97-f2a71b09f2d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2691a66e-8ba7-4a90-b74d-009e9e24a67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3ee70855-d669-4d1b-aa97-f2a71b09f2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9e8ca430-310d-416c-ab76-06abc418a76e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2691a66e-8ba7-4a90-b74d-009e9e24a67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9e8ca430-310d-416c-ab76-06abc418a76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aa4d8423-ecd2-466b-8901-7c38aab8a9ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2691a66e-8ba7-4a90-b74d-009e9e24a67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aa4d8423-ecd2-466b-8901-7c38aab8a9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1106c1c7-a982-4639-b41f-830ee236a2b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2691a66e-8ba7-4a90-b74d-009e9e24a67c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1106c1c7-a982-4639-b41f-830ee236a2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c04fcbfe-ac78-4f1e-bddd-81aa417c2aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a09f2b3-4fa3-43bf-81c9-376c8437fbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c04fcbfe-ac78-4f1e-bddd-81aa417c2aab" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a09f2b3-4fa3-43bf-81c9-376c8437fbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1dbea628-284f-4606-aae5-b934f37d6dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a09f2b3-4fa3-43bf-81c9-376c8437fbf5" xlink:to="loc_us-gaap_AwardTypeAxis_1dbea628-284f-4606-aae5-b934f37d6dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbdb8b92-374e-498a-89d3-c4d1a6553ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1dbea628-284f-4606-aae5-b934f37d6dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbdb8b92-374e-498a-89d3-c4d1a6553ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e9a70202-7e54-468b-80c8-a8494a7e7afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbdb8b92-374e-498a-89d3-c4d1a6553ff9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e9a70202-7e54-468b-80c8-a8494a7e7afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a09f2b3-4fa3-43bf-81c9-376c8437fbf5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_46b953aa-be55-4d7e-b9aa-116a323de098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_46b953aa-be55-4d7e-b9aa-116a323de098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0376c80f-c248-4b54-acf6-44fc4f7f88ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0376c80f-c248-4b54-acf6-44fc4f7f88ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c276f266-123f-4b2b-a933-f1d9cc980b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c276f266-123f-4b2b-a933-f1d9cc980b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ebef7b7f-466b-4179-ae3e-b4aa7fb81a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ebef7b7f-466b-4179-ae3e-b4aa7fb81a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2ca16edf-880c-4b7f-9abe-ad07120e767c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fabd45a-dfe7-42c6-9f26-27365af0cdec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2ca16edf-880c-4b7f-9abe-ad07120e767c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c9ada0e-fb20-4fc7-a2d7-c782f1fab5a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bb81561-4e65-4547-88c8-764208fc8425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c9ada0e-fb20-4fc7-a2d7-c782f1fab5a5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bb81561-4e65-4547-88c8-764208fc8425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ea7becfe-d4eb-47a6-9136-9172d11da95f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bb81561-4e65-4547-88c8-764208fc8425" xlink:to="loc_us-gaap_AwardTypeAxis_ea7becfe-d4eb-47a6-9136-9172d11da95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87624f97-9b71-4ac5-a435-d054a6eadf8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ea7becfe-d4eb-47a6-9136-9172d11da95f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87624f97-9b71-4ac5-a435-d054a6eadf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d684f903-5a61-4846-8b62-13166cd11c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87624f97-9b71-4ac5-a435-d054a6eadf8e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d684f903-5a61-4846-8b62-13166cd11c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b1826bd1-e993-422d-844e-4a4e174fd8af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87624f97-9b71-4ac5-a435-d054a6eadf8e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b1826bd1-e993-422d-844e-4a4e174fd8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a35c354e-3d55-4a19-8546-fa94df13225e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bb81561-4e65-4547-88c8-764208fc8425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a35c354e-3d55-4a19-8546-fa94df13225e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f67d6aae-3ff7-409a-8979-b604a152bbf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a35c354e-3d55-4a19-8546-fa94df13225e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f67d6aae-3ff7-409a-8979-b604a152bbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_04bbb812-6631-474e-b71f-996a3e9f8975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a35c354e-3d55-4a19-8546-fa94df13225e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_04bbb812-6631-474e-b71f-996a3e9f8975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04b03792-7c50-4779-8bb6-3e302b80d059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a35c354e-3d55-4a19-8546-fa94df13225e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04b03792-7c50-4779-8bb6-3e302b80d059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a6db5ba-2314-45b8-8207-472dfdb46b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04b03792-7c50-4779-8bb6-3e302b80d059" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a6db5ba-2314-45b8-8207-472dfdb46b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ebda9286-bda0-4525-9b63-a8c08c688166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04b03792-7c50-4779-8bb6-3e302b80d059" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ebda9286-bda0-4525-9b63-a8c08c688166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a5b058bc-9c9e-4a69-810e-0c80cb172298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04b03792-7c50-4779-8bb6-3e302b80d059" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a5b058bc-9c9e-4a69-810e-0c80cb172298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bd9eae2f-6181-4419-9162-9cc75f124db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04b03792-7c50-4779-8bb6-3e302b80d059" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bd9eae2f-6181-4419-9162-9cc75f124db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d7dee0c-058a-4521-9cea-0e8ab307d4f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04b03792-7c50-4779-8bb6-3e302b80d059" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d7dee0c-058a-4521-9cea-0e8ab307d4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c183287-2781-4f3a-9f14-85b2bc321625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a35c354e-3d55-4a19-8546-fa94df13225e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c183287-2781-4f3a-9f14-85b2bc321625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e44247e6-8e17-48e5-97ea-d208893d176a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c183287-2781-4f3a-9f14-85b2bc321625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e44247e6-8e17-48e5-97ea-d208893d176a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1b17a31e-549f-4ffe-9bf1-a944177d512c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c183287-2781-4f3a-9f14-85b2bc321625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1b17a31e-549f-4ffe-9bf1-a944177d512c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4cb7ed11-54b1-4bba-ae00-833e2881222c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c183287-2781-4f3a-9f14-85b2bc321625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4cb7ed11-54b1-4bba-ae00-833e2881222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e8ce3583-4644-46b2-adcf-195503692a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c183287-2781-4f3a-9f14-85b2bc321625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e8ce3583-4644-46b2-adcf-195503692a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2613e007-5caf-49fe-909d-5e006075bee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8c183287-2781-4f3a-9f14-85b2bc321625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2613e007-5caf-49fe-909d-5e006075bee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20201231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04c4173c-ee27-42f1-acf0-cfedac5e2a55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e50f003-9028-473e-acdc-aab04ca1a114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04c4173c-ee27-42f1-acf0-cfedac5e2a55" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e50f003-9028-473e-acdc-aab04ca1a114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_01c4decb-2ca4-4c76-9755-4d6b7b0178e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e50f003-9028-473e-acdc-aab04ca1a114" xlink:to="loc_us-gaap_AwardTypeAxis_01c4decb-2ca4-4c76-9755-4d6b7b0178e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_073ff669-34b8-4c75-8aac-1334c384a807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_01c4decb-2ca4-4c76-9755-4d6b7b0178e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_073ff669-34b8-4c75-8aac-1334c384a807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_84756d35-2e40-4717-80ce-6738e32b8ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_073ff669-34b8-4c75-8aac-1334c384a807" xlink:to="loc_us-gaap_PerformanceSharesMember_84756d35-2e40-4717-80ce-6738e32b8ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e50f003-9028-473e-acdc-aab04ca1a114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_81156bd0-e8a8-4418-8c9f-3905151528cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_81156bd0-e8a8-4418-8c9f-3905151528cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1261bb1b-d3d4-4285-a19b-3a9e12899124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1261bb1b-d3d4-4285-a19b-3a9e12899124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ddc9cf19-0839-4621-adb4-baa91bc0e43b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1261bb1b-d3d4-4285-a19b-3a9e12899124" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ddc9cf19-0839-4621-adb4-baa91bc0e43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51801b57-af3e-4443-a62b-2648b5725321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1261bb1b-d3d4-4285-a19b-3a9e12899124" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51801b57-af3e-4443-a62b-2648b5725321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d7bc70af-0bd1-45ec-b364-5bc1c2079113" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1261bb1b-d3d4-4285-a19b-3a9e12899124" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d7bc70af-0bd1-45ec-b364-5bc1c2079113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_58d7f111-7bc4-436b-b550-e1086eb3b060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1261bb1b-d3d4-4285-a19b-3a9e12899124" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_58d7f111-7bc4-436b-b550-e1086eb3b060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd873cf3-63f6-455a-9465-c17a8e89c04e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1261bb1b-d3d4-4285-a19b-3a9e12899124" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd873cf3-63f6-455a-9465-c17a8e89c04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4430727-fa5d-4fd4-9ae1-4041f47fbc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4430727-fa5d-4fd4-9ae1-4041f47fbc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5ebb5635-06b5-4b49-b744-18b4d4e06bfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4430727-fa5d-4fd4-9ae1-4041f47fbc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5ebb5635-06b5-4b49-b744-18b4d4e06bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e3bedb53-9121-4cf8-9304-d5015e65ba9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4430727-fa5d-4fd4-9ae1-4041f47fbc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e3bedb53-9121-4cf8-9304-d5015e65ba9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e872caf6-9dda-45ab-871e-85e5f87ff5e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4430727-fa5d-4fd4-9ae1-4041f47fbc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e872caf6-9dda-45ab-871e-85e5f87ff5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab9bb91b-3f8f-4d59-baaf-8a0025fb8561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4430727-fa5d-4fd4-9ae1-4041f47fbc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab9bb91b-3f8f-4d59-baaf-8a0025fb8561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_732c5b2e-f7e8-4ae7-9f34-e588626f8755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4430727-fa5d-4fd4-9ae1-4041f47fbc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_732c5b2e-f7e8-4ae7-9f34-e588626f8755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fc253800-013b-4a02-8b58-e4961220517d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fc253800-013b-4a02-8b58-e4961220517d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5168c547-9a8e-4a5b-8f5a-bb8fe9b08cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5168c547-9a8e-4a5b-8f5a-bb8fe9b08cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_df3e0163-6e8f-4e2a-b5ae-a73219b262b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b317a38-002b-4257-a3f8-a9b7b9e2d336" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_df3e0163-6e8f-4e2a-b5ae-a73219b262b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cah-20201231_g1.jpg
<TEXT>
begin 644 cah-20201231_g1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
MD (4 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0OP"_:#TVZUGX"?'#P?XWL[*41WMWX0\36NIQ6[G)"NUM(X0G!P"1T-?AO\
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M18H+:Y=WW9^=-R1@IYG]0NIZ9INM:?-I.L:?!=VMQ&8[BVN8EDCE0]596!#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5YSX>_:__96\5V?C?4_#_P"T3X,N
M;/X:7\EC\0;Y?$5N+?PY<QEA)%>REPENRE&#!R-NTYQ7$?\ !4K]K=_V%/\
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MX2_\'3=E\.--_P""0W[&.G?!S6=1U'PA;Z?81^%=0UB%8[NZTU= MQ;2SHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ?E[_P '>^OZGH__  1PU;3K"X*1:K\0]"M;U0?]9$))9PI_X'#&
M?^ UTO[4&A:?X8_X-8;KP]I:H+>R_9%T>&(H,!@NC6HW?4]2><DUUG_!RY\
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M3E8V-E<30C/0$7.NVYQZJ1ZX /V=HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H^)_#.@>-/#6H^#O%>D
MPW^EZM8S66I6-RNZ.YMY4*21L.ZLK$$>AKY(_P"",'_!.CXP?\$N?@9XU_9=
M\9_$[1_%/@Q?B+J&L?#"XLVF^V6.DW.W%I=K)&J"0,GF$QLX+S2<X K[%HH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OBW_@EI_P3$^(7['7QS^/_
M .US^TAXXT#Q-\3?CGX^EU.6[\/^>UMI.C*[R6UA&TZ(^5:5@V% *PP#DIFO
MM*B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKAOVE_&/B
M/X?? /Q9XU\(:C]DU/3-&EGLKGR4D\N0=#M<%3]""* .YHK\N/\ AXO^V3_T
M6+_RWM._^1Z/^'B_[9/_ $6+_P M[3O_ )'H _4>BORX_P"'B_[9/_18O_+>
MT[_Y'H_X>+_MD_\ 18O_ "WM._\ D>@#]1Z*_+C_ (>+_MD_]%B_\M[3O_D>
MC_AXO^V3_P!%B_\ +>T[_P"1Z /U'HK\N/\ AXO^V3_T6+_RWM._^1Z^W?V!
M_BW\0OC5\ U\:_$WQ!_:>IG6;F W/V2*']VFS:-L2*O&3SC- 'M5%%% !111
M0 45E^(/&?AKPM+'#KNI>0TREHQY+MD#K]T&L_\ X6Y\//\ H8/_ "4F_P#B
M* .DHKF_^%N?#S_H8/\ R4F_^(H_X6Y\//\ H8/_ "4F_P#B* .DHKF_^%N?
M#S_H8/\ R4F_^(H_X6Y\//\ H8/_ "4F_P#B* .DHKF_^%N?#S_H8/\ R4F_
M^(IT7Q8\ 32K#%K^6=@JC[++R3_P"@#HJ*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KS/\ ;*_Y-9\=?]B]/_(5Z97F
M?[97_)K/CK_L7I_Y"@#\EZ*** "BBB@ HHHH *_2;_@EI_R:RG_8PWG\HZ_-
MFOTF_P""6G_)K*?]C#>?RCH ^CJ*** "BBB@#S#X_P#_ "$M._ZX2?\ H0KS
MZO0?C_\ \A+3O^N$G_H0KSZ@ HHHH **** "I]+_ .0E;_\ 7=/_ $(5!4^E
M_P#(2M_^NZ?^A"@#Z)HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BO(_P!KW]JC_AE3PII/B?\ X03^WO[4U%K7R/[4^R^5
MB,ONW>5)NZ8Q@?6O ?\ A\7_ -6Z?^7=_P#<E 'VU17Q+_P^+_ZMT_\ +N_^
MY*/^'Q?_ %;I_P"7=_\ <E 'VU17Q+_P^+_ZMT_\N[_[DH_X?%_]6Z?^7=_]
MR4 ?;5%?$O\ P^+_ .K=/_+N_P#N2C_A\7_U;I_Y=W_W)0!]M45G^$=>_P"$
MJ\*:9XG^R>1_:6G0W7D>9N\OS(U?;NP,XSC.!GTK0H **** "BBN&\3?&C_A
M'=>N=$_X1KSOL\FWS?MFW=P#TV''7UH [FBO-_\ AH/_ *E'_P G_P#[71_P
MT'_U*/\ Y/\ _P!KH ](HKS?_AH/_J4?_)__ .UT?\-!_P#4H_\ D_\ _:Z
M/2**\W_X:#_ZE'_R?_\ M='_  T'_P!2C_Y/_P#VN@#TBBN-\%_%S_A+]>31
M/^$?^S[XV;S?M>_&!GIL'\Z[*@ HHHH *\S_ &RO^36?'7_8O3_R%>F5YG^V
M5_R:SXZ_[%Z?^0H _'OXC_$OP%\(?!M[\0OB9XJM-%T73T#7>H7LFU$R0 ..
M68D@!0"22  37)_LW?M8?!+]JSP7+XU^$/BI;F.T8+J>GW86.ZL&.[:)H\G:
M&"DA@2I .#D$#S?_ (*A?"7XC_%+X Z-?_#/P4?%%UX1\;Z?X@OO">S?_;-K
M )5DMM@!,F?,!*#)8*P 9MHKP;]@+Q)^R1\4_P!G[X@Z#X1MY/ OQ)/PUO=/
M\;:E?R20QQV?ER*M\J!_*9(MZ;I-BR# SPPR ?7OPY_;)_9<^+GC^;X7?#;X
MWZ%K&O0[\:?:7))FV E_*8@+-@ D^66X!/09JQX\_:S_ &;?AA\1[+X1>/\
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M=2N++4WOM2OYVDFN9?[6O-TCLQ)9B>2237UGI?\ R$K?_KNG_H0H ^B:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y&_P""
MO/\ R2GPI_V,,G_HAJ_+G]I7]KCX&?LF^'+;Q#\8_%@M&OYA'I^FVJ"6[NOG
M579(\C*(&#,Q(  QRQ53^HW_  5Y_P"24^%/^QAD_P#1#5^ '_!7+P%XZ\(?
M&71OVEY_A<_BSP:OA*WT/4W2 2G0YDU1;DW&T@A?-0^2&. =[*6&Y00#[L\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR_\ $CX3>%'5=4\4> M8TC369]H%Q<V4T,9)/3YG'-?*7_!-']OK]F'X2?\
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M@IHWA'X?VTWFV_PX\*^:+B/2M^!YU]+)LFNY\ &151 J)@@'U_1110 4444
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M$\H_B[?Z3<:?9_$_XF>+?&F@6%S"8VATS4-9N9;0[#]U9(0DJC^[*I[U]M4
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M/C7\,_AC%;0? #2(OC+X:TC3;*_,0-YX@GM+NX:2:]9R8X&D1/L\:95=[;P
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MT;:ZV07FOW]W;OYEM))&=\$T3X#97=A@&!  /-?^"NG@3Q#^SOK'PY_X+%?
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M<U]]U\L?\%8/V</C/^TM\.?A!H/P3\&_VU=^%OVC_!7BG78O[1MK;[+I-AJ
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MK'P)I=U>0)I5E'<6L,4^HW0DCRURD5N6%QO7:99G.2Y(_-GXX:JOQ_\ V?\
M]KC]K/X3Z3)HOP<_:6^./PS\$^$KE4:S7Q%86VJVFF:UKD:\ 0WYFD@$AP9(
MX"[<G)^L_P#@MW\./V^_C]<_#7X#?L[?LDZY\4/@[=ZC/J7QOT?P[\2=(\-W
M.OP0[?L>BM/?3HZVLLFZ2X\M&,B(L89-S&CXH?##]M;_ (*$?L _$7]F+Q9_
MP3\MOV:-<\+V_AZ_^#$-_P#$+1]:L+S4--O5OK>!5THD6,$3V%M"VX8V79V
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cah-20201231_g2.jpg
<TEXT>
begin 644 cah-20201231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^SEI'Q/L_@EJWQ_\$VOC3441]/\ "-QXJLTU2Z5UW(T=JT@E<,O(*J<CD5^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9^S_ /##QY#:IXGG\&6NB66I:D][87-Y''';$QMY$%M$2Q<MEV) &TM]G_\
M!0A(I_\ @\1_9LWJKK_PB&E,,C(R$UD@_G@U^X^D:/I'A_3(=%T'2[:QL[9-
MEO:6D"Q11+_=55 "CV JS0!^./\ P>O_ /*-SX:?]EPM/_3/JM<__P '1O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1OA!H6G/<W/B(W'VJ_=4MD24R[]L E78P:.T*L" 35[5?^":?_!PA_P72_:
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MB+1M#M8M;&CZQ:K/;3W,'A;3Q TD;@J^R21)0&&-T:GG&*\<USX+_MX?#?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M +&"]_\ 2[0*\O\ ^#D3_E!I^P9_V)^B?^HS:5ZA_P '6W_)T_[!?_8P7O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M++[3--UKRX(9=L:?9HS@8!ZE2: /5J*\3_X6Y\0_^A@_\E(?_B*/^%N?$/\
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MO[)_Q6_:W_X*(_M>^$=4_:R^)'PR\+Z'\0-(N1;?"W6UTG4]2OI]'@6"6XO
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MGP[X6\)^*-.L_!%MJFGR6^H76G7%@EPEY<*YX\\.L\:A1MBE0'<?F/UKI?\
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M^"G_  3\^(GP5_9W^)7AG1OVJ=2F^,OQ8OI]5\5?&F3P[#YT>IM&L4,D%B)
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MI_\ )5 'Q917VG_PZJ\=_P#0=\"?^ NJ?_)5'_#JKQW_ -!WP)_X"ZI_\E4
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M?_CM %BBJ_\ PS+^V%_T5[P)_P"$_<__ !VC_AF7]L+_ **]X$_\)^Y_^.T
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M&Q&6Q8_ZJYNIW$"3CF+:2/O9'W)7Y^?MC^*]'_92_P""Z/[/W[4WQ7U*'2_
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M^,9])>_@L[H'4O%$3)F-Y9KJ-[>WF9"RP+(I .#7@L/_  2ZU>3_ (+(7'[
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MM/O[*=98;F"10Z2QNI*NC*0P8$@@@B@#C?V9?V9O@C^QU\#M!_9N_9Q\$_\
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M.F>+[.?5;4Q?ZT26J2&52G\0*Y7OBO1Z "BBB@ HHHH **** "BBB@ HHHH
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MI')'I4T<1=/WUQ*RZE(@<*Y\HADR<>@?\'$4,,__  19^/Z3Q*ZCPC P#KD
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MBBB@ HHHH **** "BBB@"E;>&_#MGK=QXEM-!LHM2NXUCN]0CM46>9%^ZKR
M;F [ GBKM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cah-20201231_g3.jpg
<TEXT>
begin 644 cah-20201231_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBMXR_P"$X\/VNBV7Q;%SJX;3?$EO=WUI')&+=$7RTBU VDL2EF 6$;M[A9
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M\&:3?:C8X^Q7]YIT4LUO@[AL=E+)@\\$<UK4 ?DC_P $^?\ E3LU_P#[-O\
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M!@$@'T;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH ^3_P#@N1^RQJG[9/\ P2E^-'P1\-Z8UYK3^%3K&@6T29DFOM.ECOXH8_\
M;E-MY(]?-QT-?.W_  2MT*P_X*M_\&UGAO\ 9IA^(H\/7NJ?#F\^'FJ:Q_9W
MVUM(DLI7M(F:#S8O,_T9+>0)YB_+(O(K].:\*_8<_P"">'[/O_!/*Q\>>'_V
M;GURRT/Q]XUN/%-[X=U#4$FLM,O9U"R+9(L:M#$42)=C,^!$@!X.0#Y=LO\
M@@+]C_X(A7?_  1L_P"&LMWVK6!?_P#"Q_\ A!,;<:VFJ;/[/^W<_<\K/VCO
MOQ_#7L&F?\$L_P"SO^".S?\ !)O_ (7IOW?#>;PG_P )_P#\(QC[Y8_:?L/V
MGMN_U?G]OO5];T4 ?.'_  2?_P""??\ P[ _8E\.?L<_\+;_ .$X_P"$?U#4
M;K_A(_[ _LSS_M5W+<;?L_GS[-OF;<^8<XS@9Q7'_P#!:O\ X)2?\/@_V6-
M_9H_X7U_PKO^P_B!:^)_[;_X1;^U_/\ )L;ZU^S^3]JMMN?MN_?O./*QM.[*
M_7]% 'XD_%?_ (- ?$_C#Q'IOPF\#_\ !3/QGI?P#M]675&^%]_9W-U'IMTV
M3<-91M=_9E9RS[)7C+QB3#F8J6?[8_X**?\ !$WX9_MH?\$W/!W_  35^#7Q
M/7X5>%O ^JZ7<:)?KX<_M<K!96\\(B>,W-N7>0SEWE+DE@Q()8D?;U% 'YT?
M\%(O^" W_#P?]AKX"_L7_P##6/\ PB/_  I'1[&Q_P"$D_X03[?_ &U]GTR&
MQW_9_MT/V;=Y7F8\R3&[;DXW'J/^"K?_  1._P"'G7Q4^ OQ,_X:8_X0C_A2
M.H3W7V+_ (0S^TO[:\R>PEV[_MD'V;'V'&=LF?-SCY<-]WT4 ?#'[;/_  1<
M_P"&Q?\ @J5\$_\ @I7_ ,-)_P#".?\ "G;?2XO^$+_X0[[9_:_V/4KF]S]L
M^V1_9]_VC9_J9-NS=SG:.8_X++?\&_?PQ_X*E>-_#_[1OPX^,U_\*?C#X8MH
MK>R\8:;8F>*^@AD,L"SHDD4B2Q.28[B-PZ!L%7"H$_0ZB@#\M/\ @EY_P;6Z
M=^R#^U4O[=?[:/[5^L?'3XHZ?N;P[>:M;3"#3YC&8A=RR7,\TUW.L?RQEBBQ
M9)"LP1T]D\3?\$7/^$B_X+>^'O\ @LG_ ,-)^3_8.CO8?\*X_P"$.W>?NT2Y
MTO?_ &A]L&W_ (^?-Q]G/W-F>=P^YZ* /AC]O#_@BY_PVU_P4L^!?_!1#_AI
M/_A&?^%+7&ER_P#"'_\ "'?;?[9^QZH]_C[7]LB^S[]_E_ZJ3;C=S]VO*/\
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M #SH ]$HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKY&_X*\_\ )*?"G_8PR?\
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M^$?B)^T3^T_J'C^P^'$1C\":+)II@CM2 !')(3(Y)7:AP,DF./+E4"GZ[HH
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M_P"0E;_]=T_]"% 'T31110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 45XEJG@7]O274[F72/COX(AM&G<VL4OA>1F2,L=JD[N2!@$U!
M_P (#_P4$_Z+_P"!/_"4D_\ BJ /.O\ @KS_ ,DI\*?]C#)_Z(:O@2OT1^+W
M[)?[5_QYTFTT/XK_ !5\":K:V-P9[6+^PKN#9(5*DYAE0G@D8)(K@?\ AU5X
M[_Z#O@3_ ,!=4_\ DJ@#XLHK[3_X=5>._P#H.^!/_ 75/_DJC_AU5X[_ .@[
MX$_\!=4_^2J /BRBOM/_ (=5>._^@[X$_P# 75/_ )*H_P"'57CO_H.^!/\
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MG_X[0!8HJO\ \,R_MA?]%>\"?^$_<_\ QVC_ (9E_;"_Z*]X$_\ "?N?_CM
M%BBJ_P#PS+^V%_T5[P)_X3]S_P#':/\ AF7]L+_HKW@3_P )^Y_^.T 6*GTO
M_D)6_P#UW3_T(50_X9E_;"_Z*]X$_P#"?N?_ ([2Q?LT_MBPRK-%\8/ @9&#
M*?\ A'[G@C_MI0!]+T5X7_P@/_!03_HO_@3_ ,)23_XJC_A ?^"@G_1?_ G_
M (2DG_Q5 'NE%>??!GPY^TEHFIWLOQQ^(_A[7+1X%%C%HNCM;-%)NY9B2=PQ
MQBO0: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA4OB*]81VFFZV;Z+4[.*:4_+&;G8T4>>K(W3!( /,OVOOV,_B]_P1<^%#?\
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MOBW<6FM:Q>VVL)%'/?7(0I<R;)V4N8PQ"H 0!@]*/ W[1O\ P1?_ &TO@EI
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ME_9%MJ,D6=KSQV-U+"CD$J-I&",U^EE 'Y+_ /!OM^PWXB^/7[(/P2_X*/\
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MJ_ ?]I'X8:7XO\):T@74-&U6(E&*G*R(ZD/%(IY62-E=3RK UPOQ,_X*<?\
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M/X@5RO?%>CT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[9K')?6$<K*O]@6!P"X.!FONG2M)TK0["/2M$TRWL[6+/E6UK"L<:9))PJ@
M9))^I- 'Y(^!_P!J;7O^#@SQ)\%OV/\ 6O!MWH_A7P#;0>,/VQ]%N;1XHUUW
M3[R6UL_"KJW\$]_:37;Q-S]GBB.0ZD5]I:[_ ,$X/V=&_;!^*?[?G[5]QX7\
M<V>L^#=+TCP[I7CKPU;26'@/1;"WE:^6.6Y=XREQ*[W$DACCV %<E2Q/E_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH " 1@BJ6A>'/#WA:Q.F>&=!LM.MC*TAM["U2%"['+-M0 9)Y)ZFKM% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %*V\-^';/6[CQ+::#91:E=QK'=ZA':HL\R+]U7D W,!V!/%7:** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cah-20201231_g4.jpg
<TEXT>
begin 644 cah-20201231_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*&OOG_@W-\.6'A3_ (+D?M]^$?"4$-E:Z;XPUZSTR(QEHX(X_$UXD8V@C*J
MO&1D#J* /V)^*7[8'[)7P.\31>"OC7^U'\.O!^LS1J\.D^*?&UAI]S(K?=98
MIY4<@Y&"!S79-XT\')X2_P"$^?Q9I@T+[$+S^VC?Q_9/LY7<)O.SL\O;SOSC
M'.:_FZ_::_X)W_\ !$G]E[6/C1JW_!4;_@J[J7Q=^.>O:S?7.ER?#RVE-[97
MK1LQ%Y;0?:HH[G[0S;HYYTC1$10%)-=Q_P $:OB9XV\8_P#!K-^V'X'\3Z_<
M7NG^%(/$UOX?AN92XLK>;1;:=X(\GY8_.>63:/XIG/>@#]Y;_P#:E_9DTJ_\
M/:5JG[1G@2VNO%TKQ^%+:X\7V22:TZ2&-EM%,N;DB0%"(]Q##'7BK'Q5_:._
M9Y^!-WIVG_&_X\^#/!L^L2>7I,'BKQ1::<]Z^<;85N)$,IR0,+GK7X'?\&W_
M /P0O^%W[:WP%^''_!13]HCXQ^++B]^'OQ("_#SP=;/ ^E)IVFW_ -M>"=)8
MVD99;Z:Z<K&Z*-S$AS(0.?\ ^"<'[#G@C_@X^_X*<_M-_M0_MS^-O$]YX5\%
MZO%9^']"T?4C:LD-S<WL=A;+(5;RX+>VLGRB!2\DJNQY<. ?T3VOQ0^&E]XP
M;X>67Q$T*;7U@$S:'%J\+7@B*!PYA#;]I1E;.,88'H:^$?\ @G3\%/V^O __
M  5;_:'^(W[07[;&D^./A=K=SK!\ ?#FT^*,^JS^&U?5TD@633G&RQ\NW#0D
M+]PG8.#7YP_\$B?V7]<_8J_X.I/%G[)^K_$/5O%-MX$\$7^G^']7UR?S+LZ.
M=*LYM.AD; !,5G+;Q?* H\O"JJ@*/6_^"#__ "LL?MT_]A#Q3_ZE$- '[-7_
M .T?^SQI?A;5_'&I_'GP7;:)H#JFNZQ/XIM$M=-9B0HN)3)LA)(( <C)!K6^
M&WQ3^&'QE\)P>/?A!\1]!\5Z%<LRVVM>&]8@OK24J<,%F@9D8CO@\5_-%_P0
M@_X)2_"G_@JY^TG^TEX-_:7\?^*XOAUX!\70W\OA#PWK'V./4M7O;G4HK>ZF
M;:V[R(;:Y"X (,_W@I=7^D_^#6C0/$7[)W_!5_\ :\_X)Z>'O&>H:EX+\(7>
MH+9)?39,LVF:T;"&Z* !5FD@FQ(5 R44<A5P ?O11110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <_\6/AEX2^-7PL\2_!
MOQ]8FZT+Q;X?O=%UJV!P9K2Z@>"9,\XRDC#\:_G _98_:_\ VS?^#3O]H[Q]
M^RC^TU^SOJ?COX0>+M<.H>'-:LIVLX;Z1%\N/4;&X9'A=Y+=8DGM7(=&BC^9
M=G[S^E^J/B+PQX;\7Z3)H/BWP]8ZI8S8\ZRU&T2>)\=,HX(/XB@#^7C_ (**
M_M_?MB?\'0GQD\"_LX?L;_L0:A8:%X-U&>>VF-X]Y)%+<JD;W6HW@2.VLK=5
MC&%.3G.'<LJ#ZS_X.#=$NO#7_!9;_@GIX<OI(WFT_7/#EM,\1)5FC\162DC(
M!QD<9 K]TO#/A/PKX*TA- \&^&M/TBPB),=EIEDEO"A/7"( H_*M"@#X2_X.
M-?V!?B3_ ,%#_P#@F'XC^%WP6T9]4\9^%=<L_%?AG1HB ^I36JRQ2VZ9ZR-;
M7%QL7^*0(O&[-?E'I/\ P<^^+M._X)4K_P $RV_9-\7M\>H? G_"M(+Y4 MQ
M']F_LY;DP8^T_;EAP/L_ED&8;MX!V5_2364? G@<^)QXV/@W2O[:"[1J_P#9
MT7VK;C;CS=N_&..O2@#\:OV=?@%_P4J_X(@_\&\L/B']GG]GKPYXM^)VN^+;
MCQ7\5O OBK1+G4FTO2KVV6V8);VTT;330P6UD9HCN5 ]QD$1'/YL?\% OVI/
M^"/G_!0']GGPOHO[%/\ P3?\5>#OVJ?$NHZ?#J-GX'TA;;1FN3Q=PP6=M<.E
MR)7SY02VCD^8%F7:4?\ K1K&TOX=?#[1-?F\5Z+X%T:SU2Y+?:-2M=,BCN)=
MQRVZ15#-D]<GF@#\@?\ @H'^T7_P4,_X).?\$S/V8/ /Q%_9+\#_ !?^%=AX
M%T30_P!HBR\5>'Y=8GT^2W2VWV3-YQMHXGA$ENEQ+%*BRP@D_/&&_,S]J/2/
M^">W_!2S]LKX.> ?^"!W['/Q!\!^.=1UX77C"ZN(F@LK ^;;M#=) EU<I:);
M;99))4,42@+@.3D?UD30PW,+V]Q$LD<BE71UR&!X((/45E^%_ 7@7P.LR>"O
M!>DZ.+E@UP-+TZ*W$I'0MY:C<1D]?6@#6K\0?&7_ "NT^$_^R?R?^HE>U^WU
M% '\K7_!*;]A:?P[_P '0*_LT3Z7(NA?"+XJ^)M9CBQE8;33_M#V$P4\ /(+
M#GT9?05]>?\ !&#3/B%K7_!8+_@ISHWPCO\ [+XKN]5\90^&+K>%\G46\0:B
MML^20!B4H<Y&,5^]-% '\J__  1N_;2_9$_8=^$WQ4_9Z^-W_!.WQ'\0/VNM
M;\57FG?#_P _P9#?W_VB6U2WBT\FY/G6+Q72SRRF.,NXE&=Q0 >P?\$3]7M+
M#_@W6_;Z^%VH$P:[H=KJ]QJFG2C$MNDVBK"FY>HR]I.O/>,^E?T;1^#/!\7B
M5_&<7A335UB2+RI-66QC%RR8 VF7&\C  QG'%:5 'YO?\&GD,47_  1-^'CQ
MQ*ID\1>(FD(&-Q_M6X&3ZG  _ 5^9WP?_:8^.7_!KG_P5,^.7PZ^)G[+^N>,
M_AO\7]3%QX0FTJ0V[ZG!'=7,VF2VLK(\<KHEY-;S0CYED;(/R@/_ $I5^(WQ
MX^(G_!S#_P $U/V^_B#XH^%'PP\3?M,?!KQ/J>H7'@G2KN.35+?3;6YN1<01
MXMF%U:S6R_Z/A_W++N*@Y4H >#?\$=/BM^T+\=/^#IWQ?\9OVI?A;-X(\:^*
M?!NH:G?>#[ERTNC6DVDV4EA:R%@&\Q+)K56W*K;@=R(V5'LG_!!__E98_;I_
M["'BG_U*(:]"_P""%W[ O_!0SXA_\%+OBI_P68_X*3_".'X>Z_XRT633?#GA
M Q"&8O*+:(R^09))+>&&VM$@43'S)#(6/"Y;]C* /PQ_X,Z/^2_?MM_]CAX<
M_P#2KQ'1_P $'_\ E98_;I_["'BG_P!2B&OW.HH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ')1_P /B_\ JW3_ ,N[_P"Y* /MJBOB7_A\7_U;I_Y=W_W)1_P^+_ZMT_\
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M_@I3^US:7-O97?QQABFNW9+6&30]-5IF52Q" P98A020.@!/:IO^'B_[9/\
MT6+_ ,M[3O\ Y'H _4>BORX_X>+_ +9/_18O_+>T[_Y'H_X>+_MD_P#18O\
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M2!D<JH->F4 %%%% !7F?[97_ ":SXZ_[%Z?^0KTRO,_VRO\ DUGQU_V+T_\
M(4 ?DO7QQ_P4]_;.^-'P>U ? 7]GFQM[?7+CP7=>)->\07#D/ING1LZ!K<9
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M):?\FLI_V,-Y_*.@#Z.HHHH **** /,/C_\ \A+3O^N$G_H0KSZO0?C_ /\
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M)M+_ .0E;_\ 7=/_ $(4 ?1-%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\C?\%>?^24^%/^QAD_]$-7P)7WW_P5Y_Y)3X4_
M[&&3_P!$-7P)0!^6/Q6G^-?[7W[=^N>"=._:,U/PQXDT'Q_J^B>!-#MM0DMH
M]-BM-,OI8KP!#N43O;HDDB L%F;.046OL?XY_';]HW]GKX!>#?!5GX$'CKXO
M>)X%TBUDT-";$7R1#S+V4NJ$1#B0@JJYSDHO-?)G[;4G['7[4WQXDU#PUJ%_
M\/\ QOH'B'6-+\9:SJ#1VLKMI^E7EQ;W0C65@Z>?:)%YOR2$87C,9K[/_P""
M='Q \>_%+]BOP#XX^)U]/=:U=Z9-'<W=TQ,MQ'%<S0PRNQY9GBCC8L>6+9.2
M: //_P#@CEXX\9_$/]CX^)?'OBS4=9U"3Q9?J][JEZ\\I7$1"[G)( R<#H,U
M)_P54^*GQ0\!?#CP1X/^'WQ#G\&6?C3QW::-XA\9VSF-M*M9,Y;S 08AU<L&
M4[8F&0":Y[_@BSJ^E^'_ -@R?7M;OXK2RLO$NIW%Y=3N%2&)$B9W8GH H))]
M!65_P4U^,'@[XN^$O@SX'T3XDVK?"[XC^.Q;>*_$VDW:&%[:WGB0QB?E47>9
M23T#09/"D4 :'[ GBGXD^"?VO/B/^R_+^T'JGQ0\':)H%IJ=AXBU:_-Y)9W4
MABS;>=O<<B23*AL9AR IW"OLVOA;]C?0/!W[.G_!23QA^S/^SEK\M]X O?!$
M6KZIIWV_[7'INH(T2@B7).=L@!!)/[X _=7'W30!^R?PC_Y)3X8_[%ZR_P#1
M"5T-<]\(_P#DE/AC_L7K+_T0E=#0 4444 %>&?$S_D>]2_Z[C_T$5[G7AGQ,
M_P"1[U+_ *[C_P!!% 'Q#_P6A\&>+-<^ WP[^(6G_"G5/'?A?X>?&G0?%/Q'
M\&Z-9?:[G5-!M1<"<+;?\O(CDDAF,)^5EB);"J2/+_\ @C=#^PC^T1JUI^T]
M\%?B#;'XH>&CXPTO7-"TZY6TN&T;4?$]]?6IO[1D$KA4>%HV)VH6V]1@?1W_
M  40_:T^(W[%7@/P=\<=%\$V^K>!H/'EE9?%J^_L^XN;G0M F619-2B2%@<1
M2^3O)5_E<X7/(^#?^"<WBOX._M%?M_\ P>\<?LH6<&HW_@I/BC>?&KQ=HU@T
M4$^F:GKMZVAV=S<;0MQ(S,+B.,DLL>&' (4 ](_:/^ G[0F@_P#!6S]G/]H7
M]HGXZ1:\=8^+?B/2O '@[0[0P:7X<T!-*O9(-V_YY[Z9!"T\IP R[%RBIC]+
M:^0/^"A?_)\_[&O_ &5/7/\ TP7=>_>*_P!IWX2^"_VB_"?[+&O:K=)XP\:Z
M/?ZIH%HEB[0RV]F 9V:4#:A&X8!Y/:@#X>_X*C_L0_L63O\ #S]C;X!_L??"
M[1?B/\>_%KZ</$]AX#L%O-"T.U476L:I$_E969(,(C'!WS@@AE!K] _A7\,/
M WP4^&N@_"'X9Z!%I?A[PUI,&FZ-I\.2L%O"@1%R>6. ,L<DG))))-?*GPWA
M'QD_X+D?$SQ9?CS;?X+?!+0O#VG0/RL%WK5S/?RSKZ.T-ND>1_",=S7V50!U
M?P8_Y'N#_KA)_P"@U[+7C7P8_P"1[@_ZX2?^@U[+0 4444 %>9_ME?\ )K/C
MK_L7I_Y"O3*\S_;*_P"36?'7_8O3_P A0!^2]?(__!3K]@S5/VBM#E^.'PFU
MS4;+QOHGAR?3CIVGP[QKUFVX_9&^9=K?O),-R"'((/!7ZXHH ^:O!/\ P37\
M"67[/7CCX._%3X@ZIXKUSXCWBWWBSQC<1B.XDNXV#P21(2P18G&X*2<[F!^4
MA1S?P&_X)F>-_"/Q>\+_ !/_ &BOVFM2^(4'P^A\KP+I%Q8&&.SP $D<M(Y)
M7:A '.Z-"7(4+7US10!X3IG[%,VJ3?&/2?BU\9=7\4^'OBO*OV70YXGC'AV,
M-<-MMV>:1209HR"$0 P+E2.!Y9\(_P#@ECXX\/\ CSP=<?'']J/4?&O@WX<7
M8N?!?A232_(2*12#%YK&1LJA5<+@Y"A057*G[)HH *_2;_@EI_R:RG_8PWG\
MHZ_-FOTF_P""6G_)K*?]C#>?RCH ^CJ*** "BBB@#S#X_P#_ "$M._ZX2?\
MH0KSZO0?C_\ \A+3O^N$G_H0KSZ@#XZ_:S_X(J_LA_M6?M&Z%\??$/@HV$EU
MJTT_Q-LM+UR^LD\4V_\ 9]Q;0K(EM*B"422Q[Y0%>2(2(S'?7M/QU_85_98_
M:,^#&B? +XE?"BT/AOPN]M)X2@T:>73YM!DMTV0264ULR26S(@"C8P!7@@CB
MO7** /'_ -F_]A#]F#]E'X?^(/AU\'/A]);6_BV1Y/%NIZEJMS>ZCK4CHT9:
MYO)Y&FD(5F"C< F]BH4L2>T^!?P-^%O[-7PET3X&?!3PO_8OA7PY:FVT;2_M
ML]S]GB+LY7S9W>1_F=CEF)YKK** ./\ AM\!/A-\(O%OC'QU\//"G]GZKX_U
MM-7\6W7VZ>7[?>K D"R[9798L1QHNV,*O&<9))[?2_\ D)6__7=/_0A4%3Z7
M_P A*W_Z[I_Z$* /HFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ.%%?:O_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\ 1.]"_P#!1#_\30!\L_\
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M$WC72[G4/AY'\8/!L6F0^*(K>/S9X[62*XF GCB_>O#)L8)SR>* /KBBBB@
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M96/J- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEU^V0W@G'PWD_9,@\&)XC_M*VYUQ?$\U\;3[/YGG_P#'LRR>9Y?E<[=^[Y:
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M>2TNX$EBE0I+%(H974C!!!X(([4^B@#\3M8_9<_:,\$_M1>(/^#;[P--/9_
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M^(T_AP7?Q.L+V?3K9$TZXN]Y^QR)(IS#C(#]<8[@ ^PJ*^+?@=X=_P"#@_\
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MF1[5R%F!0,NTD?>SVK]$J\0_:I_8U_X:9^-/P-^,'_"Q_P"Q/^%,?$";Q/\
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M_A/O"]SH_P#;_P#9GVS[!YHQYOD>;%YN/[N]<^HKO_A[X4_X0/P#H?@?[?\
M:_[&T>VL?M7E>7YWDQ+'OVY.W.W.,G&<9- 'P]_P<2?#J]T']B&/]OGX7Z__
M &#\4_V:]>M?&'P^\0I ),;IX;:\L)5/W[:XADQ)'T<Q(#E<@^^_\$ROV2O"
M_P"QA^QCX/\ A+HVKRZQJU]:'7O&GB>[&;G7]=O\7-]?S,<LS22N0NXDK&D:
M9.VM7_@H=^R'_P -Z_L6_$#]D'_A87_"*?\ "=:.EA_PD/\ 9/V[[#MGBEW^
M1YL7F_ZO&/,7KG/&*Z/XQ?!KQQX[_97\0_L__#7XNR^#M?U7P3/H.D^.+?2S
M<2Z3-):F!;V. 31[G3.]5\Q<,!\W% 'Q+^TKX[U#_@M;^T@W[ WP%627]GGX
M8>,[.\_:)^(Z+FU\2:E83I<P>%-.?I-B>.-[J9>(PB@,#M$OKG_!<[P5X.A_
MX)8?M'_$6+PGIJ^(+CX.7NFSZXMC&+R2SC+RQVS38WF)9)9'"$[0TC$#))KP
MO]G+_@C#_P %:?V2/@SH?[/?[.G_  7HM/"_@_PY;M#I&C6?[)7AR18@SL[L
MTDMT\DLC.S,TDC,[,Q+,2<U]O_MT_LP?\-I_L?\ Q$_91_X3C_A&O^$^\+W.
MC_V__9GVS[!YHQYOD>;%YN/[N]<^HH ZC]GO_D@?@?\ [$_3/_26.NOK'^'O
MA3_A _ .A^!_M_VO^QM'MK'[5Y7E^=Y,2Q[]N3MSMSC)QG&36Q0 4444 %%%
M% !7YF_\%.OAY^U7\3O^"SO[/_AG]CC]HC2OAAXQ_P"%)^+Y1XGUCPC%K<(M
M5O-/\V#[-*RKEB5P^<C;[U^F5>(>._V-?^$V_;^^'_[<_P#PL?[-_P (+\/]
M;\,?\(O_ &/O^W?VA/;2_:/M/G#RO+^SXV>4V[?G<N,$ S_V&/@U_P %!/A'
M_P )3_PW9^VAX?\ B]_:'V'_ (1;^POAU;Z!_9/E_:/M._R7;S_-WV^,XV>2
M<??-?!/QV_8%T37O^"]%C^RI8^-9;7X)_%ZPM_CK\2OAJ+<&UU7Q'HMQ)9JG
M7 @N;B:TNKA"")GMN>B;?UUKPCQ-^Q-_PD?_  4@\+?\%!?^%F>3_P (U\)]
M0\%?\(C_ &-N^T_:KZ*[^U_:O.&S;Y>SRO*.=V=XQ@@'9?M7_M6?!#]BCX"Z
M_P#M(_M#^+TT;PQX=MO,N90N^:YE8[8K:WC',T\KE42,<EF'0 D?F_\ $KX#
M?M*_&;]AC]L;_@JY^U7X.N?"?CKXH?LW:[X?^'7PWGR;CP9X'M[&ZNH[2ZQ@
MF]NG9KB=#_JV*KA3NC3Z:_X*J_\ !,+X]?\ !0WQU\(_&WP?_;@A^$I^$>O7
M&O:;8W?PMM?$]O>ZPPC6VO7AN[J.#?;*LOE;XY-K3LP((!&W^RQ^Q5_P4$\%
M^)_$=C^WK_P5$B_:#\!>(O!UYHLW@.?X%:/X91)KAX0;EKJQE:20"!;B$PD!
M6%SN)RBT ?//_!5*:TU#_@V!*Z$ZN]]\*/A['HA@QAKB2^T46Q0=_P!X8R !
MVZ5^FU?GC\,_^"+G[1>DO\//V<OC3^WU-XR_9L^$?BNRUSP1\-YO!,4&KWJ6
M$GFZ7INIZDLI%S:6CB/"K$OFB)0P4*FW]#J "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cah-20201231_g5.jpg
<TEXT>
begin 644 cah-20201231_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#?6DQ4X8)-"S(V#P<'BOYF?^#?;_ ()._"K_ (*O?%+X^^%OVG_'_BV+X<^
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MCX-?&3PKXMT6V9EN-8\,>(;:_M8F R0TL#LBD#DY/ K\[?V-?^"V/B_]J/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .;^,?PJ\'_';X1^*?@C\0K)KG0?&/AV]T36[=&
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M;ZB@#D/VA/\ D@?CC_L3]3_])9*_&W_@R0M;:^_9/^.EE>V\<T,WCVP26*5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEY$S037D\\T4H2(3))#%;Q(@06_!";4'LW[)O_!"[_@H3_P2,_X+0>%?'?[
M-QJ_C']GK6DM8_'FJ>(/$5A:O%I4\DD5S9W<.^,WEQ;8%U$\,(!/ECY<N" ?
MNA17R5^UQ_P6T_8"_8<_:63]E/\ :2^(.JZ%XF?P9<>)_/\ [%DDLA8Q6UW<
M8\Y3S,XLY42( L\C1H,EQ2?L??\ !:_]AC]LC]D7QK^W%X:\2ZYX-^'7P]U6
M73_%6L^/]+6R%M*D4,OR^5),LI99X0J(S2,TJ)LW,H(!];45^97PR_X.V?\
M@CY\2?C#!\)YO&OC;PY:W=Z+:U\9>)O"@M]'=BVU6:1)GFAC)(^>6%%4<N4
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M_P#!*KPAH_B3]JOQM?QW_B)Y1X>\+^'M.^V:EJ*Q;?-D2,LB)&N]07E=%RP
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M NHZDS+;/=+&\4EI.R@LD4T;D;@"5=(FP0I! /G/_@M;_P $>O\ @GU\&O\
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M#4G33Q8V]PZ@7"OM$TMU*9#C]YY2[B=HQA_\&T?PD\#_  "_X+W_ +8/P/\
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MMTWD-.268 [B(E /W<HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8_M$_LK_ !'@\2^&;VXDMGF6"2">SNH\>9;7$,@5X95W*2K#E65E+*RL?5:
M"BBB@ HHHH **** "BBB@ HHHH **^<OV8?^"EOP=_:9_;"^,W[#5IX1UWPS
MX_\ @O?0C5=.U]8 NKV$W,6H69BD8M 5>!CO"LHN8<CYN/HV@ HHHH ****
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MQMDA>UG=$,L7E",*Q5<@<#%?;7_!X=X8T31/^"/'AK0]/L42VT?XM:%%IT8
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MRW87/F;2#C;S7Z)_\&^OQ\_:$^/7[#=A-^T%^QHWP=?PM;Z9H'A2!M%N+/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKX7T_1_[1^S^3]J^S6T<'F^7N;9NV;MNYL9QDXS7444 ?%'_  6X_P""//\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.>M<]_PT'_U*/_D__P#:Z@^/_P#R$M._ZX2?^A"OEOXG_MP_!7X5_M@?#/\
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MVMO@_P#\)9'X6NKE]!7_ (2#4+#[*UPD(F/^A7$._=Y,7W]V-O&,G(!\G?\
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M;?$GXP^,?^"U'PZN_P!LCX,S?"^QTWP=XFTSX#I::I;ZK!XLN93&U])=7<+
M6LHM((Y([1H_XF/FD@*^?^WM^QK\%?@S^V#\ OVE=$L]2U3QUX__ &K='_MK
MQ+K^HM=7%O9#3]2:/3K7=@6]I&54K$@&2JEBVU<=?X<\+_MB_M\?MD?"/XT?
M'3]DV^^"_@+X*7&HZQ]C\1>([.^U+Q#KES:&UCBA6T9A':P!F<RN1YI( 4<[
M?5O^"@'P$^+/QM\>?L[ZU\,/"G]IVW@7X]Z;XC\52_;H(?L.F16-]%)/B5U,
MN'FC&R,,YW9"D D &1^V'\$_VJM&_::T7]K;]DKP!X>\8:M-\,-6\!ZSX?\
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M^3;VDFF7=W)&OH&FD+$>JBO#/A;\ _B3\8-,_:4\'_ N/3;C7OAE^VY#X_\
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M10 4444 %%%% !1110 4444 %%1W=W:6%K+?W]S'!!!&TDTTSA4C0#)9B>
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M'H9GMN?4?A6UX@_X)F_M%_'O]B36OV9_VW/^"@NH_$GQZGC>V\4_#WXPZ/\
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MCW[<G;G;G&3C.,F@#X>_X.)/AU>Z#^Q#'^WS\+]?_L'XI_LUZ]:^,/A]XA2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cah-20201231_g6.jpg
<TEXT>
begin 644 cah-20201231_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXQ:^&[NXFA2# @5#>WCJ(P-F\A,=*^'/VO=(_9Q^(/\ P27^(7C_ /X)X?\
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M#]HC0_&>G2WGBQ_LOVEKF1/+BEDCGE,=U$DDKFW6,(F%W9 /Z/?^&K_V;_\
MAHK_ (9'_P"%SZ#_ ,+,_LG^T_\ A"?MH_M#['MW>?Y?79MYS7(_$+_@HW^Q
M?\/9OB5H6I_M&>$QKOPFT8ZCX[T:;50DNC1DHL9N1@^4'>6) >>9%K\Z-'O+
MN^_X/#;2^U"Q:UN)_P!G9'FM7(+0N;(%D..I!R/PKB/V3_AI\./C;_P7D_X*
M,_#7XH>%+#Q#X>U3X?+'J6E:A&)8+CRS8N%=>^V1%..Q7VH ]3_X)R_\%B_B
M)_P4Z_X)>_M!^,O&_P"U3X%^%_QATY-?O=(D@D-K;^!-%6UMDL[Z7"R2F".9
MI6,S[W9MW& JK]G?L3_'GP]\&/\ @F-X)^.?[6W[:OA#QG9:7X<:?Q-\9_[9
M"Z5JI-U(BSI/,L9;)*1*-H9G 4 DC/XZ_P#!'OX)?"73?^#8+]JW]H2P^'^F
M1>-M3T'QAHE_XG2W NY].BTZTECMF?O&LC,P'J37*?M!$_$[_@F5_P $G_V0
M?'>HW$/PV^)OQ$DA\>11W#11RQQZS96B;RI!&(-1O"#D8Y(Y&0 ?O%^R/_P4
MF_84_;PN]4TS]DC]IOPSXVOM%C$NJ:9IT[Q7=O%NV><;>94E,6XA?,"E,D#.
M2*Y+XR?\%G_^"6/[/OQDN/@!\8?VW_ ^B>+;*[^RZCI<U[)(MA/D Q7,T2-#
M;.I/S+*ZE>=P&#7F?AG_ ()7?\$G?V5_^"D?@G]IKX2>*M$^$/Q*L/!]Q9:+
M\,?"_B/3M(L/$%F4GBGNY=-*>==$(^&D1@H:!'8%U#5^/_[19_9(^./[%/[2
M/B[_ ()F?\$=;KQ=\/HM;U+4?%'[5?Q;\3V[7^FW,?E22OI7VD&\<$E9!&DQ
M<_:,S1_.54 _3?\ X+U?MF_'KX"?$[]C0_LQ_'2^T31/B3\;++3_ !#+X?NX
MWM]<TN6:PPC. PDB9)6(*G!#Y!YK],J_G9_:5U74-9_X)Y?\$C+O4[MYI$^)
M&D0*[G)$<5Y8Q1K]%1%4>P%?T->(=>TOPMH%]XGUN9X[+3;.6ZO)(X'E9(HT
M+N0B LY"@_*H)/0 GB@#^?\ _91\1?\ !9W_ (. ]=^+'[4_P"_X*J2?!.P\
M(>+[C3/!_P )-&U"YM'@A6-9K<7<=JR,L3+(L9N9EF,DL<XV*(PM?IA_P0R_
M:3_;\^+_ .Q5J+?\%1_A+K_@WQ]X&U^XTVXU[Q;H)TDZ[IL<,<L>H.K*B$J6
MEC>1 $80J^<LU?GAJ/\ P0V_8^_X*KZWXG_X*6?\$*?V]]=^'.I7?BZ]CN[&
M;3;ZQLX-8Q'/,MO+'Y-[IT;&:.4*8Y@-_P BJNU5\F\0?\%2?VZOBG_P0!_:
MQ_9P_:4^(%SKOC_X1>/]%\#:SXXBG\RXO-)OM1:WG@EG0 7!S97,#3-S)%<J
M&);+, ?M[^SW_P %9/\ @F]^U;\7[CX"?L\?MC>"O%7B^#S=FB:=J)$EV(P6
MD-JSJJ78559B8&<!06Z FM[]K/\ X*+?L/\ ["MQHUC^UM^TMX9\#W7B!C_8
M]CJURS7%R@;:91#$KR"(,<&4J$!X+"OP)U+]DW]L'QS\#/V8O%/[#'_!!?5_
MA=XW^%^JZ%XAL_C-H_C33I[GQA;);K-++=(L<,DQGE\JX#222>4F^)5V/@?5
MGP3^ 7P0_;V_X.IOVF-#_;5^'>C>.+3X<_#NR3P1X-\6V*7MA# L.EQ"?[/*
M#'( +J60*ZLH>]+@;@I !^JGA/\ ;_\ V*?'E]XNT[P1^T]X-UB7P%X93Q%X
MP_LS6HYUTK27MQ<I>RLA*B%H&60."05((K@]<_X+.?\ !*WPWJ_A'0]9_;L^
M'L-QXZ@6;PQC60\=S$TK0K*\B@I;HTB.H>8HI*G!.*_';]BCX.?"W]GW]K+_
M (*P_!7X*6J6WA7PW\$?%5EHEA%.9$L85@N_]%5B2=L))A )) C ))!KRG5_
MV&/V6=%_X-$-._;+7X,:#-\4-;\:_;9?'4VGHVJ1+'XFFTE;9+@CS$M_LT('
MD@B,L=Y7=@T ?T!Z-_P4[_X)^^(?VHY?V*]#_:S\&W7Q0AN7M7\)0ZENF-R@
M)>U$F/*:X7:VZ .9%*L"H((JW^UQ_P %'?V&_P!@^72;7]KC]I?PUX(NM<!;
M2=/U.X>2ZN8PVTRK!"KR>4&X,A4(#P6K\0/^"@7['/[-_P"R!\%O^"87Q;_9
M[^$^C^&?&.L^*O#5WXC\6Z79)%J&M74J:3>/<7<RC=</Y[R.I<G8'*IM7Y:=
M\3O$WCSXU_\ !P]^T_XD\9_\$LG_ &N9/".FV_A_0_ ^J:]9VUIX;L$CMXTN
MUANX9HY"P#E2%!1[F23AFR #]X-6_;#_ &6=#_9O'[8&I?'WPLOPN-E#=CQY
M'JT<FF>3+,L"/YZ$KS,ZQXZASM.""*\Y7_@KU_P3*?XS>'OV?(OVV/ ;^+_%
M5M93Z#I,>K;A<B[C22U0S >5'),DL;)$[J[B1,*=PS^,-E^SS^V!^RU_P;K_
M +;GPG_:*_9UU[X9^#[GQUHNN_"WPUKVLPW[65E=ZY8B6UCFC8[UB$%N"Q"[
MG=GV@LU8?_!5#_@GS^R;^SW_ ,&U/[,_[2OPP^"NAZ/\2-6D\):QJWCNPM F
MJZA)JNCSWMPD]UCS)8Q(8RB,2(O*4)M&<@'Z)?\ !13_ (+M:'^R3_P5X^#O
M["+?%7P7X<\ ")M1^-_B?5)0USI9DLKB6TT^0M\EJKJ;2<L 7<3Q@%%W!_TR
ML+^SU2QAU/3KE)K>YA66"9#E71@"K#V((-?A;_P4C_9F_9Z^.'_!R;^R3I7Q
M4^#>@:U9?%?X9QZC\1+*]L@\6O7,5EJ$44EP"?G*1VMLBYZ+"@[5^Z5A86>E
MV,.F:=;)#;VT*Q00H,*B* %4>P  H EHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OD#_@L/_P2D_X>Q_"SP#\-/^%]?\(#_P (-\0(/$_VW_A%O[5^V^7!+%]G
MV?:K?R\^;G?N;&W&TYR/K^B@ KY ^)?_  2D_P"%B?\ !9+X>_\ !6S_ (7U
M]C_X0/X?S^&/^%?_ /"+>9]N\R'4X_M'V[[4OE8_M'.SR&SY.-WSY7Z_HH ^
M(++_ ((L^%;W_@J!\??^"A?COXX/J^A_'SX02> -9^'$7AK[.UA:2V6DVDTP
MU#[2_FEDTQOD^SIC[1]X^7\_R-H?_!J_^T?<?LWZ_P#L+>,O^"NOB=_@?#?W
M&H^!O!&G^!XE2VOY)O-CFOB;@-<11N3(;9'1'F/F@Q$$-^S%% 'Y^^(?^"&N
MJ^*OBU^QO\6=:_:Q1[C]DKPS8:,UO'X"VCQ8MJEO&DI;[>?L)9;=<C$_+$^U
M>E_MY_\ !+/_ (;<_;-_9N_:Z_X7K_PC'_#/?BBXUC_A'O\ A&/MO]O^;/92
M^5Y_VF+[+C['C=Y<N?,S@;<'ZWHH ^0/^'4O_&Y+_A[9_P +Z_YI_P#\(Q_P
MK_\ X1;_ *8^7]H^W?:OQV>1[;N]>7>#O^#??P'::Q^V</B7^T3=:]HW[7VI
M&]N-.L?"PLIO"DBWM]>0LDS74HO&CENXR"8X@?L_*X?"_HA10!^+_B?_ (-6
M_P!J+XX_LLZ1^R=^TK_P6 U_6O"_@":)/A/HEI\/8SINBQ*Q5I+B W:274GD
MLT40:;%NKL%9E;8/IG_@J'_P1 \9?MO_ !D^'W[9W[.?[7VH_!WX]^ =$72F
M\=:+H[&'5[<!^'CCG5X&!FN "'D!CF:)U=0I7]!Z* /SQ_8B_P"#?#X/? 7]
MG7XV?#3]JWXSZU\9/&W[1-L\'Q1\>ZE$;:>2/,CQBV#R3.DD<TC3>:[,7D2,
ME0$5!X9\,/\ @V#^/$NN?#WX.?M2_P#!4CQ-\0_V??A/XF36?!OPN'ATVDCL
MC,8[>6<W+^7&JLT>5#$1O(L0@WY'[ T4 ?G=_P %./\ @B#\5_VN_P!MKP9_
MP4*_8Y_;:U'X(?$[P[H(T+4]4MM#-\EU9@S 2H!-'B01W$D;(X9)%V?<*$MI
M_P#!-7_@A-IO_!/+]K'XI_M.ZC^UEKWQ+/Q5\*PZ9KEEXIT/%_)>,T,M[?3W
MWVE_M#3SK-)L\I-@F"[FV;F^_J* /RB_8U_X-P?C?^RE\$?CW^R4W_!1K4=6
M^%/Q7\$ZOH7A?PQ-X3D9-"N[\P+_ &K+%]L6.:=(8!$538)-Q8-'RI]-^,O_
M  ;X_#+XX?\ !)GX;?\ !-;Q?\>KV/Q#\)7%WX*^*VF^'A!-;7PDF8R-9_:&
M/E,DQ5HA.#E$<."HK]$** /S0_8#_P"" WQ*^#W[7EK^W1_P44_;FUS]H3Q]
MX?\ #<N@^"AJ]C+%;Z3:R12PN[--/(\K^5/.%4!%5IY)#O=@R^0^$O\ @UH^
M.W@WX:?$+]C3PO\ \%7_ !9I'[.GB^]O-4LOA[8>$86NAJ#Q@6IN[AIOWT,4
MD5L\L<?E+<B  B%F#K^QM% 'YO\ BS_@W^U3QE^S7^R3^S[J_P"V''YO[+/C
M%-;36XOAW@>)8H[R.XCMO)_M#_0R$B6,R;YLG+[1]VOT?95=2CJ"",$$<$4M
M% 'XW_$O_@UQ^/WPN^,GC'Q5_P $Q/\ @J3XP^!G@CQ]>O/K?@73H[V..U#E
MB8HY;.[A$\:!W6(2('C0[?,;):OIG]E#_@WP_9&_9Q_X)K>._P#@G/XHU_5/
M%UO\4PUQ\0/&L\"6UY>7R[#;7%O'F18!;/%')#&S2 .&9B^]@?O>B@#\C_@3
M_P &TOQ^LOB;\+-&_;(_X*?^)?BE\'?@?J\=_P##CX<)H#6.#$5,$4TIN)-L
M2!%CV@.?*W1QM$K&O'/^"P_AC_@GU\0O^"T36T7_  4#^)/[''QTT?PM:1^(
M?B?'HR1:%XHT][&-X7@OH=1MYH)O)8VC/)A'-KY>PE S_NG7CO[47_!/G]B3
M]M:YT_4/VK/V8/!WCF\TF(Q:;J.NZ0CW5M$26,23KB01EB6V;MN><9H _&3_
M (("?LB?"GXZ?M"_\% ?AC^S3\4M7U7X9^)/!)\ >'_BCJZO?RZA+?PWL,NI
M/N,?VN1G5[E@&0,)%^X'7'W=K/\ P04_M?\ X(<Z3_P1D_X:L\O^R]0:Z_X6
M1_P@N?-SK\VK[?[/^W#;_KO)S]H/W=^.=@^V?@!^S;\ ?V5/AY#\)_V;O@]X
M>\$>'(9VG72/#>EQVL+S, &E<( 9)&"J"[$L=HR>!7;4 ?"'[9W_  1._P"&
MNOA9^RU\-/\ AIC_ (1[_AFG4-*NOMO_  AGVO\ X2/[%!9Q;=GVR/['O^R9
MSNFV^9C#;<GE?V_O^"&WQ?\ C-^VG<_\%#O^">O[<NK? /XH>(- 31O',]IH
M_P!LM-<MU2.)9& D39((X800RNK&")QY;H7;]&:* /SD\$_\&\W@CP%_P2(^
M(O\ P3(T/]IC59O$/Q6U:#6/&GQ6UC0C>23Z@E]:73.ED;E"(B+4($,Y;=*\
MC,Q8K76?MP_\$3O^&S/^"4'PK_X)@_\ #3'_  C?_"L]/\,VO_"<?\(9]L_M
M+^R-,:PW?8_MD7D^;N\S'G/LQMR_WJ^[Z* /SJ_X*I_\$.OBG^W)\6_@U^T=
M^S1^VC??"+XB?"706T2#Q':Z-),\UJPXFA,4\;P2KOG!7<RNLV,KMRWZ#>%=
M+U+0_"^FZ+K.MOJ=Y9V$,%WJ4D>QKJ5$"M*5RVTL06QDXSU/6K]% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<Q\
M:]7U/P_\&O%NOZ+>/;7ECX8O[BTN(S\T4J6\C*P]P0#^%=/7(?M"?\D#\<?]
MB?J?_I+)0!_/_P#\$S_ W_!QQ_P5$_9%U/\ :T^ W_!6VXTQ=.\07ND6GAOQ
M)=NDUW<VT,,N/,2V>-%?SE4%N 0<X'-?>?\ P0L_X+:G]HK_ ()F^(/VA/\
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M (-^OAY^U1^SU\/]-\.?$GPCI_A#6-'^(NCSM%J>NW=\UL)WEG5LR[O/>Y0
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M"S^%VCQ^+M"^,^K>&]'\0I:@75II!@M9#9(_:+>H;;ZBOVBH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K'^(7A3_ (3SP#KG@?[?]D_MG1[FQ^U>5YGD
M^=$T>_;D;L;LXR,XQD5L44 ?*'_!&W_@F#_PZ3_9'N?V6/\ A>'_  L#[1XP
MO==_MW_A&O[*V_:(K>/R?(^TW&=OD9W[^=^-HQST'_!6#_@GW_P\_P#V)?$?
M['/_  MO_A!_^$@U#3KK_A(_[ _M/R/LMW%<;?L_GP;]WE[<^8,9S@XQ7T?1
M0!X?\3_V#/A'\>OV _\ AWQ\=)9M<\+W'@.P\-ZAJ%K$+:=GM(85AO85)D$4
MJ301SH"7"NB@[P#G\W_A]_P:O?&+6]6\'?!;]KO_ (*E^,?B3^SW\/-82_\
M#'PF;2YK99E0MY=O([7<B0HJ,T>Y%9A&\BQ>1OR/V0HH ^._VM/^"3%G^TY_
MP40_9_\ V\=.^-\7AFW^!$4D<'@N#PF+A-61G+*JW N8Q:A00H BD&!VZ5+X
M-_X)2?\ ")?\%DO%G_!6S_A?7VC_ (2CX?Q^&/\ A7__  BVS[-LALX_M'V[
M[4=^?LF=GD+_ *S&[Y<GZ_HH _.O_@F9_P $1?C5_P $V/VV_B!\9_!?[<=_
MJWP?\8ZGJ>IP_"=M%DB7[9=NK1S3R?:#&\D"+Y8E$>9% RJ=OT4HHH ****
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M<=2__!4'_@GNG[3\/[&)_:Z\%'XFW%PEM#X475096N7&5M?- \K[0V0!!O\
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M;=E\>OVI?BK^P=^P/\6;G_@I=H7POU[Q;J6E7/CI_&.J/#<_$-7DMM^GP^7
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M(+YG_"4?9I+=_+\K[<OV+=Y&-VZ?&_H<<L_X*9?\$*O%7[5?[5VF_P#!0/\
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MI&@Z1!Y=O:J\CROM7U:1W<DY)9B3R:ZN@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT?\ #0?_ %*/_D__ /:Z /2**\W_ .&@_P#J4?\ R?\ _M=26OQ\^TW,=O\
M\(GM\R0+G[?G&3C_ )YT >B4444 %%%% !1110 4444 %%%% !1110 4444
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M $(4 ?1-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2/1_&/C_ ,8:SXW\1^'8#E-%N-4NVN18CWBC,:L.S[P,@9(!]A?!C_D>X/\
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M_B[\/?A'?PZUIFAZC!-)K/AB9GD^PZC9LV_[,\RR&*7Y0KER-Y4;?U'^/_\
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MHFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDD@LTZG))_T<9R02?MZN _9Z_9?^"'[+/A6?PA\$O!,6DVUW,)K^=IGFGNY
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M KS/]LK_ )-9\=?]B]/_ "%>F5YG^V5_R:SXZ_[%Z?\ D* /R7HHHH ****
M"BBB@ K])O\ @EI_R:RG_8PWG\HZ_-FOTF_X):?\FLI_V,-Y_*.@#Z.HHHH
M**** /,/C_\ \A+3O^N$G_H0KSZO0?C_ /\ (2T[_KA)_P"A"O/J "BBB@ H
MHHH *GTO_D)6_P#UW3_T(5!4^E_\A*W_ .NZ?^A"@#Z)HHHH **** "BBB@
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MO[/FL>++[4]-^,&@R032[HW^W*,C '0X-?2/_"KOAG_T3O0O_!1#_P#$T?\
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M^_X0[4?^@QH/_A3V/_QZC_A#M1_Z#&@_^%/8_P#QZOV!_P"%7?#/_HG>A?\
M@HA_^)H_X5=\,_\ HG>A?^"B'_XF@#\?O^$.U'_H,:#_ .%/8_\ QZOMS]@?
M]HSX$?!7X!KX*^)OQ:T'3-3&LW,YMO[02;]V^S:=T19><'C.:^I?^%7?#/\
MZ)WH7_@HA_\ B:/^%7?#/_HG>A?^"B'_ .)H X7_ (;G_9'_ .B]:#_W^?\
M^)H_X;G_ &1_^B]:#_W^?_XFNZ_X5=\,_P#HG>A?^"B'_P")H_X5=\,_^B=Z
M%_X*(?\ XF@#A?\ AN?]D?\ Z+UH/_?Y_P#XFC_AN?\ 9'_Z+UH/_?Y__B:[
MK_A5WPS_ .B=Z%_X*(?_ (FC_A5WPS_Z)WH7_@HA_P#B: /"?B_^UI^S7XIO
MK*;0OC1H,ZPQ.LA^V!<$D8^]BN/_ .&BO@3_ -%9T'_P8I_C7U-_PJ[X9_\
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MOX>UFYMV929]3NK>W@6:^N)' +D$,2W&%4* #]&J*** "BBB@ HHHH ****
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M;]H2XBO_ (T?&G6Y/&_Q=U1.=FHW0W0Z=&<G;;V<!2W1 2@*R%,!\5YU;?\
M*SC>_P#9B%M_ZFD]?<?AZUGL= L;*ZCV2PV<22+D'#! ",CCK7RQ!^S-\;D_
MX+J77[9#>"<?#>3]DR#P8GB/^TK;G7%\3S7QM/L_F>?_ ,>S+)YGE^5SMW[O
MEH X/XF_\K('PM_[-0\0_P#I\M:I?\%O-,T[PI\8/V)OCSH*);^+M*_;#\,>
M&=/U&-?WQTK68KJWU*V!'.R2**,MVQ'SUS5#_@H'X#_X*(?"W_@JI\/?VZ?V
M-/V"_P#A>.CZ/\%-2\(ZOIO_  M+2/#/V:YN=22Y#^9?,S/A(APL14[_ +P(
MP8OAS\#/^"E'_!1/]LSX7_M$_P#!0W]F'P[\"?AM\#M4N=?\)_#*R\?VWB74
MM?\ $;PM!;WMU=68$$<%LK/)&H"OO;!#*Q* 'Z(4444 %%%% !1110 4RXM[
M>\MY+2[@26*5"DL4BAE=2,$$'@@CM3Z* /Q.UC]ES]HSP3^U%X@_X-OO TT]
MG\!?B)XGC^)^G^)+?4-D^B_#A[B275_#D0!#1[]42&VC8;CY=U*S@K(0/VD\
M-^'-!\'>';#PCX5T>WT[2]*LHK/3=/LXA'#;6\2!(XD4<*JJH4 <  "OEGQ!
M^S-\;K[_ (+A>&_VP+7P3N^'5A^S)J'A.[\1?VE;#R]8DUZ&[2V^SF3SSF!&
M?S!&8QC!8-Q7UG0!\(?\&R__ "@Y^!'_ &#];_\ 3_J-'_!N)_RC(L?^RH>-
M?_4AOJ[S_@AC^S-\;OV.O^"5?PF_9N_:.\$_\(YXT\,V>J)KFB_VE;7GV9IM
M7O;B,>=:R21/F*:-OD=L;L'!! ^1/V#/$7_!<[_@GK^SW=?LL>#O^")EMXT@
MM?&>OZEIGC6\_:/\.Z?%-'?ZG<7<;O9#S9 J"8 CS-S =%)P #W+_@F)IFG?
M#G_@K9^W_P#!/P2B6OA>U\7>!/%$&F0+MB@U;6-#FGU*0 <;Y9(8Y&_WAGU/
MWY7RE_P2K_8O^-7[,_A/XA?'+]K?Q#HVJ?&GXW^-7\4_$-_#I=M/TL+$L%EI
M-LS_ #20VL"[0QR=SN-S@*Q^K: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***^/?^"L'[5W[9_[/^O? WX1?L-)\.4\8
M?%[XC3^'!=_$ZPO9].MD33KB[WG['(DBG,.,@/UQCN #["HKXM^!WAW_ (.#
M_P#A9=DO[2/Q(_9*7P>]I>KJ,G@K0_$<FI13&TF%J\27+I$ZK=&!I%9E+1"0
M*P8@C;_X)E?\%%O$'[2O[/'CNX_;"L-!\$?%7X'>)-2T'XWZ19,\.GZ;):F2
M5-0A\YW<64UJHE21F()CEP2JYH ^MZ*_-_PY_P %<_VO]5_8;E_;/M?@+H%[
M>?&OXS6G@S]D[P/=6]S8R7=C>W#P6&I:U.TCE5E2*>Z*QI&!%&@#8E#IZ!\"
MOVP_^"A?P0_;D\"?L4_\%)]#^$FJ+\8O#NKWWPS\9_""#4;6*/4=*A2XOM-O
M+>_ED8C[._FQS(5!V8*DD^6 ?<%%? _[0'_!:;PU8_\ !2_X2_\ !/3]F#3H
M?$YU'XC2Z!\8_%YL)9=/T&9;"ZF31X9U*HVH%H2\@RPA2%D*EV;ROOB@ HHH
MH **** "BBB@ HK\W7_:A_X+@?M,?M=_'GX6_L2:O^S-I/@SX0^/H?#EN?B=
MI&NG4;AGT^WN]Y:RE:-Q^^(SA#QT[G7_ &BOVL/^"P?_  3\_90TW]J[]KS2
M?@AXPT_PO\3+7_A:VG?"G1-7+6_@B=;>%[ZU-W,KB]M[AI7=2CQM$ZD[/+<D
M _0NBOE#_@I!_P %!?$G[/\ \!_ ,7['5EH'C7XJ_'/Q%IVA_!/2[YGFTZ_-
MR$GFU.?R75S8V]H6F>16 &Z+) ;-<1\6?VL?^"EWQ?\ VN?%/[%'[ NE?"&U
MOOA!X1T6\^*WQ%^*FF:FUE>ZOJ5N\]M8Z?9V4P=%,4?G/(\DFP2!,;E!D /N
M:BOSXTK_ (+,_%-_^"?.J_%?5?@#I3?M!:5\:W^"9^'%GJKG2KOQY]K2V1(K
M@_/]B,<BW9R=PC5DWD@2'N?V7/VO?V[?A[^V?I_["O\ P4I\.?#&76?''@F[
M\3?#+QO\)X[^WT[4#8R0IJ.E3V]]))*+B(3QS+(I"-$>0&R  ?9U%%% !111
M0 4444 %%>'_ /!2K]H[QY^R%^P3\6/VG/A?8Z9<^(? _@R[U;1[?6;=Y;22
M>)<J)4C=&9/4!E/O7R[X+F_X.=/''@[2?&NF>/\ ]B6*VUC3(+VWBGT?Q4'1
M)8UD4-AB,@,,X)&>] 'Z)45\B?!K]N7XX>&_^"H?C;_@G;^UKI7ANSBUOPO!
MXN^ GB/0K*:W77M,3*:C8S^;-('O+:49 3:7A1I"B@KG+;_@I-X^\2?MI?&S
M1_!6DZ.WP!_9F\ 7-S\6/%?]G2W&H:EXG2W>\?2[!UF6(+:VJ;I\H["4K$0N
MX-0!]GT5^7]__P %./\ @K3\%_V;_"7_  5"_:9^#'P4L_V??$=WI%]X@\#:
M!/J9\6^&?#NJSP0VE^]W+)]ENIT^TP22PK$G#[1L(8I[/_P6A_X+ ^"?^"9'
MP-U72? .GKXK^-.J^&+K4O!G@FWLY;D6MI&'$NL7ZQ8,-A!L=BS,IE:,QJ1A
MWC /MFBL#X4>)=1\:?"[PUXQUA8Q=ZMH%G>70A4J@DE@1VV@DX&6.!DUOT %
M%%% !1110 445\._\%#_ -JK_@H_X<_;F^%O[%7_  3UF^#MIJ/C3P#KGB/5
M=1^+FFZE- BV%Q;1[(VL) RDBXZ%&!QU'< ^XJ*^(?!>G_\ !PYI'A7QSJ?Q
M:\6?LI:C?V_@:]F\ 6/@S1M?+W'B!'B>VANOM<L:"UDC6>)F5PR/)&_(5E/2
M_LU?\%;?@Q\3_P#@EC-_P4E^+>WPY#X1\.W?_"SO#^TI/H^O6/[J\TQ8Y#N$
MC7 584<[W6X@SR] 'US17YW2?\%"_P#@IG8_LX?L_>![GX)?#V']I+]IG5]2
MN_#6@ZO;7UMH'@K0K:V^W22ZEME:XN+B&T>WWQJT1:6=D !CVOVG[./_  4)
M_:7^$W[0?Q/_ &0_^"G^D_#^T\2> OA0WQ0T?QO\+X[N/2]8\*QS26]V\EM>
M2/+;W%O-'M(WE7#Y 4 ,X!]NT5^9_@W_ (*@_P#!3?P7\/OAI_P4"_:@^!WP
MJTK]F_XI^)-*M#H&B3W_ /PE?@S2=8GC@TG5;ZXED-K<H6FMS-''&C*)TV@$
M,%_3"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+*WGO=)40O+8K="7=&[P!HA,!E2V[&17U9^W3^S!_P -I_L?_$3]E'_A./\
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MX>^%/^$#\ Z'X'^W_:_[&T>VL?M7E>7YWDQ+'OVY.W.W.,G&<9-;% !1110
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M>I82>;I>FZGJ2RD7-I:.(\*L2^:(E#!0J;?T.H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cah-20201231_g7.jpg
<TEXT>
begin 644 cah-20201231_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#X)_X.4/VE?CO^R7_ ,$JO%'QH_9O^)^I^$/%-GXGT6WM=;TAU6>.
M*6\5)%!8$8920>*^9_\ @D__ ,%;OC[XD_X(+?M#?M"_M+?%+4=9^*?P3N/$
MEB=5UED-T;DV,<NFAR !_P ?4Q@''_++OW]@_P"#MC_E"WXQ_P"QP\/_ /I<
ME?C=^VQXR\<_LM>./VA?^";O@+3KAE_:IC^%NM:"D0*I)-+#!?W##'3S+N=H
MFQ][R^<T ?HI_P &GO[=?[=W[7/Q2^-GAC]L_P#: \2>,UT'PQX9U#0;;7YD
M86BWHNIA(FU1CS(O)/TQ7Z/^%O\ @KG_ ,$S_&O[1)_9/\*_MI^!+[Q__:)T
M^/08=6XFO Q0VL<Y'D2S[P5\I)"^[Y=N>*_'GX/WFO?L:_$?_@K%I_P)N[BQ
MNO GPRTC2/#MY9DI+9116=S9I/&5Y1XX_G!'W2@/:OF_X;?L>_'G]HO_ ()!
M^ OAI^S!_P $+]3?QM+?P:[X>_:AT?QIIZ:AJ=P+YV<[/+2?R?*#0) 9ML;1
MI(!O4Y /Z3OVL/VW_P!DS]ACP79_$']K7X\Z!X&TO4;HVVFRZQ<-YM[* "R0
MPQAI9BH(+;%.T$$X!%?GO^SK_P %(OB#^T?_ ,'(5[\'/@U^U(WBWX#:G\#H
M]=\/Z1HNHQSZ5-<_9[;=.A49\P2-(&4G*MN5@""!X+\4_AO+^W?_ ,''?[-O
MP-_X*'>!4U.ST']F;3M:U#X?^(HDEL[C6S875U=QS0 M'+BZW&1>5?[$J-N0
M8.I^QQ^S3\"OV4?^#O'Q_P#"O]G7P7IOAKPT_P ()=23PYH\*Q6FFW%S9V$L
MT<,2\0HSDR", *OFX4!=H !]S_\ !%/QO\3KO]G7XD^(_C__ ,%$/"'Q\;3O
MB9J+1^+_  ]J[S6OAZQ2TM6_LZ>2:*+RWB^>5N"H68'=UQZ;\"?^"O'_  3.
M_::^,Q_9\^ _[:'@CQ+XP+R):Z-8ZB0U\R EEM9'58[LA59L0L_RJ6Z FOP+
M^#GQ+\=_#7_@V,_:W_X02^N+5M?_ &I/[&U>ZM7*LEA.FD^<A(_AD"B%A_$L
MS*>#7Z7>$_\ @BS_ ,$:]#_9._98^,GC/Q)H_P '=;\.1>'M9\/?$G1/$UAH
M6H>*M:DL4O$CN+N[1OM;R21M<K&O[Q1$1&4C#*0#[7_:T_X*D_\ !/G]A;Q1
M8>!_VK_VJO"_@[6]2MEN+31;R:6>\,#,569X+=))(XV*L [A5)5L$[3CYW_X
M+?\ [>E[H?\ P1#\<?MJ?L!?M'0&1[C0SX9\=^#-1CF79)K=I;3JCC< VUI8
MG4C<IW*0""!\I?M=ZC^Q[\;_ /@K'\:/ _[''_!("Y_:R^.*:3:Z7\3M:^(O
MB:VB\)>&I1#'"AA^W"18ID2-(B8S P,,BPG(<GXQ_9LO=2F_X,]/VE]+OYR4
MTW]HZSMK2$2;D@C^T>%Y"B'^[OD=OJQ/>@#^C+]BCQ?XF^(7[&GPD\?>--9F
MU'6=<^&.@ZAJVH7!!DNKF;3H))96Q_$SLS'W-?DM^U?\;_\ @I1_P55_X+-_
M%#_@FU^RQ_P4!;]G/PC\']'B>W72[B6WU3Q!<>7;M-,H@>*>?YYS\HE6-(41
MMI9V)_5C_@GM_P F"_ __LC_ (9_]-5M7YC?MV_\$Q/^"9O_  7:_;D^)UW^
MR;^UAKOP[_:-^$DL&F_$:>V\+W'V.YN;>26TCD>.<6[RRQ&V$)NK:4H$$)P^
M4) /;O\ @B#XT_X*_P#PM_:&^+7["7_!3#3/$_C;P]X+B6\^'OQOU/1)TM-8
M3S8T>V2^>-1>;TF250Q:6,QSHS, H3Z>\1_\%<_^":'A#]HP_LF>)OVT_ ME
M\0$U :?+H,^JX$-X6"_99+C'D1S[B$\II X;Y=N>*_*/]@+]L?\ X*=?\$[O
MVA/VG_\ @E-^U=\?9/BCJ?PU_9^USQG\/?$TFI3:C-8WEKID=W:I'/<*)S#)
M#<)F&7=Y4D*K'\K$O\:_LF?LR?%?]J'_ ((]ZI\/OA;_ ,$/[_XD^+_&^N7E
M_I_[4$?C*P74([^/4"@6-)HO/6)1&8'@\X)*S/(1N8$ ']-W[3G[6?[-G[&7
MPT?XP_M2?&;0_!'AQ+E;9-2UNZV>?.P)6&%%!>:0JK-LC5FPK'& 2.1^$'_!
M2_\ 8%^/OBCP;X(^#7[6/@SQ%K7Q"L+F]\&Z1INK*]SJD-NLS7!2+AE:,6\Y
M=&"LOE-D#%?CA^TUX!^)7[3'_!23_@FE^Q/_ ,%+O#5VUA;_  ?@N_&_AOQ!
M<AUO]>CCNDECN=C%97F?3+)9.2&\YEZ,:[/Q/^RO^S;^R3_P>(?L^^"OV7_A
MYHOA+1=?^&.J:[J_AKPW:QVUC9:E)H?B2V?RK>(".W#P6MLY1%4$L6Q\U 'Z
M<?$7_@L;_P $O?A/X8O/%_C[]MWP)8V-AXGN/#MWMU,S3)J< 0SVWDQ*TK-$
M)(]Y"E4WKN(W#-CXC?\ !7G_ ()D?"7Q%X1\+?$+]M[X?:=>>.].M]0\+@ZX
MLL5W9W'^HN6ECW1P0R?PR2LBM@X/!K\8_P#@F;^PQ^RY^T)\$_\ @I9\<OCI
M\%] \6:_X>USQ;9^%+_7=/2XDT)XX-3NC<69<'[/.9!"?.3#CR5 (!8'RSP;
M^PI^RY)_P:*>,/VS[OX/Z'<_% ^-K>\A\;W6G))J=M&GB:TTD6L5P?GC@^SL
M^8E.PLY8J6P0 ?T<?M,?M;?LT_L;?#)OC'^U#\:="\%>&_M"6\6IZU=[!<3,
M"RQ0HH+SR%59MD:LVU6., D4_P!G3]M?]D_]K?X3WGQR_9N^/7AWQ?X5TYI%
MU35M)O-PL&C3S'2XC8"2!@F'VR*IVD'&"#7X)_M\_$+XD_%W]MO_ ()T_![Q
M1^S!>_M"Z-8_LG^'_%EO\()-8CLT\3:K<:=>-<M)+,CQ,%73;6:1'5A(D+1D
M8DKW[_@F;^SI^V+\(OV_OVE/C<?^":NK?LW?!+XD_!'4%NO J:]9W>FZ?KMK
M# 86A%N(Q'O5[UUC$2J@N7"X7:* /T;\8?\ !;/_ ()/> _#'A[QEXG_ &\O
MA]%IOBN65-!N;?53<?:1%*8I)"L2LT<2R*R&5PJ;E8;OE./ ?^"_7_!:.^_X
M)U? #X>O^S)X[\'W?BSXHZU:_8-3NYUO!9^'WC9Y-7MHU)CG4XC1)&+1CS0V
MU^!7YJ?\$X?^">/[(_Q"_P"#83X_?M5?$GX&Z!K?Q!6W\1WNA^,-0LEEU#2%
MTV&)[:.UF8;K9/-61G6,CS!*P?<, <S^WUX%\%^._P#@WJ_8&^+GBSPO9WWB
M4>,QX8_MF>/=/_9"SZF!9;B<^5^XB^7I\@]* /Z3?@Y\9OA7^T)\--*^,GP2
M\>:;XG\+:Y"\ND:[I%P);:[19&C9D8=0'1U^JFOQ-^,WB3_@L?\ MT_\%S/V
MB?V)_P!C3_@I!J/POT'X=V-GJVGZ?J#LUG%;M;:>C11"*%V#&6Y+\\=:_;+X
M.?!GX5_L]_#32O@W\$O >F^&/"VAPO%I&A:1;B*VM$:1I&5%'0%W=OJQK\!?
M%_P>_P""H'QF_P"#DW]K'0O^"5_[2?A+X9>,+71;"?Q%JWC"(/!=:;]ETE3
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M[:4%XXY8KB+Y)H52)XW&!L#!CG:/T4HH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "D=TC0R2,%51EF)P *6O+_ -M[7M9\
M+?L7?%[Q/X<E>/4--^%^OW5@Z EEFCTZ=T(QWW 4 ?G7^Q5^U3^T;^W9^S+^
MW!_P4'M?VM[OX?\ A;6=;U'PU\"]4U_69XM$\&:9I5EA=:6)0ZQ-,T\4DT@1
MFWP.!QP?K#]CK]K;X7_ #]@OX*ZO^V-^WAX,\8ZUXQ TG3/B4FK$V?B[4GN)
M=BVTDD:&1B,)@JO*&O@3]@31=*TO_@S*\8WVG[/.U+X8?$"YOMG7S1J>IPC=
M[^7%'^&*^4?V^O#MKXO_ .#=_P#X)[>$[Z>6*#5/B!]DFE@?:Z)))>(2I[,
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M"NW^-O[2'QZ\->$?"M[)''IVLZIJ*B.^=T+HEN$W-<,R N%C#$J"V, FL/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBO,_VRO^36?'7_8O3_R% 'IE%?B7
M10!^VE%?B710!^VE%?B710!^VE%?B77Z3?\ !+3_ )-93_L8;S^4= 'T=111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGS$7)3(S[=!\1OC?\&O@^;9?BO\ %?PYX:-[G[&NNZU!:F;'4H)&!8#N1P*
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MO3_R%>F5YG^V5_R:SXZ_[%Z?^0H _)>OS%_;:D_8Z_:F^/$FH>&M0O\ X?\
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M_P $T="^%GQ*\<:QHWAY_'DVIZ=# H9KW2XI,"U?)&(VG\YP1C#*K#..:?[
MVH_!V?\ ;E^)WQ/_ &4--_L7X::)X%$%_H\EYL>]O$:-A-';N[2",>7+B0C
M+$<>9BO2=2_X**6<7['EA^T3^R)\"+RX\(>%_%$6A>(-%U:P2&;3=-BAC9YH
M([:9U"*KQH"6PI;)7:":\_\ @UXW\(_MN_\ !2^V^-?[//A74;/P3HGPZGTK
MQAJ\VG_95O9IH[A$C('#/^^AP&Y(MB?NHIH ^:_A#XM_8P^*OPNUG6/VL[#Q
ML_C?QAXT-YJWQ-T33FE@\.AI5,<3R.^T;P)B0L<A"N,#**%_8CPK!!:^&--M
M;;79=4CCL(5CU.>57>[4( )F90%8L/F)  )/%?DQH_Q3T[X"?L9_$O\ X)M^
M/?AKK#_$S4?&(AT>QM-+,D>H^9+:F.=6ZDX@RF =X:+;G)*_J/\ L_>$-=^'
MOP%\$> ?%#AM3T/PAINGZBP?<#/#:QQR'/?YE/- '[A?"/\ Y)3X8_[%ZR_]
M$)70USWPC_Y)3X8_[%ZR_P#1"5T- !1110 5X9\3/^1[U+_KN/\ T$5[G7AG
MQ,_Y'O4O^NX_]!% 'Y'?\%S-<@^*?Q\\2_LY?%_XK:MH'@[P]^S)J?C+P9X;
MLM<DT^W\4^)?MTL#),49?M?V:WB61;;)/[QGQMW _8/[,'P6^,G_  3_ /@5
M\3]%\4>,_$'Q1\*>'-0U'7/A7H4-Q/J7B&+25M?.71=\P!N91*CI -S$B15+
M= OB?_!9?Q+^Q_\ M ?#KXI_LD_%_P"%(U'XA^ ?@O=?$'PAJ^JV,<:P0M(U
MN9;&X603;UEB7S4VA" F[?C ZK_@E,/$WPF^/'[1O[$UA\6->\:> OA)XJT-
M/ FJ^)M3-]>6":AIQN;K2S<GF1+:1515/S)O(.#P #F_^":?QF_;1^*G_!17
MX[+^V-IH\,W0\!^%K_P[\-[/63=V_A>QGEU QP.RXC>[90'FD4?,S;<A45%Y
M?X.?!S]HW_@I+%\7?VN[K]M[XG?#_4]&^(>N^'O@UX<\&>)S9:-HEOI4S00S
MW]I@QWSSS(6G6;(*$J" 5">Q?L^?\IH?VC/^R6>!_P">HUX_)^SCI,FI_'_X
ME_LH?\%--2\!_ Z7QOKTGQY\$Q^"8VN]%UF",'6DT^^O-CV)F7GS%C=%+!XF
M;*E0#FOC[^W9KG[6_P"Q-^R'X@UO]IW5/@E_PN'Q'/>_$3QQX4\4#17LK32=
M+O\ ^TECN'.V*-[I$VJ^X;O+7YCC/U%_P33^$GPL\,^'M<^*GP9_X*0_$;]H
M70M=\FT6[\9_$.#7K;2YH2[,L/E1KY$K"1=ZM\Q"IP._S+_P3N^#7[$J_LW?
ML5? S]L;X1)J?Q"N_"'B/Q%\)+3Q%;RS:=&EU/\ ;[B-HW8033BWFM9$$L;N
MNP,NT\GU3]FWP#\/_A!_P7!^+7@/]F[0-/T;PEJ'P)T75?B+HN@6Z0V-MXG;
M4YDM6:*/"1326.Z0@*"VXN<EB: /T3^#'_(]P?\ 7"3_ -!KV6O&O@Q_R/<'
M_7"3_P!!KV6@ HHHH *\S_;*_P"36?'7_8O3_P A7IE>9_ME?\FL^.O^Q>G_
M )"@#\EZ*** "BBB@ HHHH *_2;_ ():?\FLI_V,-Y_*.OS9K])O^"6G_)K*
M?]C#>?RCH ^CJ*** "BBB@#S#X__ /(2T[_KA)_Z$*\(_:'_ &<O@M^U;\)]
M2^"/Q_\  =KXB\-:KL-S87+O&RR(P9)8Y(V62&16&5D1E8=CR:]W^/\ _P A
M+3O^N$G_ *$*\^H ^7_^"=__  2T^ G[ EIJ7BKP]H_]J^.M7N-0@O?&&H:E
M=7EP-+EU&>YMK.,W#MY2K&\7F; OFRHTCEC@@US_ ((W_P#!/7Q%\8Y_C/J_
MP0DDN+S7_P"WK[PT/$-Z-!NM5W;OMLNF";[*\A(R08]C')9222?J"B@#R/\
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MQ+8V-IJDQ\56)5X[3SO*VCS?E/[]\GOA?[HKH_\ A#M1_P"@QH/_ (4]C_\
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M\0^']%TF2_EO[]Y-;:YN=0O)<>;=7-Q,[23RM@9=V)PJJ,*H ^[/^%7?#/\
MZ)WH7_@HA_\ B:/^%7?#/_HG>A?^"B'_ .)H ^*?#VH?L8^%?C1XC_:&T'Q=
MH,'C#Q;I5CIOB#5_[?D;[7:V?F?9H_*:0Q1[/-D^9$5FW?,3@8\;^-/[#?\
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M._V?/B7\4_%GPZ^'UOXK\86/PVT2"^:Q2YG6*UT_:\Z.]],K>>D*J?W*M(6
M!KY\'_!QGI#?%AO@.O\ P2+_ &Q3XV7PZ-?;PD/A;;?VB-*,YMQ??9_MOF>0
M9@8O-QMW@KG/% 'Z0T5\-?&G_@N)X:^#/B'X<_#UO^">7[2/B/QI\1? 4OBV
M#P#X:\"6]QK6BV4=T;:1;ZT-TKPR*X4G 90)$RV3BNQ_8Q_X+$_ #]K[XX77
M[+GB#X,_%;X-_%&'2FU.R\ _&OP6=$O]6LD.'N+/]Y(DZ+U(W!B S!2J,P /
MK2BBB@ HHHH **** "BBO/OVK?V@;3]E/]G+QA^TAJ?PY\1>+++P7HLFK:CH
M/A2&&34)[6+#3O"D\L:,8XM\I!<$K&P7<V%(!Z#17GWPV_:C^!_Q3_9CTO\
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M+N#4 ?9]%?E_?_\ !3C_ (*T_!?]F_PE_P %0OVF?@Q\%+/]GWQ'=Z1?>(/
MV@3ZF?%OAGP[JL\$-I?O=RR?9;J=/M,$DL*Q)P^T;"&*>S_\%H?^"P/@G_@F
M1\#=5TGP#IZ^*_C3JOABZU+P9X)M[.6Y%K:1AQ+K%^L6##80;'8LS*96C,:D
M8=XP#[9HK ^%'B74?&GPN\->,=86,7>K:!9WET(5*H))8$=MH).!EC@9-;]
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MG2S)-=3) )9#)=W+Q1;Y<KM53&H*X"@'UQ1110 4444 %%%% 'RA_P %TO\
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MCX"Z_P#M(_M#^+TT;PQX=MO,N90N^:YE8[8K:WC',T\KE42,<EF'0 D?F_\
M$KX#?M*_&;]AC]L;_@JY^U7X.N?"?CKXH?LW:[X?^'7PWGR;CP9X'M[&ZNH[
M2ZQ@F]NG9KB=#_JV*KA3NC3Z:_X*J_\ !,+X]?\ !0WQU\(_&WP?_;@A^$I^
M$>O7&O:;8W?PMM?$]O>ZPPC6VO7AN[J.#?;*LOE;XY-K3LP((!&W^RQ^Q5_P
M4$\%^)_$=C^WK_P5$B_:#\!>(O!UYHLW@.?X%:/X91)KAX0;EKJQE:20"!;B
M$PD!6%SN)RBT ?//_!5*:TU#_@V!*Z$ZN]]\*/A['HA@QAKB2^T46Q0=_P!X
M8R !VZ5^FU?GC\,_^"+G[1>DO\//V<OC3^WU-XR_9L^$?BNRUSP1\-YO!,4&
MKWJ6$GFZ7INIZDLI%S:6CB/"K$OFB)0P4*FW]#J "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>cah-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cah="http://www.cardinal.com/20201231"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cah-20201231.xsd" xlink:type="simple"/>
    <context id="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77ba0c60824e4b95b074e0fa4e5f5b85_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ice1200d475ba40da95d038803bdd462f_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d8949488e504051b168d44d36fc8172_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae3c66df6beb43fb8dc9aec45034e9af_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icf177919053f4d84b5deede4be106b52_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8d920529cbde451191352192e3af656c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3ea5286e8327464ba54819290fd52747_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8ae2531be3ff4d52a622e624ada4da07_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icdf5ab90557c4000a09c6f27f8f43161_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i330e68ab5e5340ebadc011e5a0a59586_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i866db22bd82141a4a400612301c75ffb_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id0f0b3868edd4abb9835771227d980e0_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02b85a2b00dd4f0491c62b22e62fdd52_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief43f820ca8b46dbb807687b9aba78b0_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i333fddf2954c4f8f84d124aceab9eb34_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if43031c026d442a18ff9382d1b9cffc6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c921ca8f3fd4b668c26209f32686128_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic337060106e84e76a53c24d5a516bded_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i531c55176bb64260a4950658a062d0e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1cd1437e597b4e2682afe89f0b8f38a1_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="iefe8fb0429c640549ebd225f00c39fdd_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i90bccc700f344156818dd2a91922ae30_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i08f87960dc81422e8cc8681a4821d475_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i3530dfeec0384b169ee4ba603c672780_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i3c429f356e364a318686f6a96b4c0d70_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4f0d9a0a1c01475c97b8ad225ba6ed8a_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i087a2162c6ab4ee08231b8375275a66f_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic709b0f6e31348dc92cb361418750b1a_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i356ad0db94fd4af2945d43260c52b004_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7a37151dd9974055b9fd8a3b9f329fda_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8ffbcc7b8b47419fafc54db6c65fa67c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i961814e0fb934b26a59874c0a47b5c36_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i34bce33b39294b5990a6d2671d45efc1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a67a68103174862933d81e69761227a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ae7680d35a94fe791314d93518ad333_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i15dfaa9ce43d4c8dbe8e43f793325ab5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc62359854904e73a95bee6e706c2f64_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i02eca4589f2a4542b34a4ac4b0e54bbc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i327c9e14b86548eeaa15e0b1195a1713_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1d7546c5d1f84a4a8f9ddb1310f520fc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i83d7259b2a09452ea238e9d70eb94fcb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5b3c71ac478a4d02806d3987db7fca7c_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i342dbbcc001646b78a3682ec6c4a043a_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ac4657e05a9499ab00fb27b5751039b_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i69b8b80a81a246308be8e9d7ae9fb68e_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c695c989c1c488a9a822944847a51bb_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7239edd43644a128d30e8bbd0ab2a9e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i964a6019a431419c8e09883bc4b9d02c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i41b5d7dfd6a54361850263e4fd529847_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6ae7a3375f4c4b319354a025e78a9375_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i7285527fa33149449338e908558152ee_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9263daec240f40e18bbc79b563561d69_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iea6044c7ef014ad7b58ff6abb8cf7620_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifdfa6e7ff1fd4ff4894046a2aef75fa0_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i316bc31c1a6f4eb1a59f8bfb2c2df15c_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4523a176fdd843a1871b85358e66f672_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6f12e42d72c7409cbec2d494d04aea14_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i715f3cb5de28419892c4abe4c201b08b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i29dfcbbc4b87452b99f5496e7a8ee237_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4cb6bb1cf27c4f7a8d9e429c5c296315_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifaca494a8cb54963b9c8eabe88a49bf4_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id23cc7d0aa564d63919be6c6c1cfef81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79f208ee71c540dc96e55d1ea0309d92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98dea8eab827433d8bb7d45c1cfb404b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i14b14c71bbc54f248f49427b82d4c76a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib84ce22fc5e7432ea0e7678515ad59b0_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9662598991e54a289ce467d4c55860b1_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i63febb3b06bd4185a6a3f45a6da44204_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb5434fa06a945a9812fd66b941db4b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0576298a2e542fd95ac14b7815c72ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec244ced74e54c48890cb31ded0bdebf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a7db73217be4f9980a875418215b27c_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3386edf96d3941c387073f4c10dfd3a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i20ba7d43ca1e4e5bad3683d334fed42a_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94ec4ab4e33146c497406aa05665b794_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3be0113a67424f1d89bc62eba84876b6_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i56f4dc613d0944dfb65ad3407fdd7d98_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i036a1401ef2c457fb47d9dd79ed6fc99_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8e4b7722d85145d78ebc17885b5a4d24_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6a47a213956c4b9eb61252e2288e47f9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i474cf5f364454a11b22f24b06699e4df_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:FloatingRateNotesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifb2a9682f8564e3fb789bdc866101ff9_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c200f19e4364602a4c4db803bbe7e50_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.4Notesdue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i01211baf31064f409c8fa4c5b5b54b09_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i770887e4d98143a78ad85ee309204ca5_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A3.2Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaae728c0a7a4428ab31591199c01df2c_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:FloatingRateNotesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1bea82ad95804e6abff0fd8562560862_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A3.41Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2763cf8f732c46ac822b3a4e9cc9afce_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A4.6Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i907c1e70968546c7bd30ff773af28457_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A4.9Notesdue2045Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic9f2efa674d6441590242649316ec9a6_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A4.368Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i92aefd5c72f64cb89f421ad0100e879f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia70ce6414d4f4266bf2f26ca4eafbb15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91ee5d4795d74c0d97f3782625ff9fd1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie044a19677f140da979d3894dde5c9de_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0763235728b4e798df4a93f91297014_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i24af2662052e41a9916032cdb61e8d12_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i90dc05ceb60c40f0ac677345f92bae29_I20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="i38d2978456e542b7b3180f73a3e78c5f_I20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="i56512e9ae3444aa3993b873d559a9163_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id328a673f19941118ace9480b141deae_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia24262f3a922415db5013e0f3ae80122_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a4ad47536df474f94e261a74c430702_I20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="i2b7d20f207654f5896c816a15da9291c_I20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="i2b50640db30b49a9aeed0c6c228e045d_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i8a7e2cc7591649299a8be4db64de4bf6_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="iaf2d67987fbf44f9b89a411201940603_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i6a938e1fa9214d8cb46bb9c82947ad31_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="ia0b1626635494e759538b3e69c1d8c44_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06d03eb8370c4ad5b575e1b109ddc573_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i028cb05d5d774ece897a4eae7abde3c9_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:DOJInvestigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87230ed321a245fc91bc68615d9f61a5_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4465d750964497c99036784264b593a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic03700ae57af494fb31290e42a1720fd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8f1203c9a1ad44c4874a799063ecc408_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7325d606c00e4365b83eaf72e2f134be_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i08769690807c428b9015f5d581f80d13_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibbe4dd4c7b6c4b83bbef659b5664d7ff_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2334754903a5458bb5821f0515733377_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f1f3a98a99a4d27b6451bfb560ba396_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6112186cca62432382db406081a60a17_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i888db2833efb4657a6fefd55514539c8_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab7bd98acbea40449f8bd35c7616c720_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f7180f4c5144dceb597f6050eb94368_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i26e6e263c6fd4a699bb0c1af198967e1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i93d039e782a9419a9742c71dc850ce33_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65806b475fdc4876a59494d73901adb7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i159fa2bd7a66408badeaa0faea3b677d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7445253c20dd435886df7adff515242f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e83590d4a854a7190b78c1a5c2d284f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d6381aaa6914a0aa526a6b8b3989a7e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8b55dcaca51f44599a00a8fa68d79d85_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib957a62df7f549839a60399d078c4472_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if41b93ee69de4e0d9701c057ae9ab8db_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic35295a277e6424d9f0eb8e2c6404476_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0f82a2865f2b492a8c478c3a57f6df30_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i796ef5fe827b4eccb2c3f684dc6db76d_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b687b1f81d948059485e5e2a6425863_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib15a63d640244c34a6d0227562acaad5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib37c4b044c234377901beeef0ec945bd_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6845881719c14946a18825ca27e660d9_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i478d2dd73460414f88583f29a46256a5_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38f0432b47e6439c90226e210f3f5025_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id909840ad6bb4ab089bf9cbd591c6393_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i31ae9f550b884047875a86b44b481e30_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id293a6a8b52246f59bdad843b0eedcfc_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie3f98e4ee19e4429b6719301c1f07c3a_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib3c9f00156d0450788ebefaa19e489ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i169899f3ed7e4646b50fcb3a6ea5433a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i516dad7d9d244946b3629a4006f58d73_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie565dceec6384b15bc38825036cc1367_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9e8a2cc4f32e492b978886cfa6468d14_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic07137665bed4e8395c06d5d163722d4_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e9ec7b4d1de47779baac1a8003f4ac0_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5611e497378475180730c7bb2d349b0_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98af1fc7fbb546ada30bf032dc682c07_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec0a2a9c3a084ecda280560e320b49ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i956ec3fd41944891af79cc5fc668a58d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3907143d601446b2b2dadc450da37c6e_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5035cf75d04e4c4c800fa6271658ffaf_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i26d16186a3eb4d6cb347ef265ebd81c2_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic22e6eb5fc5b44eb8e366a0e404097eb_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3ff998854edd4eda8d8b8b0671924582_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i672ee4b7a6194291882b5780e5e828a0_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i341d682d330c4e5392a574b97873cfbc_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6447be5f30b14c9eae4c5ec00d2365d8_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if4bc1df9803142bca96ee5920f3f9477_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i618e7649eb974fa9a8bdda5a0b6c884e_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4a603a9a33074afd94135cf3f2682615_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i351ff459d8c147dc85efc9f57fefc562_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7a9dbdf0124e48049351c12013836acc_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3403a67c72846a2b090eb4c1dcfe35b_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id84c7d3f10b5448eae225db35d9ff12b_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i21a4a9e6c3b742fcb7a36c82c033f21c_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if2240c3e8e514deebd1a13337be4bed5_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d7ee7ef7fae4a23a4607553d24f1f27_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i94a02c3a95ca45b7a140f7699a115bef_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b2f1f0f8f9e4cdb9a87fac1bfc1dc87_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i67c2756a2d8e492a8d27ef7d759a0159_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic482ae4cb0e845e983854f115696e92f_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if5f48b5e33984bdc8b86b397bfccce23_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b678754b9524d1195c6310b764861aa_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id8df2c21ec314065818f504c97c1bc8f_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if7d29d41390f4acf84c102913fb223e5_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8216fd9e5c90433ea29335aa86cb447c_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i482f6ccb403f4a52af97d8ca515a61b8_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i95d2c4ed996940f9a46e1b79a9311ba9_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i555180dfd31f4d28b52ece1a6f81a588_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i97ef54c441584928af5eb60384fe7457_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9fc0478dc85442c2942659ad0aeebd71_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i235c9cf737b84394aae05f413fa3c155_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2d75526aa5047f9adcfa5c2aeac6208_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id0bce5f6fb544487b4e3560b83f1110a_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i46dd8327f8a44abf95b9a0332180575f_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9b9e9461ba0a47d18b3547d957221cd6_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i761af129229b4859917784980b5aa533_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i83001f54baa54c32ab564685b11c5fd7_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55908a6cac3f444daad213a201d855ec_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i99f293e06fa54cba94cd2fe57d28abad_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:SterileSurgicalGownRecallAxis">cah:SterileSurgicalGownRecallMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i704d2da68a27491caa5fcefcc86490a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d5964aeb73c4db18da5611b91ef7334_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i89a6b93ede39460b8242e3fedc07e841_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57ef56323da34ba69ad0fcaae008d16f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie417bfafb8654792b0622431ec8134ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d0bffbd8bb54efaa2c7c406881f23ab_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if99bd32109874e86a903049a33a5df8d_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib87c6a3a8d094aeaba3759a9a6ff0c4e_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic0de7af799774156a7e1dd567937f30d_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0fba9c013a7b43dd90febed8d8b6afe3_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia18cb4783d8449c285fe5638df3c4776_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib7d0b551d8034adaa39776dff9c6b47b_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia1e48cb861974ac9b185da35f6452945_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i52a2b1e5f55d48c5a3fbb4e2c6d024d6_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51b81892e14d49f39bb77a27503cd87d_D20190701-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if9de38f44efc4734a6acc21a07c418b0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id6a9264343844c3188592efd3e0a1c18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i130d53f3f6b041848bc6ad14a45add16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibdedc1cec79f497e8b28d714bde083dd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia83b442716234d0f8c45c343f0fa6ae7_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i95f32f5a14a64f12ade71f4f086f5c9d_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iea7a98aa2bac4b76bab476be13a2fb31_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i625efca7a8ef454c8cbb29134f0f0c7a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="stateag">
        <measure>cah:StateAG</measure>
    </unit>
    <unit id="lawsuit">
        <measure>cah:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>cah:plaintiff</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="segment">
        <measure>cah:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV80L2ZyYWc6NjczYmU1NTkxNjdlNDU5ZDkxZDA3MzQ4NmJiOTFjNWYvdGFibGU6ZDYyNzk1OTFjNDYxNGQ1M2FjMjczODdkYmM5ZDNiZGYvdGFibGVyYW5nZTpkNjI3OTU5MWM0NjE0ZDUzYWMyNzM4N2RiYzlkM2JkZl8yLTEtMS0xLTA_ab4c95de-2326-404a-869e-cbea67a09933">0000721371</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV80L2ZyYWc6NjczYmU1NTkxNjdlNDU5ZDkxZDA3MzQ4NmJiOTFjNWYvdGFibGU6ZDYyNzk1OTFjNDYxNGQ1M2FjMjczODdkYmM5ZDNiZGYvdGFibGVyYW5nZTpkNjI3OTU5MWM0NjE0ZDUzYWMyNzM4N2RiYzlkM2JkZl8zLTEtMS0xLTA_4aeb9e7f-9494-4725-b77a-3329abdeb9d7">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV80L2ZyYWc6NjczYmU1NTkxNjdlNDU5ZDkxZDA3MzQ4NmJiOTFjNWYvdGFibGU6ZDYyNzk1OTFjNDYxNGQ1M2FjMjczODdkYmM5ZDNiZGYvdGFibGVyYW5nZTpkNjI3OTU5MWM0NjE0ZDUzYWMyNzM4N2RiYzlkM2JkZl80LTEtMS0xLTA_0cef7fb8-7432-4645-b2f6-123c57f90c1d">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV80L2ZyYWc6NjczYmU1NTkxNjdlNDU5ZDkxZDA3MzQ4NmJiOTFjNWYvdGFibGU6ZDYyNzk1OTFjNDYxNGQ1M2FjMjczODdkYmM5ZDNiZGYvdGFibGVyYW5nZTpkNjI3OTU5MWM0NjE0ZDUzYWMyNzM4N2RiYzlkM2JkZl81LTEtMS0xLTA_6fc461cc-3ca3-4cbb-9e02-c37700152307">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV80L2ZyYWc6NjczYmU1NTkxNjdlNDU5ZDkxZDA3MzQ4NmJiOTFjNWYvdGFibGU6ZDYyNzk1OTFjNDYxNGQ1M2FjMjczODdkYmM5ZDNiZGYvdGFibGVyYW5nZTpkNjI3OTU5MWM0NjE0ZDUzYWMyNzM4N2RiYzlkM2JkZl82LTEtMS0xLTA_5207f150-7049-4790-8e1a-c8dc71e46770">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM184NQ_b474052f-f162-4128-a84e-677841bbcf20">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6YjUxMjcxYzVlYjcxNDQ2NjhmZmRmMWU3ODlhZDY1YzMvdGFibGVyYW5nZTpiNTEyNzFjNWViNzE0NDY2OGZmZGYxZTc4OWFkNjVjM18wLTAtMS0xLTA_6bd0c712-a791-4745-b5ad-94487adacbdf">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xMjI_5974113b-58e9-40d1-9e10-31e19f27690c">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6ZWY5YjI5NGE4NDg3NDZmOWIwYTdlMDM4Y2Q1ZTE4ZDQvdGFibGVyYW5nZTplZjliMjk0YTg0ODc0NmY5YjBhN2UwMzhjZDVlMThkNF8wLTAtMS0xLTA_7b473323-51f1-40eb-ba53-bcf410066771">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xNTc4_ffac97a4-28ab-4b94-b565-de0f0a90a9a7">1-11373</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xNTc5_fdf7caca-105a-48b7-b469-2f3ffbef91cd">Cardinal Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl8wLTAtMS0xLTA_380f828d-4c28-44ee-baf3-13b0dc64fd99">OH</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl8wLTYtMS0xLTA_5dbdd9a0-ec01-4936-a634-6d9c70fc5445">31-0958666</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl8zLTAtMS0xLTA_ed797803-eb11-4dba-bea4-10bef4607820">7000 Cardinal Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl8zLTItMS0xLTA_d57f302d-e3fb-410e-b978-35db9c4b91c9">Dublin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl8zLTQtMS0xLTA_5999803f-ebb5-4b9b-9d93-544eac136817">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl8zLTYtMS0xLTA_14b97211-2d50-43a5-a342-3e33d4e8f3c1">43017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl82LTQtMS0xLTA_a7e73169-7ce3-4d95-9cba-603936e7f91a">(614)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MjVkM2JkYzY5NzExNDJhYmFmYjJjYWUzNDRlOGU2MjIvdGFibGVyYW5nZToyNWQzYmRjNjk3MTE0MmFiYWZiMmNhZTM0NGU4ZTYyMl82LTYtMS0xLTA_d14090e1-983a-43a0-b453-90cee731131e">757-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6YjkwMmY2NGQ1MDcxNDJhZWIwMjg5YjRmMTg0ODY3MWMvdGFibGVyYW5nZTpiOTAyZjY0ZDUwNzE0MmFlYjAyODliNGYxODQ4NjcxY18yLTAtMS0xLTA_7b698113-33c4-4ac0-b746-bba998a9d841">Common shares (without par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6YjkwMmY2NGQ1MDcxNDJhZWIwMjg5YjRmMTg0ODY3MWMvdGFibGVyYW5nZTpiOTAyZjY0ZDUwNzE0MmFlYjAyODliNGYxODQ4NjcxY18yLTEtMS0xLTA_b00f6340-3903-4fb4-9d2d-b26f6926d880">CAH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6YjkwMmY2NGQ1MDcxNDJhZWIwMjg5YjRmMTg0ODY3MWMvdGFibGVyYW5nZTpiOTAyZjY0ZDUwNzE0MmFlYjAyODliNGYxODQ4NjcxY18yLTItMS0xLTA_f9087b94-2cfa-438c-b787-a00a3928a82b">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xNTgw_106b0c96-4c9d-46b4-9ae9-bc8b950ffb93">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xNTgx_d962f212-6d50-450f-a8a0-2022e69c48de">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MWRlZDcxZTZmZjgwNDQ3MDg4N2VjNjI2NWVkNTc2MGEvdGFibGVyYW5nZToxZGVkNzFlNmZmODA0NDcwODg3ZWM2MjY1ZWQ1NzYwYV8wLTAtMS0xLTA_4c0af603-07f2-48a6-a382-3c95011ce66a">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MWRlZDcxZTZmZjgwNDQ3MDg4N2VjNjI2NWVkNTc2MGEvdGFibGVyYW5nZToxZGVkNzFlNmZmODA0NDcwODg3ZWM2MjY1ZWQ1NzYwYV8xLTQtMS0xLTA_1a30c307-20eb-4a88-8da3-1f63dd07e2f0">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGFibGU6MWRlZDcxZTZmZjgwNDQ3MDg4N2VjNjI2NWVkNTc2MGEvdGFibGVyYW5nZToxZGVkNzFlNmZmODA0NDcwODg3ZWM2MjY1ZWQ1NzYwYV8yLTQtMS0xLTA_6a1cce77-a526-44d6-813d-c332316f4a14">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xNTgy_2b9ac65c-f220-4c7f-a69c-d77d1226be8f">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i77ba0c60824e4b95b074e0fa4e5f5b85_I20210131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xL2ZyYWc6ODNhNzM0MzU0MzI1NGU1Yzg2MmMyNmQxMzIxOTIxZTMvdGV4dHJlZ2lvbjo4M2E3MzQzNTQzMjU0ZTVjODYyYzI2ZDEzMjE5MjFlM18xNTc2_afde361f-7e47-4aa5-a631-b69551ec9bf7"
      unitRef="shares">293667560</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMi0xLTEtMS0w_25298851-b43d-425a-b8ac-26cfa28fce46"
      unitRef="usd">41541000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMi0zLTEtMS0w_599dc1c1-d5ea-49e3-b99f-b999cc6faa9f"
      unitRef="usd">39735000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMi01LTEtMS0w_021e096f-8eb7-4440-aaaf-73c6f0e68422"
      unitRef="usd">80606000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMi03LTEtMS0w_a42c2144-14c5-45a9-8fe9-1a50384193d4"
      unitRef="usd">77076000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMy0xLTEtMS0w_16fecd0d-4e7c-472d-8114-2ef894d6ee5e"
      unitRef="usd">39765000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMy0zLTEtMS0w_14f38e83-36be-42a2-abd0-6e934ea9517d"
      unitRef="usd">38021000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMy01LTEtMS0w_a7481e1c-eb59-417a-8f76-ce33b8d4a2e2"
      unitRef="usd">77115000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMy03LTEtMS0w_d3814ab0-e0bc-416c-96f4-dab25287e804"
      unitRef="usd">73683000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNC0xLTEtMS0w_f9b47339-2a46-44d4-aec4-e00325dbf447"
      unitRef="usd">1776000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNC0zLTEtMS0w_3c2532e1-faa7-4d1c-985b-5bf4d6acb624"
      unitRef="usd">1714000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNC01LTEtMS0w_a50d7ef2-2281-4729-ae23-4ee3d5cade67"
      unitRef="usd">3491000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNC03LTEtMS0w_399882e0-0f64-4200-9206-a9e7ada02568"
      unitRef="usd">3393000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNy0xLTEtMS0w_66b38d36-62fe-4316-8e94-6c984db1fd0d"
      unitRef="usd">1147000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNy0zLTEtMS0w_b017a8c0-73d3-4eb8-9445-18415a3a2dd8"
      unitRef="usd">1163000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNy01LTEtMS0w_fb932573-83e2-4cb2-a64e-b0a5f5888351"
      unitRef="usd">2284000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfNy03LTEtMS0w_30afedbe-ab76-4d45-9f99-f4d4ef9a4e84"
      unitRef="usd">2270000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOC0xLTEtMS0w_1d49d59e-d4f6-4531-a0fc-7af0ef528c35"
      unitRef="usd">20000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOC0zLTEtMS0w_532b6077-e6f6-481b-a9ce-b8f2e403829d"
      unitRef="usd">56000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOC01LTEtMS0w_a3def86f-b09a-4b55-9e80-4936bb65d333"
      unitRef="usd">57000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOC03LTEtMS0w_b417d94f-b1d3-4834-afca-0dd321a4ac89"
      unitRef="usd">86000000</us-gaap:RestructuringCharges>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOS0xLTEtMS0w_98f02279-0f7a-4d6e-9813-83b65bf36c6f"
      unitRef="usd">116000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOS0zLTEtMS0w_d9cf8045-8bdd-46a9-aab1-abd1578f28b4"
      unitRef="usd">133000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOS01LTEtMS0w_b513cf24-776e-43d8-af84-d2683b5e6125"
      unitRef="usd">234000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfOS03LTEtMS0w_c5c42528-adaf-4117-ab8c-8bf901c0bdb8"
      unitRef="usd">265000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTAtMS0xLTEtMA_017ea4f6-7b9e-4864-842f-ac75983e6e8e"
      unitRef="usd">0</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTAtMy0xLTEtMA_5db294a2-f670-40be-863f-f84340cda42d"
      unitRef="usd">-7000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTAtNS0xLTEtMA_ee813a46-a5aa-4654-9cd4-bdbe3ade0353"
      unitRef="usd">-9000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTAtNy0xLTEtMA_54930c21-39e4-4170-8d9f-2b00e17ba8e9"
      unitRef="usd">-8000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTEtMS0xLTEtMA_056213ef-62d2-4518-9565-099ea6cfb147"
      unitRef="usd">-32000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTEtMy0xLTEtMA_87033f3a-f6ec-4463-9bd0-d1ec1fa80baa"
      unitRef="usd">-21000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTEtNS0xLTEtMA_d1445ec0-c54b-4e68-bca6-a1a06d513982"
      unitRef="usd">-1070000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTEtNy0xLTEtMA_8164fa97-1770-48e1-9329-beddbb7a2558"
      unitRef="usd">-5694000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTItMS0xLTEtMA_5cc83a94-de18-4489-a607-2f39e4ae3a3c"
      unitRef="usd">461000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTItMy0xLTEtMA_b64ce230-267d-42e9-9e7c-70da5216480a"
      unitRef="usd">334000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTItNS0xLTEtMA_44c7d799-3968-4671-a0c8-4f900e3ffc0c"
      unitRef="usd">-163000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTItNy0xLTEtMA_4b3caae6-162a-4c95-b59f-8bf13a9ce45d"
      unitRef="usd">-4930000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTQtMS0xLTEtMA_b6778388-4ff3-4846-9eb0-a142c144d8ae"
      unitRef="usd">12000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTQtMy0xLTEtMA_88ed116c-ba91-4b2c-a2b5-fd325b7ebce9"
      unitRef="usd">12000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTQtNS0xLTEtMA_acbabe62-4f54-442c-ab66-2fd62372c2f1"
      unitRef="usd">19000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTQtNy0xLTEtMA_bd6bf353-6d14-44dc-8996-8affcdd933ab"
      unitRef="usd">-2000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTUtMS0xLTEtMA_3bcca4a6-399b-43b3-8007-2da2526b3350"
      unitRef="usd">46000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTUtMy0xLTEtMA_d58619d0-fe30-42c1-86a9-74289eb1f05c"
      unitRef="usd">63000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTUtNS0xLTEtMA_737cd494-836e-4ae4-9598-429aaa599571"
      unitRef="usd">91000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTUtNy0xLTEtMA_cefbeb2f-9153-499f-a66a-7cbd113b7001"
      unitRef="usd">129000000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTYtMS0xLTEtMA_b0b3b784-e3d9-42f3-916f-8753f049c893"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTYtMy0xLTEtMA_aacbbd47-72e0-41e0-bb7f-f610b718da97"
      unitRef="usd">-4000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTYtNS0xLTEtMA_37c1445f-af69-4651-a61e-45a6f47601cd"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTYtNy0xLTEtMA_e0a8b30a-55e9-4f19-a3a3-657b74926385"
      unitRef="usd">-4000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTctMS0xLTEtMA_c48ed16d-a11f-4b1b-867b-59f9290b5550"
      unitRef="usd">427000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTctMy0xLTEtMA_cc8fbad7-827e-4518-8cb2-e50f86ec2692"
      unitRef="usd">279000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTctNS0xLTEtMA_4c611f5f-b047-45f9-b49b-27f19ec3866c"
      unitRef="usd">-236000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTctNy0xLTEtMA_2979cfaa-2eea-45d5-a070-190c8e8c255e"
      unitRef="usd">-5065000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTktMS0xLTEtMA_38177116-b29d-4c02-bc35-fbe743b13c8a"
      unitRef="usd">203000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTktMy0xLTEtMA_0d08e31a-6c21-432a-ad35-0da87a4c5262"
      unitRef="usd">-59000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTktNS0xLTEtMA_3cf7f183-6d02-4a2e-b7e3-69e5942863e7"
      unitRef="usd">613000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMTktNy0xLTEtMA_3f9faa73-0a54-4a2e-8534-0181fcdd8b90"
      unitRef="usd">364000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjAtMS0xLTEtMA_05b749b6-efbb-45e6-a2ac-0b62f1163517"
      unitRef="usd">630000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjAtMy0xLTEtMA_ccbff9b9-aad2-4da1-b721-5321e60bad73"
      unitRef="usd">220000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjAtNS0xLTEtMA_45d94a1f-88dd-4849-8417-f554bd7e3e21"
      unitRef="usd">377000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjAtNy0xLTEtMA_0ea03550-01f8-431e-ad67-6f6706f833de"
      unitRef="usd">-4701000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjUtMS0xLTEtMA_3eb2b372-1c8a-42b5-8109-9067790c4f31"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjUtMy0xLTEtMA_d88656f1-d0de-404f-97cc-c10015089ad9"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjUtNS0xLTEtMA_8c9e147f-2d1e-4f92-a344-6b248a79fef6"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjUtNy0xLTEtMA_19e7e849-aaee-45c9-b3cd-e9e6fdb4fcca"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjYtMS0xLTEtMA_9b28f5eb-4bb3-4438-a5dc-ebc1433d96c4"
      unitRef="usd">629000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjYtMy0xLTEtMA_f8c42494-9f5c-4f05-adad-e438d75563d0"
      unitRef="usd">220000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjYtNS0xLTEtMA_bf32d39f-2888-4757-9f5a-a51a091a165c"
      unitRef="usd">376000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjYtNy0xLTEtMA_ed48cbdf-b16d-486e-83be-7e9b3ca64412"
      unitRef="usd">-4702000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjktMS0xLTEtMA_a292dd8a-5a4f-451c-8371-21242f1331b7"
      unitRef="usdPerShare">2.14</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjktMy0xLTEtMA_c915b76f-5e07-4f9b-b3e6-2b658311809d"
      unitRef="usdPerShare">0.75</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjktNS0xLTEtMA_a3f95be4-e6fc-486e-97d3-92d496c713d3"
      unitRef="usdPerShare">1.28</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMjktNy0xLTEtMA_90030e0c-272e-4268-a823-d1e2b513b489"
      unitRef="usdPerShare">-15.99</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzAtMS0xLTEtMA_94eaf558-d352-405c-8c5d-2921ded0b97b"
      unitRef="usdPerShare">2.13</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzAtMy0xLTEtMA_67ccc16a-b6c4-401f-a3a4-eba37aefb699"
      unitRef="usdPerShare">0.75</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzAtNS0xLTEtMA_a17c62f8-48c2-4144-b58c-ef2eb21e3fe3"
      unitRef="usdPerShare">1.27</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzAtNy0xLTEtMA_3758ae09-ba96-456d-ba1b-521404fe65ab"
      unitRef="usdPerShare">-15.99</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzMtMS0xLTEtMA_1704f9c4-97cf-4c41-a2a7-7281a037916b"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzMtMy0xLTEtMA_09bcb73d-9c60-44e5-bd44-7a97cf70fc0b"
      unitRef="shares">292000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzMtNS0xLTEtMA_1996e7b9-e7fd-4e79-a193-ddf4a069211a"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzMtNy0xLTEtMA_38fdc708-b27d-43ac-9b62-45439a13633c"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzQtMS0xLTEtMA_da7e3ba7-22f7-4abb-9b53-3939e94f31a4"
      unitRef="shares">295000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzQtMy0xLTEtMA_09985a6e-4e31-42f2-993f-2c4f895da606"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzQtNS0xLTEtMA_1e781454-f510-4cb0-ba13-d03a3443f663"
      unitRef="shares">295000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzQtNy0xLTEtMA_c633cc11-19d0-416e-a16a-685839df02ad"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzYtMS0xLTEtMA_08d782e0-ecd0-44a5-9540-1afaa69a41f6"
      unitRef="usdPerShare">0.4859</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzYtMy0xLTEtMA_87dfb523-0eed-4fc1-b9be-ce7cd2670061"
      unitRef="usdPerShare">0.4811</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzYtNS0xLTEtMA_8080d569-a904-46fc-adf6-dfeba86bd1c3"
      unitRef="usdPerShare">0.9718</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82MS9mcmFnOmExZDY3ZjcxNmE5NzQ0ZmU5YjcyMTQ5OTQ1YzdkYWQwL3RhYmxlOjliYWMzMTVkNmUyYTQ4ZDc5MzFjNWUwNTVlYzYxOTk4L3RhYmxlcmFuZ2U6OWJhYzMxNWQ2ZTJhNDhkNzkzMWM1ZTA1NWVjNjE5OThfMzYtNy0xLTEtMA_d6710252-85d2-4916-ae94-646c4d0b005f"
      unitRef="usdPerShare">0.9622</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ProfitLoss
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMi0xLTEtMS0w_47e22d89-1879-415d-919b-90c4e07189f7"
      unitRef="usd">630000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMi0zLTEtMS0w_db68d73c-9c03-4fc6-bb1f-026e95349789"
      unitRef="usd">220000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMi01LTEtMS0w_f1fc5cb8-552c-4966-943c-29ad9d536090"
      unitRef="usd">377000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMi03LTEtMS0w_0a2fd817-f00e-4808-ad80-e858cccf8160"
      unitRef="usd">-4701000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNS0xLTEtMS0w_4e44391d-4a30-416e-a08f-8ed1b0a0989f"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNS0zLTEtMS0w_6ef172e5-8c6c-40b7-acee-5c7fcf9f8d80"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNS01LTEtMS0w_0f4185ac-e9bc-4831-a3a4-b275e9036cfe"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNS03LTEtMS0w_445d1159-1e44-406a-8a27-2f5aedac8daf"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNy0xLTEtMS0w_614b3d0e-83d1-44d7-9054-684b4d9dd47f"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNy0zLTEtMS0w_cc39116e-af96-4e68-89a5-279def6a3b6b"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNy01LTEtMS0w_14da8600-bb2b-4277-b851-3fd059de887d"
      unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfNy03LTEtMS0w_aea7b612-90c6-4197-9464-e274f68b88b6"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfOC0xLTEtMS0w_2785b137-a168-41d7-9c76-71e9ddf7f0b3"
      unitRef="usd">34000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfOC0zLTEtMS0w_dd4a1478-fafd-4a9d-894a-66550d9ca8c1"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfOC01LTEtMS0w_97c10711-7b0d-45d2-8af6-f157b71c8ab3"
      unitRef="usd">51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfOC03LTEtMS0w_57972ed0-e4f8-46ce-9a75-b16a1ecf1c24"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTAtMS0xLTEtMA_839c8f40-7c7f-4d2e-a9a5-5d2a7285d855"
      unitRef="usd">664000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTAtMy0xLTEtMA_e9c91b61-0efc-499d-865e-3c9a722400aa"
      unitRef="usd">218000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTAtNS0xLTEtMA_24cca5d6-e30c-4122-85cc-37cc750ea52e"
      unitRef="usd">428000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTAtNy0xLTEtMA_a50eb2dd-37d2-49ab-9ab1-e8548e83ca69"
      unitRef="usd">-4725000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTItMS0xLTEtMA_b2728767-d3c8-4bee-a030-2764bd22e450"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTItMy0xLTEtMA_e7206e1c-9b0f-4b06-bc7e-20ccb0425f93"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTItNS0xLTEtMA_50c6c1e3-36ab-453f-b601-c72362c3875a"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTItNy0xLTEtMA_d9dc5e94-b54c-4af5-b488-a049aee8d43a"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTQtMS0xLTEtMA_f07cb22b-b51b-4422-a1c3-52ae29b4c07e"
      unitRef="usd">663000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTQtMy0xLTEtMA_b57b9b9d-6876-4a12-b691-06d48e414b88"
      unitRef="usd">218000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTQtNS0xLTEtMA_e20bcdca-0f45-4a3d-8e6d-1e3b5f31b58a"
      unitRef="usd">427000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82NC9mcmFnOjMwY2UyNGYwYWNhMjQwYTg4NzdhZDdkMmZjNTdlZDkyL3RhYmxlOmRiMGNiZThiM2VlZjRlMWFhMmMxZWZjYWM4YjliZTljL3RhYmxlcmFuZ2U6ZGIwY2JlOGIzZWVmNGUxYWEyYzFlZmNhYzhiOWJlOWNfMTQtNy0xLTEtMA_2ec5aff7-73c8-4500-9af8-e6a5e0d82e3f"
      unitRef="usd">-4726000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMy0xLTEtMS0w_c45d2178-d29a-423b-ac51-5506b005b4de"
      unitRef="usd">3737000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMy0zLTEtMS0w_51345052-4229-452a-97ce-ed10cdabc724"
      unitRef="usd">2771000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfNC0xLTEtMS0w_9b779b39-c2c7-4cb4-af23-a09801970843"
      unitRef="usd">8728000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfNC0zLTEtMS0w_97a5ce97-1c86-401b-a8de-b2931f99865c"
      unitRef="usd">8264000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfNS0xLTEtMS0w_12f4e410-6da7-48e9-9943-f5537c70dde5"
      unitRef="usd">14443000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfNS0zLTEtMS0w_c4fd0bea-83af-4034-963a-87bec28a3363"
      unitRef="usd">13198000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfNy0xLTEtMS0w_7bc2ce45-6576-4285-b9a3-9030e81e0e03"
      unitRef="usd">3205000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfNy0zLTEtMS0w_94fff864-2662-4a71-a3f9-04af904ec748"
      unitRef="usd">1707000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfOC0xLTEtMS0w_8c3bdf2c-0f38-484e-9646-fe5a0c346a72"
      unitRef="usd">30113000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfOC0zLTEtMS0w_58828c97-b67b-4484-ba53-607f3b56cbe7"
      unitRef="usd">25940000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTAtMS0xLTEtMA_185bd42d-005b-4cc0-bbe6-103b8093c9c6"
      unitRef="usd">2386000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTAtMy0xLTEtMA_6f4b7320-6dd2-483a-8502-17311b3f2836"
      unitRef="usd">2366000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTEtMS0xLTEtMA_ee4742f3-3b1e-48a0-89d4-9f8e45d03405"
      unitRef="usd">11102000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTEtMy0xLTEtMA_c1f2466b-4d74-4729-8c22-9c8e4428ea56"
      unitRef="usd">11275000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTMtMS0xLTEtMA_e9a0de8b-7161-4221-9aea-f42acc7ca306"
      unitRef="usd">1118000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTMtMy0xLTEtMA_56181167-5acf-4eb8-8703-99d57c8b9e52"
      unitRef="usd">1185000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTQtMS0xLTEtMA_9405130b-6e12-41d6-975a-37c33c8488d9"
      unitRef="usd">44719000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTQtMy0xLTEtMA_3cc37948-3e36-4f6c-b88f-030d05e0c982"
      unitRef="usd">40766000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTgtMS0xLTEtMA_148fa4a2-857b-4027-9da3-e9726179fe48"
      unitRef="usd">23235000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTgtMy0xLTEtMA_b7dbc57a-a0fb-48a6-9bfe-63836fcc6721"
      unitRef="usd">21374000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTktMS0xLTEtMA_053e648f-efe8-45d1-9b75-786cf9487f4d"
      unitRef="usd">13000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMTktMy0xLTEtMA_e269c532-9d7b-4d30-8f32-52ad94880221"
      unitRef="usd">10000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjAtMS0xLTEtMA_03840fc2-17c0-43df-845d-15a1d04d854f"
      unitRef="usd">2502000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjAtMy0xLTEtMA_b8e7cfbc-3768-4a44-93bc-be3dbe1f81a0"
      unitRef="usd">2231000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjEtMS0xLTEtMA_87cd4e36-b8fb-4489-a165-9a63b35f9574"
      unitRef="usd">25750000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjEtMy0xLTEtMA_7adc1b04-adba-4ed3-bbda-405e7264b2fe"
      unitRef="usd">23615000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjMtMS0xLTEtMA_48d6fe47-17b3-4bfe-a62c-a83407e3ce32"
      unitRef="usd">6720000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjMtMy0xLTEtMA_5a968977-6c86-4bcf-bd38-dd2d91a70430"
      unitRef="usd">6765000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjQtMS0xLTEtMA_59a77bb4-5b39-4c43-84c5-82ec680e2563"
      unitRef="usd">10274000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjQtMy0xLTEtMA_d6f314c6-180e-4a8b-ac2d-c31d1ab48582"
      unitRef="usd">8594000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjgxNmY4YTk0MjQ0YjRkMTE5MTMwMGY1ZmYzMGQ0NWM3XzMyOTg1MzQ4ODM0NTM_0b4cf445-2893-406e-9016-af53c6e3dddc"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjgxNmY4YTk0MjQ0YjRkMTE5MTMwMGY1ZmYzMGQ0NWM3XzMyOTg1MzQ4ODM0NTM_66e24bbd-d466-4593-ae38-c4f0858bf472"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjgxNmY4YTk0MjQ0YjRkMTE5MTMwMGY1ZmYzMGQ0NWM3XzMyOTg1MzQ4ODM0NjI_88368891-df3a-49ab-a50c-9163304063a1"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjgxNmY4YTk0MjQ0YjRkMTE5MTMwMGY1ZmYzMGQ0NWM3XzMyOTg1MzQ4ODM0NjI_8d5d39cd-6af4-4f5b-b70f-c79887451124"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjgtMS0xLTEtMA_8433447c-dd75-4127-8663-bb19643b4e3d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMjgtMy0xLTEtMA_551056a7-54ae-4b39-aec9-609ce807a170"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNTc4YTU4YmZjMDQ1OGI5MGQ1YjVkYmM3OGI0ZWRkXzMyOTg1MzQ4ODM2MjA_170b9842-6c1d-43a3-98db-16cfb3027d3e"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNTc4YTU4YmZjMDQ1OGI5MGQ1YjVkYmM3OGI0ZWRkXzMyOTg1MzQ4ODM2MjA_ff6f0b38-869d-4b2b-ab6f-d135494b6b38"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNTc4YTU4YmZjMDQ1OGI5MGQ1YjVkYmM3OGI0ZWRkXzMyOTg1MzQ4ODM2MDQ_1b76026c-ecc6-4878-bc47-0b5dc889a7da"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNTc4YTU4YmZjMDQ1OGI5MGQ1YjVkYmM3OGI0ZWRkXzMyOTg1MzQ4ODM2MDQ_70c3dd72-bf06-42c1-b959-9129273dcb08"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzAtMS0xLTEtMA_de131e80-38b3-4852-9f75-42fd7bc93535"
      unitRef="usd">2778000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzAtMy0xLTEtMA_3777223f-da31-4e5a-9495-8651b564a4c1"
      unitRef="usd">2789000000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzEtMS0xLTEtMA_6ad79bec-daf5-4415-b6c3-829db27c9600"
      unitRef="usd">1255000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzEtMy0xLTEtMA_46bac30e-4441-4780-ba37-5a26195b4b15"
      unitRef="usd">1170000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlZjFiZThiYzA2MzRlM2U4OTcxNDk3M2I1NjhjNTMwXzMyOTg1MzQ4ODM2NTQ_2929e101-f88c-4dd4-9c2d-b7719d850ff3"
      unitRef="shares">33000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNlZjFiZThiYzA2MzRlM2U4OTcxNDk3M2I1NjhjNTMwXzMyOTg1MzQ4ODM2NDg_2353fb84-be87-412e-bb57-9cbb41cf61e5"
      unitRef="shares">34000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzItMS0xLTEtMA_5e1eff8b-a737-49cc-96f7-05f03c53de76"
      unitRef="usd">2009000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzItMy0xLTEtMA_8cc007c0-8761-4cb4-adad-3529c8f85b9a"
      unitRef="usd">2066000000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzMtMS0xLTEtMA_91d58854-68a3-4bbe-9408-83aa3c16b2d4"
      unitRef="usd">-53000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzMtMy0xLTEtMA_d2d39451-ae81-4ee1-94d7-86183e24a691"
      unitRef="usd">-104000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzQtMS0xLTEtMA_511d331b-8562-407a-8d7e-c97e6d06f0ec"
      unitRef="usd">1971000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzQtMy0xLTEtMA_604b049f-62e8-4963-8bca-079e39d1b8fa"
      unitRef="usd">1789000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzUtMS0xLTEtMA_d255b58d-4d1c-4d17-bad2-136f0b0f03b6"
      unitRef="usd">4000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzUtMy0xLTEtMA_1d71ec0c-0212-4c37-a08b-cba93d0be1b3"
      unitRef="usd">3000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzYtMS0xLTEtMA_e342ea57-34fb-45ed-b5b9-a9c228c2d1aa"
      unitRef="usd">1975000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzYtMy0xLTEtMA_7f2708ea-a49f-49c9-ad12-6e9992eec738"
      unitRef="usd">1792000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzctMS0xLTEtMA_514a4fcf-a9ee-43ad-acd1-a88f3448251c"
      unitRef="usd">44719000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV82Ny9mcmFnOmY2MDA3ZDYyMTE5YTQ5MTViM2Q2ZWIyMTYwMTI1YmQ1L3RhYmxlOjI0OGNhMTNjMGQ0YTQyODA4YzlhZjcyM2ZmNmEzMDFlL3RhYmxlcmFuZ2U6MjQ4Y2ExM2MwZDRhNDI4MDhjOWFmNzIzZmY2YTMwMWVfMzctMy0xLTEtMA_0a64aa49-9652-4321-bcb1-1e4a066cb0db"
      unitRef="usd">40766000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="icf177919053f4d84b5deede4be106b52_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy0xLTEtMS0w_0b099dfb-411c-4eef-a4f6-ff9bcb5e85e4"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf177919053f4d84b5deede4be106b52_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy0zLTEtMS0w_f021a42b-24d4-4f47-bc9b-65bdf23b4eaa"
      unitRef="usd">2760000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d920529cbde451191352192e3af656c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy01LTEtMS0w_5adcb09e-34fa-481f-b874-129d7d2ab77d"
      unitRef="usd">771000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i3ea5286e8327464ba54819290fd52747_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy03LTEtMS0w_e7ec0b27-7d43-4e7d-a48e-517ffa4a7ec2"
      unitRef="shares">-33000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i3ea5286e8327464ba54819290fd52747_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy05LTEtMS0w_0715d916-2882-4ae5-b5da-e547338d9c29"
      unitRef="usd">-2022000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ae2531be3ff4d52a622e624ada4da07_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy0xMS0xLTEtMA_5532ace7-af73-4193-8584-c01b8e534226"
      unitRef="usd">-87000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icdf5ab90557c4000a09c6f27f8f43161_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy0xMy0xLTEtMA_537be243-0e58-4f11-bca8-815842b93a6d"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i330e68ab5e5340ebadc011e5a0a59586_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMy0xNS0xLTEtMA_1ee54e14-6771-4248-a70d-4d5316c3a542"
      unitRef="usd">1425000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNC01LTEtMS0w_9b28f5eb-4bb3-4438-a5dc-ebc1433d96c4"
      unitRef="usd">629000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i866db22bd82141a4a400612301c75ffb_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNC0xMy0xLTEtMA_e73d0613-2ce8-407c-a2a1-272bbbc0bbec"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNC0xNS0xLTEtMA_b444b647-462d-4f9f-9e83-00dccf9035ac"
      unitRef="usd">630000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNS0xMS0xLTEtMA_2785b137-a168-41d7-9c76-71e9ddf7f0b3"
      unitRef="usd">34000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNS0xNS0xLTEtMA_1089d6d9-f3da-49cd-a956-eb11536d258d"
      unitRef="usd">34000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id0f0b3868edd4abb9835771227d980e0_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNy0xLTEtMS0w_60838326-82ad-4835-a912-4a82e50f0097"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id0f0b3868edd4abb9835771227d980e0_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNy0zLTEtMS0w_32ae3847-7342-4f65-a24f-20a235d79faa"
      unitRef="usd">17000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i02b85a2b00dd4f0491c62b22e62fdd52_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNy03LTEtMS0w_6de65b8a-e965-4db2-9161-a010518e09da"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i02b85a2b00dd4f0491c62b22e62fdd52_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNy05LTEtMS0w_0f4e9602-061c-41c5-b018-9616be0f3177"
      unitRef="usd">13000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfNy0xNS0xLTEtMA_f4329832-cda1-4ac7-8247-7e63e7f07ced"
      unitRef="usd">30000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:Dividends
      contextRef="ief43f820ca8b46dbb807687b9aba78b0_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfOS01LTEtMS0w_7347a18b-e122-4145-9f6e-f091162d289e"
      unitRef="usd">144000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfOS0xNS0xLTEtMA_57c35d20-ba9b-467b-8179-a34630bb6814"
      unitRef="usd">144000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="id0f0b3868edd4abb9835771227d980e0_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTAtMy0xLTEtMzQ5OQ_6b9f2156-a24f-4322-b033-66fc43871390"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ief43f820ca8b46dbb807687b9aba78b0_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTAtNS0xLTEtMA_3e78a274-3a19-485f-b896-134e00cde9c2"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i866db22bd82141a4a400612301c75ffb_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTAtMTMtMS0xLTA_26cadf08-b428-4352-ac6d-30c63fc9ed49"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTAtMTUtMS0xLTA_a9e7673b-d0d8-42c9-b390-45381204996e"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i333fddf2954c4f8f84d124aceab9eb34_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItMS0xLTEtMA_380428a0-87f7-42bc-9c4b-4be7ea456444"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i333fddf2954c4f8f84d124aceab9eb34_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItMy0xLTEtMA_3dd39e3d-27dc-4780-b9ff-404968d72ad2"
      unitRef="usd">2778000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if43031c026d442a18ff9382d1b9cffc6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItNS0xLTEtMA_b32ed5ee-807c-41cf-b6c6-6e1410dd4d83"
      unitRef="usd">1255000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i2c921ca8f3fd4b668c26209f32686128_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItNy0xLTEtMA_217984dc-2ca8-4a3c-968d-1a068af21007"
      unitRef="shares">33000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i2c921ca8f3fd4b668c26209f32686128_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItOS0xLTEtMA_c17aaa45-776a-43cb-9880-18eeeb397309"
      unitRef="usd">2009000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic337060106e84e76a53c24d5a516bded_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItMTEtMS0xLTA_f9d9c4ad-a441-489a-b46f-9883c550b302"
      unitRef="usd">-53000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i531c55176bb64260a4950658a062d0e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItMTMtMS0xLTA_c00f07f0-4d8c-4b5e-9466-cd081ced6aaf"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmNlNzM1OTE3MWU3ZjQzOGViZDg0ODE2ODg2MmRhNzQwL3RhYmxlcmFuZ2U6Y2U3MzU5MTcxZTdmNDM4ZWJkODQ4MTY4ODYyZGE3NDBfMTItMTUtMS0xLTA_ba4f5027-1f3f-4923-9809-e69c7425cad9"
      unitRef="usd">1975000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1cd1437e597b4e2682afe89f0b8f38a1_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS0xLTEtMS0w_2e1772bc-524f-4f29-9837-412a225b982e"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cd1437e597b4e2682afe89f0b8f38a1_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS0zLTEtMS0w_e8167df6-538d-48c1-95c5-8bd604e7fd00"
      unitRef="usd">2669000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iefe8fb0429c640549ebd225f00c39fdd_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS01LTEtMS0w_9a362ab7-ab9d-4df7-94d0-87a1b54d3a91"
      unitRef="usd">371000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i90bccc700f344156818dd2a91922ae30_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS03LTEtMS0w_60fbf962-bf68-43f3-ab07-4212b5606112"
      unitRef="shares">34000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i90bccc700f344156818dd2a91922ae30_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS05LTEtMS0w_5dd22dce-6ba0-41d2-89f9-052842144584"
      unitRef="usd">2039000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08f87960dc81422e8cc8681a4821d475_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS0xMS0xLTEtMA_ff6fd45a-0b9e-4ba9-9a2c-05665f43e393"
      unitRef="usd">-101000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3530dfeec0384b169ee4ba603c672780_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS0xMy0xLTEtMA_f12a92ec-237f-4416-b8cf-ef91f462b1db"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3c429f356e364a318686f6a96b4c0d70_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMS0xNS0xLTEtMA_1c01113f-afaf-41f9-b8f8-0ad121f8e730"
      unitRef="usd">903000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMi01LTEtMS0w_75380183-d6c7-4521-b907-d6a48d0659ac"
      unitRef="usd">220000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i4f0d9a0a1c01475c97b8ad225ba6ed8a_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMi0xMy0xLTEtMA_be85fbfa-e5f6-43fe-aa22-d5c670c1687f"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMi0xNS0xLTEtMA_c82ac67f-e5e4-4809-990b-5045961098cd"
      unitRef="usd">220000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i087a2162c6ab4ee08231b8375275a66f_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMy0xMS0xLTEtMA_2e90acb2-fc9d-40e7-abfd-3923234add3a"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMy0xNS0xLTEtMA_aaa6e2f3-6fa9-4588-b592-70779050d0d9"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic709b0f6e31348dc92cb361418750b1a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNS0xLTEtMS0w_17cefcf7-eb8b-45fa-b4fa-e338cfd092a7"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic709b0f6e31348dc92cb361418750b1a_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNS0zLTEtMS0w_3a5daa1c-a30a-421e-a4f0-c737bfa75212"
      unitRef="usd">13000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i356ad0db94fd4af2945d43260c52b004_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNS03LTEtMS0w_0b2b78fb-616c-4542-9dc0-3a9b5f906ebe"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i356ad0db94fd4af2945d43260c52b004_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNS05LTEtMS0w_a8c96be7-cd6e-4f69-bcf8-6e4dabb4fcb0"
      unitRef="usd">10000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNS0xNS0xLTEtMA_89b7fbdf-0ea4-4f3f-87af-8f7b879a9e98"
      unitRef="usd">23000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic709b0f6e31348dc92cb361418750b1a_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNi0zLTEtMS0w_8096c90b-b7ba-4ce9-b2aa-a59058028d0a"
      unitRef="usd">70000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i356ad0db94fd4af2945d43260c52b004_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNi03LTEtMS0w_f925e0d5-786b-4003-830c-5b29ec375d84"
      unitRef="shares">1000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i356ad0db94fd4af2945d43260c52b004_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNi05LTEtMS0w_b596da7b-aaa9-466d-9dc7-cae3e311ecd6"
      unitRef="usd">70000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNi0xNS0xLTEtMA_f77d5a77-093f-4b13-85a8-33a343d3d78a"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="i7a37151dd9974055b9fd8a3b9f329fda_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNy01LTEtMS0w_30b11832-ef18-4460-9a86-5362ed44b659"
      unitRef="usd">143000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfNy0xNS0xLTEtMA_12e04309-4335-4f2d-8d2e-bf2f42bcd1eb"
      unitRef="usd">143000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i7a37151dd9974055b9fd8a3b9f329fda_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfOC01LTEtMS0w_e57682cf-698f-4cf5-959b-3bf94c4496d1"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i4f0d9a0a1c01475c97b8ad225ba6ed8a_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfOC0xMy0xLTEtMA_b8e0e9ca-6d72-4bc4-b2ad-1d1f0a247dc6"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfOC0xNS0xLTEtMA_5823c5be-e6c7-4681-8deb-0140bc2152dd"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8ffbcc7b8b47419fafc54db6c65fa67c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtMS0xLTEtMA_43fa44b6-5009-4671-a06f-0caf409c41ab"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ffbcc7b8b47419fafc54db6c65fa67c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtMy0xLTEtMA_2570386d-9bb4-4552-9e31-353248b8ec12"
      unitRef="usd">2752000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i961814e0fb934b26a59874c0a47b5c36_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtNS0xLTEtMA_259c1a07-0f77-4d2c-8e9e-ee3dbd524a29"
      unitRef="usd">449000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i34bce33b39294b5990a6d2671d45efc1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtNy0xLTEtMA_5dc989c8-12c6-44f1-8ca8-d1ee66d10ad9"
      unitRef="shares">35000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i34bce33b39294b5990a6d2671d45efc1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtOS0xLTEtMA_cad68161-f213-4985-9abf-54fe1ca36e46"
      unitRef="usd">2099000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a67a68103174862933d81e69761227a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtMTEtMS0xLTA_1d264911-24b7-4828-9d70-0d9da9eb1b6b"
      unitRef="usd">-103000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ae7680d35a94fe791314d93518ad333_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtMTMtMS0xLTA_f28a690b-c925-42d9-9c0d-133c51c4d8f5"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15dfaa9ce43d4c8dbe8e43f793325ab5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjJlYjg5ZDM5ZTJmNjRmZDQ4ZmJiZTA0YmNmM2RiNThhL3RhYmxlcmFuZ2U6MmViODlkMzllMmY2NGZkNDhmYmJlMDRiY2YzZGI1OGFfMTAtMTUtMS0xLTA_5291704d-6628-485c-8271-4182b2db6059"
      unitRef="usd">1002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ifc62359854904e73a95bee6e706c2f64_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy0xLTEtMS0w_63b10f4d-bea4-4144-b9d9-4e3e7f6c756e"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc62359854904e73a95bee6e706c2f64_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy0zLTEtMS0w_d85fe81f-6c99-42d7-9e90-e908f772131d"
      unitRef="usd">2789000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02eca4589f2a4542b34a4ac4b0e54bbc_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy01LTEtMS0w_141d099c-a70c-4929-a478-0873b75a593e"
      unitRef="usd">1170000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i327c9e14b86548eeaa15e0b1195a1713_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy03LTEtMS0w_d686c2f8-dd07-4d5c-9a25-1a93eccb40b7"
      unitRef="shares">-35000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i327c9e14b86548eeaa15e0b1195a1713_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy05LTEtMS0w_bd59eb4d-d66c-4dc1-9eea-046469beaa4b"
      unitRef="usd">-2066000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d7546c5d1f84a4a8f9ddb1310f520fc_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy0xMS0xLTEtMA_31b275f4-10a8-4a74-9570-05a18bd82340"
      unitRef="usd">-104000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83d7259b2a09452ea238e9d70eb94fcb_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy0xMy0xLTEtMA_d3cd03eb-5b00-4c19-a888-f1372fa44ee9"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMy0xNS0xLTEtMA_2959b142-0216-4b6d-9a74-43310812bfb3"
      unitRef="usd">1792000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNC01LTEtMS0w_75e0ab69-0e13-49ec-959b-6e7e3705f6be"
      unitRef="usd">376000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i5b3c71ac478a4d02806d3987db7fca7c_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNC0xMy0xLTEtMA_4e39e17b-ec64-4d7a-8b69-e8c4c8cb263a"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNC0xNS0xLTEtMA_c182e57e-e794-4df9-b83c-d279760ddb78"
      unitRef="usd">377000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i342dbbcc001646b78a3682ec6c4a043a_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNS0xMS0xLTEtMA_6e305aa7-940e-402e-9e3b-54fd79fa96f3"
      unitRef="usd">51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNS0xNS0xLTEtMA_5bace3b2-df60-46ec-a081-cbafe2229b17"
      unitRef="usd">51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0ac4657e05a9499ab00fb27b5751039b_D20200701-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNy0xLTEtMS0w_b8270b07-914b-4bf6-a6f0-3fe19b7207f3"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0ac4657e05a9499ab00fb27b5751039b_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNy0zLTEtMS0w_a1c2ca39-0122-4574-9493-cf20659af5b8"
      unitRef="usd">11000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNy03LTEtMS0w_d61bb805-3ab2-4508-b825-c8060436af7a"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i69b8b80a81a246308be8e9d7ae9fb68e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNy05LTEtMS0w_cdd525f5-4e69-45fb-a8a7-efe9854db8f5"
      unitRef="usd">57000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfNy0xNS0xLTEtMA_cbfd2e69-e302-490b-9cc9-20e72685315c"
      unitRef="usd">46000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:Dividends
      contextRef="i3c695c989c1c488a9a822944847a51bb_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfOS01LTEtMS0w_ad068914-1f2f-4805-89ab-2b115190f4af"
      unitRef="usd">289000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfOS0xNS0xLTEtMA_531e786b-5f5f-4378-aab3-422cce467379"
      unitRef="usd">289000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i3c695c989c1c488a9a822944847a51bb_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTAtNS0xLTEtMA_83d4bd2c-40ea-49ce-8db4-1068e0998a45"
      unitRef="usd">-2000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i5b3c71ac478a4d02806d3987db7fca7c_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTAtMTMtMS0xLTA_278a3f9b-428e-412b-97e7-e5caa1091e99"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTAtMTUtMS0xLTA_fad3d4f2-07eb-4621-97f0-29dc184d6d19"
      unitRef="usd">-2000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i333fddf2954c4f8f84d124aceab9eb34_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItMS0xLTEtMA_f70a6e86-529d-49da-b232-9c8024e09906"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i333fddf2954c4f8f84d124aceab9eb34_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItMy0xLTEtMA_1b00fa32-eff7-448d-bd5e-08d686ad40cf"
      unitRef="usd">2778000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if43031c026d442a18ff9382d1b9cffc6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItNS0xLTEtMA_64014fd8-bf16-484c-b522-5a6212e51531"
      unitRef="usd">1255000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i2c921ca8f3fd4b668c26209f32686128_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItNy0xLTEtMA_21fdd407-3e5b-445e-8c9f-bdc8ddec2499"
      unitRef="shares">33000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i2c921ca8f3fd4b668c26209f32686128_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItOS0xLTEtMA_12fbd443-6735-4d5d-b14f-42f249d697fc"
      unitRef="usd">2009000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic337060106e84e76a53c24d5a516bded_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItMTEtMS0xLTA_23df502c-ff3c-4430-a664-5c573ca30dd2"
      unitRef="usd">-53000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i531c55176bb64260a4950658a062d0e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItMTMtMS0xLTA_e676d70f-db1d-4736-84f0-211e95f85cb2"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOmQ5M2NkNmUxN2I0YjQ2YWU5NGY4OTEwMzJkZTI5ZWViL3RhYmxlcmFuZ2U6ZDkzY2Q2ZTE3YjRiNDZhZTk0Zjg5MTAzMmRlMjllZWJfMTItMTUtMS0xLTA_93b1a616-807c-46d2-8504-df12c42bdf22"
      unitRef="usd">1975000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic7239edd43644a128d30e8bbd0ab2a9e_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS0xLTEtMS0w_5eb58318-3122-4c8d-a582-95912b5b4701"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7239edd43644a128d30e8bbd0ab2a9e_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS0zLTEtMS0w_703d6432-fa47-4999-b7da-cf61e0eb3ec0"
      unitRef="usd">2763000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i964a6019a431419c8e09883bc4b9d02c_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS01LTEtMS0w_5f18e710-ef15-41bd-8d74-c456d7e1c354"
      unitRef="usd">5434000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i41b5d7dfd6a54361850263e4fd529847_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS03LTEtMS0w_be41f600-f184-4200-84d8-cac7cdcac69f"
      unitRef="shares">28000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i41b5d7dfd6a54361850263e4fd529847_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS05LTEtMS0w_ce775084-268f-4462-bbd3-475ece6799e8"
      unitRef="usd">1790000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ae7a3375f4c4b319354a025e78a9375_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS0xMS0xLTEtMA_f926453c-eb87-4e32-b340-f41557fb03e4"
      unitRef="usd">-79000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7285527fa33149449338e908558152ee_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS0xMy0xLTEtMA_37a5e891-54d3-4fac-bd1d-edd23ba81097"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9263daec240f40e18bbc79b563561d69_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMS0xNS0xLTEtMA_34fb0adb-bc99-4c8a-bece-e6dc2b782746"
      unitRef="usd">6330000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMi01LTEtMS0w_6196a363-b213-4ca9-82e7-0b0439b2d112"
      unitRef="usd">-4702000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="iea6044c7ef014ad7b58ff6abb8cf7620_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMi0xMy0xLTEtMA_74366959-ec60-4c47-860f-542f8fa4adc8"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMi0xNS0xLTEtMA_f25a9773-733b-4e91-8937-a0bd4038468d"
      unitRef="usd">-4701000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifdfa6e7ff1fd4ff4894046a2aef75fa0_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMy0xMS0xLTEtMA_77d1216e-a3ba-44ac-bdfc-36fb02144ca7"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfMy0xNS0xLTEtMA_d6e32505-8167-4d26-9095-232f802e4e1f"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i316bc31c1a6f4eb1a59f8bfb2c2df15c_D20190701-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNS0xLTEtMS0w_ab889fbb-2fa6-4252-8d08-04fa31cf4c67"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i316bc31c1a6f4eb1a59f8bfb2c2df15c_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNS0zLTEtMS0w_64396ad6-168a-43ef-8078-60ae3b69bb25"
      unitRef="usd">11000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4523a176fdd843a1871b85358e66f672_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNS03LTEtMS0w_42a82331-a723-4382-8b83-14b5180316fa"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4523a176fdd843a1871b85358e66f672_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNS05LTEtMS0w_ecfd5e0a-69f0-4760-870a-b35dc7f3a992"
      unitRef="usd">41000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNS0xNS0xLTEtMA_69bcbd06-d17e-479e-85c6-14bcee747a8c"
      unitRef="usd">30000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i4523a176fdd843a1871b85358e66f672_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNi03LTEtMS0w_9fd1accb-5ee7-4ff3-852d-1998ff8fa098"
      unitRef="shares">7000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4523a176fdd843a1871b85358e66f672_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNi05LTEtMS0w_507bf911-45ae-4bea-8a77-d9cd85557ebd"
      unitRef="usd">350000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNi0xNS0xLTEtMA_d102021c-7d99-4714-a596-3f6d2a2a7320"
      unitRef="usd">350000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="i6f12e42d72c7409cbec2d494d04aea14_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNy01LTEtMS0w_07009b3f-d900-44aa-a060-622dbd56059d"
      unitRef="usd">284000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfNy0xNS0xLTEtMA_2a4d8986-7241-42e4-a248-de680ddd69c3"
      unitRef="usd">284000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i6f12e42d72c7409cbec2d494d04aea14_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOC01LTEtMS0w_0450e562-5aeb-4f6c-ab34-4b0c424a115b"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="iea6044c7ef014ad7b58ff6abb8cf7620_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOC0xMy0xLTEtMA_2f604e33-e854-4b09-b9ef-fe1d142d1f38"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOC0xNS0xLTEtMA_538bc6c5-ff86-45da-af6b-70c5d2ccd8e4"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8ffbcc7b8b47419fafc54db6c65fa67c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS0xLTEtMS0w_45844265-c3d4-4bda-9a85-f3ef8c87f001"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ffbcc7b8b47419fafc54db6c65fa67c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS0zLTEtMS0w_6ce1be1e-a4a8-400e-863b-0cab6755b84e"
      unitRef="usd">2752000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i961814e0fb934b26a59874c0a47b5c36_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS01LTEtMS0w_f2e03442-c5f3-44bd-8173-bf4e58c1b4c1"
      unitRef="usd">449000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i34bce33b39294b5990a6d2671d45efc1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS03LTEtMS0w_78ca5b74-7d08-4a28-9d14-54e26448cdb8"
      unitRef="shares">35000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i34bce33b39294b5990a6d2671d45efc1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS05LTEtMS0w_a67e1371-52be-4c4c-9869-135d7721bc72"
      unitRef="usd">2099000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a67a68103174862933d81e69761227a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS0xMS0xLTEtMA_f53c9585-6272-4629-acce-187c40f70509"
      unitRef="usd">-103000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ae7680d35a94fe791314d93518ad333_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS0xMy0xLTEtMA_d8bcd574-1d5c-4ac6-97f9-2ffdba7b006b"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15dfaa9ce43d4c8dbe8e43f793325ab5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83My9mcmFnOjY2MjUzYjkxMzU0MjQzN2Y4MDg5Mzc4MTI1ZDM4MGYxL3RhYmxlOjU4YWY2NTUzMzViNjQxMTNhMDEzYjYwMTc0MTQwMGNjL3RhYmxlcmFuZ2U6NThhZjY1NTMzNWI2NDExM2EwMTNiNjAxNzQxNDAwY2NfOS0xNS0xLTEtMA_836bd423-6236-4890-be15-feec5020a37e"
      unitRef="usd">1002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMy0xLTEtMS0w_63efd5df-3b5c-479c-b124-280661088817"
      unitRef="usd">377000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMy0zLTEtMS0w_1ad69d8a-265a-4dc2-a834-b28567b89a9e"
      unitRef="usd">-4701000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNi0xLTEtMS0w_b3555ad7-4e12-44c6-a616-237ecad8ed52"
      unitRef="usd">404000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNi0zLTEtMS0w_46d082e6-7759-433b-9fa5-ef1f50816b57"
      unitRef="usd">464000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfOC0xLTEtMS0w_a1896ab9-59a1-46de-88b4-1c76bf1eba67"
      unitRef="usd">-9000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfOC0zLTEtMS0w_cb9aba46-c316-409e-82d9-78c5e8b5cc1f"
      unitRef="usd">-8000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfOS0xLTEtMS0w_9ab55001-9bfe-4d5b-836f-66187b25ab76"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfOS0zLTEtMS0w_d93e2e25-3b77-4e02-963b-16f751bfd8b9"
      unitRef="usd">-4000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTAtMS0xLTEtMA_46415682-b3a4-44ba-b02e-2cf50fd33bad"
      unitRef="usd">51000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTAtMy0xLTEtMA_037d1587-67aa-4778-93a0-5db916c1b911"
      unitRef="usd">41000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTItMS0xLTEtMA_286e1185-1b58-4e13-9da1-f5623cc87abd"
      unitRef="usd">35000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTItMy0xLTEtMA_4284c4fb-508c-4b82-9976-a11f6fe10fe1"
      unitRef="usd">47000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTQtMS0xLTEtMA_381396f4-61ba-4e32-b979-84a1400effb0"
      unitRef="usd">499000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTQtMy0xLTEtMA_dabe13a6-2a56-4606-b586-b1721fa09345"
      unitRef="usd">-121000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTUtMS0xLTEtMA_700988f8-5058-403b-9685-ef2af5b281ff"
      unitRef="usd">1256000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTUtMy0xLTEtMA_6e033fa0-4fef-436c-957a-3df4503f34fe"
      unitRef="usd">991000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTYtMS0xLTEtMA_c2a2089a-3621-409c-8f74-7e2c95da5d16"
      unitRef="usd">1861000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTYtMy0xLTEtMA_7ec191ed-eda1-47ba-85e3-f4079fa29135"
      unitRef="usd">-77000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTctMS0xLTEtMA_b29debfe-d079-4a4d-910f-c0e2ff0ffb27"
      unitRef="usd">-504000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTctMy0xLTEtMA_96334113-7728-412f-86d3-ae5dbbe70d75"
      unitRef="usd">-5128000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTgtMS0xLTEtMA_1f24f9f6-1f7b-4ec5-852d-37f1808aef71"
      unitRef="usd">1487000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMTgtMy0xLTEtMA_462b625f-a095-43a3-86fe-16f2b0623ba7"
      unitRef="usd">44000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjEtMS0xLTEtMA_d8748fe0-44e1-4366-86eb-4bd13032f889"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjEtMy0xLTEtMA_92b77d66-1223-448a-a482-951c161340b6"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjItMS0xLTEtMA_65999742-1a06-4b30-9f6a-d949205ed1ee"
      unitRef="usd">174000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjItMy0xLTEtMA_19b40382-ce74-416a-bab1-a0e481a60b26"
      unitRef="usd">149000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjMtMS0xLTEtMA_64c7c407-ec04-4d6a-a0f2-e0f8630466ba"
      unitRef="usd">18000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjMtMy0xLTEtMA_fce92204-dd0a-4653-828f-788bca154400"
      unitRef="usd">6000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjQtMS0xLTEtMA_e6db36d6-0075-48ba-949e-1084411e7e76"
      unitRef="usd">4000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjQtMy0xLTEtMA_168929fd-afe6-4c0a-81f1-b885cd8f64c4"
      unitRef="usd">2000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjYtMS0xLTEtMA_09ed9d2e-1cc9-45c0-826a-80686baa7740"
      unitRef="usd">0</cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets>
    <cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjYtMy0xLTEtMA_0f170b31-2f49-4217-a494-dee18dd26771"
      unitRef="usd">2000000</cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjctMS0xLTEtMA_60285dbc-346e-46e0-94ca-9f79e4b42596"
      unitRef="usd">-191000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMjctMy0xLTEtMA_3b828680-58fe-4885-ab5d-8f55da872b18"
      unitRef="usd">-151000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzAtMS0xLTEtMA_ccfd4dfd-a7f4-4cae-8528-8f6a08e10958"
      unitRef="usd">0</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzAtMy0xLTEtMA_81e380ea-7ddc-4149-a909-9194b113caea"
      unitRef="usd">681000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzEtMS0xLTEtMA_36fdfee9-3df2-4053-8fc2-c50b44c769d2"
      unitRef="usd">49000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzEtMy0xLTEtMA_49b9ed73-c67b-4cac-8fef-25787ceaedb7"
      unitRef="usd">793000000</us-gaap:RepaymentsOfLongTermDebt>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzItMS0xLTEtMA_0300a67a-6042-49a6-a41f-23f4531914c2"
      unitRef="usd">-6000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzItMy0xLTEtMA_f12eb40c-5fb0-4dfb-8204-c118363f657d"
      unitRef="usd">-11000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzQtMS0xLTEtMA_e9906218-bc2e-4714-a81c-58d40b9b37e6"
      unitRef="usd">289000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzQtMy0xLTEtMA_af0e6f60-2c6c-4b10-98a5-1d74b628b0c9"
      unitRef="usd">287000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzUtMS0xLTEtMA_18d912c2-02d8-4333-b54f-5b765d650230"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzUtMy0xLTEtMA_16856b87-b9ab-4cdd-a663-c450e4743845"
      unitRef="usd">350000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzYtMS0xLTEtMA_b0fde22f-b4e2-4b9c-9ca3-bb99d75ad111"
      unitRef="usd">-344000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzYtMy0xLTEtMA_9877e529-607e-43f7-88cf-0de6577fadbb"
      unitRef="usd">-760000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzgtMS0xLTEtMA_3a815126-f0ad-4ac9-9fac-a40236966fd6"
      unitRef="usd">14000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfMzgtMy0xLTEtMA_752a7433-8831-4baf-b63f-1600c9e2724b"
      unitRef="usd">-5000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNDAtMS0xLTEtMA_84784535-18ce-48a0-adc2-3d56318ba424"
      unitRef="usd">966000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNDAtMy0xLTEtMA_2da7559e-dcc3-4a57-8732-2ca7f05fd43f"
      unitRef="usd">-872000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNDEtMS0xLTEtMA_51345052-4229-452a-97ce-ed10cdabc724"
      unitRef="usd">2771000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9263daec240f40e18bbc79b563561d69_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNDEtMy0xLTEtMA_7e1ef14a-000e-480e-bb2e-e95004c555ad"
      unitRef="usd">2531000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNDItMS0xLTEtMA_3667f029-7996-4384-92b5-07d826e7c0a7"
      unitRef="usd">3737000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i15dfaa9ce43d4c8dbe8e43f793325ab5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV83Ni9mcmFnOjE0MjFlMDkwMGQ3ZDRiOGM5MTU2ZGI0OWRiYTA5MDMzL3RhYmxlOjU2NWE5YmM3ZjI3ZTRmMmU4MzVmYjMyNzk1NTczYTA4L3RhYmxlcmFuZ2U6NTY1YTliYzdmMjdlNGYyZTgzNWZiMzI3OTU1NzNhMDhfNDItMy0xLTEtMA_a975e676-a236-4f7e-ab19-1da9b0f71338"
      unitRef="usd">1659000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84Mi9mcmFnOjVmNjhhNzgxZTUxNzQxYmVhM2ZiMjlkY2EwOWUwODBmL3RleHRyZWdpb246NWY2OGE3ODFlNTE3NDFiZWEzZmIyOWRjYTA5ZTA4MGZfMzI5ODUzNDkwMTQ1OA_13735e2d-b884-41b0-88a1-ea3fff0b0955">&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;1. Basis of Presentation and Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns is in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2020 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2021 and June&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic also affected our businesses in a variety of ways beginning in the third quarter of fiscal 2020 and continuing into fiscal 2021. We cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. and global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow. Our estimates, judgments and assumptions related to COVID-19 could ultimately differ over time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84Mi9mcmFnOjVmNjhhNzgxZTUxNzQxYmVhM2ZiMjlkY2EwOWUwODBmL3RleHRyZWdpb246NWY2OGE3ODFlNTE3NDFiZWEzZmIyOWRjYTA5ZTA4MGZfNDU3MA_b5df1fee-dc66-4200-b0c7-936c6ab38744">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns is in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2020 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2021 and June&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic also affected our businesses in a variety of ways beginning in the third quarter of fiscal 2020 and continuing into fiscal 2021. We cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. and global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow. Our estimates, judgments and assumptions related to COVID-19 could ultimately differ over time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual &lt;/span&gt;&lt;/div&gt;Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K").</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84Mi9mcmFnOjVmNjhhNzgxZTUxNzQxYmVhM2ZiMjlkY2EwOWUwODBmL3RleHRyZWdpb246NWY2OGE3ODFlNTE3NDFiZWEzZmIyOWRjYTA5ZTA4MGZfMzI5ODUzNDkwMTQ1Nw_e7e1a02e-1d25-4ae6-942c-cd1fa99f87e2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RleHRyZWdpb246NGI2OTA2Njc2MWQxNDRkMGJiNmYwZmJiNTk5ZjgzYTVfMTA2Ng_e8a598e6-33a7-4b17-94bb-feb4c20b0f47">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;2. Restructuring and Employee Severance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of lease costs associated with vacant facilities, accelerated depreciation, vendor transition fees, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring costs during both the three and six months ended December&#160;31, 2020 and 2019 were primarily related to implementation of certain enterprise-wide cost-savings measures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RleHRyZWdpb246NGI2OTA2Njc2MWQxNDRkMGJiNmYwZmJiNTk5ZjgzYTVfMTA2NA_15f164ae-7dfb-4bb8-adc4-83b0ef898287">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmE4MTFlMjlkZDhlZTRkNzA5M2I4NTU1ZGM4NDE0YWE2L3RhYmxlcmFuZ2U6YTgxMWUyOWRkOGVlNGQ3MDkzYjg1NTVkYzg0MTRhYTZfMi0xLTEtMS0w_5855668e-a3e7-4f03-be99-a14c36f41762"
      unitRef="usd">8000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmE4MTFlMjlkZDhlZTRkNzA5M2I4NTU1ZGM4NDE0YWE2L3RhYmxlcmFuZ2U6YTgxMWUyOWRkOGVlNGQ3MDkzYjg1NTVkYzg0MTRhYTZfMi0zLTEtMS0w_6e157480-2dc1-4b17-a179-1e942bf44242"
      unitRef="usd">42000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmE4MTFlMjlkZDhlZTRkNzA5M2I4NTU1ZGM4NDE0YWE2L3RhYmxlcmFuZ2U6YTgxMWUyOWRkOGVlNGQ3MDkzYjg1NTVkYzg0MTRhYTZfMy0xLTEtMS0w_2a4a5c50-9b01-4e14-ba79-4b828b046453"
      unitRef="usd">12000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmE4MTFlMjlkZDhlZTRkNzA5M2I4NTU1ZGM4NDE0YWE2L3RhYmxlcmFuZ2U6YTgxMWUyOWRkOGVlNGQ3MDkzYjg1NTVkYzg0MTRhYTZfMy0zLTEtMS0w_778b9918-7352-47ec-9fb4-489a435a9e5b"
      unitRef="usd">14000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmE4MTFlMjlkZDhlZTRkNzA5M2I4NTU1ZGM4NDE0YWE2L3RhYmxlcmFuZ2U6YTgxMWUyOWRkOGVlNGQ3MDkzYjg1NTVkYzg0MTRhYTZfNC0xLTEtMS0w_b9484e85-b3dc-4a30-8d80-bf5e4b332c14"
      unitRef="usd">20000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmE4MTFlMjlkZDhlZTRkNzA5M2I4NTU1ZGM4NDE0YWE2L3RhYmxlcmFuZ2U6YTgxMWUyOWRkOGVlNGQ3MDkzYjg1NTVkYzg0MTRhYTZfNC0zLTEtMS0w_3dbed43e-0138-4589-8ebe-fc0fb11ea6b2"
      unitRef="usd">56000000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOjlkNzc4MWQwMmY2MDQwNmRhYjA1ZjRkN2E1M2FkOGYwL3RhYmxlcmFuZ2U6OWQ3NzgxZDAyZjYwNDA2ZGFiMDVmNGQ3YTUzYWQ4ZjBfMi0xLTEtMS0w_12bd848a-9c7b-40d4-84da-fd6bedac8995"
      unitRef="usd">32000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOjlkNzc4MWQwMmY2MDQwNmRhYjA1ZjRkN2E1M2FkOGYwL3RhYmxlcmFuZ2U6OWQ3NzgxZDAyZjYwNDA2ZGFiMDVmNGQ3YTUzYWQ4ZjBfMi0zLTEtMS0w_6e67740a-bfbb-4bea-b4f1-dd07e1bccdca"
      unitRef="usd">62000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOjlkNzc4MWQwMmY2MDQwNmRhYjA1ZjRkN2E1M2FkOGYwL3RhYmxlcmFuZ2U6OWQ3NzgxZDAyZjYwNDA2ZGFiMDVmNGQ3YTUzYWQ4ZjBfMy0xLTEtMS0w_f5f6088c-7e2a-453e-a021-f25f7a0353b1"
      unitRef="usd">25000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOjlkNzc4MWQwMmY2MDQwNmRhYjA1ZjRkN2E1M2FkOGYwL3RhYmxlcmFuZ2U6OWQ3NzgxZDAyZjYwNDA2ZGFiMDVmNGQ3YTUzYWQ4ZjBfMy0zLTEtMS0w_6b8b39b7-6ff3-460a-b76f-e520ef3c5698"
      unitRef="usd">24000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOjlkNzc4MWQwMmY2MDQwNmRhYjA1ZjRkN2E1M2FkOGYwL3RhYmxlcmFuZ2U6OWQ3NzgxZDAyZjYwNDA2ZGFiMDVmNGQ3YTUzYWQ4ZjBfNC0xLTEtMS0w_20916a9d-80cc-40b2-9632-736abd02ee95"
      unitRef="usd">57000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOjlkNzc4MWQwMmY2MDQwNmRhYjA1ZjRkN2E1M2FkOGYwL3RhYmxlcmFuZ2U6OWQ3NzgxZDAyZjYwNDA2ZGFiMDVmNGQ3YTUzYWQ4ZjBfNC0zLTEtMS0w_60ea036b-0bdd-4719-83e8-12a69ba7990c"
      unitRef="usd">86000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RleHRyZWdpb246NGI2OTA2Njc2MWQxNDRkMGJiNmYwZmJiNTk5ZjgzYTVfMTA3MQ_17a53419-3d3e-4ea3-b3fc-75850d72d083">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i715f3cb5de28419892c4abe4c201b08b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMS0xLTEtMS0w_7f4675c5-624d-4d2e-b09c-cee692344aa9"
      unitRef="usd">68000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i29dfcbbc4b87452b99f5496e7a8ee237_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMS0zLTEtMS0w_cf8a2bad-ac73-46a1-a931-018abc528625"
      unitRef="usd">28000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMS01LTEtMS0w_02098078-94b6-467c-acc0-64201f8929db"
      unitRef="usd">96000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCosts
      contextRef="i4cb6bb1cf27c4f7a8d9e429c5c296315_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMi0xLTEtMS0w_fd0a9ed4-510b-4c71-96c6-81071d50d0d9"
      unitRef="usd">22000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="ifaca494a8cb54963b9c8eabe88a49bf4_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMi0zLTEtMS0w_7141d170-95fc-481a-89d1-348e1195a2d8"
      unitRef="usd">19000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMi01LTEtMS0w_7803a793-0440-4825-b69e-992cee0bad6d"
      unitRef="usd">41000000</us-gaap:RestructuringCosts>
    <us-gaap:PaymentsForRestructuring
      contextRef="i4cb6bb1cf27c4f7a8d9e429c5c296315_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMy0xLTEtMS0w_b77fabb4-c3ff-430d-bd72-36a232ccdfaf"
      unitRef="usd">34000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ifaca494a8cb54963b9c8eabe88a49bf4_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMy0zLTEtMS0w_5bd3f18f-f5af-46ed-a590-d730c4ef70fe"
      unitRef="usd">19000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfMy01LTEtMS0w_878bd712-3576-47f1-9183-7bfd44ee4193"
      unitRef="usd">53000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="id23cc7d0aa564d63919be6c6c1cfef81_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfNC0xLTEtMS0w_9c6ad174-207a-416a-8efb-aa2849b7aedb"
      unitRef="usd">56000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i79f208ee71c540dc96e55d1ea0309d92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfNC0zLTEtMS0w_febdc505-f8f5-4173-89ab-8bb78d5f1e6b"
      unitRef="usd">28000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84NS9mcmFnOjRiNjkwNjY3NjFkMTQ0ZDBiYjZmMGZiYjU5OWY4M2E1L3RhYmxlOmJlZjJhZjA3NjNmNDQyYWFiYTMwZGVjZGRmYzkwOWY0L3RhYmxlcmFuZ2U6YmVmMmFmMDc2M2Y0NDJhYWJhMzBkZWNkZGZjOTA5ZjRfNC01LTEtMS0w_72d262a3-98b3-40ad-9e51-1ef42fae9656"
      unitRef="usd">84000000</us-gaap:RestructuringReserve>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTEyOQ_d499ec34-6557-46bf-a22a-09c3cc445451">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;3. Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,357&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,659&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,740&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D, trademarks and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,570&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,592&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;671&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;836&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;776&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,853&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,679&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,877&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,703&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D, trademarks and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortization of intangible assets was $113 million and $127 million for the three months ended December 31, 2020 and 2019, respectively, and $228 million and $256 million for the six months ended December&#160;31, 2020 and 2019, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2021 through 2025 is as follows: $217 million, $398 million, $359 million, $329 million and $278 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTEzNg_031f33ce-4cc5-41ca-aa49-6bcd77231a20">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,357&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,659&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,740&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i98dea8eab827433d8bb7d45c1cfb404b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMS0xLTEtMS0w_6d83c49d-2287-4a81-9d64-3389283baf2e"
      unitRef="usd">2657000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i14b14c71bbc54f248f49427b82d4c76a_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMS0zLTEtMS0w_93ad5daa-8d64-4441-9973-e2a7c022b983"
      unitRef="usd">5700000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMS01LTEtMS0w_d844bc90-cf03-4e82-bb31-9ef07457d03b"
      unitRef="usd">8357000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ib84ce22fc5e7432ea0e7678515ad59b0_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMi0xLTEtMS0w_08190193-fde8-4bd0-9d6c-a7c8f411afa6"
      unitRef="usd">2000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i9662598991e54a289ce467d4c55860b1_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMi0zLTEtMS0w_bba06ae2-dc34-4d6b-b2b4-a1cd94177013"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMi01LTEtMS0w_a20974ab-d898-4648-8043-e53f9282f1ce"
      unitRef="usd">2000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib84ce22fc5e7432ea0e7678515ad59b0_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMy0xLTEtMS0w_028cb761-c457-4936-b300-1b70d5ff77c4"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i9662598991e54a289ce467d4c55860b1_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMy0zLTEtMS0w_ace2e56b-4595-4cb7-a632-6ed1ef4752d4"
      unitRef="usd">40000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfMy01LTEtMS0w_b50fd6e6-7dad-43f4-8bee-f2d8a85531ed"
      unitRef="usd">40000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i63febb3b06bd4185a6a3f45a6da44204_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfNC0xLTEtMS0w_f27e72e5-8617-4577-9600-167012b30c5f"
      unitRef="usd">2659000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idb5434fa06a945a9812fd66b941db4b3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfNC0zLTEtMS0w_6f5c7e08-2b97-4a64-9f1b-f4600d065502"
      unitRef="usd">5740000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjFlZjJlZmIzODNiNzQ3ZjM5NDVlNTUwZDY5MDMzY2NmL3RhYmxlcmFuZ2U6MWVmMmVmYjM4M2I3NDdmMzk0NWU1NTBkNjkwMzNjY2ZfNC01LTEtMS0w_5858e7a3-2b56-4bd6-8742-f2bf2da71518"
      unitRef="usd">8399000000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTE0Nw_10c8a59c-0355-4b1e-acfa-62959e72377a">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D, trademarks and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,570&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,592&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;671&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;836&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;776&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,853&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,679&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,877&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,703&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D, trademarks and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie0576298a2e542fd95ac14b7815c72ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMy0xLTEtMS0w_82c86fcc-c35b-4b26-8895-42632e375cbc"
      unitRef="usd">24000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie0576298a2e542fd95ac14b7815c72ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMy01LTEtMS0w_38238d76-e291-429e-a21b-eb148e2181cb"
      unitRef="usd">24000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfNC0xLTEtMS0w_130ff865-7913-4d67-aedf-20d9e689cc04"
      unitRef="usd">24000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfNC01LTEtMS0w_8978820c-f0cf-45d3-98ca-6efd0bd39e0e"
      unitRef="usd">24000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iec244ced74e54c48890cb31ded0bdebf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfNy0xLTEtMS0w_15901ca0-15e3-48ff-9401-01741b9389f0"
      unitRef="usd">3570000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iec244ced74e54c48890cb31ded0bdebf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfNy0zLTEtMS0w_30b9f8a3-4665-4089-a9a9-e72cce67ec29"
      unitRef="usd">1978000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iec244ced74e54c48890cb31ded0bdebf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfNy01LTEtMS0w_058141b8-c933-4757-b663-be9f91121b98"
      unitRef="usd">1592000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i2a7db73217be4f9980a875418215b27c_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfNy03LTEtMS0w_9f20391e-e5e4-4d80-a2b0-3b2ca92ab241">P13Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3386edf96d3941c387073f4c10dfd3a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOC0xLTEtMS0w_77f7350c-ffc3-4bb8-aeb9-0d41215b4296"
      unitRef="usd">671000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3386edf96d3941c387073f4c10dfd3a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOC0zLTEtMS0w_0aec9d9d-fb56-4652-8468-e7fe9c18b6a1"
      unitRef="usd">360000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3386edf96d3941c387073f4c10dfd3a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOC01LTEtMS0w_b574895d-e8b0-4c4c-a022-3aae914e06be"
      unitRef="usd">311000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i20ba7d43ca1e4e5bad3683d334fed42a_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOC03LTEtMS0w_5e32fabf-9a0e-4957-a9b8-c6d5c0993b64">P12Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i94ec4ab4e33146c497406aa05665b794_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOS0xLTEtMS0w_942b0fb8-378e-4ff1-929b-52cc4c20254b"
      unitRef="usd">1612000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i94ec4ab4e33146c497406aa05665b794_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOS0zLTEtMS0w_6e4de367-389f-43bc-8a9f-7b783f3b50cc"
      unitRef="usd">836000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i94ec4ab4e33146c497406aa05665b794_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOS01LTEtMS0w_c2411600-75fb-4827-8cc4-f926e3ef744e"
      unitRef="usd">776000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i3be0113a67424f1d89bc62eba84876b6_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfOS03LTEtMS0w_811c6138-a444-46b0-b5de-bb3e6f31fc43">P11Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTAtMS0xLTEtMA_36fc2b9e-8fda-4128-a3e6-a3da8282d15b"
      unitRef="usd">5853000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTAtMy0xLTEtMA_d41ed163-0427-4b4c-a762-4f2006382428"
      unitRef="usd">3174000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTAtNS0xLTEtMA_7ad52785-1c7e-4580-966b-07b4c3abe414"
      unitRef="usd">2679000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTAtNy0xLTEtMA_819f7438-8922-45f6-9ddc-7492f0d51275">P12Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTEtMS0xLTEtMA_f8b24703-4004-4827-9565-8430cbe417d8"
      unitRef="usd">5877000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTEtMy0xLTEtMA_34d2a352-00c0-47fd-bfa7-0196f378fcbf"
      unitRef="usd">3174000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjU2Y2JiMzA0YWYwZjQ3ZWVhNTE0NjNmNDU2Nzk4MWUxL3RhYmxlcmFuZ2U6NTZjYmIzMDRhZjBmNDdlZWE1MTQ2M2Y0NTY3OTgxZTFfMTEtNS0xLTEtMA_e1555922-ca37-4039-bdea-b9dc49452240"
      unitRef="usd">2703000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i56f4dc613d0944dfb65ad3407fdd7d98_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMy0xLTEtMS0w_e6fc8ff3-915f-4a0f-982e-15a62ed97905"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i56f4dc613d0944dfb65ad3407fdd7d98_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMy01LTEtMS0w_dc6d9a7c-2fef-47b2-ad8e-54b33a68c5da"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfNC0xLTEtMS0w_72b8885c-477d-4b31-9d81-2363a6726997"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfNC01LTEtMS0w_4b40c765-ce9c-4d07-9f4c-2fd02fe93d58"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i036a1401ef2c457fb47d9dd79ed6fc99_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfNy0xLTEtMS0w_1fc28a2e-a577-46bd-b561-5b164cddd9c3"
      unitRef="usd">3554000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i036a1401ef2c457fb47d9dd79ed6fc99_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfNy0zLTEtMS0w_b993081c-1587-4ed8-919c-cfaf8cfd8c6c"
      unitRef="usd">1828000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i036a1401ef2c457fb47d9dd79ed6fc99_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfNy01LTEtMS0w_217b1efc-904d-4d94-81aa-0bb51d1b1e19"
      unitRef="usd">1726000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8e4b7722d85145d78ebc17885b5a4d24_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfOC0xLTEtMS0w_1953c47a-bcfe-42e1-99fd-4ec01d2caa5c"
      unitRef="usd">673000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8e4b7722d85145d78ebc17885b5a4d24_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfOC0zLTEtMS0w_c71b6313-2bc4-4f5b-a45a-b96f01bb8a52"
      unitRef="usd">341000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8e4b7722d85145d78ebc17885b5a4d24_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfOC01LTEtMS0w_6c5f0ee9-6325-4f63-a655-6051e25fa6d3"
      unitRef="usd">332000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6a47a213956c4b9eb61252e2288e47f9_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfOS0xLTEtMS0w_bf449b0b-d481-48f7-aa6d-994cebb8206d"
      unitRef="usd">1604000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6a47a213956c4b9eb61252e2288e47f9_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfOS0zLTEtMS0w_05d1c7f1-3e9d-4fd4-9372-5ed290b6cc47"
      unitRef="usd">767000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6a47a213956c4b9eb61252e2288e47f9_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfOS01LTEtMS0w_879dd938-49f4-4a53-a6b2-7a007c94fa04"
      unitRef="usd">837000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMTAtMS0xLTEtMA_e022b3e3-1d9b-487f-a9ef-94c2a9da6941"
      unitRef="usd">5831000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMTAtMy0xLTEtMA_fd7c161d-b84d-4725-abec-fbb1ac9cbb31"
      unitRef="usd">2936000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMTAtNS0xLTEtMA_68e17a15-cb49-4532-a7b3-c77f78dcec60"
      unitRef="usd">2895000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMTEtMS0xLTEtMA_284eee7a-f4dc-4cad-8fa9-9d356ba8f2d8"
      unitRef="usd">5854000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMTEtMy0xLTEtMA_4a89cc31-2737-4234-b8d6-35eed67d0d53"
      unitRef="usd">2936000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RhYmxlOjczMGRiZTVjZjM1ODRkNzc4ZGMzZDI3MDA1YzU3OTA1L3RhYmxlcmFuZ2U6NzMwZGJlNWNmMzU4NGQ3NzhkYzNkMjcwMDVjNTc5MDVfMTEtNS0xLTEtMA_7cac256a-e689-4bea-a645-3e4ea411d03a"
      unitRef="usd">2918000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfODgy_0a8a1b85-998e-4097-b113-63b135e8efac"
      unitRef="usd">113000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfODg5_62935a0d-5336-4cb4-95d6-1535bf871e89"
      unitRef="usd">127000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfOTQ4_f595b924-9155-4423-b9a5-a4eb475a89aa"
      unitRef="usd">228000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfOTU1_c5ce1628-3108-4353-9a08-5819fef95887"
      unitRef="usd">256000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTEwMg_a67aac98-ba06-41f1-9ccc-8bc79de19e58"
      unitRef="usd">217000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTEwNg_8fc4c758-71f7-4bc1-81a3-43a4ac57b576"
      unitRef="usd">398000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTExMA_ff7b5185-76d9-4084-b571-9856c19e71ff"
      unitRef="usd">359000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTExNA_ab7645d2-ca23-4436-b503-3bfce97b4edb"
      unitRef="usd">329000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV84OC9mcmFnOjMyM2Y2NTVhMGQ5MzQ4M2ZiNTU4MDUwM2UyOTAwODYwL3RleHRyZWdpb246MzIzZjY1NWEwZDkzNDgzZmI1NTgwNTAzZTI5MDA4NjBfMTEyMQ_c7e45ec5-aef1-4363-958e-43b24ff6c416"
      unitRef="usd">278000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMjA0Nw_8ec46927-a08d-4648-8052-64558f94f6ef">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;4. Long-Term Obligations and Other Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Long-Term Debt and Other Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and June&#160;30, 2020, we had total long-term obligations, including the current portion and other short-term borrowings, of $6.7 billion and $6.8 billion, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These obligations are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $23.2 billion and $21.4 billion at December&#160;31, 2020 and June&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended December&#160;31, 2020, we early repurchased $40 million of the Floating Rate Notes due 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $2 million of the 2.616% Notes due 2022. The repurchases were paid for with available cash. In connection with the early debt repurchases, we recorded a $1 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;loss on early extinguishment of debt during the six months ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we repaid the full principal of the 2.4% Notes due 2019 at maturity for $450&#160;million. During the six months ended December 31, 2019, we early repurchased $207&#160;million of the 2.616% Notes due 2022, $10&#160;million of the 3.2% Notes due 2022, $14&#160;million of the Floating Rate Notes due 2022, $81&#160;million of the 3.41% Notes due 2027, $6&#160;million of the 4.6% Notes due 2043,$2&#160;million of the 4.9% Notes due 2045, and $21&#160;million of the 4.368% Notes due 2047. The repurchases were paid for with available cash and other short-term borrowings. In connection with the early debt repurchases, we recorded a $4 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;loss on early extinguishment of debt during the three and six months ended December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Financing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;December&#160;31, 2020, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#x201c;CHF&#x201d;) through September 30, 2022. CHF was organized for&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. &lt;/span&gt;&lt;/div&gt;Our revolving credit and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter through December 2020, a consolidated net leverage ratio of no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021. As of December&#160;31, 2020, we were in compliance with this financial covenant.</us-gaap:DebtDisclosureTextBlock>
    <cah:TotalLongTermandShortTermObligations
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMTcx_f8abb7ef-f702-41cd-906e-b1f8b41d14b5"
      unitRef="usd">6700000000</cah:TotalLongTermandShortTermObligations>
    <cah:TotalLongTermandShortTermObligations
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMTc4_f9d6fb79-00e9-4805-afff-7bea364a76bf"
      unitRef="usd">6800000000</cah:TotalLongTermandShortTermObligations>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzI5ODUzNDg4NjY4OA_bcb36f71-c252-42b8-ad39-6d7339f243cc"
      unitRef="usd">23200000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzI5ODUzNDg4NjY5Ng_0c0376b7-36f5-476e-b797-1a681269967a"
      unitRef="usd">21400000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <cah:NotesPayableRepurchased
      contextRef="i474cf5f364454a11b22f24b06699e4df_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDUyMg_b9930e4f-4acb-483c-bd5f-78c2b3d39b23"
      unitRef="usd">40000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="ifb2a9682f8564e3fb789bdc866101ff9_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDUzOA_fadf06c5-25bb-4d2f-b593-c1748b11a1e0"
      unitRef="usd">2000000</cah:NotesPayableRepurchased>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDIzOQ_37c1445f-af69-4651-a61e-45a6f47601cd"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <cah:NotesPayableRepurchased
      contextRef="i0c200f19e4364602a4c4db803bbe7e50_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDYxOQ_554332fc-2e7e-4d07-a69d-abee8086ed63"
      unitRef="usd">450000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="i01211baf31064f409c8fa4c5b5b54b09_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDYzMA_73ff5159-b638-41f2-a447-29784801e103"
      unitRef="usd">207000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="i770887e4d98143a78ad85ee309204ca5_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDYzNA_ad5919ca-bbc7-481f-8cd3-f3ace241b894"
      unitRef="usd">10000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="iaae728c0a7a4428ab31591199c01df2c_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDYzNw_5144f93d-cc23-4b7a-a71b-32e9e8618315"
      unitRef="usd">14000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="i1bea82ad95804e6abff0fd8562560862_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDY0Mg_9ab49f17-c6c1-4b14-b3dc-81830b75d80c"
      unitRef="usd">81000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="i2763cf8f732c46ac822b3a4e9cc9afce_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDY0Ng_7e95a76b-7ab4-4a76-aa61-ae3b6e82cdc7"
      unitRef="usd">6000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="i907c1e70968546c7bd30ff773af28457_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDY0OQ_1dfdd934-f0ec-4381-9b50-a858d8b7ff25"
      unitRef="usd">2000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="ic9f2efa674d6441590242649316ec9a6_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMzg0ODI5MDcwMDY1Mw_59a588d9-e3ca-4bbf-8162-dcc79af2976c"
      unitRef="usd">21000000</cah:NotesPayableRepurchased>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfOTc3_08b147c4-c064-40e5-9c61-825c1f2d8c3c"
      unitRef="usd">-4000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfOTc3_e87b2634-fea3-463b-a792-c370b875021d"
      unitRef="usd">-4000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i92aefd5c72f64cb89f421ad0100e879f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMTI4NQ_b3b9e3f3-beeb-476b-9dd2-0d72ff183fb3"
      unitRef="usd">2000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia70ce6414d4f4266bf2f26ca4eafbb15_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMTMyNQ_7a01d479-6afa-4bd4-a14f-8dd9c98ded82"
      unitRef="usd">2000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i91ee5d4795d74c0d97f3782625ff9fd1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV85Ny9mcmFnOmE0ZGM0Y2IxNzA4MDQ3OGE5ZGMzNWVkMzU0MTg2N2ZkL3RleHRyZWdpb246YTRkYzRjYjE3MDgwNDc4YTlkYzM1ZWQzNTQxODY3ZmRfMTM3MA_7ad1d2b0-3f59-42eb-a537-4e4ee2b720f6"
      unitRef="usd">1000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzE1Mjk4_bca364ea-15a6-450b-bae9-27b3529046d0">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;5. Commitments, Contingent Liabilities and Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Generic Sourcing Venture with CVS Health Corporation ("CVS Health")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $45.6 million to CVS Health for the remainder of the initial term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New York Opioid Stewardship Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the U.S. District Court for the Southern District of New York ruled that the OSA was unconstitutional and enjoined its enforcement (the "Ruling"). In April 2019, the State, among other things, amended the OSA so that the assessment would only cover opioid sales in 2017 and 2018, subject to the State's appeal of the Ruling. In September 2020, the U.S. Court of Appeals for the Second Circuit reversed the Ruling and, as a result, New York will likely seek to collect amounts due from distributors and manufacturers for 2017 and 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41&#160;million for calendar year 2017 and 2018 based on the estimated payment amount, which is our best estimate of the OSA payments probable at December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We become involved from time to time in disputes, litigation and regulatory matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory &lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings/(loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Opioid Lawsuits and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,300 lawsuits relating to &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;States &amp;amp; Political Subdivisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 2,800 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#x201c;MDL&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A trial in West Virginia in the Cabell County and City of Huntington cases is scheduled for May 2021 and a trial is scheduled to begin in September 2021 in the case brought by the Ohio Attorney General. Trial dates remain uncertain due in part to uncertainties arising from the COVID-19 pandemic. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). This Settlement Framework is the basis for the ongoing negotiation of definitive terms and documentation. Negotiations under the Settlement Framework continue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of these discussions, we have recorded total pre-tax charges of $1.02&#160;billion and $5.63&#160;billion in litigation charges/(recoveries), net in the six months ended December 31, 2020 and 2019, respectively. In total, we have $6.59&#160;billion accrued at December 31, 2020, included in deferred income taxes and other liabilities in the condensed consolidated balance sheets, which represents the cash component. We are unable to estimate the range of possible loss associated with these matters. Definitive terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. We continue to &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Private Plaintiffs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Settlement Framework does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private parties had brought approximately 423 lawsuits as of February 1, 2021. Of these, 127 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Affirmative Insurance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#x201c;National Union Fire Insurance&#x201d;), seeking a declaration that defense costs are recoverable under our insurance for certain of the lawsuits described above. We have not recorded a receivable for any recoveries related to the litigation against National Union Fire Insurance at December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these requests. We are unable to predict the outcome of any of these investigations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cordis Product Liability Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of February 1, 2021, we are named as a defendant in 373 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 4,800 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 31 lawsuits involving similar claims by approximately 36 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We continue to vigorously defend ourselves in these lawsuits and are engaged in resolution discussions with certain plaintiffs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, we had a total of $508 million net of estimated insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits which are presented on a gross basis in the condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;end of the range to be approximately $990 million, net of estimated insurance recoveries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Louisiana Sheriffs' Pension &amp;amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In November 2020, we filed a motion to dismiss the amended complaint. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Specialty Solutions DOJ Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, we received investigative demands from the United States Attorney&#x2019;s Office for the District of Massachusetts (the "USAO") pertaining to the U.S. federal healthcare fraud and abuse laws. These requests sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with these requests and are engaged in resolution discussions with the USAO. In connection with these discussions, we recorded $13 million of expense within litigation charges/(recoveries) on our condensed consolidated statement of operations during the three months ended December&#160;31, 2020. We are not able to estimate a range of reasonably possible additional losses for this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Civil Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pharmaceutical Pricing Antitrust Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Active Pharmaceutical Ingredient Impurity Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. &lt;/span&gt;&lt;/div&gt;In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#x201c;Sartan MDL&#x201d;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter. We were also named as a defendant in a Multidistrict Litigation alleging impurities in Zantac and its generic form, ranitidine (the "Zantac MDL"); however, all claims against us in the Zantac MDL have been dismissed, in some cases, with prejudice.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="ie044a19677f140da979d3894dde5c9de_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzI1NA_fba909a0-b642-4a22-abf9-e9b5a175b5e8">P10Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <cah:MaximumQuarterlyPayment
      contextRef="ie044a19677f140da979d3894dde5c9de_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzQ1NQ_cab72b11-942f-4171-b41d-e46877aa1060"
      unitRef="usd">45600000</cah:MaximumQuarterlyPayment>
    <cah:AggregateAnnualAssessment
      contextRef="ib0763235728b4e798df4a93f91297014_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5MzU2OTc_0b43c45e-0c4e-487e-9a56-6481cbaf06ea"
      unitRef="usd">100000000</cah:AggregateAnnualAssessment>
    <cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct
      contextRef="i24af2662052e41a9916032cdb61e8d12_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5MzU3MDQ_b7b4aa79-68aa-44f0-bb2f-73af7ca43634"
      unitRef="usd">41000000</cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i90dc05ceb60c40f0ac677345f92bae29_I20210201"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzQxMzY_ad18c790-4112-4992-beb7-d647d22b3e76"
      unitRef="number">3300</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i38d2978456e542b7b3180f73a3e78c5f_I20210201"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzQ2OTk_2762dea4-4de3-446f-8d71-33423e6c7e5c"
      unitRef="number">2800</cah:LossContingencyLawsuitsNumber>
    <cah:NumberofStateAttorneysGeneralfilinglawsuits
      contextRef="i90dc05ceb60c40f0ac677345f92bae29_I20210201"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzU0ODc_17646102-a662-42cc-a43c-71ee0404abe2"
      unitRef="stateag">25</cah:NumberofStateAttorneysGeneralfilinglawsuits>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i56512e9ae3444aa3993b873d559a9163_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5MzU3MTE_b3fea09e-3157-4fff-8452-4328cb7ff292"
      unitRef="usd">-1020000000.00</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="id328a673f19941118ace9480b141deae_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5MzU3MjE_32d05193-fa88-46a4-82e6-8b427081b660"
      unitRef="usd">-5630000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LitigationReserve
      contextRef="ia24262f3a922415db5013e0f3ae80122_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5MzU3NzI_7de866c9-a9d2-45ad-8765-16ab5307ea89"
      unitRef="usd">6590000000</us-gaap:LitigationReserve>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i2a4ad47536df474f94e261a74c430702_I20210201"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5MzU3OTk_75837b26-6fd2-473e-bcc4-b75fa7cb5c3b"
      unitRef="lawsuit">423</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i2b7d20f207654f5896c816a15da9291c_I20210201"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzkzOTU_db70e94d-d0ec-47bc-b2c7-ef2b0f32cf7c"
      unitRef="lawsuit">127</cah:LossContingencyLawsuitsNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i2b50640db30b49a9aeed0c6c228e045d_D20210201-20210201"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzEwMDcz_069eb644-ed6d-41d8-b8da-5628516080f3"
      unitRef="lawsuit">373</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i8a7e2cc7591649299a8be4db64de4bf6_D20210201-20210201"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzEwMTk2_52ca27be-a2c7-4836-a580-4cdd3c878986"
      unitRef="plaintiff">4800</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="iaf2d67987fbf44f9b89a411201940603_D20210201-20210201"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzEwMzQ1_3c1ddadd-6165-4ec7-821f-5b27d9a1b531"
      unitRef="lawsuit">31</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i6a938e1fa9214d8cb46bb9c82947ad31_D20210201-20210201"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzEwMzk5_6424b60e-5625-40b6-a0cc-bfd04cdef061"
      unitRef="plaintiff">36</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ia0b1626635494e759538b3e69c1d8c44_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzEwNjE0_1d766d54-7802-44b9-98cc-25e824f870f9"
      unitRef="usd">508000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i06d03eb8370c4ad5b575e1b109ddc573_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzExMDI0_4a8c8224-228c-4f28-a86e-e9e21326889e"
      unitRef="usd">990000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i028cb05d5d774ece897a4eae7abde3c9_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDAvZnJhZzpiYWQzOGQxOWVhZmE0NGNiYjRiNTJjOWUxY2JhZDFjZS90ZXh0cmVnaW9uOmJhZDM4ZDE5ZWFmYTQ0Y2JiNGI1MmM5ZTFjYmFkMWNlXzMyOTg1MzQ5Mzk4NjQ_754b8d83-6922-42d1-8bed-e4ef1226e36b"
      unitRef="usd">-13000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzMyOTg1MzQ5MTIyMDQ_e8825dc9-55f3-4f91-9619-d22c0bca6ccc">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;6. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in our provision for/(benefit from) income taxes as a percentage of pretax earnings (&#x201c;effective tax rate&#x201d;) are generally due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Self-Insurance Pre-tax Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended December&#160;31, 2020, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, is currently deductible on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss is being carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accordingly, our provision for income taxes during the three months ended December&#160;31, 2020 included a $420 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to file for a federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our condensed consolidated balance sheet at December&#160;31, 2020. We also increased our non-current deferred tax liability by approximately $700 million during the six months ended December&#160;31, 2020 related to this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;challenge these tax benefits. The actual amount of the tax benefit may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Opioid Litigation Charges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the $1.02 billion and $5.63 billion pre-tax charges for the opioid litigation, during the six months ended December&#160;31, 2020 and 2019, respectively, the net tax benefits are $35 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million and $469 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision for/(benefit from) income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the initial opioid accrual during the six months ended December 31, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the three months ended September 30, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent. The inclusion of the relatively lower tax benefit of the current fiscal year charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax expense increased by approximately $150 million during the three months ended December&#160;31, 2020 while the amount of tax benefit increased by approximately $300 million during the six months ended December&#160;31, 2020 compared to the tax impacts that would have been recognized without the opioid litigation charge and is expected to significantly increase our provision for income taxes during the remainder of fiscal 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Effective Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended&#160;December&#160;31, 2020&#160;and&#160;2019, the effective tax rate was&#160;(47.6) percent and&#160;21.0&#160;percent, respectively. The change in the effective tax rate compared to the prior period was primarily due to the $420 million benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss, partially offset by the adverse tax impacts of the opioid litigation accrual.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended&#160;December&#160;31, 2020&#160;and&#160;2019, the effective tax rate was 259.7&#160;percent and&#160;7.2&#160;percent, respectively. Included in the effective tax rate for the six months ended December 31, 2020 was the $420 million benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss. Included in both the six months ended December 31, 2020 and 2019 were net tax benefits related to the treatment of the tax impacts of opioid litigation charges. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and June&#160;30, 2020, we had $989 million and $998 million of unrecognized tax benefits, respectively. The December&#160;31, 2020 and June&#160;30, 2020 balances include $745 million and $753 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and June&#160;30, 2020, we had $150 million and $146 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $370 million, exclusive of penalties and interest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Tax Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $181 million and $176 million at December&#160;31, 2020 and June&#160;30, 2020, respectively, and is included in other assets in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $19 million at both December&#160;31, 2020 and June&#160;30, 2020, and is included in other assets in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i87230ed321a245fc91bc68615d9f61a5_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQzOTgwNDY1NDcwOTM_e022fa13-e4cc-4439-88d4-0dbf3d0d36bd"
      unitRef="usd">420000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReceivable
      contextRef="id4465d750964497c99036784264b593a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQzOTgwNDY1NDYxNjI_75570c2b-58a9-47ae-8cca-7b64cf19be1d"
      unitRef="usd">974000000</us-gaap:IncomeTaxReceivable>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="ic03700ae57af494fb31290e42a1720fd_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzNjEwMTI_1e3efadf-5ccb-47d6-8a22-d75e3bcc0c81"
      unitRef="usd">700000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:LitigationSettlementExpense
      contextRef="i56512e9ae3444aa3993b873d559a9163_D20200701-20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYxMDU_db44a638-378d-49b8-b689-a357efe97be1"
      unitRef="usd">1020000000.00</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="id328a673f19941118ace9480b141deae_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYwODQ_5ab1155f-43f4-4b04-b08d-94357e0fd089"
      unitRef="usd">5630000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8f1203c9a1ad44c4874a799063ecc408_D20200701-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYwMzE_fc68b125-c974-4a9a-9c9e-41716db01e9d"
      unitRef="usd">35000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7325d606c00e4365b83eaf72e2f134be_D20190701-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYwMzk_3a81173d-8464-4019-9053-8e7c9189af9a"
      unitRef="usd">488000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i08769690807c428b9015f5d581f80d13_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYwNzY_4281af6a-c487-469e-aa8f-f4e7e3d3ac20"
      unitRef="usd">34000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ibbe4dd4c7b6c4b83bbef659b5664d7ff_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYwNTg_09442ce2-2ead-4cf2-9aa1-ee2feaf8088f"
      unitRef="usd">469000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2334754903a5458bb5821f0515733377_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMzYxMjQ_ee015cf4-a0ce-4f12-84a9-5bd6620e0c05"
      unitRef="usd">-150000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i56512e9ae3444aa3993b873d559a9163_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzNTAzOTA_84f47c8a-f192-44fa-9b34-0cd3ee868440"
      unitRef="usd">300000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzE0NjM_7d9fb3a8-2762-4f53-b3ee-db5d17bf88e3"
      unitRef="number">-0.476</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzE0Nzg_45a1a2f6-172e-4f13-8b97-2a6ef9faa249"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i87230ed321a245fc91bc68615d9f61a5_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzEwOTk1MTE2MzEzNzkw_e022fa13-e4cc-4439-88d4-0dbf3d0d36bd"
      unitRef="usd">420000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzE2OTI_cc025117-3733-4070-9c80-3962e5fcc405"
      unitRef="number">2.597</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzE3MDc_ce3484e9-dda3-4895-942f-5dcbb7994767"
      unitRef="number">0.072</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i87230ed321a245fc91bc68615d9f61a5_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzNjAxNTE_e022fa13-e4cc-4439-88d4-0dbf3d0d36bd"
      unitRef="usd">420000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk3NTA_9a3a8fd5-b4e6-4cfe-b1d1-5dab09263c11"
      unitRef="usd">989000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzE5MzE_43a3d081-491f-4ca9-b11b-27b0aa83a444"
      unitRef="usd">998000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk3NTg_ca93ce37-82ce-4143-8b7d-5509b2fadebb"
      unitRef="usd">745000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzIwMTY_af7ca404-bca2-4e89-a82a-b0fc0afd6569"
      unitRef="usd">753000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk3NzQ_d36dd2a1-fc2c-46bc-a991-6342bb3a2c7a"
      unitRef="usd">150000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk3NjY_7da4960b-1f15-4a13-a617-e0f4c978e187"
      unitRef="usd">146000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i9f1f3a98a99a4d27b6451bfb560ba396_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzMwNDM_a75181b8-2bb3-4cfc-81f8-d665e5e745d9"
      unitRef="usd">0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i6112186cca62432382db406081a60a17_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzMwNzQ_11c81184-1833-497e-9123-616215fc8f8c"
      unitRef="usd">370000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:OpenTaxYear
      contextRef="i888db2833efb4657a6fefd55514539c8_D20201001-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzMzNDY_0dd92d7e-4ce1-4ce9-9284-0eef0bea05dd">2008</us-gaap:OpenTaxYear>
    <cah:IndemnificationReceivable
      contextRef="iab7bd98acbea40449f8bd35c7616c720_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk3OTA_56e6477f-a2c2-4eef-b428-70995bf9704e"
      unitRef="usd">181000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i7f7180f4c5144dceb597f6050eb94368_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk3ODI_d3100ab3-ac64-48eb-a640-4c82d6711ef5"
      unitRef="usd">176000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i26e6e263c6fd4a699bb0c1af198967e1_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk4MDI_28c7dee1-e449-4947-b923-849ec5989cc1"
      unitRef="usd">19000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i93d039e782a9419a9742c71dc850ce33_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDMvZnJhZzoyMjBlNjYyYmY0YzI0NDc1Yjg4YzBjMmU5OWIxZDAxOS90ZXh0cmVnaW9uOjIyMGU2NjJiZjRjMjQ0NzViODhjMGMyZTk5YjFkMDE5XzQ5NDc4MDIzMjk4MDI_bbdcd16b-5767-4500-bfa1-7a836111fad6"
      unitRef="usd">19000000</cah:IndemnificationReceivable>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90ZXh0cmVnaW9uOjk2MzY2ODk3NzUwNzQ3MzhhNGQ3YzIxZmU4ZTc3M2Y0XzMyOTg1MzQ4ODY3ODM_c5794a8c-6613-4105-8ebb-93d022ddfe2b">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;7. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,920&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,920&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90ZXh0cmVnaW9uOjk2MzY2ODk3NzUwNzQ3MzhhNGQ3YzIxZmU4ZTc3M2Y0XzEyNDg_e9ad65e7-cffc-4a31-a9b3-bc06a851d791">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,920&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,920&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i65806b475fdc4876a59494d73901adb7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzMtMS0xLTEtMA_b9fe3d2a-528f-4831-a07f-f1886dab4961"
      unitRef="usd">1920000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i159fa2bd7a66408badeaa0faea3b677d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzMtMy0xLTEtMA_937ee4b7-dd7f-44cc-a5d6-9b312c4b106b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7445253c20dd435886df7adff515242f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzMtNS0xLTEtMA_2337d582-caad-4f06-9431-a78a2f7e897d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0e83590d4a854a7190b78c1a5c2d284f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzMtNy0xLTEtMA_02a1b92b-242d-4384-96ad-c963245fa773"
      unitRef="usd">1920000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i65806b475fdc4876a59494d73901adb7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzUtMS0xLTEtMA_d30084a0-e6a8-48f6-a31a-1b1f92413e34"
      unitRef="usd">120000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i159fa2bd7a66408badeaa0faea3b677d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzUtMy0xLTEtMA_41eb4e38-ef3d-466c-9782-eb454c42cd71"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7445253c20dd435886df7adff515242f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzUtNS0xLTEtMA_83abbeeb-9bef-4cc2-a073-8466fad68f36"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0e83590d4a854a7190b78c1a5c2d284f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzUtNy0xLTEtMA_ddca6df4-b9d3-4c9c-b524-7f050cefb347"
      unitRef="usd">120000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i65806b475fdc4876a59494d73901adb7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzYtMS0xLTEtMA_37890f9d-3112-4112-af23-d5c2c383594d"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i159fa2bd7a66408badeaa0faea3b677d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzYtMy0xLTEtMA_0f55a28b-b390-469a-8f11-1b2ae9ee711c"
      unitRef="usd">5000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i7445253c20dd435886df7adff515242f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzYtNS0xLTEtMA_5a4a3327-219f-48c7-b3d1-b3e12e24555f"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i0e83590d4a854a7190b78c1a5c2d284f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpmYzZkNzg2OWU4MWQ0MmU4ODU2OTdkNzBmZWVjMGM1Yy90YWJsZXJhbmdlOmZjNmQ3ODY5ZTgxZDQyZTg4NTY5N2Q3MGZlZWMwYzVjXzYtNy0xLTEtMA_7230ed11-50a8-4f58-9bf5-08606d6bb5f4"
      unitRef="usd">5000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2d6381aaa6914a0aa526a6b8b3989a7e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzMtMS0xLTEtMA_3d06c298-dde6-4dd3-952c-bca9c5b67689"
      unitRef="usd">721000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8b55dcaca51f44599a00a8fa68d79d85_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzMtMy0xLTEtMA_e752bbcb-4436-41be-9496-7620c836d201"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib957a62df7f549839a60399d078c4472_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzMtNS0xLTEtMA_7f4ba0f4-72b5-4423-ad02-942b8c372fcf"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if41b93ee69de4e0d9701c057ae9ab8db_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzMtNy0xLTEtMA_8a4b11de-e1a1-4610-a7ee-24a2530dedc3"
      unitRef="usd">721000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2d6381aaa6914a0aa526a6b8b3989a7e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzUtMS0xLTEtMA_093d3254-fa70-4ac6-b400-0049370161a6"
      unitRef="usd">114000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8b55dcaca51f44599a00a8fa68d79d85_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzUtMy0xLTEtMA_6c9c6d00-50ad-45dd-8d3d-9705c4d72865"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib957a62df7f549839a60399d078c4472_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzUtNS0xLTEtMA_99b3cefc-a52f-4b8a-8cc9-3e22af1ff34e"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if41b93ee69de4e0d9701c057ae9ab8db_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzUtNy0xLTEtMA_aab4016c-ac64-4650-9abc-f26a5e27af28"
      unitRef="usd">114000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i2d6381aaa6914a0aa526a6b8b3989a7e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzYtMS0xLTEtMA_57db8432-a8ab-4ab6-9f1f-8452b1b2d046"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i8b55dcaca51f44599a00a8fa68d79d85_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzYtMy0xLTEtMA_c4536a3f-1932-43f5-8468-47c09d350222"
      unitRef="usd">53000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ib957a62df7f549839a60399d078c4472_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzYtNS0xLTEtMA_005018e2-79a0-4ee0-818a-e3eb6e7ae6b2"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="if41b93ee69de4e0d9701c057ae9ab8db_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDYvZnJhZzo5NjM2Njg5Nzc1MDc0NzM4YTRkN2MyMWZlOGU3NzNmNC90YWJsZTpkZGVhNmI0YWJmOGE0ZmNhYTlkNjcxMWExOTIzMTVmYS90YWJsZXJhbmdlOmRkZWE2YjRhYmY4YTRmY2FhOWQ2NzExYTE5MjMxNWZhXzYtNy0xLTEtMA_63307f1b-d628-486e-9173-3a36afda320f"
      unitRef="usd">53000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjUwOTg_f2f24798-4b5d-419f-98cb-0bdfa11691bb">&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;8. Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Currency Exchange Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commodity Price Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and six months ended December&#160;31, 2020 and 2019, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the debt repayment as described in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#iac867f2b870144f0baf920261d30f765_97" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 4&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, two pay-floating interest rate swaps with notional amounts of $200 million matured in the second quarter of fiscal 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended December&#160;31, 2019, we entered into forward interest rate swaps with a total notional amount of $100&#160;million to hedge probable, but not firmly committed, future transactions associated with our debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gains recognized in other comprehensive loss were $8&#160;million for the three months ended December&#160;31, 2020 and $7&#160;million for the six months ended December&#160;31, 2020, respectively, and immaterial for the three and six months ended December&#160;31, 2019. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and six months ended December&#160;31, 2020 and 2019. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, we entered into a &#xa5;64.0 billion ($600 million) cross-currency swap maturing in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $27&#160;million loss and a $1&#160;million gain during the three months ended December&#160;31, 2020 and 2019, respectively, and a $52&#160;million loss and a $17&#160;million gain during the six months ended December&#160;31, 2020 and 2019, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $5&#160;million during the three months ended December&#160;31, 2020 and 2019, and $10&#160;million and $6&#160;million during the six months ended December&#160;31, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Economic (Non-Designated) Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $4&#160;million loss and $2&#160;million loss during the three months ended December&#160;31, 2020 and 2019, respectively, and a $5 million loss and $7 million loss during the six months ended December&#160;31, 2020 and 2019, respectively. The principal currencies managed through foreign currency contracts are Chinese renminbi, Canadian dollar, Brazilian real and Japanese yen.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at December&#160;31, 2020 and June&#160;30, 2020 approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,733&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyNTg_1adb44f1-d4cd-439d-9a61-361b4322e393"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyNTg_3cf8527e-1053-4359-b3a4-b6e1694eb39d"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyNTg_cbda5875-7428-4047-be8b-3bbc92d91203"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyNTg_ea75b992-5092-4a23-ab7a-0596c24e883d"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <cah:DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount
      contextRef="ic35295a277e6424d9f0eb8e2c6404476_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzM2Mjk_81f5a1e1-d90a-4296-94b0-e362687345f0"
      unitRef="usd">200000000</cah:DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i0f82a2865f2b492a8c478c3a57f6df30_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzYwNDczMTM5ODM1OTA_4753b4e1-98a3-4e23-b943-6102c757adea"
      unitRef="usd">100000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i796ef5fe827b4eccb2c3f684dc6db76d_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjQzNzQ_2d7e2ffa-91e2-4cfe-a41c-7745a6e22dfa"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i8b687b1f81d948059485e5e2a6425863_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjQzODI_c6b73cab-7907-45d6-9a20-0bad4ffbcef7"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ib15a63d640244c34a6d0227562acaad5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzUxMjU_54c6acf6-6e42-4f20-b787-58f523bba8a9"
      unitRef="jpy">64000000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ib15a63d640244c34a6d0227562acaad5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzUxMjk_fe748a37-e20b-4607-96dc-dd0b46d9a8cc"
      unitRef="usd">600000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib37c4b044c234377901beeef0ec945bd_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzM4NDgyOTA3Mzc0MjI_98e9e866-6607-41e4-a1e2-68e2202e5987"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6845881719c14946a18825ca27e660d9_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzM4NDgyOTA3Mzc0MzA_bda6767c-6080-448f-b9c8-90b5853d23fe"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i478d2dd73460414f88583f29a46256a5_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzYwNDczMTM5OTI3NjA_1417c383-d772-4faa-87e5-53e33a0c0b11"
      unitRef="usd">-52000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i38f0432b47e6439c90226e210f3f5025_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzYwNDczMTM5OTI3NzM_cfd5e724-537a-4cb9-9260-5c03806a9ebe"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ib37c4b044c234377901beeef0ec945bd_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjQzOTQ_d35611fd-e50d-446e-b072-24d0c75345da"
      unitRef="usd">5000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i6845881719c14946a18825ca27e660d9_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjQzOTQ_e6b3e0c2-2d0c-4b4f-b835-3c496bb2d9fd"
      unitRef="usd">5000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i478d2dd73460414f88583f29a46256a5_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjQ4NzA_0b6f74cb-3bd6-45c5-8b50-49deaa7be6bd"
      unitRef="usd">10000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i38f0432b47e6439c90226e210f3f5025_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzMyOTg1MzQ5MjQ4NzQ_f77b597c-6e5e-413e-9468-1b6ceb81d374"
      unitRef="usd">6000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="id909840ad6bb4ab089bf9cbd591c6393_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzM4NDgyOTA3Mzc1NDA_5cf1dcba-aad2-4ec8-b5e2-b7d765d1913d"
      unitRef="usd">-4000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i31ae9f550b884047875a86b44b481e30_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzM4NDgyOTA3Mzc1NDg_ebc16aea-50bf-4e2b-bd6b-d16879ef50f6"
      unitRef="usd">-2000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="id293a6a8b52246f59bdad843b0eedcfc_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzY1NjU_f71cc8cb-38b2-4320-8f12-732da00e9e2e"
      unitRef="usd">-5000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ie3f98e4ee19e4429b6719301c1f07c3a_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzY1NzI_2a1cdd77-4677-4c9c-8331-e0d479dd16ae"
      unitRef="usd">-7000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90ZXh0cmVnaW9uOjg2MGU5ZDE0ODAyYzRkMTFiNmFhNTVjM2MxYzEwN2IxXzc0MjU_ae6cbaba-b431-48ae-a989-ae145bc6df54">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,733&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ib3c9f00156d0450788ebefaa19e489ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90YWJsZTo5OWU4YmYyOWIzMzk0ODYzYjc3MGVmZGMyY2FjMTRlYy90YWJsZXJhbmdlOjk5ZThiZjI5YjMzOTQ4NjNiNzcwZWZkYzJjYWMxNGVjXzEtMS0xLTEtMA_84b89eb4-4510-4b48-892e-ccfb2a38d51b"
      unitRef="usd">7414000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i169899f3ed7e4646b50fcb3a6ea5433a_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90YWJsZTo5OWU4YmYyOWIzMzk0ODYzYjc3MGVmZGMyY2FjMTRlYy90YWJsZXJhbmdlOjk5ZThiZjI5YjMzOTQ4NjNiNzcwZWZkYzJjYWMxNGVjXzEtMy0xLTEtMA_b6038863-f233-45c5-946d-38bd7b36d653"
      unitRef="usd">7273000000</us-gaap:DebtInstrumentFairValue>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90YWJsZTo5OWU4YmYyOWIzMzk0ODYzYjc3MGVmZGMyY2FjMTRlYy90YWJsZXJhbmdlOjk5ZThiZjI5YjMzOTQ4NjNiNzcwZWZkYzJjYWMxNGVjXzItMS0xLTEtMA_0de4d92e-7e11-4f74-b128-e56f03717630"
      unitRef="usd">6733000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMDkvZnJhZzo4NjBlOWQxNDgwMmM0ZDExYjZhYTU1YzNjMWMxMDdiMS90YWJsZTo5OWU4YmYyOWIzMzk0ODYzYjc3MGVmZGMyY2FjMTRlYy90YWJsZXJhbmdlOjk5ZThiZjI5YjMzOTQ4NjNiNzcwZWZkYzJjYWMxNGVjXzItMy0xLTEtMA_cd70e9b2-254f-4378-95fb-ab8be43ed59e"
      unitRef="usd">6775000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90ZXh0cmVnaW9uOjM3NTdlN2U1MmQ3ZDQwMGJiMzI0MWMzYmY3NmI2ODNjXzc0MA_6530dfcf-9b74-4199-b5dd-bcca36ba8628">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;9. Shareholders' Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended December&#160;31, 2019, we repurchased 7.3 million common shares having an aggregate cost of $350 million. The average price paid per common share was $48.00. These repurchases were made under an accelerated share repurchase ("ASR") program, which began on August 20, 2019 and was completed on December 4, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We funded the repurchases with available cash and short-term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income attributable to Cardinal Health, Inc. net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <cah:TreasuryStockAcquiredShares
      contextRef="i4523a176fdd843a1871b85358e66f672_D20190701-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90ZXh0cmVnaW9uOjM3NTdlN2U1MmQ3ZDQwMGJiMzI0MWMzYmY3NmI2ODNjXzM4NDgyOTA2OTkwMDI_d2a913e3-c8c5-4135-90af-7320a836eea8"
      unitRef="shares">7300000</cah:TreasuryStockAcquiredShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90ZXh0cmVnaW9uOjM3NTdlN2U1MmQ3ZDQwMGJiMzI0MWMzYmY3NmI2ODNjXzMyOTg1MzQ4ODU1ODU_3a031054-b493-4f66-ab2e-7291ca8e655f"
      unitRef="usd">350000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i4523a176fdd843a1871b85358e66f672_D20190701-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90ZXh0cmVnaW9uOjM3NTdlN2U1MmQ3ZDQwMGJiMzI0MWMzYmY3NmI2ODNjXzM4NDgyOTA2OTg5ODg_cd95818e-7417-4156-8f61-5e402f820e15"
      unitRef="usdPerShare">48.00</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90ZXh0cmVnaW9uOjM3NTdlN2U1MmQ3ZDQwMGJiMzI0MWMzYmY3NmI2ODNjXzczOQ_ed5153f4-8734-4887-9ece-605abac3c912">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income attributable to Cardinal Health, Inc. net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i516dad7d9d244946b3629a4006f58d73_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzEtMS0xLTEtMA_be52da7d-5c74-4b21-b974-4d1da4bc4e90"
      unitRef="usd">-92000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie565dceec6384b15bc38825036cc1367_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzEtMy0xLTEtMA_302a31c6-fa84-4ca8-928a-fdd1bfca5e48"
      unitRef="usd">-12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9e8a2cc4f32e492b978886cfa6468d14_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzEtNS0xLTEtMA_48c4f0c9-d02a-4f50-99f9-8cefcc92e5d3"
      unitRef="usd">-104000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic07137665bed4e8395c06d5d163722d4_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzItMS0xLTEtMA_ea99c04f-96de-4143-a2cd-148d9c90cea4"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9e9ec7b4d1de47779baac1a8003f4ac0_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzItMy0xLTEtMA_ae1c9ccb-068b-418e-8491-84b23c645d95"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i342dbbcc001646b78a3682ec6c4a043a_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzItNS0xLTEtMA_adcefd7d-9c01-412e-827d-53fa1af90dcc"
      unitRef="usd">48000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic07137665bed4e8395c06d5d163722d4_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzMtMS0xLTEtMA_37916cdd-32af-48f8-b83c-3102821fc24e"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9e9ec7b4d1de47779baac1a8003f4ac0_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzMtMy0xLTEtMA_dfd33ea3-f664-47c0-a332-8d33b509fa8d"
      unitRef="usd">-3000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i342dbbcc001646b78a3682ec6c4a043a_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzMtNS0xLTEtMA_311785e5-1171-46ad-ba25-afc13ef2b566"
      unitRef="usd">-3000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic07137665bed4e8395c06d5d163722d4_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzQtMS0xLTEtMA_a818ef3b-661a-48a9-b447-61823fc2a5b7"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9e9ec7b4d1de47779baac1a8003f4ac0_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzQtMy0xLTEtMA_87029f60-7c0d-4af0-9e31-6d9c11eb15f2"
      unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie5611e497378475180730c7bb2d349b0_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzQtNS0xLTEtMA_793c6123-c8ce-4be0-9e0d-126349202f24"
      unitRef="usd">51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98af1fc7fbb546ada30bf032dc682c07_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzUtMS0xLTEtMA_e2b4dffe-3bca-4721-8bfc-bdf57ef19a12"
      unitRef="usd">-59000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec0a2a9c3a084ecda280560e320b49ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzUtMy0xLTEtMA_23bd66a1-87bc-4bf2-b7d1-494492bdb1ec"
      unitRef="usd">6000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i956ec3fd41944891af79cc5fc668a58d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTUvZnJhZzozNzU3ZTdlNTJkN2Q0MDBiYjMyNDFjM2JmNzZiNjgzYy90YWJsZTpjNmJmZmVmZDY2MjU0ODhjYjVmYTA2NTQ5NmNjYzllZi90YWJsZXJhbmdlOmM2YmZmZWZkNjYyNTQ4OGNiNWZhMDY1NDk2Y2NjOWVmXzUtNS0xLTEtMA_04882224-6f72-4c1e-b4e4-a93acb817d80"
      unitRef="usd">-53000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzMyOTg1MzQ4ODQzNTc_7e343bb3-e0d6-4d47-95b6-1ee135b07457">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;10. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were 4 million for the three and six months ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were 4 million for the three months ended December&#160;31, 2019 and 6 million for the six months ended December&#160;31, 2019 (1 million of which were anti-dilutive as a result of the year-to-date net loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzU5OQ_db7e8dde-7d74-4052-bc61-ede15913bedc">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTpkODRlM2MwNTkzMmQ0MTMwYmZjYzQ5YzRjNTUzNGI0MS90YWJsZXJhbmdlOmQ4NGUzYzA1OTMyZDQxMzBiZmNjNDljNGM1NTM0YjQxXzItMS0xLTEtMA_70a706f0-49f3-4f20-b0e5-35f1e4a8e37d"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTpkODRlM2MwNTkzMmQ0MTMwYmZjYzQ5YzRjNTUzNGI0MS90YWJsZXJhbmdlOmQ4NGUzYzA1OTMyZDQxMzBiZmNjNDljNGM1NTM0YjQxXzItMy0xLTEtMA_8bd50a8c-e848-4b42-ace6-fccc9ef3238c"
      unitRef="shares">292000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTpkODRlM2MwNTkzMmQ0MTMwYmZjYzQ5YzRjNTUzNGI0MS90YWJsZXJhbmdlOmQ4NGUzYzA1OTMyZDQxMzBiZmNjNDljNGM1NTM0YjQxXzQtMS0xLTEtMA_25355634-1d6a-4a83-8c51-dfe1000c6675"
      unitRef="shares">1000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTpkODRlM2MwNTkzMmQ0MTMwYmZjYzQ5YzRjNTUzNGI0MS90YWJsZXJhbmdlOmQ4NGUzYzA1OTMyZDQxMzBiZmNjNDljNGM1NTM0YjQxXzQtMy0xLTEtMA_94542bf7-e915-4236-b762-884a73d321dd"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTpkODRlM2MwNTkzMmQ0MTMwYmZjYzQ5YzRjNTUzNGI0MS90YWJsZXJhbmdlOmQ4NGUzYzA1OTMyZDQxMzBiZmNjNDljNGM1NTM0YjQxXzUtMS0xLTEtMA_bdf6a132-1a3e-4b93-a909-67089f894caf"
      unitRef="shares">295000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTpkODRlM2MwNTkzMmQ0MTMwYmZjYzQ5YzRjNTUzNGI0MS90YWJsZXJhbmdlOmQ4NGUzYzA1OTMyZDQxMzBiZmNjNDljNGM1NTM0YjQxXzUtMy0xLTEtMA_94a9f698-7078-4d56-bba8-d6ca43b3d218"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTo4ZTlkNTI1OWY3ZjU0NjA2OTIwZDg4MzQ2M2ViMDFiNy90YWJsZXJhbmdlOjhlOWQ1MjU5ZjdmNTQ2MDY5MjBkODgzNDYzZWIwMWI3XzItMS0xLTEtMA_fdf013a8-1bf8-441d-99ce-e823e8ee00b0"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTo4ZTlkNTI1OWY3ZjU0NjA2OTIwZDg4MzQ2M2ViMDFiNy90YWJsZXJhbmdlOjhlOWQ1MjU5ZjdmNTQ2MDY5MjBkODgzNDYzZWIwMWI3XzItMy0xLTEtMA_ef0d402f-ce11-4bc6-98a2-cb6f5599963e"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTo4ZTlkNTI1OWY3ZjU0NjA2OTIwZDg4MzQ2M2ViMDFiNy90YWJsZXJhbmdlOjhlOWQ1MjU5ZjdmNTQ2MDY5MjBkODgzNDYzZWIwMWI3XzQtMS0xLTEtMA_35e4fb4d-2cf6-425e-b59f-3bfda24bd811"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTo4ZTlkNTI1OWY3ZjU0NjA2OTIwZDg4MzQ2M2ViMDFiNy90YWJsZXJhbmdlOjhlOWQ1MjU5ZjdmNTQ2MDY5MjBkODgzNDYzZWIwMWI3XzQtMy0xLTEtMA_0bce88ed-7dd0-4a82-a0c3-a80a3d014e37"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTo4ZTlkNTI1OWY3ZjU0NjA2OTIwZDg4MzQ2M2ViMDFiNy90YWJsZXJhbmdlOjhlOWQ1MjU5ZjdmNTQ2MDY5MjBkODgzNDYzZWIwMWI3XzUtMS0xLTEtMA_f3bf9004-acfa-4af4-9d4a-816106c07cf2"
      unitRef="shares">295000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90YWJsZTo4ZTlkNTI1OWY3ZjU0NjA2OTIwZDg4MzQ2M2ViMDFiNy90YWJsZXJhbmdlOjhlOWQ1MjU5ZjdmNTQ2MDY5MjBkODgzNDYzZWIwMWI3XzUtMy0xLTEtMA_048ca07b-fa85-41ab-8b38-c5302304d795"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzI5Mw_1735f8be-d686-4e6f-9167-b0fbb4aab5e1"
      unitRef="shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzI5Mw_7e0ca281-a006-4098-b257-65507cbad5eb"
      unitRef="shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzQ5NDc4MDIzMjU5OTY_2d091ae4-b1fe-4d87-b380-fb0b233f4d79"
      unitRef="shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzQ5NDc4MDIzMjU5OTE_d78c8cc8-178e-46f0-8774-b900c173b7c2"
      unitRef="shares">6000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <cah:Sharesthatwouldbeantidilutiveasaresultofnetloss
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMTgvZnJhZzo4ZDJmY2FhZmM4ODQ0NjQwYmNmMGNlNjhkNTQyZTQzMC90ZXh0cmVnaW9uOjhkMmZjYWFmYzg4NDQ2NDBiY2YwY2U2OGQ1NDJlNDMwXzQ5NDc4MDIzMjU5NzU_5fd3fd75-3ec3-428b-a58e-1f3083612ba9"
      unitRef="shares">1000000</cah:Sharesthatwouldbeantidilutiveasaresultofnetloss>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzUwNDg_dc482083-764e-4fed-9a81-000ebf48d8c0">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;11. Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37,040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;213&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37,236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,729&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;525&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,310&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,737&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,735&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;71,956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68,713&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;392&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;429&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;72,348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69,142&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,944&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;996&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,940&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,615&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;77,082&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;77,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40,360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,670&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,737&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,735&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;74,980&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,615&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;77,082&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;77,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;amp;A") expenses. Segment SG&amp;amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on early extinguishment of debt; and provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $6 million and $17 million for the three months ended December&#160;31, 2020 and 2019, and $11 million and $20 million for the six months ended December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the opioid litigation as discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#iac867f2b870144f0baf920261d30f765_100" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 5&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized pre-tax charges of $1.02 billion and $5.63&#160;billion&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the six months ended December&#160;31, 2020 and 2019, respectively, which were retained at Corporate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the New York Opioid Stewardship Act as discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#iac867f2b870144f0baf920261d30f765_100" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 5&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized a pre-tax charge of $41&#160;million during the six months ended December&#160;31, 2020, related to calendar year 2017 and 2018 assessments, which was retained at corporate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with a voluntary recall for certain surgical gowns and a voluntary recall and field actions for surgical procedure packs containing affected gowns, we recognized a pre-tax charge of $96 million during the three and six months ended December&#160;31, 2019 which was retained at Corporate. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;413&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;649&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;461&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;815&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;466&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23,567&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15,259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,893&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,719&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzEwMQ_83dc1dbc-d4bc-4a1a-8758-5712eecbe9ee"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzEwMQ_eade499d-73c4-475b-adc2-4173be26220a"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzQzOTgwNDY1MzAwOTA_83dc1dbc-d4bc-4a1a-8758-5712eecbe9ee"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzQzOTgwNDY1MzAwOTA_eade499d-73c4-475b-adc2-4173be26220a"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzUwNjU_043337ee-892f-4706-8750-8d40d0f44045">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37,040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;196&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;213&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37,236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,729&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;525&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,310&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,737&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,735&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;71,956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;68,713&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;392&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;429&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;72,348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69,142&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,944&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;996&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,940&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,615&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;77,082&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;77,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i3907143d601446b2b2dadc450da37c6e_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzItMS0xLTEtMA_47c2797f-88e2-419e-8e5e-3ecdb20d8bd9"
      unitRef="usd">37040000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5035cf75d04e4c4c800fa6271658ffaf_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzItMy0xLTEtMA_46a45316-0e58-46a4-877c-04d21efb2959"
      unitRef="usd">35501000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26d16186a3eb4d6cb347ef265ebd81c2_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzMtMS0xLTEtMA_00a90759-48f0-470c-b9e8-91e266236683"
      unitRef="usd">196000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic22e6eb5fc5b44eb8e366a0e404097eb_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzMtMy0xLTEtMA_7b601f34-7032-476f-bd11-df0f26673306"
      unitRef="usd">213000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ff998854edd4eda8d8b8b0671924582_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzQtMS0xLTEtMA_91ba1784-7536-4fef-a5af-339810856dd2"
      unitRef="usd">37236000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i672ee4b7a6194291882b5780e5e828a0_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzQtMy0xLTEtMA_3e17b580-3a9e-4165-9c79-0cf0618cd6a9"
      unitRef="usd">35714000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i341d682d330c4e5392a574b97873cfbc_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzUtMS0xLTEtMA_eccd76db-8d83-4d55-a19d-e669166de6ea"
      unitRef="usd">3729000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6447be5f30b14c9eae4c5ec00d2365d8_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzUtMy0xLTEtMA_e956798c-343f-4540-be04-e06a2295d802"
      unitRef="usd">3498000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4bc1df9803142bca96ee5920f3f9477_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzYtMS0xLTEtMA_491c7c26-aecf-4eed-90c2-1a8454ebbcaa"
      unitRef="usd">581000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i618e7649eb974fa9a8bdda5a0b6c884e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzYtMy0xLTEtMA_9785df46-858b-488c-ae88-a9658aa67271"
      unitRef="usd">525000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a603a9a33074afd94135cf3f2682615_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzctMS0xLTEtMA_bab3e29e-6ea9-4aa1-a99b-add586ce0a4c"
      unitRef="usd">4310000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i351ff459d8c147dc85efc9f57fefc562_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzctMy0xLTEtMA_2caae90d-0ce0-4920-a459-2d36d5a73b0d"
      unitRef="usd">4023000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a9dbdf0124e48049351c12013836acc_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzgtMS0xLTEtMA_6a1c2c2a-b214-46e1-b9a8-cb1203597d5b"
      unitRef="usd">41546000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3403a67c72846a2b090eb4c1dcfe35b_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzgtMy0xLTEtMA_4ce5231b-89f1-46db-b0a0-4ae117bee250"
      unitRef="usd">39737000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id84c7d3f10b5448eae225db35d9ff12b_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzktMS0xLTEtMA_c519da6c-a918-4ca0-8846-6cc64b8b232f"
      unitRef="usd">-5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i21a4a9e6c3b742fcb7a36c82c033f21c_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzktMy0xLTEtMA_b4af66ba-791a-4c0a-84e6-f03714a1baf7"
      unitRef="usd">-2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzEwLTEtMS0xLTA_ff071527-061f-4e88-b6d3-ce2637cc8c5e"
      unitRef="usd">41541000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo0MzcxZmU3NTM1N2E0MGU5YjE0MWU3ZmMwNmU0MzM1OS90YWJsZXJhbmdlOjQzNzFmZTc1MzU3YTQwZTliMTQxZTdmYzA2ZTQzMzU5XzEwLTMtMS0xLTA_b868c0b9-5fb7-4c19-bcce-d9c5fdb20019"
      unitRef="usd">39735000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2240c3e8e514deebd1a13337be4bed5_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzItMS0xLTEtMA_fcfdf8a8-d831-4a07-885d-9f5a5a5c86d3"
      unitRef="usd">71956000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d7ee7ef7fae4a23a4607553d24f1f27_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzItMy0xLTEtMA_0bfbf872-643e-4ff1-9789-cc826e0d9e1c"
      unitRef="usd">68713000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i94a02c3a95ca45b7a140f7699a115bef_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzMtMS0xLTEtMA_d0c953dc-c13e-4d94-b956-a49d1626ac0f"
      unitRef="usd">392000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b2f1f0f8f9e4cdb9a87fac1bfc1dc87_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzMtMy0xLTEtMA_83b07a3b-9a1f-484c-bcb2-9ec507e60533"
      unitRef="usd">429000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67c2756a2d8e492a8d27ef7d759a0159_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzQtMS0xLTEtMA_e8859a95-25d1-4a18-bf75-91b83e48e83c"
      unitRef="usd">72348000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic482ae4cb0e845e983854f115696e92f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzQtMy0xLTEtMA_3dc28e95-dbb3-4227-a7f3-1fc6899a61d8"
      unitRef="usd">69142000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5f48b5e33984bdc8b86b397bfccce23_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzUtMS0xLTEtMA_19b9778c-4e5d-4eb2-b863-a7c7c9024bea"
      unitRef="usd">7167000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b678754b9524d1195c6310b764861aa_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzUtMy0xLTEtMA_90a2e76c-db76-4da2-97d0-3959ab018cab"
      unitRef="usd">6944000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8df2c21ec314065818f504c97c1bc8f_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzYtMS0xLTEtMA_18a272dc-710e-41f1-a1e6-db2de4046421"
      unitRef="usd">1100000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7d29d41390f4acf84c102913fb223e5_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzYtMy0xLTEtMA_c47c3675-c8b8-4960-9f7f-4f666e81c705"
      unitRef="usd">996000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8216fd9e5c90433ea29335aa86cb447c_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzctMS0xLTEtMA_2613f558-8e8a-405c-ab1f-7bfa51ef2735"
      unitRef="usd">8267000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i482f6ccb403f4a52af97d8ca515a61b8_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzctMy0xLTEtMA_cc06872c-0ce4-4a50-82b9-2888cd8f538c"
      unitRef="usd">7940000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95d2c4ed996940f9a46e1b79a9311ba9_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzgtMS0xLTEtMA_1d64c796-65aa-44e7-abf4-b668c8480064"
      unitRef="usd">80615000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i555180dfd31f4d28b52ece1a6f81a588_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzgtMy0xLTEtMA_ad1ea73d-f508-4be4-ad43-80c8cce10574"
      unitRef="usd">77082000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97ef54c441584928af5eb60384fe7457_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzktMS0xLTEtMA_56449087-159e-43f2-9cbe-31924a0d835d"
      unitRef="usd">-9000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9fc0478dc85442c2942659ad0aeebd71_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzktMy0xLTEtMA_32d6c8d3-ad8f-4123-97de-a65f6d6e21b6"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzEwLTEtMS0xLTA_eba8f0fe-d5cb-4c2b-b6eb-6cdb7062bf3d"
      unitRef="usd">80606000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkYjkxNDI3NWRkZTM0NDg4ODU2MzUxNGY3NGE3MzMxNC90YWJsZXJhbmdlOmRiOTE0Mjc1ZGRlMzQ0ODg4NTYzNTE0Zjc0YTczMzE0XzEwLTMtMS0xLTA_a42c2144-14c5-45a9-8fe9-1a50384193d4"
      unitRef="usd">77076000000</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzUwNTQ_606c7fa0-0803-480e-8661-8ddb2393a72f">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40,360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,670&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,737&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,735&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;74,980&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,615&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;77,082&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;77,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="i235c9cf737b84394aae05f413fa3c155_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzItMS0xLTEtMA_cad52e31-bc0c-489c-b202-b0e52824e953"
      unitRef="usd">40360000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib2d75526aa5047f9adcfa5c2aeac6208_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzItMy0xLTEtMA_9f870e31-b28e-48fb-8248-4d8ba68c81fb"
      unitRef="usd">38670000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0bce5f6fb544487b4e3560b83f1110a_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzMtMS0xLTEtMA_5481c992-6dc4-495e-8625-c40993a0566c"
      unitRef="usd">1186000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46dd8327f8a44abf95b9a0332180575f_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzMtMy0xLTEtMA_1fad40fe-5c53-4d0b-aca0-1eaa7381708d"
      unitRef="usd">1067000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a9dbdf0124e48049351c12013836acc_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzQtMS0xLTEtMA_34fcd773-37a8-4679-9bb4-bb225caee5f8"
      unitRef="usd">41546000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3403a67c72846a2b090eb4c1dcfe35b_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzQtMy0xLTEtMA_ef6c729e-372d-4a8f-9448-29ae6184bb4a"
      unitRef="usd">39737000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id84c7d3f10b5448eae225db35d9ff12b_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzUtMS0xLTEtMA_2b175319-4fe5-4df3-baf0-2578baa3cfa9"
      unitRef="usd">-5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i21a4a9e6c3b742fcb7a36c82c033f21c_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzUtMy0xLTEtMA_87251c85-ae2d-4484-abed-34d4e996b3fd"
      unitRef="usd">-2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzYtMS0xLTEtMA_0d65eb96-55a9-4ff4-bafd-eb6fb2f0233c"
      unitRef="usd">41541000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTpkZjUxYzcyMjYyZjQ0MDc2ODgzNTE1N2Q3ODFkZGU3Mi90YWJsZXJhbmdlOmRmNTFjNzIyNjJmNDQwNzY4ODM1MTU3ZDc4MWRkZTcyXzYtMy0xLTEtMA_85a0a73a-4baf-484c-ba2b-be30ce808ea8"
      unitRef="usd">39735000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b9e9461ba0a47d18b3547d957221cd6_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzItMS0xLTEtMA_fb799775-960b-4e99-9c4b-3e0c40073b2e"
      unitRef="usd">78336000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i761af129229b4859917784980b5aa533_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzItMy0xLTEtMA_fda483a6-b0eb-413d-90ad-e2e2518297be"
      unitRef="usd">74980000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83001f54baa54c32ab564685b11c5fd7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzMtMS0xLTEtMA_65c24f3f-dd2f-4826-acda-fa8b589021da"
      unitRef="usd">2279000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55908a6cac3f444daad213a201d855ec_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzMtMy0xLTEtMA_e67c26dd-b30e-4f0d-8c1f-e256f8254a8d"
      unitRef="usd">2102000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95d2c4ed996940f9a46e1b79a9311ba9_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzQtMS0xLTEtMA_f79a4f5c-536a-4ca7-9fdc-baeeac62cfab"
      unitRef="usd">80615000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i555180dfd31f4d28b52ece1a6f81a588_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzQtMy0xLTEtMA_dc6dc3ac-3274-4fd6-bbfd-bbdf37547ca9"
      unitRef="usd">77082000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97ef54c441584928af5eb60384fe7457_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzUtMS0xLTEtMA_55cdd02a-aef0-45f7-a596-c35fe48257f2"
      unitRef="usd">-9000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9fc0478dc85442c2942659ad0aeebd71_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzUtMy0xLTEtMA_48374aa3-9dc9-4104-803d-196f73fa4202"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzYtMS0xLTEtMA_4590d3f2-43e2-4347-887a-00da091472b3"
      unitRef="usd">80606000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTo3ZDdmMDYxZDJmOTk0ZTZmYjA3Y2Y3ZjFjNGM2MGYzZC90YWJsZXJhbmdlOjdkN2YwNjFkMmY5OTRlNmZiMDdjZjdmMWM0YzYwZjNkXzYtMy0xLTEtMA_b3c813cf-a2cc-4b1e-a210-235c95f9ce8f"
      unitRef="usd">77076000000</us-gaap:Revenues>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzQzMTU_51f46904-3055-482f-a65f-9cbe7541d859"
      unitRef="usd">6000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzEwOTk1MTE2MzI4NTM_4c56e4bd-0c74-4ddd-98ab-a1d830d5c5c6"
      unitRef="usd">17000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzQzNjU_0653edaa-bd41-461c-8ed0-29fb80acfd11"
      unitRef="usd">11000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzQzNzI_58556d51-4b67-4838-93ff-bddab796caef"
      unitRef="usd">20000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i56512e9ae3444aa3993b873d559a9163_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzM4NDgyOTA3MDk3NTk_b3fea09e-3157-4fff-8452-4328cb7ff292"
      unitRef="usd">-1020000000.00</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="id328a673f19941118ace9480b141deae_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzM4NDgyOTA3MDk3Njc_32d05193-fa88-46a4-82e6-8b427081b660"
      unitRef="usd">-5630000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct
      contextRef="i24af2662052e41a9916032cdb61e8d12_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzMyOTg1MzQ4OTcxNDQ_27d75f4a-6fdb-48ed-a06d-5dda8b472a58"
      unitRef="usd">41000000</cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct>
    <us-gaap:InventoryRecallExpense
      contextRef="i99f293e06fa54cba94cd2fe57d28abad_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzMyOTg1MzQ4OTU4OTg_3549363e-22e1-40d7-95c4-93d748ea0f35"
      unitRef="usd">96000000</us-gaap:InventoryRecallExpense>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzUwNjk_c7eb88ca-33c3-44ce-a16c-800121eb8a24">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;413&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;649&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;461&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;815&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;466&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3ff998854edd4eda8d8b8b0671924582_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzItMS0xLTEtMA_e4dc2210-ba64-4805-aade-f324ba0189d2"
      unitRef="usd">413000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i672ee4b7a6194291882b5780e5e828a0_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzItMy0xLTEtMA_ff6bf733-8daa-4fc9-8abf-c7ccab86e4aa"
      unitRef="usd">462000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4a603a9a33074afd94135cf3f2682615_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzMtMS0xLTEtMA_493724bf-a8d2-42a7-8aa7-6c44c5d90c2e"
      unitRef="usd">236000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i351ff459d8c147dc85efc9f57fefc562_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzMtMy0xLTEtMA_4cf54cb6-877a-437e-8386-969ccf24f069"
      unitRef="usd">195000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7a9dbdf0124e48049351c12013836acc_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzQtMS0xLTEtMA_ea8835bc-4828-49b3-9689-884a2832bd29"
      unitRef="usd">649000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia3403a67c72846a2b090eb4c1dcfe35b_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzQtMy0xLTEtMA_95f7423a-b0dd-4779-a8cf-7457c9b32c6f"
      unitRef="usd">657000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id84c7d3f10b5448eae225db35d9ff12b_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzUtMS0xLTEtMA_bed417b0-00e6-47bb-8a67-8deabbf94353"
      unitRef="usd">-188000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i21a4a9e6c3b742fcb7a36c82c033f21c_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzUtMy0xLTEtMA_752c9559-c481-429d-b65c-c5156db3f215"
      unitRef="usd">-323000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzYtMS0xLTEtMA_37d5d55e-da2d-4bc7-9667-a7a611cf7639"
      unitRef="usd">461000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphODJiYWJmNGUzODg0OTNhOGY1N2NjMGYzN2IzZGUwNS90YWJsZXJhbmdlOmE4MmJhYmY0ZTM4ODQ5M2E4ZjU3Y2MwZjM3YjNkZTA1XzYtMy0xLTEtMA_ba111e5f-06a0-4c76-ac60-31966d4d9ba3"
      unitRef="usd">334000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i67c2756a2d8e492a8d27ef7d759a0159_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzItMS0xLTEtMA_c01aa255-7114-456c-808f-b807bae09bd8"
      unitRef="usd">815000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic482ae4cb0e845e983854f115696e92f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzItMy0xLTEtMA_a6bc19fb-4f49-4bad-9f86-da9519452323"
      unitRef="usd">860000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8216fd9e5c90433ea29335aa86cb447c_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzMtMS0xLTEtMA_5a2a8e74-9d4b-4a00-8e40-675ce6b770f6"
      unitRef="usd">466000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i482f6ccb403f4a52af97d8ca515a61b8_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzMtMy0xLTEtMA_7d6f84bd-cc9e-4180-9952-4121834c5c96"
      unitRef="usd">365000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i95d2c4ed996940f9a46e1b79a9311ba9_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzQtMS0xLTEtMA_98b24c7f-b1dc-4504-aed9-58883766380f"
      unitRef="usd">1281000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i555180dfd31f4d28b52ece1a6f81a588_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzQtMy0xLTEtMA_3946cca2-e973-47bd-8b85-4e9e3ec218ad"
      unitRef="usd">1225000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i97ef54c441584928af5eb60384fe7457_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzUtMS0xLTEtMA_5b37ba70-085e-4439-8cab-5511a53d3b59"
      unitRef="usd">-1444000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9fc0478dc85442c2942659ad0aeebd71_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzUtMy0xLTEtMA_a0142964-e2df-45b2-9939-da7719447539"
      unitRef="usd">-6155000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzYtMS0xLTEtMA_49cf5625-009b-4197-996e-6dd1fd29edea"
      unitRef="usd">-163000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTphZmRlODk5ODU5Njg0YzRkYjNlOTFjNTA1ZTM2ZTEyMC90YWJsZXJhbmdlOmFmZGU4OTk4NTk2ODRjNGRiM2U5MWM1MDVlMzZlMTIwXzYtMy0xLTEtMA_bde96e9b-8cb7-47a9-bba3-f5df3b57a49c"
      unitRef="usd">-4930000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90ZXh0cmVnaW9uOjkyOTZiNGE3NmVlZjQzOTliM2I2OWNjZGM5YWY2MWUzXzUwNjc_44973233-7266-4ce4-9645-22d00fae6be2">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23,567&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15,259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,893&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,719&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="i704d2da68a27491caa5fcefcc86490a6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzEtMS0xLTEtMA_4e712fd6-2a93-4126-9ef9-14717175fc8a"
      unitRef="usd">23567000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0d5964aeb73c4db18da5611b91ef7334_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzEtMy0xLTEtMA_3c487270-5673-4956-8add-873307b060d8"
      unitRef="usd">22398000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i89a6b93ede39460b8242e3fedc07e841_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzItMS0xLTEtMA_33424899-6126-4499-847c-62357717e8c1"
      unitRef="usd">15259000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i57ef56323da34ba69ad0fcaae008d16f_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzItMy0xLTEtMA_8f042edf-a737-4d39-87b6-a39406fca9a8"
      unitRef="usd">14691000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie417bfafb8654792b0622431ec8134ce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzMtMS0xLTEtMA_43ed4f86-dc6c-42d9-a014-076367ed1def"
      unitRef="usd">5893000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8d0bffbd8bb54efaa2c7c406881f23ab_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzMtMy0xLTEtMA_65aad398-0486-48e4-9ebb-38df05e2066b"
      unitRef="usd">3677000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzQtMS0xLTEtMA_7507f1a0-c399-4402-b0d0-50acc9b81a30"
      unitRef="usd">44719000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMjQvZnJhZzo5Mjk2YjRhNzZlZWY0Mzk5YjNiNjljY2RjOWFmNjFlMy90YWJsZTplNzk5NmM5MjU0MmU0YTU0YWYxOGU4MDg2ZmY0OTlmMS90YWJsZXJhbmdlOmU3OTk2YzkyNTQyZTRhNTRhZjE4ZTgwODZmZjQ5OWYxXzQtMy0xLTEtMA_7d198f3d-eeff-4b60-9231-497210c37cb7"
      unitRef="usd">40766000000</us-gaap:Assets>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzMyOTg1MzQ4ODU5NDM_da0609ba-9f02-4a8a-9a4e-e9f7d96a6568">&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;12. Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain stock incentive plans (collectively, the &#x201c;Plans&#x201d;) for the benefit of certain of our officers, directors and employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total tax benefit related to share-based compensation was $3 million for both the three months ended December&#160;31, 2020 and 2019, and $7 million for both the six months ended December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48.29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $111 million, which is expected to be recognized over a weighted-average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all stock option transactions under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Common Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;67.08&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;67.27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $0.3 million, which is expected to be recognized over a weighted-average period of two years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide additional detail related to stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of outstanding options at period end&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of exercisable options at period end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of exercisable options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53.89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $38 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzI0MTQ_67c045d8-d338-4bde-b188-34f568c83c0f">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if99bd32109874e86a903049a33a5df8d_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzItMS0xLTEtMA_f5b5ddc7-ab14-400a-868b-eb622c7725cf"
      unitRef="usd">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib87c6a3a8d094aeaba3759a9a6ff0c4e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzItMy0xLTEtMA_efda2ce4-5035-4c9e-a624-78d86a0761b0"
      unitRef="usd">16000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic0de7af799774156a7e1dd567937f30d_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzMtMS0xLTEtMA_e43c478d-3a0d-442a-858b-66f17f699999"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0fba9c013a7b43dd90febed8d8b6afe3_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzMtMy0xLTEtMA_dc46346a-b7dc-4239-a57f-0cabe9df0b53"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia18cb4783d8449c285fe5638df3c4776_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzQtMS0xLTEtMA_64d1b575-4c6d-472a-895a-9bb2ce5884af"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib7d0b551d8034adaa39776dff9c6b47b_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzQtMy0xLTEtMA_4d22c192-fbfe-4ae1-adbb-68bd8b213fee"
      unitRef="usd">4000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzUtMS0xLTEtMA_5bfd7f73-b392-47d5-b180-b571f4e012d5"
      unitRef="usd">23000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if4b641bae7424eb28eaa17637d338e6e_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpiYjZmOTJkZGZhZGU0MmZjODEyNTgxZjZlNjE4MjM1NS90YWJsZXJhbmdlOmJiNmY5MmRkZmFkZTQyZmM4MTI1ODFmNmU2MTgyMzU1XzUtMy0xLTEtMA_25191a0b-331d-497b-8a5e-935c0219d4b3"
      unitRef="usd">21000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzItMS0xLTEtMA_e64a53f7-046c-4529-ad53-c0b196364433"
      unitRef="usd">36000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia1e48cb861974ac9b185da35f6452945_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzItMy0xLTEtMA_90ae39b9-8ad5-47dd-876c-f2dc0b90b359"
      unitRef="usd">33000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzMtMS0xLTEtMA_1198b165-95ef-442e-b410-ad7b393d1dd8"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i52a2b1e5f55d48c5a3fbb4e2c6d024d6_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzMtMy0xLTEtMA_6e974791-6e7e-4e5d-8a8f-575f889ffac7"
      unitRef="usd">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzQtMS0xLTEtMA_45c653eb-5746-48ac-a617-60e5ef1cad3a"
      unitRef="usd">15000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i51b81892e14d49f39bb77a27503cd87d_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzQtMy0xLTEtMA_b4734e30-4eb5-4ec7-9568-440d2ad50493"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzUtMS0xLTEtMA_64c91b9a-459e-4b58-8c08-804e367d83aa"
      unitRef="usd">51000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice1200d475ba40da95d038803bdd462f_D20190701-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTowNjg2OTBmNDM1MWM0YzU0ODUyMTdiMDk4MGE5N2FhMi90YWJsZXJhbmdlOjA2ODY5MGY0MzUxYzRjNTQ4NTIxN2IwOTgwYTk3YWEyXzUtMy0xLTEtMA_96734f95-8933-482c-b8d6-d535c055a28c"
      unitRef="usd">41000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzI5NA_211ddb01-48c8-4850-b3da-04de2204d56e"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzM2MA_d71f7c38-30c0-4cdb-b30c-044c42feee78"
      unitRef="usd">7000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzUyNQ_1c4a16ff-aa81-4cf4-9159-8cf601204a65">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzI0MjU_030686c0-72a2-49b8-9061-50edb67b133a">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48.29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if9de38f44efc4734a6acc21a07c418b0_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzEtMS0xLTEtMA_6a70c19f-1037-4119-8816-48a3c723f8d6"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if9de38f44efc4734a6acc21a07c418b0_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzEtMy0xLTEtMA_a6e1553d-2dfd-43c0-864a-fc0a9c06c03e"
      unitRef="usdPerShare">45.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzItMS0xLTEtMA_9c795559-4dcf-4343-bc07-783337412abc"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzItMy0xLTEtMA_c2d5a2da-2f19-4a0f-8462-669135b37c77"
      unitRef="usdPerShare">53.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzMtMS0xLTEtMA_e7dedd4c-959d-4e99-9582-2e2c680d0727"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzMtMy0xLTEtMA_93979af1-103e-4a97-b003-ad6d686e7869"
      unitRef="usdPerShare">49.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzQtMS0xLTEtMA_092c2082-ad1c-417a-9b20-8f636e938791"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzQtMy0xLTEtMA_75575df0-2b83-4efc-ad6b-b9856164cbb5"
      unitRef="usdPerShare">48.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id6a9264343844c3188592efd3e0a1c18_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzUtMS0xLTEtMA_5f49bb8b-26ea-4db0-9753-4d50ed8dab32"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id6a9264343844c3188592efd3e0a1c18_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphODQ2NjU0NTg5Yjc0MzI3OWY3NGQzMjZiMzIzZWJmOS90YWJsZXJhbmdlOmE4NDY2NTQ1ODliNzQzMjc5Zjc0ZDMyNmIzMjNlYmY5XzUtMy0xLTEtMA_150208f2-37c5-4ce4-98d9-e2c1443c7b15"
      unitRef="usdPerShare">48.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id6a9264343844c3188592efd3e0a1c18_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzg3Mg_ff6b4e23-347b-47a2-a423-b546972f1c1e"
      unitRef="usd">111000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzk0NQ_5b625245-6d62-449b-9e82-b6cfb3ebd61e">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzEwNTk_54e6171f-72e6-4788-a5d0-b76c51444e4a">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cah:ExercisablePeriodOfPlansInYears
      contextRef="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzEwODY_6947fa6c-4742-468c-8d5e-147f1ff001f1">P10Y</cah:ExercisablePeriodOfPlansInYears>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzI0MzA_6c51a419-e6f9-47dc-b733-317e46322294">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all stock option transactions under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Common Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;67.08&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;67.27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzEtMS0xLTEtMA_4ca75862-acee-4541-aa61-89b14d0a8b41"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iae3c66df6beb43fb8dc9aec45034e9af_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzEtMy0xLTEtMA_7209cdb8-5b33-4083-a179-a633b1315101"
      unitRef="usdPerShare">65.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzItMS0xLTEtMA_8e12909f-dbb0-4105-abab-ffc0d04884c7"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzItMy0xLTEtMA_de3cd7c3-91d5-4969-8a2d-874b380b8312"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzMtMS0xLTEtMA_721e31b9-65fa-46a1-96b6-5c6593643403"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzMtMy0xLTEtMA_8823e544-f3ee-4d9f-989d-29edff26e3a5"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzQtMS0xLTEtMA_9c512cad-e6b6-465c-9ca3-8b32a77763d0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzQtMy0xLTEtMA_1b68c22d-10aa-4a7c-bfbc-192056ccefb9"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzUtMS0xLTEtMA_99f34743-966c-4aa8-b427-f9e9a5c61939"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzUtMy0xLTEtMA_417b2762-ab62-49fb-aa94-351179700314"
      unitRef="usdPerShare">67.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzYtMS0xLTEtMA_eab39eda-26b7-4dbd-9be2-df0c4199c884"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i6d8949488e504051b168d44d36fc8172_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTpkYzE5OGNkMGY2MDc0NzQ1YTFjYjViMDllNDUyNzRkNy90YWJsZXJhbmdlOmRjMTk4Y2QwZjYwNzQ3NDVhMWNiNWIwOWU0NTI3NGQ3XzYtMy0xLTEtMA_17c84d7e-7a62-41ab-93b3-3f4aca699c88"
      unitRef="usdPerShare">67.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i130d53f3f6b041848bc6ad14a45add16_I20201231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzE0NTU_01fc1c78-5995-4957-a005-f0b0055a33b9"
      unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzE1Mzg_2e7de27e-69a6-4c88-9f2c-418bfcc8ee77">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <cah:AdditionalStockOptionPlanDataTableTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzI0NTI_e9c86ba3-1a74-495e-a2af-827e32db0947">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide additional detail related to stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of outstanding options at period end&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of exercisable options at period end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of exercisable options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cah:AdditionalStockOptionPlanDataTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i130d53f3f6b041848bc6ad14a45add16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTo3OGFkM2FjNTI3MmM0NTk2Yjk4MjUyYjUxNzdhZGQyMC90YWJsZXJhbmdlOjc4YWQzYWM1MjcyYzQ1OTZiOTgyNTJiNTE3N2FkZDIwXzEtMS0xLTEtMA_d2ca9b75-b79f-4556-8c9e-84355b810d79"
      unitRef="usd">9000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ibdedc1cec79f497e8b28d714bde083dd_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTo3OGFkM2FjNTI3MmM0NTk2Yjk4MjUyYjUxNzdhZGQyMC90YWJsZXJhbmdlOjc4YWQzYWM1MjcyYzQ1OTZiOTgyNTJiNTE3N2FkZDIwXzEtMy0xLTEtMA_b2af43fa-d198-4adf-a909-ce68fe1ddfbf"
      unitRef="usd">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i130d53f3f6b041848bc6ad14a45add16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTo3OGFkM2FjNTI3MmM0NTk2Yjk4MjUyYjUxNzdhZGQyMC90YWJsZXJhbmdlOjc4YWQzYWM1MjcyYzQ1OTZiOTgyNTJiNTE3N2FkZDIwXzItMS0xLTEtMA_b7c0c4f4-d02a-4f07-b7a7-c0ab3fd21639"
      unitRef="usd">9000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ibdedc1cec79f497e8b28d714bde083dd_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTo3OGFkM2FjNTI3MmM0NTk2Yjk4MjUyYjUxNzdhZGQyMC90YWJsZXJhbmdlOjc4YWQzYWM1MjcyYzQ1OTZiOTgyNTJiNTE3N2FkZDIwXzItMy0xLTEtMA_768bfa35-6a5a-4f53-a644-eefdc5b635cd"
      unitRef="usd">12000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphNDBmMzg5YjExYWM0NjU3YTMxNDFjZTM0YjgwODAxMy90YWJsZXJhbmdlOmE0MGYzODliMTFhYzQ2NTdhMzE0MWNlMzRiODA4MDEzXzEtMS0xLTEtMA_91e0e320-937e-43d1-9153-d4316f8c7215">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i52a2b1e5f55d48c5a3fbb4e2c6d024d6_D20190701-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphNDBmMzg5YjExYWM0NjU3YTMxNDFjZTM0YjgwODAxMy90YWJsZXJhbmdlOmE0MGYzODliMTFhYzQ2NTdhMzE0MWNlMzRiODA4MDEzXzEtMy0xLTEtMA_51da4baf-b4da-4e1a-a8b8-40539f24e8b7">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie0e0e500bbf648608a196ee65d217d33_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphNDBmMzg5YjExYWM0NjU3YTMxNDFjZTM0YjgwODAxMy90YWJsZXJhbmdlOmE0MGYzODliMTFhYzQ2NTdhMzE0MWNlMzRiODA4MDEzXzItMS0xLTEtMA_2fa5f343-408e-4f2a-b6a4-fef5df231da7">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i52a2b1e5f55d48c5a3fbb4e2c6d024d6_D20190701-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTphNDBmMzg5YjExYWM0NjU3YTMxNDFjZTM0YjgwODAxMy90YWJsZXJhbmdlOmE0MGYzODliMTFhYzQ2NTdhMzE0MWNlMzRiODA4MDEzXzItMy0xLTEtMA_9f48caa6-3804-419d-87a1-efc3d11e6cf9">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <cah:VestingPeriodinyearsforShares
      contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzMyOTg1MzQ4ODU5MzY_77f40a4e-9b04-43b2-b791-c36411004404"
      unitRef="number">3</cah:VestingPeriodinyearsforShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ia83b442716234d0f8c45c343f0fa6ae7_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzE4NDQ_e7eb077d-5ed7-4955-bcc4-9425789bbb48"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i95f32f5a14a64f12ade71f4f086f5c9d_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzE4NTA_6678e061-e343-4e61-8726-1e97e0f65d96"
      unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzI0NTA_e9d5e729-cbb1-4e54-8c38-e05cf965b8ea">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53.89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iea7a98aa2bac4b76bab476be13a2fb31_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzEtMS0xLTEtMA_6e134238-16d1-48e9-8b4a-cffb5a723893"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iea7a98aa2bac4b76bab476be13a2fb31_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzEtMy0xLTEtMA_331d965a-4b69-45d6-b4b8-92fb044a74b4"
      unitRef="usdPerShare">54.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzItMS0xLTEtMA_109de2ab-705f-47ed-9e24-473a3ca78f4d"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzItMy0xLTEtMA_a5b55fe1-f345-4216-ac09-1e4c48980417"
      unitRef="usdPerShare">55.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzMtMS0xLTEtMA_f4ee5248-283f-4381-813a-25c4adecb454"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzMtMy0xLTEtMA_2a54c07f-7038-421e-9f7a-b288027fba88"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzQtMS0xLTEtMA_f41f7624-bacf-4370-915b-87f53d7b169c"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzQtMy0xLTEtMA_0537dc28-a160-463f-b95b-f0eefaa9b982"
      unitRef="usdPerShare">52.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i625efca7a8ef454c8cbb29134f0f0c7a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzUtMS0xLTEtMA_3befb5e7-bad8-4d08-8745-a5d3a6a5226b"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i625efca7a8ef454c8cbb29134f0f0c7a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90YWJsZTplZjZlY2E3Nzc2ZDE0ZTY5YmJjNjVjNDZhMTk1ZjkyYS90YWJsZXJhbmdlOmVmNmVjYTc3NzZkMTRlNjliYmM2NWM0NmExOTVmOTJhXzUtMy0xLTEtMA_15f6c4b6-8b97-46b1-aabd-eb4ab9ceaf0e"
      unitRef="usdPerShare">53.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i625efca7a8ef454c8cbb29134f0f0c7a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzIyNTk_85fe3f26-aee9-41d6-8e2b-b78c1fb7f127"
      unitRef="usd">38000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i93a7e60b3c2e4b09afa9428f5ac40692_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFjODY3ZjJiODcwMTQ0ZjBiYWY5MjAyNjFkMzBmNzY1L3NlYzphYzg2N2YyYjg3MDE0NGYwYmFmOTIwMjYxZDMwZjc2NV8xMzAvZnJhZzo5YTcyYjVkYjg3MzY0YTM3OWJkZTg3Yzc2ZmIyNmY5ZC90ZXh0cmVnaW9uOjlhNzJiNWRiODczNjRhMzc5YmRlODdjNzZmYjI2ZjlkXzIzMzI_f2f058d0-3c9e-4b91-bfc1-6799cd69a270">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166054962408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardinal Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000721371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-0958666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Cardinal Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">43017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">757-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares (without par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,667,560<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166058005752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 41,541<span></span>
</td>
<td class="nump">$ 39,735<span></span>
</td>
<td class="nump">$ 80,606<span></span>
</td>
<td class="nump">$ 77,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">39,765<span></span>
</td>
<td class="nump">38,021<span></span>
</td>
<td class="nump">77,115<span></span>
</td>
<td class="nump">73,683<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,776<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
<td class="nump">3,491<span></span>
</td>
<td class="nump">3,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Distribution, selling, general and administrative expenses</a></td>
<td class="nump">1,147<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
<td class="nump">2,284<span></span>
</td>
<td class="nump">2,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and employee severance</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Amortizationandotheracquisitionrelatedcosts', window );">Amortization and other acquisition-related costs</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation (recoveries)/charges, net</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
<td class="nump">5,694<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating earnings/(loss)</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="num">(4,930)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/expense, net</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Extinguishment of Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Earnings/(loss) before income taxes</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="num">(5,065)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for/(benefit from) income taxes</a></td>
<td class="num">(203)<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="num">(613)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">377<span></span>
</td>
<td class="num">(4,701)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings/(loss) attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 629<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
<td class="num">$ (4,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings/(loss) per common share attributable to Cardinal Health, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic (in shares)</a></td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="num">$ (15.99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income (Loss) from Continuing Operations, Per Diluted Share</a></td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="num">$ (15.99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share</a></td>
<td class="nump">$ 0.4859<span></span>
</td>
<td class="nump">$ 0.4811<span></span>
</td>
<td class="nump">$ 0.9718<span></span>
</td>
<td class="nump">$ 0.9622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Amortizationandotheracquisitionrelatedcosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Amortizationandotheracquisitionrelatedcosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166054961912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 630<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 377<span></span>
</td>
<td class="num">$ (4,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">21<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Net unrealized gain/(loss) on derivative instruments, net of tax</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income/(loss)</a></td>
<td class="nump">664<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="num">(4,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 427<span></span>
</td>
<td class="num">$ (4,726)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166054752376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">$ 3,737<span></span>
</td>
<td class="nump">$ 2,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">8,728<span></span>
</td>
<td class="nump">8,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">14,443<span></span>
</td>
<td class="nump">13,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">3,205<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">30,113<span></span>
</td>
<td class="nump">25,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,386<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangibles, net</a></td>
<td class="nump">11,102<span></span>
</td>
<td class="nump">11,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">44,719<span></span>
</td>
<td class="nump">40,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">23,235<span></span>
</td>
<td class="nump">21,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations and other short-term borrowings</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,502<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">25,750<span></span>
</td>
<td class="nump">23,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">6,720<span></span>
</td>
<td class="nump">6,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">10,274<span></span>
</td>
<td class="nump">8,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Authorized&#8212;500 thousand shares, Issued&#8212;none</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Authorized&#8212;755 million shares, Issued&#8212;327 million shares at December 31, 2020 and June 30, 2020, respectively</a></td>
<td class="nump">2,778<span></span>
</td>
<td class="nump">2,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Common shares in treasury, at cost: 33 million shares and 34 million shares at December 31, 2020 and June 30, 2020, respectively</a></td>
<td class="num">(2,009)<span></span>
</td>
<td class="num">(2,066)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Cardinal Health, Inc. shareholders' equity</a></td>
<td class="nump">1,971<span></span>
</td>
<td class="nump">1,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 44,719<span></span>
</td>
<td class="nump">$ 40,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Common shares in treasury</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166054012856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Common shares in treasury</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166050345992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2019</a></td>
<td class="nump">$ 6,330<span></span>
</td>
<td class="nump">$ 2,763<span></span>
</td>
<td class="nump">$ 5,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (79)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(4,701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">(4,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2019</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">$ 2,752<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,099)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Sep. 30, 2019</a></td>
<td class="nump">903<span></span>
</td>
<td class="nump">$ 2,669<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2019</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">$ 2,752<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,099)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2020</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2020</a></td>
<td class="nump">$ 1,792<span></span>
</td>
<td class="nump">$ 2,789<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2020</a></td>
<td class="num">(34,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2020</a></td>
<td class="num">$ (2,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="num">$ (46)<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 2,778<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Dec. 31, 2020</a></td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Sep. 30, 2020</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">$ 2,760<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 2,778<span></span>
</td>
<td class="nump">$ 1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Dec. 31, 2020</a></td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166054953480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 377<span></span>
</td>
<td class="num">$ (4,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Extinguishment of Debt</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">(Increase)/decrease in trade receivables</a></td>
<td class="num">(499)<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(1,256)<span></span>
</td>
<td class="num">(991)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase/(decrease) in accounts payable</a></td>
<td class="nump">1,861<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other accrued liabilities and operating items, net</a></td>
<td class="nump">504<span></span>
</td>
<td class="nump">5,128<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,487<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of subsidiaries, net of cash acquired</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(174)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments', window );">Purchase of investments</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments', window );">Proceeds from investments</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets', window );">Proceeds from divestitures and disposal of property and equipment and held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(191)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Reduction of long-term obligations</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation', window );">Net proceeds/(tax withholdings) from share-based compensation</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends on common shares</a></td>
<td class="num">(289)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(344)<span></span>
</td>
<td class="num">(760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rates changes on cash and equivalents</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</a></td>
<td class="nump">966<span></span>
</td>
<td class="num">(872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents at beginning of period</a></td>
<td class="nump">2,771<span></span>
</td>
<td class="nump">2,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents at end of period</a></td>
<td class="nump">$ 3,737<span></span>
</td>
<td class="nump">$ 1,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Netproceedstaxwithholdingsfromsharebasedcompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from divestitures and disposal of property and equipment and held for sale assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from purchases of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Purchaseofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166049119192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns is in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2020 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2021 and June&#160;30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic also affected our businesses in a variety of ways beginning in the third quarter of fiscal 2020 and continuing into fiscal 2021. We cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. and global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow. Our estimates, judgments and assumptions related to COVID-19 could ultimately differ over time.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K").</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166047809640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of lease costs associated with vacant facilities, accelerated depreciation, vendor transition fees, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs during both the three and six months ended December&#160;31, 2020 and 2019 were primarily related to implementation of certain enterprise-wide cost-savings measures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(53)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166049272264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,357</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,659</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,740</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,399</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,570</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,978</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,592</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">671</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">360</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">311</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,612</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">836</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">776</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,853</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,174</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,679</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,877</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,174</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,703</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,831&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,895&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $113 million and $127 million for the three months ended December 31, 2020 and 2019, respectively, and $228 million and $256 million for the six months ended December&#160;31, 2020 and 2019, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2021 through 2025 is as follows: $217 million, $398 million, $359 million, $329 million and $278 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166047815784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract', window );"><strong>Long-Term Obligations and Other Short-Term Borrowings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Obligations and Other Short-Term Borrowings</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Long-Term Obligations and Other Short-Term Borrowings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and June&#160;30, 2020, we had total long-term obligations, including the current portion and other short-term borrowings, of $6.7 billion and $6.8 billion, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These obligations are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $23.2 billion and $21.4 billion at December&#160;31, 2020 and June&#160;30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2020, we early repurchased $40 million of the Floating Rate Notes due 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $2 million of the 2.616% Notes due 2022. The repurchases were paid for with available cash. In connection with the early debt repurchases, we recorded a $1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss on early extinguishment of debt during the six months ended December&#160;31, 2020. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we repaid the full principal of the 2.4% Notes due 2019 at maturity for $450&#160;million. During the six months ended December 31, 2019, we early repurchased $207&#160;million of the 2.616% Notes due 2022, $10&#160;million of the 3.2% Notes due 2022, $14&#160;million of the Floating Rate Notes due 2022, $81&#160;million of the 3.41% Notes due 2027, $6&#160;million of the 4.6% Notes due 2043,$2&#160;million of the 4.9% Notes due 2045, and $21&#160;million of the 4.368% Notes due 2047. The repurchases were paid for with available cash and other short-term borrowings. In connection with the early debt repurchases, we recorded a $4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss on early extinguishment of debt during the three and six months ended December 31, 2019. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;December&#160;31, 2020, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2022. CHF was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div>Our revolving credit and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter through December 2020, a consolidated net leverage ratio of no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021. As of December&#160;31, 2020, we were in compliance with this financial covenant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Obligations and Other Short-Term Borrowings [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LongTermObligationsandOtherShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166048971128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingent Liabilities and Litigation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $45.6 million to CVS Health for the remainder of the initial term.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the U.S. District Court for the Southern District of New York ruled that the OSA was unconstitutional and enjoined its enforcement (the "Ruling"). In April 2019, the State, among other things, amended the OSA so that the assessment would only cover opioid sales in 2017 and 2018, subject to the State's appeal of the Ruling. In September 2020, the U.S. Court of Appeals for the Second Circuit reversed the Ruling and, as a result, New York will likely seek to collect amounts due from distributors and manufacturers for 2017 and 2018. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41&#160;million for calendar year 2017 and 2018 based on the estimated payment amount, which is our best estimate of the OSA payments probable at December 31, 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory </span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings/(loss).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,300 lawsuits relating to </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 2,800 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#8220;MDL&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in West Virginia in the Cabell County and City of Huntington cases is scheduled for May 2021 and a trial is scheduled to begin in September 2021 in the case brought by the Ohio Attorney General. Trial dates remain uncertain due in part to uncertainties arising from the COVID-19 pandemic. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). This Settlement Framework is the basis for the ongoing negotiation of definitive terms and documentation. Negotiations under the Settlement Framework continue.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these discussions, we have recorded total pre-tax charges of $1.02&#160;billion and $5.63&#160;billion in litigation charges/(recoveries), net in the six months ended December 31, 2020 and 2019, respectively. In total, we have $6.59&#160;billion accrued at December 31, 2020, included in deferred income taxes and other liabilities in the condensed consolidated balance sheets, which represents the cash component. We are unable to estimate the range of possible loss associated with these matters. Definitive terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. We continue to </span></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Framework does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private parties had brought approximately 423 lawsuits as of February 1, 2021. Of these, 127 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in these matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Affirmative Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#8220;National Union Fire Insurance&#8221;), seeking a declaration that defense costs are recoverable under our insurance for certain of the lawsuits described above. We have not recorded a receivable for any recoveries related to the litigation against National Union Fire Insurance at December 31, 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these requests. We are unable to predict the outcome of any of these investigations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 1, 2021, we are named as a defendant in 373 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 4,800 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 31 lawsuits involving similar claims by approximately 36 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We continue to vigorously defend ourselves in these lawsuits and are engaged in resolution discussions with certain plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had a total of $508 million net of estimated insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits which are presented on a gross basis in the condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">end of the range to be approximately $990 million, net of estimated insurance recoveries.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In November 2020, we filed a motion to dismiss the amended complaint. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Solutions DOJ Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we received investigative demands from the United States Attorney&#8217;s Office for the District of Massachusetts (the "USAO") pertaining to the U.S. federal healthcare fraud and abuse laws. These requests sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with these requests and are engaged in resolution discussions with the USAO. In connection with these discussions, we recorded $13 million of expense within litigation charges/(recoveries) on our condensed consolidated statement of operations during the three months ended December&#160;31, 2020. We are not able to estimate a range of reasonably possible additional losses for this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. </span></div>In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#8220;Sartan MDL&#8221;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter. We were also named as a defendant in a Multidistrict Litigation alleging impurities in Zantac and its generic form, ranitidine (the "Zantac MDL"); however, all claims against us in the Zantac MDL have been dismissed, in some cases, with prejudice.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166047765032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of pretax earnings (&#8220;effective tax rate&#8221;) are generally due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2020, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, is currently deductible on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss is being carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our provision for income taxes during the three months ended December&#160;31, 2020 included a $420 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to file for a federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our condensed consolidated balance sheet at December&#160;31, 2020. We also increased our non-current deferred tax liability by approximately $700 million during the six months ended December&#160;31, 2020 related to this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">challenge these tax benefits. The actual amount of the tax benefit may differ materially from these estimates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $1.02 billion and $5.63 billion pre-tax charges for the opioid litigation, during the six months ended December&#160;31, 2020 and 2019, respectively, the net tax benefits are $35 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million and $469 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision for/(benefit from) income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid accrual during the six months ended December 31, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the three months ended September 30, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent. The inclusion of the relatively lower tax benefit of the current fiscal year charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax expense increased by approximately $150 million during the three months ended December&#160;31, 2020 while the amount of tax benefit increased by approximately $300 million during the six months ended December&#160;31, 2020 compared to the tax impacts that would have been recognized without the opioid litigation charge and is expected to significantly increase our provision for income taxes during the remainder of fiscal 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;December&#160;31, 2020&#160;and&#160;2019, the effective tax rate was&#160;(47.6) percent and&#160;21.0&#160;percent, respectively. The change in the effective tax rate compared to the prior period was primarily due to the $420 million benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss, partially offset by the adverse tax impacts of the opioid litigation accrual.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended&#160;December&#160;31, 2020&#160;and&#160;2019, the effective tax rate was 259.7&#160;percent and&#160;7.2&#160;percent, respectively. Included in the effective tax rate for the six months ended December 31, 2020 was the $420 million benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss. Included in both the six months ended December 31, 2020 and 2019 were net tax benefits related to the treatment of the tax impacts of opioid litigation charges. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and June&#160;30, 2020, we had $989 million and $998 million of unrecognized tax benefits, respectively. The December&#160;31, 2020 and June&#160;30, 2020 balances include $745 million and $753 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and June&#160;30, 2020, we had $150 million and $146 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $370 million, exclusive of penalties and interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $181 million and $176 million at December&#160;31, 2020 and June&#160;30, 2020, respectively, and is included in other assets in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $19 million at both December&#160;31, 2020 and June&#160;30, 2020, and is included in other assets in the condensed consolidated balance sheet.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166049037512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,920</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,920</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166049669848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and six months ended December&#160;31, 2020 and 2019, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the debt repayment as described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iac867f2b870144f0baf920261d30f765_97" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, two pay-floating interest rate swaps with notional amounts of $200 million matured in the second quarter of fiscal 2020. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2019, we entered into forward interest rate swaps with a total notional amount of $100&#160;million to hedge probable, but not firmly committed, future transactions associated with our debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive loss were $8&#160;million for the three months ended December&#160;31, 2020 and $7&#160;million for the six months ended December&#160;31, 2020, respectively, and immaterial for the three and six months ended December&#160;31, 2019. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and six months ended December&#160;31, 2020 and 2019. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we entered into a &#165;64.0 billion ($600 million) cross-currency swap maturing in 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $27&#160;million loss and a $1&#160;million gain during the three months ended December&#160;31, 2020 and 2019, respectively, and a $52&#160;million loss and a $17&#160;million gain during the six months ended December&#160;31, 2020 and 2019, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $5&#160;million during the three months ended December&#160;31, 2020 and 2019, and $10&#160;million and $6&#160;million during the six months ended December&#160;31, 2020 and 2019, respectively. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $4&#160;million loss and $2&#160;million loss during the three months ended December&#160;31, 2020 and 2019, respectively, and a $5 million loss and $7 million loss during the six months ended December&#160;31, 2020 and 2019, respectively. The principal currencies managed through foreign currency contracts are Chinese renminbi, Canadian dollar, Brazilian real and Japanese yen.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at December&#160;31, 2020 and June&#160;30, 2020 approximate fair value due to their short-term maturities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,414</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,733</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,775&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166049311512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Shareholders' Equity</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2019, we repurchased 7.3 million common shares having an aggregate cost of $350 million. The average price paid per common share was $48.00. These repurchases were made under an accelerated share repurchase ("ASR") program, which began on August 20, 2019 and was completed on December 4, 2019.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded the repurchases with available cash and short-term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(104)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to Cardinal Health, Inc. net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(53)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166047744936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">295</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">295</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were 4 million for the three and six months ended December&#160;31, 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were 4 million for the three months ended December&#160;31, 2019 and 6 million for the six months ended December&#160;31, 2019 (1 million of which were anti-dilutive as a result of the year-to-date net loss).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166049239016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37,040</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,501</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37,236</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,714</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,729</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,498</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">581</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">525</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,310</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,023</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,737</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,541</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,735</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71,956</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">68,713</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">392</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">429</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">72,348</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69,142</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,167</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,944</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,100</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">996</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,267</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,940</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,615</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77,082</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77,076</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40,360</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,670</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,186</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,067</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,737</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,541</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,735</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78,336</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74,980</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,279</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,102</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,615</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77,082</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77,076</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on early extinguishment of debt; and provision for income taxes. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $6 million and $17 million for the three months ended December&#160;31, 2020 and 2019, and $11 million and $20 million for the six months ended December&#160;31, 2020 and 2019, respectively.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid litigation as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iac867f2b870144f0baf920261d30f765_100" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized pre-tax charges of $1.02 billion and $5.63&#160;billion</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the six months ended December&#160;31, 2020 and 2019, respectively, which were retained at Corporate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the New York Opioid Stewardship Act as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iac867f2b870144f0baf920261d30f765_100" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized a pre-tax charge of $41&#160;million during the six months ended December&#160;31, 2020, related to calendar year 2017 and 2018 assessments, which was retained at corporate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a voluntary recall for certain surgical gowns and a voluntary recall and field actions for surgical procedure packs containing affected gowns, we recognized a pre-tax charge of $96 million during the three and six months ended December&#160;31, 2019 which was retained at Corporate. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">413</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">649</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">461</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">815</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">466</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating loss</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(163)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,930)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23,567</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,398&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15,259</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,893</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,677&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,719</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,766&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166049042520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $3 million for both the three months ended December&#160;31, 2020 and 2019, and $7 million for both the six months ended December&#160;31, 2020 and 2019.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.92&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.24&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48.29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $111 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.15&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">67.08</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">67.27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $0.3 million, which is expected to be recognized over a weighted-average period of two years. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.24&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53.89</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $38 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166047535880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Financial Accounting Standards</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns is in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2020 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2021 and June&#160;30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic also affected our businesses in a variety of ways beginning in the third quarter of fiscal 2020 and continuing into fiscal 2021. We cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. and global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow. Our estimates, judgments and assumptions related to COVID-19 could ultimately differ over time.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual </span></div>Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K").<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166047758904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(53)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166047535880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,357</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,659</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,740</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,399</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,570</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,978</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,592</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">671</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">360</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">311</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,612</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">836</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">776</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,853</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,174</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,679</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,877</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,174</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,703</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,831&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,895&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166048992344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,920</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,920</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166049004296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,414</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,733</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,775&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166047897304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(104)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to Cardinal Health, Inc. net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(53)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166073265192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">295</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">295</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166053895800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37,040</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,501</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">196</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37,236</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,714</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,729</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,498</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">581</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">525</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,310</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,023</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,737</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,541</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,735</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71,956</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">68,713</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">392</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">429</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">72,348</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69,142</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,167</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,944</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,100</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">996</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,267</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,940</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,615</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77,082</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77,076</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40,360</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,670</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,186</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,067</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,737</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,541</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,735</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78,336</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74,980</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,279</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,102</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,615</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77,082</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77,076</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Segment Profit by Reportable Segment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">413</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">649</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">461</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">815</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">466</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating loss</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(163)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,930)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Assets by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23,567</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,398&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15,259</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,893</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,677&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,719</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,766&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166059546936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Total Share-based Compensation Expense by Type of Award</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Transactions Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.15&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">67.08</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">67.27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_AdditionalStockOptionPlanDataTableTextBlock', window );">Schedule of Additional Data Related to Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Transactions Related to Restricted Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.92&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.24&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48.29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Transactions Related to Performance Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.24&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53.89</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AdditionalStockOptionPlanDataTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A disclosure of additional data related to all stock option activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AdditionalStockOptionPlanDataTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166057967976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and employee severance</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166051091368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee- Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Exit and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166051491496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance Narative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166053908296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 8,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Transfers</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">8,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">2,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Transfers</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">2,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Transfers</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 5,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166051694568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">5,853<span></span>
</td>
<td class="nump">5,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">3,174<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 2,679<span></span>
</td>
<td class="nump">2,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Intangible, Total other intangible assets</a></td>
<td class="nump">$ 5,877<span></span>
</td>
<td class="nump">5,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Intangible, Total other intangible assets</a></td>
<td class="nump">2,703<span></span>
</td>
<td class="nump">2,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember', window );">IPR&amp;D, trademarks and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">3,570<span></span>
</td>
<td class="nump">3,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,978<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember', window );">Trademarks, trade names and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 671<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 311<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 1,612<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 776<span></span>
</td>
<td class="nump">$ 837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166049934200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 8,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated annual amortization of intangible assets - Remainder of Fiscal Year</a></td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated annual amortization of intangible assets - Year One</a></td>
<td class="nump">398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated annual amortization of intangible assets - Year Two</a></td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated annual amortization of intangible assets - Year Three</a></td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated annual amortization of intangible assets - Year Four</a></td>
<td class="nump">$ 278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166049979512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TotalLongTermandShortTermObligations', window );">Total Long-Term and Short-Term Obligations</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">23,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A2.4Notesdue2020Member', window );">2.4% Notes due 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member', window );">2.616% Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A3.41Notesdue2027Member', window );">3.41% Notes due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember', window );">Committed Receivables Sales Facility Program [Member] | Short Term Credit Facilities Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A4.6Notesdue2043Member', window );">4.6% Notes due 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A4.9Notesdue2045Member', window );">4.9% Notes due 2045 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A4.368Notesdue2047Member', window );">4.368% Notes due 2047 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member', window );">Floating Rate Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A3.2Notesdue2022Member', window );">3.2% Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NotesPayableRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal Amount of Notes Payable Repurchased during the year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NotesPayableRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TotalLongTermandShortTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Long-Term and Short-Term Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TotalLongTermandShortTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A2.4Notesdue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A2.4Notesdue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A3.41Notesdue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A3.41Notesdue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A4.6Notesdue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A4.6Notesdue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A4.9Notesdue2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A4.9Notesdue2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A4.368Notesdue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A4.368Notesdue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A3.2Notesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A3.2Notesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166054812520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TotalLongTermandShortTermObligations', window );">Total Long-Term and Short-Term Obligations</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Long-term Debt and Lease Obligation, Current</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Lease Obligation</a></td>
<td class="nump">$ 6,720<span></span>
</td>
<td class="nump">$ 6,765<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TotalLongTermandShortTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Long-Term and Short-Term Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TotalLongTermandShortTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166045976792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 01, 2021 </div>
<div>lawsuit </div>
<div>plaintiff </div>
<div>StateAG</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,443.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,443.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,198.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
<td class="nump">1,070.0<span></span>
</td>
<td class="nump">$ 5,694.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods and Services Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,765.0<span></span>
</td>
<td class="nump">38,021.0<span></span>
</td>
<td class="nump">77,115.0<span></span>
</td>
<td class="nump">73,683.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,147.0<span></span>
</td>
<td class="nump">$ 1,163.0<span></span>
</td>
<td class="nump">2,284.0<span></span>
</td>
<td class="nump">2,270.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,502.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,502.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,231.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsStateDomain', window );">Opioid Lawsuits State [Domain] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NumberofStateAttorneysGeneralfilinglawsuits', window );">Number of State Attorneys General filing lawsuits | StateAG</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | lawsuit</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct', window );">Estimated Liability for New York Opioid Stewardship Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_AggregateAnnualAssessment', window );">Aggregate Annual Assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_DOJInvestigationMember', window );">DOJ Investigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=cah_CVSHealthMember', window );">CVS Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Long-term Purchase Commitment, Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_MaximumQuarterlyPayment', window );">Maximum quarterly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | lawsuit</a></td>
<td class="nump">373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember', window );">Alameda County [Member] | Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember', window );">Other Jurisdictions [Member] | Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember', window );">Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="nump">423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember', window );">Class Action Lawsuits [Member] | Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020.0<span></span>
</td>
<td class="nump">$ 5,630.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,590.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,590.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AggregateAnnualAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Annual Assessment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AggregateAnnualAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Liability for New York Opioid Stewardship Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LossContingencyLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Lawsuits, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LossContingencyLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_MaximumQuarterlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_MaximumQuarterlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NumberofStateAttorneysGeneralfilinglawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of State Attorneys General filing lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NumberofStateAttorneysGeneralfilinglawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsStateDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsStateDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_DOJInvestigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_DOJInvestigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cah_CVSHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cah_CVSHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_AlamedaCountyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_PlaintiffTypeAxis=cah_PrivatePartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166046008968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">$ (203)<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="num">$ (613)<span></span>
</td>
<td class="num">$ (364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="num">(47.60%)<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">259.70%<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">$ 10,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember', window );">Net Operating Loss Carryback [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income Taxes Receivable</a></td>
<td class="nump">974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember', window );">Patient Recovery Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification Receivable</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_CareFusionMember', window );">CareFusion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification Receivable</a></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="nump">6,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(488)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
<td class="nump">$ 5,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IndemnificationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IndemnificationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_CareFusionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_CareFusionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166055011320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward contracts</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward contracts</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward contracts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=117331979&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166062416920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details)<br> &#165; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>JPY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax', window );">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Currency Swap [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">&#165; 64,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest Income (Expense), Nonoperating, Net</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount', window );">Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558989&amp;loc=d3e80720-113993<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166049820632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings', window );">Carrying Amount of Long-Term and other Short-Term Borrowings</a></td>
<td class="nump">$ 6,733<span></span>
</td>
<td class="nump">$ 6,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 7,414<span></span>
</td>
<td class="nump">$ 7,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying Amount of Long-Term and other Short-Term Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CarryingAmountofLongTermandotherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166051690664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Narrative) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TreasuryStockAcquiredShares', window );">Treasury Stock Acquired Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TreasuryStockAcquiredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock Acquired Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TreasuryStockAcquiredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166141676744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="nump">$ 1,425<span></span>
</td>
<td class="nump">$ 903<span></span>
</td>
<td class="nump">$ 1,792<span></span>
</td>
<td class="nump">$ 6,330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Gain/(Loss) on Derivatives, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">$ (53)<span></span>
</td>
<td class="num">$ (103)<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
<td class="num">$ (103)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166047643112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss', window );">shares that would be antidilutive as a result of net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>shares that would be antidilutive as a result of net loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Sharesthatwouldbeantidilutiveasaresultofnetloss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166054916968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares&#8211;basic (in shares)</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Employee stock options, restricted share units, and performance share units (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares&#8211;diluted (in shares)</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166045912216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="nump">$ 5,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project costs on investment and other spending</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project costs on investment and other spending</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct', window );">Estimated Liability for New York Opioid Stewardship Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
<td class="nump">5,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SterileSurgicalGownRecallAxis=cah_SterileSurgicalGownRecallMember', window );">Sterile Surgical Gown Recall [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRecallExpense', window );">Inventory Recall Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Liability for New York Opioid Stewardship Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ProjectCostsOnInvestmentAndOtherSpending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ProjectCostsOnInvestmentAndOtherSpending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRecallExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRecallExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SterileSurgicalGownRecallAxis=cah_SterileSurgicalGownRecallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SterileSurgicalGownRecallAxis=cah_SterileSurgicalGownRecallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166050884984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Revenue by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 41,541<span></span>
</td>
<td class="nump">$ 39,735<span></span>
</td>
<td class="nump">$ 80,606<span></span>
</td>
<td class="nump">$ 77,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">41,546<span></span>
</td>
<td class="nump">39,737<span></span>
</td>
<td class="nump">80,615<span></span>
</td>
<td class="nump">77,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">37,236<span></span>
</td>
<td class="nump">35,714<span></span>
</td>
<td class="nump">72,348<span></span>
</td>
<td class="nump">69,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">4,310<span></span>
</td>
<td class="nump">4,023<span></span>
</td>
<td class="nump">8,267<span></span>
</td>
<td class="nump">7,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember', window );">Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">37,040<span></span>
</td>
<td class="nump">35,501<span></span>
</td>
<td class="nump">71,956<span></span>
</td>
<td class="nump">68,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember', window );">Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember', window );">Medical distribution and products [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,729<span></span>
</td>
<td class="nump">3,498<span></span>
</td>
<td class="nump">7,167<span></span>
</td>
<td class="nump">6,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember', window );">Cardinal Health At Home [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 581<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166050704200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">$ 461<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="num">$ (163)<span></span>
</td>
<td class="num">$ (4,930)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">649<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="nump">815<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">466<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (188)<span></span>
</td>
<td class="num">$ (323)<span></span>
</td>
<td class="num">$ (1,444)<span></span>
</td>
<td class="num">$ (6,155)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166051257256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Revenue From External Customers By Geographic Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 41,541<span></span>
</td>
<td class="nump">$ 39,735<span></span>
</td>
<td class="nump">$ 80,606<span></span>
</td>
<td class="nump">$ 77,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">40,360<span></span>
</td>
<td class="nump">38,670<span></span>
</td>
<td class="nump">78,336<span></span>
</td>
<td class="nump">74,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">2,279<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">41,546<span></span>
</td>
<td class="nump">39,737<span></span>
</td>
<td class="nump">80,615<span></span>
</td>
<td class="nump">77,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166059545320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information (Assets by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 44,719<span></span>
</td>
<td class="nump">$ 40,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">23,567<span></span>
</td>
<td class="nump">22,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">15,259<span></span>
</td>
<td class="nump">14,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 5,893<span></span>
</td>
<td class="nump">$ 3,677<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166045841320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit related to share-based compensation</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ExercisablePeriodOfPlansInYears', window );">Exercisable period of plans (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">111,000,000<span></span>
</td>
<td class="nump">$ 111,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_VestingPeriodinyearsforShares', window );">Vesting Period in years for Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ExercisablePeriodOfPlansInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The instrument's contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ExercisablePeriodOfPlansInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_VestingPeriodinyearsforShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Period in years for Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_VestingPeriodinyearsforShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166054263240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166054502008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 65.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">67.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 67.27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166057985048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) - Stock Options - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of outstanding options at period end</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of exercisable options at period end</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166051237864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 111,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 45.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">53.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">49.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">48.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 48.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140166054901656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Performance Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 54.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">55.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">52.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 53.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M)-LNZU6/Y[N.W[F9U(2$8@FAUMD0?E_E&WGYB9;K;"]L(;6647;H"^X)91Z
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MQ+:1M<3-!VGO&FI9)CLYW6/:0@(H-C:5A ""C0S0& 2Y0M>B3ORBOK\MO"&
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M\V$ Y#!C3.<-;(^3[R-T[YC9&^Z>N<2UVO-N9^$[GN/!)+F].:Z@CK,.KE,
M[D\!3OY@IYT?</.AL7L Y,B=N<X@N#^#.,0]<3L]X-BQ*'&=('!_@G"P>^*
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M4](5E:[<FO' +/P_S#J(O-1)"XQMA]5L8EPZL<VC:;P<R70%+3PB!VCA^/_
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MQSO<Z.15>DW%SGQA@-6ACZ[MN^C^:?\5X\:\NQ\]_Q1_7+??(H9JVD\C7XF
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M*NY1,EZB-%Q)T)@OH^OQU7KJY+W 9XX[<_ .SI.-4E_=XO=L&8T<(1286H?
MZ*_!&Q3" 1&-;RUFU)MTBH?O'?H'[SOYLF$&;Y3XBV>V6$87$628LUK8>[7[
M#5M_9@XO5<+X)^R"[.0\@K0V5I6M,C$HN0S_[+&-PX'"Q>@5A:152#SO8,BS
M?,\L6RVTVH%VTH3F7KRK7IO(<>F2\F U?>6D9U?W:*RN4UMK+K? 9 :W9274
M'A$>L$'-9(J+V)(E)Q^G+>HZH":OH,[AHY*V,' K,\R>Z\?$L*>9=#37R5'
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MI334(6Y9TGB.R@K0_RLIS79C#?0#_]D_4$L#!!0    ( ,F$15(KBRMN^ 4
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M(!/B4)*M"R"(S' >[JZ#@PF9U--/*ZBE7.OUC"3V,X[Z[?A+3)Z3312:II2
M1!.9N94(JTQN0'^ZVM>PM#!Z$0QCNU!>S&3"TQE3\1/@M3/8;!?!T&#/D/(\
MU1%R@BMA0#O)?S<(]^WH[?Y=&"%S4W$$<"%P'F%@&A7B;,.N\) SW8=)(V8;
MW:?Y(3O75/H[@ZB@)6_97XC3!AEU8ZIYMK^YB\LJN-85;]Y<B!]_^.XXCOL_
M7[RZ#$^#GW]J%3=DFIT*HQ]R8BD1(SN7A?J;ZGX*(\V@DU#_I>%=>":FU8I#
MLDTTU#!N-4U@U4*EX0!0;_F.SQ<^8_5MI;!/*YL^*Z5E[YH.LX[/.1!GINA+
MF%=IV-A#9]Y_HE%\M^*>1'-0+?CK9'+5#6[AQ"%!#V9XZ&F:0QL=$6:Y-?DC
MAZ3P>>?DL )G; ;LK-OW!K:BM<&4G)H7]6EDRF7-YX!08G4@NVB5XL96I4]6
MSRSEF')K3LL0*>D<^?JDLYEGG J,%F Z=+&;K>ICIY:J/CHI:-2E:CB,]UT(
M>EOW-)3]/-Q&H<4=4E_9VM7VPCNI[WD;\?JV_%;:N<)I3-,,JOWH"/=+6]]
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MH49-&T;"9:!/+UGO[O2S %/NN<>7$#LW4 "8?&C07XW+?!.%E/T>2+KO)JV
M.;CV=FQ[NV;C\GV[4'"1HYEJ$G8"$ R[/JX8V)V%>?PVON(#@9%V\9ZY([6
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M1MNNOJH-! 2$1>,S+S35=6H8PMPOLLY/M ?.!J@)]Z]F>+03A-WX7DRXNU+
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M(:NEV^.*9B5$;2Q*/PNXW-:"NM( JL23;6>%%U3D0@5RFUR#&$VXO6K?$25
MD\[TAMVU(\0B\%4=:@1I"MI.T7G1=NCWW*%O!X^DA'R@%AFKWQ"3IN?KGQ)\
M+*2_00&@AR.<649 3,[]R8F0-)\N%[9K50DXR>E%H098V9&?W?*)7ANS#222
MVOH?G"!$@A43R$23C;Q^ *])'UC$*$H%,D)J#"*7< 8X,4%1QDQ(PKV)T]&:
M$K$!D-01P$;0\V.,0>..(=%"C+_4LM#+:RZ0[FA6;^AO4F]%;@%$<;^$<_"I
M(B(0/'J;X4BU'-TS\P51PB7J1RRN$R^0#7T', NF!EM<DU!RPE0\IP9#GXP2
MCK:M#?;MT+1>V]O+QT)&$)_HG#_NA30 L98GHL(),;0$_/20&'CE3*%SC@)X
MF ^<(9P<"G!VCX3?1[89)A?$(%7 "8<.7(9[HZ)[H\"M3Y4+I%^X^<V/>!E=
M 3EH,'N+\%9FC]YI5XQZ4SH,$G.,).PA?#&TMP@8#>T;@JJJBL,'=GT(-"<_
M$BQ$V%$:9U8O@MO? ;C%J8"UVSN4'TL%F0OM599$$=GWA_.C(_";HJ"SF=L$
M\:2!4Q0^*A=+A<ZUZ3+L)W\#L0DJ7Q.XC4+"OGM* P1#EI*X+N5K'M0<%Q<9
MP:QGW&2D0XU<]GJ0<0?< W)43F;=M?7F:]!^=.F:R=W )6+*>(DS4]\8&Z]L
MDLS<@.]7S'UEEM5E'>B<83)('UNUIJD8!+%\4@]6%O !+A <:+BT[7]-V&6)
M]6A$:%"JW'$8(_:HLUA^*B2B20["3$1YK;.PG;TQV+I<*H+K1IFI>!EVL;!;
MJI^*ONF,C550<2MMOK\:)-+)(YD'5<%%<9P419NPX$H+2L-PD::;T5+;$K >
MV ^<@7RL/:=SDD$[#@PH0I7_WJH'7EYQ$@1PPLWN:RC O4'<$K@=/FSU6_;
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M9N;QLF?P@C#XNLZ-U;03OKV .3U@3CWF]']:]S+*Q1B> H+K3G-9@:T1#'^
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MXE&[ /J^5<KN)Z[ X9^&U7]02P,$%     @ R81%4EU>H"E1 P  <PD  !D
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MH(=EH?%6OEIIL>(D64-%J1HRDV14T0Z5% >00E6@1/,2PF@A=GH9ADY$;!9
MG;J1$[#;R#PG74Y=;X)+.-_/[&];CZ3ZBRUNVF3707$2GK*3Z)2]8/$T&(U'
M=#,))J.0?:S3'5%^UJ!T#7"-:<<@G"<L"N-C9:5! =RC."'>TW#<9H!L7\36
M\"?Q*8N#:33'=3R?/<&HDUG()M'D079I)!@'<3C"=13%["=E#ZT(@\D8,LZ#
M:3SM#,).QL!HXG'RE W%"T\3$FI$-6$W\NY_;KEI&,PG"6Z2&="-GVJY>!ZQ
M<?1@\WU4IE$0CV<LF0?A.'JBY:9!F$Q9$LS'XR=8+@S"T8C-X4C';#<+(O";
M@M_HB.UFHR ))VP*)YY%^[:;XU_RT'9$,R+<B&J:.$0_'^Q2U7(I-(RYN'=Q
M?,@<34YQY04CG=!$@/R%LOW=GV91-+KX9K.QL^GYP)GW3;\E1KMXS%Q-OP=I
MQ5TJ2NO2U1-=H4N(9+T'6^Z;Y?!>S\F[9);.2(U)J"V$7YFFG16Y1#/N^QT\
MDE29SO8MWU6DYDFA;--8>Q.X.:%.MN=/R_6P]$JH%5HL] QD4_Z?Y^7=4H6<
M,0KBQ&7:69!,1^@DH%=;X1$-LP37$3S^F7DJ_&_GJ7U-IK,@CET$C8/Y;%^3
M*(BF<US#4?3<J V?%[7_+U=J9F)DC:6T[!?1CGVMJOWQC<YMW#3<OG1TU(<I
MN&+=8 INJ!/NN/M5K-<XU>(%+*<)KWF:*F-)N3:=4)>[MZ:?M]$R8ZY $ 2^
ML:];9Y[1!$S'$G12Q4X&-S]^QS?EQ:O!*<*]%(7I"]>\;%^U [)!HA)G7F<:
M[/'6XU^O[ \V'<9I:\J6H1O4B%G&EE7ACM'0G_IM*(0[DFX8"GI/ES \X _J
M&TG#@IM"W;D6('=-;+U#DWX#MJ[ KAO+:<?NY,.*=%VH7*WN/:\<75]>S[:;
M,I=^PYZ, DT?HHKFP)5GD:%($ QD-@#ZYJ'B;EP^YGV=-Z$3S]S01;:^%3GY
MP (&):>I6_.L[]O<MY_-V0,X;(1=JXS4D:+.D-"[RJDD6>\OC@0B%*I ;%FM
MG.?X0!(4:+[N ?6L/I^0^WY^3@&2J9V@<BIUV1CI9>.Z?BJSW1E.SHT] [^E
MU+C!;(L!5L,S__K^AT^#4\(9\>#&& P_F&/,\"2%,:4UIQ?=7+A26[)G2B7-
M@7Y!6EI=-8,Z821@/74O"&<,M&3&"PI/;>5OO&UV/) \_;5"/:.G9UKDM?LZ
MOG)3<JF[[OYD!>.?#G.%4"332U,JPYVEZ*2'2'J><4(X8G<8XW18:Q2P0E@H
M0ZF7J5(JV1P2U1DA;YP$M1O@+*4AG>]1_>D0PPF,M$Z' J?#VL-JGHT-V>[C
M1EAPP%0I[FBRA;YKMQ\$S\3"7G03J.LL*%3])BBL=V)W3 [:*"![&>O//+!E
MYG)0\]*=C5*[@#W<,.J:D;,MW)AXXQ&EI9V,TMFD8>?<\1O9^_U#*9I$"(7K
M-&:\ASK'(S#]4J=H*[!6_Q)N6EUSL@2\0CM1M4M%L$*G;SN_4BIQYJ_!(6=H
M#SN[-/L:[EI1KBP)9"RBC4%O1+<M"D,F2"IG&,JO(JT<2/U\N*7P=/)Z\B[+
MV"[W' :ECN8N0VV1LE\D38O@X'\13MO?M8PTE2.0-K[-$ _;#-=8$#$U%T'-
M)MQEBQ7[; UZER<SA6.7PGUSR>^=-R)[%?6WF/84M8ZG7@ARZE8-*H1Q54<[
MYP(&'Q74G[ :SE2M"OF;.]@19W#X)OV085^$Y^A[%GU=)N=)W#[)?,[Y70HU
M1UI;H1OK4JK?,^A!E3^*+?N[TE_9)Z_[C15;-/!F+4OV*K7/!8#O0> 0&'>V
M?):V03^=(8MA&0+/11\PF#9@S'H)L#W=(]?L(Y$^B@1GMYA.$*,H'75EZ$?V
M3NFH#^8?4M#CI11YYL[:*7.YCJ6A19RF(J-3>CI'-20#,7=)"G-E2GHZ_D_"
M=)X<PM1'FAL?OX$NNOC#0/5<YM$):;>FTZ!TY#CLCS_1HC$FIFO2'430J5(X
MG^P-&+5PR7C.DLGNC#2;8:Z(H[B9+'I9EVNRBAO1$C<KQ>,_YD '4PO&'%PQ
M]C6"CQ.,<,D1P<,@FH5TC28[P@?C,1UH)$$XF3Q4P%7L%UB6Q'0N=(*A+!Z=
M'C)G8TWJM8B';T*^><+9B<+MRSWE=W#Y2U4(%B.0'P 1Q<$$DRUNHB">SUHX
MPDD03>8L' ?)/.QM- EF\YC%&)2;<;B6%48:!U-@[0;J*= \] EUV/LFC59_
MY;Z\4PPBA/WGZ?9I^W'_E?^FW2WW_S/@ V)0(KASL03IZ'PZ&3#MO[;['U:5
M[@OW0EG,%>Z66G.A:0'>+Q5R9_V#-FC_R\/UOP%02P,$%     @ R81%4K:=
M"\Q2!@  -!0  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULS5AM3]M(
M$/XKHQPZ@12<V'%"H( 4:.]-ZA65MGPXW8>-/4E6V%ZSNR:DO_YFUG;JA!CH
MZ:A. MNQ=Y^=E^>9'?MTJ?2M62!:>$B3S)QU%M;F)[V>B1:8"N.I'#-Z,E,Z
M%99^ZGG/Y!I%[":E22_H]T>]5,BL<W[J[EWI\U-5V$1F>*7!%&DJ].H"$[4\
MZ_B=^L9'.5]8OM$[/\W%'*_1?LZO-/WJK5%BF6)FI,I X^RL,_%/+D(>[P9\
MD;@TC6M@3Z9*W?*/W^.S3I\-P@0CRPB"3O=XB4G"0&3&787962_)$YO7-?HO
MSG?R92H,7JKD1L9V<=89=R#&F2@2^U$M?\/*GR'C12HQ[@C+<FPXZ$!4&*O2
M:C)9D,JL/(N'*@Z-">-^RX2@FA XN\N%G)5OA17GIUHM0?-H0N,+YZJ;3<;)
MC)-R;34]E33/GE\OA,;#"_(KADN54JZ-X'"=]BRA\YA>5"%=E$A!"]((WJO,
M+@R\RV*,-^?WR*JU:4%MVD7P).!;C#P8^%T(^D'_";S!VM6!PQL\Z>K4N7HE
M5L0L"Q.M139'=_W79&JL)IK\_<1BX7JQT"T6_@=Q?1K)#SQH0X,;!%:>I7\@
MKD2W(+.(G"&F0YZ(S, ^,<1)X!Z351?L N'GG\9!T']SQ<_=M?_F $C?[N$4
M,YQ)"VH&$6H'3)>JT'2:2;IENA!+38A*&Q!9#)CFB5HA&@\^$<",UE-+F<W!
MBFE"9FAU+V,T8)45"9A&%J*F*_C UV3 "NPJ1UY5+(6.3PA5(VZP"X@;F$Y1
M.W[LDXVI3!)",0>.+73PC^$C4CYE9&F\6Q6*C!RKU]D#_X@/(WA7.5!%4.4;
M]G"$_. -^'"%VE5!BO NP!&$\.EI'_<@&/#!AVOY\ H>#49\&+S0H^ YC_PA
M.?6L2T.?#J'ODE_FV(J'-8\T)H+MM:H=8RD,[ UJCQT5I\HN'!^M2WY:A@H?
MA\H%AVG( >JZJ[VCW5"&8OY"(*\9:J<^^$R1,;LS8&!.983O%81;ZLBI"^84
M!2V29 7W-)'$"7A74(1$EO%)9H;BE7#Y,:#NW51V=X5"&Z]M,1%%ND"(A%F0
M%%E<K,*[0MZ+Q"'9A;# XW.Q<AHL<HH%6\"R)&&Q@4Y<+9HMMVCYE51+Y@%5
M14J5VT9-,Z%ZMWU;03C9H'.7V!5A;B&G,>4LD:J"S#YHB_F-VUHQ/IQ0A*A3
M@#]5QL[0,/+SCR)#&/2K!+*\PJ%W',"O54H"& Z\T0B^E#/V_0,(C[T@A$NF
M?<(@%#XBR@SE>L#8"X/-91YSQ2TU]H)CF.QX7);:4@_4+AVR)C9('RECNY"A
M*[6<FM2%M3*DH-AVF['.UL:T1#U3EGC#@HO4/*/<Q:6N?-^O@]^%Y4)&"Y#&
M23RJH*?8G.1H*&!9!UU40:=\214[]BQ5S=!K5U\^Y"4U=I:=UQ&'2QH[CP^H
M(VD<;=T>AEDU8J95ZE9SZT-,D?1@0G3>M&X;A*5#&:.MKC*'(L0H)(A;"B]I
MK,!:0Y10*BAE&BK>)RLG(WI855WZVS;B!9+;*-P;^OO7ZBIS]4A,'PI+<<YB
M-N61G(;$\='0HXV@EE.]>=3G=V7H=CQIT=?VL*WU'^O,V7#D]<?U6G6:6H<&
M1S]8DIN,:E-BWQN\GA)W<,K4O1>(.)9L&SD>(_5TR<:VW#3^9*OW>!SC38),
MYG.-<X(BN5)5HI>UZ)M$5".U:[G9VG[>M?;@F'NPX&F<ICQWXQPS!EONHO&\
MV3?;,=7(?30;&E&'P&\!+/U$SEH="8EMWPFSRP^&:;9AS8UO=WMFRG)9L6-P
MR"YS+-9#J[B4C99[\UU(O"]?<L@*0WR3U,IOS)DKD1"++NHYK!1\L#R%*%*2
MU:E'Z#G:LFI6N'$7:AF4=3 5*W"O564)_HI:,4@0]GG)J#+C&UK9BE2%RFOU
M^G_3]N0M!F[O;_OK#.SPTQR\O'(W(_(]S9#O<8\R#+G;J>MWWR/&#;UP6#=$
M+RS;^WV/&J-AX/GCYQHCW^/7$.JZQC^Z-6K+3%M%'HQ?JR"#G#W6UX9JO%U?
M&7J-+SDI$FGX>Y6A@! 1RH\ZZ[OK3V*3\DO0M^'E][3WQ#FJHY#@C*;VO:-A
M!W3YC:K\857NO@O1^Y%5J;M<H" *\P!Z/E/*UC]X@?6'PO-_ %!+ P04
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M4?1R@<\+QZ79+<1 /]HN_P%02P,$%     @ R81%4JAB(N_) @  #P8  !D
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MXK<E36S4SH'>YTK9G>$2]/^ ^3]02P,$%     @ R81%4O: ,//V @  9@8
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M0ZQ+85KQAP"M-^#SA3&T6?@ VT_+Y ]02P,$%     @ R81%4DN[X'OW @
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M$<O*L:5$<!IFS*1",0E7R*3+#^%:\2,XN//S]M,P=H3AQ6+>N)S6+I-W7)[
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M@+( \WPA)>XV-D#UP=+_"U!+ P04    " #)A$52;!^67#@#  "#"P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6RU5EU/VS 4_2M6Q -(@\3I-VHK
MM7QHDX:&J-@>ICV8Y+;Q<.S.=EOZ[V<[:1+6)B 8+ZWM^)YS?7-\<H<;(1]5
M J#14\JX&GF)ULMSWU=1 BE19V()W#R9"YD2;:9RX:NE!!*[H)3Y81!T_910
M[HV';NU6CH=BI1GE<"N16J4ID=LI,+$9>=C;+=S11:+M@C\>+LD"9J#OE[?2
MS/P"):8I<$4%1Q+F(V^"SZ=X8 /<CN\4-JHR1O8H#T(\VLF7>.0%-B-@$&D+
M0<S?&BZ ,8MD\OB3@WH%IPVLCG?HU^[PYC /1,&%8#]HK).1U_=0#'.R8OI.
M;#Y#?J".Q8L$4^X7;?*]@8>BE=(BS8--!BGEV3]YR@M1"0AQ34"8!X0N[XS(
M97E)-!D/I=@@:7<;-#MP1W71)CG*[5N9:6F>4A.GQW>@M%Q%>B4I7R#"8W25
M+IG8 J 9K$$2'@$Z_DK) V544U!HHI2(*-$0FU1U@EZ%,+'%=_$GZ/@2-*',
MC(X0Y>B&,F;>CQKZVIS'9N5'>>[3+/>P)O<NNA%<)PI=\1CBY_&^J4-1C'!7
MC&G8"'@)T1EJX4\H#,+@?G:)CH].&F!;18U;#K;UJAJ;&<@UH)]W@C%DI+4A
M,O[50-,N:-J.IEU#,X4%Y=Q23 FS53]4T0RBZR#LC5V/!]VAOSY VREH.XVT
MDSBFNNX%9J&="ET;'Z;K%G3=1KI;LC6FH)53FM )2$3BW^:BN-5#.73W<CCM
MM XGT2N2Z#4F803W0IU[>Z3]]F'.?L'9;^;,;]6I41!SU^]"J']/_ QY4" /
M/E*?."B])GB_0G.,:NFZ_<.EPQ67PV\7:1Y;90S#&L:P9 S_LTYSP&=";=6(
M!I?>@UOOE&H.4.7MU'@"+KT(-YO1-8GL!V.+KIZH=C7XYFKPDF9Q:3NX\Z&J
M+0T'-SO.ZU2[[S)AG6I+E\'--M.LVGV+P8,:QM)C<+/)O$&U_7W5UN91.A(>
MO%>U@[TOV5[!_4I?E()<N.Y/H4BLN,Y:I&*UZ# G65]5;L_:TQLBC0H48C W
MH<%9SQQ89AU?-M%BZ;JL!Z%-S^:&B>F20=H-YOE<"+V;6(*B[Q[_!5!+ P04
M    " #)A$52AH<Q]+H"   /"   &0   'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6RE5MMNVS ,_17!Z$,+K/4U7E<X!IHXQ0JL6]&@V\.P!]5F8J&RE$G*
MI7\_27:\U'&"8'N))8KG')(BQ"1K+EYE":#0IJ),#IU2J<6-Z\J\A K+*[X
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M*:"^SQF3CXO207.S.OD/4$L#!!0    ( ,F$15(8DO&930,  .<+   9
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M30#>7PBA'Q8F037;C_X 4$L#!!0    ( ,F$15+X_:"I"@4   48   9
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M9?JY(AUHL4FNUPNAX;*>/*XI":@T O!^*81^'9@%\H]&XQ]02P,$%     @
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MVI+"\2TUVLE\:L7#YS?K/\;!JV!66) Y"W\//.G?=(8=X)$UWH7R@>U_)FE
M/6W/9:&(_X)]*FMW@+L3DD6ILD(0!33YCU_21!PH*#OU"BA50&6%;H."DRHX
M;3UT4X5N6P^]5"$.W4IBCQ.WP!)/QISM =?2RII^B+,?:ZM\!507RJ/DZM=
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MHT^P1[@64+^O&9-O+]I!=A4_^0=02P,$%     @ R81%4M5DXV_5 @  O@<
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M81U/$)@8Y<(O;&K;5@1)Z<CD-9@5Y%)77_%8YV$'P#S[ 9T:T'D)Z+T!Z-:
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MLDY;38MJ0Z8([7!IB)MK6&8\8-%Z [Y?&2Z\>N,=-"-[] =02P,$%     @
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M_P=&YHPS\X9 '?H&YL;W15#S?0^?\7W5IW![H_I-&L+W1ARTIRX^K[H!#G^
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MIA]&[.C>DP*5L49E![X*N:OR<*?3:E1N8-M[,+?-BO0WJS'E49S)R=;/\;5
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M$DH=7R:Y]K]@6V&C &0;;611&=L("B;**_E1%>+ P/*T&\250=PT2$X8H,H
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M&<K/!F *(*^O*!7[C3)0?(B,_@!02P,$%     @ R81%4B<,QT%# P  M0L
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M*^JM!'HKZJT$>NOH89M ;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95
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MC:"(RE%(Y2BF<A14.8JJ'(55CN(J1X&5H\@J4&05*+(*%%D%BJP"15:!(JM
MD56@R"I09!4HLDH4626*K!)%5HDBJT215:+(*E%DE2BR2A19)8JL"D56A2*K
M0I%5H<BJ4&15*+(J%%D5BJP*15:%(FN&(FN&(FN&(FN&(FN&(FN&(FOVG[*^
M&[/\ZS?Y[36M==D<\EGWN<3D$U!+ 0(4 Q0    ( ,F$15('04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ R81%4IGMV3#N    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ R81%4IE<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #)A$52
MKW.2U"8%  !:%0  &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ R81%4J9E>$GB!@  L1P  !@
M     ("!:0T  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M ,F$15)*:J4-T0,  $L-   8              " @8$4  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " #)A$52,*_W<Q,&  !C&0  &
M            @(&(&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ R81%4FN+ME:  @  *@<  !@              ("!T1X  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ,F$15+47*B 1@D  / [
M   8              " @8<A  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " #)A$52!SC7S[4&  #_&0  &               @($#*P
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ R81%4NNIQFGL
M!P  ]Q,  !@              ("![C$  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( ,F$15)&BH\[)@0  $D*   8              "
M@1 Z  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #)A$52
MZAT@GYL$  #\"P  &0              @(%L/@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,F$15(KBRMN^ 4  !(0   9
M      " @3Y#  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ R81%4J]A/$NP%@  ?C\  !D              ("!;4D  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #)A$52S67I3U8-  #1*0
M&0              @(%48   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( ,F$15+L(;/8C00  - *   9              " @>%M  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ R81%4HO>?M7K
M"P  7B8  !D              ("!I7(  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " #)A$52YI\%5ML#  ! "   &0
M@(''?@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,F$
M15)=7J I40,  ',)   9              " @=F"  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ R81%4K>GZY=K"P  _B   !D
M         ("!888  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " #)A$52MIT+S%(&   T%   &0              @($#D@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,F$15*("MM=\P<  .83
M   9              " @8R8  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ R81%4F56M3@@ P  0 @  !D              ("!MJ
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #)A$528GPS
M[$H$  #?"@  &0              @($-I   >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( ,F$15(1T_1.G@0  .8*   9
M  " @8ZH  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
MR81%4JAB(N_) @  #P8  !D              ("!8ZT  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " #)A$52]H P\_8"  !F!@  &0
M            @(%CL   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( ,F$15)+N^![]P(  '\'   9              " @9"S  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ R81%4L_R%>V)!0
MO1   !D              ("!OK8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " #)A$52[#41^<<$  ""#P  &0              @(%^
MO   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ,F$15+-
M&++OXP(  +P(   9              " @7S!  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ R81%4FP?EEPX P  @PL  !D
M     ("!EL0  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,F$15+X_:"I"@4   48   9              "
M@=W6  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ R81%
M4N[(<0]E @  #P8  !D              ("!'MP  'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " #)A$5264^.=J<&  !I(0  &0
M        @(&ZW@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( ,F$15(TC#RH$@8  ,H;   9              " @9CE  !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ R81%4MS2'(T,!   WQ(
M !D              ("!X>L  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " #)A$52Y9H\2*4$  ! $@  &0              @($D\
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ,F$15*@5>L$
MI (  *\&   9              " @0#U  !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ R81%4F'D@)3R @  @P@  !D
M ("!V_<  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #)
MA$52W4; +?8$  "6%P  &0              @($$^P  >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ,F$15+59.-OU0(  +X'   9
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M970T."YX;6Q02P$"% ,4    " #)A$52\JD96H8#  #<#0  &0
M    @(%H$P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M ,F$15*&&+AUK@(  +D(   9              " @247 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ R81%4O-\)1 *!   /Q,  !D
M             ("!"AH! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " #)A$52I>3@6D(#  "4#   &0              @(%+'@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( ,F$15(G#,=!0P,
M +4+   9              " @<0A 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ R81%4F8/3RU' P  %@H  !D              ("!
M/B4! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #)A$52
M1G;2<Q8$  #(#P  &0              @(&\* $ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( ,F$15+:IHF7K@,  '0,   9
M      " @0DM 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ R81%4I$8<'1B @  6@T   T              ( ![C ! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #)A$52EXJ[',     3 @  "P
M@ %[,P$ 7W)E;',O+G)E;'-02P$"% ,4    " #)A$52V@$]JGT$  "O)0
M#P              @ %D- $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MR81%4@P_D/SE 0  ?R$  !H              ( !#CD! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ R81%4H_AMVG3 0  -B$  !,
M             ( !*SL! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $
,0 !W$0  +ST!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>227</ContextCount>
  <ElementCount>309</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings</Role>
      <ShortName>Condensed Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Restructuring and Employee Severance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</Role>
      <ShortName>Restructuring and Employee Severance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Commitments, Contingent Liabilities and Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129109 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2133110 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2137111 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2144112 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Restructuring and Employee Severance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</Role>
      <ShortName>Restructuring and Employee Severance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstruments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2334307 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2338308 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2345309 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails</Role>
      <ShortName>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails</Role>
      <ShortName>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Restructuring and Employee Severance Narative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails</Role>
      <ShortName>Restructuring and Employee Severance Narative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails</Role>
      <ShortName>Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2431415 - Disclosure - Shareholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2439419 - Disclosure - Segment Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2440420 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Revenue by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Segment Profit by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails</Role>
      <ShortName>Segment Information Revenue From External Customers By Geographic Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Assets by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Share-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2447425 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2448426 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2450428 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cah-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cah-20201231.htm">cah-20201231.htm</File>
    <File>a21q2_10qx123120xexhibit311.htm</File>
    <File>a21q2_10qx123120xexhibit312.htm</File>
    <File>a21q2_10qx123120xexhibit321.htm</File>
    <File>a21q2_10qx123120xexhibit991.htm</File>
    <File>cah-20201231.xsd</File>
    <File>cah-20201231_cal.xml</File>
    <File>cah-20201231_def.xml</File>
    <File>cah-20201231_lab.xml</File>
    <File>cah-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cah-20201231_g1.jpg</File>
    <File>cah-20201231_g2.jpg</File>
    <File>cah-20201231_g3.jpg</File>
    <File>cah-20201231_g4.jpg</File>
    <File>cah-20201231_g5.jpg</File>
    <File>cah-20201231_g6.jpg</File>
    <File>cah-20201231_g7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cah-20201231.htm": {
   "axisCustom": 6,
   "axisStandard": 24,
   "contextCount": 227,
   "dts": {
    "calculationLink": {
     "local": [
      "cah-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cah-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cah-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cah-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cah-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cah-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 468,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 22,
   "keyStandard": 287,
   "memberCustom": 33,
   "memberStandard": 38,
   "nsprefix": "cah",
   "nsuri": "http://www.cardinal.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cardinal.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Goodwill and Other Intangible Assets",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets",
     "shortName": "Goodwill and Other Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Commitments, Contingent Liabilities and Litigation",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation",
     "shortName": "Commitments, Contingent Liabilities and Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Income Taxes",
     "role": "http://www.cardinal.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Fair Value Measurements",
     "role": "http://www.cardinal.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "ice1200d475ba40da95d038803bdd462f_D20190701-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Financial Instruments",
     "role": "http://www.cardinal.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "ice1200d475ba40da95d038803bdd462f_D20190701-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129109 - Disclosure - Shareholders' Equity",
     "role": "http://www.cardinal.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133110 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137111 - Disclosure - Segment Information",
     "role": "http://www.cardinal.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144112 - Disclosure - Share-Based Compensation",
     "role": "http://www.cardinal.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Earnings",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
     "shortName": "Condensed Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Restructuring and Employee Severance (Tables)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables",
     "shortName": "Restructuring and Employee Severance (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334307 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338308 - Disclosure - Segment Information (Tables)",
     "role": "http://www.cardinal.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345309 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
     "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "iae3c66df6beb43fb8dc9aec45034e9af_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
     "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "iae3c66df6beb43fb8dc9aec45034e9af_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Restructuring and Employee Severance Narative (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails",
     "shortName": "Restructuring and Employee Severance Narative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "iae3c66df6beb43fb8dc9aec45034e9af_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i6d8949488e504051b168d44d36fc8172_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i6d8949488e504051b168d44d36fc8172_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i6d8949488e504051b168d44d36fc8172_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Other Intangible Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i6d8949488e504051b168d44d36fc8172_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "cah:TotalLongTermandShortTermObligations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "iae3c66df6beb43fb8dc9aec45034e9af_I20200630",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i6d8949488e504051b168d44d36fc8172_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "cah:TotalLongTermandShortTermObligations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i6d8949488e504051b168d44d36fc8172_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
     "shortName": "Commitments, Contingent Liabilities and Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i38d2978456e542b7b3180f73a3e78c5f_I20210201",
      "decimals": "0",
      "lang": "en-US",
      "name": "cah:LossContingencyLawsuitsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Income Taxes (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "iae3c66df6beb43fb8dc9aec45034e9af_I20200630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "span",
       "div",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "if41b93ee69de4e0d9701c057ae9ab8db_I20200630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i6d8949488e504051b168d44d36fc8172_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i6d8949488e504051b168d44d36fc8172_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "span",
       "div",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Financial Instruments (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i796ef5fe827b4eccb2c3f684dc6db76d_D20201001-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i6d8949488e504051b168d44d36fc8172_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails",
     "shortName": "Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i6d8949488e504051b168d44d36fc8172_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431415 - Disclosure - Shareholders' Equity (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i4523a176fdd843a1871b85358e66f672_D20190701-20191231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i330e68ab5e5340ebadc011e5a0a59586_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i516dad7d9d244946b3629a4006f58d73_I20200630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439419 - Disclosure - Segment Information (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i99f293e06fa54cba94cd2fe57d28abad_D20190701-20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:InventoryRecallExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440420 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
     "shortName": "Segment Information (Revenue by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i3ff998854edd4eda8d8b8b0671924582_D20201001-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
     "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i7a9dbdf0124e48049351c12013836acc_D20201001-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
     "shortName": "Segment Information Revenue From External Customers By Geographic Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i235c9cf737b84394aae05f413fa3c155_D20201001-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i6d8949488e504051b168d44d36fc8172_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i6d8949488e504051b168d44d36fc8172_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
     "shortName": "Segment Information (Assets by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i704d2da68a27491caa5fcefcc86490a6_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Share-Based Compensation (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447425 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
     "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i9ece70ac1f8a4583984d39caf72ee3e8_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "iae3c66df6beb43fb8dc9aec45034e9af_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448426 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "iae3c66df6beb43fb8dc9aec45034e9af_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i130d53f3f6b041848bc6ad14a45add16_I20201231",
      "decimals": "5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
     "shortName": "Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:AdditionalStockOptionPlanDataTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i130d53f3f6b041848bc6ad14a45add16_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i857dc018a76c42c1823968b2e5d1a794_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450428 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "if9de38f44efc4734a6acc21a07c418b0_I20200630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "iea7a98aa2bac4b76bab476be13a2fb31_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "iea7a98aa2bac4b76bab476be13a2fb31_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "ic7239edd43644a128d30e8bbd0ab2a9e_I20190630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "ic7239edd43644a128d30e8bbd0ab2a9e_I20190630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Restructuring and Employee Severance",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance",
     "shortName": "Restructuring and Employee Severance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20201231.htm",
      "contextRef": "i292a929f46bf46fe94b105fb03c5b52e_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 73,
   "tag": {
    "cah_A2.4Notesdue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.4% Notes due 2020",
        "label": "2.4% Notes due 2020 [Member]",
        "terseLabel": "2.4% Notes due 2020 [Member]"
       }
      }
     },
     "localname": "A2.4Notesdue2020Member",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A2.616Notesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.616% Notes due 2022",
        "label": "2.616% Notes due 2022 [Member]",
        "terseLabel": "2.616% Notes due 2022 [Member]"
       }
      }
     },
     "localname": "A2.616Notesdue2022Member",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A3.2Notesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.2% Notes due 2022",
        "label": "3.2% Notes due 2022 [Member]",
        "terseLabel": "3.2% Notes due 2022 [Member]"
       }
      }
     },
     "localname": "A3.2Notesdue2022Member",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A3.41Notesdue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.41% Notes due 2027",
        "label": "3.41% Notes due 2027 [Member]",
        "terseLabel": "3.41% Notes due 2027 [Member]"
       }
      }
     },
     "localname": "A3.41Notesdue2027Member",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A4.368Notesdue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.368% Notes due 2047",
        "label": "4.368% Notes due 2047 [Member]",
        "terseLabel": "4.368% Notes due 2047 [Member]"
       }
      }
     },
     "localname": "A4.368Notesdue2047Member",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A4.6Notesdue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.6% Notes due 2043",
        "label": "4.6% Notes due 2043 [Member]",
        "terseLabel": "4.6% Notes due 2043 [Member]"
       }
      }
     },
     "localname": "A4.6Notesdue2043Member",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A4.9Notesdue2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.9% Notes due 2045",
        "label": "4.9% Notes due 2045 [Member]",
        "terseLabel": "4.9% Notes due 2045 [Member]"
       }
      }
     },
     "localname": "A4.9Notesdue2045Member",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_AdditionalStockOptionPlanDataTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A disclosure of additional data related to all stock option activity",
        "label": "Additional Stock Option Plan Data [Table Text Block]",
        "terseLabel": "Schedule of Additional Data Related to Stock Option Activity"
       }
      }
     },
     "localname": "AdditionalStockOptionPlanDataTableTextBlock",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cah_AggregateAnnualAssessment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Annual Assessment",
        "label": "Aggregate Annual Assessment",
        "terseLabel": "Aggregate Annual Assessment"
       }
      }
     },
     "localname": "AggregateAnnualAssessment",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_AlamedaCountyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alameda County [Member]",
        "label": "Alameda County [Member]",
        "terseLabel": "Alameda County [Member]"
       }
      }
     },
     "localname": "AlamedaCountyMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Amortizationandotheracquisitionrelatedcosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Amortization and other acquisition-related costs",
        "terseLabel": "Amortization and other acquisition-related costs"
       }
      }
     },
     "localname": "Amortizationandotheracquisitionrelatedcosts",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CARESActDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act",
        "label": "CARES Act [Domain]",
        "terseLabel": "Net Operating Loss Carryback [Domain]"
       }
      }
     },
     "localname": "CARESActDomain",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CVSHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CVS Health [Member]",
        "label": "CVS Health [Member]",
        "terseLabel": "CVS Health"
       }
      }
     },
     "localname": "CVSHealthMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CardinalHealthAtHomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health At Home [Member]",
        "label": "Cardinal Health At Home [Member]",
        "terseLabel": "Cardinal Health At Home [Member]"
       }
      }
     },
     "localname": "CardinalHealthAtHomeMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CareFusionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CareFusion [Member]",
        "label": "CareFusion [Member]",
        "terseLabel": "CareFusion [Member]"
       }
      }
     },
     "localname": "CareFusionMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CarryingAmountofLongTermandotherShortTermBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "label": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings"
       }
      }
     },
     "localname": "CarryingAmountofLongTermandotherShortTermBorrowings",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ClassActionLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Action Lawsuits [Member]",
        "label": "Class Action Lawsuits [Member]",
        "terseLabel": "Class Action Lawsuits [Member]"
       }
      }
     },
     "localname": "ClassActionLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CommittedReceivablesSalesFacilityProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.",
        "label": "Committed Receivables Sales Facility Program [Member]",
        "terseLabel": "Committed Receivables Sales Facility Program [Member]"
       }
      }
     },
     "localname": "CommittedReceivablesSalesFacilityProgramMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_DOJInvestigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DOJ Investigation",
        "label": "DOJ Investigation [Member]",
        "terseLabel": "DOJ Investigation [Member]"
       }
      }
     },
     "localname": "DOJInvestigationMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount",
        "label": "Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount",
        "terseLabel": "Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount"
       }
      }
     },
     "localname": "DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Liability for New York Opioid Stewardship Act",
        "label": "Estimated Liability for New York Opioid Stewardship Act",
        "terseLabel": "Estimated Liability for New York Opioid Stewardship Act"
       }
      }
     },
     "localname": "EstimatedLiabilityForNewYorkOpioidStewardshipAct",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ExercisablePeriodOfPlansInYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The instrument's contractual term.",
        "label": "Exercisable period of plans, in years",
        "terseLabel": "Exercisable period of plans (in years)"
       }
      }
     },
     "localname": "ExercisablePeriodOfPlansInYears",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cah_FacilityExitAndOtherCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.",
        "label": "Facility Exit and Other Costs",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityExitAndOtherCosts",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_FloatingRateNotesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating Rate Notes due 2022",
        "label": "Floating Rate Notes due 2022 [Member]",
        "terseLabel": "Floating Rate Notes due 2022 [Member]"
       }
      }
     },
     "localname": "FloatingRateNotesdue2022Member",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_GownRecallAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gown Recall [Axis]",
        "label": "Gown Recall [Axis]",
        "terseLabel": "Gown Recall [Axis]"
       }
      }
     },
     "localname": "GownRecallAxis",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_GownRecallDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Gown Recall [Axis]",
        "label": "Gown Recall [Domain]",
        "terseLabel": "Gown Recall [Domain]"
       }
      }
     },
     "localname": "GownRecallDomain",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IPRDTrademarksandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "IPR&amp;D,TrademarksandOther [Member]",
        "terseLabel": "IPR&amp;D, trademarks and other"
       }
      }
     },
     "localname": "IPRDTrademarksandOtherMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IndemnificationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.",
        "label": "Indemnification Receivable",
        "terseLabel": "Indemnification Receivable"
       }
      }
     },
     "localname": "IndemnificationReceivable",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_LawsuitTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Axis]",
        "terseLabel": "Lawsuit Type [Axis]"
       }
      }
     },
     "localname": "LawsuitTypeAxis",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_LawsuitTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Domain]",
        "terseLabel": "Lawsuit Type [Domain]"
       }
      }
     },
     "localname": "LawsuitTypeDomain",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_LongTermObligationsandOtherShortTermBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]",
        "label": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]"
       }
      }
     },
     "localname": "LongTermObligationsandOtherShortTermBorrowingsAbstract",
     "nsuri": "http://www.cardinal.com/20201231",
     "xbrltype": "stringItemType"
    },
    "cah_LossContingencyLawsuitsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Lawsuits, Number",
        "label": "Loss Contingency, Lawsuits, Number",
        "verboseLabel": "Loss Contingency, Lawsuits, Number"
       }
      }
     },
     "localname": "LossContingencyLawsuitsNumber",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_MaximumQuarterlyPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved.",
        "label": "Maximum Quarterly Payment",
        "terseLabel": "Maximum quarterly payment"
       }
      }
     },
     "localname": "MaximumQuarterlyPayment",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_MedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical [Member]",
        "label": "Medical Member",
        "terseLabel": "Medical"
       }
      }
     },
     "localname": "MedicalMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicaldistributionandproductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical distribution and products [Member]",
        "label": "Medical distribution and products [Member]",
        "terseLabel": "Medical distribution and products [Member]"
       }
      }
     },
     "localname": "MedicaldistributionandproductsMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NarativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Narative [Abstract]",
        "label": "Narative [Abstract]",
        "terseLabel": "Narative [Abstract]"
       }
      }
     },
     "localname": "NarativeAbstract",
     "nsuri": "http://www.cardinal.com/20201231",
     "xbrltype": "stringItemType"
    },
    "cah_NetOperatingLossCarrybackAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryback",
        "label": "Net Operating Loss Carryback [Axis]",
        "terseLabel": "Net Operating Loss Carryback [Axis]"
       }
      }
     },
     "localname": "NetOperatingLossCarrybackAxis",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_NetOperatingLossCarrybackMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryback",
        "label": "Net Operating Loss Carryback [Member]",
        "terseLabel": "Net Operating Loss Carryback [Member]"
       }
      }
     },
     "localname": "NetOperatingLossCarrybackMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.",
        "label": "Net proceeds/(tax withholdings) from share-based compensation",
        "terseLabel": "Net proceeds/(tax withholdings) from share-based compensation"
       }
      }
     },
     "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_NewYorkOpioidStewardshipActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York Opioid Stewardship Act",
        "label": "New York Opioid Stewardship Act [Member]",
        "terseLabel": "New York Opioid Stewardship Act [Member]"
       }
      }
     },
     "localname": "NewYorkOpioidStewardshipActMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NotesPayableRepurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal Amount of Notes Payable Repurchased during the year",
        "label": "Notes Payable Repurchased",
        "terseLabel": "Notes Payable Repurchased"
       }
      }
     },
     "localname": "NotesPayableRepurchased",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_NuclearPrecisionHealthServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuclear Precision Health Services [Member]",
        "label": "Nuclear Precision Health Services [Member]",
        "terseLabel": "Nuclear Precision Health Services [Member]"
       }
      }
     },
     "localname": "NuclearPrecisionHealthServicesMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NumberofStateAttorneysGeneralfilinglawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of State Attorneys General filing lawsuits",
        "label": "Number of State Attorneys General filing lawsuits",
        "terseLabel": "Number of State Attorneys General filing lawsuits"
       }
      }
     },
     "localname": "NumberofStateAttorneysGeneralfilinglawsuits",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_OpioidLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Lawsuits [Member]",
        "label": "Opioid Lawsuits [Member]",
        "terseLabel": "Opioid Lawsuits [Member]"
       }
      }
     },
     "localname": "OpioidLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLawsuitsStateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Lawsuits State and Political Subdivisions [Domain]",
        "label": "Opioid Lawsuits State [Domain]",
        "terseLabel": "Opioid Lawsuits State [Domain]"
       }
      }
     },
     "localname": "OpioidLawsuitsStateDomain",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLitigationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation",
        "label": "Opioid Litigation [Axis]",
        "terseLabel": "Opioid Litigation [Axis]"
       }
      }
     },
     "localname": "OpioidLitigationAxis",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_OpioidLitigationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation [Domain]",
        "label": "Opioid Litigation [Domain]",
        "terseLabel": "Opioid Litigation [Domain]"
       }
      }
     },
     "localname": "OpioidLitigationDomain",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OtherJurisdictionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Jurisdictions [Member]",
        "label": "Other Jurisdictions [Member]",
        "terseLabel": "Other Jurisdictions [Member]"
       }
      }
     },
     "localname": "OtherJurisdictionsMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PatientRecoveryBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient Recovery Business [Member]",
        "label": "Patient Recovery Business [Member]",
        "terseLabel": "Patient Recovery Business"
       }
      }
     },
     "localname": "PatientRecoveryBusinessMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalDistributionandSpecialtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Distribution and Specialty [Member]",
        "label": "Pharmaceutical Distribution and Specialty [Member]",
        "terseLabel": "Pharmaceutical Distribution and Specialty [Member]"
       }
      }
     },
     "localname": "PharmaceuticalDistributionandSpecialtyMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical [Member]",
        "label": "Pharmaceutical Member",
        "terseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PlaintiffTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Axis]",
        "terseLabel": "Plaintiff Type [Axis]"
       }
      }
     },
     "localname": "PlaintiffTypeAxis",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_PlaintiffTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Domain]",
        "terseLabel": "Plaintiff Type [Domain]"
       }
      }
     },
     "localname": "PlaintiffTypeDomain",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PrivatePartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Parties [Member]",
        "label": "Private Parties [Member]",
        "terseLabel": "Private Parties [Member]"
       }
      }
     },
     "localname": "PrivatePartiesMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from divestitures and disposal of property and equipment and held for sale assets",
        "label": "Proceeds from divestitures and disposal of property and equipment and held for sale assets",
        "terseLabel": "Proceeds from divestitures and disposal of property and equipment and held for sale assets"
       }
      }
     },
     "localname": "Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of available-for-sale securities and other investments.",
        "label": "Proceeds from sale of available-for-sale securities and other investments",
        "terseLabel": "Proceeds from investments"
       }
      }
     },
     "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ProductLiabilityLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability Lawsuits [Member]",
        "label": "Product Liability Lawsuits [Member]",
        "terseLabel": "Product Liability Lawsuits"
       }
      }
     },
     "localname": "ProductLiabilityLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ProjectCostsOnInvestmentAndOtherSpending": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.",
        "label": "Project Costs On Investment And Other Spending",
        "terseLabel": "Project costs on investment and other spending"
       }
      }
     },
     "localname": "ProjectCostsOnInvestmentAndOtherSpending",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Purchaseofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from purchases of available-for-sale securities and other investments.",
        "label": "Purchase of available-for-sale securities and other investments",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "Purchaseofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]",
        "label": "Segment Revenue from External Customers by Geographic Area [Line Items]",
        "terseLabel": "Segment Revenue from External Customers by Geographic Area [Line Items]"
       }
      }
     },
     "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Revenue from External Customers by Geographic Area [Table]",
        "label": "Segment Revenue from External Customers by Geographic Area [Table]",
        "terseLabel": "Segment Revenue from External Customers by Geographic Area [Table]"
       }
      }
     },
     "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaTable",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_Sharesthatwouldbeantidilutiveasaresultofnetloss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "shares that would be antidilutive as a result of net loss",
        "label": "shares that would be antidilutive as a result of net loss",
        "terseLabel": "shares that would be antidilutive as a result of net loss"
       }
      }
     },
     "localname": "Sharesthatwouldbeantidilutiveasaresultofnetloss",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cah_ShortTermCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other short-term credit facilities and an unsecured line of credit",
        "label": "Short Term Credit Facilities Member",
        "terseLabel": "Short Term Credit Facilities Member"
       }
      }
     },
     "localname": "ShortTermCreditFacilitiesMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_SterileSurgicalGownRecallAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sterile Surgical Gown Recall [Axis] [Axis]",
        "label": "Sterile Surgical Gown Recall [Axis]",
        "terseLabel": "Sterile Surgical Gown Recall [Axis]"
       }
      }
     },
     "localname": "SterileSurgicalGownRecallAxis",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_SterileSurgicalGownRecallDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Sterile Surgical Gown Recall [Axis] [Axis]",
        "label": "Sterile Surgical Gown Recall [Domain]",
        "terseLabel": "Sterile Surgical Gown Recall [Domain]"
       }
      }
     },
     "localname": "SterileSurgicalGownRecallDomain",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_SterileSurgicalGownRecallMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sterile Surgical Gown Recall [Member]",
        "label": "Sterile Surgical Gown Recall [Member]",
        "terseLabel": "Sterile Surgical Gown Recall [Member]"
       }
      }
     },
     "localname": "SterileSurgicalGownRecallMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMatterAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matter [Axis]",
        "label": "Tax Matter [Axis]",
        "terseLabel": "Tax Matter [Axis]"
       }
      }
     },
     "localname": "TaxMatterAxis",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMatterDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matter [Axis]",
        "label": "Tax Matter [Domain]",
        "terseLabel": "Tax Matter [Domain]"
       }
      }
     },
     "localname": "TaxMatterDomain",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMattersAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matters Agreement [Axis]",
        "label": "Tax Matters Agreement [Axis]",
        "terseLabel": "Tax Matters Agreement [Axis]"
       }
      }
     },
     "localname": "TaxMattersAgreementAxis",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMattersAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matters Agreement [Axis]",
        "label": "Tax Matters Agreement [Domain]",
        "terseLabel": "Tax Matters Agreement [Domain]"
       }
      }
     },
     "localname": "TaxMattersAgreementDomain",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TotalLongTermandShortTermObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Long-Term and Short-Term Obligations",
        "label": "Total Long-Term and Short-Term Obligations",
        "terseLabel": "Total Long-Term and Short-Term Obligations"
       }
      }
     },
     "localname": "TotalLongTermandShortTermObligations",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_TotalOpioidLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Opioid Litigation",
        "label": "Total Opioid Litigation [Member]",
        "terseLabel": "Total Opioid Litigation [Member]"
       }
      }
     },
     "localname": "TotalOpioidLitigationMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TrademarksAndPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Trademarks And Patents Member",
        "terseLabel": "Trademarks, trade names and patents"
       }
      }
     },
     "localname": "TrademarksAndPatentsMember",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TreasuryStockAcquiredShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Stock Acquired Shares",
        "label": "Treasury Stock Acquired Shares",
        "terseLabel": "Treasury Stock Acquired Shares"
       }
      }
     },
     "localname": "TreasuryStockAcquiredShares",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cah_VestingPeriodinyearsforShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period in years for Shares",
        "label": "Vesting Period in years for Shares",
        "terseLabel": "Vesting Period in years for Shares"
       }
      }
     },
     "localname": "VestingPeriodinyearsforShares",
     "nsuri": "http://www.cardinal.com/20201231",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r120",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r140",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r120",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r140",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r152",
      "r226",
      "r228",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r239",
      "r242",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r420",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r239",
      "r242",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r420",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r152",
      "r226",
      "r228",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r229",
      "r239",
      "r242",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r420",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r229",
      "r239",
      "r242",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r420",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r148",
      "r149",
      "r226",
      "r227",
      "r421",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r148",
      "r149",
      "r226",
      "r227",
      "r421",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r197",
      "r240",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r390",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r40",
      "r45",
      "r46",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r41",
      "r45",
      "r46",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r43",
      "r44",
      "r45",
      "r405",
      "r428",
      "r429"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r42",
      "r45",
      "r46",
      "r88",
      "r89",
      "r90",
      "r311",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r244",
      "r267",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r77",
      "r165",
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r42",
      "r45",
      "r46",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r82",
      "r128",
      "r135",
      "r142",
      "r155",
      "r305",
      "r312",
      "r354",
      "r385",
      "r404"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r38",
      "r82",
      "r155",
      "r305",
      "r312",
      "r354"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r246",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r327",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r238",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r238",
      "r241",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r24",
      "r79"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and equivalents at end of period",
        "periodStartLabel": "Cash and equivalents at beginning of period",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r355"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments, Contingent Liabilities and Litigation"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per common share"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common shares, without par value:"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "terseLabel": "Common shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Authorized\u2014755 million shares, Issued\u2014327 million shares at December 31, 2020 and June 30, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r60",
      "r396",
      "r416"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r49",
      "r51",
      "r59",
      "r303",
      "r316",
      "r395",
      "r415"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income/(loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r144",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r64",
      "r381"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold",
        "verboseLabel": "Cost of Goods and Services Sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Currency Swap [Member]"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r386",
      "r387",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r30",
      "r84",
      "r216",
      "r219",
      "r220",
      "r221",
      "r365",
      "r366",
      "r368",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred income taxes and other liabilities"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r77",
      "r123"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.",
        "label": "Derivative Assets (Liabilities), at Fair Value, Net",
        "terseLabel": "Forward contracts"
       }
      }
     },
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r328",
      "r329",
      "r333",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r325",
      "r328",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r332",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r319",
      "r320",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative Liability, Notional Amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r318",
      "r321",
      "r322",
      "r325",
      "r326",
      "r331",
      "r333",
      "r340",
      "r341",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "verboseLabel": "Developed technology and other"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r238",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r222",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings/(loss) per common share attributable to Cardinal Health, Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r107",
      "r109",
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share [Text Block]"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rates changes on cash and equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit related to share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee- Related Costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r92",
      "r97",
      "r99",
      "r112",
      "r156",
      "r215",
      "r222",
      "r270",
      "r271",
      "r272",
      "r288",
      "r289",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring",
        "verboseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r346",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r345",
      "r346",
      "r348",
      "r349",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Disclosures"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r230",
      "r231",
      "r236",
      "r237",
      "r346",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r230",
      "r231",
      "r236",
      "r237",
      "r346",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "verboseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r346",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r350",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated annual amortization of intangible assets - Year One"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated annual amortization of intangible assets - Remainder of Fiscal Year"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r166",
      "r168",
      "r171",
      "r175",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r171",
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r166",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r171",
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted- Average Remaining Amortization Period (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r230",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation (recoveries)/charges, net"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r77",
      "r209",
      "r210"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on Extinguishment of Debt",
        "verboseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r158",
      "r159",
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, Transfers"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r63",
      "r82",
      "r128",
      "r134",
      "r138",
      "r141",
      "r144",
      "r155",
      "r354"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r325",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r85",
      "r128",
      "r134",
      "r138",
      "r141",
      "r144"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings/(loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r54",
      "r61",
      "r91",
      "r93",
      "r94",
      "r95",
      "r96",
      "r102",
      "r104",
      "r105",
      "r391",
      "r392",
      "r397",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r54",
      "r61",
      "r91",
      "r93",
      "r94",
      "r95",
      "r96",
      "r102",
      "r104",
      "r105",
      "r106",
      "r397",
      "r412",
      "r414",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income (Loss) from Continuing Operations, Per Diluted Share"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r238",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r279",
      "r285",
      "r286",
      "r290",
      "r292",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r83",
      "r98",
      "r99",
      "r126",
      "r277",
      "r291",
      "r293",
      "r418"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for/(benefit from) income taxes",
        "negatedTerseLabel": "Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReceivable": {
     "auth_ref": [
      "r23",
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.",
        "label": "Income Taxes Receivable",
        "terseLabel": "Income Taxes Receivable"
       }
      }
     },
     "localname": "IncomeTaxReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Increase/(decrease) in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other accrued liabilities and operating items, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "(Increase)/decrease in trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r167",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r167",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r164",
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Net Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r55",
      "r122",
      "r364",
      "r367",
      "r398"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest Income (Expense), Nonoperating, Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS) [Member]"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r36"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net",
        "verboseLabel": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRecallExpense": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.",
        "label": "Inventory Recall Expense",
        "terseLabel": "Inventory Recall Expense"
       }
      }
     },
     "localname": "InventoryRecallExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r82",
      "r155",
      "r354",
      "r389",
      "r408"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r82",
      "r155",
      "r306",
      "r312",
      "r313",
      "r354"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r31",
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Estimated Litigation Liability"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation Settlement, Expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion",
        "verboseLabel": "Long-term Debt and Lease Obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations and other short-term borrowings",
        "verboseLabel": "Long-term Debt and Lease Obligation, Current"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r30",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Long-term Purchase Commitment, Period",
        "terseLabel": "Long-term Purchase Commitment, Period"
       }
      }
     },
     "localname": "LongtermPurchaseCommitmentPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss Contingency Accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss Contingency, New Claims Filed, Number"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss Contingency, Number of Plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r35",
      "r82",
      "r155",
      "r354",
      "r388",
      "r407"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r75",
      "r78"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r47",
      "r50",
      "r57",
      "r78",
      "r82",
      "r91",
      "r93",
      "r94",
      "r95",
      "r96",
      "r98",
      "r99",
      "r103",
      "r128",
      "r134",
      "r138",
      "r141",
      "r144",
      "r155",
      "r354",
      "r393",
      "r413"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net earnings/(loss) attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r47",
      "r50",
      "r98",
      "r99",
      "r308",
      "r315"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Financial Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r222",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in CCYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open Tax Year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r128",
      "r134",
      "r138",
      "r141",
      "r144"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Total operating earnings",
        "totalLabel": "Operating earnings/(loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r28"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "verboseLabel": "Other Accrued Liabilities, Current"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in other comprehensive income.",
        "label": "Other Comprehensive Income Location [Axis]",
        "terseLabel": "Other Comprehensive Income Location [Axis]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in other comprehensive income.",
        "label": "Other Comprehensive Income Location [Domain]",
        "terseLabel": "Other Comprehensive Income Location [Domain]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r45",
      "r53",
      "r356",
      "r358",
      "r362"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax",
        "terseLabel": "Net unrealized gain/(loss) on derivative instruments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r48",
      "r51",
      "r53",
      "r58",
      "r215",
      "r356",
      "r361",
      "r362",
      "r394",
      "r414"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive income/(loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r48",
      "r51",
      "r303",
      "r304",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r41",
      "r43",
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Nonoperating Income (Expense) [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Payments for Repurchase of Common Stock",
        "terseLabel": "Payments for Repurchase of Common Stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r72",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "Payments and other adjustments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends on common shares"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of subsidiaries, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Share Units",
        "verboseLabel": "Performance Share Unit"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred shares, without par value:"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred shares, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Authorized\u2014500 thousand shares, Issued\u2014none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from (Repayments of) Short-term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r47",
      "r50",
      "r73",
      "r82",
      "r91",
      "r98",
      "r99",
      "r128",
      "r134",
      "r138",
      "r141",
      "r144",
      "r155",
      "r303",
      "r307",
      "r309",
      "r315",
      "r316",
      "r354",
      "r399"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings/(loss)",
        "totalLabel": "Net earnings/(loss)",
        "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r178",
      "r410"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r62",
      "r157"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r16",
      "r22",
      "r409",
      "r430"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r45",
      "r46",
      "r53",
      "r356",
      "r360",
      "r362"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r135",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Assets by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r134",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r134",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Segment Profit by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r133",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Reduction of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Restricted Share Unit"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring and Employee Severance"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeverance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r77",
      "r181",
      "r186",
      "r190"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring and employee severance",
        "totalLabel": "Total restructuring and employee severance"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring Charges [Abstract]"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Additions",
        "verboseLabel": "Restructuring Costs"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r182",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r222",
      "r273",
      "r406",
      "r427",
      "r429"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r92",
      "r97",
      "r99",
      "r156",
      "r270",
      "r271",
      "r272",
      "r288",
      "r289",
      "r424",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r56",
      "r82",
      "r119",
      "r120",
      "r133",
      "r139",
      "r140",
      "r147",
      "r148",
      "r152",
      "r155",
      "r354",
      "r399"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r45",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r166",
      "r170",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r166",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r162",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r162",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill by Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r174",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r184",
      "r185",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r184",
      "r185",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r182",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r128",
      "r131",
      "r137",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r246",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r249",
      "r261",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Transactions Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r32",
      "r80",
      "r113",
      "r114",
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r115",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r144",
      "r152",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r117",
      "r118",
      "r128",
      "r132",
      "r138",
      "r142",
      "r143",
      "r144",
      "r145",
      "r147",
      "r151",
      "r152",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Distribution, selling, general and administrative expenses",
        "verboseLabel": "Selling, General and Administrative Expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r77",
      "r181",
      "r186",
      "r190"
     ],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "verboseLabel": "Employee-related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "periodStartLabel": "Nonvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Performance Share Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested at end of period (in usd per share)",
        "periodStartLabel": "Nonvested at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share",
        "verboseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of outstanding options at period end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r251",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price per Common Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r243",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Target performance goal (as a percent)",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of exercisable options at period end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r115",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r144",
      "r152",
      "r162",
      "r180",
      "r183",
      "r191",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Operating and Reportable Segment"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r34",
      "r88",
      "r89",
      "r90",
      "r92",
      "r97",
      "r99",
      "r112",
      "r156",
      "r215",
      "r222",
      "r270",
      "r271",
      "r272",
      "r288",
      "r289",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "verboseLabel": "Statement of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r112",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r215",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r215",
      "r222",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r222",
      "r245",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "negatedTerseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r82",
      "r154",
      "r155",
      "r354"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Cardinal Health, Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r82",
      "r88",
      "r89",
      "r90",
      "r92",
      "r97",
      "r155",
      "r156",
      "r222",
      "r270",
      "r271",
      "r272",
      "r288",
      "r289",
      "r301",
      "r302",
      "r314",
      "r354",
      "r356",
      "r357",
      "r362",
      "r425",
      "r426"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r222",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r363",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r363",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r363",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury shares acquired, average price per share (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r33",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock",
        "verboseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r33",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)",
        "terseLabel": "Common shares in treasury"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r15",
      "r215",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Treasury shares acquired (in shares)",
        "negatedTerseLabel": "Treasury Stock, Shares, Acquired"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r33",
      "r223",
      "r224"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Common shares in treasury, at cost: 33 million shares and 34 million shares at December 31, 2020 and June 30, 2020, respectively",
        "negatedPeriodEndLabel": "Treasury, balance at end of period",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r215",
      "r222",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r276",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Employee stock options, restricted share units, and performance share units (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r101",
      "r106"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares\u2013diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r100",
      "r106"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares\u2013basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121558989&loc=d3e80720-113993"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r441": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r442": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r443": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r444": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r445": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r446": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0000721371-21-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000721371-21-000011-xbrl.zip
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MAI-JQ=^Q*A+X!)!69K0*$$JCYBP'#@C"!&VEEA@MX6'O-8UED'@Y7"6+0L$
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M[;<'UCY[KQ=VCA9U'_J8_R<+VU&_WMRU<OFQ?V&QF(ZR4X_]5$^KXEM\J=^
MD_]2_^*@@Z7A?]G[J_.W9Y?O_!?LL]_>O#_[\&'MX_TC+C#\B2$K\49HA"/F
M3^#8HO>/'$\X^1:#N>4*P%<<P+_'&)V/I4C9Y:V("SH&8#\'!?RD<=K]0LD*
M']Z[;)7K<-ML$,Z)I^+!ZU<E@S:75?@0:"W<9I7/7&PI?\/],7^3[?3_4$L#
M!!0    ( ,F$15(0>S\6"0@  )LG   ?    83(Q<3)?,3!Q>#$R,S$R,'AE
M>&AI8FET,S$R+FAT;>U:;6\;-Q+^?K^"E7&I T@KK5[\(CL&7-M!7*1)+_4A
MN$\':CFKY9E:;DFN9/77WPRY>K-E6ZX3GVI<@2K>Y7 X)!\^\Y#+XQ_./Y]=
M_>O7"Y:YD6*__O.GCY=GK-9H-K]VSIK-\ZMS]N'JEX^L&[5B=F5X;J63.N>J
MV;SX5&.US+FBWVQ.)I-HTHFT&3:OOC3)5;>IM+80"2=J)\?T!G^!BY._'?_0
M:+!SG90CR!U+#' '@I56YD/V58"]9HU&976FBZF1P\RQ=JO=8E^UN99C'LJ=
M= I.9GZ.F^'YN.D;.1YH,3TY%G+,I'A7D[U.N[V_G_!.#Z![V$L/0/ V0*\5
MB];>WH'X=XQ!-M$\U+%NJN!=;23S1@;4?K_;CO9[A3N:2.&R?MQJ_;VV8NK@
MQC6XDL.\GV X8+#8\8&"F<% &P&FD6BE>&&A/_OC2$A;*#[MRUS)'!J^TM$8
MC),)5Y5+[WV@G=.C*H+#PZ@;]R@(9_!_,6NFBB_R\36=N%O6B:/#@X-[BUM1
M?&_9@V[;4?N@_3W<=COW%R^[;?J1"*.!HVL+GK^K=6JS"@47 B'6;[&X<$O^
MOHUIN[@AXZ,E''C@WI[),(GH,]4(_LH)^M6FO]/R_QU122/E(ZFF_1]/C>2*
M?>+&Z,F/=8OKKV'!R#186?D'(!BQ7?\X"5C=1R<>2Q5V UHO;C(YD([A_+>/
MFV2_/&Y-C[NE-1 BQ(5$A96U?WUWE7 SQ(42>M;?6QV$_Y36R73Z?3O<O=WA
M-G7XLLY^YE;G[)>(?:#59NHLH=E(I\QEW+W9Z1T<K?;MP5Y54]U0D+I^9WT_
MPRN9"^2 ?B,^\/!Y\9['T:Q;+]STZAC%<13OT0A<LHR/@1D82Y@@U[M,6O9>
MFQ&+6XU_,)VR,VZP'L;P ;AR69U=YDF$$W3X.B>HO643]!.W."VX5$93=IWK
MB0(QA'J8)P.%-HX)#9;E&A,V-L%ESG@^967N3$DI#E.XS^8XE9R-\,G'F_($
M7QFF1\@[3@>[.P8Y)& M-U,R&?%KP':7?%I\)S 8;%)Y*8!MD$$B#:9^-,NQ
M.D:"V95-,IEDS);TLZ@_ 0.5$^K 2%J%&H'DQD2Z##MH"TA\@.2WP- T<3TR
M-P[*8+H\#*\7DIV_"B2!I<@4>4*M+R:YCGA$<RPV2^4R3Y%E."E6_#M1I4"?
M"*2E&:TC"*514U8@#@C"!&VE%ABMX&%O-8W+0'@I7">+4J$! E,C>GQSUL>3
M<)NQ5.F)G:'6P%!:ASK:,4XO0]P897T)?'86S)UH7R_^NEN&OZN5R7JS<]".
M]X]LA;!*1A"%Z#25^+AKW_J9O&3<@,<,8D"2_L>Y96!)7DF;40TR&R&#$HO2
M,VX $J5MB?6(6PV*3&]3&)V P->6[2)6!"#X B N;I*,YT-@ITA;7TJ%%G&'
M-^+>+H0HXIX(3^%1TH8D#Z E_XRX;0G+ 5L4R\8-I2L-I=@0]?,VPM&",O^S
ME-9^>XM1N\O?;@5L???/P>( X<SY!/@XK.J4FQ->VLVK4)(< $*D:BFD75T:
M=(#<-9;6,R):0>[]D-!><.DR'QM0W&.NRKL+W-0KKJ9"B;R*L5BMI/#G!+8<
M6"DD-Y(Z((,Z\!DB)T^EI8SM5ZGUZ=WSI[:  3GD:ZI4<-J2E;@A0-K';OD@
M%ID?:P0=L2Q_\*\!D"$R,]8'\2PFWFY,#[86TQL3V1UH;TZ!&R,<5\58"@(N
M[3+]60^W"'H2I(1FOZ495MA6D@^DDFY*0F!=L[3./ @]OL(263%=$K0^I=Q4
M'2I*4R"^K1<N2:*-\ %X:3N$'/6(0IAC"12T?L@$97N ,JXS62"KOV(P)UL"
MYJCK9<7%F*O2$QE--J0I2DLYQFFR:R3B7'5L0,SA<;UJ]/#%BDBJ-FC3@2[=
M_1%LDCKXW!I(>*>/[YW88";I_8J$,!(8CT<?-? Z$2BV!(&>3L/,WD4([>8K
MK>=+UL+P"21*:5\G26D(!TLY=HW7D;8.W].Q.?JR"3KZO<04C:YW[ZF2(J"1
MWFY95X'CI@O\002=4>3E/*ZW(:J,V[D@(6+T"P"$SQA^/"HVGS(EKT%5IQ*W
M[.O/'J)G@WZK=W.]U[*;\P>78K9JZ@L.(TI=1NZ"S@A[3Q J=^3O/#J.$MAI
M8^?:P+] EZ.1= [@@80QT*@^J%Q(C,\[V45\(S];XG_\EX3X;%'"[Z7$\/T"
M+//$GU^\_?^F[448^52AM,,AD@@\VC/3[CN1@#"IDOI\\S0!?DU9.D@]GZ>]
M2/4GK+-SIR>!K]KGA!.+-;3'!5:T,&>]>X%:25NL@FA#!5H/4L&B3K#E"+&"
M(^0[4V6;M2=TKUP&;-.NZA2S?6J03NH( ? DB"#RA^,5VNHA6<I\K-48*&/F
M?%B=\9N*-V%4*#T%+)UD.C E7\$R8N^;R(GH,40X7?0/_S?S>HX#YJF2O8>!
M024R?;,3[[6.>G6ZLQ"S#<%,=PN6.M/SG?F&%PAT45T<Z,7MJ%VY7W]S8.63
M]VIA9R]J/53^8.6'"CO[\Z@>KUQ]Z)]9S*:CZM13/]/3JKCW*_W\0_A+8<I_
MJG^ST\7UX7^_/6<<;A0"^_GTM\^?_*?SSQ\_GGZY=0?@B7<G_L2,57"GQ8".
MF#\ 9+,^/W$ZT<D+4X,?PUNW#U8N77S?P?MKC,]9)B%E[^=\_SF([V>-T^;W
M6):H^-8=KT*'2V[]<$0]AGMO?57DW5I4X0-$:NGN5GGD/DWU&ZZM^0MT)_\%
M4$L#!!0    ( ,F$15("3KP%  4  &07   ?    83(Q<3)?,3!Q>#$R,S$R
M,'AE>&AI8FET,S(Q+FAT;>U8;6_;. S^?K^"2W%="\2O<5K'R0KDTA;MKF_7
M=ACNTT&QY5HWQ?)DI6GVZX^2XS5)DW6WM]X.+5 C,BE2)!_2I'HO]L\'UW]>
M'$"F1APNWOQV<CR AN4X;UL#Q]F_WH>CZ],3"&S7@VM)\I(I)G+"'>?@K &-
M3*DB<IS)9&)/6K:0-\[UI:-%!0X7HJ1VHI+&7D^_P2<ER=XOO1>6!?LB'H]H
MKB"6E"B:P+AD^0V\36CY#BQKQC40Q52RFTR![_H>O!7R';LE%5TQQ>E>+:?G
M5.N>8Y3TAB*9[O42=@LL>=5@?M .O);?&7I^$- @#;W$#6B;!ATW#%W7_<O#
M0SK(7NTIU9335XT1RZV,:OU1X-N[[4)U)RQ16>2Y[J^-!59%[Y1%.+O)HQB/
M0R62%1ER6C,,A4RHM&+!.2E*&M4_N@DK"TZF$<LYRZEE-G5'1-Z@\J%02HPB
MK?B62L5BPF=*C+Z*/#M3IV,'7EL?2TG\3VK%LQ/;YL2.2A[26I[="<.U9-?V
MUM(^*=:W_=#_'F*#UGKRO%C'>*+R!OJ[+$C^JM%JU!L*DB0(NL@%KU!S\KX-
MJU_<:>;N'#(,E)<C60419:8"TV$F!.4*&6VXYJ^K*59*1HQ/HY=]R0B',R*E
MF+QLEIB15DDE2RNNDGV@"$_4:Y:3"KV[*,2@:X;F"K\'=QD;,@7H4:_G:/YY
MOSD&B7-949T04TL39]SF]8.\694,W] Z[S'K?&W=0+LY14?K>@4B!951&&2,
MIG!P1^.Q8K<4SE/DH!)(GLS1#UE.\E@?I*9?C&4Y)FB!$N"%\,:^L@<V7-%8
M"]_<\';<KM=JNTT@)?034>B*MNBD^;*RD-P[BQAY.H?-V[A@6<?=J?UW1>20
MY+2TSN\XG4(_5IKBNZ[_9=;^/2XQ2-/OB_Y@I;FG+,X(Y8!Q_)V,TQ')\^9:
M?*"1 R(QKU'Y$25<94TXSF,;MK17-C="WW>[ S'"6C U*Z^[;4#UFI2(OE,;
MCG2]E\VU"*L!6LEH0FS@BS^*SX6>RHC:W&B'W7\1BEFQLCA-5=1:'9SJ%<L3
M1&9D:::G"->6MUW;]8-U+SK)-_;K4%V@,)&P&"YI(20F0@Z'0H[ <ZT_(!72
MQ//]F$C,9Z#HO@3V:4Q'0URVO*9N:5S\@.2*L%SW/IH]_8B+4F%;I#N;<@D:
M"Y!;.D,-O29,,H0W;F/EO20@<6QD,%HV(1US/@7]@N,:)DQE1HVD[\=,WJM>
M0MH6V0:TS6MO)=L?JP*FB\2^$,4<W&%6Y3>T+@U>IQ7 EM>N<;L;CO3VW5#@
M_FV$:Z>K\^3_"5G_OP99EB,N1]47<88\1"7+816>4\(D(J20M-18:&H^PCG@
M?FK.B80"P5$VEZ"+DA,S)9@*B%QC7D%)%%0:Y<N8MA^+OQ)%U'F:*.[K\<34
M53BD0XGY/*URH=VLII+/Q*[Y"L^9TS;F?,6,L#P1B.)^$@C;K2^9!'8ZMMM:
MWY9_:<ONA_;N3N>)6O85?;C.BA7N^\'H,CWXYD:PVRW-$TZ/!T?]@Q/3D?3?
M')[VS\X>MN7?Q#<SH&D8(B^4@K,$:DM_#L>M:-^^D[-^#G^LZUP_8[!;7:_:
MS^7JN5Q]JER][E^=GYG1YOSDI'_Y7*K6.6UI!GPN4P_'WZ^Y?IJK8$N7M86H
M;JLC23G157'M]>VLYKGW6\@0H396#[<\<@TV>U;WS^8F?.\?4$L#!!0    (
M ,F$15+$+@DTTQD  "*<   ?    83(Q<3)?,3!Q>#$R,S$R,'AE>&AI8FET
M.3DQ+FAT;>T]:7/;1I;?]U=@E-HD4T5*E.1,;,EQE2,G&^_D6MN9U'[::@(-
MLBT0C>D&2#&_?M_1%T!2]NPD2TX5IFIB$4=WH]]]]O,_O?KI[MU___Q-MFQ7
M5?;S+U]___HN.YM>7/QZ?7=Q\>K=J^R[=S]\GSTYGUUF[XRHK6J5KD5U<?'-
MCV?9V;)MFYN+B\UF<[ZY/M=F<?'NS04.]>2BTMK*\Z(MSEX\QROP7RF*%__V
M_$_3:?9*Y]U*UFV6&RE:662=5?4B^[60]CZ;3MU3=[K9&K58MMG5[.HR^U6;
M>[46?+]5;25?^'&>7_#OYQ<TR?.Y+K8OGA=JG:GBJS,U>_I,E//KJV>%*)Z4
MY?7\4EQ_^70V?_;T^HLGLW+V/Y>PR MXG-^Q[;:27YVM5#U=2IS_YLG5^9=?
M-.WM1A7M\N9R-OOWL]ZCK7QHIZ)2B_HFA^5( [=;,:^D?V"N32'---=5)1HK
M;_P?MX6R326V-ZJN5"VG]-+M2I@%3#[7;:M7-SCQ6II6Y:)RD]!\?-NMZ=FS
M\R>77^"R6@/_+_S$;L7GM.*+MMB]=WUY_NSITX.W9^>7!^\].NS5^=73JS]B
MV"?7AV^GPU[03O!NP'[;1M1?G5V?^1<:412 =#>S[+)ID_%^GT>OF@=\^#;!
M#$+E(209B#!FJ8$<W" PKC8WG\SH?[=X9UJ*E:JV-Y^]-$I4V8_"&+WY;&*!
M(J=6&E7R4U;])@$]85[ZN6'L_1(&(>QRV,SX^\W#4LU5FP'F7#Z_P.?3?;L@
M3-Q#%?M0G5^>XVMNG'_NK8/W'AOW?6=;56Y_WZV\_M!67N%6OFV!B1$_>R,7
MPB "9-]JLX$_I]]K?8^_7]>E-BN![#/[F&WZ0SYGB!E/]G[.2PO\&)BRJK-V
MJ6PF&5,FV:>?/+VZFMUNY(3^NKSU5W1GAI<ZZR^(&HA4P2*%R1JC:]W5-C.R
ME"9K=79'^P4K_TZ*JEU.8*/R<WI'M3:SW=RJ0@FCI)UD75U):V%1$DBOQLV"
M<?[>*2-MIN&JV2B0.=E/G<E*!=^UL-E&M4MZX:W,.P/2"Q[%P;]YR)>B7D@0
M,JN5LA; ,H$/SJN.H <?E+VLZP[6]48VVK09@ U NLHN9]._9@!*&K14%D@Y
MVTKX-%D7L&?_V=7RTT\N_S*[O9Y-4&[-LL_Q2;<K="&,XW;HSQ.:[^^=,$ 9
MU18^"J>TZ9S_E:Z.H*)K.:%/P7?AVPSBW_#-I[#8ST6EX27:"5%O/3AY'P2@
M;8&H:Q$8MLN7?@Q8E8#]DU6%_^(DM=P@X"HI+&ZXH=%HW[,-;&TK:[RH#>R(
M]11ALY4H9#;?TJTZF\NEJ,I,EX!BZ2<!94A$8)LUVJ)& ,_BG!L)"-#"EZ[$
MUCT./PH >=Y6-.B<KFL#BV;JFF\9NV2=PZ.EH\/*T6&RLG8I<,?*"L;J[>):
MR0ULF\5E(O *>(7A?6BP# !2*F-;^MP_9V*NNS8KN[8S,I-KG&Z"R&\;F(O_
M? ]_P7)I(TN@@#I'^FVD(3X!:S_/WL&4L#&P,Q8^V>:=#60I[2.K =#"M$ [
M. ?"-0>A(^ ]H^P]P[VKW36B"-J)7'<5R#0!M)^)O$7<!\+J*D:-0I5(L1Y.
ML/>ET2MX$]0\_SFR0(P$\:8:TNK@R]2JJ10OFF%%*!972A\)(QQ:F0/YIY]\
M\?3V(-OLZTO(L]V55C?TTTGE:25+8')/^W+9<5J^I("*Z_9FB@\=@_<22_A+
M^-3_Y_D'&_7%.0K LQ<../ /HIF#.[#.G_[V^M7T\ED&.E A5RKO\RB)I&R!
MU52JW3**(9$!;G<EXI<A1FL0LUNCYAT1+]S!YQ'T&P6L9RX]BR\8D8'W9!JH
MA&@=*&FSE,2!:%4+#>I5O6).N.@J9@A,,-DOM4*D)&%-5*=0$:D%6S35=D*4
MB,/ 9%WN7Q5K :(+=?D-&"! <SDPA$[B:F"!-0@D0,YGM_L_>",=6<D'6+-"
ME@2R<%&K$G1 6&4A0?FW;A=,US!'4,S[;-<TR./*;"4+U!GQN68I@#WDLB,M
M$BD/UVH=J>*6XIIQY<(O1 ,CJDK<3> @0"&P6P N@%G</6 R! +Z3G@!/P;Y
M@&. KX"?UO#S9YX-=^8E\DP3Q6[<!,26\/4$Q%JW"$@_N"Y+*]O>/N3 ]!%Y
M3) M- #R@\8HV+1XS\E>YCK\[;S%O /X^16.9D7%(X6/ALMN<+2Z.L""1R!'
M. #HPCM%LTH4%&HM SA@ ?!(A^H'BJ>X  &PL\C#9-%'IF0TA+#_ EX'WN&U
M@"AMD:+QN8[8+\@[B5/7H&#2&IIN7@&C;;<)Y EY84R4]S"SPQ^[!'$N%OSE
M-*LPCD>[50'3@^6:[12,*$18L$WG7IHBFKN]I\5%I 2$MD@Y.&/K=@9)M6&!
MN(?H^#-'-GXD-I[K52-;Q>@#6&,)<QV@8*OO94L_-TL%,GKC^:Q,V3I2(__K
MWB>8CB ]$DC[RA+HYH(8@>/@'EA K M9P[3Y0'R,T#MAZ+5@,]<+L&!0 0+-
M8>O$H2Y5ZV7[0<AFE8#1EY[GCDSW6#!&@9MH8BN$MG \=PZ@*]$2!S#B<P=
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M>POK0TAF<(_$'DJ!D>VQ"G$('_592_R\T]:YQR=51;EZU?BRUZ"HG(CK!K
MRA4W=29F>M#XQM5$T5QN]!&=3B?"ZOS_06](.B,FZK.1Z+CH]_?"R@]4WY,,
MD)#Q29:ID7-RF22]&29Q(K ()"OK\%<E\E 6N!+OG3D=_(H_L^<G2<0D;'V)
M6=,%(?<=SOHRYS#<[L)Z!=P]L[G%9O4P6>B;%(NDL!E$H4/N4W  ?*O-]&55
MC5A\5*88=28J9E^IH.;6_2S7TM4;NY(UMNET],Q4&,2E("PGX:/UEJ!^3,/E
M7#G%_)/S7@._1!MP;^QVQ)(3L>5Z#6$^\_2/&<3.4X4EQS5&0">#ZK308+71
M6 +)6G7CHQHC@$\$P)5<*%L%DSRQEQT_4*X=Y5Y!,$EI/M3^4/)$78@T'V@$
M^(D ?*EMHY##SSLJ,UX8W34$L^&=D5A/#78['-9G2*UT(2LG3P^[EDG"^O+"
M?;G$U-C:=2.FZ? < "Z<<RDCZ0I&M#@%M C-:(<LNN]<1TL$.'NO5#)$GGI!
M)<*B PUMG3?,1]I&##AN*3(8HW7'E;*U!36KZ'7D[ZGCW(+<NR$XZ7:A7/9N
M+&*6[/U6&.)9T.EA)L.,$)],H#<8C:$4@VWD%;Y=-5H1U&O2[O1@[ZGW_3HU
M:FF$O3>PLF9TJIX":L6DQXDOUT9[4>3W23U3J_E,!X[&P T^:,<!_K'2*[ D
M]I1O\>LYEE:B@(HYB<-2A="3J](+S #.;<;'7DW\Y#U!6<L6SY884>H$_+'.
MA^H#R:YK53\+R:6DV5#6YW@$'?3#(>7P/IT1 ?^Z$B;G+AM4,Z!V!(;,;S&B
MEQ9 P)(Z.GWA$7PE=H81 ;\D5XV5QV X-O-)R_7P:!Y:C_R F!QK:$?J^\.I
M+TIY['.-?34FH?<AQAE<%]@R<\6V(((IU<\?Y3))7=P^:L;!=T5N/G>0%J8N
MM7Q 28F9+JQ\^J9:?^2>T' W:+^J_".@!/INUHK5D:!T]L(5#/0WMM^_;Y*V
ML8N-_D(/%VP]Z4[)D0CR4< =N3&8"W^X@Y#2]KB[36EZ?1M#+R'?!3)HS2AW
M0B_>7-0H9;A*:<^8T>G.D4WWIDNB]?=\YSD\,JH NX\R<#&19NTJF'C].RWP
M#G_"1I($C(T=J==PP89EW 1JEHH=>GQ6,;4&HI8N>ZI<W?E8=QIV!%6 $D %
MGP0Z@("-6&.#2BQ?Z1_R-"+_B9W#$3 ,TZHH6[UCGL6MGYH0FASA=W3]P*D%
MO5K)W2,C!QW-$*X+$W+XZ!P K$7;7VCNF<>^ WEB#S#*#0S%D*$.(,D^;8@7
M\(O*I*</3 XMV<WT2*E[>K9FKW=C,OR(IJ?%9EQ+E()54=EB%WK2H5I*$ VZ
M$O7:D@N51],1WIB[%$#.9P@:V<'&""4 !:,CKGAA.+1\P*9.#3I5NSH>AGRX
MD\-''6CIW7 @!J=V6TO )^ZO5P]/@XT9WKXVWJ,W-QCTZ]24MHW[-&+S,;'9
M^T\+W^F06Y&M=!&1AW$LGM\<CPZ7PZX?P_KYB,:^_1JU>*S91^+;/6)?L*0&
MF1 ;G?^+;2BOT:J:\B%%0%,**:3IJ@:' ,0 CHL"X2%9;?(-(X(=$\%B/3FF
MID:H3/Y13""LPU/&NT,M9%RR1WK.+G9O%(72RFJ YX@+Q]?P7)1EDB2X4PT0
M8 )W_P,KCKR<H40O6I&^60#&C.+]Q)@$5E8H3&KU)SJ/\#XFO.>BOD=2Q.::
M"J.#:W\^G&/25,Z81&\RL3_?G8\6WTB4/73T,O7EY [H=$+>".?CQU6&VJ4[
M.F1_7V4*IKC4\Q*8 NH0,M>UQB-I9+U61M<QDE*Y*AD\Z\"U?65/#V#3FGH9
MD/Z*XM_-&DY"Y@.>,ERW/^UZ_W(31S+]#MT*>H?(<X9^:LWM?.:(BZ>3)#]L
M0^9K+OHPY;X3/DETDK6@JY8EAB<><M?#<LX-A?F<!)=MKHP_=\$=#9.8:906
M)7N5M%&I\796+=F)@4=]=:X(PZLV(Q:='D>CTU%<7U?.86)^X8[(\*Q'< HC
MN018PKFCUQ_M=T@Q9/<\V3&N8QZEI-#E#Q;P]+NV(C*3*QSSZ#DMHN?>HCRJ
M5MS+4#*.%C\>.C>>^GYL_!M TQ^#*9,^=-2!KI?:-'@)NS5DP)Z</ .,063E
M5 :9+VOXN,5XAN!QC6/8)@6$*C! S=TFB7BY:SJ JLP66A=TYB5++5$ON+X)
MC%^L>)%T.B6*(71YCSTG3TCWZ"F)[F0$U#$HM6P2!/TDR8Q,F_E%0@\G@;IS
MB^'6".)C,6;N#23PO N;%93P/(_N4%KS[/8--HK]EA^B2Y>WF97A%&-\\FIV
M-<..:ZOL<C;]Z_F' (K@>[876,< S3L\>%MC Q3WP=PS=^*_U5V-L8'A'3ZX
M<'BUJ40]O#8')4NN=P9 ECB\9I<8MQA>S?==W.R[",+T_9ZO<#G..TNHU#WH
M7^$J)1>[SGBP'4:Z<S4=Z6,Z'K<_V_H!2FTVPA332NM[\E]B@2,;O7Y0ESW1
M2'$/6B9J>Z&TMO!MR^)K8%-@JB$8,QR"!%M#.Y6S]YB1I6O:!KHAI2>&TXA-
MMNA4@8K")'V#F@FUN% :F!1%:A>;FPYF.<]^E8D^6>NDDP$E-S:%J]TT<JTL
MGR#PR.>CX26;UH=E >?YB$\?V-T.^JS\\^2S)T'P=Q_E9+(L+^:ZV,(_RW95
MO?A?4$L#!!0    ( ,F$15+/+N?;_R0" +Y\&P 0    8V%H+3(P,C Q,C,Q
M+FAT;>R]:W<32;(H^GW_BKJ>.;/IM9#)]X/NX2P:&X;>V(!MFFV^],JG7492
MJ:LD;+/.C[^1)<DO;"P;R5(),=,@J:JR,N,=D9$1O_W?DTX[^Q+**B^Z_U[#
MZV@M^[_/?OO_6JW__7WG3;91N$$G=/O9BS*8?O#9<=X_S#[Z4'W.8EETLH]%
M^3G_8EJM^ID71>^TS \.^QE!!%^Y6#[5D5@EF6\9@V*+1>1:6IG8BL@ZZZFC
MD;#'!T^EQ%$K'5L6.[C->0V?A&EI))BEADDLT6/_U#@E9#TBP@P&LR9J>*W
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M?^1O-]SQUMY[].GH]WS_XS[?.GI^NGWT\O/6U]\[VU_W\1NZW=[_VCO<_WI
MMLG^Z?[1 =W:V$3;K_:/]SLO.V_W7A]O'>V??-K8.OYTY,CVGPJ](9].]S\Z
ML7WDONYW/N#MO<\GVT>^O;WQ@7_:^ SW/J=;7]^S[0Z\?^_ET?;'_2_^U<O<
MOOH@/FWLGVY__8SKWS?V3[9?O<=;Y.71%HSU=L-_WN]LP1C;^:=7XV?^A'?Q
M[J>]WN?MH]?T[=X'OO5Q"VT?;:)/&Q^^[G_<@O&VV#;9R?>_MC]OD3\^?VJK
MTS=[F_VM773R9N_Y7\8RI[D/+4*):#'$3$L)'5K.!B.D05I3NO8,P1]),)5
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M$R0#.K1$!6.P%%1Z2E40M33 >@0W^+!X<,-Z8KBE6Z<$-Q<P"$G/)+>&(6_
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M0C1CBDG#L5U"'GWP4U1SP*J3A.IT=I4*Q@PFRE,4E+4>&3!\=1CE.#7?R'W
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M%4&%$0F(\O"S,$N!F:W@&X02JY@+A$3'0^K;"5(L2"$5Q]QXKL<E;QMA1RP
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M*2$PPA&XL/GH?$[6!1;+CDCD $T1 P\":PI$#'/,6X6HM4$&WJ1S)]]!)+N
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M#Q(A;"21" ?*SD1K,6\V3G;"EZ+])1TWN7130W"C<0C<,ZFY3ZU_O):12D7
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MQ#JC10A<DW3R3K-&-#Y9$6Y=>MWG7=,>>DG/^_\I.K=E5#=3SF(5I& Z@$W
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MS4HRX'KS&>8"$!U6A*G;4:3Z7^,.0[YP@Z%9N7GB0J\_-B'J^F_]\_Y P!#
MQVV <-)X;7,,O!.R.B+0-Y]#UBVRPH+L'HJR5$BN-WS/N")<]ETIT3P3X[MG
MGU8VQLK&^(Z-\;I;\]C:VR_)\4YU$^LZ"_5Z:^T_4G$ F%%%1+AAK-Z&C%>%
M"QY>9T1X%S5X"::['\K1)%7<Q>'/G_2I@UE2ENFA5 (RZ9=$>7XLUN!!G]2
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MP_7K1"&/A5@;):6NG90>9&2NBGV$<P[/:@&/I(E T_J5KQ:2X8*8;JK>-.5
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M%J@.?_9%4"K2 1;$2>&4*81#%D/CQ:;HJJ[WA3'%^<,YT ^CO!:XB()8YIO
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MIG@ALSQ0&,5TY!N>HR%^^?(.E%@&-A9S08G-:IA*\86#@')!,]1 :8YM "U
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M!C]EHC/2W4CWS;&-*G0!D]EL'V0VVSL5BCBQ?CN"ZXJJZ/WBE#[J]C1C-WY
M=77PP)(%HE =W[/$5AV7]V!564MLVS'5NH%-8TZ=P#P[X R+!@,>Q8$'RP7^
M0M;>4Z%RP[J=._8<"^)#>./,Q09F3%2\.QZ89C,>!#0Y98$;$]7ZJOL'U@I'
M<Q993!0>NO%4=O?!&GHUDAZK?=/JQ2<NES_!MAH#62X_K'-;#2225>+#>E9@
M:XO?V93J:P78NZ$2/<.2^&FMA1:V#@+R(Q&! '=6HL+E*O<WR;>5)H52++D\
M#,GK8_EQ%$:P*+QE+^U3?OS+)'CY8^%*\O1#N,U?+7W1;>\':A;BW/"TX!B+
M#+5?R1>WTI^P28A]08I_LG'+(H^^W([++?2(PNOU/@.KI=CX/O&U/.YXW!SU
MN[M49'<[S7:WO_>J45BVURE7-KKU;LO5C^<W-.COM:%!U=8Y4"GEH05Z&;OX
MF/>)G."6E0 EBLIV@*M:HD@6'17B;U@ YX#%_LZ9&\TW:8.2"@\$^_][2!$]
M' S^N6E$P&%/_72'UIMWOO>#A=5N7?YS:_(_3*^7O-M8_^\\2/=QS2\GH#K]
M?LEFP$(_,/>6W8=G+[.OAO?J2D=I?6%'[>!I=('.+KI I]?L"2UBKY=VOP7+
MENM"M-5NV\WA>"M=H+S#B??:LVY_Q>&D7\+B^SV&>V54_4"B1;7=+5_2>HPS
M'_8"_\K#V(VH.?+G)1?V?/&DV>T!\)"XJX#-6:XGVA=LMQC*%N(OSW_B'I\Y
M$?FE+DQGM )#PG1&RVE6NEU77_P=G\U$)T%LCT;>)/)/G/>&S<$%.E%1&\;?
MB%5 YK?4IZMM@:GKLO!*4;?QW,5+].)?V6^NCU>Y=W-]*?C4BQ[\5'5;G&@<
M1=^B)]D7,@G@1T,^;<#'/5Y$^0,DF!5R=W;I>&$LIE:H%O#XXX8%.XP J_ ;
MZ366C>78%)@G%.<73>?"=!>RS;N;-MN7/6*W[]7<$.,STA:L$^[ZM[5NO[M]
ME^H-]-SICYMR3*5&T]:PV<E\N$K2'Y0#_V&"+KM=W,W1"31[DF322N&>U\=A
MB+Z)N"U<4^XWTU68N!J4_TCEL-$'&MW#1T447PT/-MRQUCO",&WV"N'Y(8'G
M%PE/3-VK$U_M?%,T+#\.K-LYZ ;WE_ZM1\2CH!'&D]"9.BRXI[ZWP93Z76\@
M07*FH_1+3-T60(!%<>3#&K,D A(F$9!\.E\C(;QXG'"S>!8!O2G\SO,C29!T
MNF20AQZ."83BVK <;'$=!+ 9O%PXMOFGR3,XG@9^K!\EL\",@_I!G=!5XU$9
M;"1V@D<C$-)QRKC:6(\<QB<) TLLXV#IASB-Z%N^A(#M3CC^A:+"P4L I06^
MDBV7KB-?-T4RI/W#HJ04RFWB>Y(CM?O4;'A _QTVE!P88:-O>.O"B7#[%)T3
M,Q1>?WUW9;T&L'(OTUHUV[_\C>]=!UQ0PT<6 %(0>K6ZI\2H(AMI'F"-HQ<$
M(6DZ?+;C[$YS()+0,=O/30&8#_C,!=E&OYHZU.T=.67"HUO.Q?VF"#=E3)V$
M\;K3#B-I!:/M4JE!LL$W$:&<=_N)_EA 6I*HAN(?HX+'1Q?T/;Y2<F.)?8+\
M[K35@O6CKU\Y11X]8MF9XPKN9/F2909L2".(QD.MXW@(CPM)IB[CC:22P\I*
M;MYRBGXBZ2 5V1P5()G2T.Y(<A;89"E?6'-VP_7+02&/YG8I&6HG$?&,!)TP
M5UPS<P[/LJB 39H6 (JYH9[6@:MZOG>I7I?D:]!UD QI ?$$4C'P[X!#(E#V
MK!>@%#QF6DI&%0)1+*8W54RQ$<X8ND&U&5]RK%?MN.1#_CR?,J.XUD9X*3U^
M747=V^2<1L*%&1T:,X5>@+#,S KHC4:9P7*SE?%>0D'+6BN?Q9V>71DGBB"%
M)UJ0N@:(^S26#$-=<5<_P^PDT%QXHOX([I%/L07.$1$)3PL&3 6*%W-TO0 $
M0A##QB/V._>*!C"MPYQDB30XX%VQIPU7R!P1Q5YW9<Y";S#.GY+4M-X*#P&>
M/7MFE!C9(R+4U? 3]$'X'BFE**:<*4U*D49A'FJL9,ZWLH*2BWL%F;I[0U<H
MA>@6;V&62L@ .05V/<_@62 >CA,OEB)1B 9M*KP#'-&S+H22V@4^$7OJ>*1=
MRD0.>-4?L1/PC%;Z/9Y>+Y31+- :(58E_I$:M"-JDC#_'2$1B]!!4$[R0/A.
ME%(3:F2;,WNSZF+I%X^R>9A'<PK(BDB)!M/^P!A O<MF,2891?A$[,4A0I24
MQQGB@-P161M:L9U:UM&,>B3IE&F9Y^%JZ_X*N#'GW),#%)##=,:: Z5<S\LN
M1>..T+*X+_L+Y28H,Z=!R6-4+R\C_Q+U N7UP[%$P#8QZGFKNO?+\TG&?YZ[
MJ))[?\0LP!EN2-8Y+Q*6UHH/(T%@+@R%3' "G"L+7!3=*RDAMPY_"3$,GP'<
M;-A)_;13<>]^!^;.RG$';#U\AY3G2O9O-H"N^#*23J=60_/D(=AYHK1$PKF,
MWE'RH*&C"4D-M=P,1G2^PB<UULOEL:;U=Q"H-SQXX*T[: 'X^AU8=/4$G@\R
MW[OF08FS?)O+K.-0SM#%_6ZZ/))3*LLJ->JTB65E=Z[=&>Z]II-G-8KBWZ]<
MCDWK=6B%L3UOZ-J&O&U40F;ZEG65OMW/5>G+F^' JR[/>;F"WJ:7=Q]G3ZS&
M/70Q1 K7K1^[4V%E3=" U^=/ 4?Z<;0YRH!"#RX18=J)]^3C;PL'1\ 7<-FC
M\@> RF#2#(W<6W9[5V:W#RJ1W8ZUV9W6JR3'74Q4+9WG3C]OO]IIB*3)73:Y
MRR9WV>0N5R]WN6-RETWNLLE=KGKN,J[J3/]Z]K#6U>F<'3WA>5LEXPD4A\Y@
MUT3G06O_BD._U1SV]S_=$LR7;G<O(_A,HO,I)CK_[/P1.U.,&:!)_88MG0A6
M_LI#L)MM7JV4YR*:V T^PU+AQ[+PJ8O[\U>NI05-N.MP]&'-6=2P)B($[5GL
MACFNZ%$@SQNH\UKG-@OG^-"<PER4$K20&35VP*?HNV:V["8@DA^6@?]=>&G2
M #ZM,G/]6W+$DQ^(3?D?,3K2UE^*X24, ]WZP>_BU^()C_-I^$H[$$XVMYTE
M&>SJ(?*UP;YB6*_HV4D< J3"T (!=PL*( 6A[@ WZ#1Z);*>9-C(G[C2%P6K
M46"(W9,SX)6 AHI*9@Y.Q=& L1O'YBI()?LU;.JBU[" HIPI;%_$Q<*Y\-@O
M 2QSP%:(/N1;[KJ4V>1'Z+=/7=B:URSD4>32&Y/M8M#-MQTZ?N($OTJ?>Q^P
M!4> /QS$DE/:GZ+\X W2$8+F'<#TAKEX,E-I\#25!FNGU;Y;@=C$]>W?BR'6
M&S4[[=XV*N832E0,8-N*#'E*ADD>$,9!7G2;PS2KHR@E*.,W?]%ICO2?_"/V
MN'R\I3*(7A>M)!+[<K=%R=!S[E)8AYZ8<O(F8BH:YD#%]!2*A 7[[@=P#N_W
M4 1KL,^,B ?- 0(8@L1T@P8()C^(+D')7X#4P0M3[TE3PRCX#JG\XD;#)("<
M6T[00+O95PA-TM/@\VG@W'"/<DZ=!?X,I'\BI8$0X,NI'\@D-2?,K==XT1DE
M>2,BC06[_60NCQ=M+<,.7I%W/]8056)L)"7EKJ@'"L8J_R!/^;!AMS>8")Z-
M'@%'<.IB@IH.Z#/ &R*89\D*B!13>0;Z0X)OP>XNI5^WV1^V__0*S6QIKXD/
MUD7C6=G%-TO5?DVDJ@VO]A<\2#BA02+%(RFEZ3^H9JWSBDI<"/AU[&(T&*1A
M2(FU2M-KZ*I3TJD(4)JK8VH\FFQ,:GB8=@5L=5=#UJ&BMTTW5_%%)5,#0*@-
MNJVL5('UZ'8!6"6%%MA9#'L#@3A2H;=,;OU^@/>8^-4Q5]IL[Y(^UGD:=5JT
M\).A3F""UT& TE4:#)X>!?W@A5$0+XS"_7P4[OU29*><@2=\"N\3GX+PP_@+
M$,%$AU\8W.NU$[T?O"1A@#("\Z0P_IVKM(@>D\HY O+439U4#TELK,GI-%N)
M86&GD%PB)/%*NP;3OT$%6#(W*/N3@-_X[@WM*>/PN4\K&H1#1^P ,]K5;\4G
MJ<=(%&0@>8-ZQ?"_Z5JOH\V=-LEOA$5Q,KTIU+O/R2QN4:51=,+"@S30VE&_
M?7BGM:,^-%G7#I_UY16>%UE0I5G'I'-AUA2F29-*I5+P154/YB;>JUPJE;"J
M4G63@EV!3Y:MHL'L>1=_ST2G2,<7J>Y@C 7DL?2L'L@]S'IMB]Q!T*J=1;S0
M2OS$SVZ!]F#+H*A1$B]8XGWZ5::.3^3KP1LVD!M9SC*CWG6$;2\\9TZH58':
M/JB*##,:*T08Y:3MS[YW??D-S?BWZ+%$DA JP149^/3-3SZ^!U.@*W2\DI6/
MY41*Y*/BCWFKPJ6AN7P;4HXJ[X!R]RX!/*J&0XKGU"4R22 &@F4FI>(@=0AA
M:<?V31-NN?0=I_Y@K!_):..XX'O7%S?(5W2NBU0W;#8!JVP*^>=AXINS@!]_
MXK?65W_!O$?FX#U9]A]Y0SJK<.HT!^W!GU8 )!A<#XB$<VQ(D%L*)-!!OG[-
M1T^8TDH)7[35FY\G]-T2XX.:=?2J%.S5)'J:1$^3Z&D2/:N7Z-DUB9XFT=,D
M>E8]T=/D;)J<39.S:7(V:Y2S^:0980(<;_G2]2DP;,)3)CQU*(?I:;9=)']&
MCI.+9;O!'*CA)X81TF:PVH"Q*ZVKRUM^PUU_*2+3\-W[E48VWP)*? KE]BD?
MQ DM=5W0,T]1T@V@K49)]^:-U*JDF\CU40/+&F?HI,WM6I??HFZK]G)-*]-R
M426\%[:7$YU>@%I5WX;GVFZN4J)>MI[+2Y&ODVQ752 8Z'HQ:/;'V=9RU/<&
M:;(PD4!#GNJ/M59P0*%@);E362X9@RH-3D"6GV![CI:4Y?U*M.?8298WSZQ/
M_-J/'#EY,NWGE\>Z5-OC>#'EBI)W\+J!<A>3>XEZD6*OPTP3'VHD)Q* 453+
M_-.D&Q$FZB1-]YK6AQFV>0*-"1M,85K,=<#%)AS,I&#VG$]%;G<83[[+JX1R
MO*DZB1KGWENAZ$%,2:<^,AIR"/P <[Q#$9G6[B+*AOCN![+=H=JA2I2!%TQ
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M.6>7WU "WC[I9=T)..6SKHU-I([1INO)4B!+#QLNJ)78<XYMMHG)ZOQIS.O
MN=4KJ<3YPZO+)(Q9#TRC;L*324(E"O]09NOKC<Y!UL8L51DW9W^*E$A/)HZJ
MC,R(/#\.S;'$(<7B[B'.%X4OH&Z&Z-ZA?$T>BEY3E.$IRERTO$]M:VD**%DX
M<K4L$^+/\4I*'J6E,6T3$!^B-4BYFFLWIY 9ZX2BI,A#]R59M,FM^"TCO53:
MIA!A&^<@XRIB03,^T>1GZ_G99SN-2ZR&;K23G50MO0@K@%)=.I\QUR]=&0<[
MRBY5?T &X@D,QOM+_]8C75O)WZ2M\/W3<0#2,%]@B3'';OJ8\6%3-J.JB5&M
MH5/]4$I@N%EBX)CD\P8^"A:$+.?&:PF>^C,Y7("E4JU4]5G4((&[0%G,<12N
MS3GUI5,[<)V%LV=M["BPO2JP])(.III)16A00X!Q8(P;1[*GF^K@;KO,60#4
ML;@-9R[;?DAQH"G<@$X8!90K:<TXV@'B6<T.%$]+=VGVM?+91-F?@!Z,-0H!
MQV: >#V_QZ<D,J+[I5"48+?"_B252CFI]"'3\BEQ)O%^*BZ$PZ'##7.RZ=WI
MP![I(+9-,_K#4*1V0^GV8XJ*!MJ'29= Y<]4J%[Q,J9SECQI@JGR(;V!K2);
MT*3 $!7.8N6PUP<-J=J>B!1X270/D*:H9E(22/F<X15V[,HIY^@_Q9[WY-5@
M5+Z:-CP%'94'I.W!-^B.GPHG*0%\B9%9ASH3!U9,YJ7&.J"3LFOI,-F+:-HJ
M%6AC3*WF[>--+KC)!3>YX"87O'JYX'V3"VYRP4TN>-5SP8^6UKVC=O 4*=NC
MSDYAYTZO.>R4"SMOF;(]'HWWG[(-RXZ+?VI2MJN5LKW.(P=IMU<.'GO-#:S$
ME.FGS]098N;&E\ 7G3W(V?3!P^BM]8W=E0['KZ?GY)_,9.R8C)UM$V33+H"A
M"/@EZ7)B)+;T):39,M<>E?%3 QF11T%C?%SG=^P!0]-\T$&5Q$+5"FG4$TX+
MRZL,0WX'A_*8\O722$YNSST210LX592,(E)+Z:-;4D^QK 9(NQ.RY9*CMQD]
MZTGT-!,(U<Z#Y^ ,?7Q3-1G4I9!XI.=\:#T3Z8 .SAGG3,Q"@I/W6^@00VM%
M 03+!+A,@10-$.C4:0A9^/DB'0^T]-0G.-)@WMD]B0ZY70&"6PT=F>05?#+V
MM*/I:]<OAO K%SW\'"$W\3 !C^+ 2T:#_M*\:EHS/D5'IO4]#IP0<VD(2#<L
M</PX%(]0XZ7, ^)>4P\!X.#%7O:)IO4K^DEG_);B,LLHZ="$#*'U>6(QCM["
MT;_LCCRE<33'MDUX>R)*M-J4$*R*UBB9GJ5/']*>:N(= 41X*WVZZUF[-":5
M!91ABQT/@R5 ALEMXX_U/5""L3UGKLN]:Z"*$*%)GNH@R^DZ=WWX>I7^AH(7
M^#B]2[ L[#4* +LSFL;FV*J35II+)\6*.+&/&2"]XNY2\+-[(2B2MXKF72'Q
M;<CUW6#6 IN"' Z1T1CU;J7]<?HG)90@M5 @1AY2]KJJ>G3Z-)O1K@[D!@;@
M_(&T(=&?YL'PL=Z"<U-#6I09=-4EUGV+Y$),*8)ICGV8)#GDM[U=R\J1A1D;
MWJV:&DV=*4EVE=X?!VD6EIYQ(;/4&\@E:0.W*4Z_BQS9.D<4!J1'R2R@1.*:
MY)0# KTH<"9QVL=7RS'+Z0,\4RP4!\"S7#!DWH-.*&\\[!SL4%F+_;N(NRZ7
MKB-?1W%9)7Q(;Y7;U&0ER IJ"M2F!E7M84/ED(WPBDZ' Z9] =^\_OKN"LR3
M",B)4=05!?+JC&+,;+G&(L3,W, :%I]DFM$*0M)-C13QV>YN&_@N?]0H#3OK
M==).L;LVCJ;H]\Q5G0U508>-Y9C1+>?B0E>$FS*F3L(HSK7#9.Y5>=6T^_*J
M&5GGW7ZBDA60EB2JH?C'J.#QT462!)Q<U@_N$V1WIZT6K!]]_5K023E7LN0U
M5T8^95*2*2U^(ZGDL/)6#9H%-EG*%P\T:#8-F:M+>H0YZBBJE8]I"1B4QJ[P
M*ONA)AD9:9':G],D]Z0R46&%R"U)U%#FIU"[7UES_Q;'UC:*5%5Z4M>Q1;E:
MJKJ*#-Z,_27,3U&'IIN3&U-P<15YPEKVO*NZ?BT;@O^<YEB_$?GPM6.;@GFF
ME--O/9#.OUH+H.RX]0ST1W2*S6;_-Y(;(>, 07OW!5S<F5ZRO=$H^2!S-<NZ
M!V$M9&L+/L?!^LJ)"%$WBU))=,F03>?2D_JFJD9&J>)"DLNGI+.(1 3R]$0V
M,$TO-I6='['?J<*H;'D(WFN!O#YGQ1X>NH*[*WUX>X/"/KQO1<D$U0UDSHRW
M5_:(,RT+,FF+'=*5Z<#ITBJZ/-0HLFHDDC-1(E>0B4NS@$NE(S5NA!HA\]@L
ME0\%4M(%.9W!LT \EGDLEJF?1\_=P\"6N"#5+D3959[O,ZFAUBVDS)42I3(]
MWUFHW<I%_M4'+X"TYKEV4ND7ST5KBWG4((4,VI1FL) 3[%(T 42MG+AM8R\.
MJ2L,VC&S0+1H28E'6<^"Z]2RJXT)4IX5'6AS7$.@O E7-E^L.;F5AZ[D4L(M
MB#7O97^A*IK >/&P.?W+<]2'+P 4Z(S,&G!*'*.E@U/O4455]:HXP0&X)D:3
M8]4,?'FN6VL7^8LJL:<:-"!5Y[Q(J"\I_$G:) C,A:$0"0[V?(B B:+[#:6V
M]Z*>L7X$_J&@T095C"$1"W&N1/\6A7-X8RJ:Y]+%.5-ER2!/K5N,5E ,8BJL
MK0PZ=*;")S6^RV6PIO5WI?1N>FN..X'\T@]7 5)+[QW8=/4@G@]B'W3LH,21
MOLWE*T,MR+3I_D@.N^Z55V#?8N?:M>'>:R9B5JDH_OW*_=BT7H=6&-OSS"0+
M>>%00_^0:V]9MS#;_5P+LXPW%EG5Y3GO58#;]-[NXRQ;72V(5J00J5NW9'VE
MS;WT:"4P)%8WYZM6$J44E C3@@UL1)Z+NBU<;0''6A]4_0!0&2363L8]H45.
MX3NTV=[$LH3G'_XD)#_O^1E^#O\ZN] ,]A6-:;,&%SJB%)@7U/B*JF0JI/#M
MF'I#K4:A$V+(=B70M>?&0^-K"+@8&!"=Z9+ZY43#)"A(YX1UC5-64&=8,4-0
M-IHB U-D8(H,3)%!38L,!J;(P!09F"(#4V1@B@Q,D8$I,C!%!E4J,GBF>>*B
M!V*23B5M[J;U7O0IVSU$GN23)KFKRNB7[["DASKK9M!C.W$H<\HH?"4"4,41
MNI#G!^.SG?T.%[PQ/;3VUT/KR>?59WIH83?D3NM5TDF+LIC*=].BG[=?E>^I
M58_<#^-^,NXGXWXR[J?:N)^&QOUDW$_&_51U]].T]/2>;CM10XS/:D6!>$1Y
M=Q]^.1SLW[O4:0(F][]LMSGL]XS3JHQ >G<'M.6E::=?P4X#:\5U$OO\D^]=
M_NWUZR^:(?-15$\?;!1@;9I)[#C!JU,N<WT_N*E+S@GZ9\X^ V-00W0X7,:*
M_BHJ),^27O>R&DB?0$@YOND@*JQZ9(X7:J6>LNQ?)A%1BK4?Z2TT<]IF(GQK
MF,+SP4L\"Z(K/7/O_TMY-G&03C-,,G92&.EM4Y<!%WE8!7"A+-ATYH6GR#$'
MXK*0W!65@?R&N3%3*:P\H%?"T@V+>]=,Y-REBU#BD!IXA<U*@2TP'X8JP# W
MQUKX(>(QY-0R6#7*QV0?CQS,F;;,*KWP%MV#KL-O4A\F#NY0.Z9$'^Q<G#IH
M8 \JGUZT@A5OI_KZ[#0KI"UJEH&#:S E#H"7.A<;*BM6G5M5YPO?V#V=S?>N
M?4280A:5GJE-/0SP"$O4;CCVH0TQ6S0S[F[!H\"Q0^E*=<*(ALC1R!1/FS!"
MSMBT=D8F_6)^_8T84;(ZKTS#E&C8(>:581(_I1AC)M,EY58"Y<F>N++"@ 6*
M.G6XD&^-10H^A,?(P3.MI*]N! 6E# I*E84:&L\GH\:D&U<;(D&9V?@+D:LE
M]RD&R0 20P>XEL8XP)9<6"IY8RS3(JFA@?B9YR2%U!NV*D<=B5_'R92_Y/U)
M_BNCBGAX;RS21AOH/ <<8Z9U0+O+6?UA29<<7ONY0N/#OT[2 M-K2IN8FEMR
MCY69L'U80(QF3,<:8F?V68P"0TF+Z59R^) 1L$')"UPF(LMJY5.ZKC\F*9Y*
MB(:JFB-$M)&4OQ.]WXF<P)SQ;ZE]"4F1M)Q< 443O&I:I[K410MLD7V+\N36
M2V8!)S).#BC,J>9*;CM5 2$R6F&_4[P>:$8G$=\/6V!!:IN7J,[_T,UO42T^
MPIQ@+_KALCTZ=!PV'U,4;!@<P\N6&_[) *K=;[83&LX/3OW\X?WGI/2 NE?@
MP*PH?+J8#Q42WLDRADDZY8M&6>+M*IHX8>-URV4A8AQD70#_P#ST\S,\T=D%
M4:I'K0.2"4R!.ER#LORIU05\MV VCT7L'&[!&%\#C"&Z[E#5$8A8900$F,GL
MID8"7;.<KE7U.A?'%836N:B]D3/,@-M0A1("%G0^-\;>#'3MV$"]H-&@FDC]
MAB9\SF[P5G$6"]BM2/''/8C)%5IC$O7RBP8!C;IJ4864=H%[4> +10%V(N\U
MAJ5 R;K8CXG+^B-^I]5R%)&&$"::(!'*#< -H\$42)8:1B@6TK/0U^\Y62*I
M]?!??X:)1@E"70%0H9=@F5[T2ABM_7"K&^S0,N:;@[/E/H&Y]=4'0CLA,=-K
M]C=+F:L8@(VHO<;+!&B982,J'-OQ=')&EDJ%&NO>!G!;7OJSF:1WF9$0<,&(
MBNE)M\>TA#"(EZ+.14Q  8JG-EWJLOT'B!-LH22+;.G4P ]@H6#=U^LP])5@
M47?EZ^D-ZGCJ/OV(W D'_N"%49 62("4>_WZXP>0<C^CL+&ZL"4-P++YFN_&
M\#PU7^(N39\@W>B<Z5M!6VK)[-]E\H<PG.0T0V'Z,Z5)H#7A,E0_1/V(T+;I
MQQ=T@"_8,C .J(^6#^(*$T6^T-K2.4#=V\C  =%'.R4KB^HS$I$O;"T!48*D
M:OB1D39H2KDT7#RQNF@\'?;DT$I="*BIF9=G+:UH+5+4I-*L.L)L2U[9J[RI
MDB!]MLH:I;0D):^)YITIC5J21:KW;GI"$1O*[J*!<J&*3I'ZUE%PH EB!XZ0
MI?)X"Q)]TJ85'@4L,_-!DJ$6AE.I9(\U'"0F&R(NI3E>5 :=5G&FDW]D?SFU
M2:I3E*(HJ^CD6/C9POH 9).?=H#0N[*%S!4SDM?1([TR2O$2M9;^)+11?";C
MC#;4S>ISZA]T:KU.W&O8(T04G1)2PC^+CICH?U%%?3$)M 7[G2?]'>5,IF1A
M]"LU5K%,5:RI8:A1YPH<%-Y$&TXP0A?+Y-$).OWX9012K(%(@&L)#I^8M$WK
M*[JC0NI#J_(/DSEH=*50R7N@6NJNW 0Z#<K2Z1N6M*<"Y%EO )I;M18S<N]
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MG$I%J3:[345 O6DRQLVAGN_)L0/1=2R]40O@MCHL4"6"8GTE7/+BSL5OX?\
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M )+V1BR4\VS'Q7Z93L07H86? N3M6+1WBD-JI6D)(, '#/MH7G/,H^Z,>Q:
MT\62.]M?P/'%JF'#NIT[]MSB=[8;3SD<T8^ W #D[KW8-R#<"KD=!T $\'VR
M5:!*?P%'C@"LTYB  !\[ 9PO<BZ3G_+9C-M1"-L/8Q?3N\4*?AR(PWH\$K"=
M2?3 B1U_VK2V1E<",PW<EA.6!U%_,X@<;R.(Z-E"?I>4.,02Q'6&NG6FT5Q>
M*?JOY!W:2G_")G!?PND*?[)@P;7CJ=NWFQ4L8O)\N2NEW$*" 9+MTLT.S.RR
M9<A_4/]XI<*,CD=L23]ZE7U!CBRA]XFOY7''8Y!973RQ#$++%TM@- D8*WJ*
M^*[;:;:[_<*O6\UVX7</+-OKC ZQ;+L[++6L#,FOT%F?[HJ"*'VN_L5Y9]CI
M/9R2485U'DA#V#)C4U#8_FNAVZV226:'N1377C_,-]U:I2N7'P%7M421+#HJ
MQ%?N:FL#["45'@CV_[?IU8>%P3\[3W;JISOT>S&AI=/JM%&]6%CMUN4_MR;_
M=5%4:/)MO$.EEK_A-M;_.P_2?5SSRTG V>^7; 8L] -S;]E]>/8R^VIXKZYT
ME-87=M0.CJX+P%&:+7&<;96!/OQR.-C[K=WI-$?#XJ]W7K;;'/9[VR@#Y?/S
M>*\]Z_977#;Z+2R^WU7RYW"X=!(=2+:\NP/:\M)FN%^5T20^ C5?I>99[^$*
M@*_@Q1\Y"V-=>7]05WD04.75GNV6RA$W#[#F  V.DW<V=*OF;"C3XD:S* ,4
MA'>6_!;I] 6(A(XUD08ITO*+?G/033[!10,TAQV/S.29$X21]4?, K@2<(&9
M=MGAS^$?K0::X4NPQP&P[GU#GV&&:\@A9VZR=V&%:RLUZ#FV !E"]=FX:7ZW
MY%[(\31P*86PW.3>8LMEX-\Y"U@>K.07[7XK,:ZG8N8'+A3- \[SK7M+&/:=
M%EK?Z&-9>Z^L;]KXWFXK][V%/H7TK;:_6()%G\ &WRB\-2'\S2+KUH_=J35G
M8/M/.!<(N?: 0J;6K1/-_3C*AZE$,N'$"0EZML1!"$3MS(# O0@VK\XEO"*!
M?^.$^'/TD\!7_H+V!,2BG2O@"X8L3 0@J"*92=>TOL$'2'8:\$)L7NF#%(SD
MMC?N6;B<7G131PG196\T2CZ89>FE@/*:5I4=HP]KDVWT)%@5DCFTH53F%(L<
MYH9^*G=8AI$2D;(MAVIBA-%;_"4/&#G[R+5GP]GN4?EH6I_C !@:=,'[2__6
M(_$%=R].^['">!(Z4X<%]^E.F 42?G:9/J0D):T+H@]).*6W%H";17'DPQJS
MY'['S[CHY+H,0#0$ '9]SSEB[]L<6'/#JY5/< J_\_Q(^7'1JYG(<M^C"YW>
M(KR?\#/T1\9!P(G#X80Q< 1JS:B<Q$'F*)D%9ARX&KY).1_6C.) L" \*MS1
M"@F:),E#"/E:88EE',"%R\-4-JP\"-N=</P+4>B@B 4LTBM!T+J.?-T4^9+V
M#XN2$2"WF9$&[3YY:@?TWZ&4#.T12"#T^2Z<B#RT)+V0\M[X@>^Q&R>(0^NU
M,VV +@<OG-'OWL&!_85C6U?",7UOG6.M7J?UZLWKK^^NZ-_M5Q?6:_L ?>0>
MC P2,S8/8.:6$P.(RLB/8#%$J&+N6P#SBUXGN0Y?67/_%B=M-0A+BA+PXM C
M#8FZG++30JK+P -PB[FN;Q.%ONAJ,09Y_:B7 Y&X)12BQ-,>JGC$5$0+$M=^
M^NX)W?B^)^\]H2SJ&@)>\QMDQR;^MVR7.8O0@CV&,<H!T 1P""S^6! [21/!
M-;H$3:$AM8:BGY*&UQDD\')")91)H5L[;]-Z':Y>Z$)**,$@I8$3$J9<U$,
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M*6=9U3]@:3\6%V=$3VD2^UPRE(_.,CFZB.D "\!GKL7ON"T2OOW9S+%QTC*
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M@A>_/@<S3;8:#+, W]H78M/_]NGKV!.4\UV5G\&"%1%K;=#)*OELFOLHSWN
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M4K?G,E#C^N[;NOUJLEN_3/;J<2\\OK!3SR8;57G>,CQO-L9/2L=UX!(R"8^
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M4198T-2!-3XK,SJQB)E<,A.V=L6Z*BQ4\6S8K;T&PT05SW6+YTRP&P\Q:9G
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M03F2Y;\T0=$V24A4**>HU[;P$-'VZ.**/JU G[::?2H.K89#4\N.4"8KJH%
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M TX[##C/>_[HI"SH[Y-6G(]'HT'7G8RL.XH'_8MDLR+>2HCW9I;\1(XL6J&
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M9_S-^S^Z^T_?'KX]^)"?+7_?P>.O>\=_'.V]/SIZ^_K7=)Y:4 K02.XH21C
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MK 4/KFIP(^Y<Y;#&PENNL3Y@5K]SB )F]^Z/F Y%<BG0C&218: BN7.7\=[
M6D5%I1:,"+^QQ:_'4Z_(T</#12+5SP5=/ODT/[GN(7,[K>^M$#NAG_5(&S1"
M*.%Q3R!D8@DULKPTPAMM//%<:VNLIM1PKKFR DSRA;G*Q4XL%&0!"K+W82JC
MRP8LM2$<D403XMDKHHUUB#I"!#$X<9LVMNB,BL@+EWLIL53E&JMVC54&[-FV
MY2* O73CL@#V+0'[4K@:(U%IZ9!( B";*8VL=0QQ2KV/7"JF3(T@>]TC<:K
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M_6Y;[1R%"E9./S<GB/ZD5[G[@+QU<^S&U-(4\%D(?'8O$0;NE>=8H>@Q@$\
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M&A0ZY1M;0!X+:RRL<4588T&?>J//A'?28)40)J+@/0.352BD%:.(>JL2:*#
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MN-!SU>:<W#</<_1TPZ]<QN#-QB?83;8#>^)BK:N+MF/G"^Q?$(U^!).J-1S
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M7)M#K@%/GCU\PZTSK6R&FVCTC/D1JJT*-Y\F3&,M-0Q@KNZ;!7<\7;!*\)$
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MV+<$^Y9@WZ<<[+ML#/I9O.P2PBOOUX%:E80$J_TD'ZY4)2(K-_^D^<S.1;1
M79RHS0]C)^K[5O/KM]/FU\^LNF:^SP[<Y^O!T>[K _C_H]C[])GOTI?DFA/U
M]1NZM[]-FW#-W4_O?C1WWG_;??VO5O/H\^G!$?R__TT<?/UR_GG_K[2;/_?E
M[ZBM,#I*Q)A5N;^O0C#?#J7HN*?8X30[AK#NL;$TQQ1-;8)A.,K1<;M[%F/C
M0SZNSIZ'>R F<J[Q/6C0[0=_&,-).^ZE&P3C1;<_J$W0^:-(PO;?1"0BN8U(
MA>1 $IS.Y9,YTLSAF+315"\@"?7Q4^?(EM3-GK?*HS;RP.;@<+A(CB:X*B5Q
M+"7]L90\GY/?94(V>B7;]F+Y'J0;-<L=:!Y7FT;QY?,QMBGFY&.+W9)Q=C^#
MI<L@C[^D/F8>[\)PK]2FK-?^80_D81<^=]AOO+P4)-Q@Y-DEQGA/KJJ'K64S
M'%:(OCL,5GH.QD#LY4]M;/W6ZC3@9NU\)'*M=O/<WK[914EJO >R<EW6T][:
M1UKC69OM@,E5C!81CY7O8C+FF&@46G1O_1;K5"-LN14B5Z0&V)TK0!I0(0I;
M3Y*V7&AF- _,>)L4C9%%/63V<-EY>[5<F#45GR=UJ>UU6T8_K.UU])+O[K]J
MYP"B@YW#]L'^^V_-\VVQ2]_PYOY'<O!ZES?A_I\_O:17:WM]WO_R8_?3QQQ
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M?-V&[S2/FCOOSCY_>M7ZO _7?_W7UX/7[X\^GW\[A>_A:PF51W\=[<*8=G?
M0J&?<7/G7X>?/_WK$)[EV\&GYK>#UP=?]W(;W:_OT^Z'J5,:!9:@$EX@27E
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MI:KRFA04:2XUBBI%XXEVT@)98')E?9H%+)XL6!1WP\+ ,-W50W%M1$!1@^W
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M48$&.6PUVPO#8#(*B'>F#KP&TP-Q5R_"/8;M-6#*>@H7%*8;[:6Q>PKO[J&
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M.\>M=K1^!!LR6!HY'XQ\8-HA:.,J*Y#K.;I;&OQJL.'K' QW/'G9W9_"=Z/
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M_-]1-/_PV-UA%;L;W1Q>_MX_NH3G!J?AZ>U!>/1"$1B#G=[^?GDX>!\??SB
M9_<_'\_'[BX/;@[_>$^/8(X?+]]>'EZ^"8]N_X+Y7EP>_G%X\_'D4WR*\WSQ
M,IZ)W9W <R_>G)DLH[%6/(AC&P7,<A+PA/! 4ZI"J42BE)I7-#*:,ADJ[*05
ML3A+96I"FR2$J=0()N#W!@R],?H;BJFY2^W8).OB2ZWB:*VH5H*Q;%>A?()
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M60*R_K(V!#OD@IG^5=(<F"^B0B1"()[%=(^Z=YNWBI\@6EK5Y%>X],$;GTZ
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M9X0+GC*J4J)5%H?*1-%6$?@.IRJE5IHD,HC3) U8'(:!M(($J<BBA!!BA4Y
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M<Q@+'Y2Q@B9J^0(^ML\"+K/5T<_QGPA=6CM0G%%W%W8T0,.\2#K]3A7[:[2
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MSF$L?%#&"IJHY>/(- $4#C2TT]LK;G*]10D?'BH,5+0EG!C//!SXT&FWWO\
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M>%XM7([\Y41)6F\#J%N,(.>Q!YW >.1@8I##45!->30B5P["FTRN;6:)%8V
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M_WWX>_2-"6Z89!%1&@GB."ADA.?(L*!RP4:<F-C8-G<<7(RL_+ZQ.DO>7!A
MS"W+^5:"->;AM 0C]J1O)SS1PP92;.6[:??Z^+#OGI0UF ^==FO@"=.MM_^
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M"9U+A\ZAD<1*YXE)#O'$#>+.!F22EBCGC">&"\IHKM,KIS.3KRB$O78WJ#)
M[0ZTT93(%$P4WF#.6+34,":LU=([SI4OB=JSH\U8@)JP0)ZCXL@$#I!C,4;
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MQZQ=41&:@D2@2+#L>BJ1B<D@PA6!/S!CVN;R*9M"3F<%7A,_KD67WU-;TR8
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MZ=Q>.K>7SNVE<WOIW/X$-7.$"AX3;97TG'JB*3-2.QI%(%89/C,VME0$!HI
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M:LRYG1"C'9$"&1%3=FZ/R'&"@?TIQPP+).2"K:5S>^G<_A2U$ZFECD21A A
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M.I$]U:T6(';;1VDCZW8:II=;>(B,"8G#>9M"?K%N7</,N-OWUJ+]BW V'_Q
M R^_BXK9$G;)+?<S+\?I "BR=Y&_\SL-?=[I3@L^G>5>*@V-OLZZ(;'Y#FR*
M=P:^$VG3[G6CWB4T*]SG\8?=C[R^;0-N#Y^$[FE>1Y?M0K(HW,5:EV6-$'>J
MH?6=FNWWUVG>736X+CP>W >,NVAD\&O==5NH10H7SY,]VYWBCNT@G "O08?=
M)5-GH3G==I3!;(#61KH'LT3G8 #M@3<ZSKI@A@Y=Z$83+@Q0 <-SZHKJY+>]
M'EJ>/>C-8D@_[6Z'>(B[[K-P 0WF>]N:^RZ#?P-#7QL[HU<OV7&RZ.@J [+*
M@%R.ZU09D"5F0)(1KM<J [+*@*PR(%<V U(L:P;DZR<[AD-&S&?*=4QJ+)FU
MXOH3M>-Y3<U8Y/W)UM(:C465ZS@)(-WG,FQWVED6?;R+MMYOI>YJ-5,@7UP4
M95(XFP!%REF.)DS G'3TI\W++'N[M(A,35%C4I6./9+5L"@_ 5348L86G/]9
M#-0+)$%."$W[77<139W>.0',K% ?!)?K*-_X@RTOGG[/VV_W#-TV\[;VJ5M.
M.&W7;70[W6B_-A!2-Q09--N<7Y"#X,4W++GY+R H;B*71QF$:_;HM]=M2#_2
M[?\\O]L2..PK;^?N7>1;%HV):EL&U\JBJ/2KC.R4#9EN9 E_D>#$5T:8!:=V
M5 @SUSS$=&/S0+=TH4/^?[-HIY'97I9'%(03JZW\P*^12P3<(]%VNU6<O-WJ
M"?2:W?PCAY>N:$Q6(=2*(U28&2^3$?#* $4K@%IB@&+QQN91R&9I=/,S[AQQ
MX(7F[=\!L)KM+.BF]P,/#G3GW'6CCXWLO")*JPY#8?S)F\"A.>/9*AQ:+ [1
M$*77ZG;:S2*6YZ].V[HTP$Z%,:N.,?1YC)G&(;@8GU_EUAMVZ^W7HKP<4N73
MJWQZK]Z0*<!&;&Q^<"?0H'P%<6$8JB5DY9<0&%5"WP)-Q5L5O"PSO*B-S7SG
MNZ=MB'ZOD&75D04&E+"W@"S52<$R POG&YN?6QUWTLA"$DT:?=)]Z>"B2FF0
MFNEU&MV&*_;'G[-<>K1/<BH<6G4<"N/_-G!HS@.!EQ.[G_"A=IS7^0'=Y\L@
MPN%:C79GT%KG>]QE<P[4WV^-"NA:CZFY2!_QBS_104AA_J2]@\5C\!2GFH^K
M,'KY?.3K-!_G\296$_%U)Z*H]@Y+O'?(Z^;=%Z.J=@(KO1/(1Y/->28_WXE4
M9:\+ME>UL?D).E5WJP/NM;!8&$_VY.9]P@2_5TQ%R_4Y\$SZ'#5"%I!<*VH)
M+3_!+5R6C7^[G%2T%V)PDU3C>TQ,5^5I1M/1>KL;Z<O+)K0%IO-< 0F3)]V6
MD&([3:[NZJD058)#E>#0DU98"0ZMA> 075*>6@D.+;(/*L&A-18<4ANWWZH$
MAQXS""YFVA(15J-Q^<I '-<H(>4+#L&;R61\Y\T+#FWU15&G%CM80IVAY13U
M&72,3;S=F%%/>6%+2/XD?PU4B@J*MAWW3Z_1Z6L,M/U B:FHW8DP_R7]UUT5
MJ?OX@=VK(%)\XFY+26%%V;O^]4*T4"?<X51G4=IK7D=6]S(7ZET%]=^B?##<
MW;A<AK>H'!R4<(T[U4T?ZA.'"^5.K^(#^94[KM>";^47U+WN:;L#3YV.E\U]
MSHFU*)<5['PDF06?68W'DSF!IKJJ M1?P&5)34UXV?)/!Q9XD/#:7+XHYSV!
M/)%:J62DE8B9TEWWZYK%@>TYT^GISG7$W^6[AC5[O/?9^\+[<+"__9^MW0_1
M=BWZGZW/>P=;]?HL@0^OH-BU7-T\FE\>-&"U=\V\=W7/7^A6Z_5[=Y4Z<$P5
MT$E4Z-A*X?Q;&.)GH.C/K4^']>B@%OWG\,.'K8^O;RAK T-_Z@QV"J%G S4?
M:3W5_'P:@AX5&IZY8)"8UA=8G2569XG566)UEKC49XFL.DNLSA*KL\1E/TM\
M;]KI-?QWVKUH;OY_4$L#!!0    ( ,F$15(B\("8QQ$   V[   0    8V%H
M+3(P,C Q,C,Q+GAS9.T=:W/CMO%[?@7J+[W,1+8HT<^)+Z/SX^*.[ZQ:OK3]
ME(%(2$*/)!0 M*W^^BY 4J),$B0E.50KS60N,HE] +O8![ $?O[EU??0,^&"
MLN#RP#IL'R 2.,REP?CRX-O3;>OLX)>//_SP\U]:K7]^>KQ'U\P)?1)(=,4)
MEL1%+U1.T#]<(KZC$6<^^@?CW^DS;K4^:J K-IUQ.IY(U&EWK+=O^<7YJ#,\
M.[7=%L;M4<L>M9W6^1D>M4;MH3-TNTYWU+%_&E^<GEJC\[/S46MH.=#,<<_A
MUPENG;=/[&$7VZ?6:5LC?147PID0'R/H6" N7L7EP43*Z<71T<O+R^%+]Y#Q
M\5&GW;:._OGE?J";'L1M/1I\7VK].N1>TKY[I%X/L2!)<P=/EEH[F,.P8>_0
M83Y =-I6IVLEC14J:D!. R%QX,R1!RP(0C\?P)7\2,ZFY @:M: 5X=1)TW'E
M'"Y-Y/@H>GF L)2<#D-);AGWK\D(AQZ A,$?(?;HB!(7E, C2LQ+#5*O)>9C
M(K]BGX@I=DB%<?CX T)*.M2?,BY1D $=83'4K HN-5BK;;74 $;RO&<.EEI)
MTUW+ !T13PKU5VN!XO!5N ='U1D(16N,\;0^$VG B)'X27UF4LIJG9^?'[TJ
M[2MD(ZM/NGU+_6Q9G7IDBQ2S.FWXJY7 ;8*'Q<RKQT,"MR8/^?.M"BMIR*\1
MH.+E7/%BG53D)7\.5QR)!$"1/:Y#4!#G<,R>CQP6!I+/2B>#, $F?]2?!TLH
M74+K\Y$ J1^%]'$0,*FQJ"?QL^F4!B,6/8!'2ILN$I5Z)*/$XF;<1LZ\U?^[
MP-SAS"N9Y$=3SJ:$2TI$VN5H!!-.1I<'X'A:B5W]W</#0V D:9'!OSPMU.LC
M "'>_:(C":S2U,L# ;+P2#0T6]QO!QQ,S7X#B!-Z6LK_Z[UWR:AN[P&$!O3_
MH?-33NIV'D $A#.KR%[!/\%[1-W+@RL&L7(?CX$]]?S;XUUQZ*,)+P 2K G>
MA3P^MB$<A?]0:Q%>MY"&1 KTYZ.W &]0A8*X#\%'_?MM3V/@N(D!\,WLJ RW
MK%>Y8/'#9"2-XQNX) !@^"&81UV58PR@-SH:%6QT@WD N8FH/OY5$1KD8VGY
M=$ H<T@MH!@U2N->-!&(C5""?B_#Q9!?,1]Z.($V])G<0;;IUYA.*^ V2U89
MB54DNT0)1:1V7<J?L*=B_L&$$+G>%%W&9)9@M]VVJTDPQHHBM'MII<:XCSET
M;T(D!88W)[IEM&8YVI"BK")']&&)RH^[+M>T/1Q,8&@FS',)%S=_A%3.-F9J
M<U";Y7O<;I^L8FG3A/Z*(E)[&:=\'A:36X^];"XH6F T2_2DW3Y=R7<"?J0)
M[) </V%!86S[J4[@P!V$OH_Y#*83'0=T! 8LD#U'KY= W-B' 70@+:HJV;5H
M&&3=L=J6%64H5#@>$R$G\(<FIP2:)HB (HI)ZNF[((H65%%"=J\!E:3S9VI"
M)8V =+SS/AH!_CS^M4NN?!V!?<6< \0S>22.VK4!50@<BKU%2["_@0M*(JZ)
MQ-3[4]1H!:Y,"F>WN_9[*=R<U9]0Q"R:<YL&F//[(_H0L[Q+*OI(A.2A(T,.
M@P$C<>-//38C9$">"8\VB:II53DBLR^R+;T:LZ0(2SBU B18T1SM7E:+(7["
M0Z^Z.ZF*SB2W;ONXFYW 5>2&/D3H]Y,M->(]!PP6I$*/Q%,AMF2E$%=,R+H.
MX+W9,%O\$WNUB8X^)&RAF"\D635(S=W>ON=*[I[B(?6HVJCI"<' /<+(J@J@
MJEH"@)O6OTWR9%;&4UNO%*^@C"D>T8+)J':J$H8%JWO-S)4E!' Z?MNT=KW%
M:]:0,UNO1-?7D(3,3@KW,V,P83T/QN9!3@B_@YX$8PH.'^9*C8V$4CSFH/+<
MRD[O!*66FT:*%EA1A'8OJ?D(UXLI*V(SAI0@LVR$4$5JNQA2E@VX*H=U0X^P
M4=)R"&&=JLQ20S4@8[6 6]/";I2FT?I:EJWWCU90A80)M58PAQBJV#%A!,6<
M[*;[K2[$MV_>35N*")E51*44ZZM(YO5>*_*$-5]4V[ 29/":9=ZU]2;5"C*?
M$]I-^=ZS8/Q$N/\P].A8\R(2D0PF8!?5NT^,<_92IR*K)E9CS&;95C;@5@1:
M"@M*D4@)6E.)&BSH[,5:((!Z(=U*N,T!WG$W&Y:O).)=C/CJR:.FG5X-N=E8
MGT 2O2%I[RUVB43FNWC79%@WK-\ );,BG-KM\\TH0FH?4)'?2<6X8KY/I:Z_
MN6)Z+Q-^IE8E80SOX4<TI-7+B.H@-3OR,RN;NZ7P_X06%%!Z-54)?T%D+]'\
MP:\YN5?";9[.YQ"IK2_?G9R[46GY$WZM'H:E08SSKM.VL@EQ!(TT^&Z.\ZJ9
MJPF%<7YT()/)[(RGY;#SR>@MIOPW[(7D"\%J?+39J"J7?&#SS.A8V64#A0=I
M1"B-:=?%4"]'-*$PIH*=;C>;[1>(9!>3O=R!G3]DHVA92SOON8.-F[HLP(_$
M";G:I-0E=34MW[O0-IM,V[8R.S^%VI!Z 7E O, 7!1>+8"-A"*D*0C3G*:HQ
MW%&SFY1!W@5J&[N>U<V#-1O=8RN;_B\J,5-X=EP$-2UN,0:SP3WI9K.R7''L
MI+G-&=55 \=*N,SF\-2V,NND!;+:]5 R9[#G*U0W0E)?56>EG)=:=Y*&Q2ZY
MSBKJG\2-67G.;"L;6>4J3VHU;<X<6O:N>IE.EBW3R?UZ[<'J7V?6^_@2/.NY
ME5U/W?$/*[-C6,^M%L(;G6JWW<TNN>1)8A=]:G9(5_6H%3 936+7LJU,[),O
MIAUWI]F1OIK@8$P$59_D]QPG]$-=@J^M?\X!'?=,U'6:&Z5IU@.U*5E-#V(6
M$ T04$4I+F+'EW=D"/J@6/EQ-U4G.1VGKT(7&-)>?#"ELGN27<5B_Y5@3TY@
MN*IJ1UVT1L_9[5K9K8N$ NKK> 9HH#01];%)0@9%='Y2\C[<R[9("/5<[VK(
MS7[9[F87?%>5\R[Z[IHR6=6QKTO&;.V/;6N#2K#CD4%-43T2AT'"Z5'-MC[+
MRV>!AA3?A/JT4#G04!*U'NM /GE-/?C+O>D/WE>'-L"86>M.;"NS[+FZUBVS
M&Y]5!@Q'6 12+&OPB&F]O.WH_#SF&P'CNZFQ<97_73!BW*]5#),#:0XK3JWL
MCF^,!*6P[/3@U\S'B^#-?O^LF]USR!'$+KKT[(BNG(Z78S*;R'/;RJY?Y4EI
MQWUN=J ?R3,)0K+^IURKH#8*U6[;G4QJE2O4F-#^FRR3H.,G?<Y&5+Z'N*L2
M, O=LCM5'!_ZD#R,Z.UE7V&2WW+FW[Q*PD&25Z&0S"=<?)I])FS,\71"G1XG
MN/9BVV:HF;6B8W<RU1QY6I%8 D4;)<31G#KZ-$,+^D@SL%<1S4M4]/(>=J$4
MLUGT7;N3V;G.-0AQV<[>$"ROO4/^IH[R]*<D$/5REGQH8]X"]CM;=J41M30F
ME$:U\Y)884.Q"(<QB;&/NP7;NSE2V<E,)G=HU]I<+,=F-GLGX/.JBVS7TYK<
M$5\<!_#$)/;R&]V\JI^0I"AD;-1[ 7%N1-YK4S?KQZG=R=^ SM6/]/D$FIWB
MMC%+RH_J\54%L8JMO6;ER;;G>0/)G.\/4VV,.886COHIO@4NX7)"^AX\V[!&
MU:1JUJ0SNY._A5VJ2< &TGR@B!&4Y@1I5O1>MV9FKS^YDG1=30I[UUCB^2F)
M*>EN7'>J4S3KS;G=R6R&5=2;.0M(\9 ^A#&M3GN5*9K\Z7FV?+(F==1A_0K#
M-V#HO8W0>GP8U>NX;7>R"^^5S=*2)7I[R*=F+MXUT^SM;=4ZBM<G7*?A^EJ7
M)C6O.B-FU;/L3HUTJ:KJI;C;:=W[^6CY^LSH[Z4K-M4%F_$=PUHS'3SY_0M^
MI7[H_SW$7!+NS?IXIMX?(#R$*0WC?7DPPIZZ&E#=$WIY4-@^4(='#=6M@)*'
MZB9!=?GRQ91PRMPG?=6?&_)XI21Z-XPN%((79$C5[:HAD*0R5&T^<Q9.+P^B
MAE02_P!%]P5&3WP6@##Y[ [>*.2+2T7?]F\ 7%*/#$(^5O<4?68OP2.!']XU
M\S$-TOV,^(ZZ60I6I[N5.A9=/GWA:OSE_8J^XX<YH([.I\]Z;6& X9];K*H0
MY*S/U8*L_X7X0\*+NED72].][@-N^%L56SP3/OL4"AH0(<R=+ %JO$\>-)-T
M-%+-S%J9V[1I_J\\+$1/&^9[_")",+XE2E<,T'1?OH:.1S#O<^)0 7BC&I\!
MX<_4(27=J@;;= ^?\.L7K#Y7$KTQ)_J=6><, $WW115QSX\P<6:),GT-WXII
MR8.50)5W*KIEO9[#@FE+QH17T$ B'X 85NQI3C'GLR%VOO=>J2A4/3/0!N3D
MR@N7^JJ(GFG!+/=.!?_!N+QSB5>Y>:6R%R3?"0@I"H5E@-C2@ ,\IALZ\Y-[
M9M5L8AE4XU,MXJ?<1>4T;)KWG@><N?A*72@T,XLAMVG3_#],*:-N-3W*;]MT
M#VX]IFW3(R1M7YDDP@V)NLK,W)<RJ*9[E=P?T(NY+[3.F78;Y[R>&>[9A]V3
ML\60VJ<ELZ*P?=,B^$)<E9ZY5$1%VE3?E#:-C&G)5*D&VW0/ER>TOM'3;( -
M $WW!9S<OXDCM?]^".Z"9R+T272)8Q],2>""!A=& ]41;&EPD!-,F^*ZPN9;
M$]%IH]#',\7,(YF&W)FHM;Q""1:VWU:!J5W=>$K-3T0TVQ4C2.-3,+V"8%*]
MG(9;HW3@CTY2WJA;ZKUR6S<MBB>N3[Z:Z;VYGO-'2'F\MU.<#AEAWBNJT.@K
M67>'$%>,./,%5AL*^!E3S=&(<?5$J,.]DL-,F3+8=&["B_N\-MXM-2V_ 8?J
MXE;-!PUF!',!'2K1@!*H=]*!RLL7=_W'ZR>.7>)C_GU^1(YY@IIAFIZF_=A'
M;4R=5\6WAAH[8"7>38^O@8-GG>"(7XD[)FI_3R^OA8JX?J:L^OPX(XAHU'E_
M/5\EV87#M";6&JMX?^*4KW> >UE>N2JVAK//ZX>_19%[I6BJJ'739F%^#M=\
MR>Z6\:_DY5^,?X^"OX$DJL!/3.BTYQ0K>GU$VVH(^GK&DC[FT4&CYO7.O+9-
M"[5P';UDYZ<,K.E^+;:O32'_VU9;$^_#^$[C(%#B5W6!JSH&2!DU'1.JT&>H
MLDAGZ7.,H@QT)61;&D,6EBF8%;84K&F%A1E$;D-1ZAVR[9KF'++-\U2V>5R:
MF^:V;KH7>@TCB2\@J)C'$ZE8HSA)K02\>H3VKDZL:H'0]E4$O5URJK1,G&G=
M="^N>H\W PASS-R_;=4TUXO2ZU3!MZH[5(78^L.O)_(J/WGPKG#:U,+Q7AV6
M"8E:6\*FJ"+3;&O""ITI_0U2;N'2J*ZT9&^UL'W3ZI=>(G.ISI94-JS209>*
M*1/88R.(>H C.8.'Y(^03A4&^#TAGALO0.#XYN\*"W$;H+*E(=75;X.H<JLD
M\GC;K&D=F'O9*^T>X\*9TD2L%*SI?MV!(OD!'4&@JM N"E4+]=0 L9W+0KWN
MH6VE*AS*MN.+FC<M*IWW@NF-%N&B0]/C&) 57F!;(,25<&UI3!F5%K*1WHSO
M2<EX0&;B,PD(Q]X(YELP]N+]^N*TM0Z.AFL8X\J*2N47VZ*[A2FQ*;8I =J:
M2 <F$9?T/SBN<=$3"*O=0Z$C3AY]3>,8*S%KX=A2WQX?6Q(?9S/*.TEG^.8D
MG7L:$(6X6 ?6PMET)5CWL%.](*^H==-S=UXF4ZF69LOFY@KZ\_0V_%E3'Y^J
M!D=5AF0"+;D3#LGJ0]*?8'#T#@'L8$ROEPOT!E.B[D<IJ^2MAZ-I#;YYA3&C
M0K$0[>P_C/17BW?!O]0&?_'F41G<.]F7!*C*VGWA3E;9IDHI8--2FYN4BE_0
M;,UJ5>?PQ#JI8?<+VS?=DZCL14ZP?&&AYPX)Q+3450<JTV>"A7H9>I ]0(#@
M,5$\CVKC:;C6:E$NTPO</@1>05FULPFB:2DNG_W=D[^"ERK=]RF$:+HW,%OL
MU%QIE\ZMW-9-]^+M_H IM,IONS41UG(H4"=LV!9A],9C3L8J\0<P[*DC&84P
M?J9O@&A\D42?3""<"9BCCS_\%U!+ P04    " #)A$52\+=M6A4;   ]& $
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M@R\Q#Q>+L6@.S';^SK-PLR=<7/%\.CLY&>Z)&G@$+G^?!Z9O@[E]6]:D<^J
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MB8][8^C5,3VEI3?4W'53+R9=\Q\' '[^[O\ 4$L#!!0    ( ,F$15)%FCZ
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M>.LNB.&WE$I\;\<Q3Y9LH[R[<L;VYJ;([]>WZ@W,Q[,T*A=<5':!Z* 1GQ1
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MY@VRY)QD+EKB)-5$9BZ(-Z9TE#91I*31S.U2&VM(,A\)^0S!Y3$2J\SAJG?
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M2(U-7EJ2@:-5#B82RPP0!EP;'A2J=9>-<F!B']DNA^/U&-$-&!&7E$H5''I
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MH97D&/DW4(Z5^7379K]GS&\*,#N;1) &:70X>PCEIJQ$2G-PT2OE=)M:"5W
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MH0>2?HO%@V9*Z7^NUYV77E\O7^<N6&YM>.=E2 ;?(P7!H@U/:6EG[4CI(R8
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MT]GF)NOJ MO?%I#P3W!7N5Y"*:H5_33].)[@=^FG-^\&4XX*&(=7I]J"W5)
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M#SEVW O2A^9B;]"W^$Z]F_UB^>'+S2_7Z972H4<IN2%<E 3["$!"L)38[%/
M#3%[WB8U_7BL0R55-U]C6O-T[ASI\N[@FS$?XZ9Z/?\P1@O\+[/?IFM3?)6M
MESAP!3D2#J7E;TB.N, M$<K28HIIOIW4OW-]>G20)U!UJ@V[LQ92KNSM[ 5V
M<[+>!=KN-.?C%.$<^<N5B>E"=P^I#DP\%9)Q0-5.U$KTO9(@UFE.+$])"6L,
MX_2I$KXG0?E\?!\CS*%XODEJ85E%%4 3IR"B*:1+;Q_<'WE6%$30 K3IP_/0
MB4+5Z>A"\PFRK-Q]<&WF?HVLKM29QNRXR0JW)\>(=$F24*R@1%&10PB@&.O
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MEK;OZP\7\7+]U\M_M;#B+'$TGJLK(+*V@$5%\$DIL"B\]%IJI"$GGB\\YLT
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MK^./=-%.&Z]7#VCK"9'A#Y\#'CN*8CNY8F*5T287K,"L77"\Q81*A$&K4 9
M8S@="TBH1%Y23812R?%:FRV$JBPHIRW+0>1"77:PPR=4^LT70)N"T3%"HE83
MV7+!*? _I;11*UU(A-/LB1G2-L.1/=_LB3'8Z)'IV56N=^O6]S?7Z^MX63;#
ML#GLNUR?YW_$BQLZ$]K9[$6%K+ -"&AC[G.U@%@S5E>]IR%5._,M)"]Q].9
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MZ-=8M2NVE#[UN*^KN&P4$)Z?83-"(<=2ES.$IU-QV0XS;,9@9989-CLH^EA
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MO::>["1^8O3%W=OM)3&;__EO_P]02P,$%     @ R81%4A@E/_9X2   2E<
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M#R]L23C:$+^VW=N_9L(P<FSV]*ETF\S$@XW1>_'J</_7Y=;P# CM&WZ!DGS
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MIS7_I_M(6&(6B[5,/_DV_:-#C7R6W+X1E.X5U,\J%'=,E/=#0: %U]U%9+B
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M %#IY4N/J1Z5. =,DQ\FB=TTVO/66I#LC+?$6*;?\/8-T^@]7YVD=38V7DQ
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M=^2^$2O=_XJ1;,"?#NKD]2<)0>8\]5&N/O). *CS#G/W\/!P-Y39.6L\^C/
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M#D@0XJ,1*%M]T<M3*F'&=FD1.%=AG\>OXQ@X"7C)*YS>U#S\:$K7S7;9]D>
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M@:?B_^=+9RN4)SM1 &2VT&.QG;Z452S!'L\X'[>%(IG@7#<3%:4W]CNE>'<
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MV0'?\Z+/!E4<G?+;6!9T5BQMJD31XQAI(%XTOZI>;^7A3(V%_'54@8MY9!%
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MPQ5_(6V$,:7\>)JW-9>]3:KD2E.>3;R&8^>5@K<G_YC#\<5O,G&)DS(-9GB
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M53ENUVMU*EULLZ]\CX_98M<15>>WENBW6JZ(\)Y:A6PG)O\ FEP!^N-;&M\
MV>I2V9^+T2C)0T\=@!@K59)4=_D6W, .&^D/PU)YOZTO39L@."%_77)M4(&[
M>XP_PWO,WT'H \1@?$W'5A#;%JP9$V26M5,_UYZEQS2-CG@>=KNY1D4VHXVX
M4I+S;'Q_6O*Y43O.".H:9F9F@<A\@V*O+F]]Y7=-5INUW3FB:M@H0,@1Y.<
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M?N6,Q9JPDJKC_WGF\'_;_[;_1D,)1OX/4$L#!!0    ( ,F$15)H]K^9*5L
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MC&"3I9D:CG)Z,!2M9':GA)RP[.#K_@8G]<6GUB08?[/#H,K^$/I:8I'L^4V
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M;+_WL]3!X&3#4-,H.]NI0"'8MCW'YA'<T4R]5NZ_^>'9A65CA5F+*\(;9)L
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MD1BF6GHF:M'0JWLF:H$';-=O R**97])-"&(LC)ORJAC;AVFT!]><S,;P!^
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MVDG)CS!D;PY%?);/(2.7P5Y'F!I!G]MAIF)W<DJO:=_-<SA?X[EMKUXE7ZT
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M]6A\GUV+D^4P>.E,<&^%8VJ]^[$#MY]XL3RXHMK(\NU@KS52:&B"M&2!0=B
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MR[389BN=Z?$RK>7^9=DKCZ67C)(!=A4RJ1O85/TZ;#Z&=5IO89CES1U<[>C
M)!L1OD +7\K]_XC!W&YWEP_N##'I=WW_@OTB1^O%Q9ME32JF6:TTR*(7MJ;0
M:QL0O1S=N;;XW^@1(^,1L/DE8K]Q&*GNR*N^%1[@'?4<Z95$DB'*"QUR*?R3
MV>S#ZV8*G'HT/84$C6&A$[TW$.$H ?N@84MPTO:<3S#B!!0/$ X; VL('4]-
MN6;#S+<-O10PE_O4[N5X[SA9"YDQ VQZ'4%9T&9YK$$44XI3&;IXG21;+3R(
MMX@L<NGYX"LE'+M]ZH#N;+R+CZJ&R [NSP-!F4_;$+*&>7Q?XGT@K(%B;])%
M8)Q(=73EU(&^BU2**SS#()][GMF%DOYN?S3CZT?KTLWI2N&/<L)3K5^(*&:?
MV/;QZ7FDRNF8^,\<) /H"XM)))6JD8;A27#T[N22\V:C1.5"UQ-^^M[^Q$*1
MP%!WTP6%Y39"AV,<80VS,1*C+"9_#6.>LEY].'2CXY176@#^Y#1&$E=H;UO*
ML>2ZVP9DJ*4*#^99GA)KL=W:.8Y ^/_%W=?_'?\[_M\;LE_ &D=V7F\Z9=Z-
M]%L46.K28>Q*!CA5#RE2<_<EQH[^Q]/O2W>Y(CX(.%60F'],@%IS_'/?_DVA
MZ]QF(/*/"!]\YE^."+R&06;B:"4S[>X5<^[77N=9RN1]'O#-@0<@O8X[;*Z:
M81%.8>]%<8ZB?Z-Y '4.:>8Q/.")%:(?> #+%8A UH64_ =P&6E7GWD #_ K
MY"I)<(M1; 1[%Z[R?95Q1/"Z!=%M X4\ "$KG&=%U?!OYMW;" >9E![[8BV/
M#GR_)X@'F,SQ?_R?_EK57P^='H0.DW\;D%3 D3?HG[)?L__.H^S<O[X;@MR'
M-,\2=EX7.-(2SBXDO\OC;$<ZLC/865;"234D=1D!JT;_1L+^@-=,WZIKS'V)
MH-L#T5_?EE!$'O!3JI_R/9:TNHEL]A^DK:0/\91&( ]P[><!AV0%,<4\X.U1
M&K>NA!NKQ3^7]^][*?^"\0L]IL.U\^K ,O4P[+@(SW#2 H+(VRNGR2SY$NZA
MZVB-N;_VV-_ET?=?ER@V%'H.Z:<?PDX\-L[^3+]NEOYOMX[TF"$9\M86H0O/
MI,"Y0_6K;X2F$7(66[6X.JG)C=7I??SOOGVR1/DM@DB;X:L\X$/<P9-?P9]2
M"- \^[KF.V!U^W^) _]6YHK^X@'J)<W(*I&T?:C4(/"W]? WY?%J,1;\>12_
M&Q'$R[G<Q*-SWG]9UF2]':.0*SD>,7L$@7:_]RR3NWA:C?]XH^F^S:'+]\6_
M)/\"86_TZBWP)\@#UKZCL5&(!YP@<C$\@/D:6$K60<CIWY2/U5]7#G^?%MGP
M[\H']3>%<U_"^N%+FB ;84RQ%#<[::XDPGD7T^Z^8[FQSWL]:F)_K_BSR?6]
MS"ZDEIP8PYP4)(>VNMUQ\V)Y(HD)?^>V(3Z\>5^B,P*>YHI&LKSPWK#I8XGK
ME,IW:6\:7@71Z\A2?A-;7@:C[/H+O<R'IK>$%S\,RE1&:8W]\B1TD!/1=#(:
M:-C,MH<XLVT8<?:EB@_<+;!>4^V)\3E)[(-7@U=/'(>ILD';[OML%FHZ_&7/
M\P,"0(10 MH?FT81IUS44\5[<1XWK.]]")=,<I9RI)Q;_'7?I-=\.14MLC!A
M-YI4?%/'*/?<QJXK358:D"9SAD.>)^S#&T.HA4 HJYGJEL3PP^1,-\MSE3,/
MZM:5^>THZOIE+=&M;D[N<GQW,BO>H1F7P&R%LQ\3$%:I2I FC$ZL[S<Y/$5.
MR'+R1I3U1;-32AD--XO+YMVI,H7MES[=V"/[Q]/19]C)W!9,*JHB$&%3!^!*
MYFT&%7_H.4,WEXF*72A^?==,YF7!?C7,SMUC6NMP_4$J?'29U ]"<X;MM*07
M>$789@J5'(PC+)XQ4LW5'8CPC/4LKLNPZI2B2QGNMG<1\E:?3OYM1:<LL%AN
M/B1%[F;8D5D)ZTZ^DVXAR3\,H7_/W_A9_LS[0PJMWW[9W$NZL*'8(>&>\M,*
MB4J#<? 0U)"U[\V4OV__\1<U]L/RM<,Z&QS6F0OFOQ7KY,\:&&Y!5Q\G36&C
M:;56S;W4NBE4VDYV%+U7"G?3QTWVX^W7Y/B&OHP=KBXR-SNN6&^W:[MRQ7@^
M%&"U_WVQ4O;Y_?\C@TG+WU1K"^@=F.J,F?\%2;334 8+1B[=>@*PK<-P0-FD
M/SE(I;@JJ\KWRI6S5E6JK<.O\$A%W,S)YP'GU-<J&M?1'AFX)O"$V9AB=@BE
MK[Q>,?+^.!5^ZA^\K%O63MIIMWG*QS7;([6]1TP*$$*HZCO:Z H308CH)O*"
MD#\CJ]U0505!JOC0<51C1&ZJF2SNY,&7XY,+*+<H3/?+_L][=ON4R\E&QE\Y
MX[GEHG#V=P29J"D=(.2$6@<OMKEIP\I%A)XS/&##WD2EGRVGX9@GWY]_V^34
M%E"!T:4A]#BX[NS1X'H!H" $JSP"MEB!3:IF!W K4YBFP/3=B-I1IO>*X\U2
MVHS0:9*>0[IL?3#J"75D>WZXN-Q)[_<S80!Y\^2U&TK#PQ3(::.7,[+4%HD$
M[//:V&7M<C+%&Y5T355A:'MU<.7!R;F0\-*CL6!__;8]QF4]>[3XD587[<CM
M0U?-+H2PMG[%5ADNV-+U-L"1)QB["DT[XLOK=04'[%V]7UK4U%U\G?'YI([(
MQ7,9M_.V4\64IKDFA"%T#;F5-J;FRDE=^ZU8@R(<%A@"K;2<,:*TDI3PQY.9
MD<9.BZU$CT=C39?FOCBFZ^M8MSZV:P$>TY9S;MR?FY#[4%:_>_+='F5=M%U5
M^E#S^_%U'0*['Q]),Y][>A\PYL/*X]T@] *9M85 <S/B/*5X+HZFHU,GI."/
MDPMR8VT$U4I&Z"/B8^^(ACLR.4/#?#_>=^I>O,&LF3A]P^-Z#$[H%:$96WW\
M%>LT6V,P%)UH)EH+#:?C):<6#C>C-['17M>\:BJ'=MXY\FCB$%^FB%JF=J&[
M?HV]B'J V?1?H:$.G0QO<\MG!)F<9IWPHRG.]%%J$=ST-JX=\E_2=K;5,37_
M.A3\B7I8#;AX=L.3]3_Y0)T@?H.59[E(4]0!5W\@R'M?XJ'W?X$D_#,P(3<@
M7B:C$=!8*Z0-I-6MI?2C@!:YETP58_[F5+!M6;83L!_S+'3\KED<'93]9J3'
M#.T)MD4GDLOWLI[\>(#[V++GJ4N7QY$6><G@MAIBE8D^(^== Y\S.Q0NO.^&
M.Z3%-N8\(7]]W:J[F>ITMO:=<BDP>D)!G"]@?V<;<*W*L0<-V9'&/#K FF(*
MD6T[]4:IN07SL1I^ "V7%^VLZ/#;DI%]R;U'U5PVN%'K/>Y9+W.<4\C=SNV=
M$/U01A#!ZR.04MBNJCL\U7=5Q^7V/:K+6X2=#%T[\?)<MKW8_>[/ST6]^:ES
MY#R*>R]U<=JQ#952L(]SFP<@O8+/>U63:"*_03Z8DE!TJ>I5=;;#C1:;[0HB
M[I?C6T0BM$^2BKWYF9A)%#N3M &A5IZ(UZ1>*\TV(/#5J0UU<%*&L*M;=1[\
M!;OTI[S8Q(A<3AAJ59@<0MX W^$!:A-(U%T[N-%:_*+)TY3_0N>9M9IGL1"\
M;3H_S(RI@3NGE8GB"!=K,?I!I)O:MJ-$Z[7O?PJ F$2R6<G,)Y^?B@I50RFB
M;UKVZ^RYN4?@Z!+?:H8%3I,M<Y?97\6)!3U-(Z?-[CY\]&+J3D:9B<3D%%)@
M5.?2]A_)746[D[6F<Z9.B$XIJ!\06E^''?DUU9O48$;H1(D1C'!]U/<J7NTD
M\:NFD6<2CB=ECN\*W+GU9;;[F4N>YC__L'=*5.@T]>;_^)B,4& ?##6&V<G(
M7?! SWNQ@#F*^-10O1Y]SL2*P=]&DYI^4]#<%%"<::QBIG5Y7%V_^W.GCK%4
MJ0)=;NJ-&).?4VIRF.6"%Z]C&+9B!,?@P Y5289;\:1>(D&UXJ6^RXC?-:G?
M(66[PKWSG;7M[]VL>-SM$02L>M$[V,0KX+ (>DF)Z<P@QZ!^FC;]I6'[C?Z9
M!)'U.164ST/X4(0<+2%UZ/C(\0YW%/O3S\P(T0H1X&<M_I]N#6OWI>83FO)*
M%F0?=#-:)O>]>CR*HQV!/J\&]5?!86D1[VI1%88]=2XKF1=>"1P04!7E!%D
M^$$Z"=[><>,RQ8NTF;T9?L(0.L4X\XJQC1%8[S2MG-@:)C7>WD3'W<P1?K'_
MDTQ6?H]$UZ%T+WH@6QH])1]OI@M;36DN2+,PWU31S^$@26)CWLX\GVCC$X!D
MY]8]!S2N/6CLW+[_YXR]]NJ/9 #RPXRDVUUA7_QHM@M_:9!]<G(Q^5?[4(0Z
MP\2C)9%H'%?KE6>AOO?%\ZV;+@EV933^0L60(%N4(APY915KP .(V&KQDFGR
M1KSAG8N087QQ?\_NL3VRNQ5%,KBG1E%O^=ZW*4>G)<Q'_#=U H.<"HJ:R#-H
MDX9)!%&\93_U^T'&I;C0HN^;+%FN"S^V>1=1:<UC9V^.)PI51^IU\(#?(CZT
MY68,1]B19"_T1;X%!:O5+CB1V<&##>L)'RG5Q8N)7&%O9W3TQT'\5MER6MK.
MJREIEJYHZU<OI6H&JR^E]FY[]K6E9>6L'.HR^QPG$YR\S!VA":-]OR\FHB[%
M3&[/GU*X7&_ R?X2]7KZ=$WRZ#,3'K WW'+_]'GY[JB)"S.1+ T9OEE:54<S
M+06K8*:D%\,5PT>]AOW+-[IWS<&9O9:V*_L8Q\@&M;=^6N[>P:_H/^HZ"DS+
M3H-5X+PQR]*74E4^NX!E27$'\L 6K#1\MYDY@6(,IE/H2T.7#:QU"RRKZJU[
M7MS^<5_ZZ/7,M]_,MURHC;*U ,(=YWU8VC@LTQ!6\8=2#C+,'DRI')H^63=D
M<GKJS3FMNN'JE,YCPV']@G3]MY^TW@^<.E<SWC&\]W],:DAD4/X!!EB+_TQ\
MO"-3.^C$)*XR8;"&5)4[CV)TV P8O EL4RI:S8UWKX_^-M%QMK;OV0\]0W9/
MM(TNMZ_A7/*S\@,M6N?/Z%&SN*)\DUBJ&IW4!/+C'1MRFQN4&:OY'E.>$R2!
MBOBJBOJ<\?(MIS; >5/40_KYMU,TXK_]0&"Q%]:@I!L$4B/Z.]!\9G]\)RA]
M8(<_HWW"51CKZ.W>Z^3Y_+73,_NDD]N"=C[GNV[_Z=YN!8=E; MYU(7NV$*.
M)ZC"+H'0=YO!R_6&CW2ST]IK'QT..>#:\Z/G?4)N1OY;!>5[=/%;?#\UV5+&
MTY2F_)/,&_!'.EJ05@5".;B^7RY0_KT(?$8[U=EN]\FN&W)29QLMFV85IAJ^
M,!*2JE24)G3%6>T1 1E/_/@6JC"UKNU$@R8%!R5]?IWUGK\=-3.^NVE +DS^
MCV:BKOAS VSTM)]% YS[^)N\DNDR*>$,%;NA(WC[V(:=E5+?"GPSJEHE;NW?
M["'=@8*.JQSNH%0*Q9B)PPG,N*& ^D"ZBG,4IH4B550-5NNVYNXYQE_X?K%J
M?=I!J1_KA4<VK>\"?M%&(JT8AO.S/$"0#XYAF;$]AJ88N2EXA\FQJ&!TXC-U
MV]+'F[9Q<JSOC+H[9%TOX3IIJ:?=,)LFYR,:9\3%&99@:+HAU<PHG-:8;95(
M--M2Z:)=75<:N-W8Q=[^=]"32^JD72:U@(#H4S-WVI$/0O.D9O1O#3.%M4;:
MS0..:%PUZ,6K\8#,DY-$EGP99>F0XV%S01D'<T&<5VOO;]5EO=4?Z"5)MUDW
M188^U^J-+;>.R!&P%RK >]7 CB!$;%W%=AAS=HPUY;[>.$Y.?C2L=X+:X_.S
M]>/[[=FC9_;W7&Y\L06(2&87/4=H=#K2DDSPP8S%5E(T;;,[_ 0R;"K8#$?)
M)U\%E;9UE[G E[BLD]7/[8Q^;M[YZ&-^UP\^MP/-"^L,R(.T_T*+(H2L">MH
M8\)@'@_HT'6A>RTHLYS=8"(]/JX0UE5Q;)9T'H?[.JQ?#GCV+Z7<O:'C[W+&
MN^?GCA_W3-"A-\[SS:+7[GW^SE1ED!<.LLQ="'UH9?!%-1C'%6:@6D@Q;J)W
M6YSS.W//OJK(V8AQ#/=?*(HVS''-V2UWTS]>VRDZ*00;!#8I@=Z86%05BBT=
M-FE"$<:[<IXUB$&[DB;1TJCGYUPXQ+,5?9>'OHVM,$KN/']-W&UH.?K;Z149
M!\] PUQY=!-& :_*I7(1/1];V4R-3^,4,@.-YRF^-9D2AMV?ZIB+X[7!LPIO
MW_OUH"<S";HX%Z8&',G2Q,MQ'N^J5RG'21R$?MS$AWE-%N4O+BR-G(_W9.F\
M%S@TLW4+<7=J)*R7;FXRS335E6#+UC([HZ&%'!>)!*DQG66_H,()+1WNVYM'
M39/,ZDO84CV*#;L)P_),?J[&(LO.U^%(%^'PE3RW>[MV+]8IKCPC,A]P$LT.
MP*7,A%K.,]!#@GJT=Y),W%6_"^D8%R-H<<..?<OC!S3"_2>L-V3<_G$^7%U;
M2W/'F/#8O574O -+TYOVHK;Q+4'&!3?$:C-ZQR1'/L.UM*T6Z:B\IY1-]%RJ
M>Y,A<S/NTZ2]=+6D3.6FL]>CQ" /KM5+]-JNUL9(7=QP$_&W*OW/6SX&\U5_
M^H[-WW$&G?Z_VWF3X?NM]]=;F]@B&F2+^6UP"_E\_*_?5MB[!JMV/$"@:FV/
M \-2"$3?NLJW%+I6&LA0O8!H+>XAYS#.E:RU_;/9P3DT:FU'K>1/W&:K6]2?
MJVAM_/76V@Y1DBTB4K,IG# $/>V%/OZGOPOGF.1;(,AYHS'PP[//S!C>IFR9
M_Z[L!.QF>3'U!;7HQ^<;U^T.(E)7@BTCS4WA 3?0T"UD9<GW)1 '1-?_B00C
M3& /.!=/OJ&S9#6U,I_+<F2']_GO12?S %F\R%/JR"?%!7=N<UW,Q;BC6;<]
M#^'4SV?JW. !":=QB]R8!@$>T.AZ$ND5C_FGNG06T'"H(U+0<\9T#%MP$/U[
M!_'O7[ANMO-A0_\_.?^_<\E&V&H-Z5I03#TG<"[V67R]F#7LQ(J8<[9[EE",
M#X/4S]1<^RI8A852NL;4+$0+-3KW QLR[9R0,A+BBHKP  MD4A)\%*$^;?9"
MKQW<Y/^)VPJYFU"PEB8'>6\=.*FMB7C(7/7KWS3!$V S/]*W$1,>(LH,P]9
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M,F,IY/2.TI2_P2\#U*MY<<P2?Y2?5NNTB>(?YM8LY3P9C$KVE;RA- _J2^O
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M]$C4?IH15-OXBM;H-C"%TRR4$C!H$G[+5)/LLUV^/)6OU^9;FMXO==2S8Z+
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M,#(P,3(S,5]G-"YJ<&?LO =44U^W+[J1W@S2>ZB"TBPT%8F @(B(%024*(B
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M7'?[$::"WZ5!"44]<[H^ZX]J?VGVCRF6\+^EV;\J]G_K10&D! 7@Q1/< *
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MP]>&QT$1$7X/EDXS4](7ZJP:3L8WCE \#;<Y&V@X8K?B2%0EH@*DS>QC'Q_
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M[;1N/#TJZ#I<TB";/="05QJALCLV2-";*(,)@'&F%G3GO8/P:S=]1Q=_R0M
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M]1XI6DC=4&ZMZ4$QW7#CGG#8)5;8_.FN,4R0_(T7,:^2[@O!39F!^WX.?CV
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M\\EV)V3!.OB0O0P9L +3RXK(';R@5++0U>VGVI\473$RWNY=^*ZQ-/(SHD
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M-&J*DM\,"2M_QW59=I-\HE)!MU/OH^/MM&G#0\<O52P4& )_PU^J^@O^EN,
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M= S5)+XDX"X[R#]# G?3S]/-9TR^Q\1T,  P1&A@X0<23T(%OV2 !7T;>9(
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M!_8"]_&+&T6#P2B_;3I' 4U_FQ3_&*\4=_A6=OVS$T#W(_,Y/X4.[I1DDL
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M_SG]VNJ !Y5?/?_W*]E_Q[_C'P/0]/\'4$L#!!0    ( ,F$15(P^I\=TG8
M "6'   3    8V%H+3(P,C Q,C,Q7V<U+FIP9^R[>3A4__\_//8MQI(E9&2M
M;,E6MDD2DB8I0DRVD!B2K<:,R!ZB-Z(W4R@5DKV0L2N24)81,X,HF9Q)C5,S
M<]S'Y_[=VW7]_KB7[S_W=7U/U^O,R+S./+?7X_EXO)RS-;U%0TB>..YX','#
MRX.X"/]#;/U 2-@$X/P"$8$(^.#9FD78(GAYMH_M,^_VP<^W?1;@Y^?C%Q00
M%/S/$!(1AH>0H*"PF+"(Z/8!O]LA)KIC^X?MB_RO4WD%^/@$1(4$A43_'Q];
M70@I89X[O#OY>-00O%(\?%(\6WT(%&RCP'_,XT'\CX.'EX]?0% (-D,,_D"S
M)&P^'Q]LM !L,?S;!/CW"'XI >D]AC:",BZ^0FJ1.P_>S'LHK'ZTOEOVS!B@
M8>1W-4E$5$Y>89>BII;VWGW[C4U,S0X=-K<]9G?<WL'QA.O9<V[NYST\_0,"
M+P4%AUR.NA8=$QL7?SWY5DIJ6GI&9O[=?PH*B^X5EY175#YZ7/7DZ;.&QJ;F
MEM:7K]IZ>OOZ!P;?O!T:G_CX:7)J>H9"7UA<^K*\\O7;*O/GQJ_?K$WPS]]M
MOW@0?#S_V_$_]4L*]HMW.P="VW[Q\,9N?T"*7V"/H:"TC8N0;Z2,VL&;PCN/
MYCVL[Q91-SH#R/I='1.5TS"F:S*W7?N/9__W'$OZ?^79_^[8_^$7!;&#CP=.
M'I\4 HW@<LHS]R+^>_SW^/\P^,P&K/4!:N\60GBUTY)95B]!JOA:<F7S;RVW
MNR]F\L/ N)..RM"3FL%I]XW&*L(8&KA@ ![&LO*835N(%RN#5DZTUJYUX55!
MRE PWC&VG%)YTC'5XFG-N><&=8'9Q^KD1W9XN+!?G".QG""Q^*>A?S$<:6U6
M5CLP%GF5(+/*/)R=;GWLCL+*5Z2*JR,)=ZKY9QUGUY<J,'P4$N%M]=2(R*HF
M9YI_+NFUSQZ)D/XD3R3GWX$4'B SK)&$B2T$X+&% %6%.#N#Z.2U$38>'S%)
M,,#K@ 4)XDUG1NM\0E\X7YK0.#@7LN']Y%7KRZ:#ZF_#$F_7WI9D#I$_Y+0S
MU>G4%(YM%6C?UVDU=HWAY7:QS:THX9FM>#]=KTFX(D9\SRAJKR43FZ2BOX5(
M'ME"!)/Y,:'/XC8@$>>02H?O&C%FYN2L'XR9FQ1OE\J)@>M[5*_KWW#90@AY
M@\1!HNP6@E9);3!+LMX%EN&08-: HGF(N75MJ+J(KKY!LT/M^+G /3==3:\*
M6T;8+">B8SL5./&@$K/!^PPJ&;NK0WMA94R_<Z16.]72+HQP17METS5]=T?5
M'\S0M*7*H9I<,!0W@X'D<CE[U\&0NC0R4,*M>+.%N(6&9)Q0#(S9H9_0V^4_
M[8T<BRAL#A$XG3N]A>A" U=('&G7A>S--4>F5_\F01_\O< 5Z\$LBE\]+[>%
M.&'7]+K$%:?9Y)*^L=.]6TEI,331MM#N\D\+.-8FH31&$4<J90MQ905\N]#-
M'$"E#"XH/YCK,?Y7S(#!]SC>VKVXP_8>9]W,FCBZ:7T" 67\T-=;8RRUMY>J
M96H8Z#8<.&?'IY$?AY#XO6+-PVU$^V\A,N>-MQ I.*"=50N&+6"E>+N^F@OE
M-+&'/S^/1:KM*CEU(&I0H:X;DTUL76>DL*\0NQ^E];,@C2D3JZANTDY&ASC3
MO\]T_,V4>4XROX[QU<\O+>Z949I>/H[1?K<G:\GA$QW5N(7HIH)F1%8[8-^+
M%.$H<JL)>Z AM))Q]O$>YZ#^,DO':"6KXZN'MA!Q'RX,FGM1T!1>2_<=K(>(
MB_X:SQ'HIW5R8&^/#P+X0KV-CUTHM3@V;@QVS'+=W3MS*)09H^QQISVBR1I7
M'92G=(!D5B6W&!WL=+_:(!';A+UI&6F2*?0ZJQLR:/A(F7-$&&6%7'CPED][
M=R@S"I+X\\E:&\3TDAL>9S"379D&F011VYJ35.D?^,/[/5K(1.1T@T=B\,67
M^5.,6MS+@]6.ACQ)BANYH!:U"P/N:1T<!??:=V\A<JB D\%L^P 1T>%/'UXJ
MV4+0M7.O/:WJ8%JD79CICC>9NIM!WZ 7[BR\NMH;$)+D(/3+"?LNEJ/\= LA
M(+Z%2$KF\,'G=KP-Z,6V)LR@=W+4Z:5&O7]W]RD*I>##$H*"PI9#"M=ULW8<
M?/9\Y>J[(TOU6N0J12@,+O,:-"^280(7_@&\.Z@DD/ZR8PKB#37\=J#@/6X1
M$'\WF:8R)=5'%$5P]\#?\03.Q@F.*QT%FH6@PZ@IUI:O/UABF>I=UKM4E#\U
MW9AL;6LD?QRIOA!_YKBMO:Z+4F-!M[B\PJKU27@9'B5?R9TU8A6#3.9P#[D9
MR]!C\@TZTK<0XM^.#_0.S.]K_RA(LO"^H/%(CCX[[-^DX\_/Z/Z&W0'>995^
MW$*$X4!UTAJ\1OE??XA^JCWYVX B?Q: *N^T?#MM%\5[_H=*F7MZTI-O4.YJ
M\R:)H^3TT.LK&G"OFUWOM9;)$1.NZ?!_XODM8ZDH9\X5^W'<\(74J[,\/Y<"
M=@1$/T!.$S.V$"VHM3S OE\*5%]$,YR E1[%CT]JY?(6<I6F0S9/U697VED.
M+2G?CGP?VD@:Z!1O 4@<[59KO0GU#YT#,,ZTE$&&(:RK?"+XA5E321OQ?R_^
MKEL>9A7#<8LE=DMM(0)MF&5;"$@T",Z;^T?($']]LCGAZ(IC$?W70>[SR3\5
MN@)+DEE/%MO,-#E]9=''[.QX3H6VPM-/<,XQ23EHVL=1RDH78=]4>%T-!Q7Y
MG/)5),HP,C#$M-0_(FR1G_-$*WZ)<FC.2.47#WLNEGT&>E="J*8S1+<0K-N
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M>NJ8M68E[HR/.W>.Q[X.=K,3]?/%.N/W%L(_+7,+\5NO)!%]";>%"$'/3)T
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MW*%7:-K*NMPJ&CA!!&,N$!MBLP+ #;.;:+K'?;IT<^/Q,')C]NC,%F)QB:I
MP#;^N8%?OQ^#CL7""@/)"^[!G\*'=XJ/IS:Y^GX:*)6G9"Z&6\ZU,W,,R_X]
M+;3HWHV\20+.P&1RG:/47_4="Z\F)IVD@#\^V8&)7,C-@D28IU*BGIH6/<;.
MUHBW4.:#WXUW"[S.'U4*/RM^6+7F&&F$".[%,,Q@5G4=#M%-CA#P/(LM!$.&
M&<>+MD[)ZJ/4WO+,(=%>J]I4&O>AFFUP0:$1WZ*6'8C1#9.'#8=E*2[DVOT#
MXYV[\=8?HK]Q7!^"\L<;/OYP2JAR:9I0RXF/56[Y)FMKBM'6+D%P;L'?<1L:
MQP*GD:"F/$>FFG41C&?:LQP @P'4+3=KW@_&*(K*;!^$*CK_LN%5<^;<I2;]
M2Z9OE?.$,BV*_?*.O5BZXRU+-D8'AXE!(IMP8K6X[=:B<>J0L!);E7,$D,_Z
MT7&TM=.DO3W[8?V+/M:Z^,+15G>=X,*'6OF.DOT*2KS5]0K0"WT]6OM-1O@#
M1[\"44?ES%W>#MW\*@]R/A73<3QQ\EUOC0DB@,_=BMI>P9?>.J<R/Y^P/SKO
MF3V]^4#\,N? Y"<LA(P;S_LHB5>F)9GG@D<?UWW^NY?OCR?LG16A9P(,A21P
MZ,:4^7MP(R(+$C3BJLX:2AY]U%G*NE5?;']Q0DE.B%UYPWV2#-@RM!=,R; ?
MRO#<TJ]8H3J?V?ZIUGG-Y)XIPW?JP<W:DR8I+1$K*6IGTJSJ2[A >2*Z ";"
MHXQ<MAHT0.:%]F_7MQR15NJCQMQDW%@PD*&&J/#*@ ?%ANF6K*=ALEE6W1MK
MBDJ/RASQ+S</W G(?XF%U7?2X>]M"62.DC,[!F_<=C;-:ZPN6JGVU,C4%6#0
MNB!TYXWN)7'6W9MEJY^X*#L:5=AFP<,R2"C%^..D5M90D9N70O_P8P0E<&#A
M@-"N0=ZF)WP;R9 X>@OQCR8>;F/UR7W8OS&OZM[5)9*;D8,8T(0,B?HS>VE3
M_08SH5AF72\Y2_'9*.U5TU//N=][?5^^O.M<-NZ6O5A\*S;?QE)G0_?>TA]?
M[-^S=7VH;!1,G6G+.% +QZ O<D/IN3W4G80)K!#>_BEVA'9#;'KIT\47364T
M#.\6HN) 6W/9''KLS=W-4^V9R?\$(H Z4!W;AZ&8+6(XNPT7#6ZCFLUZ7G'D
M%W'2H)G+I E&^)U'Y0>&_K7V?;IA@;I\0CGOG<Z&K=8H2PYE%ZC L14$B4.]
MY-8I;HZ*SA;B8\OE7T1PC]": )PT02:1LS-J88HC9P^).@)ER#1(C3F9K5],
MIPHU$<YVO9M\6/5S1ZYFQ^E9BGUXEE%\[K*%U,]4W/1U!,<0)I&&Z*7+W.=;
MB+4(N$E#:;5N:1Q)+\A-G_N:N':1*015II)Q3QY(V++@=9,OM)C+EOF-YFKF
MDY6(M+=B7J'K,^C%1P6,CBA;L]PKTN<?'1E:O2*\WX:6=$AUZH?X3A[.#-CJ
M_ D.'@S,X"&UX7[S,Q?.0Z-$>>\L6TET4)9-Q[\B#P?5WTV$M[3E7.AZ<M!R
MPPGVB@^L!M191V'[BBW=V<=A+'#OY+F,EH*D0SM1K2_!A.5O4I<+D9>O?3_;
MU)8T'WM>_V'JV3*S7 W=G)]AEQ"MOXH\.M4!W"U+OSMV"^NB(6W/*"/+E.>/
M_)47=J$[V[LI\XLE""B&2"NF-EF7,@<AB4=C,!OW(B6V%?5@Q3G.@/<BQP@H
M;'^D15+_)A4L./D^, 5Q3&;05Z-+RU7_J%%VS5L:>;;Z!%S%#K!U']!-]EF=
MUGCMJ76&M;;/\,-@9DC/H3G!JB<A16ZM?4-#BM3A[%;9SS.J/ 6^V+&12Y<)
M8D!,<RTE[KX'4%8<^_0\<3#U892O\MW9*!+<EQNB1OE/"VTDLVV#23QD6B85
M\,;<1LF@:978%\UI_:,WMQ"*/W[K1?5<+ZNB): ]O3S6P_N9^6/1/$O%%PM6
MF@OUF&_K\T\6[-5@8R!Q)K>B"3-+8M6#Q<Q%&HXC[4]+ZUY/@I0RET>[L-*6
M9D#+E#US]\?\847-Y#DO:-7/UR/@7]N4]'O^FIN"Z%I('6A-Q?L^-LU:H$I,
M7RZ\0J=,N#0Z+NB:2S\7?K,6Z68\8G!RS!B\5JIT*FE\?/Y (6OR14UD7T7Y
MLR<\]B\>B'S]+V0'.K=!)[8=7AC<>!)W]P2HPXSJA?:_!&):M7(7[OW:?<J"
MM/;ZZ$%;ROO3=_*?\N^TO!WEXPA7U%5NW0_R1;@(M;80_61*FGV;0W0V7\^H
M4&HE(6:U]:IFZ=TP2+55IF^)&*WT8 EO [>C3F9@$4=:#!(O:N,V_688&N"=
M:T"X1RT(K,]ZW[M\O>6IN=>WHY>T(]UM'U?\NU*H?O<(JH+4),]H9RM#;S=F
M/: )=+-VHJ50U U4<6#@ EG.T^/"!:W(SD.!=RR>VR@5."@\3Z95,<0!&=9=
MH)A)76,RZWK*S,?<,'J_L<)@TJS+38V!&*.N-5GN65KN"8A IN6@@"/!9%H3
M6B)Z%-RWSMFYN+B>$WW86A5,_?55KDWEX0ZSZT5Y1C8F2QLC.Q^JR6C<Z<=)
MJ]K@ND6:A1H);\G T76XVW*DC2 Q&SIV-]1EIDB^30RJ#='S9RX_74!*G??L
M\#S[TU%VI/2SQ:)9D=RTO(OE@41,H?6%EZJHMIWN;['-@QRY"18O-PT=$L#]
M!Q:/!NGFSU,6@H# P0P.C"0>&@URAE[>G_W?N[Y[K_OE6#KOJ/KQ9,U^[;4$
M.!%UW%3TE=P9^0%RJWQJA]/S.#/Z5.^<FS>ZWW,T]U=S@]QXY>GAGW_.G&PH
M]*"+IH^H&S^Y;W8PB>=WL^R? F 8DH"92I(UWA'L%>J)[PA=Q$EXSLUGA6)W
MQ=WO2:+:Q^@U>U0ZE@7[:^26G7<Y>_4+0B.AFAU$F$<WK*R)L-&C[).$":*,
MWB^<:,V8U[>-V6-31I>+#E8;N['J[0O+[,]=XHD3KED[)WL/<4- ]D\W6XO8
M_1$%4R?*XB(A%T >G>+@: S_/O-;,8JRU)P."_': L;GVW)[CTUNRJ073Z>X
M[K73N'G'0>@KS,6U.;)3+&W8WG.@N\,4^7*=,G7P:=PM&-%A'9_285&5T.CZ
M4=JJ,R!#Y8O#XIDALZ&OE?_R8G;R_)J3A>&8(P-+4TEX>A0,,<[0/G07]6;9
M/J96\J)]<^'**6 TQSB@X>7'\@RG$V'SNQYG'C\F\.Y&W_US]_:=]2-'G!8J
M"B6U"JUYT'/31P%B'[EYLX=AT5^_NL]7.Z6N4S7DQ:I.S-)^K_M!]TYH^@WQ
MAGUV0@B94.#(5@"CM-'D<$@=?Q',>ACGVCLI:)A0%U?DGCHP]/FMVJ!"?OR,
MBYG%LQUYA1>%-$0A&S2M^2\VNQRV]#TT3I+N$-?IC:1AE;3:32A!T2^\[HL%
M5ZHLW+AG_G?J>Q5G]Q[V>?(@"=08[4+RX_?Y:FXR4 NOA<Y.Z/I>)4SX7;'[
M<%L"7K&.[2^V$+\_"'TOZJ92C%@WN.6ZN&;T-DTE)UM&AST^D7?9746":??X
M<6$.K<##DV(O58^XH\2?&.E=L*V:[U:'T<DW44UG5HO&[,33;O_*BXS2N94M
MJQ?>>E@[Y32/1EE29SIX%^;5\7!T52$5CG,[&%VU2I6RQ(0&79\<CZON]9'.
M=#8<:IG,-RU9WE=Y6](A,#U5^3G-1A7UY)K[>[(TF?8,59_6BYU61(/[;I&E
MGIO4W8J:]73&/?^J>.7NB.K+#B=-K&I*=/1+HMY88D!@1)>L6@>65L11AC/*
M/\.M0%_>0O! @T2!YE&%4$@+3*[R\@YQG[16$O<-TF"E,L*>!VS$#AX\:J1Z
M?D[ML'M@8,0#5+P+MFP+T>S.4?X&7Z2*FX<.<1J=(0[.HYG6C37!?S->P*]T
M Z08P^S8*[=9#:/AY>HWS++=8>-^MW<AW]=44+80 2A09V7-EAU-&)O7Y]Y#
M7\I%8>.2L<"E.R;.)R ]XVSSY0]O=X2:O'Y_XEU-T.TD\^2RCSP,H@@Q>'1F
M?7&MK0;-2[  C0;J'@XK>U+BG/KE2O(FYC;7//H[<K\8Q5^]:"HR/<U^W+Z?
M0X)[>+PJ7!E8CL0X,60]'?5B=* NHTRW>:)NS<0@@PB4?CT]J\3'N]IPO"5I
M[\0(OUC-BO;227^M=JH<G)A)(N! %.7L:  7A?I0<JO53T-;S;US4XQ'=Q#[
M%FSY(SJ*!'<%'LM$4LMK\AW:IP\=&3#K$OJV6Y9.!C PU)'66F'0.0C*6:.A
MH4[#EQ^O/<%1>MTFFBV,PHB/?/97W[^1GK''R[]"T"W@(E5'6?D&*K/#E4[F
MB\.>8;;>;I[U-G 86]/J_!1M\:WOM*?7L53'2WFSM^SL+NG&(62.R'^M&W:.
M@I#\L(?;FY=2&H!=[6;?B#TF9_WM%N)6RV"W(_??X7_C'P:\="HOA<E;^*!=
M76NG(;';;@OAC[F)K6>0&5^8?(NI]^5[OG,/4MAP)RYW-&.5?$X,6VA-<7]7
MZ/Z>WS=67RGN=,Y9OMG@NA'DS"(D,;"])PM]("LTD9-=OD,60/1 XQ/-G/O/
MXZ9Z3\]^:\"H7\GV#-:_=*#:D __+/W5\,';>7^Q1P1D-\PX.^]"HG2V+!S=
M_1U[*L"[K&IF,R<64HNW3^LPH#,L&"6%Y?5A&P$.PVH:H:]MXKWE=1$:3)\P
MN-R6X72FH&FE*, U-TL<0-&"TCF8!^"XD^/S)JHX2+5U.MQ\J/SHS_NQJ2'E
M,3 >!?8RW"X^<LE,3.BWVWF:Y[]H"'VQYZ@8+EBY'H/#8#O[K>2&PYY):]W@
MEMA9(4'-)!8MG+6AFLOL-X/$A(#9TR1(')/;8RT*2U\;T!;XBVT\2O[Y+32R
M4O[0+X</KWX)$](^D6E?D3"ZN()LV,U+((F;'#"EF)94.<%QQTEK$:.#KI(N
M$R\6YE_H)$YS0F&V2"LL2>O%S19!PB2 V#N/'G\PR;%8(">YE<DQ[?Y)6VJ7
M]"C59QVT/^HCDJ;\]-N;!\AM*.<!1_NH.XFT.;3(5U*CSRM^:XLQ#FJA5L9!
M[7SWBZG)G]S:V"*!G86%%-R_4BWG-"Y.+:?UDV>]((D3W$1T&#:)Q(L.QU%6
ME^<-T@FZXZP0RM6O17ESTZ:/Q#N^K@NTN.X9^BTDI-9>:P")Y,+@AH2S+$;0
MCVN':762.Y6401;IP!#"'[1FZ.IO7@S+>-[$?NRXI_TLCV+HE<K,C%<OST\$
ML4+@SZK!$Z^@:8](K?+)Q' D" N/OE[Z;K/NZY]R'OH^]O'V<";JFD[I1!3&
MN)EJS$[WO;\7>Z?FWQ^&0Z>">:B A\',)GV=X0R;X,'A :6804=SSP&3K^@X
M9&G4B?O6WHPF><72X2YPJ2(]YH#"4/U2]/-D2&(5T.XES0BQ-$$[]CYH&+V#
M@P;6N\K,P8=/0SLUQO ZCQ^3_$T8S952 R,[]TN=_<,>2A3\*E5?P)^@QSX+
MFWR(>&4] P5<I79CP;WR29!X0BM=_E8'2B W'>^UA1"1*T7-:'N%>8@F%#JE
MM-U=?I48J.:[\9M>OXX"? Q 35TRX)8[_122C#/R:1BWC*>'^493>5?-[QZ<
MM1H?8#J&6.S5S7-6RGO)>VY<JUO4!O%G%!+S^A][%PGX[8UD97#8'O1E6X%>
MMI\@:?#,A M OMW$4!1N]@CW+9$M^*%?<*Q(\(M3!O_M[I(C7>''=)C8/N*,
M%XL.3][>0VXB-\#!)B59*W0P!S.M)<"[[DDKO7N.32FVY(5&1P6&:1QX^W/.
MI,,-L%VB%T\0/CA,7[-,8!L1NR>IK<0N<2%(Q)]]A*,YWF$&0 .A%BCIN"W$
MN<X7Q\D-3=<.)+3\$"OV_'F(<NA?L;B.&4\3?>RRR2:2LQ,-":^S+\5I0R(%
M )%U!3;&GC"AH@.0,ZR%O>Y]^= T*O>VO'?Q5M&55ND+._-\S009GM<<<^]"
M>>;Y!YMX_M0]@FV_3/2GYFPAY#O$@+N06#4<F/2Q:PGN7459XE69'4I!1/KW
MU_(Q?7/1CP1S/'S/W'Q'B#R[_\21D92Z&C1MB3BCSOJ:RUH C6#0CN%F$D2\
M\-@Q2W':;*@%"8F$BSF\.U1#WCW6Y?/PQ;1W+UM*+#[_R>/U"TWXLFCMY5X,
MP5*S89"C; ]/G[Y/'UQ[RPZ"^E7X07LZ3B3T&_$YQ_YLZF&;GR4B@7R,QK?Z
M+J6%\P+"/W?J#SVK(7D2NR^0_=#;E=Y#SOX/1PNM S5B^V%8CRNR!T,>S'SS
MK.OBNO:OR]V/"7.A>U4$:0"S<S63/_R*8S6&7'S4/!H5A&#8!TYB01TJ1R:4
M]1&.X@-0OA_5DL:1(3J"WNQCSM&X!W&V"ZB4YM"7UR8_OLT_Y/MJ8M-^":-^
M,FS20Z!W]]C NW0>U <3@AQ';[NHB-U8&&UJL< Y+"S"6]TY.ZM8'D!1-U(4
MK]PQL>Z?9A]<N.Z5/[#F8XM[<>$S9D](CV#^\1SC] .Y!J74MK,\G %\!"B)
M#C$ =7&<G17T"S%:RU\@@;CJ<Q.,3U?'Y[Y-M<E5\.Z%F(6?$)MJKPQ [:K!
M4"JXC\2X#^>/SLU=ISA])0B$;+9>7W6H&LYQVGUJ_;3#^S@=EKB.D^MTT2P#
M6T6N1W%DA%A]8-@VZ$!CQ):J <S-D% @:D'[UN]2LZ-,Y3*UB2IOA\^?0Z[4
M*YU_[KE\8&QV]%W>7J4##II1"R0@G,21C&*]W_9X^T^\^"CF)JL*1*ODTO7D
M>ZX_S@/8\#*[==>Y(^Q4R/J#8R^E/#\[ZJI2[ W5SMJR:1+":HF'<:")(C8I
M NHEM81"X]?_B2$BQ0&L\N?A!*N&P<K=YJ#W7;UVW3%HZ>W&L1X;CH:ISB ^
M@7T.&MJ^1R/I&OX2MXQ,R\,"MABI[V11&8?)YQWVS-F%W0V.W$PY/HVBO%'=
M* LGG*+NG8$IOV-2#W^^U7#_2 8<UD$U><8@#0EJ;3(2V+NACU2D+QA5R[ET
M-JO;O<AZSXN/>_(FYQ<#\DNMX]]%9IRTZ?5M:0QSS636S42Q#L,M]9]?Z&FE
M/C)@-V? .@,$)7'XHN3J!& 0&+EQKB7D_JFV?,<?NGI+J=_&HZ+4WRJ^_2)=
M?7C'&$+CB(0]':JX 0=,$ ,N4U9CKC6"=W>8#F$^VRYD6Q\5XHA,0UJ=*[!S
MNPF]V ;J&OR6/P"09XS0MA!PM^MU1RFL0;O!M/Y"DB3*,=,9RW"UP6=)?S[P
M64WNBZ_DRO# *3,C0R8IE0HXUH'[O%LY2O),&%^Z%W SF5X&65$<NZ3UWDXY
MXJZO#?H/?;FUCZG&WZ\6I5)4>2]DYY]X?E);-/;Y^CBLNS6H:QM,)19<'DD^
M'$WNO^C@=<'>"C"KER#D;='OJ=G/>/TQPOJ/V<!XUT];-4;XB79]I">"TP)'
MQQ(=8#!3L3BXULB\STH$OP-%O81#3)]Z)@\'G1"UP% 3=YS R)EN2CRXH,.0
M<8K>=V=QL^S,#^W@ 11'R1ZXV[6%0)!IK[<0+4CX;6JP3&^G9#-3+O?A40WJ
M$L4KKE"X/+U>H_Z8W1G'MSHC4:3&6(Z,/R06R480QK"2'7O@F)F#Z\!WF',)
M$-0N[_T0-V2@$%R2\CR+SSAI,O1)4-ZRTQ/U6%O-#E?=;C[9*_S.1-"DCD;-
ML!8A=L,,/Q29TJG!7.N$>\NEO.I@SZG,2^+D<YU9V,S#X5Z1_L4:2>Z'_>*7
MRIP1MG BVXAOM^^E2"9.6R.YFDR!:#00A%YS9NMS@KC9A -X?W $,.N9U__T
M&ZMBEE)9U->F+#_O=E^N-,S"1J'X_/$&JT7<;#9;)B9&WPH'"1O UC_G=FPA
M_.#5@VTQ2($%.^XF&LC&XL\V9E@*"'$T%;U76!5ZG2]NA3>W_6.SX7T$C7?E
M!K'U<F'<2?9!7T12%B&1*;8TN$B79^0"19#DNE0H2E8_.ML" \V_^&CY76OB
M&NB&/3@0GQ>E(?U\\B)5/S))!/'G!K2C"V9*=,E)="@6X7EJ>=B.67@3%RIU
M]5Q,2_TN=<NEFF"1U9A,;NCVQK\W-"R'K@_JNU\W>W6I'RC%ZQUB?G#Z7AU3
MV$<SWL_*N5N4ESGP5$DP)B+9X@5!&K8M#$W[%]T2NR:RN(6@X+RXM01Q&+NU
M0YEB XJ!F\E?8(^S3I'9>,GA9TVY6189M\_+'V"J'HT%))10,)AT^Q+]UA7@
MUZ-DVGWB3G( ,<WS2PMI ;4SQ*WAJ^O\T!D1 ]WUVO6'J<=W4?)?-_1Y"07?
MC9&@(#A[N%7HR]B;5#DR[6Z9&:@$QW@;Z16_MP5U<7=IM)-826 R3JJM/O"C
MG/W+'%K?<FCBDFW_4DY>WJZC%;)K\]K<1&)(+KBWB*,8QCX<%\NZ-+;"1&58
MBB\DV/=)@YX6B8VK+9&KGG,5&CSI[B4FI1ZG[WC(?KK:?^XIB/S/QFA!I\GV
M[0MP>FEW%$?7[M*1O*!,3YOL=%&_9V=MB,JCA;VU*S=FO15%U#OBG)RO/D51
M3#5NF/[)?_(Y8).K!(G ^D,@%*:]5&PJN@'70U*)(]&J!C$I)?/U)E.IUW#I
M3(H76'WJY4><OD!-T?7 B3Z%1WW.J'MLV[Y5-O_]CWST#"*M =M(ZK-R[:(V
MC'+DDR'AN0I[^43<'J\PKQY/NY649F<].2/!H(DH&8R40M#-2YEJ8T^E=C^K
M^!L*QBZ@A>)ZZ5#* C7M>H=G6MIO9Y7)C:/DI./77C46:L8%NN&*DX\/=94Y
M6$[1,(Q 0 R2@ E>TBC'%#"#I:L'H=>''Y#(ADF3I!<VE+2SSF=^WXX[_9JO
M7L9XS6P*>GC/6SB0X]B1]8)"Z_)=F%O7#=;@SFS03>3AF"5839;22"+?* (I
M(V]4 CYX4 ;#<\#%R//=ULN):$,BK1VK0J3EHWB(8>LI*H>X#\D!.#E\++=2
MM^D-FLX+(%/U@UZEK$%CD:RS'4VQH3'(B(VFRX4_WZTKZ)H^<^]&BW7NP?N"
M&7 O/$* 6]I.@BZA2X[4:%U51[$UJ4H,X]7=-#T^Y7H3]_RHG836'?6>[O+L
MEJY7/BO?8:C4;>7(3$&B4< $),8';$!B8G!]T<##@4SS[PYC%QL^<HQBH^6^
MZZ0S?N@NV:=ZE >UEDS2$IF&P4OS?09OO!*!.HY,+R36RB1!8H8 "A)M9%^
MWJOLNA'WV\N!XTA?%P:KG#/1O%^_CL_6'-3L7RF.4GO4U^J\9+Q4>%%B0>TT
M<FYH;WFBZ'_)J"O=OG\!<"7.;$ BC@#*D?L0AB KH7[/G)0:L TIX6E#%S<7
MJRYH+YE<_>*1'T]W41D^;+,GX_/9,-5\A-74P/P.@-Q'%(21%&F)J[!]\K6-
M5119=?EO0M>[6+?&@3$G&>2/!J-]+).?51RI6$B$P:R 1)+9QF :ZQ28R[2W
M9P:E7MM"H%8]<WM#&9;O],.NA1:Z>X56QGUR\U7-=_U2Z#WQ4@@A\W,R"TY8
M(;%;,]K91K>N8Q>SR#G[C7CL#=IWN>S#?!JVA/7UGC)2"J&0\![5E-:-IBS2
MGB>S;0GO(>M&IMDM2Z?@H/'H&P>&E 7W?OU*LSRC7JT^0#MXL$!5ZLCN_ITN
M1P3^ST.VCS"&:LKMJILQHNL_94ZP<L"'E:!M3XGQC;KF;)]%/\'#LXI[AX=U
M_,5V^I:.BE8RO6.RJF="_UH];G_LX$-A42RR8@)5_XG>49D\D73H@9BQBQUB
MIWL61"6UMJ[]@4N&PKT?C:%DL?[YA*-_N,9^<H5QY5J6C=6/1_&&UN=J.ZZ\
MJ547B/E3?':_D1&B<BJ/V*U!IC5M(1H'.7+R)Y@##P%Y>FR.I>D\HJS'*B"N
M<WQ,_3Z#%'+@#Q(7J?]3H":E5V#VG^ZPCSPL/?5RA]3#.P^^Z-VWB]_]'15P
M'07WKZ]-P384@R%T<B:YB9R&QS[YUKEW"NLX40$0BG'1!T^]:.I[T_CYJ*SI
MPR7IJ!R+J0%S(D<E")Y4TM&10UGL0BG62LV*1T;2N);E-^Z49)DMB2/B5> ^
M+MA.H)(;Z@;)N[9OI]T' YD.)M5:AOGOVL37HB(SEKQI(>3?X9:M5S[4ZB3!
MDAH:5GKB9UYXB>T/":?!US\_CJ;E0Z),4H9E%#,5ET[<::U![8U:-)!S#&?V
M2:NK5TK%/_]I'5#BH5'\)L3CGP+OI,XB;C8Q##O3R.* 2O[L8] 0K IH3(-4
M7+A&2WRAB&K9^U7+^,(IR3>R](+8??M["P(#=6MJ$MS^YZM"9\5@)@T2]0)B
M6<7<%YU&A%ZW,JDIO!'<R)(V/V2[GYJ:1+2]OO6Y_XG'O4J_#[)Q"NNB0_J^
M;_Z\_&OZ7[,N.3?A)O*)_$7.AP=.>>(X^=?@<_?OOPE'X*ZR2OV998" &6)7
M"/:O_]1>7F06%29%DB%H6H9<F1'8"E!9Q \=I\F-7PI&65N(M!KC++24:=NU
MX'E31[VCGT=BIFP(QS][#POQ&_$M8X'+5(;'0VB "M@186W8-,5 5OMXX<T!
M5-^-=O;QLW,:#:46&/?FEAU'@@J#6K+E]YQLO'I\V<2+M7W/ICG:CY2-170J
MXZ\RJ0Q[IATFJT.^,K2DK."1?JEP]H^UA9=Q%7F,I?T/WIR5KHD0N('D*+NP
MU?&&W'2X-\XKC<Y4LTX#'A\X,O1<N6#;TRV.GAY:*>N;5OU]MY8]--KC/$K)
MZ8D(GB,(IK<%)%$)9^#?Z;@SLZQI9BY'NIQB,%.RCI5S 0L_4+,>I8\L+5V6
MH ;E)2?=['R?UU0Q/%\[P2"".D$<>2WT- X2^0+4P1'A%N'Y*O!'Q@C[XM(P
M+>/E4_J/6\XUM$V$U\D=51O6?1;V:1=R3O/FE]"-7OKZ&JPP!5Z"3+@R3P*M
M*='DV5:6(T!:&UQ I5*\*W&+%L/9AW^-6%6F[,G\"7QS5C;;=U7:C&A"Q@OO
M<'R[3*8UHAJ+LLD!=: IEA7 )>%O,''=/N8=P!9BX/Y-H4R"RO?<IR'R+1/V
M"V+IA-&KS..!(LK#N_X@!$1OW\SGV<1Q9*(@L4_L\X39+40S*K,Y-P-=7T.4
M(%[R5J>SZA?F#!9RR)6K;C\Q5=\8THX1^G",[%[MN-!N)[JLZ?:'ZJN]@I4A
M=D^0@3.D;->X*=9-;C*95E0/YM+0B>%+WK']YLNE3^8NU#8=<?@Y8E63(5"=
M?F*(>8OTYOB.-?=E= 3T&1+YB(?%KN!T7%T72?P*Q62<&#AK$>?;F!L^N]?X
MB24@= C;6%G,&HG'<117%I$W"XF C9/7NMQH94OV@]6R_5N(E#NMZ?D]Z=J%
M\83Q6U?)OG$B;N]/Y_2)(EA(>,T#6/*,?3\5<*A>!W6TZAY20_Y>RE%RGK24
M* K16_/9(Y'W_)_\BSKK(7YY@11TY-Z"O(@W9-$X6T@"UL!)>?A#S4 N \/V
M(W8;^'X@!ADHK7X+JP!;C[60<[ZIWJGW\'_Y,DI\XHK[-=>=O)%*5RY:^P[#
M"ZF/W!2[9L ^3>R6M%1:1(%:HE_W <,GN.6ZNM%LM'"<OK/H^'LP^'IR^J.6
MT+@#W0')&ONP)=:881<.GIL-EV\KM:F((]W:@]KQGYM%P;W8-1Q]=(;=5R8'
M= %?-M.;0[-W^[:<;;E_\K;/;HW])]P.W15=B7WW2O6#$!4%>))!/0ANM_S]
MH!7@OYC;34J#5)@K:9TZJP=E/];55>483W2."O3%GOYC:]!YN!5QPW^RTYK[
M@$S[M@[NU>Y"*\5YL1*951SIR95>& *R350[I28Y+N)?.AMKI_VO?[:/)*^-
M.6F@R#ER&<GZ,6]6=Q30J$#D>C=5@3!* NS1TVDT8@ZD&A?;[UF4HF=@/,A$
MWHHV>SUA4)XY,+/GAL><Y+#\/^JB_>ZJ$8;8,&(W?5YAS!@#J@^F-EE9]TO/
MVH/-#^VJCB-X99W1+AD1@H@>Z<Y[QCP_8SDJ3FQ7O"U8O;UKAI; [P-R6+A;
M;8-I-7C< \XI4WF=L/@G\YJ_L#/E9SKM[[5D"'3?-KO'WY77E$3T1M.RJ<UH
MQF&V#Z&?A86E!,PM9G!G0?L%"W$_9ZW!7L^6@AM!FN]) LWUJ;\T%S12 O1I
M!Y0D>I,B0G_"(('.=R33;E)??!Q_\X[Q +S2:/A6 _2TS _=W* ;"M&QJ0[H
M#8,9XM=;#Y!E1-IS$G .FPPK:(.92,B:8__A,5.P^1DUVZB[3+*I_7S@I_5,
MHSOCDO,GI<H+\[UKF\).[RH]"_F!]I#$T^V[E?!B3'0R82]<3\?(M'MA=(-D
M%<N7F#6,3/!?_:?^5\,NX&2Z]18[S&K4U&PD)8MEEL_P");"3"95S ))26.9
M3W7N-R@&?B(E+Y-F0XP#'P@;7$MMI[Z7^!YQ2#5 )WH%Y0%?>LH<EDZ1<*D<
M8[YB:K)*]>:?UH&1>)$]UW"F;/:)>;<#DO%H7Z>)@M&WY)9@OH51T#**U0S6
M,75H53UUMWP0H)7^4\"L3_TH<SZ76?Y^_DM-7;0'X_<3W_'QL$X;O8#A&'GK
M2^,2IAO8<B* JQL<I<@L3JV9^9HQ!-B*9MU30'-G\8.X,X)CX;JP9%0=HTV$
MW5;,S*AP_OJ%*G"P-.+ZU)=8CFSN*>;C(A@H\@B#A9W6,F++3%::+F^$;4*F
MLWJ?0=!4ZXSGCAO^LNQ9MA3Q;1$'UNX-V ?$;VVB",X#N)E\1B\-=TH09TZ3
MMA#.$^Y5E^>UX?\]6\[-U[N[T$Q:R]^ HR N^MV);J5S%)HW2K@M@K_K1[HL
M;]%Z\2%R^>**R3(:N)'&*8[M'F7OE]E"?&N[_,<=$C."35KAJ'!ST;Y$06*W
M#=FO73S6I7E,MVEX- .29LHR.V_6AJNG9TUG/G.HKWDG?7Y3ZLL[Y9U2KRXB
M86J:K&=B((G7Y1; S!B33=IIXC;>J13RM[,H2J(ZH:"YM61HB!5V*FS.VBFV
M0=_^2'5)ZP(2-,=!HG9,3\PN: )=#Z/$#P-IZ/T\[\?*K O,X[6A3QSC6<%=
ML85>]V,E/5O_>:OS(#,R_+E8H\&[A+1>4G-NM\&L/"1^'GRZL#[#1S^509-Y
M@-__Z1=1+DZL)Z9')T&.I="[RG,V\';4D?6KNX<M[*V]BS=+P.^0, ,H@L2B
MF'R0B&Q4%'L/-(5JQ-SJY']3IM[*U"(Q%7=-;F)RKY$IX@G[O]W5N.SGK^J_
M;U9LCX4]@N^7$@MN=LDWH^%"@WGV]E,C ECN;8)P",$ ;E?IEO9R>8LH)%CV
M]WRXY6$CD?+HF.3D+W/'7BPE*F/$GO2ZOX(F28 ;F7\;71R$881\"LE]T/U]
M_G<N_U=*:ZJE56S,.?VZ:'7>_N"UBM@?E$L;!P[R'[S6CX?I#O_VXP)HL A2
M/LR<8O$S20Q9@+10B99J'G%W 8+2.V7 YN9:M7'@&TO\4FT$<)0_C^K1;Z26
MQ-M0VE4_N-2:AKY,RJ2V8CAPXEG^\,44OI[!VBS<P%#X3K_XY/LR(WG6PS)/
M3+#(ZLQA$ROWJ_\*3_:+*(@E(F=S,XE Q/&G[ /P2E,FJ!"[CY-#<#?;HLE]
MJ"R?BP"RUTK>-<_OE7N\IUA&4(%3#>\G]9>QHO%E>P?$4E5TV-M2_RVQ%=>+
MIGC1J3T84&>4(_,#=:M,&FR-4E:18&;GE!(OZGFZ9:OGQZUK_..DV%0O$C%F
MJ;,WYNB!JGXR[0<RK:2U)S>+6&_?BTL9#S&73[4T"4NH!,V=(V0>AS1Z?0YF
M[GG)<SY^G[07[H_CWNSN@?U$F,-S9-(@L5CV!5 =UK1PM!^A@#/HZ<%>EA28
MZ445((:")2M'"G_\OKA/(^+$WQ.[TG..G+R, ?Z-V,O'0(*Z6([\.A:.$P::
M18F3@T;L:7IUF7CM!:JH?G/MJESK01AYCSM_>L<[/ZGY9_=TS\W8.V:.H[R=
M! ##41YC$_'*W%<<(4 '$G6"TT=M!9UIN(RVTB855&'P^H-/U[Z'%D\*_WB4
M'V/HK7OJ^XI:O]@3#9JR>@05N(!$4K'$[A[J"U0:0?5MV%,??N#RY?5=!N+O
MOB^X;RB$(QJ,D@B^;RQS(KVU.2J:C_NV$(IDOQ&LJB7AT-1#58-Y\:@'K=JS
M.,@RF&_- -P;RY'#+&#7O.&"=>&2T#22M0)H]##4$SW@5:JFA^DSV]RPCZH2
M&_%84^A+-[7^Y+P8>R9R/!?46__/1([T_05T%X8?CX9GQ3489/V=?^K_%%-#
M'>$+^1YJ6J38=-0P5=?@<REU8R3!&1\(?\WW5TF#D,1I;LKS=:WSY= X\.Q/
M3L0KZWW_\)">HDK=X674%\U06V3=YV;A#<4Y8<2@!>^8U>6/AZC*1CY?]RGE
M?10,UD1L3L__P\-*X\A-0&(WMQ^>,K:TI>7.5+ B0%6"-N<J>+<%(QYW\L^(
M>&WCNXN9(7[)FU-(XR&FW8Y )X5'?M_KSW%@C94"V\/D5G0>A&;5(9%V^*=C
MW#MTT(3IY3;AR>XYZ-$?B0MYRLAXS+:PO?KS8*.=<JURM4Y%$T9%MDN<:<:1
MK;+CUOXF@>8K713WM7I8YHC$>2WL7KG5] 7$/<?;9U/M$TOW_SKXTD';O],F
M6CDNFTSX/K&.=((YN$PU)-K(=(=$-]@6G*O;.X6P%[;H@"+F9N]KHNU'W0[-
MAW$MB\Y,P6KZU]]NA<&,*_=/9CR_?1^GGJNQ+R90MT(#$0LSP#-(22>V"#QW
MC-QHP+"B_Q%_7, <[;T3I],_EEN >YQ/;Z*-HWY4D1ZAK<2?W1V499MA,ZA
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M* /B ]T]S?ZZ]\YZ'_RAFNDD=WY/"<LK=)^"H^K!<FO+P3V$*.S+IM-"72C
M?1U478<55-46 M$)]W2R!&1N V0= 8\'9-DV-P,AGQ9#,0V]8>(-#SM:#'5#
M1!.=K!/J[ZZB  \#4 O)L6IDV;=P"]'T.&(/F8V^K=M,95#!X^3FV(0RG70.
M29UA"LZMK! @4_^0493[V!$4+[PJ[-"T-$4#!GW[Z4;0%SYO(8@Y0<>G"-(A
M%&6",K,QV([>0<),G"I;#G4Q/7.XXE)8M;KQ%<D?$95FV[B"(E[$W*8"IU S
MUL3MV[2J&#;Q3'\/4K^98J4B]\OKODM#GQBU80OUMI8;%I5^TR\.G^9O/XIX
MA7L&Q_M?N+<\00$GR8E8X!QNIF0%+LFO4]=O=%]ORTWA8!X]N_]:YO2Q (]%
M\9]O4KSS%L)WG_]9(S6U841'<G9Q%[.Q"\B47R08K46=%S 9:#&\U &H!]!\
ME+W$P^A%_@JFW'CKBLE(>A+)6ZA3X&:;AFK]=5IH@ 2<)X,:^FG;#T-R<SHT
MV2C0?W$WN6?$K$?%^,64,7L8(YQ]2C-I"O.Z(>>M7O_(B^R8N22%PZ)[Q)I^
M#''M 7LZF;./G 1)@K;<1NZC+81P7<HO+HIMOP9A*)TC8<HJN*)7+>$S[>'+
M Y%W;T^YV"'P+MMB'ZXGRRU$[R(D%F=&%^(88S@Z)/!8AXM6/;<"ODHNBTS9
M]+)4<2]BM>,,E#;#/\\9YOS^?90C#\0T K+$(%+Z]>C6]&MB)!$D,C2FM1#,
M<FDRI5XJV'TPHD&+YJ[-4U_V>PI.[+]8P!$'FK&(H&9:;N>^\YZ$J;0%5$]=
MYG7+-D(M,.P)"+>(/OQ\9#W&8,G#(VRY3,205^36JSVF^Z>&(3-X =E!IG&N
M'DQB#W5&"!*M6ACEX<@RYS;OUW&L7]5WW+.$J^1)Z<77F;MM+R<^^UDN_4 G
M2"F7P=C)LT ",+AI-*V5(Q/%.@>LKST$]EL\O58JZ6CRH_J)K)EG[:^1SANO
M,A/-VB\B!*5D)2/*.X]QB^$Z^(RYA6V$J?[W/A1PEF&V6/PQS$0\U'/R&C*5
M"J0+^X^;B#ONUOS')Z'VUI.RA+?')+6HA@?L"\T(=UV.H S@2O1 TPK(?/_Y
MFWGC85" B7-O^]!L971:L>B6);;*2[=5T>3KT92.EOU:*6.9;T4"/YO>&7IS
M>YM38H'+5?WB3HODF]:J\(5@!*%5$-1!*FT]50_%4;/F[TQBTGY6! 0SBG_\
M>"S'>I6I"APC=9P5>7TTDUM4GFBMP.U T[)(P"R,=Z,WB8 +$@Q!@\>)=*<+
M(7#KZH%113AVEMA"&'QF!5E/L=YTCI*)1= SYY=SHW/5*. \$53'<JRR^K&"
MELY;"/'=\.>1G/T&DCZK!'N.&HI"IE"#;\C_W&"U$]5QT_7MTD'OOIIRJ#@X
MUPC8X@C8XA1H]_:SV.=![4&")#AEUEN73D4N%1MCI<0//W_0UEPP;KOC6?[Q
MKV-ODAR^'!\JO",;UE7USAJ62LDG\+Y,OY5NM!PQ& GN-[C=$<3TLF'RFW6J
M,:NRFL1* [#GO9J<0Q_/9F7;!;0ZS 1JN<6;%1^7/O 2-S.TEX^V#NJN<R2'
MZ5,<V02.)M.K9PNA8  I<#P!R1DZ:?>WEDL)DPM8*[WE8_G[A(I, S+/+[EE
M5-ZA;_IUU$$BS=LB"KS+"N,V;#_IG0C-DUO*7C,W%\)SP_V VLEFV5[[BY!+
M2GA@R6K\HY=YZI?.WUESR/C,=^ ,Z0D,G8NYC%'Z*W0X&32O8.%!@8?]K!$9
MUG7@F(\1\\:#.2XIKM'JET5:V/AN!>(LGK7",N_0845O/Y9%&*4VVC,.,X-8
M9""@Y$?5XNCMMEOR*OL_<6R>: [.T-,B,L<_Z(8LS3[9VR[B=\PP,*?;Y_O_
M=3O_O\?_[X=R;O]ZSA9"E, 78EJRTD^4)09Z4B\HZ 6R=VRLW]GG9RAZ6)GW
MZA'9_Z6]-XUJ8MO"10,HK1+Z5H@*BM*J="I-B6P$1,064(0H*(V(J+1*2$DO
M(D2Q06!#%$1$A(AT(DCH41%II172J: $J8B&@B256YQSQ[C[G#/&._N^<<=[
M?^Z/]2<C:]5::\[YS6]6S357$]B*!K%^H4N&^,70LP"?Y+-\G/ZR$)-YF.'&
M4SLMQ/2MQN=-;N?0$FPUHGUF.FARA,-^!=]4[%PGBTI./-O26A=O_-47T[7M
MR6]=:8P C2E2TI .VB]/ZL_)07!1FP1'4]DHV7-($V*,9E$4NC7SL]-E\)<@
M=%_M4'C:R(\08[ISV?EUL6\-SS^\.YCQ(%[2]G<WP0[^#=DS+ I#"OD'X68&
M2=9[LGS&)23,N[8Z\^@'2_TW]+L]ZM]VX<I!B ..C"-IJHC7&$F(T4%Y)E95
MD$Z=K@"_O$9]^4\;XJ'HA([)U5!QTA=.YW7K8X^_C1G*&0Z<71CN:S]WJ\:B
M[NZU \4Z$MMW:%<?9BRTAR8#*N&7K>T@*E,[E6F@=F9K=U3!V5O>CIIQ><_Z
M*J0O?L!N?X ="OV/=4W_^]*IZQ$-?@R\F9/).SA 5.(?Z24X7'SDI'@HQ6F0
ME5?V5E>TV7G1>87X](4+T67X57P[R.W&;QO\'J@XM<Q<IDR4QS[^WN+%G$64
MIKT:66N-J)36GLL/L)]<=8X^'P[/]0[;2^ZN;JAUGBT:\2"<?WB'?G6/G<0*
M,7>#?!B=CFYQ*XYK<@R<3BQ/_B<G9S2X<@H1^8DK4W\(,8G!'WC6N01:3<A$
MDXW%FHC?Y5\;3)D!?-*5+$$4;DGR@2P%T< B1;CEK.?9<+#53H@91-WY;2%&
M4-YX!%[)N\!7%A0!@:%I8&5*RVAH^6^W!,N<,UG7J_=D !4N$=&U>F_B/G99
MM0R]Z#3^<J!\B\Q)5HF@" R<2P)>X)M=PU@+'6677+#8Z2TZ)ZI?U^5<_I+I
M<%TSVL_G]#UG+1T'K6/)3NIKQ:9-X$!@Z0[X$Q1BJE'9KI808@Z1$#<AAOL*
MKN?ZH(A'XMNBT9S1)X((!VBBI8+2#1?,<+/=)JV 4H.E-MFV['&*Y^37T8*<
M([?]7I1V>.[,))XPD!]$^O U4\TFH\5,2BL0KVWQ4;>.@V_'*SL41H?:/S\=
M]-'3@C=Z]'Y([1[II+H-CPX\8#P7^>W(-\,)]@*+@! SALH[.4&(*4$W6T^(
MX7D3$GC'D D-1W8[4Z#)*$ZQE8RF,AVO_W:5.,!9W9EBK7*O,38YU=?/JW3Q
M^/? VR)?,\S2/1O*QX_X5UN[\(+Y!B]@-U3I>N)"*-:N(9PTK[XJ(4;T6!##
M+P?"=TXMLM>0C-96.?_8T*/_?'L'6QK#$VL&50&&R?#M98&";![+?YXX3%53
M__8<W,DN[6A<!;Y9D!!<0&5F1SGS0/3ZI@>B=>0;5'F0<8A@.$S<@!J^$!,(
M^G[KB>":5%WVB:0Q:-4U@@O$NP,>V<@H_F>P[4XAIN(*^'F3V!0.)N %7L6(
M-TWPUI%O:X*4#0@QQG/(9TJJ^MTCE7(8=5WN,[<4JB)1F^_9B[U.5(\><!VN
M^E@7$P86>3_C7"Y)?UOGK*ZNOM0K,4F#8.I2K1N_GLK+)/UE8/Q*>)X)M,XE
MO9+BN+51UP39X@;<'6[09H[?B.R=LU$EW!#Q2X@;9!9#63?XZU@TK!=<WS2Y
M>: Z7?^;B]?9X][?W58\6*/P8IW^!3N)?,D'V'J0P0%_GR<O1H$+&W!_>2K5
MM@'+H=%);=U7YE#7+DLT@?U\!I\I5?\@%\[4+)CN?EAS[W3Z6XRV5(<(,SN,
M,T_/RVJ71*0F^$=[_3CA3S0 V<9BM?ISY9!UP]1%M_LFAQI8:WHEIO]U:]#X
M]PQY3 +1\&+X\EU0*;GP5",+S2DCC30N^7<,,00Y'C$QL,:OC&CCC=J_*RG#
MR%;#&\[I,^?QU$U"S!),YK[4IL<W/+S"7K7K+<O:X]L"7V$ <3T#L$\U( =[
M)?H&E[^4HRU,&X!OH0S+O+N:RK4<:^S3M"#V59Z7Q$WLF#FQ\!>U_8Y%8?*G
MP@!U)I&\)$>YA^@AGX"51&5D9/G#C*^6K]<,=0W_0.7@7'AIL!HKL(KG9>!<
M?CRFX(.Z KZR>TW,T2[KD)NBMW?ACJ*L_Z^P0/J+J0[G#I,(D8):H@RQ1XBI
MDD Y=U;[@,]$=#USJ#0LB#$+[,^PY)D=V-WO''&Q;K!3=E>ZTZKW[R](>NB+
M_';[?[*R4)[G\CL3(@[I N5_A<8?=VLF7R,K-D0]FQX(-J#3DK5QKKNY/2[I
M_)K&EPHN"@[R-]4&OAK^L(C;5X>BQ5UB3Q2YXD,6SQ_6'C_!$;]-^>X^!J3P
MM_J=+'GF,Q,V*;/IU^T5Y04&E*K;FA(G2ZMS+YY0$.'B_[J#+G@2.:@N@X;(
MVS2>C@OC\EEZN/D/C;MA5UXTWY0SUT32Y@=S%I*JR2+=T..9 U7P709%\;+X
M_.Z7E34N)4>J%)R5IGN=UU2\U7SQYH6Q["6)4L)JSM!#CCUC*A'1_=ZXNA&:
M[;QF5FJTQUOB\!G+G9>S%=S6AV3CMXJ%G)02B5/?WHV)]?C?.6/PA@9YD!<W
MV"JAYISL)I#[R/\--I]$#*)K68G$#?!6:&A!6PT^6'Q\QA9XO>\.^4#=R^N3
M_5TZI>O?]\L/K'MAN<=@21G=O08AYNUFJ%AP8QLXG4SY.L5]NGP$#CO:Q3T'
MY[)L KBDOE"^7MG9;Z71I0ZU%7X72[K-V?HWYIU5?AX=U=1L8E0L9.P"'!M1
M?O]6$G(37-\9BF1VXHV0 > YK0DG[<8A<U\)R@A^N%3&4-6+2:WK7]6-\/8&
MFIVK&S;XKP\ZUOCAVH6&DL4+L]YZS>0QU3;<BX#FT'C<*B#0Z/A"^ZNIMK*]
MM'V]OVWT)3,--OE;S)R_+3YR4>/$GD=/?".U7R/N@E?4$'P27A4(H<+N--SA
M-@^\%*+Y/;-9+Z7!=(6;<65)2^3>@<NW_U@1L]!YLRUQM]+FN]F[3*+'6[7-
M28C40<BD':\V]'V^>0F7X?N:L__&0HMFVFOE'X_E#&.R]Z6\]94_\MGPR2X1
M9Y]:[O8^:W5.#'-X5H9)&BG<&XMM6J*T^O>;Q:K_<)?">6;2Y/<]5PU(%9-Z
MWAV7+6N55,\[S8^$ F;%H& Z.!M,)R7G#*(4SGH=1XITG6]S^7&+QJ9UF6I]
M^9*/HOG/*]ZGW1OGM1].A\O3N-LYY"04RN?@S:%IR^791L=;/=RU16H@W2O^
M924U.2&^@Y2NEB/GFA:A[,\!<I]9%]Y(Y")=5+D0HA2<"@0:N"4ME<<5\4T$
M>=0*Z\ (&UF7%:\YDHWO(Q-?4'(-,_P6ZVP?G?08PS^?:AFG)E!%S*BR<,?2
M#L(9BEFC+H=\G^ZVL? *<JYL_>]W7WP_;"$\_0R<19V+S +W 1S*TQTC\IP'
M-J+X1^M\LN-P4"#/L.S/\#/W/O/?7&X[54>Y8ZON,TH:5VQ=^EA>N!FF7N0Y
M![OG;TR;/11+0>09"O$4]>TJ+5O&9;<F6>U7O8J=<6/@^)GD5>#(ZS-"3('"
M*XVI1OE_J&:G(&T(O[3.X.$_W5WCLM(^)O;E;X.U&(O66&C/IO.(/G_?, NB
MMLI()7]QW1,]OX%?^I9G\Z>,T6!9_%;)PPOML1_Q\F#S'P ]#S47VNPBRT#3
M;6R<+L3P-]R"CW__\@L=-3'AP'.>P0G=]7Y(TD59P>0^/!AIP;GQYU4"VFD%
M69#'U^1M)M+ :EP3(-ICTTY.X1M 'W;\-NB8N%CBW9CWU"4LQE0ARM5ZSO!#
MV,(CFPI\",$-MH.Z6'M(?@PAYGJ^=,7PN:KNLP,>SVL&=29OTHZ_V5#[)W9.
MYVIK;7DPTV0$0"0[(1QW^=A0!O\ S&-@1^L1^3GIZ5>1\>05YJ'P/N-R?G;
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M57:6\NY845>S4F5BO: G7_%#JO.GOIVVF%.[<!%]> EB.Q[RILHB$\0-T#E
M"J#G4JLFBA,;@@E#2U%MW1Y-*JS6FN\DW5"SVIL3;PK,,_72L^U/Q6G9E>-;
M0>AB5$+#Q2(\W,7HY"O4<QLXH4GA$^[<%E %MF><:2PZI7-\/[2_[ZWR-]DG
MG)<VDF-A-S0P O6"AGKN3D$%@B%.XD2JJ&.6W'.<U"'K'25O=67U:@.-GQDS
MK?RKZI*00/_TEV=L[-P/O7O7.?CONOK?+^-AS<$FPVTF*O^X!F$[L5=;'SKZ
MJV9XCAXYP)]V7O7<YT1K@*WD9^+7R^(Q_HW7!-FV*K JG<3^1L<GXE95\6+P
M6#BXY3@Q[Y'#V;C#;ZY/R'ME2)VT5!R\IYNY/U#PF!HP)T+\2*L<3D>=7BKD
MM"2186T>57@V1$34LS!_HYO%MDLKKCE%V&0K<2GO@6O_R":[AD@AW8BF( G1
M0-YK/*:R2"E+18G:*P4/^*M9WBHVFFU+W@556QW+@I8RL]>[7Z7DU]^:=+I[
MB_=2XB&*,5;@&2$F#J?<:(6,"3$50)N)F%T982M$F34I@NM;$6V7NMG99]4N
MN58A>_\@L7]N'&'5)ZG9DTW6QM_7]?#@D#J':-#!'M@ WT)- #'K-5(2@#,F
MBI/1A<PI4MFP145TO)=ZB&&#3? 6IE?<UX9:_4=/]1-]=;VKYSN;R2DXZ"@Y
MF0KM"QU3I0LQ3931W(XN'CYZCOEEJ)!CVC8\O!1YMW@BW=V15C*MD=3]SLZ\
MRMWBVXI3)YQ#S<9K1%]J+Y?GZ^18\I6LN+Y]?#&>%OH#9+<"=H%:AC[;4^ O
MU" 0&VQIP7ZW;RGOX^L&&?/?;1DBER1]O6[H)V%PA4?^S3,I0Y:=$[:=S&+^
MFH.005.^U1]U_8W:Q ^(+H>49/A#R2SXV:?O[DOAMU=:JZN,W[6^V[%GYS#-
MG+-<))2[6_"H(9BCQP!GYWB2]H7>?']XZ\5896H2P2[:Z!SAS /\GI*81RX[
MF.K[VS*E3K S]MV^D7Q '&P&;;6B'9DF? 4)UDW.B<!,.*9YCJDER[,Z\V+P
MF:Y+;I O<=6ER[<2/SU2T#TSW::=VT+<N'R."0TBXFZ!S<>!((GG4$]J!!@_
M)@<GL6)FQF^\OG/!Z'UDB<BEN.[VUD2G0@6GG_K\MB>4;NKX!P V)LUV 6FS
MA ">//\P%,6>*1=B3K[EQ#".P[EV0^9U(>?*9\>XV-6:H?I,>[,+6>&1IPQ4
M1]-;3-EXZ$"HV'+:)A!(&O=B!+3-)=.@O2&.+#?V%VB^>8E832>EO*IM3\>V
MN"\0=?.5;H5&&%@-91Y;_>=^H_XASR.Z3^9>EFY[+M%'AO9@4\C*OTDR?&_!
MJ\8ML/1,\S"Y*JJMDP.F-"B#:ADSSKV'^C5=MT^L91@_3C;9N0N8*@A8_1);
M'=P&^.(R:#51G:'2,SFUL[D\<31L3!YDFTLR^L))\/&=4=>!ZK6;ZZ;FSQU4
M65WVDWWN]N!%']J_9J,1P\'F$#.R"K$5D&M8YOGML"9C 'Q*V)08'<!237GP
MTA.;VJ .[NQ\7L'K'YMT5JJ0S;Y9N6;/2F+:<!<.\C(9;64!L\ME)E_"];P=
M2(_M:C1P2>GPV=3'IO=6A<YJ!KM5O<E)?_;>>CQ;)W7KFO.C40=_TB_M6HN2
MP_@]R)O)'8)<5(K!<]=I51O:/(08#5NSF4O1-.:/)W^R!\\G3X=/?]@_'K-=
MVJM ](#RS<=BS(;OXXC[Q=="3*5<C1 SV'^%1VH=JAR95K'P.,B^I[D]T^'-
M]I-7Y6]U'E_TQ8[FLBZ!S1'&U'/)T'Y;S;>\C7;T-@Z.>[=V)Q/.#V8%<4'3
M'B&&Y'_,NL?DW=1Y <T(<P%4!+^<QB91N6>U47P9^%)V")WK9%!.5)+M%F(;
M33M<R054#<+7X)*M38N_;Z7,9=Q]UAX16N(ENF-4]^ >KQJ=J?*S*7PE;--R
M9FX2%3KJED*M=6,'\5:B,N+T_0+C<[(2(V(M$95[MQCDRA.?OCM?PKUO] ]H
M^6.[Y_4\(29:/D&UE;Q<\9X$;R+/9D-4;BHZAV3DO:T6K B-TR-+PBBP&^-N
M%FFVP:4D&-&)/BX3,UY:NF5MALR9@$QS$7S,R63W#1C@C[\6-=Z<I<)=N/?S
MN'=39KN^TKW-2MM>W8J7M)9S/!NK) +G/2-VD:L"XL&S)G)@<^VD>$X,<)4J
M;^V&:Q, ;?>6DM_^PJ=@+^J^HJ:LQR23B$]NCN]IO?CS1U' RM-KB?W1H:TY
MV(0&JU,,G/0T=RDRJ^B80\#C;]R+DHR:VE111X5-C*-'=U_=CA'!&\()7']X
M8KE.;PM$FXT+IN?19)\!_J[V+5'$]4A_C;9/Q<;7J\>\8O]\._5GTPWDY(V.
MK?'-+RG/IL486-@"CQP(@W20YB4:0OZM = _N2WN<2 )[F(UA)CO]K'>4WRY
MSN4'\+3 9GU$D=A-JXJ*!QEK.,7)YW[_,6R&GS4([JDT&WL]V^;WH3K3B;S5
M59.0,3*1$"^)6T]LSE^/[O44V&P#!M131OV::= ?7:$:=L$L&_#0@'7P99XC
M'.5V/7#NMU7:RPEV2N[:(XH8Q^RZJ]./Z)B8++ZBXKZ!QC4H0'@!H>A 1*D_
MJJ'7E+0&*>8ULS>JYPZ<'>M(,5NZ<U76LDMWZQO:W*HE,M7@BPF\ <_&<TJY
M 1"YS20#7TV]%AYRF.76L7Q@[#IQ'37%I89<E)1Z\D5_2#82M*XZ+C)YAU5>
MQY2(I\#K?S,'U:.3"KECQ^JY/0+R[[DXJB3UU"/X4OX6^#5' Y25H:8.J59^
M&WJ3$]$^.<_=H>"P(T5=9(FEU20Q<L2CG2K68(4&)Q*H*G>]P(\Y,AW9=QJQ
M,2X?!T]#[BG,'>:;'EO<EO%(-?9>'^%5*.;T[-WQ=6O=5]EI@M ^"KRI]AH0
MA!]E=4;A:I23$^BDZ^AXSB6!@.:OM(W1X0(+E\.Z)4_LIZQ>OLCY^$>)SM85
MG<921[LQL:$.Q% X#)&>XN&_4Y]_HM;$4IJ\1;GS+'Q'L)LX\>VDQ*O:NHK,
M'QU<!OWY8'7)F*/^BT>')Y33=40W]8JW/1SHM5U)' &A ]1X7*U>'.!+AC?;
MID"WC^!O^&A]G&M4AWL8*S32GQW\OO/(YHNQCR>]:%TZ\MRH>;]LZ83*E<YZ
M71A>_'48Q[V*RG0@^FPG(HV'LA"I;[PM0;WPG]\!^:)>VZUPPXB+,?G!^QK5
MPQM)J[X?U3Q@)'59W'/WS1?*QMU?8CG_*@CEQ5="3#66KRK&O2\H1ZSY1H)4
M<W TUQD*:,'A[!E=81PKI^']A1=ZBL<GYHS.&.QA+;0%2$9_^S2#].&K4_@J
M6$1JD;<IB%H=-7OY$5^.DTQF@*GWJ%!UU5S2SHWEQVG-BF4-)K%GSW_U4*U9
M6&WPZD[TF-ZAR,OGG22FO95_HB"5@$C+,-U&A1@Z<-57D/&L"JO!/PI/,8VL
M[&&](III=S$^]^;M[I*>SZ_J*FJKC$S?/,-,J#BMSF':&B)# '1H+@U=0\]U
MT)<THKH7M@^.A1):=AI-M8=>HRJ;=;L^HT3$[IV8JJD88+,?RU[W)7VXK.UL
M(27J=REAK<2G08^I#M2+K\R&'Z.LQ2W/@]E8"DGL#1V3V0L/H5ZEIS7-YNB'
MNU&LGNJB%[H>$E,\^0R'^AU6B6??-MS4M>EAU_%\D DJ%CPG +C+"25WX##&
MC5<]&=:*4<S09!]+V$U+T)CW1%-]G:OCWOS))><-JO)2K.S3A^0+K*^.8L38
MW_^E7DKK\N%3?%44"3AM,J+'[)S= 35V[JOC8./XZE&E@=RE[OJN(%V.\9&]
MMUZ9ZCU953S9Z V=H$%AQ1G66H_@X7T<(8;MHEQ3\=@N)E1I";B>4."B\>;A
M\[;3XNK-.C;38K_V7E]4I _/=G%:4;9_!- $40(:[&W0&GDQF*B:T$X3L79\
M>,SU_"ON_6S7/1V@19#8I-?>;:(A)M)F24K*'[S 9N?EE(-Q%Y8_B5ZFYQAZ
M%:BTO&I\GF@83>'M]$JW/\39Z?6:]2U2MM+0+B3D</BBXZG-GM>\FY^(L9<,
M?B++U[*A >7*(-B$9PF[(-))O'U\-7AS ,\6SIAS:N1(Q%5)_39ETE;!44?S
M)4-,)G\<L^V*V!G[6&I#DN]^7."(O1(7A(VP?!6)9@#:1XI[57Z;KF5#\. 4
M'X7:AXKH/2O&1[LN&87HR&X8,ADR5#NW=H1]+'M?F7JZ4VO#2=RY/D^<M+7+
M$WB $97<X/?,T'?.O==PSCA1_^B*S*:,<3L],<,+VX*)?ZWME +2'_ZC&+42
MV$JNM6RAC90B4C.6S>.NCAWY(L/6CD^_ ZIF$WL#Y<\9&Q6.:GHZJ3NK:DEO
MV?[=:KDB,,&>_AI 9-?T6QNP\MR8PVG &:,]"*UIN#):M+,YQZ+1A]4FR;&I
MLL0'WS-3>;&GLNU]N;JV$^WFL^(B00Z57D85M]5# =W0?_GR-[[7..,-08<Q
M3H6/3>+&#L7B?"H$'[_>KW@3):5!UV_)B'KUR2[?YZIM70'5:KG.2Q+:=1\;
M#,".\IH6@!6-VJT\9^+ SL:B*$:9A$=-8TVOM?)#+Z_85\X11B^JV]O;+$BA
MC>:!:2Y6:S&=U3RW411K%'DN_(V"!X@>\@:$#@OT&(+B5.N5T,/&38&()8S7
M^G3%IX+A^35S<O9S3<.M+[4O:W-L'H7J,WZ*7E5OLITHH)KR-5&IVZ'3R85-
M& NM;O FU5D[R(KA?I=GR3_,V7@W,'RU0HP0 ^_EJS^:4>P4O_V4=L)E777=
M[@&O[,(,LS.*CWLE3U(?_S4T_^_-8RJ4KQK<0M-H"$%]FS5$8<]PW+N:M2U>
MP]\B\[4Y/H4/'Q>)YUERM;YMLRF]62D:EQ6D,Q=034SUN$;\"%10^&8]'>0X
MJAK \!-B?,&6^W"<)<J%*JD5R("@XFO0@@H8,&_]F6=K+>!QW^;51\[?%.E$
MV@$,0']"E6[<_%U[G:"&2G] 5(4I#.<&P*B1S)A09#B4)QDU/@B(*WQE*>_T
M_GN%+F?Q],EL-'ZC+-=#>4&M.(TLWR=WEX^#EG.04Q<FL7W@.;5'<"QJX6X#
M2B7#X66XMQ]U[JK)^=7%>/H_WS9_[<QX>E$KL7(XD3B(J[#DFY%0],!RT?&2
MLI>KK$@#[1KE%8)T03J7/$NI^38;\.7RY*787/]97HUSO>:%UX%B_?S#3'("
M^&*AV86B!)<>[;?6HKN)PC&Q[6WUJ.,/G_&\BA%I*=@3=W17C\@N/=%& T'R
M+\IU/'08-V[@BLZWEN\.118R@"1D-<1]^!!Y[R,W9/3>8X$[S$-);-M"X.7$
M"0<-AQ6.S]0NV;(SKW3RE7L0J6&.)B(=QMOQ#5=)C0?.JB%JQ\:B.[I.#/W0
M@\RN\'>^.YX2?6ZJ)N>KY*3\CNO^SM9M8:+BNTT]J2\H;"]4J[Q@@$-M12P$
MA51ZI3/'HRG']T0Y!9H% HPD=GD['Q_R?"#*[?>_]\G!M-WRC6VHWJF6N@>R
M ")]E$Z1B,9QNP37C:Q5&3:63FD'!(]^>^]%;+9U;%?Y^I-E/W@Z_^NNJZ'W
M''U_3!F^=];-X;UKL.>6"-)!QF.B&7\UW"S$R.!XBHA29YM4@YL@3T!"=Y=D
MZO:RD@=D3^F-<J;F:#7[9L=K_R2%_C/Q\'\V[!M:'"!*I1=150#Z R&FQKV4
MAT4FM35@EX+C_'-5:<?ZJWN2N&/SDQ.@K^>MG5VF)==6Z-=+J*O/X0NI*XG2
M?/=ZP1TFK,B[1'#N:S2,3CC2_UO+JF/I2VVR7S^[NMXKNUA4,4!3.=WAV:VF
M)ESNJ?-EZ([5LH.%F%7=G&)65@<6]A1BQD&H#EEKSP39<VRP$O1;O!+[FCS*
M[]F!])%UB((*5N1$PVE>+(;H!C:CI,NOV\5.4&IK=!94:=3'1P_U< ]QM(NA
M,/K1QE)M_!]]^9&#>B]]G;&7H$]C8U*80\^]+OM]UE=E@_!F+%_)8IR[%9I,
M@.H9JG%%J"9W JE9"D%D241]9,W;)Q-Q\SX3<HZC;*.?NCG^^J(E(BF&>3@T
M;E$$6W7X?\ ,%@T^1H9N@BU?X(HP%OX%Z!=[FX?[4!./?7%^_A%OCW7ZY'F=
M#^QS:F\7*:PIOCR/"W$H?"6]#AIT !BM1Z2'L:U:?NU75N<G%'\+0WJ6\-?(
M#GVS?=B1!R\'363;+G_\H?N3E1;S)DJL^H+(9[(:U;='#FFAK0)]R2L(SIRQ
M:'+[Y$;!*[,Y%<)QCMO=&B.O]BME]TIT!PKH*V_8KKLQN^)9H).[K\$T?ORE
M32=?)8:[*KY)\:(,X4#^7-"W "%&\O.F4>WD@)JI0:)R-1.[?-62*F>.JSM$
M]0?'47HI\X3OS/D>/3G>#F")6Z:%F-7A<ZLGX#U+/>S^;[/*=PNK#M\_?RIG
M3^29((5OK'<A'JI"S&DW6&]J5HN!&R/BQP]S?PM*?PDQ:3BY<)H$D&2M*)'"
MU\C9>)<AV'DL,[@D4\0PV:4^Z[K1SR^13^\/*C<=P);_-49;M$=DBH28341!
M <C.^@XL82@&@EO &=3E$F\'0ZWMC3M0.W\6;> !&55=V?"U@B%I*W[,JR?F
MT9.D+Q5>#XVG)^BKY>ZO*@D9>4,I!<Z31Q,033<N *?R-OVS]([D,%]O4K6N
M3XBI17'4=I2+-?/K_FD]TO )C+HR->@!0@LM9"@.EK"'@'%D6)!>..XI*'WW
MDS^W<0.)^"FO;OS/TZSM;Q]@4ZATIEN*QRLLVQXW.P]1\4@S7,PSGQEJW +'
M,I6N.J</M(9</J5/IH9<7'4_TS;#=]>E.@D:2,_&O_! G:(?=J03-5^I\! ?
M;S_WQJJ="^G6;I&F89296KBND9J=<2S'^432)V?/?K.WX\>IT(&Y42RB.<PU
M@N-X:]&UH+B<>!A1+-,R!!CKD+>\J)'('J5Z/LG"Q%+@L_6KR8FI&QZ.G#3Z
M<(9U%,\ 3D%I2S G$B\1O$2)#^@-)Z_Q^N;/]-X89+1/)F:-:.#"SH KE/LO
M3]J>WR3&Q(]Y=%Y!"78M]V;HB"9=_ZT)>QYJ[8B,(E>YM86?&(-O'WJ>9WP2
M>ORG8&,;IV/AL(E\X@$UK0+\B>78,=J@N7>9+RS?U7"M(MK-%2]W@K#F]4#
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MGL\X=<_T^_#;6OA)--: ZH.#K,4GP=E\EN,D;?8.C76PR/$8=)B-J[>IC6.
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M_*!3N&,7QF\T([;B#HHR)<QQ8Z!YZ609!.M\!< 3A7?J/VKED=JWD=7*3QK
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M=-7,(?L':_*>GT%IZY8$J'586_W>DB4 M(W E5_D%;E<U)-_S^NZRQJPU((
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M/PN8W++B:0QBL4CO4P0R/3^DU$JF04-]B)/Q7%^A)#WSEN:6B*T=#NPG[=L
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M,!*E,VC(RW!(>0CD69_:XT79,_"[*&$>#CW P-V9#K@?NC) 4.'1^>N&K)=
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M, G;MY\H2=A(>J_-WMP+>>-/JV8RS(!1=]='1\9*KMR6VHA]RO6<097/DX4
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MOA;$O$ ;(I%7OGT3$+@G;"?UQ0>U2)DG=-<9YQGM]W;:<)V^&'_TPX)"W74
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M3W.0Y3WTBZ!HO<K?^4W]K>[@EV[KG^9\K+Y[>5'C=>*=?2_.Z8J-Z1+OX_;
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MJ+M7P5%1WZP"9$(3,,$UO9T=(KPX5(R?8%9!+7;30WS8!R%6UX;2F-1WHJ:
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M08PI3@ E7/,;(3&@@DB %$.^3WP!I1._'1EC;B2V$;'>TKH1U#$(DX1(@I(
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MF?_4ZX\4F_"(_Y*FL*04UP\RIS>RBIUXK7<TO]"TCL-;"*6W$$0D0(04ZR6
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M\,]D-5GC<MI"LG^$>^S+1[WUOM,OUKI,.5TV*S8+F"\C18#P0P001!2P0$H
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M@3NZ _=9N)6/R?=]N(<[D!W,S=LU1D\CC?-LO:J>ERU3;@JG;NR/1$FI4(P
M]['F<8$18%!P8[!)/PFECWRK$A#GAYH=*V\E]3:BVM@QK@!;&GB#P#:VL=</
M,7?+[RP8@UJ!IT>;UB(\J_6!=7C^CIZ6HMD8OBV*M12OJ[IW-0U5)T?':6U!
M*$I$)'P@?)$ 1+FV#'D,01 +*6+N2\BB'NX^=TEFZOYK(NUJ5:XV74Z/FA:[
M%>+*HTI3H:=W[TJFY3JWK(EWP3Q:6H3C3,N$=M^(4^%NY_5&<U!KSEV*:6VV
MWB@=6&;]G^1>X/.-)NCR\5H(_<X5U<G,A_QCGCVD6NF%Q#"2!.KI\$,,4!!0
MP&0@@5(^ADI$VAZS<I>=&VANME<MJ]<(>]4<)&:YMQ'8OO9G)[[=;#8D:B-S
M5G_ G,J"VJ!Q07G0SL=/5B;41LEVN5"KZ^<6L?V?51S0VU5-;8N 1@GSE00P
M5H$VSY $&"40^$DD0AE%3(2TCWDVD?PS->IJ(2M77A4-.YDOSW7Z1_;SC3&;
MWXT/T#*LM7E7]*LR&S=ASVF;A0O15?;OP[W8<T:FBS ],?Y%;LE"2V!:/FZJ
ML# F HA\ 7A$D,E?1  S/P&18F$D0T*E<"J3?7R8N9G$&RF]^UK,7@[(?2B=
MG(\7 #2-X['P&@E'J&S3C<$(_L;]D9[#UWA"VQ-^QE-7]PDAYTM)M1$M>5IH
M6OD/29?E[6>9/Z1\FV^+DHA%+-$,$ A3+5]& !,> DXI"V$@$P&MND#:#C@W
M0FAD]K9">[74WD;L'C5>K(#O)HTQX!R9/IX-29>(\&$1G2P4_&)D'6/ [6'J
M#/ZV>,R$4=_V2CT-]W:XKY^%MNE \$N6R_1F53,_?_RB#<EB6;U;O])T5=4;
MQCR 3/\!*(EB@#"1@/H)!'$D)98R@E*)'AX&>PEFZB-H!&_J%?)'K]R)[E'Q
M]W51UIM&TQ"LZH/B9ODY3)&=-3@PXM-0_$;H*V^#]T9NKR6X9R0?O(BT.V!#
MFI,.HT]J8KJCLF]V]GA"W\Z0I7Z0%&^:XNO:WEW?K:M*6Z^E2GE:+I(X\0-.
M]9XTQ % $1: Q#&JPIP3A$7D8Z=.ON>'G)LYNI&X9XEZ"XSMZ&E8Y$:FI2UH
M&VF]'UOR>HW  W*1/3K#=GP\.^K$_1YM43CL]FA]9T^+2C^^,)PEBP^K-]],
M\,XZ+6Z-"?!!O9:L7"AA,N:8)IB01'K?RQ5@.)(@22@.$PXCWU=]#*ES \_4
M?C(B>WKI?BJRR3@R0CO:2F?!9R%24.$(*)@D !%$  F4T/:L,B7I_$!PXE8[
M;1C<)ZVBUK*2ID/>TC@=$LVQ;=*+8'0W0VVA&=3Z/#OHM$:G+08'MJ;UC?UH
M_TLN:;'.'ZO0HSH [9K_L4YS*1:1A &32H*(4LTY2',]BP,?\$COHAE. I\D
M&\*WXYR.T7JP_,ALLQ&V.4+W:"-I_V/U+K!#%:LP2C! L0@UV#@$3"@(]%K+
M&0DD(3#IL;H.B_@4Z^H6]DKD)OZQN/(V8@\'N1VS7XK@-)S>&S5G.K? 8T@B
M[QIN4@JWT'N?O&UNF3@^JSDN_[ NBY*N3#/7NCC'PD=12 E20 8LT"2$*<!^
MF( @\F.:(.7KE6#"\IBGY'3YY*:K==D2LZO:Y;2Q6">G&D&6<(XQ2+C>1B"8
M<$!(J/0_A>_'1/'$EY/5K!QNHL<O0+DWS8<E*&<RP78+V[-.V<C+X0#A<]L
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MO7BGWA=OQ(\_?;I=>*=V3[;@W5?V2&)>ZOU[F2KU1=_;>(:00AP' @%M.DF
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M6?029-J3C4NP.C@ N>AA;OPJ9+IX4X7B?KZCR^4FZVK!$XE@F& @24P!@C
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M&7DA?#(=6FKOY78Z:DVJ'W[<3<:JVDW4\W1]9F:<=PP#8#KD[N$2<2;=20R
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MMU/)[_*%[6LQWL>V%=*CI<?D3;JJ\FTSU20,]R^".]V+02%C7$D!].J0F)
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MA"(8@X1&D:8J9JR2B %(8NY3%?A!X-2)T'[HN5%935X[&;U:[E[5FAPFP,Z
M&0?6D3FP)Z+.YHT[.$-:/0ZC3VH,N:.R;R/U>$)/9\F:%?*/M5Y_WIBXL,83
M&+ $*ADC(!*8:&KB": 4FH::81CXH912N+E*CHTR-Q;:">E54CHZ2HX":>DF
MN12>L9TD>\B,X$'MA&!0_\C1@:;UCG3I>N ;Z;QXXGXW3?GX#^NR*.E*:!KZ
M+VD"4Z6X?M [D1OYYIO,>5K(CWG*Y0*BF$K%$8A\%@"DD@!@E1 @?08YUW_C
M&"WJF-//)<U+2S*91GJ7[V]?A_$^Q9;P'BT])F_2E4G5-O[+)GK7Y.6M"V'^
M6>?G.:;G3?5VQ#SR0Q.W%4:8Z$4&*T!-* 8E,M#_%T%$_>;M>+,2W_F[L=%@
MLC=#KL1W^$Y8KI?SF^6Q5^#+F^%LV]VTM+_R-OI[#0#>!@&O@F &#6_ZS=DL
M.MTXBOY]M+CI-Q^#];;I.7P_0ZD9N/B2-85P7C;I/+)X+TN]%Z/%[:9$SD)2
M4UJ/2@ C* &*2 28'Q 0<)I$BF*.?+RIKV6WFKD,;T563TMLC;P@59(5Z29W
MJM"&;"I2FE=M5$PY&?W#JJ+,)NW*;4ERFAN[=65PO*=9'#9BFTRO1CQO)WG5
MLL9@755XN3Z'M3.Q]P%M2'9V&G]2BNV#S#Y/]GI&SS*BV=U=MJIJ?]7-[Z[7
MY6V6I__0WP\4C NLR4PJIFUUY7-MID,.HH0FC!"9,+?8F8ZQYN86JD5M*IU<
M>70KJ&-!T0YT[=AI(,S&/GVKX6JJ_S5=%*_/@^9>8/0\'(.6&>T8;MIBH^?U
M/B@Y:G'+I;%VQPVZ77/>:O2J*6MEQC4EG1ZK0)\O\EOY4NOX^\*/32">+P'G
M$04HC#A@$4. *4@(DY)HLND7HS>(?'/CIG;TVA=M.A>F#)]I$O1)+HV%5]=]
M.]8?6?\IJD:H>J.G'^G:*7?@:;?<]C_?9$ZXO=]NVW=[H:LGDU@5;3;*76WJ
M\3TV$8N>T<VKE!LE>'%0V,<)>AQ&Q&<*EAP4W]-!EL,.TSOI0Z[6TI3!>O--
M4^6*+E^MBS*[TZSY\O%7F=WD]/XVY=>F).T>6TA!HEB&""B)]4;;EP)@PO1N
M&P4)H=A/$N%4C>\"6>:V(#2JU$7D-LIX6VV,BW"GCU<IY,(=@T^E'?%/-$$C
MD_S(<],G:>525 =.:>DMSM0)+Y?B=B0=YN)'NH?.5J4:M+EAGO=)WNOW_-8L
M"@M* XE$& &"0@R0Z1Y&8RJ GP@44RI8++EM#.V),>;&FW7!CT9.KR6H?>CH
M*32[*6X@C$:FKA'AL0^Q'0"FB6)M/^;IBJ?WFMVO[[+UJO*^GH30$^O<G-F:
MK=BCI*=KM3G%YYX!JR-0]]2=DT7LGA&]';I[[M*^MJEIT\C+:E[,[KB)!L=$
MR#A@'& 1,,V+W <,0ZCW;7[BQRB@L7!JK'9BG+EQXQ,Q*V^!8V#].5QMC<"+
MT1K=P','JH?5U@G#L!;9\:$FMK8Z]3VTI+HO[QO57Q= ,$U<KU?B%;U/35D$
M;8S)5AV$5^L\UXO+@JA84A/G%FJ%-4\HJAF#2* 8HB1F @FW)$.GT>?&'HU8
MWGV6;TZ"EZ:41VEJ=V1[?<WKHIA%5=RCNH!MNV*[9@$X35B20!DP:1P*"*!8
M?PJ$!00PZ<<B"# .$K%XD#G+GGW*VE*,-VGOMC-4M8DV4U/)WBJV<N4UTH\Y
M,78KPVA@C[Q>#()RCY2-'F@-F[7A(L#$B1L]L#G,W>CS$/?M^]N/GU[O:LOJ
MM^>#8<]-!D>@H*(< 5__"5 2*T#]B (APTA(!F'(D>T>OFN@N2TW6M9_IG?W
M?WE]M2O5W%I;[/>KG>B>W],/A=G(%+2#ZU#8'F5B.T&SW^D/!=Y$V_VW*[Y<
M"[V[3U?;>MJFS':Q;;N@C9Z5_.K]OLJ^+J6XJ>J#J_72W"#D@UQF]V;'8"[1
M]PMMOE85P66^*0[>_*9ZLOYG*?GM*OUC+:M_I7>F)9O<E &7W]*B2@EO/:JY
MMRDO;@Z*EUO!=D*E*WW[O=FV9*8R>9'>K*JZX'MRM00QOS5^BY8(Q1D9*A'F
M4F]]H(+F-N]KA\>E\_;)W"XV2K1]+U;77U*YY;/^;JM7:EN)5G+((8P4X) 2
M@!A/ /.Y @S%0:PP\86R:H1Q9IS9K6EUD9*MG!=6^3W$U<[,'@"ML5>S'D#U
MK.AR$H;AJ[H<#O4,E5U.ZGN\NLOIRWNVC>5Z)5]7,4T5S9C A5S>RI5A_WK(
MQLJ(./'C  L0A+'I<IT$@ I!0,P2JB(,!0^M#J^<1YX;:[0$]VI[[HGH30?0
M%W77.<>>K=:S@1#$V"<"0!8G "&A&9MS#B"7$0H"%E :NGE61IF/:;PJUQ]>
MO?6NRS)/V;JLCH&T3?.1NCM1[/&W8_91,!V9ZSO '"$]W1FA0=O-6@\^;0]9
M5TP.&L,Z/Z#?XO%+NDI+^4X_5+S5F\'53:I?E^NBD&5Q?6?<TO^H-AQOOIE8
M./G?DN:_Z-=T 6$B"?(YX#*) *+2&)I2@C!14#*,0B*=NHKW$V-NR\H;O;&[
MJQ85NEJMZ=*C+=G-'BS=ZN;12CD/>$89SVCCQG,])\Z.],:?CI$9L%8 5!IX
M.Q6\2H<KSPA>!0RWM;FRF IG<KP,R2&9LJ<DD]+F96CM<^B%3[LXZT/>&"O_
MDZR.]U8W;U<JR^^J(5\^-K^L"P8+1!!A" &!8P&0BF) ]>8=B-!/@B2(D0Q8
MS\P.6QGF1J7M[(U&3F^KA==2XZI*[6^NN+",L_V,_?_<O6N3VSB2-OI7&+%Q
M=KLC"C,D 8+ S*?RK<=O>-I^;?=N[)D/"ES+W)6E&E%R=^VO/P!)74H2*8 $
M6=RS&]'C;I/,S ?"@P20%S<:'7D<1N;0<89@2(J%+X@CI5$XJ_%2J1*^.'6D
M0WA_JA]KMOFXOZTVBBUM,MXOK%C9[?C'U1NU*7X8%7ZH\GY3E$:K-W5$2U7.
MY94R&MH*N@L<ZXRC)#8;ZC0!B$@&J,YB0!).*&9,Q[E7*L0(.LZ-==O/0J+Z
M+.0N.EH;67.;_QX9__;$YJ@Q.GK3Q'M59AN>J RW):7]*'J,GX<;A;_PH(],
M\3,8;^_U8,01";E>C*'FI.O)B#B?KS=CBO*/'?EBF+98JB^[S4,AV/*7]>^K
MS\K\8=F<&Z:Q$!EBF0V&LZ'.C  2*P($XE+#F& ;$><8/G)#UMS6AT;=:*]O
M9!6.:HU[A$3<0OIV*$E _,;VIJ>%SCV@)""$$\64#(/2*WK!$9R. (9;7Y@L
MAL'1E-,P!M=7^OG\AJ7K#E=5:P;#VS:A^D.Q4N^WZGNYX%D.S2\A 9@@"%"F
M)6 Y@R#6$DF:"9B[T:R;N+DQ[6GS%3]?^0:L;FYO.+!&IE7;K;CI87>J:O0/
MJVQ4:1OP+,(-EI!NY V)DWJ$;M:?.W>.;_6,?:A.<YMXX4/,#D<0I:G @"59
M"A B*: IDH"*+%-(R1PCK_/4JU+FQAC[9)+Z8NDOGK?F5W%TO"$?BL[8M^&5
M?H=L@5$"GSHQ"'K??570M'?;7;9>W&-W/MQSTJ]%4<<5VWU?G3MU&NWP=?VK
ML62]VAJKEM6AI9E_JMSW';#I9S!G"@B)S29.BAA0(BE02B4YUKE*,J]SP6'J
MS(U&;H5&V5VX)[<,&RY'$IIL$,9F*QN[<[ D:DRYB.9Y;DVT-V>,\)X@R ;E
MP&$:34N60="[8-4P7_4_&_N[<>3,!E#:3 0KS,AE*]ED,I3-C!602F1CSS7!
M'""!,: RIB#-$JD3$?-,IJX'9"X"YT:AC<[1J=)5:L=>[1[G/4[ WSXO"PWG
MR&3X8DBZ'Y^%1G2B,[0 R'H=I/G U'&:YO29R8[4?(PZ/5?S>F]@@^>FG.WV
MJ2DHDL-$\#C)@>:IV1L3:';):<9 PHWQE'/-F5>UZC9!<R/EXX%:=-"T9Y_G
M<TC=/-000(U,M]<P&J%,RRTD1FG^?"[K93I MUC<V@:Z[7E_S\U\[.]L:V9:
M\Z--H*:),-M>JDD"4(818#@C(,80)TE&2"Z<>.#*M^<V]>WON=:O1]?C<]QN
M^U@#T)C@L#P8$.XNT@! )O*&]FA42=NG* 5J"=N!0H>S<_[&9'Y-BZJG+DS;
M(WV]%5L1H$J1?\>*S;^SY4Z]*4JQ7)>[C5K$+,;<>"D \=CX+%@F@*G4%MU,
M6,)I2B3RS&WN$C<W^JI/X8JCSKYN2R>VKLY+*,1&=V$.BMY%5M6HTC4Z*AO2
MCW$!):PWTREQ8I_&Q?I+S\;IK7XT\J;X44BUDN5")BBF::+LP9.E#90#RE(!
MD(2,9CK+X@SO^XU]=2>.@P"G7_SSCF)?)Z"*@WY^%''$S8T-_&"89N+?-MU[
M?E^8&7(J'S\^Z:R]L.E\@EX^,*!Y>I4?4#8.HYEU"<6< )K$%*"4($ 19P88
M:A9XA07D?OUKSB7,;>$^4;!G5=A+$-TFZ"!H1IZH7JCTZY5^S?+@?=*?"9F^
M1_HU&Z_V1[_Z8.\N>.<AVE6C/9M.D>9(93QC!BXHS8J;8$ U-W_"1&J:YRAE
M<K%=VVI_3C_A#EE>\_P@<<1MM941B6?7Y$5]E,;.KFU?LXTL;&N+ORFVW'Z[
MLS>][86VO ?!C1T"03LR3W1FI31M.XW&=[Y50_HTT[L%5^!F>JWBIFZF=\ON
M*\WT;KX2H.Z\^1>U^:$^KY?+=W4\X8*@.(-QGH)8<N/PYSH%#"?F3X1AXV50
ME4&OD+\;\N;F:CPOK][H&_W#:APU*@\I2'\%<#>J"0CCR'0S",%AE>K;<1FM
M8OT5D2]7N;[=_LX*]AVO#2W=\.NZ.J90\I/:5 G/QJBJ*5S=^>UZHT:6(\QM
MPH+ , >(\1Q0VX0MQSDQ+)2D$,?]JCCT46=N#.72CO/$O#'Z<?8:5<<-UV1C
M-?;N[&28#J:<#DS3B;,>F(E[; [!=IQ:$+TT>J&R$$/0:Z\0,>BK?CQ=;K9&
ML%JQ3;'^;54^*E'H0LGF9$1!+7/""!!YAHP'*!- $B$!S%.=YSG5-'7*%^N4
M,C]6K17U/%_J1K*;\H+A,SJ3N4+CS$A.IG<0C7G_A&3,OYT33+> 27C#R<8]
M';@]W,\;:WH]EU_7]W4I]$^;]:/:;)^L#V";1[PU__71/K)@$/$\UK:7@Z8
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M8!:;^28A90 A*@"'.@=,(<E90A3,M>LFH4W([*;BJ9YU280>VX562&_O%D(
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M^(F?&_'NM:\N&NO$X//N9I[A<9[#X;;U&@_DT4^13O"]0/8DBSCZQRBQ;OV
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MEJPL"VU<&JN8E732<[2*:;I21K+I(%M']A[JG>:0"01S")@6MN0:T8!+9$N
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MF<8<I!PK@%)B&S-Q!>),\XR:_2E23D%5OH+GMD@]USTZ5;Y.U]RKWR<NP&=
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MA L:YSQSNM,.I]+L**ZQR)9\J[1O+CKJ#K#6US.F1+^M9!7UIZ)/YFW/76>
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M1)W+>F/GU:?L-B0=7<DZ7IZL!]EM TX[CCD\W<_Y_/BH5H:$JV(T0A%-<L8
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MO=W2RRSUCF?[4>A7]L?KC9+%]C7;;)Z:!+NZH)]*J1E[G8&<(@B0U,)L';D
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MC7Z!3^ZOVA[\,/ZYE.G/UZ]:>?7(_/J3_4_!_^^.;<Q,6CXU9[:"I=+LY1*
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M+N*5Q=&YR=7J^=6W>?,(OPNW)?%E1WODE>]E!SITXY,!8S%A+Y0^6LZI/<H
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M;*KL:>MWU8I&/ZRFUA531S.B=6V9C?IXK.HV1FK5'K,P]0_ C?'F,:PCTV:
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MQ:A1\.^H+Q56WF35J$:!Z;1VU3@">MX95CZ">/KR.WMLKK?B7,<)1V9=3FQ
M>PPE(+:TE<A3'L=(09S%7A>&%R+FML#N-8RLBGVO"B^!=+PG' 3/V)>$?LCX
MWQ"V&A_T>O!2RK1W@ZU67EP,MC_9-Z?R>?!!U<:E2:#9QY<OH+%)0XX!)"H%
M"%$SXU-NZZ<K)%C*L$Z\\K-=A,Z- Y[E4JRK/DS'4*GR+EJI]J.X_LB[441H
M/$<FC8L0[KIKU4\'G:.]TNT-.GMD&;IC%#9'T$'NQ!E^[DA<YN=YO-LS3L&F
MB]<Y^6_J+A'5?7=UQ%E>/^A<Q"PC&L4Q($)K6T "V7)V9BQXEJ=93!5!B5<
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M=PQ\KP3VCB*F?_O48Z_PKU;2 J=$L<06/L*V::+(!: <00 S>[:78<&P5SK
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M3"$F8@X2EF/C^V@.*!$<" 6S1+ LE\QI*W3EVW/C*J->X^FXWTZ=PW7[$F\
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M1(JG&ADRQFZU3/R&G1LY5U+;^/]/YJG[)"C/,H5N>+OQ2G@41R:9 X!'D>]
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M^_8>/R^6ZXFW+DKB''+R')1A&IR7"E!FZ3U#K83O$0+W7M\)#:)]-!PCU4:
M\0Z7TT7^=9Y?T=X\L3DFR5T$Z;(&I6CG#"E%VCFCSMD+C\7T"(L[+^\$"MD^
M* Z7:".0^+@,\]6T"OX2UMDKK3$ED$DS4 PE.,0,AGX_2&4+<=3G?G'O_9V
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MZJ2!W7D7-Z]7JPOBQ,CBK L).-."..&T) LY&[S^,*%AP@\RGN9QDL9.:(R
MK -TT0"J;J6.'RP0P12C*%A1@%Q'8SNAP6O4$"1%.]8IX]/0]TL=9+%.,1!R
M&%SUI8T6@76Y/IA$(IC88+Y.MT:[J4VG?=TQ(52V.:1A1FGMIF?LQ,6I 76
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MP9="/GH<9*1?)^J.K[2X?,G'>MX^X3G&:!,'1KLV^8BIUGXK"1)CYM$9J>Q
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M'GV#RR_XR[>/])Q:QK=:W[ HHV,B,P;2&E.'PCD@DTVAFD-!_YD<[2"7-1Q
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M!G#:O:9[8LBA,599T+1-@%*QU$R:!YV5T2I(;LP@MK0[B6T<CIPRRNY5:0W
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M#=*?V(V\-MH^AC] &T!9#4*03/Y#GC!I5)Z1G)!0HC@YPD%' 49G;[BU*-Q
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MW@!R=K3W%1E$*"I0&&'J[=^V0*C53HPY(Z35XD%'^:@MLR>M%3K&T!PIZN;
M<JO>C@5MO>8,8HH)E VRG@]2G&!3<84+DLT@M[4^FY;9O13=M65V'ZF/79NZ
MN]_3.9%B)/MK8[9U7$JNMS#5GF(K,.@D>+<*]N?4,KN7UK[?,KN/",<'P>Y>
M3_+J$]+R(!YXK,/ "S@=ZA5<2AJ)J$SHU,_RO%IFCP#"\6(<&PJ["ZV#*E:I
M.F;8R]J5XPMXD32(Z%/FA?[+K L0#J]5/WW#[,$P.%Z$;7>SR%B"MS; II!
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MJ-&2IC%6HUS3PS)#B8998B09TV5&\=VGCET(>KR.%KT(K!E57V:4.=/1V>@
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M_N_QRL8F>QZ/G*'$W8"_^SN%CU5B[W%&O.6/BYL4Z0=<KV>;MO:)Y=P$<L;
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MXWR%$U%S_+4K2U@724XR@L<@P:%"YXI4(77I1SH\GWV'G-;ZDWI.;1\N^@8
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M!I3F#J(B/HF4(O=:)!W%N1 FQISDU0?"CA'+T0C['>=QUA!C\G:877+"\%+
M1%Y7T1)%7ANZ"9B7T?KLR5\^%\;D 1AKUI@X+L:.$4M/5NP$I_B7N_(AH7)"
M"J@@>I]!173@,44H*J1D>")?I6W,.P05G:"XCRCE[+#H0"?6-&]Y/+A[.XB>
M&9>M )^,)U<ENKK3+Y"_PJ+,:'SA39[2GSU9)W[D^5$S:RG"#C#Y0UA\(G;5
M_WGSKYO)[^'ZF]OMGL"K(*(SD;"#P1+;/",2N=(@0U&^#E#&-IUG>Y]P7(P.
MC(S9.<34 ?Y^GOZ.B^7G7=1HQ[DL3D"V-7:S]8% :0F:R#!*B&!#DVV13Q]K
MW)BG+=(&%$@'\/H1YZ0LM;UJS;4']\:KY1U]O^+R*HD8).D&:%T7WF$Q$)AF
M('T4JZV)T309/K#W"<=U']N"KHV8.L#?#Y_JN/%U=WJXKKWI?Z,@L4Z*?3N]
M#R$Q?R0WY><I<?)FI7G\RFDN"F,. A>N/A[5_8M% ?)"#HO@4NHFAN_8 W>2
M!AK=03R+P+NMK:3?3M,D7#^@[)C:R&T?,TQMX[,''*@V\=Z@/?@F0MU&\J]J
MQ^\*G%L,J=%1.B,3E+IO3Z% B#8+4,R4C-IY?+Q^=NB;Z. SGYPMVB*7^V^Y
M+T 6UIM4A ;FZ/Q*1JS-&!D<8SHXEI5E;>H6]SO?N!'(N3#W74ZG@? NR<(=
MWTBS^\.:6;N&;32GX$\HHY0O"(2*0%=N;4,OECQ(CLISHT50C;WOL]N\^]:,
M5<LL?=O*-ZC?_F:QG'RN(RCO/(;%V_(CQN5C0=XK5]0F:^]Y?=\LI+:R/@]8
M!BBUDC)&*4R32V-0*B[7?AZ"W]T].N<&PB59V5^)-ROAG-!SL\_'-K.\3Q/0
M@0UF*9JDG()8\:(<1_"9>7()/.=96\^3?&$V^/ZKUT];N22M,3"PMDY#*3S6
M5;,<(CE#R#%:N]<"BQ-8T$%WR[DPM#L)=+@P.DCUK,=4W.T ^66VGA^V*J>S
MQC"=%*/K09)[';V@F\$6$,:$5&I[>IO*L"?.U O&CI#UUOD@IS.^7PS=+JF2
M1DOK-,C$*#1+M9!-\0+!%<^\0\[;I*B?/%4/>YX'D/U^F#I"$!V@:C6#Z=?9
M=':[J6Q-W68$V.T62^^RC,J2_'W- ,2:6%>$A1)]"EI3[-YFL.@>A^L28\=@
MX?' T:$%TP'8]BPP-P71&6? :$L!4ZJS#"DX@22])FH=P]+$EEU"0\F0EV,#
M<?0$LKU*,EU=,1.8!8PR@0J)UP+P!$4S7T06]*=M&X=?3%O(03 YJ2WD$)GU
M!,@MU>$A*25C,:!EW0\=O0*'*,F*!XJ5=,AHSM86<DC1?B=M(0<AX8"B_4/$
MT@'"-M'WC[B8?)P^=')]<3Y'D$S0W>"P@!-)@RF&"5%(+5F3QLSMQQFW1F7(
M>W, =G<)FMLNA:B+]<2:)&JJN&XF=3E&T#I95[2(1IX)-CW<?D,(^UG\','Y
M#A!T2P#F5XOORE8VEE08TJC@2^U%8: HLH; DP"9658BH=/8I&I]C[/UAJMC
M0/!=FG18B70 ,@J!\QU5&Q)T3B9SQZ'.@:9KG]/UK.OL>RZXL88[CTU2\5O.
M,FXTV 1$IW*\ ]!L?::X+;9[_77#MG=XO=Z>\&GR9674412L4V> ^V1(-92I
M_H &)DA?G ZH2Y.;[[CCCKL-;TB'Z@SBZ@"46\BX'3S#&7/66PB)$2%H,P21
M#?B<@E'.\<R:7)([3]3+ U [.&QWR4Z430<@>UQ'O+'?3K$@Z<A@L&:B@RL0
MF?; 1;(4T#K#VBPCV'Z<+CRO4V6]*YUP/.,[@,\VU7LW6?QSI6 INY22"77$
M+_UPEDR\J46:*11?]\8;=[8BD-M#C;MDL_4E>!3KNX)17595JS\^T']YZYLF
M)9TT&I2M*T!53.2;DKY9241(IS5735+N3QVJOPOO.-'OQ-2)<N@ 4[6_]:?K
MV;^_M:]"!BV1432+M23=$W=\E!:X+$*58KC5N068MIZF%Q2=*NPM#<:G<;X#
M^-PN(JX;]-[_.WRY#6QCBLZ1L5[G\3@/$+A54%0664IF'#99X;#].+V\+0\,
MH %XWP&"?ECM)DM?'U(0HL7HD6*,[$'5&6(AH0"T(7!MA8JJB5O]_5%Z>5T9
MVO2<QO,.4//3;(Z3C],W?Z15]^<M?VX?&B5%!%@%7"A&4$X3,4(A&=%<5,K%
MB-2FU.6I4_626!H82\-)H@-8W7/IE[O>Y*("8PI5W:$GZXV,X#779$^]"<)&
M5+;)N/$M9QEWJ7R;L.PX1G> E:/[SG4JT1LO0&M!.J&S@E#(U"J5B7R9(H8F
MC6--!PV<P?\^$BE#C0LX1&PC[Z>_Y]GJO7(U.V2]WCI,$VYYPPS+.J[AU>?9
MS71YY3TG/38*.,M(W*US#Y.O.[!5MLQ(I1[O?MRZP_ZD0_3BLI^&N?/*H@.;
MN/6-X=?9\LD7]+M'B#IM!BG*M9X[,+). O$J@,>@02A1LL\B\3;CITX^>2^A
MPC!6\KR"[ JYMW-LOA*Y)+UPO5%%EJ1,HJ9BG*SC8D($+XD@YGTV-DF72I-V
MC6=/UDM@,33RAA!$!\A:M9S\,/M,W_\)IXN52M6>DXVBW$]_6UT/=P^R6"BP
M>H?I.BP6DS+9=%E-ZY+WJZC14<"N0&?&:MT(Q6NJ('G>Q=1E 5J()@F2X4GI
MY:%I&.R.+.H.P'Z;D_RFK>IAOU6]&B2RY!G+D)@WY#_K -$9<JREB\9ZKZ5I
M4FBVS^%Z";&' >3@XN@ 8KN4;%M ]\#Y?C6?+&I1WTT=/_<;_?DLKQ6O:IFW
MSAMIZE#-59JJ3E(L-0L6,:+,,F7>)&'8@):] &PO!<!C"_N2YK6\O_G\.<R_
MSLKW,VQFY9?9]".=Z?/;>#WYN*[0"=.\8N_[3[/YLO[=Z]E\/OLW<>R4+<OG
M.5BSF3&MF=C!U)G &?(@&5BL6_*,C!!3#%"R*0$+LW0/G"W$/M.TP\%6,4C'
M1-&<C$?,%'SX%,#9* "U##87%KUOVT5]V7N<SX7;=FN>#P% 7YN'GFXT]G5=
M9@A8VQKHAR/B8LP(&:V0@>)KG]OVS)X^'J#K;1A'H.>XP0*'"+(#=_ZPUF09
M*58QMD 648/BBD.4B0%/Y+F9DG,6;<WOBQDL<!!,3AHL<(C,>@+DE@YVI2(%
M+4F#,)5S=".!E](!$XC"\9Q*;+MZ_+('"QR$A ,&"QPBEIX0-LCL?/**:LDH
M0E \TI4BZ%<&4QVM8$4)7"33Y,7L_)O:NEYF,.#]?G98=* 3WX[8O6/%538F
MIJ3IW*G4>FB-=<*O(?XJD8*I:Y&;N*4[SM.)M3T_0KY[I3M=7",7R=R.?EZ_
M*JZ3.Q]P_CE,\^PNH_/AFXS.%>,VD087D#)94!DU76!U)2.+421&_Z<>M3)O
M+8TYXJLOWT">!KQS2*S79._[3R2D3[-KDO&B[J);?CTB,;OE0P9)HCYWN($2
MGNN/OLL%^1BD*EH#QCIS/48%05H#,9>B2@@E/E;$8:Z%;X]Q\D*"Y2S]\QO>
M_3I;XK9-'EIX+C(JL%K5:AJ>@0(X!JK(:'F4RL?8@MZ]3SCNQ7@".K[;#=!$
M)I=C6H[>K;+SHQJ9F89[51[!25ED@L<((I>Z:L(3DD1AH.GN2#$'F423"&M@
M8W.W].)52C>?;Z[KX]93%2N/UEQDQ5QRWH(S+!$7A("0@@-?O,A>97+QFGCB
M)YZ[*\-T"))V+RUI+[_+,5<#+"G9XT,;F;"S+"AY!,&"DL? ,FB/DAQB<HV#
M= F83#P3%NIM>4G&;'5?O_[Z0RV>6^=@T*.-+-"57,E4P3&(=%<#6J>233&:
MTMA0?7>FKHS0(0C8;81.XWL'&:>[\?)K]E0C.INNGJ-7\R&BQ>)<!*EC?2,)
M IQR"(9[3]8:@]--QFD\>:IQ8328[+_SN(<21 >H>D3#YN$#"RF8=QKH!]W[
M=-="##9!TB'H:#7+MDGXMO4T(Z-H.&G/AF9]!_CY,%]ET[ZN5&SSO"65*2(R
M"F(5HW#6B0#!$&>\=H(,.5?>-FD8W7*6'BZRDR0\&Y;=753XK.SPQBK?9UEE
M,#EG;D'+8D!IJ^H<$/+W6?"%"ZWH+UN@9NMIQDU?M[JY3F=\;Q9G%:,L7B52
M-#K)E;/).<LY&+9R%4ND<)&1.7:86/'6.].D5/2),XUK@0:0^%,6Z 3V'XXD
MOT;2%#_63,*'P0#U6_BZ+@.9S=_AEYMY^A06==7J[//GV71%YI5(-JI46T)M
MJEU-! )OA0+FM<U&9L';=  ]?[1Q#=7P\!I8&+W9JUM5>47W::C39Q;+W^I#
M(''[ROB$F@D-Q5>Z'$8(Z#AHD^JB.I>B:I*VW?> XW:,-[9D0PEFY"*!K32M
MK?15#,9DGSGAH%IGJ3F$&")841^?(C-2BF_QM;48X(FO&+>S>SB$#,G)RTE-
MKR?-+";3Y2?<,V4_9!+[A*]OE.X>BB%M$N-(V N2!=#115!""XBI)(@%HS4B
MI\*;I(V'38P_;B-_>[/<Z\%H'0QQQ0U/Y&$612JM0C 0E?:07<X1F;7)-_'+
M3CIU#SF)HU#T^ (]G^PZ<..>S@.B5L3'E"&)&(B-WD/03D'FW!<A@DBZ2>#9
M<?K]C.@X*$%_B*@ZP-V.'*+F.9NZ0<#5]4V%*R!U96!D8-)X'8IL8O@N+D%_
MD+3W2] ?P/H.\/- XS:C3V^GZ;[*_W.S'N]"BG=]D^OH@=E\);;E<CZ)-\M5
M0<;LU]FT3H"C<UVOQF>M1W1LDL\V8F"\</"\5HA85O>($4N\3D)+G9C,3;9!
MM"6KAROZ)-S-N@5!7RKQ*RYO!W+\1')X..,>%R=P!%-T65*LZ5/@%'7&#'5=
M;!U37!1Y5=Z;)HUW[4D;-^'85#5Z $,/ZC%+DQ.H-0FY,-X EFA!19UKMLQ"
MB3Q'DXW4O,GK[VG''C>YV0#6YQ-B#Y!]/JRXU44F/1HFH&BZKU:/Y;'0?15C
MD"@C1R6;U$GM?<)Q<ZA-[>N HNFBCN&[$8AWOM2^L>Y]FMH'%;/5$31&BG<U
M8^"5\U GATI$BE-RDPU& ](PKF<P7KIA+!AT8'<?DU[=ICWH70<?R_6@._*Z
MWI8/X8^[E&2VV;.<'&#=Z:$$DN/D W&#H@AO/.<.FS@0+8CI*P5W-F0^HR%G
MATD'JO)]G]XQ[ME5"DDF:3B4XC(H4[N2LS# ?&2E,,^]:C+5>YCC]Z4.YX?A
ML[V;S3%QM"9\69'_?AGFR^9CQK=/F%[<\OY*U'[54*<V2%XGZV4/H<X"%F2D
M"H^B6"=:*,$)9^[+.1H=^>>2?I=QPBG<OY(Z9XTV4I242=FUD> +,4,S"M=C
MSK;X)OUP0Q(Q;K*E.V48#1_]U. ^LXE@39IURJ-3!0SSI/A>2HBV.'"N;N:S
MHDC6I$!RG\.-F[;I#M*#R_-X#WZV#-<]>?#2"<UUU/72BJ!LS!"1,RA>:^$,
MFJ*;]+F<T8-OM@"E.YR/@(D3/?@WT]RNJ/1-F$_K&*O;TNF'Q"]G/VS^_7]@
MN%Y^(D8=43=ZZ#<,4AIZ$EE#57\^/L-=>[Q&5YPVP+/39$6] K*K$HS261LE
MN69MZD!W'.CD@J='GWL_$<1Z)H.G.%?63<^*[@>(*0C H")#X1+=&>>@M)=9
M+4,@XKN:IT&XWVO1^X&*?/1LJ>.^9PQ;U7(JU2Y\2B]RXK*6&R<$Q:T!SV(!
MYE$7GCCGK,E;5RN+==^N^]\X^?AI>==%].M-?=A\6]9M(X_F&XG"I3 .P<M8
M[WQAP0F+D(+/''.*7#>Q9D>=ME-+=PB2=H^&:26U%V(%!QA9=>HWCF$9SS/L
M:B>RK4Z2%TT1<:;8N)0 +BM.0&=!FI#1^R8K,UO9R%?3Y21/KF\J0]_7.;NK
M4;QO_JC!$N95N1W%;3=KN;XMWQUCO4HU629R**MY=*Y.Q^406>)@?-;6.NN=
M;#*79I#3]VI##T#:=\4]9Y?JR/VUZSMA^2DL_SV[N<X1PP,.A$7]RYOKY:Q,
M<7D]6RRN@LB:U0<Y*X,!<I0+>&04W1<9@R2GV=I]!G ?^+4CU^@.B;363'\A
M=_0[3+-IFEQ/5E\\NYV7L&+<WQ>8Z3]9*2+6T>8I3/./E7V8W_SV_FRW^@!G
M',,/&)JUK3T'IKP+V6J0Z$-=7UH7)<D,16BGDG.1VS;3?QMY#D]ZYV]OEHLE
M\7PSM#]=:1U4RKIF/(H"57]$4]\4?*I&P:72IH[RH%-VZ@D<@IS'GD [*77Q
MA+^5O(VB?T?C?9G='6LI#DT^&@=8BB6"T8*GV!6"C\PGD2*6)OU )YZ[4T=B
M<* VDF0'98='DDL:RKQ6MNZ;YG64ER8R([GH3'C'4<B@SVA'GS_ON!;UK)@:
M!L\'";A7'+\MNPB]$EE)NE<$%"<IPH@N0& J0JT=0Q\KJ4V*R \\Y\AM9V?T
M! :1U&!5($,/4\*/ZQ;J,IM_7GW:$>'4E@\99K#1,X<;*"#9?,T[_%(+'\C6
MW(+)*(S*Z@S<&4&61@KP*6G((LCDO"Q1-QD1L.M )S_W//K<;;MVC+#>%Q[
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M)-TG&^@.876/#73:$R-4\B#((:S=0A*\,9H88[@2.@D3]NFIZKV![B Q/==
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M8FET,S$Q+FAT;5!+ 0(4 Q0    ( ,F$15(0>S\6"0@  )LG   ?
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M              "  =,O  !C86@M,C R,#$R,S$N:'1M4$L! A0#%     @
MR81%4B+P@)C'$0  #;L  !               ( ! %4" &-A:"TR,#(P,3(S
M,2YX<V102P$"% ,4    " #)A$52\+=M6A4;   ]& $ %
M@ 'U9@( 8V%H+3(P,C Q,C,Q7V-A;"YX;6Q02P$"% ,4    " #)A$5219H^
M@#%H  "-H00 %               @ $\@@( 8V%H+3(P,C Q,C,Q7V1E9BYX
M;6Q02P$"% ,4    " #)A$52&"4_]GA(  !*5P  $P              @ &?
MZ@( 8V%H+3(P,C Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( ,F$15)=B=B4>6<
M *UZ   3              "  4@S P!C86@M,C R,#$R,S%?9S(N:G!G4$L!
M A0#%     @ R81%4FCVOYDI6P  )6X  !,              ( !\IH# &-A
M:"TR,#(P,3(S,5]G,RYJ<&=02P$"% ,4    " #)A$52UCZ,P+Q-  !R7@
M$P              @ %,]@, 8V%H+3(P,C Q,C,Q7V<T+FIP9U!+ 0(4 Q0
M   ( ,F$15(P^I\=TG8  "6'   3              "  3E$! !C86@M,C R
M,#$R,S%?9S4N:G!G4$L! A0#%     @ R81%4L5KNV0K6P  T&L  !,
M         ( !/+L$ &-A:"TR,#(P,3(S,5]G-BYJ<&=02P$"% ,4    " #)
MA$52#OA)SX14  #V9   $P              @ &8%@4 8V%H+3(P,C Q,C,Q
M7V<W+FIP9U!+ 0(4 Q0    ( ,F$15+VRY940MX  % Q"0 4
M  "  4UK!0!C86@M,C R,#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( ,F$15+6
M\:5U49$  -O)!@ 4              "  <%)!@!C86@M,C R,#$R,S%?<')E
:+GAM;%!+!08     $0 1 '\$  !$VP8    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
